<SEC-DOCUMENT>0001193125-20-281042.txt : 20201029
<SEC-HEADER>0001193125-20-281042.hdr.sgml : 20201029
<ACCEPTANCE-DATETIME>20201029160642
ACCESSION NUMBER:		0001193125-20-281042
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		19
FILED AS OF DATE:		20201029
DATE AS OF CHANGE:		20201029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIODESIX INC
		CENTRAL INDEX KEY:			0001439725
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				203986492
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-249260
		FILM NUMBER:		201272668

	BUSINESS ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		303-417-0500

	MAIL ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d937421d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(4) <BR>Registration Number 333-249260 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><I>PROSPECTUS </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><I>4,000,000&nbsp;Shares </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g27r95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>COMMON STOCK </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT"><B><I>Biodesix, Inc. is offering
4,000,000 shares of its common stock. This is our initial public offering and no public market currently exists for our shares of common stock. The initial public offering price is $18.00 per share. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Bodoni MT"><B><I>We have been approved for listing of our common stock on The Nasdaq Global Market under the symbol &#147;BDSX.&#148; </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; as defined under the federal securities laws. Investing in our common stock involves risks. See &#147;<A HREF="#rom937421_2">Risk
 Factors</A>&#148; beginning on page 13. </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>PRICE <FONT
STYLE="font-family:Times New Roman; font-size:12pt">$</FONT>18.00 A SHARE </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Price&nbsp;to
Public</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Bodoni MT" ALIGN="center"><B><I>Underwriting<BR>Discounts</I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>and<BR>Commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></I></B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Bodoni MT; " ALIGN="center"><B><I>Proceeds&nbsp;to<BR>Biodesix</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Per share</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$18.00</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$1.26</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$16.74</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$72,000,000</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$5,040,000</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>$66,960,000</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We have agreed to reimburse the underwriters for certain FINRA-related expenses. See
&#147;Underwriters&#148; for a detailed description of the compensation payable to the underwriters. </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>We have granted the
underwriters an option to purchase up to an additional 600,000 shares of common stock to cover over-allotments at the initial public offering price less underwriting discounts and commissions. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>At our request, in addition to the directed share program described in this prospectus, the underwriters have reserved for sale at the initial public
offering price per share approximately 824,000 shares of common stock in this offering to certain individuals, including directors, existing stockholders and other persons associated with us. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Securities and Exchange Commission and state securities regulators have not approved or disapproved of these securities, or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The underwriters expect to deliver the shares of
common stock to purchasers on October&nbsp;30, 2020. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:18pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="bottom" ALIGN="center"><I>MORGAN STANLEY</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>WILLIAM BLAIR</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="bottom" ALIGN="center"><I>CANACCORD GENUITY</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><I>BTIG</I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>October&nbsp;27, 2020 </I></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g18p26.jpg" ALT="LOGO">
 </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_5">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_6">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_8">SELECTED HISTORICAL FINANCIAL AND OPERATING DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_9">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_10">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_11">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_12">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
</DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_13">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_14">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_15">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_16">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_17">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-UNITED</FONT> STATES HOLDERS OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_18">UNDERWRITERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_19">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_20">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom937421_21">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#index">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor
the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. Neither we, nor any of the underwriters, take
responsibility for, or can provide any assurance as to the reliability of, any information that others may give you. We and the underwriters are not offering to sell, or seeking offers to buy, shares of our common stock in any jurisdiction where
such offer or sale is not permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our common stock. Our business, financial
condition, results of operations, and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons in jurisdictions outside the United States who
come into possession of this prospectus and any applicable free writing prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus and any
applicable free writing prospectus applicable to such jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Until November&nbsp;21, 2020 (25 days after the date of this
prospectus), all dealers that buy, sell, or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a
prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this prospectus, unless the context otherwise requires, the terms &#147;Biodesix,&#148; &#147;company,&#148; &#147;our,&#148;
&#147;us,&#148; and &#147;we&#148; in this prospectus refer to Biodesix, Inc., the issuer of the shares of common stock offered hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters has authorized anyone to provide you any information or to make any representations other than those
contained in this prospectus or in any free writing prospectus we have prepared. Neither we, nor any of the underwriters, take responsibility for, or can provide any assurance as to the reliability of, any information that others may give you. This
prospectus is an offer to sell only the shares of common stock offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. You should assume the information contained in this prospectus and any free writing
prospectus we authorize to be delivered to you is accurate only as of their respective dates or the date or dates specified in those documents. Our business, financial condition, results of operations and prospects may have changed since those
dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside the United States: neither we nor any of the underwriters has done anything that would permit this offering
or possession or distribution of this prospectus or the offer and sale of the shares of common stock in any jurisdiction where action for that purpose is required, other than the United States. Persons outside the United States who come into
possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all references in this prospectus to the number and percentages of shares of our common stock outstanding
following the completion of this offering: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reflects the initial public offering price of $18.00 per share of common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumes that our amended and restated certificate of incorporation, which we will file in connection with the
closing of this offering, and our amended and restated bylaws adopted in connection with this offering, are effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumes the conversion of all outstanding shares of our preferred stock into an aggregate of 20,090,745 shares of
common stock immediately upon the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumes the conversion of all convertible debt into an aggregate of 1,848,280 shares of common stock immediately
upon the closing of this offering, based on interest accrued through October 15, 2020 and the initial public offering price of $18.00 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumes no exercise of the outstanding options or warrants described in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumes no exercise of the underwriters&#146; over-allotment option; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumes a 0.1684664-for-1 reverse stock split, which became effective October&nbsp;19, 2020.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The data included in this prospectus contains estimates, projections and other information concerning our industry and our business, including
estimated market size, projected growth rates and the incidence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market, medical and other information from reports, research surveys, studies and
similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this information is derived. In that regard, when we refer to
one or more sources of this type of information in any paragraph, you should assume that other information of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise
requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This industry, business, market, medical and other information involves a number of assumptions and limitations, and you are
cautioned not to give undue weight to such estimates. Third-party industry and general publications, research, surveys and studies generally state that the information contained therein has been obtained from sources believed to be reliable,
although they do not guarantee the accuracy or completeness of such information. While we believe that each of these studies and publications is reliable, we have not independently verified any of the data from third-party sources. Although we are
responsible for all of the disclosure contained in this prospectus and we believe the market position, market opportunity, market size and medical information included in this prospectus is reliable, such information is inherently imprecise. Data
regarding the industries in which we compete and our market position and market share within these industries are inherently imprecise and are subject to significant business, economic and competitive uncertainties beyond our control, but we believe
that they generally indicate size, position and market share within these industries. We believe these estimates to be accurate as of the date of this prospectus. However, this information may prove to be inaccurate because of the method by which we
obtained some of the data for the estimates or because this information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other
limitations and uncertainties. As a result, you should be aware that market, ranking and other similar industry data included in this prospectus, and estimates and beliefs based on that data, may not be reliable and are subject to change based on
various factors, including those discussed under &#147;Risk Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements.&#148; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRADEMARKS AND TRADE NAMES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Biodesix,&#148; the Biodesix logo and other trademarks or service marks of Biodesix appearing in this prospectus such as GeneStrat<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, VeriStrat<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Nodify XL2<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Nodify
CDT<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, Diagnostic Cortex<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and DeepMALDI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, among others, are our property. We
will assert, to the fullest extent under applicable law, our rights to these trademarks, service marks, trade names and copyrights. This prospectus contains additional trade names, trademarks, and service marks of other companies, which are the
property of their respective owners. We do not intend our use or display of other companies&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. Although
trademark and registered mark symbols are not used throughout, this does not in any way indicate that we are disclaiming ownership of the words and images with which these trademarks and registered marks are associated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained in greater detail elsewhere in this prospectus. This summary is not complete and does not
contain all of the information you should consider before investing in our common stock. You should read the entire prospectus carefully, especially the risks of investing in our common stock discussed under the heading &#147;Risk Factors,&#148; and
our financial statements and related notes included elsewhere in this prospectus. Unless the context otherwise requires, the terms &#147;Biodesix,&#148; &#147;company,&#148; &#147;our,&#148; &#147;us,&#148; and &#147;we&#148; in this prospectus
refer to Biodesix, Inc. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leading
data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence (AI) platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung
disease. By combining a technology agnostic approach with a holistic view of the patient&#146;s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient&#146;s care and meaningfully improve
disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe improves overall patient outcomes and lowers the overall healthcare cost by reducing the
use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and
commercialization of companion diagnostics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our core belief is that no single technology will answer all clinical questions that we
encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic Cortex<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, to
discover innovative diagnostic tests for clinical use. Because of this approach, we believe we are unique in the diagnostics market as this approach allows for a broader and more holistic understanding of each patient&#146;s disease state. Our
data-driven and technology agnostic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derive our revenue from two sources: (i)&nbsp;providing diagnostic testing in the clinical setting (Diagnostic Tests); and
(ii)&nbsp;providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third
parties as well as development and commercialization of companion diagnostics (Services). The majority of our revenues to date have been derived from our diagnostic testing business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have commercialized six diagnostic tests which are currently on market and we perform over 30 assays for research use as part of our
laboratory services that have been used by over 50 biopharmaceutical customers and academic partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have four diagnostic blood-based
tests across the lung cancer continuum of care. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Nodify XL2</I><I><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I><I> </I><I></I>and<I> Nodify
CDT</I><I><SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP></I> tests, marketed as part of our Nodify Lung<I><SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP></I><I> </I>Nodule Risk Assessment testing strategy, assess the risk of
lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>GeneStrat</I><I><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I><I> </I><I></I>and<I>
VeriStrat</I><I><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I> tests, marketed as part of our Biodesix Lung Reflex<I><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></I><I><SUP STYLE="font-size:85%; vertical-align:top">
</SUP></I>testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
of the patient&#146;s immune system to establish the patient&#146;s prognosis and help guide treatment decisions. The GeneStrat tumor profiling test and the VeriStrat immune profiling test have a
<FONT STYLE="white-space:nowrap">three-day</FONT> average turnaround time, providing physicians with timely results to facilitate treatment decisions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> testing program. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two United States Food and Drug Administration
(FDA) Emergency Use Authorization (EUA)-authorized tests, a part of our customizable program. Both diagnostic tests are owned and were developed by Bio-Rad and Bio-Rad has granted us permission to utilize both tests for commercial diagnostic
services. U.S.&nbsp;Department of Health and Human Services Secretary Alex Azar II declared a public health emergency for COVID-19 in February 2020 which justified the authorization of emergency use of diagnostic tests for the detection and/or
diagnosis of COVID-19. The Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test have been granted FDA EUA pursuant to the current emergency declaration. The Bio-Rad SARS-CoV-2 ddPCR test was FDA EUA authorized on May 1, 2020,
authorizing performance of the test in laboratories certified under CLIA to perform high complexity tests. The second test is the Platelia SARS-CoV-2 Total Ab test, which is an antibody assay intended for detecting a B-cell immune response to
SARS-CoV-2, indicating recent or prior infection. The Platelia SARS-CoV-2 Total Ab test was FDA EUA authorized on April&nbsp;29, 2020. Medical products that are granted an EUA are only permitted to commercialize their products under the terms and
conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if
other circumstances make revocation appropriate to protect the public health or safety, and we cannot predict how long the EUAs for the SARS-CoV-2 test will remain in place. Using the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total
Ab tests, we operate and have commercialized the Biodesix WorkSafe testing program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to using the Bio-Rad tests as part of our
testing program, we performed feasibility, verification, and validation studies, including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by
the manufacturer and as required by our certifying regulatory agencies for high complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories.
Post-launch development support for these tests have included improvements in on-boarding new personnel, logistics of sample collection, sample receipt and data reporting, all required to support our testing program. Additional releases of the
laboratory data management software are ongoing and planned for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These tests are utilized by healthcare providers,
including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity. Recently we announced multiple
partnerships for COVID-19 testing, and have entered into an agreement with the State of Colorado to be one of the diagnostic companies to support wide-spread COVID-19 testing for the State. Additionally, we recently announced that we will oversee
and manage onsite testing and validating testing for the Big Ten Conference athletic competitions. To date, we have not derived significant revenues from these partnerships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dedicated to continuously publishing and presenting new data on the clinical validation and utility of our diagnostic tests. Since our
inception, we have performed over 245,000 tests and continue to generate a large and growing body of clinical evidence. We have participated in 27 clinical studies, four of which are ongoing, and have published over 275 peer-reviewed publications
and presentations. We have over 140,000 samples and data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external research and development (R&amp;D) initiatives. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Market Opportunity </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Diagnostic Testing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite significant advances over the last decade, lung cancer is still the deadliest type of cancer in both men and women in the United States
today. While diagnostic testing has become routinely used at certain points in the lung cancer continuum of care, we believe there is a substantial need for novel, advanced testing to improve on the current standard of care. We estimate that in the
United States, the lung cancer continuum of care currently represents over 10&nbsp;million annual testing opportunities, and is over a $27&nbsp;billion market annually for testing alone. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g67y30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Biomarker Discovery&nbsp;&amp; Companion Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the last two decades, the use of biomarker testing in clinical trials has increased, with 55% of oncology trials involving the use of
biomarker testing in 2018 versus 15% in 2000. We believe the field of biomarker discovery and companion diagnostic development for biopharmaceutical therapeutics is set to continue growing as biopharmaceutical companies seek to <FONT
STYLE="white-space:nowrap">de-risk</FONT> their pipelines and increase chances of drug development success. We estimate that the biopharmaceutical partnering and research opportunities represent over a $2&nbsp;billion market annually. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Platform and Technologies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use combinations of tumor, immune and host profiling, radiological imaging, patient clinical profiling, and our proprietary AI platform, the
Diagnostic Cortex, to provide a holistic view of each patient&#146;s dynamic disease state. The Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of clinical diagnostic tests, which we believe overcomes
standard machine learning challenges faced in life sciences research. We employ multiple technologies, as illustrated below, including genomics, proteomics, transcriptomics, and radiomics, generated by different assay techniques, including Droplet
Digital<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> (ddPCR), next generation sequencing (NGS), liquid chromatography mass spectrometry <FONT STYLE="white-space:nowrap">(LC-MS),</FONT>
<FONT STYLE="white-space:nowrap">enzyme-linked</FONT> immunosorbent assay (ELISA), and our proprietary DeepMALDI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mass spectrometry platform for the blood-based molecular analysis of the
tumor, immune system, and host-status of each patient and/or clinical dataset. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g45j20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Competitive Advantages </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the following are our key competitive advantages: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our proprietary extensively validated deep learning platform, which is tailored to discover clinical diagnostics
that address clinical unmet needs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our data-driven approach to precision medicine combined with our data biobank, which enables us to accelerate
development of new tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our leadership in clinical proteomics, demonstrated research, development, and scientific expertise, combined
with our intellectual property portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our demonstrated success commercializing diagnostic tests across a broad continuum of care in lung disease;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our depth and breadth of point of care access to physicians allows us to drive adoption of our diagnostic tests
while incorporating real-life feedback to inform new product development; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our commercial infrastructure, which is built on extensive knowledge and experience in sales, marketing,
reimbursement, and operations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to provide swift, comprehensive and actionable insights to improve patient outcomes across lung disease and to help answer critical
clinical questions faced by physicians, researchers, and biopharmaceutical companies. To achieve this, we intend to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drive increased awareness, adoption, and reimbursement coverage of our diagnostic tests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Deepen our relationships with current biopharmaceutical customers and establish new customer opportunities;
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Introduce new diagnostic tests in lung disease; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Further demonstrate the clinical utility and economic benefits of our diagnostic tests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enhance our proprietary AI platform and expand our technology portfolio; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continue to leverage and expand our biobank. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COVID-19 Pandemic </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The COVID-19 pandemic
has disrupted, and we expect will continue to disrupt, our operations. To protect the health and well-being of our workforce, partners, vendors and customers, we provide voluntary COVID-19 testing for employees working on-site, implemented social
distance and building entry policies at work, restricted travel and facility visits, and followed the States of Colorado and Kansas&#146; public health orders and the guidance from the Centers for Disease Control and Prevention. Employees who can
perform their duties remotely are asked to work from home and those on site are asked to follow our social distance guidelines. Our sales, marketing and business development efforts have also been constrained by our operational response to the
COVID-19 pandemic due to travel restrictions. We expect to continue to adjust our operational norms in an effort to help slow the spread of COVID-19 in the coming months, including complying with government directives and guidelines as they are
modified and supplemented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The COVID-19 pandemic also has started to negatively affect, and we expect will continue to negatively affect,
our non-COVID-19 testing-related revenue and our clinical studies. For example, cancer patients may have more limited access to hospitals, healthcare providers and medical resources as they take steps to control the spread of COVID-19. Our
biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized. As a result of the COVID-19 pandemic, beginning in the latter half of March
2020, we have been receiving fewer samples for non-COVID-19 testing on a daily average basis from our clinical and biopharmaceutical customers than before the outbreak of the COVID-19 pandemic. Further, our clinical studies, such as our ongoing
INSIGHT study and our recently launched ALTITUDE study, as well as our arrangements with our biopharmaceutical customers, are expected to take longer to complete than what we expected before the outbreak of the COVID-19 pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also experiencing an increase in revenues related to an increase in the demand for our Biodesix WorkSafe testing program. We expect
that our costs to expand capacity for COVID-19 testing will increase for the remainder of 2020 and the first quarter of 2021 and we expect that the revenue that we generate from this expansion will comprise a significant portion of our revenue for
these periods. However, there is no assurance that our COVID-19 testing program will continue to be accepted by the market or that other diagnostic tests, will become more accepted, produce quicker results or are more accurate. Further, the
longevity and extent of the COVID-19 pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant decrease in new infections, due to the availability of vaccines, or otherwise, the need for a COVID-19 diagnostic test could
decrease significantly and this could have an adverse effect on our results of operations and profitability. As a result, the increase in revenue due to any increase in demand for these diagnostic tests may not be indicative of our future revenue.
See &#147;Risk Factors&#148; for a description of how the COVID-19 pandemic may adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preliminary Results for Third Quarter 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following presents our preliminary unaudited estimates of our revenues, operating expenses and net loss for the three months and nine
months ended September 30, 2020, our actual unaudited revenues, operating expenses and net loss for the three months and nine months ended September&nbsp;30, 2019, and our unaudited estimate for cash and cash equivalents as of September&nbsp;30,
2020. Our financial statements as of, and for the three </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
months and nine months ended, September&nbsp;30, 2020 are not yet available and are subject to completion of our financial closing procedures. The following information reflects our preliminary
estimates based on currently available information and is subject to change as we complete our quarter end procedures. We have provided ranges, rather than specific amounts, for revenues, operating expenses and net loss for the periods described
below primarily because we are still in the process of finalizing our financial results as of, and for the three months and nine months ended, September&nbsp;30, 2020. Our final actual reported results may vary from these preliminary estimates and
may not be indicative of our final reported financial results for these periods or for the remainder of 2020. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the three months ended September&nbsp;30, 2020, we estimate that we generated total revenue of
$8.7&nbsp;million to $9.2&nbsp;million compared to $3.9&nbsp;million for the three months ended September&nbsp;30, 2019. For the three months ended September&nbsp;30, 2020, our diagnostic test revenue comprised an estimated 93% of our total revenues
and services revenue comprised an estimated 7% of our total revenues compared to 96% and 4%, respectively, for the three months ended September&nbsp;30, 2019. COVID-19 diagnostic testing revenue comprised $5.3&nbsp;million to $5.6&nbsp;million of
our diagnostic test revenue for the three months ended September&nbsp;30, 2020. We had cash and cash equivalents of $6.5&nbsp;million as of September&nbsp;30, 2020. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the nine months ended September&nbsp;30, 2020, we estimate that we generated total revenue of
$18.1&nbsp;million to $18.5&nbsp;million compared to $16.3&nbsp;million for the nine months ended September&nbsp;30, 2019. For the nine months ended September&nbsp;30, 2020, our diagnostic test revenue comprised an estimated 85% of our total
revenues and services revenue comprised an estimated 15% of our total revenues compared to 78% and 22%, respectively, for the nine months ended September&nbsp;30, 2019. COVID-19 diagnostic testing revenue comprised $6.6&nbsp;million to
$6.9&nbsp;million of our diagnostic test revenue for the nine months ended September&nbsp;30, 2020. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due in large part
to the COVID-19 pandemic, our revenues for the six months ended June&nbsp;30, 2020 were substantially reduced as compared to the six months ended June&nbsp;30, 2019. Total revenues were down 24% for the six month period ended June&nbsp;30, 2020
compared to the six month period ended June 30, 2019 due to shelter-in-place orders which reduced our non-COVID-19 testing revenues by 34%. In the nine months ended September&nbsp;30, 2020, our revenues increased as a result of our COVID-19 testing
program revenue and an increase in non-COVID-19 testing revenue as more shelter-in-place orders were withdrawn and more lung diagnostic testing was undertaken. We estimate that our total revenues increased by 106% to 117% for the third quarter of
2020 compared to the second quarter of 2020 driven largely by increases in revenue from COVID-19 testing and a 25% to 32% increase in non-COVID-19 testing revenues. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the three months ended September&nbsp;30, 2020, we estimate that we incurred total operating expense of $15.5
million to $16.3 million compared to $13.0 million for the three months ended September&nbsp;30, 2019. For the three months ended September&nbsp;30, 2020, we estimate we incurred net losses of $8.8 million to $9.2 million compared to $9.6 million
for the three months ended September 30, 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the nine months ended September 30, 2020, we estimate that we incurred total operating expense of $38.8
million to $39.6 million compared to $39.5 million for the nine months ended September&nbsp;30, 2019. For the nine months ended September 30, 2020, we estimate we incurred net losses of $26.8 million to $27.2 million compared to $24.2 million for
the nine months ended September&nbsp;30, 2019. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information above should be read in conjunction with our financial
statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; for prior periods included elsewhere in this prospectus. Our actual results for the nine months ended
September&nbsp;30, 2020 are not yet available as a result of quarter-end closing and review procedures not being completed and may not necessarily be indicative of the results to be expected for the remainder of 2020 or any future period.
Accordingly, you should not place undue reliance upon these preliminary estimates, which are subject to risks </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and uncertainties, many of which are not within our control. Please see &#147;Risk Factors&#148; and &#147;Special Note Regarding Forward-Looking Statements&#148; for additional information
regarding factors that could result in differences between the preliminary estimates of certain of our financial results presented above and the actual financial results and other information we will report as of and for the nine months ended
September&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks and uncertainties, including those highlighted in the section titled &#147;Risk Factors&#148;
immediately following this prospectus summary. These risks include, without limitation, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we
achieve profitability, we may not be able to sustain it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The commercial success of our current and future diagnostic tests and services depends upon attaining significant
market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may encounter difficulties in managing our growth, which could disrupt our operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we fail to retain sales and marketing personnel and, as we grow, fail to increase our sales and marketing
capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical
companies, our revenue prospects could be reduced. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our commercial success and revenue growth are highly dependent on the demand for, and increased adoption of, our
diagnostic tests, including our <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing program, which are subject to a number of risks and uncertainty. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We need to ensure strong product performance and reliability to maintain and grow our business.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us
vulnerable to supply problems and price fluctuations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters, pandemics, outbreaks, or other similar
events, including a sustained outbreak or second wave of the novel strain of coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could significantly disrupt our business, and negatively impact our business, financial condition and
results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our industry is highly competitive and subject to rapid change, which could make our diagnostic tests and
services obsolete. If we are unable to continue to innovate and expand and enhance our diagnostic tests and service offerings, we could lose customers or market share. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any failure to offer high-quality support for our diagnostic tests and services may adversely affect our
relationships with providers and negatively impact our reputation among patients and providers, which may adversely affect our business, financial condition and results of operations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our,
products or services and business disruption if there are disruptions in our information technology systems, including any security or data privacy breaches or other unauthorized or improper access. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in Delaware in 2005 as Elston Technologies, Inc. Our principal executive offices are located at 2970 Wilderness Place, Suite 100, Boulder, Colorado 80301, and our telephone number is (303)
<FONT STYLE="white-space:nowrap">417-0500.</FONT> On June&nbsp;20, 2006, we changed our name to Biodesix, Inc. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is www.biodesix.com. Information contained on, or accessible from, or
hyperlinked to, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; within the meaning of the Jumpstart Our Business Startups Act (JOBS Act). As an emerging growth
company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm
pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, certain requirements related to the disclosure of executive compensation in this prospectus and in our periodic reports and proxy statements, the requirement that we hold a nonbinding
advisory vote on executive compensation and any golden parachute payments, and we have taken advantage of the ability to provide reduced disclosure of financial information in this prospectus, such as being permitted to include only two years of
audited financial information and two years of selected financial information in addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations&#148; disclosure. We may take advantage of these exemptions until we are no longer an emerging growth company. Section&nbsp;107 of the JOBS Act provides that an &#147;emerging growth company&#148; can take advantage of the
extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended (the Securities Act), for complying with new or revised accounting standards. In other words, an &#147;emerging growth company&#148; can delay
the adoption of certain accounting standards until those standards would otherwise apply to private companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take
advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we
will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more
difficult. Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than
$1.07&nbsp;billion in annual revenue; (ii)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at least $700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> (iii)&nbsp;the date on
which we have issued, in any three-year period, more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and (iv)&nbsp;the last day of the fiscal year ending after the fifth anniversary of the
completion of our initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we<I> </I>are<I> </I>a &#147;smaller<I> </I>reporting<I>
</I>company<I>&#148;</I> as defined in Item 10(f)(1) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only
two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&nbsp;the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds
$250&nbsp;million as of the end of that year&#146;s second fiscal quarter, or (ii)&nbsp;our annual revenues exceeded $100&nbsp;million during such completed fiscal year and the market value of our common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the end of that year&#146;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our
financial statements with other public companies difficult or impossible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For certain risks related to our status as an emerging growth
company, see &#147;Risk Factors&#151;Risks Related to our Common Stock and this Offering&#151;We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company,&#148; and the reduced disclosure requirements applicable to emerging
growth companies and smaller reporting companies may make our common stock less attractive to investors.&#148; </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4,000,000 shares</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Over-allotment option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">600,000 shares</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">26,254,072 shares</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We estimate that the net proceeds from the sale of shares of our common stock that we are selling in this offering will be approximately $63.0&nbsp;million (or approximately $73.0&nbsp;million if the underwriters&#146;
over-allotment option is exercised in full), at the initial public offering price of $18.00&nbsp;per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We currently expect to use the net proceeds from this offering: (1)&nbsp;approximately $30&nbsp;million to support our commercial expansion of sales, marketing, reimbursement, customer support and business development;
(2)&nbsp;approximately $16&nbsp;million to support our product pipeline and research and development; (3)&nbsp;approximately $13&nbsp;million to pay a portion of our Integrated Diagnostics acquisition milestone payment; and (4)&nbsp;the remaining
portion of such net proceeds (including if the underwriters exercise their overallotment option in full) for working capital and general corporate purposes. See the section titled &#147;Use of Proceeds&#148; for additional information.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directed share program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At our request, the underwriters have reserved up to 5% of the shares of common stock offered by this prospectus, for sale at the initial
public offering price through a directed share program to certain individuals, including our directors, employees and certain of our existing stockholders. The sales will be made at our direction by Morgan Stanley &amp; Co. LLC and its affiliates
through a directed share program. The number of shares of our common stock available for sale to the general public in this offering will be reduced to the extent that these individuals purchase such reserved shares. Any reserved shares that are not
so purchased will be offered by the underwriters to the general public on the same terms as the other shares of common stock offered by this prospectus. Shares purchased through the directed share program will not be subject to lockup restrictions
with the underwriters, except in the case of shares purchased by any of our officers or directors, employees and certain of our existing stockholders.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">For additional information, see the section titled &#147;Underwriters&#151;Directed Share
Program.&#148;</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market trading symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#147;BDSX&#148;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock that will be outstanding after this offering is based on 22,254,072
shares of our common stock (reflecting the conversion of all of our shares of preferred stock and convertible debt into shares of our common stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) outstanding as of October 15, 2020,
and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,817,440 shares of common stock issuable upon the exercise of outstanding stock options as of October 15, 2020,
with a weighted-average exercise price of $2.80 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">79,104 shares of common stock that will be outstanding upon the vesting of restricted stock units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">103,326 shares of common stock issuable upon the exercise of outstanding warrants to purchase shares of Series G
Preferred Stock as of October&nbsp;15, 2020, with a weighted-average exercise price of $4.46 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,893,395 shares of common stock reserved for future issuance under our 2020 Equity Incentive Plan (the 2020
Incentive Plan), which will become effective immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">338,106 shares of common stock reserved for future issuance under our 2020 Employee Stock Purchase Plan (ESPP),
which will become effective immediately prior to the completion of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, unless we specifically
state otherwise, all information in this prospectus assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a 0.1684664-for-1 reverse stock split, which became effective October&nbsp;19, 2020; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that our amended and restated certificate of incorporation, which we will file in connection with the closing of
this offering, and our amended and restated bylaws adopted in connection with this offering, are effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of all outstanding shares of our preferred stock into an aggregate of 20,090,745 shares of common
stock immediately upon the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of all convertible debt into an aggregate of 1,848,280 shares of common stock immediately upon the
closing of this offering, based on interest accrued through October&nbsp;15, 2020 and the initial public offering price of $18.00 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options or warrants described above; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the underwriters&#146; over-allotment option. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, in addition to the directed share program described in this prospectus, the underwriters have reserved for sale at the initial
public offering price per share approximately 824,000 shares of common stock in this offering to certain individuals, including directors, existing stockholders and other persons associated with us. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY HISTORICAL FINANCIAL AND OPERATING DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth Biodesix, Inc.&#146;s summary historical financial and operating data as of the dates and for the periods
indicated. The summary historical financial and operating data as of June&nbsp;30, 2020 and 2019 and for the six months ended June&nbsp;30, 2020 and 2019 have been derived from our unaudited condensed financial statements included elsewhere in this
prospectus. The summary historical financial and operating data as of December&nbsp;31, 2019 and 2018 and for the years ended December&nbsp;31, 2019 and 2018 have been derived from our audited financial statements included elsewhere in this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary historical financial information is not necessarily indicative of the results that may be expected in any future
period, and our results of operations for any interim period are not necessarily indicative of the results to be expected for the full year. Our preliminary revenues and cash for each of the nine months ended September&nbsp;30, 2020 and
September&nbsp;30, 2019 are included in &#147;&#151;Preliminary Results for Third Quarter 2020.&#148; Such results are preliminary and are subject to change and are not necessarily indicative of the results expected for the full year. The following
summary historical financial and operating data should be read in conjunction with &#147;Capitalization,&#148; &#147;Selected Historical Financial and Operating Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations&#148; and the financial statements and related notes appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations:
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(audited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales, marketing, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of put option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(30,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(26,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(68.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(64.88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(126.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(130.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares outstanding, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of long-term debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(248,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250,564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250,564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(246,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma statement of operations and comprehensive loss data and pro forma balance sheet data give effect
to the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 20,090,745 shares of common stock upon the completion of this offering and the conversion of all convertible debt into an aggregate of 1,848,280 shares
of common stock immediately upon the closing of this offering, based on interest accrued through October&nbsp;15, 2020 and the initial public offering price of $18.00 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma as adjusted information discussed above gives effect to the adjustment described in footnote
(1)&nbsp;and the receipt of $63.0&nbsp;million in net proceeds from our sale of common stock in this offering at the initial public offering price of $18.00 per share, after deducting underwriting discounts and commissions and estimated offering
expenses payable by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of common shares that convertible debt was assumed to convert to was based on our estimated common
stock price as of June&nbsp;30, 2020, as determined by our board of directors with assistance from a valuation firm. The ultimate conversion price will be based on the fair value of our common stock at the completion of this public offering.
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties
described below, as well as other information included in this prospectus, including our financial statements and related notes appearing at the end of this prospectus, before making an investment decision. The risks described below are not the only
ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition and
results of operations. In such case, the trading price of our common stock could decline, and you may lose all or part of your investment. This prospectus also contains forward-looking statements and estimates that involve risks and uncertainties.
Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Business and Industry </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have
a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we achieve profitability, we may not be able to sustain it. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred losses since our inception, and expect to continue to incur losses for the foreseeable future. We have reported net losses of
$18.0&nbsp;million, $30.7 million and $26.2 million for the six months ended June 30, 2020 and for the years ended December 31, 2019 and 2018, respectively. As a result of these losses, as of June 30, 2020, we had $11.7&nbsp;million in cash and cash
equivalents, and an accumulated deficit of approximately $248.8&nbsp;million. Based on our current planned operations, we expect our cash and cash equivalents, together with amounts raised in 2020, including the proceeds from this offering, will
enable us to fund our operating expenses for at least the next twelve months. We have based this estimate on assumptions that in the future may prove to be wrong, and we could use our capital resources sooner than we currently expect. We expect to
continue to incur significant net losses for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this offering, we expect that our sales and marketing,
research and development, regulatory and other expenses will continue to increase as we expand our marketing efforts for our diagnostic tests and services, expand existing relationships with our customers, obtain regulatory clearances or approvals
for future enhancements to our existing diagnostic tests and services and conduct further clinical trials. In addition, we expect our general and administrative expenses to increase following this offering due to the additional costs associated with
scaling our business operations and testing capacity, particularly with respect to our <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic testing capacity, as well as being a public company, including due to legal, accounting, insurance,
exchange listing and compliance, investor relations and other expenses. As a result, we expect to continue to incur operating losses and may never achieve profitability. We will need to generate significant additional revenue in order to achieve and
sustain profitability. Even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. If we do not achieve or sustain profitability, it will be more difficult for us to finance our business and
accomplish our strategic objectives, either of which would have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The commercial success of our current and future diagnostic tests and services and our revenue growth depends upon attaining significant market
acceptance among payers, providers, clinics, patients, and biopharmaceutical companies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part,
on the acceptance of our diagnostic tests and services as being safe and relatively simple for medical personnel to learn and use, clinically flexible, operationally versatile and, with respect to providers and payers, cost effective. We cannot
predict how quickly, if at all, payers, providers, clinics and patients will accept future diagnostic tests and services or, if accepted, how frequently they will be used. These constituents must believe that our diagnostic tests offer benefits over
other available alternatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The degree of market acceptance of our current and future diagnostic tests and services depends on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether there is adequate utilization of our tests by clinicians, biopharmaceutical companies and other target
groups based on the potential and perceived advantages of our diagnostic tests over those of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of use of our diagnostic tests relative to those currently on the market;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to provide incremental data that show the clinical benefits and cost effectiveness, and operational
benefits, of our diagnostic tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the coverage and reimbursement acceptance of our products and services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing pressure, including from group purchasing organizations (GPOs), seeking to obtain discounts on our
diagnostic tests based on the collective bargaining power of the GPO members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative publicity regarding our or our competitors&#146; diagnostic tests resulting from defects or errors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our tests relative to those of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements by the FDA or other regulatory authorities; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations or warnings contained in the labeling cleared or approved by the FDA or other authorities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, even if our diagnostic tests achieve widespread market acceptance, they may not maintain that market
acceptance over time if competing diagnostic tests or technologies, which are more cost effective or are received more favorably, are introduced. Failure to achieve or maintain market acceptance and/or market share would limit our ability to
generate revenue and would have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect
increased revenues from our <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic and antibody testing program over the course of 2020 and the first quarter of 2021, and we expect that such revenue will comprise a significant portion of our
revenue over the same period.&nbsp;However, there is no assurance that our <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic and antibody testing program will continue to be accepted by the market or that other diagnostic tests will become
more accepted, produce quicker results or are more accurate.&nbsp;Further, the longevity and extent of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant
decrease in new infections, due to the availability of vaccines, or otherwise, the need for a <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic test could decrease significantly and this could have an adverse effect on our results of
operation and profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, we had 154 employees. Over the next several years, we expect to increase significantly the number of our employees
and the scope of our operations, particularly in the areas of sales, marketing and reimbursement, product development, regulatory affairs and other functional areas, including finance, accounting, quality and legal. Additionally, we expect to expand
our testing capacity as we commercialize additional diagnostic tests. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational quality and financial systems, expand our facilities and continue to
recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to manage the expansion of our operations or recruit and train additional qualified personnel in an effective manner. Any inability to
manage growth could delay the execution of our business plans or disrupt our operations and have a material and adverse effect on our prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have experienced multiple cycles of growth and anticipate further growth in our business operations. This future
growth could create strain on our organizational, administrative and operational </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
infrastructure, including laboratory operations, quality control, customer service and sales organization management. We expect to continue to increase headcount and to hire more specialized
personnel in the future as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, laboratory personnel, client and account services personnel, and sales and marketing staff and improve and maintain
our technology to properly manage our growth. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in retaining our existing employees, our business may
be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to maintain the quality or expected turnaround times of our diagnostic tests and services, or satisfy
customer demand as it grows. We may not be able to expand our <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing capacity rapidly enough to meet the current and anticipated demand. Our ability to manage our growth properly will require us to
continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain, and failure to complete this in a
timely and efficient manner could materially adversely affect our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to retain sales and marketing personnel and, as we grow,
fail to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited experience marketing and selling our diagnostic tests. We currently rely on our direct sales force to sell our diagnostic tests
in the United States, and any failure to maintain and grow our direct sales force will negatively affect our business, financial condition and results of operations. The members of our direct sales force are highly trained and possess substantial
technical expertise, which we believe is critical in increasing adoption of our diagnostic tests. The members of our United States&nbsp;sales force are <FONT STYLE="white-space:nowrap">at-will</FONT> employees. The loss of these personnel to
competitors, or otherwise, will negatively affect our business, financial condition and results of operations. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical expertise and
qualifications, or if we are unable to successfully instill such technical expertise in replacement personnel, it may negatively affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to generate future growth, we plan to continue to expand and leverage our sales and marketing infrastructure. Identifying and
recruiting qualified sales and marketing personnel and training them on how to promote our diagnostic tests, on applicable federal and state laws and regulations and on our internal policies and procedures requires significant time, expense and
attention. It often takes several months or more before a sales representative is fully trained and productive. Our sales force may subject us to higher fixed costs than those of companies with competing techniques or diagnostic tests that utilize
independent third parties, which could place us at a competitive disadvantage. It will negatively affect our business, financial condition and results of operations if our efforts to expand and train our sales force do not generate a corresponding
increase in revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our diagnostic tests. Any failure to hire, develop and retain talented sales personnel, to achieve desired
productivity levels in a reasonable period of time, or timely reduce fixed costs, could negatively affect our business, financial condition and results of operations. Our ability to increase our customer base and achieve broader market acceptance of
our diagnostic tests will depend to a significant extent on our ability to expand our marketing efforts. We plan to dedicate significant resources to our marketing programs. It will negatively affect our business, financial condition and results of
operations if our marketing efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of our diagnostic tests in a cost-effective manner is critical to
achieving broad acceptance of our diagnostic tests. Promotion activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our
brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness
that is critical for broad use of our diagnostic tests, which in turn could have a material adverse effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical
companies, our revenue prospects could be reduced. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We collaborate with biopharmaceutical companies to analyze patient samples for
multiple applications primarily to support clinical trials, including patient identification, companion or complementary diagnostics and retrospective testing. In the six months ended June 30, 2020 and 2019, revenue from our top biopharmaceutical
customer accounted for 6% and 25% of our total revenue, respectively. In the years ended December 31, 2019 and 2018, revenue from our top biopharmaceutical customer accounted for 21% and 7% of our total revenue, respectively. The revenue
attributable to our biopharmaceutical customers may also fluctuate in the future, which could have a material adverse effect on our financial condition and results of operations. In addition, the termination of these relationships could result in a
temporary or permanent loss of revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future success depends in part on our ability to maintain these relationships and to
establish new relationships. Many factors have the potential to impact such collaborations, including the type of biomarker support required and our ability to deliver it and our biopharmaceutical customers&#146; satisfaction with our tests or
services and other factors that may be beyond our control. Furthermore, our biopharmaceutical customers may decide to decrease or discontinue their use of our tests due to changes in research and product development plans, failures in their clinical
trials, financial constraints, or utilization of internal testing resources or tests performed by other parties, or other circumstances outside of our control. In addition to reducing our revenue, the loss of one or more of these relationships may
reduce our exposure to research and clinical trials that facilitate the collection and incorporation of new information into our biobank and proprietary AI platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We engage in conversations with biopharmaceutical companies regarding potential commercial opportunities on an ongoing basis. There is no
assurance that any of these conversations will result in a commercial agreement, or if an agreement is reached, that the resulting relationship will be successful or that clinical or research studies conducted as part of the engagement will produce
successful outcomes. Speculation in the industry about our existing or potential relationships with biopharmaceutical companies can also be a catalyst for adverse speculation about us, our tests and our technology, which can adversely affect our
reputation and our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and
could cause our operating results to fall below expectations or any guidance we may provide. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our quarterly and annual revenue and
operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. Our quarterly and annual operating results may fluctuate as a result of a variety of factors, many of which are outside our
control and, as a result, may not fully reflect the underlying performance of our business. These fluctuations may occur due to a variety of factors, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for our diagnostic tests, which may vary significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of manufacturing our diagnostic tests, which may vary depending on the quantity of production
and the terms of our agreements with third-party suppliers and manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional tests and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated pricing pressures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate at which we grow our sales force and the speed at which newly hired salespeople become effective, and
the cost and level of investment therein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree of competition in our industry and any change in the competitive landscape of our industry, including
consolidation among our competitors or future partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement policies with respect to lung cancer treatment equipment, and potential future
diagnostic tests that compete with our diagnostic tests; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of clinical trials for our diagnostic tests or any enhancements to such tests
we develop or competing diagnostic tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">positive or negative coverage, or public perception, of our diagnostic tests or those of our competitors or
broader industry trends; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact, if any, of the spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and the resulting effects
on the number of patients treated or the demand for our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-COVID-19</FONT></FONT> diagnostic tests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research, development, licenses, regulatory approval,
commercialization activities, acquisitions and other strategic transactions, or other significant events relating to our diagnostic tests, which may change from time to time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of obtaining regulatory approvals or clearances for planned or future improvements or
enhancements to our diagnostic tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in governmental regulations or in the status of regulatory approvals or applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing, discounts and incentives for our diagnostic tests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we expect increased revenue from our <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic and antibody testing program
over the course of 2020 and the first quarter of 2021, and we expect that such revenue will comprise a significant portion of our revenue over the same period. We can provide no assurances that the demand for our
<FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic and antibody testing program will be sustained, and even if it is, the period of time for which it would be sustained. As a result, the increase in revenue due to any increase in demand for
our <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic and antibody testing program is not indicative of results expected for any future period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual financial results.
As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Further, our historical results are not necessarily indicative of results
expected for any future period, and quarterly results are not necessarily indicative of the results to be expected for the full year or any other period, and accordingly should not be relied upon as indicative of future performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors
for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common
stock could decline substantially. Such a stock price decline could occur even when we have met any publicly stated guidance we may provide, and could in turn negatively impact our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We need to ensure strong product performance and reliability to maintain and grow our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We need to maintain and continuously improve the performance and reliability of our diagnostic tests, including our Biodesix WorkSafe testing
program, the Nodify XL2 and Nodify CDT tests, and the GeneStrat and VeriStrat tests, to achieve our profitability objectives. Poor product performance and reliability could lead to customer dissatisfaction, adversely affect our reputation and
revenues, and increase our service and distribution costs and working capital requirements. Our diagnostic tests may contain errors or defects, and while we have made efforts to test them extensively, we cannot assure that our current diagnostic
tests, or those developed in the future, will not have performance problems. Performance issues with our diagnostic tests will increase our costs in the near-term and accordingly adversely affect our business, financial condition and results of
operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making
us vulnerable to supply problems and price fluctuations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party suppliers, including in some instances single
source suppliers, to provide us with certain components of our diagnostic tests. The number of suppliers feeding into the production of our diagnostic tests is in excess of 65 worldwide. We consider a select few of these suppliers, located in the
United States, Europe and China, as critical single source providers of components. <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> Laboratories, as described below, is the sole source supplier for our GeneStrat tests and <FONT
STYLE="white-space:nowrap">COVID-19</FONT> diagnostic and antibody testing program. Oncimmune is also the sole source supplier for our Nodify CDT tests. While we have initiated the second source qualification process for the majority of these
critical components, we may not be successful in securing second sourcing for all of them at all or on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we
may purchase supplies through purchase orders and may not have long-term supply agreements with, or guaranteed commitments from, many of our suppliers, including single source suppliers. Additionally, at present, we rely on contract manufacturers
for the production of supplies for our diagnostic test. Many of our suppliers and contract manufacturers are not obligated to perform services or supply diagnostic testing materials for any specific period, in any specific quantity or at any
specific price, except as may be provided in a particular purchase order. We depend on our suppliers and contract manufacturers to provide us and our customers with materials in a timely manner that meet our and their quality, quantity and cost
requirements. These suppliers and contract manufacturers may encounter problems during manufacturing for a variety of reasons, any of which could delay or impede their ability to meet our demand. These suppliers and contract manufacturers may cease
producing the components we purchase from them or otherwise decide to cease doing business with us. Further, we maintain limited volumes of inventory from most of our suppliers and contract manufacturers. If we inaccurately forecast demand for
finished goods, we may be unable to meet customer demand which could harm our competitive position and reputation. In addition, if we fail to effectively manage our relationships with our suppliers and contract manufacturers, we may be required to
change suppliers or contract manufacturers. While we believe replacement suppliers exist for all materials, components and services necessary to manufacture our diagnostic tests, establishing additional or replacement suppliers for any of these
materials, components or services, if required, could be time-consuming and expensive, may result in interruptions in our operations and product delivery, may affect the performance of our diagnostic tests or could require that we modify their
processes. Even if we are able to find replacement suppliers, we will be required to verify that the new supplier maintains facilities, procedures and operations that comply with our quality expectations and applicable regulatory requirements. Any
of these events could require that we obtain a new regulatory authority approval before we implement the change, which we may not obtain on a timely basis or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our third-party suppliers fail to deliver the required commercial quantities of materials on a timely basis and at commercially reasonable
prices, and we are unable to find one or more replacement suppliers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality on a timely basis, the continued commercialization of our diagnostic tests,
the supply of our diagnostic tests to customers and the development of any future diagnostic tests will be delayed, limited or prevented, which could have material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a nonexclusive license and supply agreement with <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> in August 2019. We rely on <FONT
STYLE="white-space:nowrap">Bio-Rad</FONT> to supply equipment and reagents used to perform ddPCR testing, a service offered by us under a variety of fee for service agreements and the core technology powering the GeneStrat test. Under the terms of
this arrangement, we were granted <FONT STYLE="white-space:nowrap">non-exclusive</FONT> rights to utilize the intellectual property, machinery, materials, reagents, supplies and <FONT STYLE="white-space:nowrap">know-how</FONT> necessary for the
performance of ddPCR in cancer detection testing for third parties in the United States. We agreed to purchase all of the necessary supplies and reagents for such testing exclusively from <FONT STYLE="white-space:nowrap">Bio-Rad.</FONT> As further
consideration for the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, we agreed to pay a royalty of two and one half percent (2.5%) on net service fees (such fees are defined in the
<FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License Agreement with <FONT STYLE="white-space:nowrap">Bio-Rad)</FONT> collected from contracted third parties who receive ddPCR services from us. In addition, we have separately been granted
permission by Bio-Rad to use the Bio-Rad SARS-CoV-2 ddPCR assay </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Platelia SARS-CoV-2 Total Ab assay for commercial diagnostic services. For more information regarding this license and supply agreement and the permission granted to us by Bio-Rad with
respect to such assays, please see &#147;Business&#151;Material Agreements&#151;Agreements with Bio-Rad.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This relationship may
require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. We cannot be
certain that, following the realization of this relationship, we will achieve the revenue or specific net income that justifies our entry into it. Any termination of this relationship, or delays in entering into new strategic partnership agreements
with <FONT STYLE="white-space:nowrap">Bio-Rad,</FONT> could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to sufficiently reduce costs in the performance, manufacturing and production of our diagnostic tests to achieve sustainable gross
margins. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We partner with contract manufacturers in the development and production of supplies for our diagnostic tests. While we
are undertaking a number of initiatives designed to reduce the cost of performing our diagnostic tests, including reducing the costs of supplies, there is no guarantee that we will be able to achieve planned cost reductions from our various cost
savings initiatives. There may also be unforeseen occurrences that increase our costs, such as increased prices of the components of our diagnostic tests, changes to labor costs or less favorable terms with third-party suppliers or contract
manufacturing partners. If we are unable to reduce our costs, or if cost reductions are less significant or less timely than projected, we will not be able to achieve sustainable gross margins, which would adversely affect our ability to invest in
and grow our business and adversely impact our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A pandemic, epidemic or outbreak of an
infectious disease in the United States or worldwide, including the outbreak of the novel strain of coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide, our business may be adversely affected. <FONT
STYLE="white-space:nowrap">COVID-19</FONT> has spread to most countries and throughout the United States. Numerous state and local jurisdictions have imposed, and others in the future may impose, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;shelter-in-place&#148;</FONT></FONT> orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of <FONT STYLE="white-space:nowrap">COVID-19.</FONT>
In March&nbsp;2020, the Governor of Colorado, where our headquarters are located, issued &#147;stay at home&#148; orders limiting <FONT STYLE="white-space:nowrap">non-essential</FONT> activities, travel and business operations. Such orders or
restrictions have resulted in reduced operations at our headquarters, work stoppages, slowdowns and delays, travel restrictions and cancellation of events. Other disruptions or potential disruptions include the inability of our suppliers to
manufacture components and parts and to deliver these to us on a timely basis, or at all; disruptions in our production schedule and ability to assemble diagnostic tests; inventory shortages or obsolescence; delays in actions of regulatory bodies;
diversion of or limitations on employee resources that would otherwise be focused on the operations of our business; delays in growing or reductions in our sales organization, including through delays in hiring,
<FONT STYLE="white-space:nowrap">lay-offs,</FONT> furloughs or other losses of sales representatives; business adjustments or disruptions of certain third parties, including suppliers, medical institutions and clinical investigators with whom we
conduct business; and additional government requirements or other incremental mitigation efforts that may further impact our or our suppliers&#146; capacity to manufacture our diagnostic tests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic also has started to negatively affect, and we expect will continue to negatively
affect, our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-COVID-19</FONT></FONT> testing-related revenue and our clinical studies. For example, cancer patients may have more limited access to hospitals, healthcare providers
and medical resources as they take steps to control the spread of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Our biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical trials to advance their
pipelines, for which our tests could be utilized.&nbsp;As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, beginning in the latter half of March 2020, we have been receiving fewer samples for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-COVID-19</FONT></FONT> testing on a daily average basis from our clinical and biopharmaceutical customers than before the outbreak of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic.&nbsp;Further, our clinical studies, such as our ongoing INSIGHT study and our recently launched ALTITUDE study, as well as our arrangements with our biopharmaceutical customers, are expected
to take longer to complete than what we expected before the outbreak of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has also created an opportunity for
our diagnostic tests and we have commercialized two diagnostic tests to test for the presence of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and antibodies. We are expecting to increase our testing capacity for our <FONT
STYLE="white-space:nowrap">COVID-19</FONT> diagnostic and antibody testing program in the near term to meet the rising demand for rapid and accurate testing.&nbsp;We expect that the revenue we generate from this expansion will comprise a significant
portion of our revenue for the remainder of 2020 and the first quarter of 2021.<B></B>&nbsp;However, there is no assurance that our COVID-19 diagnostic and antibody testing program will continue to be accepted by the market or that other diagnostic
tests will become more accepted, produce quicker results or be accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant decrease in new infections, due to the
availability of vaccines, or otherwise, the need for a COVID-19 diagnostic test could decrease significantly and this could have an adverse effect on our results of operations and profitability. As a result, the increase in revenue due to any
increase in demand for these diagnostic tests may not be indicative of our future revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The extent to which the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity and spread of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> and the actions to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its impact, among others. Furthermore there is no assurance that our diagnostic tests will continue to be effective
against the virus in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the potential economic impact brought by, and the duration of, any pandemic, epidemic or outbreak
of an infectious disease, including <FONT STYLE="white-space:nowrap">COVID-19,</FONT> may be difficult to assess or predict, the widespread <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has resulted in, and may continue to result in,
significant disruption of global financial markets and a reduction in our ability to access capital, which could adversely affect our liquidity. In addition, a recession or market correction resulting from the spread of an infectious disease,
including <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could materially affect our business. Such economic recession could have a material adverse effect on our long-term business. To the extent the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#147;Risk Factors&#148; section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters and other similar events, including the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, may significantly disrupt our business, and negatively impact our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A significant portion of our employee base, operating facilities and infrastructure are centralized in Boulder, Colorado and we operate a
laboratory facility in De Soto, Kansas. Any of our facilities may be harmed or rendered inoperable by natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters, including earthquakes, wildfires, floods, nuclear disasters, riots, acts of
terrorism or other criminal activities, infectious disease outbreaks or pandemic events, including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, power outages and other infrastructure failures, which may render it difficult or
impossible for us to operate our business for some period of time. Our facilities would likely be costly to repair or replace, and any such efforts would likely require substantial time. Any disruptions in our operations could adversely affect our
business, financial condition and results of operations and harm our reputation. Moreover, although we have disaster recovery plans, they may prove inadequate. We may not carry sufficient business insurance to compensate for losses that may occur.
Any such losses or damages could have a material adverse effect on our business, financial condition and results of operations. In addition, the facilities of our suppliers and manufacturers may be harmed or rendered inoperable by such natural or <FONT
STYLE="white-space:nowrap">man-made</FONT> disasters, which may cause disruptions, difficulties or otherwise materially and adversely affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any failure to offer high-quality support for our diagnostic tests and services may adversely affect our relationships with providers and negatively
impact our reputation among patients and providers, which may adversely affect our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In implementing and using our diagnostic tests and services, providers depend on our support to resolve issues in a timely manner. We may be
unable to respond quickly enough to accommodate short-term increases in demand for customer support. Increased customer demand for support could increase costs and adversely affect our business, financial condition and results of operations. Our
sales are highly dependent on our reputation and on positive recommendations from our existing patients, care partners, providers and clinics. Any failure to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maintain high-quality customer support, or a market perception that we do not maintain high-quality customer support, could adversely affect our reputation, our ability to sell our diagnostic
tests and services, and in turn our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The sizes of the markets for our diagnostic tests and
services and any future diagnostic tests and services may be smaller than we estimate and may decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our estimates of the annual
total addressable market for our diagnostic tests and services are based on a number of internal and third-party estimates and assumptions, including, without limitation, the assumed prices at which we can sell our diagnostic tests and services in
the market. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing
the predictive accuracy of these underlying factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, our estimates of the annual total addressable market for our diagnostic
tests and services in different market segments may prove to be incorrect. If the actual number of patients who would benefit from our diagnostic tests, the price at which we can sell them or the annual total addressable market for them is smaller
than we have estimated, it may impair our sales growth and negatively affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
industry is subject to rapid change, which could make our solutions and the diagnostic tests we develop and services we offer, obsolete. If we are unable to continue to innovate and improve our diagnostic tests and services we offer, we could lose
customers or market share. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry is characterized by rapid changes, including technological and scientific breakthroughs,
frequent new product introductions and enhancements and evolving industry standards, all of which could make our current diagnostic tests and others we are developing obsolete. Our future success will depend on our ability to keep pace with the
evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent years, there have been numerous advances in technologies
relating to the diagnosis and treatment of cancer. There have also been advances in methods used to analyze very large amounts of molecular information. We must continuously enhance our offerings and develop new and improved diagnostic tests to keep
pace with evolving standards of care. If we do not leverage or scale our sample and data biobank to discover new diagnostic tests or applications or update our diagnostic tests to reflect new scientific knowledge, including about lung cancer
biology, information about new cancer therapies or relevant clinical trials, our diagnostic tests could become obsolete and sales of our current diagnostic tests and any new tests we develop could decline or fail to grow as expected. This failure to
make continuous improvements to our diagnostic tests to keep ahead of those of our competitors could result in the loss of customers or market share that would adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our, products or services and business
disruption if there are any security or data privacy breaches or other unauthorized or improper access. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with various
facets of our business, we collect and use a variety of personal data, such as names, mailing addresses, email addresses, mobile phone numbers, location information, prescription information and other medical information. Any failure to prevent or
mitigate security breaches or improper access to, use, disclosure or other misappropriation of our data or consumers&#146; personal data could result in significant liability under state (e.g., state breach notification and privacy laws such as the
California Consumer Privacy Act (CCPA)), federal (e.g., the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and the Health Information Technology for Economic and Clinical Health Act (HITECH Act)) and international laws (e.g.,
the General Data Protection Regulation (GDPR)). Such an incident may also cause a material loss of revenue from the potential adverse impact to our reputation and brand, affect our ability to retain or attract new users of our diagnostic tests and
services and potentially disrupt our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unauthorized disclosure of sensitive or confidential patient or employee data, including
personally identifiable information, whether through a breach of computer systems, systems failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by
our employees or third parties, could result in negative publicity, legal liability and damage to our reputation. Unauthorized disclosure of personally identifiable information could also expose us to sanctions for violations of data privacy laws
and regulations around the world. To the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and
the further development of our product candidates could be delayed. For example, the loss of or damage to clinical trial data, such as from completed or ongoing clinical trials, for any of our product candidates would likely result in delays in our
marketing approval efforts and significantly increased costs in an effort to recover or reproduce the data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we become more dependent
on information technologies to conduct our operations, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, may increase in frequency and sophistication. These threats pose a risk
to the security of our systems and networks, the confidentiality and the availability and integrity of our data and these risks apply both to us, and to third parties on whose systems we rely for the conduct of our business. Because the techniques
used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently and often are not recognized until launched against a target, we and our partners may be unable to anticipate these techniques or to implement
adequate preventative measures. We have in the past experienced, and may in the future experience security incidents. While no security incidents in the past have had a material adverse effect on our business, financial condition and results of
operations, we cannot predict the impact of any such future events. Further, we do not have any control over the operations of the facilities or technology of our cloud and service providers, including any third party vendors that collect, process
and store personal data on our behalf. Our systems, servers and platforms and those of our service providers may be vulnerable to computer viruses or physical or electronic <FONT STYLE="white-space:nowrap">break-ins</FONT> that our or their security
measures may not detect. Individuals able to circumvent such security measures may misappropriate our confidential or proprietary information, disrupt our operations, damage our computers or otherwise impair our reputation and business. We may need
to expend significant resources and make significant capital investments to protect against security breaches or to mitigate the impact of any such breaches. In addition, to the extent that our cloud and other service providers, experience security
breaches that result in the unauthorized or improper use of confidential data, employee data or personal data, we may not be indemnified for any losses resulting from such breaches. There can be no assurance that we or our third party providers will
be successful in preventing cyber-attacks or successfully mitigating their effects. If we are unable to prevent or mitigate the impact of such security breaches, our ability to attract and retain new customers, patients and other partners could be
harmed as they may be reluctant to entrust their data to us, and we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business or other adverse consequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have significant payer concentration, with a limited number of customers accounting for a substantial portion of our revenues. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six months ended June 30, 2020, Medicare reimbursed to us 60% of our diagnostic test revenue and one healthcare provider accounted for
13% of our total diagnostic test revenue. For the year ended December&nbsp;31, 2019, Medicare reimbursed to us 60% of our diagnostic test revenue and one biopharmaceutical customer accounted for 21% of our total revenue and 71% of our service
revenue. There are risks whenever a large percentage of total revenues are concentrated with a limited number of payers and customers. It is not possible for us to predict the level of demand for our diagnostic tests and services that will be
generated by any of these customers in the future. In addition, revenues from these larger customers may fluctuate from time to time based on these customers&#146; business needs, the timing of which may be affected by market conditions or other
factors outside of our control. These payers and customers could also potentially pressure us to reduce the prices we charge for our diagnostic tests and services, which could have an adverse effect on our margins and financial position and could
negatively affect our revenues and results of operations. If any of our largest payers terminates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its relationship with us or our tests are no longer reimbursable by such payer, such termination could negatively affect our revenues and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our results of operations will be materially harmed if we are unable to accurately forecast customer demand for, and utilization of, our diagnostic
tests and manage our inventory. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To ensure adequate inventory supply, we must forecast inventory needs and manufacture our
diagnostic tests based on our estimates of future demand for our diagnostic tests. Our ability to accurately forecast demand for them could be negatively affected by many factors, including our failure to accurately manage our expansion strategy,
product introductions by competitors, an increase or decrease in customer demand for our diagnostic tests or for those of our competitors, our failure to accurately forecast customer acceptance of new diagnostic tests, unanticipated changes in
general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would
cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for our diagnostic tests, our supply chain, manufacturing partners and/or internal manufacturing team may not
be able to deliver components and diagnostic tests to meet our requirements, and this could result in damage to our reputation, sales growth and customer relationships. In addition, if we experience a significant increase in demand, such as we are
currently experiencing with respect to our <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic and antibody testing program, additional supplies of raw materials or additional manufacturing capacity may not be available when required on
terms that are acceptable to us, or at all, or suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, which will adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience significant disruptions in our information technology systems, our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on our information technology systems for the efficient functioning of our business, including the performance, distribution and
maintenance of our diagnostic tests and services, as well as for accounting, data storage, compliance, purchasing and inventory management. We do not have redundant information technology in all aspects of our systems at this time. Our information
technology systems may be subject to computer viruses, ransomware or other malware, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, damage or interruption
from fires or other natural disasters, hardware failures, telecommunication failures and user errors, among other malfunctions. We could be subject to an unintentional event that involves a third party gaining unauthorized access to our systems,
which could disrupt our operations, corrupt our data or result in release of our confidential information. Technological interruptions would disrupt our operations, including our ability to timely ship and track diagnostic test orders and results,
project inventory requirements, manage our supply chain and otherwise adequately service our customers or disrupt our customers&#146; ability to use our diagnostic tests. In the event we experience significant disruptions, we may be unable to repair
our systems in an efficient and timely manner. Accordingly, such events may disrupt or reduce the efficiency of our entire operation and have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, we carry business interruption coverage to mitigate certain potential losses but this insurance is limited in amount, and we cannot
be certain that such potential losses will not exceed our policy limits. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium
increases or the imposition of large deductible or <FONT STYLE="white-space:nowrap">co-insurance</FONT> requirements, could have a material adverse effect on our business, financial condition and results of operations. We are increasingly dependent
on complex information technology to manage our infrastructure. Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance our existing systems. Failure to maintain or protect our information
systems and data integrity effectively could have a material adverse effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be
required to limit or halt the marketing and sale of our diagnostic tests and services. The expense and potential unavailability of insurance coverage for liabilities resulting from issues with our diagnostic tests and services could harm us and
negatively impact sales. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability as a result of the marketing and sale of our diagnostic
tests and services. For example, we may be sued if our diagnostic tests or services cause or are perceived to cause injury or are found to be otherwise unsuitable during manufacturing, marketing or sale. Any such product liability claim may include
allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. In addition, we may be subject to claims against us even if the apparent injury
is due to the actions of others or the <FONT STYLE="white-space:nowrap">pre-existing</FONT> health of the patient. For example, medical personnel, care partners and patients collect samples for our diagnostic tests. If these medical personnel, care
partners or patients are not properly trained, are negligent or use our diagnostic tests incorrectly, the capabilities of such tests may be diminished or the patient may suffer critical injury. We may also be subject to claims that are caused by the
activities of our suppliers, such as those who provide us with components and <FONT STYLE="white-space:nowrap">sub-assemblies</FONT> for our diagnostic tests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or
halt the marketing and sale of our diagnostic tests and services. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our diagnostic tests and services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">harm to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse impact on the market price of our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exhaustion of any available insurance and our capital resources. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we have adequate product liability insurance, but it may not prove to be adequate to cover all liabilities that we may incur.
Insurance coverage is increasingly expensive. We may not be able to maintain or obtain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our insurance policy contains various exclusions, and we may be
subject to a product liability claim for which we have no coverage. The potential inability to obtain sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the marketing and
sale of our diagnostic tests and services. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain,
sufficient capital to pay such amounts, which would have a material adverse effect on our business, financial condition and results of operations. In addition, any product liability claims brought against us, with or without merit, could increase
our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation in the industry, significantly increase our expenses and reduce product sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face competition from many sources, including larger companies, and we may be unable to compete
successfully. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of lung cancer diagnostic solutions companies in the United States, Europe and Asia. Notable
competitors in the United States include Veracyte, Inc., Guardant Health, Inc., and Foundation Medicine, Inc. These competitors all provide cancer-focused diagnostic tests to hospitals, researchers, clinicians, laboratories and other medical
facilities. Many of these organizations are significantly larger with greater financial and personnel resources than us, and enjoy significantly greater market share and have greater resources than we do. As a consequence, they may be able to spend
more on product development, marketing, sales and other product initiatives than we can. Some of our competitors have: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantially greater name recognition; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broader, deeper or longer-term relations with healthcare professionals, customers and third-party payers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">more established distribution networks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional lines of diagnostic tests and the ability to offer rebates or bundle them to offer greater discounts
or other incentives to gain a competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater experience in conducting research and development, manufacturing, clinical trials, marketing and
obtaining regulatory clearance or approval for diagnostic tests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater financial and human resources for product development, sales and marketing and patent litigation.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our continued success depends on our ability to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">further penetrate the lung disease diagnostic solutions market and increase utilization of our diagnostic tests;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain and widen our technology lead over competitors by continuing to innovate and deliver new product
enhancements on a continuous basis; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effectively manufacture our diagnostic tests and their component parts as well as drive down the cost of
service. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, competitors with greater financial resources than ours could acquire other companies to gain
enhanced name recognition and market share, as well as new technologies or diagnostic tests that could effectively compete with our existing diagnostic tests, which may cause our revenue to decline and would harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, as well as in
acquiring technologies complementary to, or necessary for, development of our diagnostic tests. Because of the complex and technical nature of diagnostic testing and the dynamic market in which we compete, any failure to attract and retain a
sufficient number of qualified employees could materially harm our ability to develop and commercialize our diagnostic tests, which would have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we attain greater commercial success, our competitors are likely to develop diagnostic tests that offer features and functionality similar
to our diagnostic tests that are currently on the market. Improvements in existing competitive diagnostic tests or the introduction of new competitive diagnostic tests may make it more difficult for us to compete for sales, particularly if those
competitive diagnostic tests demonstrate better reliability, convenience or effectiveness or are offered at lower prices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance issues, service interruptions or price increases by our shipping carriers and warehousing
providers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expedited, reliable shipping and delivery services and secure warehousing are essential to our operations. We rely heavily on providers of
transport services for reliable and secure <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-to-point</FONT></FONT> transport of our diagnostic tests to our customers and for tracking of these shipments, and from time to time
require warehousing for our diagnostic tests, sample collection kits and supplies. Should a carrier encounter delivery performance issues such as loss, damage or destruction of any systems, it would be costly to replace such systems in a timely
manner and such occurrences may damage our reputation and lead to decreased demand for our diagnostic tests and increased cost and expense to our business. In addition, any significant increase in shipping or warehousing rates could adversely affect
our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters, civil unrest and disturbances or other service interruptions affecting delivery or warehousing services we use would adversely affect our ability
to process orders for our diagnostic tests on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on commercial courier delivery services to transport samples to our
laboratory facility in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed. Our business depends on our ability to quickly and reliably deliver test results to our customers. Blood samples are
typically received within days from the United States and outside the United States for analysis at our Boulder, Colorado and De Soto, Kansas facilities. Disruptions in delivery service, whether due to labor disruptions, bad weather, natural
disaster, civil unrest or disturbances, terrorist acts or threats or for other reasons could adversely affect specimen integrity and our ability to process samples in a timely manner and to service our customers, and ultimately our reputation and
our business. In addition, if we are unable to continue to obtain expedited delivery services on commercially reasonable terms, our operating results may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost-containment efforts of our customers, purchasing groups and governmental purchasing organizations could have a material adverse effect on our sales
and profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In an effort to reduce costs, many hospitals in the United States have become members of GPOs and Integrated
Delivery Networks (IDNs). GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors and then offer these negotiated prices to affiliated hospitals and other members. GPOs and IDNs typically award contracts on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">category-by-category</FONT></FONT> basis through a competitive bidding process. Bids are generally solicited from multiple providers with the intention of driving down pricing or reducing
the number of vendors. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain new, or maintain existing, contract positions with major GPOs and IDNs. Furthermore, the increasing leverage of
organized buying groups may reduce market prices for our diagnostic tests, thereby reducing our revenue and margins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While having a
contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual
purchase orders. Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN are generally free to purchase from other suppliers. Furthermore, GPO and IDN contracts typically are
terminable without cause by the GPO or IDN upon 60 to 90&nbsp;days&#146; notice. Accordingly, the members of such groups may choose to purchase alternative diagnostic tests due to the price or quality offered by other companies, which could result
in a decline in our revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation and other legal proceedings may adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may become involved in legal proceedings relating to patent and other intellectual property matters, product liability
claims, employee claims, tort or contract claims, federal regulatory investigations, securities class action and other legal proceedings or investigations, which could have an adverse </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in
excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or
both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could have a material adverse effect on our business, financial condition and results of
operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customers&#146; confidence and reduce long-term demand for our diagnostic tests and services, even if the regulatory
or legal action is unfounded or not material to our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain product and professional liability insurance, but this
insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our
insurance rates or prevent us from securing insurance coverage in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General economic and financial market conditions may exacerbate our
business risks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Global macroeconomic conditions and the world&#146;s financial markets remain susceptible to significant stresses,
resulting in reductions in available credit and government spending, economic downturn or stagnation, foreign currency fluctuations and volatility in the valuations of securities generally. As a result of uncertainties with respect to financial
institutions and the global credit markets and other macroeconomic challenges currently or potentially affecting the economy of the United States and other parts of the world, customers and distributors may experience serious cash flow problems and
other financial difficulties, decreasing demand for our products. Our customers and distributors may respond to such economic pressures by reducing or deferring their capital spending or reducing staff. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, events in the United States or foreign markets, such as the United Kingdom&#146;s exit from the European Union, the worldwide
effects from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and political and social unrest in various countries around the world, can impact the global economy and capital markets. Additionally, if our customers and distributors are
not successful in generating sufficient revenue or are precluded from securing financing, their businesses will suffer, which may materially and adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not realize the benefits or costs of our Co-Development and Collaboration Agreement with AVEO Oncology. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2014, we entered into a Co-Development and Collaboration Agreement with AVEO Oncology (formerly known as AVEO Pharmaceuticals, Inc.) (AVEO)
whereby the two parties agreed to various terms and conditions necessary for the co-development of AVEO&#146;s compound ficlatuzumab (the Collaboration Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were granted a limited legal interest in ficlatuzumab and may not have the right to control the development and exploitation of
ficlatuzumab. As consideration for the grant, we agreed to cover the first $15.0 million of ficlatuzumab&#146;s clinical development costs, with both parties then sharing all costs equally after the cap was reached. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October of 2016, the Collaboration Agreement was amended to eliminate the requirement that we cover all of the initial costs. Under the
amended terms, we agreed to allow AVEO to recapture its cost that it otherwise would not have been responsible for said recapture to occur out of any royalties or revenues eventually derived from the Collaboration Agreement. As part of the
Collaboration Agreement, unless we or AVEO exercise our right to opt-out of co-development, we equally share in any income received from licensing rights to ficlatuzumab to any third parties. In September 2020, we exercised our opt-out right for the
payment of half of the development and regulatory costs for ficlatuzumab. This opt-out is effective as of December 2, 2020 with remaining obligations estimated to be $0.3 million. Following the effective date, we will be entitled to a 10% royalty of
net sales of ficlatuzumab and 25% of license income generated from the licensing of ficlatuzumab. Ficlatuzumab is currently being evaluated in squamous cell carcinoma of the head and neck (SCCHN), metastatic
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pancreatic ductal cancer (PDAC), and acute myeloid leukemia (AML). For more information regarding this Collaboration Agreement, please see &#147;Business&#151;Drug Co-Development.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our relationship with AVEO may require us to incur non-recurring and other charges, increase our near and long-term expenditures, or disrupt
our management and business. We cannot be certain that, following the realization of this relationship, we will achieve the revenue or specific net income that justifies our entry into it. Any termination of this relationship, or delays in entering
into new strategic partnership agreements with AVEO, could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are exposed to significant future payments and other obligations associated with our acquisitions of Integrated Diagnostics and Oncimmune, U.S.A.,
and may not realize the advantages we expect from these acquisitions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We purchased select assets and liabilities from Integrated
Diagnostics, Inc. and IND Funding, LLC (collectively, the Seller) which included the Clinical Laboratory Improvement Amendments (CLIA)&nbsp;lab in Seattle, Washington, and all rights to the Nodify XL2 test and intellectual property rights related to
that test. The purchase was made for total consideration of $27.6&nbsp;million, consisting of $8.0&nbsp;million (10,649,604 shares) of our Series&nbsp;G Preferred Stock and contingent consideration with an initial fair market value of
$19.6&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The acquisition of Integrated Diagnostics included a contingent consideration arrangement that requires additional
consideration to be paid by us to the Seller based on the milestone of the attainment of a three consecutive month gross margin target of $2&nbsp;million within a seven-year period. The amount can be payable in stock or cash at our or the
Seller&#146;s option. The total amount of undiscounted contingent consideration which we may be required to pay under the arrangement is $37.0&nbsp;million. For the 6&nbsp;months following the achievement of the milestone, the Seller has the option
to require us to pay the contingent consideration in cash over 8 equal installments due each calendar quarter. If the Seller elects not to exercise this option, we have 12&nbsp;months to either settle the contingent consideration in two equal
quarterly cash installments or in 14,959,114 of Series&nbsp;G Preferred Stock. As of June&nbsp;30, 2020, we have not made any payments in connection with the contingent consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on October&nbsp;31, 2019 we completed an acquisition of United Kingdom-based Oncimmune, Ltd.&#146;s (Oncimmune) United
States&nbsp;operations including its CLIA lab in De Soto Kansas and its incidental pulmonary nodule (IPN)&nbsp;malignancy test, then marketed in the United States as the EarlyCDT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>-Lung. We
renamed the test and relaunched the test on February&nbsp;28, 2020 as the Nodify CDT test and the De Soto, Kansas lab will be the sole United States&nbsp;provider of the Nodify CDT test. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the acquisition, we and Oncimmune entered into several agreements to govern the relationship between the parties and to allow us to
provide the Nodify CDT test. The overarching umbrella Purchase and Commercialization Agreement (PCA)&nbsp;defines the general relationship between the parties. Included under the PCA was (a)&nbsp;an APA&nbsp;whereby we acquired all of the United
States&nbsp;assets associated with the De Soto, Kansas clinical laboratory, as well as the trademarks and patent application associated with the test; (b)&nbsp;an intellectual property license granting us the rights necessary under Oncimmune&#146;s
background intellectual property rights to perform the Nodify CDT test; (c)&nbsp;a supply agreement for supplying us with the necessary materials and reagents needed to run the Nodify CDT test; and (d)&nbsp;a development agreement where Oncimmune
agrees to assist us in further developing the Nodify CDT test. We were also granted an option through December&nbsp;31, 2020 to acquire the rights to expand the field of use of the Nodify CDT test to include lung cancer screening. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the rights granted to us, we agreed to payments of $1.2&nbsp;million and further agreed to an option fee for the
screening option of $9.0&nbsp;million due within 30&nbsp;days of exercising the option. As of June 30, 2020, we have paid $1.0 million of the agreed upon payments. In July 2020, we paid the remaining $0.2 million. We also agreed to a revenue share
payment of 8% of recognized revenue for <FONT STYLE="white-space:nowrap">non-screening</FONT> tests up to an annual minimum volume and 5%&nbsp;thereafter, with an escalating minimum through the first four years of sales. Royalty payments of
$0.1&nbsp;million were paid for the six months ended June&nbsp;30, 2020. In September 2020, we notified Oncimmune that we would not exercise this option for expansion of the field of use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our acquisitions may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT>
and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. We cannot be certain that, following the realization of these acquisitions, we will
achieve the revenue or specific net income that justifies our entry into them. This could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain
personnel necessary for our success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on our senior management and other key personnel. Our success will
depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales and marketing professionals, scientists, clinical specialists, and other highly skilled personnel and to integrate current
and additional personnel in all departments. The loss of members of our senior management, sales and marketing professionals, scientists, clinical and regulatory specialists could result in delays in product development and harm our business. If we
are not successful in attracting and retaining highly qualified personnel, it would have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development programs and laboratory operations depend on our ability to attract and retain highly skilled scientists and
technicians. We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses, particularly near our headquarters in Boulder, Colorado and our
laboratory facility in De Soto, Kansas. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting or
retaining qualified sales people. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. To induce valuable employees to remain at our company, in addition to salary and cash
incentives, we have issued and may continue to issue equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at
any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice.
Our employment arrangements with our employees provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could leave our employment at any time, with or without notice. We also do not maintain
&#147;key man&#148; insurance policies on the lives of these individuals or the lives of any of our other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our corporate culture has
contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovation, creativity and teamwork fostered by our culture and our business may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our culture has been and will continue to be a critical contributor to our success. We expect to continue to hire aggressively
as we expand, and we believe our corporate culture has been crucial in our success and our ability to attract highly skilled personnel. If we do not continue to develop our corporate culture or maintain and preserve our core values as we grow and
evolve, we may be unable to foster the innovation, curiosity, creativity, focus on execution, teamwork and the facilitation of critical knowledge transfer and knowledge sharing we believe we need to support our growth. Moreover, liquidity available
to our employee securityholders following this offering could lead to disparities of wealth among our employees, which could adversely impact relations among employees and our culture in general. Our anticipated headcount growth and our transition
from a private company to a public company may result in a change to our corporate culture, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to utilize
our net operating loss carryforwards and research and development credit may be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Sections&nbsp;382 and
383 of the Internal Revenue Code of 1986, as amended (the Code)&nbsp;a corporation that undergoes an ownership change, generally defined as a greater than 50% change by value in its equity ownership by certain shareholders over a three-year period,
is subject to limitations on its ability to utilize its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating losses (NOLs) and its research and development credit carryforwards to offset future
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
taxable income. The applicable rules generally operate by focusing on changes in ownership among stockholders considered by the rules as owning, directly or indirectly, 5% or more of the stock of
a company, as well as changes in ownership arising from new issuances of stock by the company. We believe that our NOLs are currently not subject to limitation under these rules. However, if we undergo an ownership change now or in the future
(including in connection with this offering), our ability to utilize NOLs and research and development credit carryforwards could be limited by Sections&nbsp;382 and 383 of the Code. Future changes in stock ownership may be beyond our control. In
addition, our ability to deduct net interest expense may be limited if we have insufficient taxable income for the year during which the interest is incurred, and any carryovers of such disallowed interest would be subject to the limitation rules
similar to those applicable to NOLs and other attributes. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the NOLs, research and development credit carryforwards or disallowed
interest expense carryovers, even if we attain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The terms of our secured credit agreement require us to meet certain operating and
financial covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, we entered into an agreement with Innovatus Life Sciences Lending Fund to refinance long-term debt carried over from earlier
loan agreements (the 2018 Notes). The initial amount borrowed under the 2018 Notes was $23&nbsp;million and the maturity date is February&nbsp;2023. We are required to make quarterly interest payments that began in June 2018 and outstanding
principal is due in 24 equal installments commencing in March&nbsp;2021. The agreement has been amended multiple times to adjust terms to account for our acquisitions and growth. Further, we granted the lender a security interest in all of our
assets through a pledge and security agreement, patent security agreement and trademark security agreement, each between us and the lender. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loan may be prepaid by us at any time, subject to a prepayment penalty of up to 3% of the principal amount, depending on the date of
prepayment. Upon payment of the 2018 Notes at maturity or prepayment on any earlier date, unless waived, a 2% <FONT STYLE="white-space:nowrap">back-end</FONT> facility fee will apply to the amounts paid or prepaid. The 2% fee is being recorded as
additional interest expense over the term of the 2018 Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 Notes contain customary affirmative and negative covenants for a
loan, requires us to comply with a minimum daily liquidity covenant, and has a rolling monthly revenue requirement. Failure to comply with the covenants and loan requirements may result in early amortization of the loan in a <FONT
STYLE="white-space:nowrap">24-</FONT> or <FONT STYLE="white-space:nowrap">36-month</FONT> payment schedule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 Notes also contain
certain covenants that prevent us from making acquisitions, incurring additional indebtedness, or making or terminating any agreement valued above a certain dollar threshold without the prior written consent of the lender. These covenants may
restrict our ability to pursue new business opportunities and access additional capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a default, including, among
other things, our failure to make any payment when due or our failure to comply with any covenant under the 2018 Notes, the lender could elect to declare all amounts outstanding to be immediately due and payable, and could proceed against the
collateral granted to them to secure such indebtedness, including all of our intellectual property, which could have a material adverse effect on our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to raise additional capital to fund our existing operations, develop our platform, commercialize new diagnostic tests or expand our
operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need to raise additional capital in the future to expand our business, to pursue strategic investments, to
take advantage of financing opportunities or for other reasons, including to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increase our sales and marketing efforts to drive market adoption of and address competitive developments;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fund development and marketing efforts of our diagnostic tests or any other future diagnostic tests;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our technologies into other types of cancer management and lung disease detection diagnostic tests;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire, license or invest in technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or invest in complementary businesses or assets; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">finance capital expenditures and general and administrative expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our present and future funding requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve revenue growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our rate of progress in establishing payer coverage and reimbursement arrangements with domestic and
international commercial third-party payers and government payers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of expanding our laboratory operations and offerings, including our sales and marketing efforts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our rate of progress in, and cost of the sales and marketing activities associated with, establishing adoption of
and reimbursement for our diagnostic tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our rate of progress in, and cost of research and development activities associated with, diagnostic tests in
research and early development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to international expansion; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential cost of and delays in product development as a result of any regulatory oversight applicable to our
diagnostic tests. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The various ways we could raise additional capital carry potential risks. If we raise funds by
issuing equity securities, our stockholders could experience dilution. Any preferred equity securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt
securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on
our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or diagnostic tests, pay a portion of our royalties, or grant licenses on terms
that are not favorable to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may acquire other businesses, which could require significant management attention, disrupt our business, dilute
stockholder value and adversely affect our results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our business strategy, we may in the future make
additional acquisitions or investments in complementary companies, diagnostic tests or technologies that we believe fit within our business model and can address the needs of our customers and potential customers. In the future, we may not be able
to acquire and integrate other companies, diagnostic tests or technologies in a successful manner. We may not be able to find suitable acquisition candidates, and we may not be able to complete such acquisitions on favorable terms, if at all. In
addition, the pursuit of potential acquisitions may divert the attention of management and cause us to incur additional expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. If we do complete
acquisitions, we may not ultimately strengthen our competitive position or achieve our goals, including increases in revenue, and any acquisitions we complete could be viewed negatively by our customers, investors and industry analysts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future acquisitions may reduce our cash available for operations and other uses and could result in amortization expense related to
identifiable assets acquired. We may have to pay cash, incur debt or issue equity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities to pay for any such acquisition, each of which could adversely affect our financial condition or the value of our common stock. The sale or issuance of equity to finance any such
acquisitions would result in dilution to our stockholders. The incurrence of indebtedness to finance any such acquisition would result in fixed obligations and could also include covenants or other restrictions that could impede our ability to
manage our operations. In addition, our future results of operations may be adversely affected by the dilutive effect of an acquisition, performance earn-outs or contingent bonuses associated with an acquisition. Furthermore, acquisitions may
require large, onetime charges and can result in increased debt or contingent liabilities, adverse tax consequences, additional stock-based compensation expenses and the recording and subsequent amortization of amounts related to certain purchased
intangible assets, any of which items could negatively affect our future results of operations. We may also incur goodwill impairment charges in the future if we do not realize the expected value of any such acquisitions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize, or such strategic alliance, joint
venture or acquisition may be prohibited. For example, our 2018 Notes restrict our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. Additionally, future acquisitions or
dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot
predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Governmental Regulation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
insurance coverage and reimbursement status of newly approved diagnostic tests, particularly in a new category of diagnostics and therapeutics, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future
diagnostic tests could limit our ability, and that of our collaborators, to fully commercialize our diagnostic tests and decrease our ability to generate revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford the
clinical diagnostic tests and cellular therapeutics that we and our collaborators currently or in the future plan to develop and sell. In addition, because our clinical diagnostics and diagnostic tests represent new approaches to the research,
diagnosis, detection and treatment of diseases, we cannot accurately estimate how our diagnostic tests, and those jointly created with our collaborators, would be priced, whether reimbursement could be obtained or any potential revenue generated.
Sales of our diagnostic tests will depend substantially, both domestically and internationally, on the extent to which the costs of our diagnostic tests are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management
organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payers. If reimbursement is not available, or is available only to limited levels, we may not be able to
successfully commercialize some of our diagnostic tests or services. Even if coverage is provided, the available reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our
investment in any of our diagnostic tests or services. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our diagnostic tests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly launched, cleared, authorized or approved
diagnostic tests. In the United States, many significant decisions about reimbursement for new diagnostics and medicines are typically made by the Centers for Medicare and Medicaid Services (CMS), an agency within the Department of Health and Human
Services (HHS). CMS decides whether and to what extent a new diagnostic or medicine will be covered and reimbursed under Medicare, although it frequently delegates this authority to local Medicare Administrative Contractors (MACs). Private payers
tend to follow Medicare to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel diagnostic tests such as ours. Additionally, reimbursement agencies in Europe may be more conservative than
CMS.&nbsp;For example, a number of cancer drugs have been approved for reimbursement in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the United States and have not been approved for reimbursement, or have been approved under restricted conditions, in certain European countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, the reimbursement process and timelines vary significantly. Certain countries, including a number of member states
of the EU, set prices and make reimbursement decisions for diagnostics and pharmaceutical products, or medicinal products, as they are commonly referred to in the EU, with limited participation from the marketing authorization or Conformit&eacute;
Europ&eacute;enne (CE)&nbsp;mark holders, or may take decisions that are unfavorable to the authorization or CE mark holder where they have participated in the process. We cannot be sure that such prices and reimbursement decisions will be
acceptable to us or our collaborators. If the regulatory authorities in these foreign jurisdictions set prices or make reimbursement criteria that are not commercially attractive for us or our collaborators, our revenues and the potential
profitability of our products in those countries would be negatively affected. An increasing number of countries are taking initiatives to attempt to control the healthcare budget by focusing cost-cutting efforts on medicinal products, and to a
lesser extent, medical devices, provided under their <FONT STYLE="white-space:nowrap">state-run</FONT> healthcare systems. These international price control efforts have impacted all regions of the world, but have been most prominent in the EU.
Additionally, some countries require approval of the sale price of a product before it can be marketed or mandatory discounts or profit caps may be applied. Further, after the sale price is approved, it remains subject to review during the product
lifecycle. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. As a result, we or our collaborators might obtain marketing approval for a product or service in a
particular country, but then may experience delays in the reimbursement approval or be subject to price regulations that would delay the commercial launch of our product or service, possibly for lengthy time periods, which could negatively impact
the revenues we are able to generate from the sale of that product or service in that particular country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by
governmental and third-party payers, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for newly cleared, authorized or approved devices and medicines
and, as a result, they may not cover or provide adequate payment for our clinical diagnostics to be sold by us or our collaborators. For example, in May 2018 the United States&nbsp;government released a &#147;blueprint,&#148; or plan, to reduce the
cost of drugs. This blueprint contains certain measures that HHS has been working to implement. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological
pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, which are, in some cases, designed to encourage importation from other
countries and bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to experience pricing pressures on our clinical diagnostics sold by us and our collaborators due
to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical
procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new diagnostic tests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Measures to reduce healthcare costs may hurt our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of our customers are healthcare providers who depend upon reimbursement by government and commercial insurance payers for lung
cancer diagnostic solutions services. With a vast majority of United States patients with lung cancer covered by Medicare, the Medicare reimbursement rate is an important factor in a customer&#146;s decision to use our diagnostic tests and limits
the prices we may charge for them. Commercial insurance payers may also exert downward pressure on payment rates for lung cancer treatment services. A reduction in reimbursement rates for lung cancer treatments may adversely affect our
customers&#146; businesses and cause them to enact cost reduction measures that may include reducing the scope of their programs, thereby potentially reducing demand for our diagnostic tests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare reform measures could hinder or prevent the commercial success of our diagnostic tests.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to
the healthcare system in ways that may harm our future revenues and profitability and the demand for our diagnostic tests. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the
healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower
reimbursement for the procedures associated with the use of our diagnostic tests. The effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our diagnostic tests. For example, the Patient
Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), contains a number of provisions, including those governing enrollment in federal healthcare programs,
reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been judicial challenges to certain aspects of the ACA, as well as efforts by the Trump administration and Congress to repeal,
replace or alter the implementation of certain aspects of the ACA. For example, Congress eliminated the tax penalty, starting January&nbsp;1, 2019, for not complying with the ACA&#146;s individual mandate to carry health insurance. The Further
Consolidated Appropriations Act of 2020, Pub. L. <FONT STYLE="white-space:nowrap">No.&nbsp;116-94,</FONT> signed into law December&nbsp;20, 2019, fully repealed the ACA&#146;s &#147;Cadillac Tax&#148; on certain high cost employer-sponsored
insurance plans, the annual fee imposed on certain health insurance providers based on market share (repeal effective in 2021), and the medical device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. On
December&nbsp;14, 2018, a Texas&nbsp;District Court Judge invalidated the ACA in its entirety because he concluded that the individual mandate, which was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017 (TCJA), is unconstitutional
and cannot be severed from the remainder of the ACA. The Fifth Circuit Court of Appeals affirmed the district court&#146;s ruling that the individual mandate was unconstitutional, but it remanded the case back to the district court for further
analysis of whether the mandate could be severed from the ACA; that is,, whether the entire ACA was therefore also invalid). The Supreme Court of the United States granted certiorari on March&nbsp;2, 2020, and the case is expected to be decided by <FONT
STYLE="white-space:nowrap">mid-2021.</FONT> It is unclear how this decision, subsequent appeals, and other efforts to challenge, repeal, or replace, or alter the implementation of the ACA will affect our business, financial condition and results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget
Control Act of 2011, among other things, included reductions to CMS payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through
2030 unless additional Congressional action is taken, with the exception of a temporary suspension of the 2% cut in Medicare payments from May&nbsp;1, 2020 through December&nbsp;31, 2020. Additionally, the American Taxpayer Relief Act of 2012, among
other things, reduced CMS payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trump administration and Congress may continue to pursue significant changes to the current healthcare laws. We face uncertainties that
might result from modifications or repeal of any of the provisions of the ACA, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the medical device
industry as a whole is currently unknown. Any changes to the ACA are likely to have an impact on our results of operations, and may negatively affect our business, financial condition and results of operations. We cannot predict what other
healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain
or reduce costs of healthcare may harm: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to set a price that we believe is fair for our diagnostic tests; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts our
industry. Future changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions. Future changes in healthcare policy could also
decrease our revenue and impact sales of and reimbursement for our current and future diagnostic tests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We must comply with anti-corruption,
anti-bribery, anti-money laundering and similar laws. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the Foreign Corrupt Practices Act of 1977 (FCPA), which
generally prohibits companies in the United States&nbsp;from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business and requires companies to maintain accurate books and records and
internal controls. We are also subject to requirements under the United States&nbsp;Treasury Department&#146;s Office of Foreign Assets Control, United States&nbsp;domestic bribery laws and other anti-corruption, anti-bribery and anti-money
laundering laws. While we have policies and procedures in place designed to promote compliance with such laws, our employees or other agents may nonetheless engage in prohibited conduct under these laws for which we or our executives might be held
responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have an adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, international customers may currently order our diagnostic tests, either directly from us or through a potential joint venture,
and we are subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to <FONT STYLE="white-space:nowrap">non-United</FONT> States government officials for the purpose of obtaining or retaining
business or securing any other improper advantage. Our reliance on independent distributors to sell our diagnostic tests internationally demands a high degree of vigilance in maintaining our policy against participation in corrupt activity, because
these distributors could be deemed to be our agents and we could be held responsible for their actions. Other United States&nbsp;companies in the medical device and biopharmaceutical field have faced criminal penalties under the FCPA for allowing
their agents to deviate from appropriate practices in doing business with these individuals. We are also subject to similar anti-bribery laws in the jurisdictions in which we operate, including laws promulgated by OECD countries in which we operate,
such as Israel. These laws are complex and <FONT STYLE="white-space:nowrap">far-reaching</FONT> in nature, and, as a result, we cannot assure you that we would not be required in the future to alter one or more of our practices to be in compliance
with these laws or any changes in these laws or the interpretation thereof. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and
expenses, including legal fees and could result in a material adverse effect on our business, prospects, financial condition and results of operations. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and
other remedial measures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We must comply with healthcare fraud and abuse laws. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various federal and state laws, as well as the laws of foreign countries, prohibit payments to induce the referral, purchase, order or use of
healthcare products or services and require medical device companies to limit prevent, and/or monitor, and report certain payments to third-party payers, health care professionals, and other individuals. These healthcare fraud and abuse
anti-kickback, public reporting and aggregate spend laws affect our sales, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with lung cancer treatment providers,
hospitals, physicians or other potential purchasers or users, including patients, of medical devices and services. They also impose additional administrative and compliance burdens on us. In particular, these laws influence, among other things, how
we structure our sales offerings, including discount practices, customer support, education and training programs and physician </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consulting and other service arrangements. These laws prohibit certain marketing initiatives that are commonplace in other industries. If we were to offer or pay inappropriate inducements for the
purchase, order or use of our diagnostic tests or our services, or our arrangements are perceived as inappropriate inducements, we could be subject to claims under various healthcare fraud and abuse laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restrictions under applicable United States federal and state healthcare laws and regulations include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, a criminal law, prohibits, among other things, persons and entities from
knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, leasing, ordering, or arranging for, referring, or recommending the purchase, lease,
order of any good or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Eliminating Kickbacks in Recovery Act, which prohibits knowingly and willfully soliciting, receiving,
offering or paying remuneration, directly or indirectly, in return for the referral of a patient to, or in exchange for an individual using the services of certain entities, including laboratories, if the services are covered by a health care
benefit program; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Beneficiary Inducement Statute, which prohibits any person, organization, or entity from giving anything of
value to a federal health care program beneficiary that is likely to induce or influence the beneficiary&#146;s choice of provider, practitioner, or supplier for covered services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil False Claims Act, which may be enforced through civil whistleblower or <I>qui tam</I> actions
and is often used to enforce the federal Anti-Kickback Statute and other healthcare laws and regulations, imposes civil penalties and potential exclusion from federal healthcare programs, against individuals or entities for, among other things,
knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or for making a false record or statement material to an obligation to pay the federal government or for knowingly and
improperly avoiding, decreasing or concealing an obligation to pay money to the federal government; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal criminal statutes created by HIPAA impose criminal liability for, among other things, knowingly and
willfully executing or attempting to execute a scheme to defraud any healthcare benefit program, including private insurance plans, or, in any matter involving a healthcare benefit program, for knowingly and willfully making materially false,
fictitious, or fraudulent statements in connection with the delivery of or payment for health care benefits; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to
sales or marketing arrangements and claims involving healthcare items or services reimbursed <FONT STYLE="white-space:nowrap">by&nbsp;non-governmental&nbsp;third-party</FONT> payers, including private insurers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other federal and state laws, as well as the laws of foreign countries, generally prohibit individuals or entities from knowingly presenting,
or causing to be presented, claims for payments to government or commercial payers that are false or fraudulent, or for items or services that were not provided as claimed. Efforts to ensure that our business arrangements with third parties will
comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law
involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil,
criminal and administrative penalties, damages, fines, imprisonment, exclusion of product candidates and medical devices from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm,
diminished profits and future earnings, and the curtailment or restructuring of our operations. Moreover, any investigation into our practices could cause adverse publicity and require a costly and time-consuming response. If any physicians or other
healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare
programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers can also be held liable under these laws if they are deemed to &#147;cause&#148;
the submission of false or fraudulent claims by providing inaccurate billing or coding information to customers, by providing improper financial inducements, or through certain other activities. We attempt to ensure that any billing and coding
information we provide for our diagnostic tests emphasizes the need for physicians and other providers to make independent judgments, use accurate and appropriate billing and coding that complies with all applicable payer policies, and document the
medical need for their patients as appropriate. Nevertheless, the government may not regard any billing errors that may be made by our customers as inadvertent and may examine our role in providing information to our customers, physicians and
patients concerning the benefits and potential coverage of more frequent therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA regulation of our industry generally or our tests
specifically could be disruptive to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are subject to extensive federal, state, local and foreign laws
and regulations, including FDA laws and regulations, all of which are subject to change. These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. We believe that we are in material compliance
with all statutory and regulatory requirements applicable to us, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False
Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private
third-party payers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has recently increased its attention to marketing of pharmacogenetic tests. For example, in late 2018, the
FDA issued a safety communication regarding genetic laboratory tests with claims to predict a patient&#146;s response to specific medications that have not been reviewed by the FDA and may not be supported by clinical evidence. Among other tests,
the FDA notice cited genetic tests that claim results can be used to help physicians identify which antidepressant medication would have increased effectiveness or side effects compared to other antidepressant medications. As explained by the FDA in
its update to this safety communication, the FDA sent notices to several firms marketing such pharmacogenetic tests where the FDA believes the relationship between genetic variations and the medication&#146;s effects has not been established,
including a warning letter sent to a laboratory, in part, for failing to obtain premarket review of its test. HHS recently issued an announcement stating that the FDA cannot require premarket review of any LDT without engaging in formal <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">notice-and-comment</FONT></FONT> rulemaking, as opposed to through guidance documents, compliance manuals, website statements, or other informal issuances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The HHS announcement was made on the Department&#146;s website and we can provide no assurances that the HHS statement will not be rescinded
or revised or that it would preclude the FDA from renewing its attention on diagnostic tests, including those that we provide. If this were to happen, it may impact our marketing practices relating to the relevant tests, which in turn may have an
adverse impact on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> tests we perform are currently the subject of EUAs, which permit the use of unapproved medical products or unapproved uses of medical products to be used in an emergency to diagnose, treat, or
prevent serious or life-threatening diseases or conditions when there are no adequate, approved, and available alternatives, as provided under section 564 for the Federal Food, Drug, and Cosmetic Act (FDCA).&nbsp;EUAs are temporary authorizations
that are revoked at the end of the public health emergency, when there is an adequate, approved, or available alternative, or when there are performance or safety concerns.&nbsp;These EUAs also set out conditions for laboratories who are authorized
to perform the particular test. The HHS statement mentioned above did not affect EUAs for COVID-19 laboratory-developed tests that were already in effect at the time the statement was released. The HHS statement did not affect EUAs issued for
commercially-developed COVID-19 IVD tests, which apply to test developers and authorized laboratories.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EUA for <FONT
STYLE="white-space:nowrap">Bio-Rad&#146;s</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Droplet Digital PCR test provides several conditions for authorized laboratories, including that the test
result reports will include Fact Sheets that are authorized as part of the EUA, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deviations from the authorized procedures, including specimen types, are not permitted, notification of public health authorities of intent to run the test prior to initiating testing, collection
and reporting of performance data to the FDA, including false positives, false negatives, and significant deviations from the established performance characteristics, and appropriate training and protective equipment for laboratory staff.&nbsp;This
EUA also states that authorized laboratories must maintain records associated with the EUA and be made available to the FDA for inspection upon request.&nbsp;Printed materials, advertising, and promotion related to use of the test must be consistent
with the authorized labeling and Fact Sheets, as well as other terms set forth in the EUA and any applicable requirements under the FDCA and its implementing regulations, and conspicuously bear the following statements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This test has not been FDA cleared or approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This test has been authorized by the FDA under an EUA for use by authorized laboratories; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This test has been authorized only for the detection of nucleic acid from SARS-
<FONT STYLE="white-space:nowrap">CoV-2,</FONT> not for any other viruses or pathogens; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This test is only authorized for the duration of the declaration that circumstances exist justifying the
authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of <FONT STYLE="white-space:nowrap">COVID-19</FONT> under Section&nbsp;564(b)(1) of the Act, 21 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">360bbb-3(b)(1),</FONT> unless the authorization is terminated or revoked sooner. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
statements that appear in advertising and promotional materials must not represent or suggest that this test is safe or effective for the detection of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EUA for <FONT STYLE="white-space:nowrap">Bio-Rad&#146;s</FONT> serological test for the antibodies associated with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> also sets out several conditions for authorized laboratories that mirror the conditions for the PCR test described above, except that the printed materials,
advertising, and promotion of the test must conspicuously bear the following statements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This test has not been FDA cleared or approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This test has been authorized by the FDA under an EUA for use by authorized laboratories; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This test has been authorized only for the detection of total antibodies, including IgM/IgG/IgA, against <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> not for any other viruses or pathogens; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This test is only authorized for the duration of the declaration that circumstances exist justifying the
authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of <FONT STYLE="white-space:nowrap">COVID-19</FONT> under Section&nbsp;564(b)(1) of the Act, 21 U.S.C. &#167;
<FONT STYLE="white-space:nowrap">360bbb-3(b)(1),</FONT> unless the authorization is terminated or revoked sooner. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to
comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business,
or become subject to administrative or judicial sanctions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagnostic testing industry is subject to extensive laws and
regulations, many of which have not been interpreted by the courts, including the application of the FDA&#146;s EUA authority. As noted above, the EUAs for the <FONT STYLE="white-space:nowrap">COVID-19</FONT> tests that are part of our Biodesix
WorkSafe testing program set out certain conditions for authorized laboratories using the tests, which have not received premarket clearance, approval, or a de novo from the FDA.&nbsp;If we fail to meet these conditions, the FDA may take enforcement
action, such as issuing a warning letter, seeking an injunction, seizure, fines, or criminal penalties. Pursuant to the August&nbsp;19, 2020 statement by HHS, the FDA cannot require any LDT to undergo premarket approval until it has engaged in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">notice-and-comment</FONT></FONT> rulemaking. Laboratory tests that have already received an EUA to detect the <FONT STYLE="white-space:nowrap">COVID-19</FONT> virus were
&#147;unaffected&#148; by the announcement. Tests without FDA clearance, approval, or authorization would not be considered covered countermeasures under the Public Readiness and Emergency Preparedness Act (PREP Act). The HHS statement also did not
affect EUAs issued for commercially-developed COVID-19 IVD tests, which apply to test developers and authorized laboratories. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to CLIA, a federal law that regulates clinical laboratories that perform
testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA requires virtually all laboratories to be certified by the federal government and mandates compliance with
various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate, reliable and timely. CLIA certification is also a prerequisite to be eligible to bill
state and federal health care programs, as well as many private third-party payers, for laboratory testing services. As a condition of CLIA certification, each of our laboratories is subject to survey and inspection every other year, in addition to
being subject to additional random inspections. The biennial survey is conducted by CMS, a CMS agent (typically a state agency), or, if the laboratory holds a CLIA certificate of accreditation, a <FONT STYLE="white-space:nowrap">CMS-approved</FONT>
accreditation organization. Sanctions for failure to comply with CLIA requirements, including proficiency testing violations, may include suspension, revocation, or limitation of a laboratory&#146;s CLIA certificate, which is necessary to conduct
our business, as well as the imposition of significant fines or criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any sanction imposed under CLIA, its implementing
regulations, or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license, or accreditation, could have a material adverse effect on our business. If the CLIA certificate of any
one of our laboratories is revoked, CMS could seek revocation of the CLIA certificates of our other laboratories based on their common ownership or operation, even though they are separately certified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are subject to state laws and regulations governing laboratory licensure.<B><I> </I></B>Some states have enacted state
licensure laws that are more stringent than CLIA. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-state</FONT></FONT> laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be subject to regulation in foreign jurisdictions as we seek to expand international utilization of our tests or such
jurisdictions adopt new licensure requirements, which may require review of our tests in order to offer them or may have other limitations that may limit our ability to make our tests available outside of the United States.<B><I> </I></B>Complying
with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays. Changes in state or foreign licensure laws that affect our ability to offer and provide diagnostic services
across state or foreign country lines could materially and adversely affect our business.<B><I> </I></B>In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to
receive specimens from certain states or foreign countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with applicable clinical laboratory licensure requirements
may result in a range of enforcement actions, including suspension, limitation or revocation of our CLIA certificate and/or state licenses, imposition of a directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions and
revocation of the laboratory&#146;s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations
governing clinical laboratory licensure or our failure to renew our CLIA certificate, a state or foreign license or accreditation, could have a material adverse effect on our business, financial condition and results of operations. Even if we were
able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Boulder, Colorado and De Soto, Kansas laboratories are College of American Pathologists (CAP)-accredited (Boulder) or COLA (De Soto) clinical laboratories regulated by CMS pursuant to CLIA. We also have a current CLIA certificate for each facility.
To maintain these certificates, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our laboratory from time to time. Furthermore, our diagnostic tests are categorized as Laboratory
Developed Tests (LDTs) and are not currently subject to FDA regulation, although certain components provided by third parties and used to create and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administer the test may be. LDTs are a subset of in vitro diagnostics (IVDs) that are intended for clinical use and developed, validated, and offered within a single laboratory for use only in
that laboratory. The FDA&#146;s authority to regulate LDTs has been frequently contested, and HHS recently issued a public statement purporting to rescind the FDA&#146;s policies regarding the premarket review of LDTs. According to the HHS
statement, the FDA will not require premarket review of LDTs unless it engages in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">notice-and-comment</FONT></FONT> rulemaking. There is no guarantee, however, that the HHS statement
will not be revised or rescinded, that legislation reforming the federal government&#146;s regulation of LDTs will not be passed, or that LDTs will otherwise continue to be able to operate without first receiving FDA premarket review. Failure to
adhere to any new FDA regulation would result in fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in the way that the FDA regulates tests performed by laboratories like ours could result in delay or additional expense in offering our tests
and tests that we may develop in the future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, the FDA has exercised enforcement discretion with respect to most LDTs
and has not required laboratories that furnish LDTs to comply with the agency&#146;s requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and
post-market controls). In recent years, however, the FDA publicly announced its intention to regulate certain LDTs and issued two draft guidance documents that set forth a proposed <FONT STYLE="white-space:nowrap">phased-in</FONT> risk-based
regulatory framework that would apply varying levels of FDA oversight to LDTs. However, these guidance documents were withdrawn at the end of the Obama administration and replaced by an informal discussion paper reflecting some of the feedback that
the FDA had received on LDT regulation. The FDA acknowledged that the discussion paper in January 2017 does not represent the formal position of the FDA and is not enforceable. Nevertheless, the FDA wanted to share its synthesis of the feedback that
it had received in the hope that it might advance public discussion on future LDT oversight. HHS has since issued a statement purporting to rescind FDA&#146;s policies regarding the premarket review of LDTs, stating that FDA must engage in notice
and comment rulemaking (as opposed to through guidance documents, compliance manuals, website statements, or other informal issuances) prior to requiring premarket review of LDTs. HHS issued this statement on its website and it may be subject to
change. Also, it is possible that Congress will pass legislation to reform the federal government&#146;s regulation of LDTs or that FDA will engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">notice-and-comment</FONT></FONT>
rulemaking to require premarket review of LDTs, which could result in delay or additional expense in offering our tests and tests that we may develop in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our current line of diagnostic tests are covered under CLIA and CMS, although our COVID testing program and select partnerships we may enter may cause
us to be subject to additional FDA requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws and regulations governing the marketing of diagnostic products are
evolving, extremely complex and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Pursuant to its authority under the FDCA, the FDA has jurisdiction over medical devices, including in
vitro diagnostics and, therefore, potentially our clinical laboratory tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the FDCA and its implementing regulations, the
FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical
products distributed domestically are safe and effective for their intended uses. Although the FDA has asserted that it has authority to regulate the development and use of LDTs, such as our and many other laboratories&#146; tests, as medical
devices, it has generally exercised enforcement discretion and is not otherwise regulating most tests developed and performed within a single high complexity CLIA-certified laboratory. On August&nbsp;19, 2020, HHS issued a statement purporting to
rescind the FDA&#146;s policies regarding the premarket review of LDTs, absent <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">notice-and-comment</FONT></FONT> rulemaking. the FDA&#146;s policies to date have been articulated
through guidance documents, compliance manuals, website statements, and other informal issuances. The FDA could, at any time, engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">notice-and-comment</FONT></FONT> rulemaking, or
Congress could take action to amend the law to change the current regulatory framework for in vitro diagnostics and LDTs. Further, the HHS statement was issued on its website and may be subject to change, particularly given the reasoning that
additional flexibility is needed due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our tests, as utilized in our clinical laboratory, are and would be considered
LDTs and that as a result, the FDA does not require that we obtain regulatory clearances or approvals for our LDTs or their components pursuant to the FDA&#146;s current policies and guidance. Although we believe that our tests and test components
are either exempt from FDA medical device regulations or are subject to an enforcement discretion policy, it is possible that the FDA would not agree with our determinations or that the FDA will change its regulations and policies such that our
products become regulated as medical devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In contrast with our LDTs, the FDA has regulatory jurisdiction over the two FDA <FONT
STYLE="white-space:nowrap">EUA-authorized</FONT> <FONT STYLE="white-space:nowrap">COVID-19</FONT> tests that were developed by <FONT STYLE="white-space:nowrap">Bio-Rad,</FONT> which we offer as part of our Biodesix WorkSafe testing programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations, therefore, are or may become subject to extensive regulation by the FDA in the United States. Government regulations specific
to medical devices are wide ranging and govern, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">test design, development, manufacture, and release; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory and clinical testing, labeling, packaging, storage and distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product safety and efficacy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">premarketing clearance or approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">service operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">record keeping; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product marketing, promotion and advertising, sales and distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and
removals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-market approval studies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product import and export. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA classifies medical devices into one of three classes on the basis of the intended use of the device, the risk associated with the use
of the device for that indication, as determined by the FDA, and on the controls deemed by the FDA to be necessary to reasonably ensure their safety and effectiveness. Class&nbsp;I devices, which have the lowest level of risk associated with them,
are subject to general controls. Class&nbsp;II devices are subject to general controls and special controls, including performance standards. Class&nbsp;III devices, which have the highest level of risk associated with them, are subject to general
controls and premarket approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before a new medical device or service, or a new intended use for an existing product or service, can be
marketed in the United States, a company must first submit and receive either 510(k) clearance, <FONT STYLE="white-space:nowrap">de-novo</FONT> authorization, or premarket approval (PMA)&nbsp;from the FDA, unless an exemption applies. Most
Class&nbsp;I devices and some Class&nbsp;II devices are exempt from these requirements. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is substantially equivalent to a legally-marketed
predicate device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May&nbsp;28, 1976 (preamendments device), a device that was originally on the United
States&nbsp;market pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device. To be substantially equivalent, the proposed device must have the same intended use as the predicate device, and either have the same technological
characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support substantial equivalence.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the process of obtaining PMA approval the FDA must determine that a proposed device is safe and effective for its intended use based,
in part, on extensive data, including, but not limited to, technical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining,
life-supporting or implantable devices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also allows the submission of a direct <FONT STYLE="white-space:nowrap">de-novo</FONT>
petition. This procedure allows a manufacturer whose novel device is automatically classified into Class&nbsp;III to request down-classification of its medical device into Class&nbsp;I or Class&nbsp;II on the basis that the device presents low or
moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), a medical device could only be eligible for de novo
classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the de novo classification pathway by permitting
manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 510(k), <FONT STYLE="white-space:nowrap">de-novo</FONT> or PMA process can be expensive, lengthy and unpredictable. The FDA can delay,
limit, or deny clearance or approval of a device for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body
that the diagnostic tests are safe or effective for their proposed intended uses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the disagreement of the FDA with the design or implementation of our clinical trials or the interpretation of
data from clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serious and unexpected adverse device effects experienced by participants in our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data from our clinical trials may be insufficient to support clearance or approval, where required;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturing process or facilities we use may not meet applicable requirements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change
significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by any such agency, which may include any of the following sanctions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity, warning letters, untitled letters, it has come to our attention letters, fines, injunctions,
consent decrees and civil penalties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">repair, replacement, refunds, recall or seizure of our diagnostic tests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions, partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">denial of our requests for regulatory clearance or premarket approval of new diagnostic tests or services, new
intended uses or modifications to existing diagnostic tests or services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of regulatory clearance or premarket approvals that have already been granted; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed above, we believe that our current line of diagnostic tests and their components are LDTs, subject to state licensing
requirements and federal regulation by CMS under CLIA, although our COVID testing program and select partnerships we may enter may cause us to be subject to additional FDA regulations discussed above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we believe that we are currently in material compliance with applicable laws and regulations, it is possible that the FDA, or other
regulatory agencies, would not agree with our determinations. If our products became become subject to 510(k) or other similar FDA regulations, we would need to comply with the applicable regulations or face significant civil and criminal penalties.
In addition, IVDs and CDx tests are widely considered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be Class&nbsp;III devices, and it is possible that in the future, we may develop tests that fall into this category. CDx tests in particular may require further administrative procedures in
the PMA process. Exposure to these additional regulatory requirements would also affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to develop, receive regulatory clearance or approval for, and introduce new diagnostic tests or enhancements
to existing diagnostic tests that will be accepted by the market in a timely manner. There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future diagnostic tests and failure to obtain necessary clearances or
approvals for our future diagnostic tests would adversely affect our ability to grow our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is important to our business
that we build a pipeline of diagnostic test offerings that address limitations of current lung disease diagnostic tests. As such, our success will depend in part on our ability to develop and introduce new diagnostic tests. However, we may not be
able to successfully develop and obtain regulatory clearance or approval for enhancements to our existing diagnostic tests, or new diagnostic tests for any number of reasons, including due to the cost associated with certain regulatory approval
requirements, or these diagnostic tests may not be accepted by physicians or users. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of any new diagnostic test or enhancement
to an existing diagnostic test will depend on a number of factors, including our ability to, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify and anticipate physician and patient needs properly; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop and introduce new diagnostic tests or enhancements to our existing diagnostic tests in a timely manner;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">avoid infringing upon, misappropriating or violating the intellectual property rights of third parties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrate, if required, the safety and efficacy of new diagnostic tests with data from clinical studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain the necessary regulatory clearances or approvals for new diagnostic tests or enhancements to existing
diagnostic tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply fully with FDA and foreign regulations on marketing of new diagnostic tests or modified diagnostic tests;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide adequate training to potential users of our diagnostic tests. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not develop new diagnostic tests or enhancements to our existing diagnostic tests in time to meet market demand or if there is
insufficient demand for these diagnostic tests or enhancements, or if our competitors introduce new diagnostic tests with functionalities that are superior to ours, our results of operations will suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our future diagnostic tests may require FDA clearance of a 510(k) submission. Other diagnostic tests may require the approval of a
PMA. In addition some of our future diagnostic tests may require clinical trials to support regulatory approval and we may not successfully complete these clinical trials. The FDA may not approve or clear these diagnostic tests for the indications
that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for 510(k) clearance or premarket approval of new diagnostic tests. Failure to receive clearance or approval for our new diagnostic tests would
have an adverse effect on our ability to expand our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modifications to our marketed tests may require new 510(k) clearances or PMA
approvals, or may require us to cease marketing or recall the modified tests until clearances or approvals are obtained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Modifications to our diagnostic tests may require new regulatory approvals or clearances, including 510(k) clearances or premarket approvals,
or require us to recall or cease marketing the modified systems until these clearances or approvals are obtained. The FDA requires device manufacturers to initially make and document a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determination of whether or not a modification requires a new approval, supplement or clearance. A manufacturer may determine that a modification could not significantly affect safety or efficacy
and does not represent a major change in its intended use, so that no new 510(k) clearance is necessary. However, the FDA can review a manufacturer&#146;s decision and may disagree. The FDA may also on its own initiative determine that a new
clearance or approval is required. We have made modifications to our diagnostic tests in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees
and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing our diagnostic tests as modified, which could require us to redesign our diagnostic tests and harm our operating results. In these
circumstances, we may be subject to significant enforcement actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a manufacturer determines that a modification to an <FONT
STYLE="white-space:nowrap">FDA-cleared</FONT> device could significantly affect its safety or efficacy, or would constitute a major change in its intended use, then the manufacturer must file for a new 510(k) clearance or possibly a premarket
approval application. Where we determine that modifications to our diagnostic tests require a new 510(k) clearance or premarket approval application, we may not be able to obtain those additional clearances or approvals for the modifications or
additional indications in a timely manner, or at all. Obtaining clearances and approvals can be a time consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced
diagnostic tests in a timely manner, which in turn would harm our future growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or our suppliers fail to comply with ongoing FDA or other
domestic and foreign regulatory authority requirements, or if we experience unanticipated problems with our diagnostic tests, they could be subject to restrictions or withdrawal from the market. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any medical device that we manufacture, including those for which we obtain regulatory clearance or approval, and the manufacturing processes,
reporting requirements, post-approval clinical data and promotional activities for such diagnostic test, will be subject to continued regulatory review, oversight, and periodic inspections by the FDA and other domestic and foreign regulatory bodies.
In particular, we and our suppliers may be required to comply with FDA&#146;s Quality System Regulations (QSR codified at 21 C.F.R. &#167; 820) for medical devices and International Standards Organization (ISO) regulations for the manufacture of our
diagnostic tests and other regulations which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any diagnostic test for which we obtain clearance or
approval. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other
regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, one or more of the following enforcement actions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated expenditures to address or defend such actions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">customer notifications for repair, replacement, or refunds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall, detention or seizure of our diagnostic tests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions or partial suspension or total shutdown of production; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusing or delaying our requests for 510(k) clearance or premarket approval of new diagnostic tests or modified
versions of current diagnostic tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operating restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawing 510(k) clearances on PMA approvals that have already been granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to grant export approval for our diagnostic tests; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">criminal prosecution. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these actions were to occur it would harm our reputation and cause our diagnostic test
sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our
failure to produce our diagnostic tests on a timely basis and in the required quantities, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are required to
conduct surveillance to monitor the safety or effectiveness of our diagnostic tests, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our diagnostic tests. Later
discovery of previously unknown problems with our diagnostic tests, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as
QSR, may result in changes to labeling, restrictions on such diagnostic tests or manufacturing processes, withdrawal of the diagnostic tests from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any
medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our diagnostic tests and services may in the future be subject to product recalls that could harm our reputation, business and financial results.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical devices can experience performance problems in the field that require review and possible corrective action. The
occurrence of component failures, manufacturing errors, software errors, design defects or labeling inadequacies affecting a medical device could lead to a government-mandated or voluntary recall by the device manufacturer, in particular when such
deficiencies may endanger health. The FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are
not reportable to the FDA. We may initiate voluntary recalls involving our diagnostic tests and services in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to
report those actions as recalls. Product recalls may divert management attention and financial resources, expose us to product liability or other claims, harm our reputation with customers and adversely impact our business, financial condition and
results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of
any future diagnostic tests and to manufacture, market and distribute our diagnostic tests after clearance or approval is obtained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the
regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. For example, the Verifying Accurate, Leading-edge IVCT Development (VALID) Act recently introduced in Congress would codify into law the term &#147;in
vitro clinical test&#148; in order to create a new medical product category separate from medical devices that would include products currently regulated as in vitro diagnostics as well as LDTs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and
our diagnostic tests. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of planned or future diagnostic tests. It is impossible to predict whether legislative changes
will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any change
in the laws or regulations that govern the clearance and approval processes relating to our current, planned and future diagnostic tests could make it more difficult and costly to obtain clearance or approval for new diagnostic tests or to produce,
market and distribute existing diagnostic tests. Significant delays in receiving clearance or approval or the failure to receive clearance or approval for any new diagnostic tests would have an adverse effect on our ability to expand our business.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trials may be necessary to support future product submissions to FDA. These clinical trials are
expensive and will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new diagnostic
tests and will adversely affect our business, operating results and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initiating and completing clinical trials necessary
to support any future PMA applications, and additional safety and efficacy data beyond that typically required for a 510(k) clearance, for our possible future product candidates, will be time consuming and expensive and the outcome uncertain.
Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting successful clinical studies will require the enrollment of large numbers of patients, and suitable patients may be difficult to
identify and recruit. Patient enrollment in clinical trials and completion of patient participation and <FONT STYLE="white-space:nowrap">follow-up</FONT> depends on many factors, including the size of the patient population, the nature of the trial
protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and
ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to
undergo extensive post-treatment procedures or <FONT STYLE="white-space:nowrap">follow-up</FONT> to assess the safety and effectiveness of our diagnostic tests or if they determine that the treatments received under the trial protocols are not
attractive or involve unacceptable risks or discomforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Development of sufficient and appropriate clinical protocols to demonstrate
safety and efficacy are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer <FONT
STYLE="white-space:nowrap">follow-up</FONT> period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may
cause an increase in costs and delays in the approval and attempted commercialization of our diagnostic tests or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, the FDA
may not consider our data adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the third parties on which we rely to conduct our clinical trials and to assist us with <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval for or commercialize our diagnostic tests and services. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have the ability to independently conduct our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials for our
future diagnostic tests and services and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. If these third parties do not
successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to
our clinical protocols or regulatory requirements or for other reasons, our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to
obtain regulatory approval for, or successfully commercialize, our diagnostic tests and services on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore, our third-party clinical trial
investigators may be delayed in conducting our clinical trials for reasons outside of their control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our use, disclosure, and other processing of personally identifiable information, including health
information, is subject to HIPAA and other federal, state, and foreign privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or
reputational harm and, in turn, a material adverse effect on our business, operating results and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain and
process, and our third-party vendors, collaborators, contractors and consultants maintain and process on our behalf, a large quantity of sensitive information, including confidential business, personal and patient health information in connection
with our clinical studies and our employees, and are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally identifying information, which among other things, impose
certain requirements relating to the privacy, security and transmission of personal information. Failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any of these laws and regulations could result in
notification obligations or enforcement actions against us, which could result in fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which
could have a material adverse effect on our business, financial condition, results of operations or prospects. These laws, rules and regulations evolve frequently and their scope may continually change, through new legislation, amendments to
existing legislation and changes in enforcement, and may be inconsistent from one jurisdiction to another. The interpretation and application of consumer, health-related and data protection laws, especially with respect to genetic samples and data,
in the United States, the European Union (EU) and elsewhere, are often uncertain, contradictory and in flux. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach
notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section&nbsp;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and
other personal information could apply to our operations or the operations of our collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Domestic laws in this area are complex
and developing rapidly. Many state legislatures have adopted legislation relating to privacy, data security and data breaches. Laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been
disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is costly. States are also frequently amending existing laws, requiring attention to frequently changing regulatory
requirements. For example, California recently enacted the CCPA, which became effective on January&nbsp;1, 2020. The CCPA, among other things, requires new disclosures to California consumers and affords such consumers new abilities to access and
delete their personal information, <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales of personal information and receive detailed information about how their personal information is used. The CCPA provides for fines of up to $7,500
per violation, as well as a private right of action for data breaches that is expected to increase the frequency of data breach litigation. While the CCPA has already been amended multiple times, it is unclear how this legislation will be further
modified or how it will be interpreted. Interpretations of the CCPA may continue to evolve with regulatory guidance. Additionally, a new California ballot initiative, the California Privacy Rights Act, has qualified to be included on the November
2020 ballot, and if voted into law by California voters, would impose additional data protection obligations on companies doing business in California, including additional consumer rights, including regarding certain uses of sensitive data. It
would also create a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The effects of this
legislation potentially are <FONT STYLE="white-space:nowrap">far-reaching,</FONT> however, and may require us to modify our data processing practices and policies and incur substantial compliance-related costs and expenses. The CCPA and other
changes in laws or regulations relating to privacy, data protection and information security, particularly any new or modified laws or regulations that require enhanced protection of certain types of data or new obligations with regard to data
retention, transfer or disclosure, could increase the cost of providing our offerings, require significant changes to our operations or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
even prevent us from providing certain offerings in jurisdictions in which we currently operate and in which we may operate in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these data protection laws and the narrowness of their exceptions and safe harbors, it is possible that our business
or data protection policies could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of heightened regulatory focus on data
privacy and security issues. Although we endeavor to comply with our published policies and documentation and ensure their compliance with current laws, rules and regulations, we may at times fail to do so or be alleged to have failed to do so. The
publication of our privacy policy and other documentation that provide promises and assurances about privacy and security can subject us to potential state and federal action in the United States if they are found to be deceptive, unfair, or
misrepresentative of our actual practices. Any failure by us or other parties with whom we do business to comply with this documentation or with federal, state, local or international regulations could result in proceedings against us by
governmental entities, private parties or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the data protection laws described above or any other laws that apply to us, we may
be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions,
private qui tam actions brought by individual whistleblowers in the name of the government, class action litigation and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become
subject to a corrective action plan or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, any of which could adversely affect our ability to operate our business and our results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, numerous state and federal laws and regulations govern the collection, dissemination, use, privacy,
confidentiality, security, availability, integrity, and other processing of PHI and PII. These laws and regulations include HIPAA. HIPAA establishes a set of national privacy and security standards for the protection of protected health information
(as defined in HIPAA, PHI) by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. We are a covered entity under
HIPAA when we are conducting our clinical trials. We are a covered entity with regard to our observational studies and clinical trials, and also a business associate under HIPAA for certain other business activities, and we execute business
associate agreements with our clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA requires covered entities and business associates, such as us, to develop and maintain
policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a data
breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA imposes mandatory penalties for certain violations. Penalties for violations of HIPAA and its implementing regulations
start at $119 per violation and are subject to a cap of $1,785,651 for violations of the same standard in a single calendar year. However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes state attorneys
general to file suit on behalf of their residents. Courts may award damages, costs and attorneys&#146; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil
court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities and business associates.
With regard to business associates, those audits assess the business associate&#146;s compliance with the HIPAA Privacy and Security Standards. Such audits are conducted randomly and after an entity experiences a breach affecting more than 500
individuals&#146; data. Undergoing an audit can be costly, can result in fines or onerous obligations, and can damage a business associate&#146;s reputation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to HIPAA, numerous other federal, state, and foreign laws and regulations protect the
confidentiality, privacy, availability, integrity and security of PHI and other types of PII. Some of these laws and regulations may be preempted by HIPAA with respect to PHI, or may exclude PHI from their scope but impose obligations with regard to
PII that is not PHI, and in some cases, can impose additional obligations with regard to PHI. These laws and regulations are often uncertain, contradictory, and subject to changing or differing interpretations, and we expect new laws, rules and
regulations regarding privacy, data protection, and information security to be proposed and enacted in the future. This complex, dynamic legal landscape regarding privacy, data protection, and information security creates significant compliance
issues for us and our clients and potentially exposes us to additional expense, adverse publicity and liability. While we have implemented data privacy and security measures in an effort to comply with applicable laws and regulations relating to
privacy and data protection, some PHI and other PII or confidential information is transmitted to us by third parties, who may not implement adequate security and privacy measures, but it is possible that laws, rules and regulations relating to
privacy, data protection, or information security may be interpreted and applied in a manner that is inconsistent with our practices or those of third parties who transmit PHI and other PII or confidential information to us. If we or these third
parties are found to have violated such laws, rules or regulations, it could result in government-imposed fines, orders requiring that we or these third parties change our or their practices, or criminal charges, which could adversely affect our
business. Complying with these various laws and regulations could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may eventually operate in a number of countries outside of the United States whose laws may in some cases be more stringent than the
requirements in the United States. For example, the EU has specific requirements relating to cross-border transfers of personal data to certain jurisdictions, including to the United States. In addition, some countries have stricter consumer notice
or consent requirements relating to personal data collection, use or sharing, have more stringent requirements relating to organizations&#146; privacy programs and provide stronger individual rights. Moreover, international privacy and data security
regulations may become more complex and result in greater penalties. For instance, since May&nbsp;25, 2018, the GDPR regulates the collection and use of personal data of data subjects in the EU and the European Economic Area (EEA). The GDPR applies
extra-territorially under certain circumstances and imposes stringent requirements on controllers and processors of personal data, including, for example, requirements to obtain consent or other legal bases from individuals to process their personal
data, provide robust disclosures to individuals, accommodate a set of individual data rights, provide data security breach notifications within 72 hours after discovering the breach, limit retention of personal information and apply enhanced
protections to health data and other special categories of personal data. The GDPR also applies to pseudonymized data, which is defined as &#147;the processing of personal data in such a way that the data can no longer be attributed to a specific
data subject without the use of additional information,&#148; and imposes additional obligations when we contract with third-party processors in connection with the processing of any personal data. The GDPR provides that EU member states may make
their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data, could cause our costs to increase and could harm our
financial condition. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#128;20&nbsp;million or up to 4% of the total worldwide annual turnover
of our preceding fiscal year, whichever is higher, and other administrative penalties. Further, as the GDPR has only recently become enforceable, enforcement priorities and official interpretations of certain provisions are still unclear. To comply
with the new data protection rules imposed by the GDPR, we may be required to put in place additional mechanisms ensuring compliance, which may result in other substantial expenditures. This may be onerous and adversely affect our business,
financial condition, results of operations and the profitability of our platform of diagnostic tests. Failure to comply with the GDPR and other countries&#146; privacy or data security-related laws, rules or regulations could result in material
penalties imposed by regulators, affect our compliance with contracts entered into with our collaborators and other third-party payers, and have an adverse effect on our business and financial condition. Currently, the GDPR is only applicable to us
as a processor, but as we continue to expand into the European market, the GDPR will have direct applicability to us as a controller. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GDPR also imposes strict rules on the transfer of personal data out of the EU to the United
States. These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices. In addition, these rules are consistently under scrutiny. For
example, following a decision of the Court of Justice of the EU (the ECJ) in October 2015, the transfer of personal data to United States&nbsp;companies that had certified as members of the United States Safe Harbor Scheme (Safe Harbor Scheme) was
declared invalid. In July 2016, the European Commission adopted the <FONT STYLE="white-space:nowrap">EU-United</FONT> States Privacy Shield Framework (Privacy Shield Framework) which replaced the Safe Harbor Scheme. The Privacy Shield Framework is
reviewed by European authorities annually, and the ECJ recently ruled that the Privacy Shield Framework is no longer a lawful mechanism for <FONT STYLE="white-space:nowrap">EU-United</FONT> States data transfers under the GDPR. There is currently
litigation challenging other EU mechanisms for adequate data transfers. It is uncertain whether and for how long national regulators will permit companies that have relied on the Privacy Shield Framework to come into compliance with the recent
ruling and whether alternative methods for <FONT STYLE="white-space:nowrap">EU-United</FONT> States data transfers or the standard contractual clauses might similarly be invalidated by European courts. The ECJ&#146;s ruling may lead to increased
transaction, compliance, and technological costs to support international data transfers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Organizations operating in Canada and covered
by the Personal Information Protection and Electronic Documents Act (PIPEDA), or equivalent Canadian provincial laws, must obtain an individual&#146;s consent when they collect, use or disclose that individual&#146;s personal information.
Individuals have the right to access and challenge the accuracy of their personal information held by an organization, and personal information may only be used for the purposes for which it was collected. If an organization intends to use personal
information for another purpose, it must again obtain that individual&#146;s consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We regularly monitor, defend against and respond to
attacks to our networks and other information security incidents. Despite our information security efforts, our facilities, systems, and data, as well as those of our third-party service providers, may be vulnerable to privacy and information
security incidents such as data breaches, viruses or other malicious code, coordinated attacks, data loss, phishing attacks, ransomware, denial of service attacks, or other security or IT incidents caused by threat actors, technological
vulnerabilities or human error. If we, or any of our vendors that support our IT or have access to our data, including any third party vendors that collect, process and store personal data on our behalf, fail to comply with laws requiring the
protection of personal information, or fail to safeguard and defend personal information or other critical data assets or IT systems, we may be subject to regulatory enforcement and fines as well as private civil actions. We may be required to
expend significant resources in the response, containment, mitigation of cybersecurity incidents as well as in defense against claims that our information security was unreasonable or otherwise violated applicable laws or contractual obligations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, collaborators, independent contractors and consultants may engage in misconduct or other improper activities, including
noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, collaborators,
independent contractors and consultants may engage in fraudulent or other illegal activity with respect to our business. Misconduct by these employees could include intentional, reckless and/or negligent conduct or unauthorized activity that
violates: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the
FDA authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal and state healthcare fraud and abuse laws and regulations; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laws that require the true, complete and accurate reporting of financial information or data.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and
regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive
programs and other business arrangements. Misconduct by these parties could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also involve individually identifiable information, including, without limitation, the improper use of information obtained in the course of clinical trials, which could result in regulatory
sanctions and serious harm to our reputation. Any incidents or any other conduct that leads to an employee, contractor, or other agent, or our company, receiving an FDA debarment or exclusion by the HHS Office of Inspector General (OIG) could result
in penalties, a loss of business from third parties, and severe reputational harm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we will adopt a Code
of Business Conduct and Ethics and compliance policies to govern and deter such behaviors, but it is not always possible to identify and deter misconduct by our employees and other agents, and the precautions we take to detect and prevent this
activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any
such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative
penalties, treble damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings,
additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and curtailment of our
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may
not be predictive of future trial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ongoing research and development and clinical trial activities are subject to
extensive regulation and review by numerous governmental authorities both in the United States and abroad. We are currently conducting <FONT STYLE="white-space:nowrap">pre-and</FONT> post-market clinical studies of some of our tests. In the future
we may conduct clinical trials to support approval of new diagnostic tests and services. Clinical studies may need to be conducted in compliance with FDA regulations or the FDA may take enforcement action. The data collected from these clinical
studies may ultimately be used to support marketing authorization for these diagnostic tests and services. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims or
that the FDA or foreign authorities and Notified Bodies will agree with our conclusions regarding them. Success in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and early clinical trials does not ensure that later clinical trials will
be successful, and we cannot be sure that the later trials will replicate the results of prior trials and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. The clinical trial process may fail to demonstrate that our tests are safe and
effective for the proposed indicated uses, which could cause us to abandon development of our tests and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and,
ultimately, may impact our ability to commercialize our tests and generate revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the factors that may cause or lead to a
delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a
function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical
trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions and contract research organizations to perform the trials, and would control only certain aspects of their
activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties would not relieve us
of our regulatory responsibilities. We and our third-party contractors are required to comply with good clinical practices (GCPs) which are regulations and guidelines enforced by the FDA, and comparable regulations enforced by foreign regulatory
authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sponsors, principal investigators and trial sites. If we or any third-party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed
unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to comply with these regulations may require us to repeat
clinical trials, which would delay the regulatory clearance or approval process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or
accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of these factors could be beyond our control. We may not be able to undertake additional trials, repeat trials or enter into new
arrangements with third parties without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the failure to perform by third parties, our research and development costs would increase
and we may not be able to obtain regulatory clearance or approval for our tests. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability
to market our tests, or to achieve sustained profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The results of our clinical trials may not support our product candidate claims or may
result in the discovery of adverse side effects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that the results of our future clinical trials will support
our future product claims or that the FDA will agree with our conclusions regarding them. Success in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and early clinical trials does not ensure that later clinical trials will be
successful, and we cannot be sure that the later trials will replicate the results of prior trials and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. The clinical trial process may fail to demonstrate that our product candidates are
safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and,
ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the future product&#146;s
profile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our billing, collections and claims processing activities are complex and time-consuming, and any delay in transmitting and collecting
claims or failure to comply with applicable billing requirements, could have an adverse effect on our future revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Billing for
our tests is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, such as government payers, insurance companies and patients, all of which may have different billing requirements.
We may face increased risk in our collection efforts, including long collection cycles and the risk that we may never collect at all, either of which could adversely affect our business, financial condition and results of operations. Several factors
make the billing process complex, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differences between the list price for our tests and the reimbursement rates of payers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with complex federal and state regulations related to billing government healthcare programs,
including Medicare and Medicaid, to the extent our tests are covered by such programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differences in coverage among payers and the effect of patient
<FONT STYLE="white-space:nowrap">co-payments</FONT> or <FONT STYLE="white-space:nowrap">co-insurance;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differences in information and billing requirements among payers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to codes and coding instructions governing our tests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incorrect or missing billing information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the resources required to manage the billing and claims appeals process. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These billing complexities and the related uncertainty in obtaining payment for our tests could
negatively affect our revenue and cash flow, our ability to achieve profitability and the consistency and comparability of our results of operations. In addition, if claims for our tests are not submitted to payers on a timely basis, or if we fail
to comply with applicable billing requirements, it could have an adverse effect on our revenue and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payers
require us to identify the test for which we are seeking reimbursement using a Current Procedural Terminology (CPT) code. The CPT code set is maintained by the American Medical Association (AMA). In cases where there is not a specific CPT code to
describe a test, such as with Nodify CDT and GeneStrat, the test may be billed under an unlisted molecular pathology procedure code or through the use of a combination of single gene CPT codes, depending on the payer. The PAMA authorized the
adoption of new, temporary billing codes and unique test identifiers for <FONT STYLE="white-space:nowrap">FDA-cleared</FONT> or approved tests as well as advanced diagnostic laboratory tests. The AMA has created a new section of CPT codes,
Proprietary Laboratory Analyses codes to facilitate implementation of this section of PAMA. In addition, CMS may assign unique level II Healthcare Common Procedure Coding System codes to tests that are not already described by a unique CPT code.
VeriStrat and Nodify XL2 both have test specific CPT codes, but GeneStrat and Nodify CDT do not at this time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the instance where a
code used does not describe a specific test, the insurance claim must be examined to determine what test was provided, whether the test was appropriate and medically necessary, and whether payment should be rendered, which may require a letter of
medical necessity from the ordering physician. This process can result in a delay in processing the claim, a lower reimbursement amount or denial of the claim. As a result, obtaining approvals from third-party payers to cover our tests and
establishing adequate reimbursement levels is an unpredictable, challenging, time-consuming and costly process and we may never be successful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities and our third-party manufacturers&#146; and suppliers&#146; activities involve the generation, use,
storage and disposal of hazardous materials. We work with materials, including chemicals, biological agents and compounds and samples that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and
biological waste products. Accordingly, we and our third-party manufacturers and suppliers are subject to federal, state, local and foreign environmental, health and safety laws and regulations, and permitting and licensing requirements, including
those governing the generation, use, manufacture, storage, handling, transportation, release and disposal of, and exposure to, these materials, and worker health and safety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot eliminate the risk of contamination or injury resulting from such hazardous materials. We also cannot guarantee that the procedures
utilized by our third-party manufacturers for handling and disposing of hazardous materials and wastes comply with all applicable environmental, health and safety laws and regulations. As a result, we may be held liable for any resulting damages,
costs or liabilities, including cleanup costs and liabilities, which could be significant, or our commercialization, research and development efforts and business operations may be restricted or interrupted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Environmental, health and safety laws and regulations are complex, change frequently and have tended to become more stringent. Compliance with
such laws and regulations is expensive, and current or future environmental, health and safety laws and regulations may restrict our operations. If we do not comply with applicable environmental health and safety laws and regulations, and permitting
and licensing requirements, we may be subject to fines, penalties, a suspension of our business or other sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our success may be impaired if we are unable to obtain, maintain and protect our intellectual property rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the
United States and other countries with respect to our diagnostic tests, products and services and technology. We rely on patent protection, as well as a combination of copyright, trade secret and trademark laws, to protect our proprietary technology
and prevent others from duplicating our suite of diagnostic tests and products. However, these means may afford only limited protection and may not: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevent our competitors from duplicating our diagnostic tests and products, including our <FONT
STYLE="white-space:nowrap">COVID-19</FONT> testing program and Nodify XL2, Nodify CDT, GeneStrat and VeriStrat tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevent our competitors from gaining access to our proprietary information and technology, including the
Diagnostic Cortex platform, tech platforms such as the DeepMALDI analysis and intellectual property covering technologies that allow us to develop &#147;test algorithms&#148;; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow us to gain or maintain a competitive advantage. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of our patents, including those we may license, may be challenged, invalidated, rendered unenforceable or circumvented. Consequently, we
do not know whether any of our diagnostic tests, products and services will be protectable or remain protected by valid and enforceable patents. We may not prevail if our patents are challenged by competitors or other third parties. The United
States&nbsp;federal courts or equivalent national courts or patent offices elsewhere may invalidate our patents, find them unenforceable, or narrow their scope. Furthermore, competitors may be able to design around our patents by developing similar
or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner, or obtain patent protection for more effective technologies, designs or methods, including for treating lung cancer. If these developments
were to occur, our diagnostic tests and products may become less competitive and sales may decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed numerous patent
applications seeking protection of diagnostic tests and other inventions originating from our research and development. Our patent applications may not result in issued patents, and any patents that are issued may not provide meaningful protection
against competitors or competitive technologies. Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications
issue. The scope of a patent may also be reinterpreted and significantly reduced after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any
meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with the protection or competitive advantages we are seeking. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, some of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications are, and may in the future
be, <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain or maintain an exclusive license to any such third party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent
applications, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need
the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse
effect on our competitive position, business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of
biotechnology companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology and
pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual
questions, which has in recent years been the subject of much litigation. Various courts, including the United States Supreme Court have rendered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
decisions that affect the scope of patentability of certain inventions or discoveries relating to biotechnology. These decisions state, among other things, that a patent claim that recites an
abstract idea, natural phenomenon or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature or abstract idea is uncertain, and it is
possible that certain aspects of our technology could be considered unpatentable under applicable law. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Depending on decisions
by the United States Congress, the federal courts and the United States Patent and Trademark Office (USPTO), the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&#146; ability to
obtain new patents or to enforce our existing owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patents that we might obtain or <FONT STYLE="white-space:nowrap">in-license</FONT> in the future. Additionally, our pending and
future patent applications may not result in patents being issued which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. The scope of patent protection outside of the
United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights
and, more generally, could affect the value of our intellectual property rights or narrow the scope of our owned and licensed patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
we are unable to obtain and maintain patent protection for our technology, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize diagnostic tests, products and services similar or
superior to ours, and our competitive position may be adversely affected. It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late
to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute,
maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who
have access to confidential or patentable aspects of our research and development output, such as our employees, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent
application is filed, thereby jeopardizing our ability to seek patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, while software and other of our
proprietary works may be protected under copyright law, we have chosen not to register any copyrights in these works, and instead, primarily rely on protecting our software as a trade secret. In order to bring a copyright infringement lawsuit in the
United States, the copyright must be registered. Accordingly, the remedies and damages available to us for unauthorized use of our copyrights may be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patent protection for the patents underlying our diagnostic tests, products and services, we also rely upon unpatented
trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain a competitive position. Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect.
We seek to protect such proprietary information, in part, through confidentiality agreements with our employees, collaborators, contractors, advisors, consultants and other third parties and invention assignment agreements with our employees. We
also have agreements with some of our consultants that require them to assign to us any inventions created as a result of their working with us. The confidentiality agreements are designed to protect our proprietary information and, in the case of
agreements or clauses containing invention assignment, to grant us ownership of technologies that are developed through a relationship with employees or third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that we have entered into such agreements with each party that has or may have had access to our trade secrets or
proprietary information. Additionally, despite these efforts, any of these parties may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party
illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.
If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade
secrets were to be disclosed to, or independently developed by, a competitor or other third party, our competitive position would be materially and adversely harmed. Furthermore, we expect these trade secrets,
<FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary information to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of
personnel from academic to industry scientific positions. Consequently, we may be unable to prevent our proprietary technology from being exploited in the United States and abroad, which could affect our ability to expand in domestic and
international markets or require costly efforts to protect our technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of
our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security
measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known, or be independently discovered by, competitors. To the extent that our employees, consultants, contractors or
collaborators use intellectual property rights owned by others in their work for us, disputes may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions, which could have a material adverse
effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we or our employees have misappropriated
the intellectual property rights of a third party, including trade secrets or <FONT STYLE="white-space:nowrap">know-how,</FONT> or are in breach of <FONT STYLE="white-space:nowrap">non-competition</FONT> or
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreements with our competitors, and third parties may claim an ownership interest in intellectual property we regard as our own. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees and consultants were previously employed at or engaged by universities or other medical device, diagnostic, biotechnology
or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, may have executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT
STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property rights, proprietary
information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, used, infringed, misappropriated or otherwise
violated the intellectual property rights or disclosed the alleged trade secrets or other proprietary information, of these former employers, competitors or other third parties, or to claims that we have improperly used or obtained such trade
secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our
business. Any litigation or the threat of litigation may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to
commercialize potential diagnostic tests, products and services, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other
employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property
rights we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against
any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to
those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
diagnostic tests or products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An inability to incorporate technologies or features that are important or essential to our diagnostic tests or products could have a material
adverse effect on our business, financial condition and results of operations, and may prevent us from selling our rights to our <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing program, either of the Nodify XL2 and Nodify CDT tests, or the
VeriStrat and GeneStrat tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who may be involved in the
conception or development of intellectual property rights to execute agreements assigning such intellectual property rights to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual
property rights that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they
may bring against us, to determine the ownership of what we regard as our intellectual property rights. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future diagnostic tests,
products and services. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of
patent applications and the enforcement or defense of issued patents. In 2011, the Leahy-Smith America Invents Act (Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to United States&nbsp;patent law.
These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation. These also include provisions that switched the United States from a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-to-invent</FONT></FONT> system to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-inventor-to-file</FONT></FONT> system, allow third-party submission of prior art to the USPTO during patent
prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings, including post-grant review, <I>inter partes</I> review and derivation proceedings. Under a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-inventor-to-file</FONT></FONT> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the
patent on an invention regardless of whether another inventor was the first to invent the claimed invention. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive
changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective in 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our
business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse
effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, patent reform legislation may pass in the future that
could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the United States Supreme Court and the United States&nbsp;Court of Appeals for the Federal
Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Recent United States Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and
weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Similarly, foreign courts have made, and will likely continue
to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States&nbsp;and
foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and tradenames are not adequately protected, then we may not be able to build name
recognition in our markets and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our trademarks or trade names may be challenged, infringed,
circumvented, declared generic or determined to be violating or infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these trademarks or trade names, which we need to
build name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and
possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement or dilution claims brought by owners of other trademarks. Over the long term, if we are unable to establish name recognition based on
our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not
yet registered certain of our trademarks in all of our potential markets, although we have registered several connected to our diagnostic tests, products and services in the United States. If we apply to register these and trademarks in the United
States and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections.
Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to
oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. If we
do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our efforts to enforce or protect our rights related to trademarks, trade secrets, domain names or other intellectual property rights may be
ineffective, could result in substantial costs and diversion of resources and could adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property rights, which could be
expensive, time consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors or other third parties may infringe, misappropriate or otherwise violate
our patents, the patents of our licensors or other intellectual property rights, or we may be required to defend against claims of infringement, misappropriation or other violations. In addition, our patents also may become involved in inventorship,
priority or validity disputes. To counter or defend against such claims can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke those parties to assert counterclaims against us alleging that we infringe
their patents or other intellectual property. In any such proceeding, a court or other administrative body may decide that a patent or other intellectual property right owned by us is invalid or unenforceable, or may refuse to stop the other party
from using the technology at issue on the grounds that our patents do not cover such technology. Grounds for a validity challenge could include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness,
written description, <FONT STYLE="white-space:nowrap">non-enablement</FONT> or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the
patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the
context of litigation. Such mechanisms include reexamination, post-grant review, <I>inter partes </I>review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, including opposition proceedings. Such
proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our diagnostic tests, products and services or prevent third parties from competing with our diagnostic tests, products
and services. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or
unenforceability, we could lose at least part, and perhaps all, of the patent protection on our diagnostic tests, products and services. An adverse result in any litigation or other proceeding could put one or more of our patents at risk of being
invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by
disclosure during litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, some of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent
applications are, and may in the future be, <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain an exclusive license to any such third party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest
in such patents or patent applications, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and our competitors could market competing diagnostic tests,
products, services or technology. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our patents in order to enforce such patents against third parties, and such cooperation may not be provided
to us. Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if
resolved in our favor, litigation or other proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our management and other personnel from their normal responsibilities. In addition, there
could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our common
stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient
financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources
and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.
Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may initiate
legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intellectual property landscape in the field of precision oncology is in flux, and it may remain uncertain for the coming
years. There may be significant intellectual property related litigation and proceedings relating to our owned and <FONT STYLE="white-space:nowrap">in-licensed,</FONT> and other third party, intellectual property and proprietary rights in the
future. As we move into new markets and applications for our diagnostic tests, products or services, incumbent participants in such markets may assert their patents and other intellectual property rights against us as a means of slowing our entry
into such markets or as a means to extract substantial license and royalty payments from us. Our competitors and others may now and, in the future, have significantly larger and more mature patent portfolios than we currently have. In addition,
future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection. Therefore, our commercial
success depends in part on our <FONT STYLE="white-space:nowrap">non-infringement</FONT> of the patents or other intellectual property rights of third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, we may in the future be subject to claims that we, or other parties we have agreed to indemnify, infringe, misappropriate or
otherwise violate patents or other intellectual property rights owned or controlled by third parties. Because patent applications are published sometime after filing, and because applications can take several years to issue, there may be additional
currently pending third-party patent applications that are unknown to us, which may later result in issued patents. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion
of employee resources from our business. We may not have sufficient resources to bring these actions to a successful conclusion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation and other patent challenges, both within and outside
the United States, involving patent and other intellectual property rights in the biotechnology industry, including patent infringement lawsuits, interferences, oppositions and <I>inter partes</I> review proceedings before the USPTO, and
corresponding foreign patent offices. Numerous United States&nbsp;and foreign issued patents and pending patent applications, which are owned by third parties, including our competitors, exist in the fields in which we are developing diagnostic
tests and in which we may develop future diagnostic tests, products and services. As the precision oncology industry expands and more patents are issued, the risk increases that our diagnostic tests may be subject to claims of infringement of the
patent rights of third parties. Numerous significant intellectual property issues have been litigated, are being litigated and will likely continue to be litigated, between existing and new participants in our existing and targeted markets, and
competitors have and may assert that our diagnostic tests or services infringe their intellectual property rights as part of a business strategy to impede our successful entry into or growth in those markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could incur substantial costs and divert the attention of our management and technical personnel in defending against any of these claims.
Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the inevitable uncertainty in intellectual property litigation, we could lose a patent infringement or other action asserted
against us regardless of our perception of the merits of the case. There is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold that
these third party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted
third party patents. In order to successfully challenge the validity of any such United States patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing
evidence as to the invalidity of any such United States patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such United States patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and
sell diagnostic tests, products or services, and could result in the award of substantial damages against us, including treble damages, attorney&#146;s fees, costs, and expenses if we are found to have willfully infringed. In the event of a
successful claim of infringement against us, we may be required to pay damages and ongoing royalties, which could be significant, and obtain one or more licenses from third parties, or be prohibited from selling certain diagnostic tests, products or
services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors gaining access to
the same intellectual property. In addition, we could encounter delays in diagnostic test introductions while we attempt to develop alternative diagnostic tests, products or services to avoid infringing third-party patents or intellectual property
rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing diagnostic tests, products or services, and the prohibition of sale of any of our diagnostic tests, products or services could materially
affect our business and our ability to gain market acceptance for our diagnostic tests, products and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of
the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the
course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a
substantial adverse effect on the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our agreements with some of our customers, suppliers or other
entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third
parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the priority or inventorship of our patents and other intellectual property rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property rights as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we or our licensors may have inventorship disputes arise
from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#146;
ownership of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, trade secrets or other intellectual property rights. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property rights that are important to our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain
and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be <FONT
STYLE="white-space:nowrap">non-exclusive.</FONT> If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of our diagnostic tests, products or services. The loss
of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could result in a material adverse effect
on our business, financial condition, results of operations, or prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the
foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining
our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees
and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. We
have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to <FONT STYLE="white-space:nowrap">non-United</FONT> States patent agencies. We are also dependent on our
licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property rights. The USPTO and various <FONT STYLE="white-space:nowrap">non-US</FONT> governmental patent agencies require compliance
with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in some cases, an inadvertent lapse can be cured
by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors may be able to enter the market without infringing our patents and this circumstance would have a material adverse effect on our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our diagnostic tests and any other or future diagnostic tests, products or services could be found invalid or
unenforceable if challenged. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability
and some of our patents or patent applications, including licensed patents, may be challenged, in courts or patent offices in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the United States and abroad, in opposition, derivation, reexamination, <I>inter partes</I> review, post-grant review or interference. Additionally, if we and our licensing partners initiate or
become involved in legal proceedings against a third party to enforce a patent covering one of our diagnostic tests, products, services or technologies, the defendant could counterclaim that the patent covering our diagnostic tests, products or
services is invalid or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including patent eligible subject matter, lack of novelty, obviousness or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution
of the patent withheld relevant information from the USPTO, or made a misleading statement during prosecution. In addition, the United States now awards patent priority to the first party to file a patent application, and others may submit patent
claims covering our inventions prior to us. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art
of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our diagnostic
tests or any diagnostic tests, products and services that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A successful third-party challenge to our patents could result
in the unenforceability or invalidity of such patents, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without
infringing third-party patent rights, which could have a material adverse impact on our business. Furthermore, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it
could dissuade companies from collaborating with us to license, develop or commercialize current or future diagnostic tests, products or services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be aware of all third-party intellectual property rights potentially relating to our current or future diagnostic tests, products
or services. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18&nbsp;months after
filing or, in some cases, not until such patent applications issue as patents. We, or our current or future license partners or collaborators, might not have been the first to make the inventions covered by each of our pending patent applications
and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings
declared by the USPTO. The outcome of such proceedings is uncertain, and other patent applications may have priority over our patent applications. Such proceedings could also result in substantial costs to us and divert our management&#146;s
attention and resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on licenses from third parties in relation to certain diagnostic tests, products and services and if we lose these
licenses then we may be subjected to future litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to license agreements that grant us rights to use certain
intellectual property rights, including patents and patent applications, typically in certain specified fields of use, in connection with our diagnostic tests, products and services. Some of those licensed rights could provide us with freedom to
operate for aspects of our diagnostic tests, products and services. We may need to obtain additional licenses from others to advance our research, development and commercialization activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquisition of third-party intellectual property rights is a competitive area,
and a number of more established companies are also pursuing strategies to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire third-party intellectual property rights that we may consider attractive or necessary. These established
companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or
license rights to us. In addition, we expect that competition for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquisition of third-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
party intellectual property rights for product candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or
licensing costs. We may be unable to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire the third-party intellectual property rights for product candidates on terms that would allow us to make an appropriate return on our investment. If
we are unable to successfully obtain rights to suitable product candidates, our business, financial condition, results of operations and prospects for growth could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our existing license agreements impose, and we expect that our future license agreements will impose, various diligence, royalty payment,
milestone payment, insurance and other obligations on us. If we fail to comply with these obligations or other obligations in our license agreements, our licensors may have the right to terminate these agreements, in which event we may not be able
to develop and market any product or use any technology that is covered by these agreements. If our license agreements terminate, or we experience a reduction or elimination of licensed rights under these agreements, we may have to negotiate new or
reinstated licenses with less favorable terms or we may not have sufficient intellectual property rights to operate our business. The occurrence of such events could materially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success may depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual
property rights. Our licensors may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation
against other companies that are infringing these patents or may pursue such litigation less aggressively than we would. Without protection for the intellectual property rights we license, other companies might be able to offer substantially
identical diagnostic tests for sale, which could adversely affect our competitive business position and harm our business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, disputes may also arise between us and our current or future licensors regarding intellectual property rights subject to a license
agreement, including those relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether, and the extent to which, our diagnostic tests, products, services, technology and processes infringe on
intellectual property rights of the licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether our licensor or its licensor had the right to grant the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the
intellectual property rights without their authorization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our involvement in the prosecution of licensed patents and our licensors&#146; overall patent enforcement
strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts of royalties, milestones or other payments due under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property rights by our licensors and us and our collaborators; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we currently license intellectual property rights or
technology from third parties are complex and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the
scope of our rights to the relevant intellectual property rights or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business,
financial condition, results of operations and prospects. Moreover, if disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, or
are insufficient to provide us the necessary rights to use the intellectual property rights, we may be unable to successfully develop and commercialize any affected diagnostic tests, products or services, which could have a material adverse effect
on our business, financial conditions, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Absent the license agreements, we may infringe patents
subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs to us and distract our management. If we do not prevail, we may be required to
pay damages, including treble damages, attorneys&#146; fees, costs and expenses and royalties or be enjoined from selling our diagnostic tests, products or services, which could adversely affect our ability to offer diagnostic tests, products or
services, our ability to continue operations and our financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some intellectual property that we
<FONT STYLE="white-space:nowrap">in-license</FONT> may have been developed through government funded programs and thus may be subject to federal regulations such as <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain
reporting requirements and a preference for companies based in the United States. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with manufacturers that are not based in the United States.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the intellectual property that we license may have been developed through the use of United States government funding
and therefore may be subject to certain federal regulations. As a result, the United States government may have certain rights to intellectual property embodied in our diagnostic tests, products and services pursuant to the Bayh-Dole Act of 1980
(Bayh-Dole Act). These United States government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In
addition, the United States government has the right to require us to grant exclusive, partially exclusive, or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any of these inventions to a third party if it determines that:
(i)&nbsp;adequate steps have not been taken to commercialize the invention; (ii)&nbsp;government action is necessary to meet public health or safety needs; or (iii)&nbsp;government action is necessary to meet requirements for public use under
federal regulations (also referred to as <FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;). To date, none of our commercialized products are subject to march-in rights. The United States government also has the right to take title
to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a
government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the United States government requires that any products of the
subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but
unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible.
This preference for United States manufacturers may limit our ability to contract with product manufacturers outside of the United States for products covered by such intellectual property. To the extent any of our current or future owned or
licensed intellectual property is generated through the use of United States government funding, the provisions of the Bayh-Dole Act may similarly apply. Any failure by us to comply with federal regulations regarding intellectual property rights
that were developed through the use of United States government funding could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our diagnostic tests, products and
services for an adequate amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely
paid, the natural<B> </B>expiration of a patent is generally 20&nbsp;years from its earliest United <FONT STYLE="white-space:nowrap">States&nbsp;non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and
the protection it affords, is limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if patents covering our diagnostic tests, products and services are obtained, once the patent
life has expired, we may be open to competition from competitive diagnostic tests, products and services. Given the amount of time required for the development, testing and regulatory review of potential new diagnostic tests, patents protecting such
candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing diagnostic tests, products or
services similar or identical to ours. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may attempt to commercialize competitive diagnostic tests, products or services in foreign countries where we do not have any
patents or patent applications and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on our diagnostic tests, products and services in all countries throughout the world would be
prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries
outside the United States, or from selling or importing diagnostic tests or products made using our inventions in and into the United States or other jurisdictions. Competitors may use our diagnostic tests, products, services and technologies in
jurisdictions where we have not obtained patent protection to develop their own diagnostic tests and, further, may export otherwise infringing diagnostic tests or products to territories where we have patent protection but enforcement is not as
strong as that in the United States. These diagnostic tests and products may compete with our diagnostic tests, products or services and our patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign
jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the
infringement of our patents or marketing of competing diagnostic tests, products and services in violation of our intellectual property rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result
in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke
third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries, including India, China, and certain countries in Europe, have compulsory licensing laws under which a patent owner may be
compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could
materially diminish the value of such patent. If we or any of our current or future licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our
business, financial condition and results of operations may be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make diagnostic tests or products that are similar to our Nodify XL2, Nodify CDT, GeneStrat
or VeriStrat tests or the COVID-19 tests that we use in our COVID-19 testing program or utilize similar technology that is not covered by the claims of our patents or that incorporates certain technology in our Nodify XL2, Nodify CDT, GeneStrat or
VeriStrat tests or such COVID-19 tests that is in the public domain; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our current or future licensors or collaborators, might not have been the first to make the inventions
covered by the applicable issued patent or pending patent application that we own or license now or may own or license in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our current or future licensors or collaborators, might not have been the first to file patent
applications covering certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our current or future pending patent applications will not lead to issued patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal
challenges by our competitors or other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors or other third parties might conduct research and development activities in countries where we do
not have patent rights and then use the information learned from such activities to develop competitive diagnostic tests, products and services for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent covering such intellectual property rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to our Common Stock and this Offering</B><B><I> </I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There has been no prior public market for our common stock and an active trading market may not develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. An active trading market may not develop following completion of
this offering or, if developed, may not be sustained. The lack of an active trading market may impair the value of your shares and your ability to sell your shares at the time you wish to sell them. An inactive trading market may also impair our
ability to both raise capital by selling shares of common stock and acquire other complementary diagnostic tests, technologies or businesses by using our shares of common stock as consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon closing of this offering, we expect that our common stock will be listed on the Nasdaq Global Market. If we fail to satisfy the continued
listing standards of the Nasdaq Global Market, however, we could be <FONT STYLE="white-space:nowrap">de-listed,</FONT> which would negatively impact the price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect that the price of our common stock will fluctuate substantially and you may not be able to sell the shares you purchase in this offering at or
above the offering price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price for the shares of our common stock sold in this offering is determined
by negotiation between the representatives of the underwriters and us. This price may not reflect the market price of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our common stock following this offering. In addition, the market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">volume and customer mix for our <FONT STYLE="white-space:nowrap">COVID-19,</FONT> Nodify XL2, Nodify CDT,
GeneStrat and VeriStrat testing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the introduction of new diagnostic tests or enhancements to such tests by us or others in our industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments with respect to our or others&#146; intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop, obtain regulatory clearance or approval for, and market new and enhanced diagnostic tests
on a timely basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product liability claims or other litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">quarterly variations in our results of operations or those of others in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">media exposure of our diagnostic tests or of those of others in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in governmental regulations or in the status of our regulatory approvals or applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in earnings estimates or recommendations by securities analysts; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market conditions and other factors, including factors unrelated to our operating performance or the
operating performance of our competitors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, the stock markets generally have experienced extreme price
and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual
operating performance. These fluctuations may be even more pronounced in the trading market for our common stock shortly following this offering. If the market price of shares of our common stock after this offering does not ever exceed the initial
public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
in the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Securities litigation brought against us following volatility in our stock price, regardless of
the merit or ultimate results of such litigation, could result in substantial costs, which would hurt our financial condition and operating results and divert management&#146;s attention and resources from our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock
price or trading volume to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a trading market for our common stock develops, the trading market will be influenced to
some extent by the research and reports that industry or financial analysts publish about us and our business. We do not control these analysts. As a newly public company, we may be slow to attract research coverage and the analysts who publish
information about our common stock will have had relatively little experience with us, which could affect their ability to accurately forecast our results and could make it more likely that we fail to meet their estimates. In the event we obtain
securities or industry analyst coverage, if any of the analysts who cover us provide inaccurate or unfavorable research or issue an adverse opinion regarding our stock price, our stock price could decline. If one or more of these analysts cease
coverage of us or fail to publish reports covering us regularly, we could lose visibility in the market, which in turn could cause our stock price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company,&#148; and the reduced
disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. We may take advantage of certain exemptions and relief from various
public reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (the
Sarbanes-Oxley Act). We will be exempt from any rules that could be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotations or a supplement to the auditor&#146;s report on financial statements; we will be
subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and we will not be required to hold nonbinding advisory votes on executive compensation or stockholder approval of any golden
parachute payments not previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;107 of the JOBS Act provides that an &#147;emerging growth company&#148; can
take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an &#147;emerging growth company&#148; can delay the adoption of
certain accounting standards until those standards would otherwise apply to private companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of the
extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be
subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult.
Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an &#147;emerging growth company&#148; until the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have
more than $1.07&nbsp;billion in annual revenue; (ii)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at least $700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT>
(iii)&nbsp;the date on which we have issued, in any three-year period, more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and (iv)&nbsp;the last day of the fiscal year ending after the fifth
anniversary of the completion of our initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a <I>&#147;</I>smaller reporting company<I>&#148; </I>as
defined in Item 10(f)(1) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited
financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1)&nbsp;the market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $250&nbsp;million
as of the end of that year&#146;s second fiscal quarter, or (2)&nbsp;our annual revenues exceeded $100&nbsp;million during such completed fiscal year and the market value of our common shares held by nonaffiliates exceeds $700&nbsp;million as of the
end of that year&#146;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors may find our common stock less attractive to the extent we rely on the exemptions and relief granted by the JOBS Act. If some
investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may decline or become more volatile. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating
results could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts
reported in our financial statements and accompanying notes. We base </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. It is possible that interpretation, industry practice and guidance may evolve over time. If our assumptions change or if
actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors purchasing common stock in this offering will pay a price per share that substantially exceeds the pro&nbsp;forma as adjusted net
tangible book value per share. As a result, investors purchasing common stock in this offering will incur immediate dilution of $16.40 per share, at the initial public offering price of $18.00 per share, and our pro&nbsp;forma as adjusted net
tangible book value per share as of June&nbsp;30, 2020. For more information on the dilution you may suffer as a result of investing in this offering, see the section of this prospectus entitled &#147;Dilution.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This dilution is due to the substantially lower price paid by our investors who purchased shares prior to this offering as compared to the
price offered to the public in this offering.&nbsp;It is also due to the conversion of our preferred stock and convertible debt into shares of our common stock upon the completion of this offering and the exercise of stock options granted to our
employees as the conversion and exercise prices of such securities and options are substantially below the price offered to the public in this offering.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future. This
could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial
number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell their shares, could result in a decrease in the market price
of our common stock. Immediately after this offering, we will have 26,254,072 outstanding shares of common stock based on the number of shares outstanding as of October&nbsp;15, 2020. This includes the shares that we are selling in this offering,
which may be resold in the public market immediately without restriction, unless purchased by our affiliates. Of the remaining shares, 22,254,072 shares are currently restricted as a result of securities laws or
<FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements but will be able to be sold after the offering as described in the section of this prospectus entitled &#147;Shares Eligible For Future
Sale.&#148; Moreover, after this offering, holders of an aggregate of 20,090,745 shares of our common stock issuable upon the conversion of the shares of our convertible preferred stock that will be outstanding immediately prior to the consummation
of this offering, will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders as
described in the section of this prospectus entitled &#147;Shares Eligible For Future Sale&#151;Registration Rights.&#148; We also intend to register all shares of common stock that we may issue under our equity compensation plans. Once we register
these shares, they can be freely sold in the public market, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in the section of this prospectus entitled
&#147;Underwriters.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our directors, officers and principal stockholders have significant voting power and may take actions that may not be in
the best interests of our other stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this offering, our officers, directors and principal stockholders each holding
more than 5% of our common stock will collectively control approximately 60.7% of our outstanding common stock. As a result, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these stockholders, if they act together, will be able to control the management and affairs of our company and most matters requiring stockholder approval, including the election of directors
and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change of control and might adversely affect the market price of our common stock. This concentration of ownership
may not be in the best interests of our other stockholders. At our request, in addition to the directed share program described in this prospectus, the underwriters have reserved for sale at the initial public offering price per share approximately
824,000 shares of common stock in this offering to certain individuals, including directors, existing stockholders and other persons associated with us. The calculations above do not reflect any purchases of our common stock by these individuals in
this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may allocate the net proceeds from this offering in ways that you and other stockholders may not approve. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes
described in the section titled &#147;Use of Proceeds.&#148; Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended
use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment, and the failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net
proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the United States&nbsp;government. These investments may not
yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected results, which could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to incur significant additional costs as a result of being a public company, which may adversely affect our business, financial condition and
results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we expect to incur costs associated with corporate governance
requirements that will become applicable to us as a public company, including rules and regulations of the SEC, under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the Securities Exchange Act of
1934, as amended (the Exchange Act), as well as the rules of Nasdaq. These rules and regulations are expected to significantly increase our accounting, legal and financial compliance costs and make some activities more time-consuming. We also expect
these rules and regulations to make it more expensive for us to maintain directors&#146; and officers&#146; liability insurance. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our Board of Directors
or as executive officers. Accordingly, increases in costs incurred as a result of becoming a publicly traded company may adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be
able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of becoming a public company, we will be required, under Section&nbsp;404 of the Sarbanes-Oxley Act to furnish a report by
management on, among other things, the effectiveness of our internal control over financial reporting beginning with our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2021. This
assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over
financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#146;s annual and interim financial statements will not be detected or prevented on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are further enhancing internal controls, processes and related documentation necessary to perform the evaluation needed to comply with
Section&nbsp;404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. The effectiveness of our controls and procedures may be
limited by a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">faulty human judgment and simple errors, omissions or mistakes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fraudulent action of an individual or collusion of two or more people; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inappropriate management override of procedures; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility that any enhancements to controls and procedures may still not be adequate to assure timely and
accurate financial control. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we cease to be an &#147;emerging growth company&#148; under the federal securities
laws, our auditors will be required to express an opinion on the effectiveness of our internal controls. If we are unable to confirm that our internal control over financial reporting is effective, or if our independent registered public accounting
firm is unable to express an opinion on the effectiveness of our internal controls, we could lose investor confidence in the accuracy and completeness of our financial reports, which could cause the price of our common stock to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our
disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported
within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the
control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual
acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our
stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our amended and restated certificate of incorporation and
our amended and restated bylaws that will become effective upon the closing of this offering may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in
which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common
stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Because our Board
of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation
Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding
voting stock, unless the merger or combination is approved in a prescribed manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of
Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation that will become effective upon the closing of this offering specifies that,
unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. Notwithstanding
the foregoing, the exclusive forum provision will not apply to any claim to enforce any liability or duty created by the Exchange Act or the Securities Act and for which the federal courts have exclusive jurisdiction. We believe this exclusive forum
provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other
forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other
companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended
and restated certificate of incorporation to be inapplicable or unenforceable in such action. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Claims for indemnification by our directors and
officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated articles of incorporation that will be in effect at the closing of this offering provide that we will indemnify our
directors and officers to the fullest extent permitted by Section&nbsp;145 of the Delaware General Corporate Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as
permitted by the Delaware General Corporate Law, our amended and restated articles of incorporation and our indemnification agreements that we have entered into with our directors and officers provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will indemnify our directors and officers for serving us in those capacities or for serving other business
enterprises at our request, to the fullest extent permitted by applicable law. Such law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed
to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#146;s conduct was unlawful; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is
permitted by applicable law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a
proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights conferred in our amended and restated articles of incorporation are not exclusive, and we are
authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not retroactively amend our amended and restated articles of incorporation provisions to reduce our
indemnification obligations to directors, officers, employees and agents. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements
other than statements of historical facts contained in this prospectus, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as
statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148;
&#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potentially,&#148; &#147;predict,&#148; &#147;should,&#148; &#147;will&#148; or the negative of these terms or other similar expressions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we
believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, factors, and assumptions described under the section titled
&#147;Risk Factors&#148; and elsewhere in this prospectus, regarding, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to achieve or sustain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attain significant market acceptance among payers, providers, clinics, patients, and
biopharmaceutical companies for our diagnostic tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties managing our growth, which could disrupt our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to retain sales and marketing personnel, and failure to increase our sales and marketing capabilities or
develop broad awareness of our diagnostic tests to generate revenue growth; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to maintain our current relationships, or enter into new relationships, with biopharmaceutical companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant fluctuation in our operating results, causing our operating results to fall below expectations or any
guidance we provide; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand for our <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic and antibody testing program and
our ability to meet such demand; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product performance and reliability to maintain and grow our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third party suppliers, including contract manufacturers and single source suppliers; making us vulnerable to
supply problems and price fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of a pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide,
including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters and other similar events, including the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, negatively impacting our business, financial condition and results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to offer high-quality support for our diagnostic tests, which may adversely affect our relationships with
providers and negatively impact our reputation among patients and providers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to continue to innovate and improve our diagnostic tests and services we offer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">security or data privacy breaches or other unauthorized or improper access; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant disruptions in our information technology systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the incurrence of substantial liabilities and limiting or halting the marketing and sale of our diagnostic tests
due to product liability lawsuits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to compete successfully with competition from many sources, including larger companies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance issues, service interruptions or price increases by our shipping carriers and warehousing providers;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-containment efforts of our customers, purchasing groups and integrated delivery networks having a material
adverse effect on our sales and profitability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential effects of litigation and other proceedings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic and financial market conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">current and future debt financing placing restrictions on our operating and financial flexibility;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to raise additional capital to fund our existing operations, develop our platform, commercialize new
diagnostic tests or expand our operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acquisition of other businesses, which could require significant management attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the uncertainty of the insurance coverage and reimbursement status of newly approved diagnostic tests;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future healthcare reform measures that could hinder or prevent the commercial success of our diagnostic tests;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with anti-corruption, anti-bribery, anti-money laundering and similar laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with healthcare fraud and abuse laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop, receive regulatory clearance or approval for, and introduce new diagnostic tests or
enhancements to existing diagnostic tests that will be accepted by the market in a timely manner; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to comply with ongoing FDA or other domestic and foreign regulatory authority requirements, or
unanticipated problems with our diagnostic tests, causing them to be subject to restrictions or withdrawal from the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future product recalls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal proceedings initiated by third parties alleging that we are infringing, misappropriating, or otherwise
violating their intellectual property rights, the outcome of which would be uncertain; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volatility of the trading price of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inaccurate estimates or judgments relating to our critical accounting policies, which could cause our operating
results to fall below the expectations of securities analysts and investors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks, uncertainties and factors set forth in this prospectus, including those set forth under &#147;Risk
Factors.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These risks are not exhaustive. Other sections of this prospectus may include additional factors that
could harm our business and financial performance. New risk factors may emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to
which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in
the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any
reason after the date of this prospectus or to conform these statements to actual results or to changes in our expectations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such
information forms a reasonable basis for such statements, such information may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These
statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus
and the documents that we reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and
achievements may be different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds to us from the sale of 4,000,000 shares of common stock in this offering will be approximately
$63.0&nbsp;million at the initial public offering price of $18.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their over-allotment option in full, we
estimate that the net proceeds to us will be approximately $73.0&nbsp;million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently expect to use the net proceeds from this offering: (1)&nbsp;approximately $30&nbsp;million to support our commercial expansion of
sales, marketing, reimbursement, customer support and business development; (2)&nbsp;approximately $16&nbsp;million to support our product pipeline and research and development; (3)&nbsp;approximately $13&nbsp;million to pay a portion of our
Integrated Diagnostics acquisition milestone payment; and (4)&nbsp;the remaining portion of such net proceeds (including if the underwriters exercise their overallotment option in full) for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also use a portion of our net proceeds to <FONT STYLE="white-space:nowrap">co-develop,</FONT> acquire or invest in products,
technologies or businesses that are complementary to our business. However, we currently have no agreements or commitments to complete any such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we currently anticipate that we will use the net proceeds from this offering as described above, there may be circumstances where a
reallocation of funds is necessary. Due to the uncertainties inherent in the product development process, it is difficult to estimate with certainty the exact amounts of the net proceeds from this offering that may be used for the above purposes.
The amounts and timing of our actual expenditures will depend upon numerous factors, including our sales and marketing and commercialization efforts, demand for our technology, our operating costs and the other factors described under &#147;Risk
Factors&#148; in this prospectus. Accordingly, we will have broad discretion over the uses of the net proceeds from this offering. Pending the use of the proceeds from this offering, we may invest the proceeds in from this offering in short- and
intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the United States&nbsp;government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings,
if any, to support operations and to finance the growth and development of our business. We do not intend to declare or pay cash dividends on common stock in the foreseeable future following the consummation of this offering. Any determination to
declare dividends will be made at the discretion of our Board of Directors and will depend on, among other factors, our business, financial condition, results of operations and prospects that our Board of Directors may deem relevant. The terms of
our outstanding credit facility also restrict our ability to pay dividends, and we may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our capital
stock. See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Liquidity and Capital Resources&#151;Contractual Obligations and Commitments.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and our capitalization as of June&nbsp;30, 2020, 2019, on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma basis to reflect (i)&nbsp;the conversion of all the outstanding shares of preferred stock into an
aggregate of 20,090,745 shares of common stock immediately upon the closing of this offering, (ii)&nbsp;the conversion of all convertible debt into an aggregate of 1,848,280 shares of common stock immediately upon the closing of this offering, based
on interest accrued through October&nbsp;15, 2020 and the initial public offering price of $18.00 per share, and (iii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation that will be in effect upon the closing
of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma as adjusted basis to further reflect the sale of 4,000,000 shares of common stock in this offering at
the initial public offering price of $18.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this information together with the sections of this prospectus titled &#147;Prospectus Summary&#151;Summary Historical
Financial and Operating Data,&#148; &#147;Selected Historical Financial and Operating Data,&#148; &#147;Description of Capital Stock&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and
our financial statements and related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>As<BR>Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Convertible preferred stock; $0.001 par value; 185,432,719 shares authorized, 118,766,273 issued and outstanding, actual; 0&nbsp;shares authorized and 0 shares issued and outstanding, pro forma and pro forma as adjusted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock; $0.001 par value; no shares authorized, issued and outstanding, actual;
5,000,000&nbsp;shares authorized, no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 220,000,000 shares authorized, 274,523 issued and outstanding,
actual; 200,000,000&nbsp;shares authorized pro forma and pro forma as adjusted, 22,213,548&nbsp;shares issued and outstanding, pro forma; and 26,213,548&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(248,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250,564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250,564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(246,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding share information in the table above excludes, as of June 30, 2020, the following
shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,813,063&nbsp;shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30,
2020, with a weighted-average exercise price of $2.58 per share, plus 56,301&nbsp;shares of common stock issuable upon the exercise of stock options granted subsequent to June&nbsp;30, 2020, with a weighted-average exercise price of $4.87 per share;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">52,736 shares of common stock that will be outstanding upon the vesting of restricted stock units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">103,326 shares of common stock issuable upon the exercise of outstanding warrants to purchase shares of Series G
Preferred Stock as of June&nbsp;30, 2020, with a weighted-average exercise price of $4.46 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,893,395 shares of common stock reserved for future issuance under the 2020 Incentive Plan, which will become
effective immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">338,106 shares of common stock reserved for future issuance under the ESPP, which will become effective
immediately prior to the completion of this offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value as of June&nbsp;30, 2020 was $(246.4)&nbsp;million, or $(897.72) per share of our common stock. Our
historical net tangible book value is the amount of our total tangible assets less our total liabilities and convertible preferred stock, which is not included within our stockholders&#146; deficit. Historical net tangible book value per share
represents historical net tangible book value divided by the number of shares of our common stock outstanding as of June&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of June&nbsp;30, 2020 was $(20.9)&nbsp;million, or $(0.94) per share of our common stock. Pro forma
net tangible book value per share represents our total tangible assets less our total liabilities, divided by the number of outstanding shares of common stock, after giving effect to the conversion of all outstanding shares of preferred stock into
20,090,745 shares of common stock immediately upon the closing of this offering and the conversion of all convertible debt into an aggregate of 1,848,280 shares of common stock immediately upon the closing of this offering, based on interest accrued
through October&nbsp;15, 2020 and the initial public offering price of $18.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the conversion of our
outstanding preferred stock into 20,090,745 shares of common stock immediately upon the closing of this offering, the conversion of all convertible debt into an aggregate of 1,848,280 shares of common stock immediately upon the closing of this
offering, based on interest accrued through October&nbsp;15, 2020 and the initial public offering price of $18.00 per share, and the receipt of the net proceeds from our sale of 4,000,000 shares of common stock in this offering at the initial public
offering price of $18.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2020, would have been $42.1&nbsp;million,
or $1.60 per share. This represents an immediate increase in pro forma as adjusted net tangible book value of $2.54 per share to our existing stockholders and immediate dilution of $16.40 per share to investors purchasing common stock in this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per share basis to new investors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share of our common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(897.72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in net tangible book value per share as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">896.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution of net tangible book value per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their over-allotment option in full, the pro forma as adjusted net tangible book
value per share after giving effect to this offering would be $1.94 per share, and the dilution in pro forma as adjusted net tangible book value per share to new investors in this offering would be $0.34 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of October&nbsp;15, 2020: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the total number of shares of common stock purchased from us by our existing stockholders and by new investors
purchasing shares in this offering; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the total consideration paid to us by our existing stockholders and by new investors purchasing shares in this
offering, at the initial public offering price of $18.00 per share, before deducting the underwriting discounts and commissions and estimated offering expenses payable by us in connection with this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average price per share paid by existing stockholders and by new investors purchasing shares in this
offering. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price&nbsp;Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">22,254,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">229,010,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">26,254,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">304,010,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, the above discussion and tables assume no exercise of the underwriters&#146;
over-allotment option. If the underwriters exercise their over-allotment option in full, our existing stockholders would own 82.9% and our new investors would own 17.1% of the total number of shares of common stock outstanding upon the closing of
this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock that will be outstanding after this offering is based on 22,254,072 shares of
common stock outstanding as of October&nbsp;15, 2020, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,817,440 shares of common stock issuable upon the exercise of stock options outstanding as of October&nbsp;15,
2020, with a weighted-average exercise price of $2.80 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">79,104 shares of common stock that will be outstanding upon the vesting of restricted stock units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">103,326 shares of common stock issuable upon the exercise of outstanding warrants to purchase shares of Series G
Preferred Stock as of October&nbsp;15, 2020, with a weighted-average exercise price of $4.46 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,893,395 shares of common stock reserved for future issuance under the 2020 Incentive Plan, which will become
effective immediately prior to the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">338,106 shares of common stock reserved for future issuance under the ESPP, which will become effective
immediately prior to the completion of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, to the extent any outstanding options are exercised,
new investors would experience further dilution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_8"></A>SELECTED HISTORICAL FINANCIAL AND OPERATING DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth Biodesix, Inc.&#146;s selected historical financial and operating data as of the dates and for the financial
reporting periods indicated. The selected historical financial and operating data as of June&nbsp;30, 2020 and 2019 and for the six months ended June&nbsp;30, 2020 and 2019 have been derived from our unaudited condensed financial statements included
elsewhere in this prospectus. The selected historical financial and operating data as of December&nbsp;31, 2019 and 2018 and for the years ended December&nbsp;31, 2019 and 2018 have been derived from our audited financial statements included
elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selected historical financial information is not necessarily indicative of the results that may be
expected in any future financial reporting period, and our results of operations for any interim financial reporting period are not necessarily indicative of the results to be expected for the full year. Our preliminary revenues and cash for each of
the nine months ended September&nbsp;30, 2020 and September&nbsp;30, 2019 are included in &#147;Prospectus Summary&#151;Preliminary Results for Third Quarter 2020.&#148; Such results are preliminary and are subject to change and are not necessarily
indicative of the results expected for the full year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following selected historical financial and operating data should be read in
conjunction with &#147;Capitalization,&#148; &#147;Prospectus Summary&#151;Summary Historical Financial and Operating Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and the
financial statements and related notes appearing elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(audited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales, marketing, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of put option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(30,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;(26,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(68.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(64.88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(126.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(130.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares outstanding, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June 30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of long-term debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(248,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(230,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(246,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(228,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the sections of
this prospectus titled &#147;Prospectus Summary&#151;Summary Historical Financial and Operating Data,&#148; &#147;Selected Historical Financial and Operating Data&#148; and our financial statements and the related notes to those statements included
elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that
involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives, expectations, forecasts and projections. Our actual results and the timing of selected events could differ materially from those
anticipated in these forward-looking statements as a result of several factors, including those set forth under the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. You should carefully read the &#147;Risk Factors&#148; to
gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A), is provided to supplement
the financial statements and the related notes included elsewhere in this prospectus. We intend for this discussion to provide you with information that will assist you in understanding our financial statements, the changes in key items in those
financial statements from year to year and the primary factors that accounted for those changes. The MD&amp;A is organized as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Overview</I></B>. This section provides a general description of our business as well as trends and other
factors affecting our business that we believe are necessary to understand our financial condition and results of operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Factors Affecting Our Performance</I></B>. This section provides a description of the key factors that have
historically, and that we expect to continue to, affect our business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Components of Operating Results</I></B>. This section provides a description of our revenues and operating
expenses for the six months ended June 30, 2020 and 2019 and the years ended December&nbsp;31, 2019 and 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Results of Operations</I></B>. This section provides a discussion of the results of operations on a
historical basis for the six months ended June 30, 2020 and 2019 and the years ended December&nbsp;31, 2019 and 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Liquidity and Capital Resources</I></B>. This section provides an analysis of our ability to generate cash
and to meet existing known or reasonably likely future cash requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Critical Accounting Policies and Significant Judgments and Estimates</I></B>. This section discusses the
accounting policies and estimates that we consider important to our financial condition and results of operations and that require significant judgment and estimates on the part of management in their application. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Quantitative and Qualitative Disclosures about Market Risk</I></B>. This section discusses our exposure to
interest rate risk<I>.</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data for the six months ended June 30, 2020 and 2019 and the years ended December&nbsp;31,
2019 and 2018 has been derived from our unaudited condensed financial statements for the six months ended June&nbsp;30, 2020 and 2019 and our audited financial statements for the year ended December&nbsp;31, 2019 and 2018 included elsewhere in this
prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
primary focus in lung disease. By combining a technology agnostic approach with a holistic view of the patient&#146;s disease state, we believe our solutions provide physicians with greater
insights to help personalize their patient&#146;s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe helps
improve overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that
include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the
Diagnostic Cortex, to discover innovative diagnostic tests for clinical use. The Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of diagnostic tests, which we believe overcomes standard machine
learning challenges faced in life sciences research. Our data-driven and technology agnostic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and
biopharmaceutical companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continuously incorporate new market insights and patient data to enhance our platform through a
data-driven learning loop. We regularly engage with our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape to identify additional clinical unmet needs where a diagnostic
test could help improve patient care. Additionally, we incorporate clinical and molecular profiling data from our commercial clinical testing, research studies, clinical trials, and biopharmaceutical customers or academic partnerships, to continue
to advance our platform. We have over 140,000 samples and data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external R&amp;D initiatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have commercialized six diagnostic tests which are currently available for use by physicians. Our Nodify XL2 and Nodify CDT tests, marketed
as part of our Nodify Lung<I> </I>Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer two commercial blood-based tests to help
physicians reclassify risk of malignancy in patients with suspicious lung nodules. Our GeneStrat and VeriStrat tests, marketed as part of our Biodesix Lung Reflex<I><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></I>testing strategy, are used
following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#146;s immune system to establish the patient&#146;s prognosis and help guide treatment decisions. The GeneStrat tumor profiling test
and the VeriStrat immune profiling test have a <FONT STYLE="white-space:nowrap">three-day</FONT> average turnaround time, providing physicians with timely results to facilitate treatment decisions. In response to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe testing program. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure
enabled us to rapidly commercialize two FDA EUA-authorized tests, a part of our customizable program. Both diagnostic tests are owned and were developed by Bio-Rad and Bio-Rad has granted us permission to utilize both tests for commercial diagnostic
services. For more information regarding the permission granted to us by Bio-Rad with respect to such tests, please see &#147;Business&#151;Material Agreements&#151;Agreements with Bio-Rad.&#148; HHS Secretary Azar declared a public health emergency
for COVID-19 in February 2020 which justified the authorization of emergency use of diagnostic tests for the detection and/or diagnosis of COVID-19. The Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test have been granted FDA
EUA pursuant to the current emergency declaration. The Bio-Rad SARS-CoV-2 ddPCR test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under CLIA to perform high complexity tests. The second test is
the Platelia SARS-CoV-2 Total Ab test, which is an antibody assay intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. The Platelia SARS-CoV-2 Total Ab test was FDA EUA authorized on April 29, 2020.
Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer
exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety, and we cannot predict how long the EUAs for the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
SARS-CoV-2 tests will remain in place. Using the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, we operate and have commercialized the Biodesix WorkSafe testing
program.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to using the Bio-Rad tests as part of our testing program, we performed feasibility, verification, and validation studies,
including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the manufacturer and as required by our certifying regulatory agencies for high
complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Post-launch development support for these tests have included improvements in
on-boarding new personnel, logistics of sample collection, sample receipt and data reporting, all required to support our testing program. Additional releases of the laboratory data management software are ongoing and planned for the foreseeable
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These tests are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and
educational systems to assist in their back-to-work or back-to-school strategies. Recently we announced multiple partnerships for COVID-19 testing, and have entered into an agreement with the State of Colorado to be one of the diagnostic companies
to support widespread COVID-19 testing for the State. Additionally, we recently announced that we will oversee and manage onsite testing and validating testing for the Big Ten Conference athletic competitions. To date, we have not derived
significant revenues from these partnerships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the six diagnostic tests currently on the market, we perform over 30 assays
for research use as part of our laboratory services that have been used by over 50 biopharmaceutical customers and academic partners. All of our diagnostic testing is performed at one of our two certified, high-complexity clinical laboratories in
Boulder, Colorado and De Soto, Kansas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have performed over 245,000 tests and continue to generate a large and
growing body of clinical evidence consisting of over 275 clinical and scientific peer-reviewed publications and presentations. Through ongoing study of each of our tests, we continue to grow our depth of understanding of disease biology and the
broad utility of each of our tests. We believe we are poised for rapid growth by leveraging our scientific development and laboratory operations expertise along with our commercial infrastructure which includes sales, marketing, reimbursement, and
regulatory affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, we market our tests to clinical customers through our targeted sales organization, which
includes sales representatives that are engaged in sales efforts and promotional activities primarily to pulmonologists, oncologists, cancer centers and nodule clinics. We market our tests and services to biopharmaceutical customers globally through
our targeted business development team, which promotes the broad utility of our tests and testing capabilities throughout drug development and commercialization which is of value to pharmaceutical companies and their drug-development process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generated total revenue of $9.3 million and $12.3 million for the six months ended June 30, 2020 and 2019, respectively, and generated
total revenue of $24.6&nbsp;million and $20.4&nbsp;million for the years ended December&nbsp;31, 2019 and 2018, respectively. We incurred net losses of $18.0 million and $14.6 million for the six months ended June 30, 2020 and 2019, respectively,
and net losses of $30.7&nbsp;million and $26.2&nbsp;million for the years ended December&nbsp;31, 2019 and 2018, respectively. We have funded our operations to date principally from net proceeds from the sale of convertible preferred stock, revenue
from diagnostic testing and services, and the incurrence of indebtedness. Most recently in two tranches, in March 2020, and June 2020 we raised $10&nbsp;million through the issuance of convertible debt. We had cash and cash equivalents of $11.7
million as of June 30, 2020 and $5.3&nbsp;million as of December&nbsp;31, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Factors Affecting Our Performance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there are several important factors that have impacted our operating performance and results of operations, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Testing volume and customer mix.</B> Our revenues and costs are affected by the volume of testing and mix of
customers from period to period. We evaluate both the volume of our commercial tests, or the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
number of tests that we perform for patients on behalf of clinicians, as well as tests for biopharmaceutical companies. Our performance depends on our ability to retain and broaden adoption with
existing customers, as well as attract new customers. We believe that the test volume we receive from clinicians and biopharmaceutical companies are indicators of growth in each of these customer verticals. Customer mix for our tests has the
potential to significantly impact our results of operations, as the average selling price for biopharmaceutical sample testing is currently significantly greater than our average selling price for clinical tests since we are not a contracted
provider for, or our tests are not covered by all clinical patients&#146; insurance. We evaluate our average selling price for tests that are covered by Medicare, Medicare Advantage and commercial payers to understand the trends in reimbursement and
apply those trends to our revenue recognition policies. We expect our costs to significantly increase in 2020 and the beginning of 2021 due to a significant increase in demand for <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic testing
and we expect our related revenues from such tests to also increase. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Reimbursement for clinical diagnostic testing. </B>Our revenue depends on achieving broad coverage and
reimbursement for our tests from third-party payers, including both commercial and government payers. Payment from third-party payers differs depending on whether we have entered into a contract with the payers as a &#147;participating
provider&#148; or do not have a contract and are considered a <FONT STYLE="white-space:nowrap">&#147;non-participating</FONT> provider.&#148; Payers will often reimburse <FONT STYLE="white-space:nowrap">non-participating</FONT> providers, if at all,
at a lower rate than participating providers. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Historically, we have experienced situations where commercial payers
proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments
by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications. Becoming a participating
provider generally results in higher reimbursement for covered indications and lack of reimbursement for <FONT STYLE="white-space:nowrap">non-covered</FONT> indications. As a result, the impact of becoming a participating provider with a specific
payer will vary. If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payers, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective reimbursement
adjustments can negatively impact our revenue and cause our financial results to fluctuate. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Investment in clinical studies and product innovation to support growth. </B>A significant aspect of our
business is our investment in research and development, including the development of new products and our investments in clinical utility studies. We have invested heavily in clinical studies for our on market and pipeline products. Our studies
focus primarily on the clinical utility of our tests including the ongoing INSIGHT study which seeks to enroll up to 5,000 patients to continue our clinical understanding of the predictive and prognostic value of the VeriStrat test. Our recently
launched ALTITUDE study seeks to further demonstrate the efficacy of the Nodify XL2 and Nodify CDT test. A secondary focus of our studies is understanding the economic impact of our tests in guiding treatment choices and the potential impact of our
tests in reducing overall healthcare costs. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Our clinical research has resulted in over 80 peer-reviewed publications for
our tests. In addition to clinical studies, we are collaborating with investigators from multiple academic cancer centers. We believe these studies are critical to gaining physician adoption and driving favorable coverage decisions by payers and
expect our investments in research and development to increase. Further we also expect to increase our research and development expenses to fund further innovation and develop new clinically relevant tests. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Ability to attract new biopharmaceutical customers and maintain and expand relationships with existing
customers. </B>Our business development team promotes the broad utility of our products for biopharmaceutical companies in the United States and internationally. Our revenue, business opportunities and growth depend in part on our ability to attract
new biopharmaceutical customers and to maintain and expand relationships with existing biopharmaceutical customers. We expect to increase our sales and marketing expenses in furtherance of this goal. As we continue to develop these relationships, we
expect to support a growing number of investigations and clinical trials. If our </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
relationships expand, we believe we may have opportunities to offer our platform for companion diagnostic development, novel target discovery and validation efforts, and to grow into other
commercial opportunities. For example, we believe our multi-omic data including genomic and proteomic data, in combination with clinical outcomes or claims data, has revenue-generating potential, including for novel target identification and
companion diagnostic discovery and development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Motivating and expanding our field sales force and customer support team. </B>Our field sales force is the
primary point of contact in the clinical setting. These representatives of the company must cover expansive geographic regions which limits their time for interaction and education of our products in the clinical setting. We plan to invest heavily
in the field sales force to increase the total number of sales representatives and thereby reduce the geographic footprint each representative must cover. This investment will allow the larger sales force to maximize their education and selling
efforts and achieve greater returns. Additionally, we plan to invest in the Boulder-based marketing and customer support teams to continue to provide the field team with the resources to be successful in the field. Furthermore, as we increase
testing volume for our <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic testing program, we plan to hire additional project support members to assist us in expanding testing capacity. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. See
&#147;Risk Factors&#148; for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">COVID-19</FONT> Pandemic </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has disrupted, and we expect will continue to disrupt, our operations. To protect
the health and well-being of our workforce, partners, vendors and customers, we provide voluntary <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing for employees working <FONT STYLE="white-space:nowrap">on-site,</FONT> implemented social
distance and building entry policies at work, restricted travel and facility visits, and followed the States of Colorado and Kansas&#146; public health orders and the guidance from the Centers for Disease Control and Prevention. Employees who can
perform their duties remotely are asked to work from home and those on site are asked to follow our social distance guidelines.&nbsp;Our sales, marketing and business development efforts have also been constrained by our operational response to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic due to travel restrictions.&nbsp;We expect to continue to adjust our operational norms in an effort to help slow the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> in the coming months,
including complying with government directives and guidelines as they are modified and supplemented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic also has started to negatively affect, and we expect will continue to negatively affect, our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-COVID-19</FONT></FONT>
testing-related revenue and our clinical studies. For example, cancer patients may have more limited access to hospitals, healthcare providers and medical resources as they take steps to control the spread of
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> Our biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized.&nbsp;As a result of
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, beginning in the latter half of March 2020, we have been receiving fewer samples for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-COVID-19</FONT></FONT> testing
on a daily average basis from our clinical and biopharmaceutical customers than before the outbreak of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Further, our clinical studies, such as our ongoing INSIGHT study and our recently
launched ALTITUDE study, as well as our arrangements with our biopharmaceutical customers, are expected to take longer to complete than what we expected before the outbreak of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also experiencing an increase in revenues related to an increase in the demand for our Biodesix WorkSafe testing program. We expect
that our costs to expand capacity for <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing will increase for the remainder of 2020 and the first quarter of 2021 and we expect that the revenue that we generate from this expansion will comprise a
significant portion of our revenue for these periods. However, there is no assurance that our <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing program will continue to be accepted by the market or that other diagnostic tests will become more
accepted, produce quicker results or are more accurate.&nbsp;Further, the longevity and extent of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant decrease in
new infections, due to the availability of vaccines, or otherwise, the need for a <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic test could decrease significantly and this could have an adverse
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effect on our results of operations and profitability. As a result, the increase in revenue due to any increase in demand for these diagnostic tests may not be indicative of our future revenue.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Risk Factors&#148; for a description of how the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may adversely affect
our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Operating Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derive
our revenue from two sources: (i)&nbsp;providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii)&nbsp;providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and
testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Diagnostic Tests </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diagnostic test revenue is generated from delivery of results from our diagnostic tests. In the United States, we performed tests as both an <FONT
STYLE="white-space:nowrap">in-network</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-network</FONT></FONT> service provider depending on the test performed and the contracted status of the insurer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consider diagnostic testing to be completed upon the delivery of test results to the prescribing physician, which is considered the
performance obligation. The fees for such services are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. We determine the transaction price related to our contracts by considering
the nature of the payer, the historical amount of time until payment by a payer and historical price concessions granted to groups of customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diagnostic test revenue decreased to $7.2&nbsp;million for the six months ended June&nbsp;30, 2020 compared to $8.9&nbsp;million for the six
months ended June&nbsp;30, 2019, a decrease of $1.7&nbsp;million or 19%. This decrease was primarily due to impacts from the COVID-19 pandemic which caused our primary pulmonology call point to be diverted to pandemic-related care and our sales
force being quarantined, and in many cases being locked out of call points due to the pandemic. As a result, revenue related to our non-COVID-19 diagnostic tests declined by $3.1&nbsp;million in the six months ended June&nbsp;30, 2020 when compared
to the same period in 2019. These impacts were partially offset by the commercialization of two COVID-19 diagnostic tests. The net impact of these changes was a $1.7&nbsp;million reduction in diagnostic revenues during the six months ended
June&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Services </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Services revenue is generated from the delivery of our on-market tests, pipeline tests, custom diagnostic testing, and other scientific
services for a purpose as defined by any individual customer. Often times we collaborate with large biopharmaceutical companies in an attempt to discover biomarkers that would be helpful in their drug development or marketing. The performance
obligations and related revenue for these sales is defined by a written agreement between us and our customer. These services are generally completed upon the delivery of testing results, or other contractually-defined milestone(s), to the customer,
which is considered the performance obligation. Customers for these services are typically large pharmaceutical companies where collectability is reasonably assured and therefore revenue is accrued upon completion of the performance obligations.
Revenue derived from services is often unpredictable and can cause dramatic swings in our overall net revenue line from quarter to quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six months ended June 30, 2020 and 2019, diagnostic test revenue comprised 78% and 73% of our total revenues and services revenue
comprised 22% and 27% of total revenues, respectively. Diagnostic test revenue comprised 71% and 93% of our total revenues and services revenue comprised 29% and 7% of total revenues in 2019 and 2018, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Direct costs and expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of diagnostic testing generally consists of cost of materials, direct labor, including bonus, benefit and stock-based compensation,
equipment and infrastructure expenses associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for
physicians; and in some cases, license or royalty fees due to third parties. Costs associated with performing our tests are recorded as the tests are processed regardless of whether revenue was recognized with respect to the tests. Infrastructure
expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Royalties for licensed technology are calculated as a percentage of revenues generated using the associated
technology and recorded as expense at the time the related revenue is recognized. <FONT STYLE="white-space:nowrap">One-time</FONT> royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are
amortized to expense over the expected useful life of the patents. While we do not believe the technologies underlying these licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of
possible strategic importance to us or our competitors. Under these license agreements, we are obligated to pay aggregate royalties ranging from 1% to 8% of sales in which the patents or <FONT STYLE="white-space:nowrap">know-how</FONT> are used in
the product or service sold, sometimes subject to minimum annual royalties or fees in certain agreements. For a description of our material license agreements, please see &#147;Business&#151;Intellectual Property&#148; and &#147;&#151;Material
Agreements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the aggregate cost of diagnostic testing to increase in line with the increase in the number of tests we
perform, but the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of services includes costs incurred for the performance of development services requested by our customers. Cost of development services
will vary depending on the nature, timing and scope of customer projects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of costs incurred to develop technology and include salaries and benefits, reagents and supplies used
in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, clinical studies, other outside costs and costs to develop our technology capabilities.
Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or
services are rendered. Costs to develop our technology capabilities are recorded as research and development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and
development expenses to increase in absolute dollars as we continue to innovate and develop additional products and expand our data management resources. As our services revenue grows, an increasing portion of research and development dollars are
expected to be allocated to cost of goods for biopharma service contracts. This expense, though expected to increase in absolute dollars, is expected to decrease as a percentage of revenue in the long term, though it may fluctuate as a percentage of
our revenues from period to period due to the timing and extent of these expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Sales, marketing, general and administrative
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our
direct sales force and sales management, client services, marketing and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses,
employee benefits, travel and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses. We expect our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sales and marketing expenses to increase in absolute dollars as we expand our sales force, increase our presence within the United States, and increase our marketing activities to drive further
awareness and adoption of our tests and our future products. These expenses, though expected to increase in absolute dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage of our
revenues from period to period due to the timing and extent of these expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our general and administrative expenses include costs for
our executive, accounting, finance, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel and stock-based compensation, as well as professional services fees such as consulting,
audit, tax and legal fees, and general corporate costs and allocated overhead expenses. We expect that our general and administrative expenses will continue to increase in absolute dollars after this offering, primarily due to increased headcount
and costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and requirements of the SEC, director and officer insurance premiums and investor
relations. These expenses, though expected to increase in absolute dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage from period to period due to the timing and extent of these
expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Accretion and Change in Fair Value of Contingent Consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the purchase transaction of Integrated Diagnostics, Inc., we recorded contingent consideration pertaining to the amounts
potentially payable to Integrated Diagnostics&#146; shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are
recognized as operating expenses within the statement of operations. The estimated fair value of the contingent consideration is based upon significant assumptions including probability of successful achievement of that related milestone event
(Milestone), the estimated timing in which the Milestone is achieved, and discount rates. The estimated fair value could materially differ from actual values or fair values determined using different assumptions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Other income (expense) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest expense and interest income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists of interest from our term loan and convertible debt, and interest income consists of income earned on our cash and
cash equivalents. For the first six months of 2020, our interest expense increased as compared to 2019, as our term loan does not begin principal payments until March 2021. Our interest income has not been significant to date but we expect our
interest income to increase primarily as we invest the net proceeds from this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change in fair value of put option liability
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2019, we issued $13.0&nbsp;million in convertible debt that is now scheduled to mature on June&nbsp;30, 2021. The terms of the
convertible debt provided discounts upon conversion to the note holders in certain situations, including upon the completion of this offering. The discounts included in the convertible debt created a put option liability that was separated from the
convertible debt and reflected as a liability in our balance sheet. Subsequent to the creation of the put options, changes in the fair value of the put options will be reflected as other income or expense in the statement of operations. During 2019,
we recorded a $2&nbsp;million increase in the fair value of the put options as other expense due to the increase in the conversion discount rate provided to note holders resulting from an amendment to terms of the convertible debt issued in August
and September 2019. We will estimate the fair value of the put options until they are exercised or expire. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the significant components of our results of operations for the periods presented (in thousands, except
percentages). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months<BR>Ended June 30, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(audited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 24,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 20,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales, marketing, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(393</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of put option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,930</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generate revenue from our diagnostic tests and services that we provide (in thousands, except percentages). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(audited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diagnostic revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,004</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenue was $9.3&nbsp;million for the six months ended June&nbsp;30, 2020 compared to $12.3&nbsp;million
for the six months ended June&nbsp;30, 2019, a decrease of $3.0 million, or 24%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diagnostic test revenue decreased to $7.2&nbsp;million
for the six months ended June&nbsp;30, 2020 compared to $8.9&nbsp;million for the six months ended June&nbsp;30, 2019, a decrease of $1.7&nbsp;million or 19%. This decrease was primarily due to impacts from the COVID-19 pandemic which caused our
primary pulmonology call point to be diverted to pandemic-related care and our sales force being quarantined, and in many cases being locked out of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
call points due to the pandemic. As a result, revenue related to our non-COVID-19 diagnostic tests declined by $3.1&nbsp;million in the six months ended June&nbsp;30, 2020 when compared to the
same period in 2019. These impacts were partially offset by the commercialization of two COVID-19 diagnostic tests. The net impact of these changes was a $1.7&nbsp;million reduction in diagnostic revenues during the six months ended June 30, 2020.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Services revenue decreased to $2.1&nbsp;million for the six months ended June 30, 2020 compared to $3.4 million for the six months ended
June&nbsp;30, 2019, a decrease of $1.3&nbsp;million or 38%. The decrease was partially attributed to the completion of a contract in the first half of 2019. Additionally, the impacts of COVID-19 caused planned biomarker studies to be delayed and
limited the customer access of our sales force. Additionally, services revenue decreased due to the completion of a contract in the first half of 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenue was $24.6&nbsp;million for the year ended December&nbsp;31, 2019 compared to $20.4&nbsp;million for the year ended
December&nbsp;31, 2018, an increase of 20%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diagnostic test revenue decreased to $17.3&nbsp;million for the year ended December&nbsp;31,
2019 compared to $19.0&nbsp;million for the year ended December&nbsp;31, 2018, a decrease of $1.7&nbsp;million or 9%. This decrease was the result of a decrease in tests delivered which was a result of significant restructuring of our field sales
force to increase the emphasis on tests in nodule management that came on market following the completion of our recent acquisitions in that space. We recognized $1.0&nbsp;million in additional diagnostic test revenue in 2019 for claims from a prior
period due to a change in coverage for GeneStrat which captured previously unreimbursed revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Services revenue increased to
$7.2&nbsp;million for the year ended December&nbsp;31, 2019 compared to $1.5&nbsp;million for the year ended December&nbsp;31, 2018. The increase in services revenue was due to generally higher demand for biomarker development services and the
acceleration of pharmaceutical partners&#146; development efforts at the end of 2019, which resulted in a significant services revenue in December 2019 and is not expected to be recurring. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Costs and Operating Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Direct Cost and Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue was $3.5&nbsp;million for the six months ended June&nbsp;30, 2020 compared to $2.7&nbsp;million for the six months ended
June&nbsp;30, 2019, an increase of $0.7 million, or 26%. The increase in costs were primarily driven by the release of our CDT test and our COVID-19 testing program in 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue was $6.1&nbsp;million for the year ended December&nbsp;31, 2019 compared to $4.4&nbsp;million for the year ended
December&nbsp;31, 2018, an increase of $1.7&nbsp;million, or 38%. This increase in cost of revenue was primarily due to the introduction of the Nodify XL2 test in November 2018, and which contributed $1.4&nbsp;million in additional costs without
material revenue during the 2019 period.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $5.0&nbsp;million for the six months ended June&nbsp;30, 2020 compared to $5.6&nbsp;million for the six
months ended June&nbsp;30, 2019, a decrease of $0.6&nbsp;million, or 11%. This decrease was primarily related to a reduction in external costs related to the studies and development efforts for pipeline products, partially driven by slowdowns
related to the COVID-19 pandemic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $10.5&nbsp;million for the year ended December&nbsp;31, 2019
compared to $8.2&nbsp;million for the year ended December&nbsp;31, 2018, an increase of $2.3&nbsp;million, or 28%. This increase in research and development expense in 2019 was primarily driven by a $2.0&nbsp;million increase in external costs
consisting of $1.0&nbsp;million for clinical trials, and $1.0&nbsp;million for other research studies, supplies, and services. Internal costs increased by $0.2&nbsp;million, of which less than 1% was stock-based compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our external and internal costs for the six months ended
June&nbsp;30, 2020 and 2019 and the years ended December&nbsp;31, 2019 and 2018 (in thousands, except percentages). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">External expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical trials and associated costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other external costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,721</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total external costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Internal expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses account for a significant portion of our operating expenses and consist
primarily of external and internal costs incurred in connection with the discovery and development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">External
expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments to third parties in connection with the clinical development of our product candidates, including
contract research organizations and consultants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing products for use in our preclinical studies and clinical trials, including payments to
contract manufacturing organizations (CMOs) and consultants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payments to third parties in connection with the preclinical development of our product candidates, including
outsourced professional scientific development services, consulting research fees and for sponsored research arrangements with third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory supplies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allocated facilities, depreciation and other expenses, which include direct or allocated expenses for IT, rent
and maintenance of facilities. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal expenses include employee-related costs, including salaries, related benefits
and stock-based compensation expense for employees engaged in research and development functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development
costs in the periods in which they are incurred. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers or our estimate of the level of
service that has been performed at each reporting date. We track external costs by the stage of program, clinical or preclinical. We do not track internal costs by product candidate because these costs are deployed across multiple programs and, as
such, are not separately classified. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Sales, Marketing, General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales, marketing, general and administrative expenses were $14.9&nbsp;million for the six months ended June&nbsp;30, 2020 compared to
$15.9&nbsp;million for the six months ended June&nbsp;30, 2019, a decrease of $1.0&nbsp;million, or 6%. This reduction was driven by reductions in the travel and related expenses as the COVID-19 pandemic reduced or eliminated the travel and related
expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales, marketing, general and administrative expenses were $30.6&nbsp;million for the year ended December&nbsp;31, 2019
compared to $25.9&nbsp;million for the year ended December&nbsp;31, 2018, an increase of $4.7&nbsp;million, or 18%. This increase was primarily due to an increase of $2.7&nbsp;million in personnel-related costs for expansion of our sales
organization and $1.0&nbsp;million for increased marketing activity to support sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Accretion of and Change in Fair Value of Contingent Consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accretion of and change in fair value of contingent consideration netted to $0&nbsp;for the six months ended June&nbsp;30, 2020 compared to
$2.3&nbsp;million for the six months ended June&nbsp;30, 2019, a decrease of $2.3&nbsp;million, or 100%. The amounts recorded for accretion and change in fair value reflect the passage of time as well as estimates in when the milestones that trigger
the payment of contingent consideration will be achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accretion of and change in fair value of contingent consideration were
$4.1&nbsp;million for the year ended December&nbsp;31, 2019 compared to $5.4&nbsp;million for the year ended December&nbsp;31, 2018, a decrease of $1.3&nbsp;million, or 24%. The amounts recorded for accretion and change in fair value reflect the
passage of time as well as estimates in when the milestones that trigger the payment of contingent consideration will be achieved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense was $4.2&nbsp;million for the six months ended June&nbsp;30, 2020 compared to $1.3&nbsp;million for the six months ended
June&nbsp;30, 2019, an increase of $2.9&nbsp;million. This increase was due to the addition of interest expense related to convertible notes issued to certain shareholders from August 2019 through March 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense was $3.0&nbsp;million for the year ended December&nbsp;31, 2019 compared to $2.9&nbsp;million for the year ended
December&nbsp;31, 2018, an increase of $0.1&nbsp;million, or 3%. This increase was primarily due to payment in kind interest accruing to principal on our existing term loan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Put Option Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2019, we recorded a charge of $2.0&nbsp;million related to the increase in our put option liability related to our convertible debt.
This increase was primarily due to the amendment to the conversion discounts included in our convertible debt that were issued in August and September 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Income and Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income and expense was $0.3&nbsp;million for the six months ended June&nbsp;30, 2020 compared to $0.9&nbsp;million for the six months
ended June&nbsp;30, 2019, a decrease of $0.6&nbsp;million or 64%. This decrease was driven by a non-recurring legal settlement in 2019, which was not present in 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income and expense was $1.0&nbsp;million for the year ended December&nbsp;31, 2019 compared to $0.2 million for the year ended
December&nbsp;31, 2018, an increase of $0.8 million, which was primarily proceeds related to a non-recurring legal settlement in our favor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity
and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have funded our activities primarily through private equity placement offerings, convertible debt and
long-term debt. Based on cash and cash equivalents on hand as of June&nbsp;30, 2020 and the proceeds from this offering, we believe that our existing cash, cash equivalents, and cash generated from sales of our products, will be sufficient to meet
our anticipated needs for at least the next 12 months from the date of our most recent unaudited interim condensed financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while we make
investments to support our anticipated growth. We may raise additional capital through the issuance of additional equity financing, debt financings or other sources. If this financing is not available to us at adequate levels, we may need to
reevaluate our operating plans. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other
preferences that adversely affect our existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders&#146; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of our cash flows for six months ended June&nbsp;30, 2020 and 2019 and the years ended December&nbsp;31, 2019 and
2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(Amounts in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended<BR>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(audited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash flows (used in) provided by:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,677</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(818</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(851</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,872</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(617</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our cash flows resulted in a net increase in cash of $6.4 million during the six months ended June&nbsp;30,
2020 and a net decrease in cash of $0.7&nbsp;million during the six months ended June 30, 2019. Net cash used in operating activities during the year ended June&nbsp;30, 2020 totaled $8.8&nbsp;million, a decrease of $0.9 million, or 10%, compared to
the same period in 2019. The net cash used in operating activities decreased primarily due to a $3.4 million increase in net losses, offset by an increase in non-cash charges of $0.7 million and an increase in cash provided by working capital items
of $3.6 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities during the six months ended June&nbsp;30, 2020 totaled $0.8 million, a decrease of
$33,000, or 4%, compared to the same period in 2019. A decrease in net cash used in investing activities was primarily due to a decrease of $0.5 million in the purchase of research equipment and a $0.5 million payment for Oncimmune assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities during the six months ended June&nbsp;30, 2020 totaled $16.0&nbsp;million, an increase of
$6.1&nbsp;million, or 61%, compared to the same period in 2019. The net cash provided by financing activities increased primarily due to issuances of $13.0 million in convertible debt offset by $10.0 million in proceeds from the issuance of Series H
preferred stock during 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our cash flows resulted in a net decrease in cash of $0.6&nbsp;million during the year ended
December&nbsp;31, 2019 and a net increase in cash of $0.7&nbsp;million during the year ended December&nbsp;31, 2018. Net cash used in operating activities during the year ended December&nbsp;31, 2019 totaled $21.7&nbsp;million, an increase of
$4.0&nbsp;million, or 23%, compared to the same period in 2018. The net cash used in operating activities increased primarily due to a $4.6&nbsp;million increase in net losses, and an increase in use of working capital items of $1.9 million, offset
by an increase in non-cash charges of $2.4 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities during the year ended December&nbsp;31, 2019
totaled $1.9&nbsp;million, an increase of $1.3&nbsp;million, or 203%, compared to the same period in 2018. The increase in net cash used in investing activities was primarily due to an increase of $0.8&nbsp;million in the purchase of research
equipment and a $0.5&nbsp;million payment for Oncimmune assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities during the year ended
December&nbsp;31, 2019 totaled $23.0&nbsp;million, an increase of $3.9&nbsp;million, or 21%, compared to the same period in 2018. The net cash provided by financing activities increased primarily due to increased proceeds from issuances of
$2.8&nbsp;million in convertible debt and $1.5&nbsp;million in preferred stock offset by $0.4&nbsp;million in financing costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations and Commitments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations and commitments as of June&nbsp;30, 2020 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments due by period<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;to&nbsp;3<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>4&nbsp;to&nbsp;5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More<BR>than<BR>5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term loan<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debt<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflected in accompanying balance sheets. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Convertible debt may be prepaid at our option prior to maturity. If not prepaid or otherwise converted, the
debt will convert to Series H preferred stock at maturity. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The term loan is subject to a 3% prepayment penalty. In addition, upon maturity, a 2% <FONT
STYLE="white-space:nowrap">back-end</FONT> facility fee of $460,000 is due to the lender. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We are obligated under <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating leases for all of our
facilities. Lease terms for our facilities in effect as of June&nbsp;30, 2020, ranged from less than one to three years and generally require us to pay the real estate taxes, certain insurance and operating costs. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Royalty payments that we may owe are not included as the timing of such payments is uncertain.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, we entered into an agreement with Innovatus Life Sciences Lending Fund to refinance long-term debt
carried over from earlier loan agreements (the 2018 Notes).&nbsp;The initial amount borrowed under the 2018 Notes was $23&nbsp;million and the maturity date is February&nbsp;2023.&nbsp;We are required to make quarterly interest payments that began
in June 2018 and outstanding principal is due in 24 equal installments commencing in March&nbsp;2021.&nbsp;The agreement has been amended multiple times to adjust terms to account for our acquisitions and growth. Further, we granted the lender a
security interest in all of our assets through a pledge and security agreement, patent security agreement and trademark security agreement, each between us and the lender. The loan may be prepaid by us at any time, subject to a prepayment penalty of
up to 3% of the principal amount, depending on the date of prepayment.&nbsp;Upon payment of the 2018 Notes at maturity or prepayment on any earlier date, unless waived, a 2% <FONT STYLE="white-space:nowrap">back-end</FONT> facility fee will apply to
the amounts paid or prepaid.&nbsp;The 2% fee is being recorded as additional interest expense over the term of the 2018 Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018
Notes contain customary affirmative and negative covenants for a loan, requires us to comply with a minimum daily liquidity covenant, and has a rolling monthly revenue requirement.&nbsp;Failure to comply with the covenants and loan requirements may
result in early amortization of the loan in a <FONT STYLE="white-space:nowrap">24-</FONT> or <FONT STYLE="white-space:nowrap">36-month</FONT> payment schedule. The 2018 Notes also contain certain covenants that prevent us from making acquisitions,
incurring additional indebtedness, or making or terminating any agreement valued above a certain dollar threshold without the prior written consent of the lender. These covenants may restrict our ability to pursue new business opportunities and
access additional capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the purchase transaction of Integrated Diagnostics, Inc., we recorded contingent
consideration pertaining to the amounts potentially payable to Integrated Diagnostics&#146; shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and
changes, if any, to the fair value are recognized as operating expenses within the statement of operations. The estimated fair value of the contingent consideration is based upon significant assumptions including probability of successful
achievement of the Milestone, the estimated timing in which the Milestone is achieved, and discount rates. The estimated fair value could materially differ from actual values or fair values determined using different assumptions. At June&nbsp;30,
2020, the amount that would be due in cash at the option of the seller at the time the Milestone is met would be approximately $37&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our other indebtedness, please see &#147;Certain Relationships and Related
Person Transactions&#151;Convertible Debt Financings&#148; and &#147;Description of Capital Stock&#151;Convertible Debt.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, we have not entered into any <FONT
STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with accounting principles generally accepted in the United States, we are required to make estimates and assumptions that affect
the amounts reported in the financial statements and accompanying notes. Certain of these estimates significantly influence the portrayal of our financial condition and results of operations and require us to make difficult, subjective or complex
judgments. Our critical accounting policies primarily relate to our fair value estimates, and are described in greater detail in Note 1 to our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
May 2014, the Financial Accounting Standards Board (FASB) issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09,</FONT> &#147;Revenue from Contracts with Customers&#148;, and has subsequently issued several supplemental and/or clarifying ASUs
(collectively, ASC&nbsp;606). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC&nbsp;606 is intended to provide a more consistent interpretation and application of the
principles outlined in the standard across filers in multiple industries and within the same industries compared to current practices, which should improve comparability. We adopted the new standard using the modified retrospective method on
January&nbsp;1, 2018 for contracts that are not completed as of the adoption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC&nbsp;606, an entity recognizes revenue when
its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity
determines are within the scope of ASC&nbsp;606, the entity performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction
price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the
accounting for costs to obtain or fulfill a contract. The standard also requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We examined our revenue recognition policies specific to revenue streams for the provisioning of services and providing research and
development services to third parties and came to conclusions on the impact of the new standard using the <FONT STYLE="white-space:nowrap">5-step</FONT> process prescribed by ASC&nbsp;606. As noted above, we used the modified retrospective method to
adopt the new standard which means we did not restate previously issued financial statements but recorded a <FONT STYLE="white-space:nowrap">one-time</FONT> adjustment to accumulated deficit and accounts receivable of $0.4&nbsp;million. This
adjustment reflected our ability to establish a transaction price for our <FONT STYLE="white-space:nowrap">non-Medicare</FONT> pay arrangements as of January&nbsp;1, 2018 as a result of having sufficient history to determine the transaction price
under these contracts. ASC&nbsp;606 did not have an aggregate impact our net cash provided by operating activities but resulted in offsetting changes in certain assets and liabilities presented within net cash used in operating activities in the
accompanying statement of cash flows, as noted above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diagnostic service revenues are generally completed upon the delivery of test
results to the prescribing physicians, which is considered the performance obligation. Testing services are generally completed upon the delivery of testing results for assay development and testing services, which is considered the performance
obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change in fair value of contingent consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the purchase transaction with Integrated Diagnostics, Inc., we recorded contingent consideration pertaining to the amounts
potentially payable to Integrated Diagnostics&#146; shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are
recognized as operating expenses within the statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the contingent consideration is based
upon significant assumptions including probabilities of successful achievement of the related Milestone, the estimated timing in which the Milestone is achieved, and discount rates. The estimated fair value could materially differ from actual values
or fair values determined using different assumptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Accounting for convertible debt </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2020 and 2019, we issued $26.0&nbsp;million in convertible debt that are now scheduled to mature on June&nbsp;30, 2021. The terms of the
convertible debt provided discounts upon conversion to the note holders in certain situations, including upon the completion of this offering. The discounts included in the convertible debt created a put option liability that was separated from the
convertible debt and reflected as a liability in our balance sheet. Subsequent to the creation of the put options, changes in the fair value of the put options will be reflected as other income or expense in the statement of operations. During 2019,
we recorded a $2&nbsp;million increase in the fair value of the put options as other expense due to the increase in the conversion discount rate provided to note holders resulting from an amendment to terms of the convertible debt issued in August
and September 2019. We will estimate the fair value of the put options until they are exercised or expire. The fair value of put options are based on the value of the discounts embedded in the convertible debt and the probability of various
settlement scenarios. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock-based compensation and common stock valuation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Stock-based</FONT> compensation related to stock options granted to our employees, directors and nonemployees
is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options
with performance metrics is calculated based upon expected achievement of the metrics specified in the grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Starting January&nbsp;1,
2019, upon adoption of Accounting Standards Update (ASU) <FONT STYLE="white-space:nowrap">2018-07,&nbsp;Compensation&#151;Stock</FONT> Compensation (Topic&nbsp;718),<I>&nbsp;Improvements to Nonemployee Share-Based Payment Accounting,</I>&nbsp;the
fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> <FONT STYLE="white-space:nowrap">option-pricing</FONT> model to estimate the
fair value of our stock options and stock purchase rights under our 2016 Incentive Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected
dividend yield. Starting January&nbsp;1, 2017, forfeitures were accounted for as they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for restricted stock units issued
to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in our statement of operations on a straight-line basis over the requisite
vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of an active market for our common stock, the fair value of our common stock was determined by our Board
of Directors in accordance with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the Practice Aid). In doing so, our
Board of Directors determined the best estimate of fair value </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our common stock, exercising reasonable judgment and considering numerous objective and subjective factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">valuations of our common stock performed by independent third-party valuation specialists; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy, including the status of research and development efforts, of our
products and product candidates, and the material risks related to our business and industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our results of operations and financial position, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation of publicly traded companies in the life sciences and diagnostic testing sectors, as well as
recently completed mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of marketability of our common stock as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices of our convertible preferred stock sold to investors in arm&#146;s length transactions and the rights,
preferences, and privileges of our convertible preferred stock relative to those of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public
offering or a sale of our company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trends and developments in our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market conditions affecting the life sciences and medical device industry sectors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors determined the fair value of our common stock by first determining the enterprise value of our
business, and then allocating the value among the various classes of our equity securities to derive a per share value of our common stock. The Practice Aid identifies various available methods for allocating enterprise value across classes and
series of capital stock to determine the estimated fair value of common stock at each valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In allocating enterprise value
among the various classes of stock prior to July 2020, we utilized the Option Pricing Method (OPM) given our early stage of development and the absence of a near term liquidity event. Under the OPM, shares are valued by creating a series of call
options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options. From July 2020 onwards, we have utilized a hybrid OPM
and Probability-Weighted Expected Return Method (PWERM). The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns, considering a number of
discrete possible outcomes of the business, as well as the economic and control rights of each share class. Under this hybrid method, we considered expected initial public offering liquidity scenarios as well as other
<FONT STYLE="white-space:nowrap">market-based&nbsp;non-initial&nbsp;public</FONT> offering scenarios in the event a near-term initial public offering does not occur. Additionally, in determining the estimated fair value of our common stock, our
Board of Directors also considered the fact that our stockholders could not freely trade our common stock in the public markets. Accordingly, we applied discounts to reflect the lack of marketability of our common stock based on the weighted-average
expected time to liquidity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our Board of Directors will determine the fair value of our common
stock based on our closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Recently Issued Accounting Pronouncements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is
disclosed in Note 1 to our financial statements appearing at the end of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial
position due to adverse changes in financial market prices and rates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest rate risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents, marketable securities and our
indebtedness. We consider all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. We continually monitor our positions with, and the credit quality of, the financial institutions with which
we invest. Periodically throughout the year, we have maintained balances in various operating accounts in excess of federally insured limits. Included in cash and cash equivalents are money market funds recorded at $10.6&nbsp;million and
$4.8&nbsp;million at June&nbsp;30, 2020 and December&nbsp;31, 2019, respectively. As of June&nbsp;30, 2020, a hypothetical 100 basis point increase in interest rates would not have a material impact on our investment portfolio, financial position or
results of operations. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our December 2019 Notes, August 2019 Notes and our long-term debt payable all accrue interest at fixed rates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; within the meaning of the JOBS Act. As an emerging growth company, we may take advantage of
certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section&nbsp;404 of the
Sarbanes-Oxley Act of 2002, certain requirements related to the disclosure of executive compensation in this prospectus and in our periodic reports and proxy statements, the requirement that we hold a nonbinding advisory vote on executive
compensation and any golden parachute payments, and we have taken advantage of the ability to provide reduced disclosure of financial information in this prospectus, such as being permitted to include only two years of audited financial information
and two years of selected financial information in addition to any required unaudited interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
disclosure. We may take advantage of these exemptions until we are no longer an emerging growth company. Section&nbsp;107 of the JOBS Act provides that an &#147;emerging growth company&#148; can take advantage of the extended transition period
provided in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an &#147;emerging growth company&#148; can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of the extended transition period to comply with new or
revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or
revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. Additionally, because we have taken advantage of certain
reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than
$1.07&nbsp;billion in annual revenue; (ii)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at least $700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> (iii)&nbsp;the date on
which we have issued, in any three-year period, more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; and (iv)&nbsp;until December&nbsp;31, 2025 (the year ended December&nbsp;31st following the fifth
anniversary of this offering). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we<I> </I>are<I> </I>a &#147;smaller<I> </I>reporting<I> </I>company&#148; as
defined in Item&nbsp;10(f)(1) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of
audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&nbsp;the market value of our common shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds
$250&nbsp;million as of the end of that year&#146;s second fiscal quarter, or (ii)&nbsp;our annual revenues exceeded $100&nbsp;million during such completed fiscal year and the market value of our common shares held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the end of that year&#146;s second fiscal quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <B>mission </B>is to improve every patient&#146;s lung disease care by empowering physicians with swift, comprehensive, and actionable
insights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <B>vision </B>is to be a trusted partner that the world relies on for data-driven diagnostic solutions in lung disease and
beyond. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leading
data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. By combining a
technology agnostic approach with a holistic view of the patient&#146;s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient&#146;s care and meaningfully improve disease detection,
evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe helps improve overall patient outcomes and lowers the overall healthcare cost by reducing the use of
ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and
commercialization of companion diagnostics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our core belief is that no single technology will answer all clinical questions that we
encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic Cortex, to discover innovative diagnostic tests for clinical use. The
Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of diagnostic tests, which we believe overcomes standard machine learning challenges faced in life sciences research. Our data-driven and technology
agnostic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continuously incorporate new market insights and patient data to enhance our platform through a data-driven learning loop. We regularly
engage with our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape to identify additional clinical unmet needs where a diagnostic test could help improve patient care.
Additionally, we incorporate clinical and molecular profiling data from our commercial clinical testing, research studies, clinical trials, and biopharmaceutical customers or academic partnerships, to continue to advance our platform. We have over
140,000 samples and data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external R&amp;D initiatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derive our revenue from two sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing
biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as
development and commercialization of companion diagnostics (Services). The majority of our revenues to date have been derived from our diagnostic testing business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have commercialized six diagnostic tests which are currently on market and we perform over 30 assays for research use as part of our
laboratory services that have been used by over 50 biopharmaceutical customers and academic partners. Our Nodify XL2 and Nodify CDT, marketed as part of our Nodify Lung<I> </I>Nodule Risk Assessment testing strategy, assess the risk of lung cancer
to help identify the most appropriate treatment pathway. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. Our GeneStrat and
VeriStrat tests, marketed as part of our Biodesix Lung Reflex<I><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></I>testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state
of the patient&#146;s immune system to establish the patient&#146;s prognosis and help guide treatment decisions. The GeneStrat tumor profiling test and the VeriStrat immune profiling test have a <FONT STYLE="white-space:nowrap">three-day</FONT>
average turnaround time, providing physicians with timely results to facilitate treatment decisions. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe testing program. Our scientific diagnostic expertise, technologies, and existing
commercial infrastructure enabled us to rapidly commercialize two FDA EUA-authorized tests, a part of our customizable program. Both diagnostic tests are owned and were developed by Bio-Rad and Bio-Rad has granted us permission to utilize both tests
for commercial diagnostic services. For more information regarding the permission granted to us by Bio-Rad with respect to such tests, please see &#147;Business&#151;Material Agreements&#151;Agreements with Bio-Rad.&#148; HHS Secretary Azar declared
a public health emergency for COVID-19 in February 2020 which justified the authorization of emergency use of diagnostic tests for the detection and/or diagnosis of COVID-19. The Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab
test have been granted FDA EUA pursuant to the current emergency declaration. The Bio-Rad SARS-CoV-2 ddPCR test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under CLIA to perform high
complexity tests. The second test is the Platelia SARS-CoV-2 Total Ab test, which is an antibody assay intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. The Platelia SARS-CoV-2 Total Ab test was FDA
EUA authorized on April&nbsp;29, 2020. Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that
the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety, and we
cannot predict how long the EUAs for the SARS-CoV-2 tests will remain in place. Using the <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, we operate and have commercialized the
Biodesix WorkSafe testing program.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to using the Bio-Rad tests as part of our testing program, we performed feasibility,
verification, and validation studies, including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the manufacturer and as required by our
certifying regulatory agencies for high complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Post-launch development support for these
tests have included improvements in on-boarding new personnel, logistics of sample collection, sample receipt and data reporting, all required to support our testing program. Additional releases of the laboratory data management software are ongoing
and planned for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These tests are utilized by healthcare providers, including hospitals and nursing homes, and are
also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity. Recently we announced multiple partnerships for COVID-19 testing, and have entered
into an agreement with the State of Colorado to be one of the diagnostic companies to support wide-spread COVID-19 testing for the State. Additionally, we recently announced that we will oversee and manage onsite testing and validating testing for
the Big Ten Conference athletic competitions. To date, we have not derived significant revenues from these partnerships. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to
the six diagnostic tests currently on the market, we perform over 30 assays for research use as part of our laboratory services that have been used by over 50 biopharmaceutical customers and academic partners. All of our diagnostic testing is
performed at one of our two certified, high-complexity clinical laboratories in Boulder, Colorado and De Soto, Kansas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our
inception, we have performed over 245,000 tests and continue to generate a large and growing body of clinical evidence consisting of over 275 clinical and scientific peer-reviewed publications and presentations. Through ongoing study of each of our
tests, we continue to grow our depth of understanding of disease biology and the broad utility of each of our tests. We believe we are poised for rapid growth by leveraging our scientific development and laboratory operations expertise along with
our commercial infrastructure which includes sales, marketing, reimbursement, and regulatory affairs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market Opportunity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Diagnostic Testing Market Size&nbsp;and Opportunity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite significant advances over the last decade, lung cancer is still the deadliest type of cancer in both men and women in the United States
today. While diagnostic testing has become routinely used at certain points in the continuum of care, we believe there is a substantial need for novel, advanced testing to improve on the current standard of care. We estimate that the lung cancer
continuum of care currently represents over 10&nbsp;million testing opportunities and over a $27&nbsp;billion market annually for testing alone in the United States. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g79k19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the last two decades, the use of biomarker testing in clinical trials has increased, with 55% of
oncology trials involving the use of biomarker testing in 2018 versus 15% in 2000. We believe the field of biomarker discovery and companion diagnostic development for biopharmaceutical therapeutics is set to continue growing as biopharmaceutical
companies seek to <FONT STYLE="white-space:nowrap">de-risk</FONT> their pipelines and increase their chances of drug development success. We estimate that the biopharmaceutical partnering and research opportunities represent over a $2&nbsp;billion
market annually. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Lung Cancer Continuum of Care &#150; Clinical Unmet Needs</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Standards of care in lung cancer have evolved rapidly over the past decade, along with our understanding of the disease. With the introduction
of numerous treatment options, physicians need an ever-increasing amount of information in order to select the best treatment plan for each individual patient. We believe that the lung cancer continuum of care has a variety of clinical unmet needs
ranging from initial diagnosis of lung cancer after discovery of a lung nodule to treatment guidance for early and advanced stage disease, and monitoring for disease progression. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Diagnosis</B>: We estimate approximately 1.6&nbsp;million new incidental lung nodules and potentially
4&nbsp;million lung nodules from the adoption of screening could be identified annually in the United States. Following initial discovery of a nodule, patients are typically evaluated by a pulmonologist for risk of lung cancer before an invasive
procedure is carried out to obtain a tissue sample to confirm diagnosis. This risk assessment is based on clinical factors such as the patient&#146;s smoking history and age, and radiological features such as the size and location of the nodule,
obtained from a computed tomography (CT) scan. On initial assessment, we estimate that approximately 80% of patients are identified as low to moderate risk (5-65%) where guideline recommendations for their care plan are unclear, often
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
resulting in either <I>overtreatment</I> of patients with benign nodules or <I>undertreatment</I> in patients with cancer. An estimated 17% of patients with malignant nodules are initially sent
to watchful waiting, where a <FONT STYLE="white-space:nowrap">follow-up</FONT> CT scan is scheduled in three to six months, potentially delaying their diagnosis. Conversely, we estimate that 62% of biopsies and 35% of surgeries performed on lung
nodules find benign disease, representing a significant overtreatment that incurs both risk and cost to the patient and their providers. We therefore believe that there is a clear clinical need for blood-based diagnostic testing to help improve the
initial risk assessment of pulmonary nodules, helping direct patients to the relevant treatment pathway, and ultimately improving patient outcomes and saving costs to the system. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Treatment Guidance &#150; Early Stage</B>: We estimate that there are over 700,000 testing opportunities
annually in the United States in early stage lung cancer to assess a patient&#146;s risk of recurrence following curative-intent surgery, and to detect potential target mutations for therapeutics. Depending on a patient&#146;s risk of recurrence,
they may also receive chemotherapy, radiotherapy or chemoradiation post-surgery. The assessment of risk of recurrence is primarily based on the stage of cancer at diagnosis, with stage I patients typically receiving no additional treatment beyond
surgery. However, 20 to 40% of patients with stage I disease do still recur within five years following surgery, representing a <FONT STYLE="white-space:nowrap">sub-group</FONT> of patients who may have benefitted from more intensive treatment
protocol. We believe there is a clear clinical need for blood-based diagnostic testing prior to surgery to identify stage I patients who may benefit from a more intensive treatment protocol and we also believe there is the need for identifying stage
II and IIIA patients where low risk patients may benefit from a less intensive treatment protocol. There have also been recent advances in the use of targeted therapies in early stage lung disease. These therapies typically target specific genomic
mutations or alterations found in some tumors. We believe there is therefore an emerging need for testing designed specifically for mutation detection in early stage disease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Treatment Guidance &#150; Advanced Stage:</B> We estimate that there are over 3&nbsp;million diagnostic
testing opportunities annually in the United States to guide advanced stage lung cancer treatment decisions. With nearly 50 <FONT STYLE="white-space:nowrap">FDA-approved</FONT> systemic treatment regimens listed in national treatment guidelines for <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), there is an elevated need for personalized biomarkers to help physicians identify the right patient for the right treatment. Multiple tissue-based diagnostic tests have been
approved to identify patients eligible for targeted therapies and immunotherapy; however, about 50% of patients do not have sufficient tissue collected following diagnosis to facilitate testing. To compound the issue, different molecular tests take
varying amounts of time (days versus weeks) to report results back to the ordering physician, which often leads to treatment decisions being made on incomplete information. We believe there is an imminent need for a blood-based testing solution that
measures tumor mutations and the patient&#146;s immune profile, to provide physicians with more comprehensive and timely information to assess the overall prognosis of the patient and personalize treatment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Monitoring</B>: We estimate that there are over 800,000 testing opportunities in the United States for
blood-based tumor and immune profiling to monitor for disease recurrence and progression in NSCLC patients. Unfortunately, advanced stage lung cancer is often terminal, so repeat tissue biopsy to assess the evolution of resistance mutations or to
detect disease progression is not feasible from either a cost or risk perspective to the patient, which we believe demonstrates an important need for blood-based testing to help routinely monitor these patients. As a patient progresses through
therapies, changes in their immune system occur and blood-based immune profiling could help physicians identify these changes prior to subsequent therapy selection.</P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Current Limitations in Biomarker Discovery&nbsp;and Companion Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the biopharmaceutical biomarker testing and companion diagnostic market opportunity is $2&nbsp;billion annually<I>. </I>Over the
last two decades, the use of biomarker testing in clinical trials has increased, with 55% of oncology trials involving the use of biomarker testing in 2018 versus 15% in 2000. From 2005 to 2015, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
study identified that incorporating biomarkers into clinical development programs increased their probability of therapeutic success rate from phase 1 to
<FONT STYLE="white-space:nowrap">FDA-approval</FONT> by 570%, representing an increase from 1.6% without biomarkers to 10.7% with biomarkers. We believe the field of biomarker discovery and companion diagnostic development for biopharmaceutical
therapeutics is set to continue growing as biopharmaceutical companies seek to <FONT STYLE="white-space:nowrap">de-risk</FONT> their product development efforts and increase chances of drug development success. However, we believe as the market
continues to advance, inherent limitations of both biomarker discovery and companion diagnostic development have become more apparent. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Biomarker Discovery</B><I>: </I>There are many limitations with biomarker discovery in biopharmaceutical drug
development, including: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Biomarkers with clinical utility are difficult to discover and validate in independent datasets.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Classical statistical approaches to biomarker discovery are limited. Single-omic tests fail to see the whole
biological picture. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tissue biopsies are limited by the amount of a sample that can be collected: longitudinal testing is difficult
and the biology is only from the profile of the tumor (host response is not accounted for). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical trials are expensive and take a long period of time. It is often difficult to meet enrollment goals for
clinical trials with slow diagnostic testing turnaround times. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Companion Diagnostics (CDx):</B><I> </I>While developing companion diagnostics is critical to precision
medicine, the promise of companion diagnostics has not been fully realized and there are multiple limitations that still need resolution. The path to <FONT STYLE="white-space:nowrap">co-develop</FONT> a successful companion diagnostic with a
corresponding drug has several challenges, including: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Traditional companion diagnostic agreements may fail to realize the full value of a testing opportunity, leading
to difficulty in funding appropriate commercialization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drug development is a lengthy, complex and costly process. There can be a financial impact to a pharmaceutical
company to have a drug selected by a test. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current diagnostic reimbursement policies may not always support the coverage and payment of new companion
diagnostics. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Regulatory agencies continue to work on defining the <FONT STYLE="white-space:nowrap">co-development</FONT>
process, but the environment is continually changing. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Proprietary AI Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies,
including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic Cortex, to discover innovative diagnostic tests for clinical use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of diagnostic tests, which we believe
overcomes standard machine learning challenges faced in life sciences research. Researchers commonly encounter issues with machine learning-based biological discoveries that cannot be repeated or validated when assessed in additional specimen
cohorts. This challenge occurs when the machine identifies a perfect pattern in an initial training dataset but isn&#146;t able to identify the same pattern in a new dataset. For over 15 years, we have focused on developing our platform to overcome
this challenge to ensure each test that is discovered can be further developed to perform consistently in the clinical testing environment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are able to combine blood-based biological information related to the tumor, immune system, and host-status with clinical and radiomic data
through our proprietary AI platform, which enables us to interpret the holistic disease state of each patient or clinical dataset we encounter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continuously incorporate new market insights and patient data to enhance our platform through
a data-driven learning loop. We regularly engage with our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape and learn about biological discoveries that are clinically
meaningful. Additionally, we incorporate clinical and molecular profiling data aggregated through our commercial clinical testing, research studies, clinical trials, and biopharmaceutical customers or academic partnerships, into our platform. We
have over 140,000 samples and data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external development initiatives. With our data-driven and technology agnostic approach as data inputs into the
Diagnostic Cortex, we are able to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a diagram outlining our innovative diagnostic test discovery, development and commercialization infrastructure as outlined in
the text above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g71s23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ multiple technologies, as illustrated below, including genomics, proteomics, transcriptomics, and
radiomics, generated by different assay techniques, including ddPCR, NGS, <FONT STYLE="white-space:nowrap">LC-MS,</FONT> ELISA, and our proprietary DeepMALDI mass spectrometry platform for the blood-based molecular analysis of the tumor, immune
system, and host-status of each patient and/or clinical dataset. Through our learning loop, we continuously revisit our technology strategy and roadmap to integrate new technologies into our evolving platform, which ultimately support the addition
of new service and product revenue offerings. We focus on developing technologies that are capable of single and multi-omic research and development. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g45j20.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most diagnostic companies focus their strategy on using a single technology to discover
biomarkers for a broad range of clinical questions. We believe that no single technology can interrogate the complexity of the human disease state to help solve all clinical questions. For that reason, we employ a technology agnostic approach to
solving diagnostic challenges leveraging our proprietary AI platform. Because of this approach, we believe we are unique in the diagnostics market, allowing for a broader and more holistic understanding of each patient&#146;s disease state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are experts in many technologies, but we are a true market leader with over 15 years of experience in the field of clinical proteomics. For
over 10 years, we have been discovering and developing proteomic-based diagnostic tests and have a deep understanding of how to incorporate technologies that can be applied to blood samples in order to extract important protein-based biological
information in the form of diagnostic tests, which can aid clinicians and scientists in understanding the dynamic biology of their system of interest, such as a patient with cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solutions and Products </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To help
address the current limitations with standard of care in lung cancer diagnosis, treatment, and monitoring, we use combinations of tumor, immune and host profiling, radiological imaging, patient clinical profiling, and our proprietary AI platform to
provide a holistic view of each patient&#146;s dynamic disease state. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have four blood-based diagnostic tests across the lung cancer
continuum of care to help address clinical unmet needs by physicians. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Diagnosis</B>: We believe there is a clinical need to help physicians reclassify risk of malignancy in
patients presenting with suspicious lung nodules. We offer the blood-based Nodify Lung Nodule Risk Assessment testing strategy to aid physicians in stratifying patients into distinct nodule management treatment pathways: diagnostic procedure or
imaging surveillance. Nodify Lung consists of two blood-based proteomic tests: the Nodify CDT test helps identify patients with lung nodules that are likely malignant and the Nodify XL2 test conversely helps identify those that are likely benign.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Treatment Guidance</B>: We believe there is an imminent need for a blood-based testing solution that measures
tumor-specific mutations <I>and</I> the patient&#146;s immune profile to provide physicians with more comprehensive information to assess the overall prognosis of the patient and personalize treatment plans. We offer the blood-based Biodesix Lung
Reflex testing strategy, which consists of the GeneStrat tumor profiling test and the VeriStrat<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>immune profiling test for patients diagnosed with NSCLC. With a
<FONT STYLE="white-space:nowrap">three-day</FONT> turnaround time, we are able to quickly provide critical diagnostic information to physicians to facilitate personalized treatment decisions for their patients. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Monitoring</B>: We believe longitudinally monitoring advanced NSCLC patients for the dynamic evolution of
their tumor and immune profile while on treatment can provide an earlier indication of treatment resistance and/or disease progression. We offer the Biodesix Lung Reflex testing strategy as a blood-based monitoring tool for physicians to track their
patients&#146; disease evolution. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g87n61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Diagnosis &#150; Nodule Management </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with
suspicious lung nodules. Our blood-based nodule management offering, Nodify Lung Nodule Risk Assessment assists physicians in reclassifying a patient&#146;s risk of lung cancer by incorporating their protein biomarker results with radiographic
imaging and clinical characteristics. Nodify Lung consists of the Nodify CDT and Nodify XL2 proteomic tests, which can be ordered separately or together from a single blood draw to help reclassify risk of cancer to aid physicians in stratifying
patients into distinct nodule management pathways: intervention or surveillance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nodify CDT test is used to help identify lung nodules that are likely malignant and the
Nodify XL2 test helps identify lung nodules that are likely benign. Nodify Lung is available for patients 40 years or older, with nodules between 8 and 30mm, and less than 65% <FONT STYLE="white-space:nowrap">pre-test</FONT> risk of lung cancer. The
testing strategy starts with the Nodify CDT test to determine if a nodule is likely malignant or at a higher risk of lung cancer. The Nodify CDT test helps physicians identify cancer more quickly by prioritizing patients with a higher risk of
malignancy for a diagnostic procedure, such as biopsy or surgery. If the nodule is not identified as having a high risk of malignancy by Nodify CDT, then the Nodify XL2 test is performed to help determine if the patient&#146;s nodule is likely
benign or has a reduced risk of lung cancer and may be a candidate for CT imaging surveillance. The Nodify Lung testing strategy is represented graphically in the image below starting with the patient&#146;s
<FONT STYLE="white-space:nowrap">pre-test</FONT> risk of malignancy and ending with the guideline-recommended diagnostic procedure for each risk category. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g74k22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify
risk of malignancy in patients with suspicious lung nodules. We launched the Nodify Lung combined offering of Nodify CDT and Nodify XL2 in March 2020. However, the Nodify XL2 test has been available to all physicians since September 2019 and has
been available to a select group of physicians since October 2018. We acquired the Nodify XL2 test from Integrated Diagnostics in July 2018, and acquired the Nodify CDT from Oncimmune USA in October 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Nodify CDT </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nodify CDT is
a blood-based proteomic test that helps identify patients who have a suspicious lung nodule that is likely malignant or at a higher risk of being cancerous. Results allow physicians to identify patients who may be better candidates for timely
invasive diagnostic procedures such as bronchoscopy, transthoracic needle biopsy, or surgical resection, with the hope of catching cancer earlier. Nodify CDT enhances lung nodule risk assessment to facilitate compliance with clinical treatment
guidelines such as those of the American College of Chest Physicians (ACCP). Nodify CDT is intended for use in patients who are 40 years or older, have nodules between 8 and 30mm, and <FONT STYLE="white-space:nowrap">pre-test</FONT> risk of lung
cancer of less than 65%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The test measures the levels of seven circulating autoantibodies (P53, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">NY-ESO-1,</FONT></FONT> CAGE, <FONT STYLE="white-space:nowrap">GBU4-5,</FONT> SOX2, HuD, and MAGE A4) associated with lung cancer, combined by an algorithm to report out three potential results: High Level, Moderate Level,
or No Significant Levels of Antibodies Detected (NSLAD). The seven autoantibodies have shown to be elevated for all types of lung cancer, and from the earliest stage of the disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Unlike the tumor antigens themselves, the autoantibody levels can be measured accurately through a blood sample, based upon the signal amplification generated by the immune response to cancer.
This mechanism of action likely reflects very early events in a tumor&#146;s evolution; as the immune system initiates a response to the cancer, it can also trigger an expansion of self-reactive antibodies that can be measured in circulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the test result of High Level, Moderate Level, or NSLAD, each test report includes the patient&#146;s <FONT
STYLE="white-space:nowrap">pre-test</FONT> risk of malignancy as calculated by the Solitary Pulmonary Nodule Risk Assessment calculator, and their post-test risk of cancer incorporating the result of the test. The Solitary Pulmonary Nodule Risk
Assessment calculator was developed by Stephen Swensen, M.D., of the Mayo Clinic and is designed to provide a risk of malignancy for a patient with a newly discovered incidental nodule. The model incorporates six clinical and radiologic factors into
the equation: age, nodule size, smoking status, nodule location, spiculation (nodule edge characteristic), and previous history of lung cancer. Incorporating the autoantibody levels with the risk model provides physicians with a more accurate
assessment of risk. The test has been studied in 14 peer reviewed published studies and presentations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is an example of a <FONT
STYLE="white-space:nowrap">de-identified</FONT> Nodify CDT Test Result Report describing a patient&#146;s <FONT STYLE="white-space:nowrap">pre-test</FONT> clinical risk of malignancy and the adjusted post-test risk following a High Level test
result. The physician in this scenario may consider recommending the patient for an invasive diagnostic procedure as their post-Nodify CDT risk of malignancy is considered High Risk. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g75x09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Nodify XL2 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nodify XL2 is a blood-based proteomic test that helps identify patients who have a suspicious lung nodule that is likely benign or at a reduced
risk of being cancerous. Results allow physicians to identify patients who may be better candidates for routine CT surveillance to monitor for growth or shrinkage of the nodule over time instead of an invasive diagnostic procedure. Nodify XL2 is
used for patients who are 40 years or older, have nodules between 8 and 30mm, and have a <FONT STYLE="white-space:nowrap">pre-test</FONT> risk of lung cancer of less than or equal to 50%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nodify XL2 integrates peptides measured by <FONT STYLE="white-space:nowrap">LC-MS</FONT> with clinical and radiological characteristics that
are combined by an algorithm to report out three potential results: Likely Benign, Reduced Risk, or Indeterminate. Specifically, the Nodify XL2 test measures the relative abundance of two peptides (LG3BP and C163A) in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
circulation in the patient&#146;s blood. The native proteins from which the peptides are derived, have been associated with an inflammatory response to cancer. The clinical factors are patient
age and smoking status, and radiological factors are nodule size, location, and edge characteristics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the test result of
Likely Benign, Reduced Risk, or Indeterminate, each test report includes the patient&#146;s <FONT STYLE="white-space:nowrap">pre-test</FONT> risk of lung cancer as calculated by the Solitary Pulmonary Nodule Risk Assessment calculator, and their
post-Nodify XL2 risk of malignancy incorporating the result of the test. Incorporating the peptide levels with the risk model provides physicians with a revised assessment of risk incorporating the patient&#146;s biology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is an example of a <FONT STYLE="white-space:nowrap">de-identified</FONT> Nodify XL2 Test Result Report describing a
patient&#146;s <FONT STYLE="white-space:nowrap">pre-test</FONT> clinical risk of malignancy and the adjusted post-test risk following a Likely Benign test result. The physician in this scenario may consider recommending the patient for three or <FONT
STYLE="white-space:nowrap">six-month</FONT> CT surveillance as their post-Nodify XL2 risk of malignancy is considered Very Low Risk. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g76x01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In summary, the inclusion of the Nodify Lung testing strategy into clinical practice helps physicians
reclassify risk of malignancy of low to moderate risk lung nodules by incorporating the patient&#146;s own biology into the assessment. The Nodify CDT test helps physicians identify patients with a high-risk lung nodule who may benefit from timely
intervention, which can ultimately help identify lung cancer earlier. The Nodify XL2 test helps physicians identify patients with a very low risk lung nodule who may benefit from CT surveillance and could avoid unnecessary invasive procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Blood samples for Nodify XL2 and Nodify CDT can be collected in the physician&#146;s office, laboratory, or at home through use of mobile
phlebotomy. Mobile phlebotomy options facilitate testing for patients even if they are not seen in person by the physician and instead are seen through telehealth visits. This benefits the patient as scheduling can be conveniently fit to their needs
and can keep them away from a physician&#146;s office or hospital for safety concerns, especially with the evolving coronavirus pandemic. Additionally, mobile phlebotomy benefits the physician as the logistics around a blood draw or tissue sampling
are out of their hands. We have a national network of contracted Nurses and Phlebotomists to support <FONT STYLE="white-space:nowrap">at-home</FONT> or mobile blood collection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both tests require a single blood sample shipped at ambient temperature to our certified, high-complexity clinical laboratory in De Soto,
Kansas. Nodify CDT requires whole blood and Nodify XL2 requires whole blood spotted onto our proprietary Blood Collection Device (BCD). The introduction of the BCD as a qualified specimen </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collection method for use with the Nodify XL2 test alleviated the need for serum separation processing steps by phlebotomists at blood draw sites such as centrifugation, and cold chain (dry ice)
shipments, which has increased the market access to our proteomic-based tests. Results for Nodify CDT alone are typically available within one day. If both tests are ordered for the patient and Nodify CDT returns a result of NSLAD, then both test
results are typically available within 4 to 5 days. All results are available through a portal, fax, hard copy, or mobile device. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Treatment Guidance and Monitoring </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Profiling the tumor through blood-based testing can help identify mutations in genes that may be driving growth of the tumor and may be targets
for therapeutics. However, tumors also suppress intrinsic mechanisms that prevent the patient&#146;s immune system from identifying and eliminating the cancer cells. Profiling the immune system can show if the patient&#146;s immune system may have
been subverted and therefore, is less likely to be responsive to immunotherapies. Our blood-based Biodesix Lung Reflex testing strategy consists of the GeneStrat tumor profiling test and the VeriStrat immune profiling test, which can be ordered
together or separately for patients with NSCLC. Together, the tests typically have a <FONT STYLE="white-space:nowrap">3-day</FONT> turnaround time, providing physicians with timely results to facilitate treatment decisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>GeneStrat </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GeneStrat is a
blood-based tumor profiling test that detects the guideline recommended, actionable mutations in lung cancer: <I>EGFR, KRAS, BRAF, <FONT STYLE="white-space:nowrap">EML4-ALK,</FONT> <FONT STYLE="white-space:nowrap">ROS-1,</FONT> </I>and <I>RET.
</I>Physicians can order one or any combination of the genes, whichever they deem medically necessary for the individual patient. The presence of a mutation in one of the genes could indicate the patient is a candidate for the associated
guideline-recommended targeted therapy. The GeneStrat test performance and potential clinical utility have been published in 3 peer reviewed studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GeneStrat test results are typically available within 72 hours from our receipt of the sample in
our Boulder, Colorado clinical laboratory. In a study at Eastern Carolina University, it was observed that blood-based testing was up to three weeks faster than tissue-based testing, with tissue-based testing taking a median of 26 days from sample
collection. With GeneStrat testing, results are typically available in time for the patients first oncology visit, allowing the patient to start front-line treatment as quickly as possible. In the same study, it was observed that only 4% of patients
had tissue-based molecular test results prior to start of front-line treatment. Meanwhile, after integrating Biodesix Lung Reflex testing at the institution, 72% of patients had molecular test results available. Testing with the GeneStrat test can
help physicians identify driver mutations quickly to help speed up time to treatment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g77b20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that rapid, blood-based tumor profiling with the GeneStrat test is complementary to both
targeted tissue-based testing (including <FONT STYLE="white-space:nowrap">PD-L1)</FONT> and broad genomic sequencing. Testing with GeneStrat at diagnosis can help quickly identify patients who are eligible for targeted therapies. Additionally,
blood-based testing upfront can help save valuable tissue for diagnostic evaluation, <FONT STYLE="white-space:nowrap">PD-L1</FONT> testing and broad genomic profiling for rare mutations to enroll in clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is an example of a <FONT STYLE="white-space:nowrap">de-identified</FONT> GeneStrat
Test Result Report. The patient in this scenario is positive for the EGFR Sensitizing mutation Exon 19 <FONT STYLE="FONT-FAMILY:SYMBOL">&#068;</FONT>E746-A750 variant. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g78h00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>VeriStrat </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">VeriStrat is a blood-based proteomic test that provides a personalized view of each patient&#146;s immune response to their lung cancer.
Results help inform physicians whether their patient has a more aggressive cancer and can help with treatment planning. VeriStrat profiles the patient&#146;s immune system by measuring eight protein features measured by mass spectrometry and
interpreted by a proprietary machine learning-based algorithm to produce either a VeriStrat Good or VeriStrat Poor test result. The VeriStrat testing workflow is represented by the figure below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g78x08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The presence of a VeriStrat Poor result indicates the presence of chronic inflammation and a chronic acute
phase immune response. A chronic acute phase immune response can trigger the immune system to provide growth factors to the tumor to increase blood flow and tumor growth. The test has been studied in over 85 peer-reviewed and published clinical
studies across many different types of therapies such as chemotherapy, targeted therapies, immune therapies, and combinations. The results consistently show the test to be predictive of outcomes, independent of other prognostic factors including <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression and performance status. Patients who test as VeriStrat Poor, on average, have an overall survival that is less than half of those who test as VeriStrat Good, independent of treatment type,
demonstrating that the test is strongly prognostic. Conversely, patients with a VeriStrat Good test result typically respond better to standard of care treatments than those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patients that test as VeriStrat Poor. By using the VeriStrat test for immune profiling, physicians can help identify the patients with an immune status associated with generally poor prognosis
who should be treated with alternate therapies or in clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is an example of a
<FONT STYLE="white-space:nowrap">de-identified</FONT> VeriStrat Test Result Report. The patient&#146;s test result is a VeriStrat Good result, indicating the patient has an overall good prognosis and will likely benefit from standard of care
therapies. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g79j23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GeneStrat requires whole blood and VeriStrat requires a whole blood sample spotted onto our proprietary
BCD. Both samples are shipped at ambient temperature and testing is performed in our certified, high-complexity clinical laboratory in Boulder, Colorado. GeneStrat is performed using the ddPCR technology, and the protein features in VeriStrat are
measured using matrix-assisted laser desorption/ionization time of flight <FONT STYLE="white-space:nowrap">(MALDI-ToF)</FONT> mass spectrometry. Results are typically available within 72 hours through a portal, fax, hard copy, or mobile device. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Biodesix WorkSafe <FONT STYLE="white-space:nowrap">COVID-19</FONT> Testing Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, through our partnership with Bio-Rad, we commercialized the
Biodesix WorkSafe testing program. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two diagnostic tests for the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> virus that causes <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The first test is the <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> ddPCR test, which is a molecular assay indicated for detecting active <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> infection. The test was FDA EUA
authorized on May&nbsp;1, 2020, authorizing performance of the test in laboratories certified under CLIA to perform high complexity tests. The second test is the Platelia
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Total Ab test, which is an antibody assay intended for detecting a B-cell immune response to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> indicating recent or prior infection. The test was FDA EUA authorized on April&nbsp;29, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within a month of initiating our development collaboration with <FONT STYLE="white-space:nowrap">Bio-Rad,</FONT> we were able to launch two
tests for commercial use. We were able to bring these tests to market as fast as possible due to our scientific diagnostic expertise, technologies and existing commercial infrastructure. In addition to our launch agility, we have been able to
rapidly scale our laboratory operations for high-volume testing. We remain committed to delivering rapid test results in 24 to 48 hours on average. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab tests, we operate
and have commercialized the Biodesix WorkSafe testing program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to using the Bio-Rad tests as part of our testing program, we
performed feasibility, verification, and validation studies, including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the manufacturer and
as required by our certifying regulatory agencies for high complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Post-launch development
support for these tests have included improvements in on-boarding new personnel, logistics of sample collection, sample receipt and data reporting, all required to support our testing program. Additional releases of the laboratory data management
software are ongoing and planned for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our tests are utilized by healthcare providers, including hospitals and
nursing homes and are also offered to businesses and educational systems to assist in their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">back-to-work</FONT></FONT> or back to school strategies. Recently, we announced multiple
partnerships for <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing, and Colorado Governor Jared Polis announced at a press conference on July&nbsp;23, 2020 that we will now be supporting wide-spread
<FONT STYLE="white-space:nowrap">COVID-19</FONT> testing for the State of Colorado. Additionally, we announced a partnership as the official <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing partner for the Major Lacrosse League as they
competed in their 2020 tournament. We also recently announced that we will oversee and manage onsite testing and validating testing for the Big Ten Conference athletic competitions. To date, we have not derived significant revenues from these
partnerships. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Bio-Rad</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> ddPCR test </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">Bio-Rad</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> ddPCR test, also known as a molecular or viral test, is indicated for the qualitative detection of nucleic acid from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> the virus that causes <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The test targets detection of the nucleic acid from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> (not from any other viruses or pathogens) in respiratory specimens to identify and isolate&nbsp;infected individuals. Recent studies have shown that ddPCR-based testing is more sensitive than qPCR
for detecting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> specifically in the reduction of false negative results. In one study, the ddPCR test demonstrated 95% accuracy vs. 47% for other
&#147;bulk&#148; <FONT STYLE="white-space:nowrap">RT-PCR</FONT> technologies used in other molecular tests Specimens are shipped at ambient temperature or dry ice depending on the viral transport media (VTM) used, and testing is performed using
ddPCR in our certified, high-complexity clinical laboratory in Boulder, Colorado. Results are typically available through fax, hard copy, or encrypted email within 24 to 48 hours on average from receipt of the sample. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Platelia <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Total Ab Test </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Platelia <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Total Ab assay (also known as a
serology or antibody test) is intended for use as an aid in identifying individuals who have developed an adaptive immune response to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> virus, indicating
recent or prior infection. The assay uses whole blood to detect circulating antibodies against the virus. The sensitivity is 98% and specificity is 99% eight days after the onset of symptoms.&nbsp;At this time, it is not known how long antibodies
persist following infection and if the presence of antibodies confers protective immunity. The test is intended for the qualitative detection of total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-SARS-CoV-2</FONT></FONT>
nucleocapsid antibodies (IgG, IgM and IgA) in human serum or plasma specimens. The test requires a 3 mL blood draw, and samples are shipped at ambient temperature. Testing is conducted using semi-automated ELISA technology in our certified,
high-complexity clinical laboratory in De Soto, Kansas. Results are typically available within 24 to 48 hours from receipt of the sample through fax, hard copy, or encrypted email. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Biopharmaceutical Diagnostic Discovery, Development&nbsp;and Testing Services Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our&nbsp;leadership in clinical proteomics and our technology agnostic approach to probe the cancer disease state provides our
customers with a clear and distinct advantage over other diagnostic service providers who solely focus on either genomics or proteomics. Similar to our commercial clinical testing business, our biopharmaceutical diagnostic discovery,
development&nbsp;and testing&nbsp;services&nbsp;business leverages&nbsp;the&nbsp;Diagnostic Cortex to provide an extensively validated&nbsp;and deep learning approach to&nbsp;discovering&nbsp;new&nbsp;biomarkers, which in turn helps drive the
clinical development of therapeutics. We recognize each clinical development program is complex, which is why we offer <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> diagnostic solutions, ranging from
initial biomarker discovery and feasibility projects to commercialization of companion diagnostics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To address the increasing complexity
of disease biology and new drug mechanisms of action, we employ a technology agnostic approach to uncover insights about the tumor biology and patient&#146;s immune response to cancer for therapeutics in clinical development. With our broad
technology and service offering, including the performance of over 30 assays for research use as part of our laboratory services (see diagram below), we are able to provide the depth and breadth of biomarker tools for our partners for multi-omic
analyses across their product development efforts. Although we recognize the importance of a multi-omic, technology agnostic approach in translational research, we are experts in discovering and developing proteomic-based diagnostic tests to help
interrogate the immune profile and host disease state of patients on particular therapeutics. Traditionally, oncology biomarkers have been discovered from tumor tissue,&nbsp;but with the increased trend in the number of programs featuring
immuno-oncology agents in therapeutic development, we believe there is&nbsp;a clinical unmet need for blood-based tumor markers and host/immune biomarkers to complement information obtained from tissue. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g80v11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we provide benefit to our biopharmaceutical customers as they integrate strategies for
increasing the probability of success for pivotal clinical trials. Specifically, our diagnostic testing services may help enable quicker enrollment rates for patients in prospective clinical trials, ranging from phase 1 to phase 3, and could help
identify patient populations who may experience the greatest benefit from new therapeutics. Ultimately, our goal is to help biopharmaceutical customers realize greater efficiency in their clinical development programs. Additionally, we have the
ability to access and leverage our large sample and data biobank for our partners&#146; data mining needs, including new test discovery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our biopharmaceutical discovery, diagnostic development and testing revenue continues to grow, it is important to note that we benefit
greatly from these partnerships in many ways that expand beyond revenue. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are continuously expanding our knowledge and biological understanding of multiple diseases and the rapidly evolving treatment landscape, while our Diagnostic Cortex continues to be powered
through these biomarker analyses. Additionally, our sample and data biobank continue to grow and can be further leveraged for internal test development and external partnering. Importantly, we look to supplement our product development efforts with
companion diagnostics as they are developed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have over 50 biopharmaceutical customers and academic partners who have utilized
our diagnostic tests and services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following are a few case studies of early stage biomarker discovery and development with our
biopharmaceutical customers. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>AstraZeneca: </B>We provided services to AstraZeneca to retrospectively analyze samples from the FLAURA
clinical trial (NCT02296125). The goal of this analysis was to interpret and establish the clinical utility of blood-based longitudinal monitoring of EGFR sensitizing and resistance mutations by ddPCR in advanced NSCLC patients treated with
osimertinib. The data demonstrated that these circulating DNA mutations could be tracked in blood to interpret the patient&#146;s prognosis, and could help AstraZeneca to identify disease progression 3 months (median) in advance of standard imaging.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Genentech: </B>We partnered with Genentech to discover a novel proteomic classifier for advanced NSCLC
patients treated with atezolizumab. The test was discovered on a small clinical cohort (n=77) and was independently validated on blinded samples (n=270) from the POPLAR clinical trial (NCT01903993). The validation revealed that the proteomic test
was predictive of progression free survival and overall survival for atezolizumab versus the control arm docetaxel. Additionally, an analysis compared the correlation between our proteomic classifier with standard of care biomarkers (PD-L1
expression status and tumor mutation burden), which revealed there was no significant correlation. This implies that our classifier provides unique and valuable information in the treatment of patients with advanced NSCLC. It is our belief that
Genentech could use this strategy to identify patients that could derive a longer progression free survival from atezolizumab. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Merck KGaA &amp; Pfizer: </B>We announced the initiation of a clinical phase development program for the
anti-PD-L1 checkpoint inhibitor, avelumab with Merck KGaA and Pfizer on February&nbsp;12, 2020. The new proteomic test was developed through retrospective analysis of the circulating proteome combined with our proprietary AI platform. We have
completed initial discovery of the test that identifies likely responders to avelumab and efforts are now focusing on transferring the test into our CLIA lab in Boulder, Colorado for clinical phase test validation. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competitive Advantages </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the following are our
key competitive advantages: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our proprietary extensively validated deep learning platform, which is tailored to discover diagnostic tests
that address clinical unmet needs</B><B>. </B>Our platform is an extensively validated deep learning platform optimized for discovery of diagnostic tests. By combining our data-driven and technology agnostic approach with deep learning techniques,
we believe we have overcome many standard machine learning challenges. This has enabled us to develop commercial tests for clinical unmet needs and collaborate with our biopharmaceutical customers and academic partners. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our data-driven approach to precision medicine combined with our biobank, which enables us to accelerate
development of new tests. </B>We have over 140,000 samples and data in our biobank, including tumor profiles and immune profiles, used for both internal and external research and development initiatives. Our biobank, clinical trials, commercial
testing and other partnerships provide an ongoing source of new data that further enhances our proprietary AI platform. We are continuously </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD> <P STYLE="margin-top:0pt;margin-bottom:1pt">
</P></TD>
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
identifying and incorporating new market insights and input from our customers, key opinion leaders, and scientific experts to leverage this data in developing our diagnostic tests.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our leadership in clinical proteomics, demonstrated research, development, and scientific expertise, combined
with our intellectual property portfolio.</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our leadership in clinical proteomics and our technology agnostic approach, we believe provides us with a
distinct advantage over our competitors, who focus on any single technology, such as genomics or proteomics. Our certified, high-complexity laboratories offer significant advantages in development of commercial tests. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our proprietary technologies and processes are protected by a portfolio of approximately 83 issued patents in the
United States and internationally, and 20 uniquely registered United States trademarks. We take efforts to protect our proprietary position using a variety of methods, such as a pursuit of United States and foreign patent applications related to our
proprietary technology, use of trade secrets, trademarks, <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and potential <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquisition opportunities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our demonstrated success commercializing diagnostic tests in lung disease.</B> With six diagnostic tests
launched and three currently in development, our commercial portfolio of blood-based solutions currently addresses clinical unmet needs within diagnosis, treatment and monitoring of lung cancer. Our diagnostic tests provide rapid, actionable, and
holistic diagnostic information to help inform physicians on the next steps in a patient&#146;s care plan. We have displayed agility in our R&amp;D and commercial launch efforts and within a month of initiating a development collaboration, launched
two diagnostic tests for <FONT STYLE="white-space:nowrap">COVID-19</FONT> for commercial use. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our depth and breadth of point of care access to physicians allows us to drive adoption of our diagnostic
tests while incorporating real-life feedback to inform new product development. </B>Our commercial team&#146;s primary focus is to articulate the scientific and clinical evidence behind our tests, how they impact clinical care and can ultimately
help to improve patient outcomes. Our demonstrated scientific expertise, leadership in clinical proteomics and breadth of data, including peer-reviewed publications, presentations and clinical studies, forms the basis of our relationships with major
hospitals and physician networks across the United States. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Our commercial infrastructure, which includes our extensive knowledge and experience in sales, marketing,
reimbursement and operations, provides us with the ability to launch, scale and drive revenue.</B> We believe our commitment to commercial excellence helps us to leverage insights, operational excellence and proven approaches to&nbsp;deliver revenue
growth and enhance the brand of our company and products. We are able to deploy rapid clinical testing turnaround times and develop commercial tests at scale. Scaling of our test capacity to meet volumes is then achieved by adding instrumentation
and qualified personnel to our quality systems. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to provide swift, comprehensive and actionable insights to improve patient outcomes across lung disease and to help answer critical
clinical questions faced by physicians, researchers, and biopharmaceutical companies. To achieve this, we intend to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Drive increased awareness, adoption, and reimbursement coverage of our diagnostic tests by:</B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuously educating physicians, key opinion leaders, hospital systems, advocacy groups, patients, payers,
academic research organizations, and technology assessment and guideline organizations on the clinical data and benefits of our tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">utilizing our pulmonology-focused sales force and commercial reach with targeted awareness campaigns to employ
highly targeted sales and marketing tactics in pulmonology clinics specializing in the management of lung nodules and the diagnosis of lung cancer; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing to invest in the expansion of our sales force and commercial support team; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incorporating our testing services into diagnostic pathways and protocols via a
<FONT STYLE="white-space:nowrap">top-down</FONT> strategy that introduces our diagnostic tests to the largest United States health systems; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">leveraging our clinical data to gain broad coverage from public and private payers for our tests.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Deepen our relationships with current biopharmaceutical customers and establish new customer opportunities</B>
<B>by</B>: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selling our complete offering of tests and services to biopharmaceutical companies in the United States and
internationally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">leveraging existing projects and relationships to expand sales with our current biopharmaceutical customers; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">targeting companies developing novel companion diagnostic strategies and drug development projects best suited to
our platform for new test discovery, development and commercialization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Further demonstrate the clinical utility and economic benefits of our diagnostic tests</B><B> </B><B>by</B>:
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investing in commercial clinical testing, research studies and clinical trials to further demonstrate the
clinical utility of our tests; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing rapid, actionable, and holistic diagnostic information to help inform physicians on the next steps in a
patient&#146;s care plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing timely and actionable clinical information to help improve overall patient outcomes and lower the
overall healthcare cost. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Introduce new diagnostic tests in lung disease by</B>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">engaging with our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving
diagnostic and therapeutic landscape and to identify additional clinical unmet needs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entering strategic partnerships with biopharmaceutical companies, academic research organizations, technology
providers, and other diagnostic companies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing companion diagnostic tests to support the therapeutics&#146; regulatory approval and adoption process
for our biopharmaceutical customers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Enhance our proprietary AI platform and expand our technology portfolio by:</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing to invest in R&amp;D capabilities to foster innovation in test discovery and development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, acquiring technologies and integrating new data types into our proprietary AI platform; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entering strategic partnerships across our commercial product portfolio and product development efforts in order
to<B> </B>further our development capabilities, accelerate launch of commercial products, or expand our service offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&#149;</B></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continue to expand and leverage our biobank by: </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanding and enhancing the robustness of our samples and the data set, including through our collaborations and
partnerships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuing commercial opportunities with companies and researchers who are interested in utilizing our biobank for
their own discovery and development efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monetizing these commercial opportunities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of the Current Landscape </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lung cancer (both small cell and <FONT STYLE="white-space:nowrap">non-small</FONT> cell) is the second most common cancer diagnosed in the
United States with nearly 230,000 patients diagnosed each year. It is estimated that there is a 1 in 16 chance that an individual in the United States will develop lung cancer in their lifetime, leading to nearly 135,000 patient deaths in 2020, lung
cancer is accountable for more deaths annually than the next three deadliest cancers combined (colorectal, pancreas, and breast). Additionally, every year in the United States an estimated 1.6&nbsp;million people are diagnosed with an incidental
nodule in the lung. These nodules can arise from a variety of causes ranging from smoking to fungal infections or other lung diseases. While most lung nodules are found to be benign and ultimately harmless, about 5% are found to be malignant within
two years from nodule identification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite significant advances over the last decade, lung cancer is still the deadliest type of
cancer in both men and women in the United States today. While diagnostic testing has become routinely used at certain points in the lung cancer continuum of care, we believe there is a substantial need for novel, advanced testing to improve on the
current standard of care. We estimate that in the United States, the lung cancer continuum of care currently represents over 10&nbsp;million annual testing opportunities, and is over a $27&nbsp;billion market annually for testing alone. We estimate
that the biopharmaceutical partnering and research opportunities represent over a $2 billion market annually. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Diagnosis &#150;
Nodule Management </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over 1.6&nbsp;million people are diagnosed with incidental pulmonary nodules annually in the United States.
Incidental nodules are identified when a person is being evaluated for another medical concern, typically through <FONT STYLE="white-space:nowrap">X-ray</FONT> or CT imaging. On July&nbsp;7, 2020, the United States Preventive Services Task Force
(USPSTF) published an updated draft statement to the 2013 <FONT STYLE="white-space:nowrap">low-dose</FONT> CT (LDCT) screening recommendation that proposes an expansion to the eligible population for lung cancer screening to patients 50 to 80 years
old in the United States with a smoking pack-year history of 20 or more years or who currently smoke or quit smoking within the past 15 years. Based upon the new USPSTF recommendation, we believe approximately 15&nbsp;million people are eligible for
LDCT, which we believe could potentially lead to the identification of over 4&nbsp;million lung nodules annually. However, in 2018, only 4.2% of the eligible population underwent screening. Improved patient adherence to screening is expected to
result in earlier identification of lung nodules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following initial discovery of a lung nodule, patients are typically evaluated by a
pulmonologist for risk of lung cancer. A recent study found that on average, patients wait 8 months following initial detection of a lung nodule before diagnosis of cancer. The same study also estimated that approximately two thirds of incidental
nodules found did not receive <FONT STYLE="white-space:nowrap">follow-up</FONT> after initial discovery. If a patient can be diagnosed with cancer at an early stage, their survival chances are greatly increased, including the chance of cure. The
volume of patients waiting for evaluation has led to the implementation of &#147;nodule clinics&#148; in centers around the country to try to catch cancer earlier by reducing wait times for diagnostic procedures and increasing the number of patients
that are being routinely observed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACCP guidelines for lung nodules management further detail the intervention or monitoring pathways
for a patient based on their individual risk of cancer. Several &#147;risk calculators&#148; have been developed to help translate a patient&#146;s clinical risk factors such as age, smoking status, cancer history, nodule size, location, and edge
characteristics into a risk percentage. However, standard practice is physician assessed risk of malignancy. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g81u30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As illustrated above, for patients whose lung cancer risk is determined to be High (greater than 65%),
guidelines recommend sending the patient for a stage evaluation and surgical resection if there are no metastases. If the risk of lung cancer is determined to be Very Low (less than 5%), guidelines recommend CT surveillance to monitor the nodule for
growth or shrinkage. Approximately 80% of patients fall into the Low to Moderate group <FONT STYLE="white-space:nowrap">(5-65%)</FONT> where guidelines state CT scans, positron emission tomography (PET) scans, biopsy, bronchoscopy, or surgery are
all options and should be chosen based on the physician&#146;s clinical judgement and risk threshold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a large and varied set of
clinical options, the Low to Moderate risk group represents the area of greatest need for precision diagnostic testing to help reclassify risk and direct patients to the relevant treatment pathway.<SUP STYLE="font-size:85%; vertical-align:top">
</SUP>A 2015 publication of 18 pulmonology clinics across the United States and 377 patients with lung nodules showed 62% of biopsies and 35% of surgeries were performed on patients with benign nodules. Conversely, an estimated 17% of patients with
malignant nodules are initially sent to watchful waiting, where a <FONT STYLE="white-space:nowrap">follow-up</FONT> CT scan is scheduled in three to six months, potentially delaying their diagnosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the median workup cost of $2,794 for a <FONT STYLE="white-space:nowrap">non-surgical</FONT> biopsy and $24,623 for a surgical
resection, performing invasive procedures on patients with benign nodules exposes them to potentially serious adverse events and could impede future lung function. In a population-based analysis of patients diagnosed with lung cancer from 2001 to
2010, it was identified that the incidence of at least one hospitalized adverse event occurred in 30% of the population. Specifically, the rate of incidence by invasive procedure type was 26% for a bronchoscopy, 34% for a percutaneous biopsy, and
39% for a surgical resection. A recent cost-benefit analysis showed that among Medicare claims, over 40% of the total cost in management of lung cancer was attributed to benign patients with an invasive procedure. Diagnostic tests can help reduce
unnecessary biopsies or surgeries on patents with benign nodules and can help catch those that are malignant earlier. These tests could improve patient outcomes, alleviate patient anxiety, and save costs to both the patient and the healthcare
system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>NSCLC Treatment Guidance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following confirmed diagnosis, the patient&#146;s NSCLC is staged which helps the physician direct the patient to an appropriate treatment
pathway. Unfortunately, less than half of the patients diagnosed with advanced stage disease live beyond one year post-diagnosis, with a median overall survival of 10.5 months. Additionally, it is estimated that these patients have a five-year
survival of 6%. Meanwhile, five-year survival for patients diagnosed with early stage (typically stage <FONT STYLE="white-space:nowrap">I-IIIA)</FONT> disease is 59%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Early Stage NSCLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that there are over 700,000 testing opportunities annually in the United States in early stage lung cancer to assess the risk of
recurrence following surgery, and to detect potential target mutations for therapeutics. The current standard of care in early stage disease is surgery with curative intent. Depending on the risk of recurrence for a patient, they may also receive
chemotherapy, radiotherapy or chemoradiation post-surgery. The assessment of risk of recurrence is primarily based on the stage of cancer at diagnosis, with stage I patients typically receiving no additional treatment beyond surgery. However, 20 to
40% of patients with stage I disease have a lung cancer recurrence within five years following surgery, representing a <FONT STYLE="white-space:nowrap">sub-group</FONT> of patients who may have benefited from a more intensive care plan, including
increased follow up or additional therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there is a clear clinical need for blood-based diagnostic testing prior to surgery
to identify stage I patients who may benefit from a more intensive treatment protocol and we also believe there is the need for identifying stage II and IIIA patients where low risk patients may benefit from a less intensive treatment protocol.
There have also been recent advances in the use of targeted therapies in early stage lung disease, which we believe will lead to the need for testing designed specifically for mutation detection. Beyond clinical testing, we believe diagnostic
testing for research use as part of our laboratory services could help biopharmaceutical companies identify new patient targets for neoadjuvant or adjuvant therapy in earlier stage disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Advanced Stage NSCLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that there are over 1.5&nbsp;million diagnostic testing opportunities annually in the United States to guide advanced stage lung
cancer treatment decisions. We believe there is a need for blood-based testing solutions that measure tumor mutations and the patient&#146;s immune profile, providing physicians with holistic and timely information to assess the overall prognosis of
the patient and personalize treatment plans when tissue is not available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Traditionally, therapeutics for advanced NSCLC have been <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> based on improvement in response, or survival for a population in a given tumor type. However, data have shown that it is not a one size fits all approach as each patient responds differently based on
their individual biology. Today, the NCCN guidelines recommend nearly 50 <FONT STYLE="white-space:nowrap">FDA-approved</FONT> systemic treatment regimens for patients with advanced NSCLC. Although an increasing number of these therapeutics have
companion diagnostic tests to inform treatment, there remains a need for more comprehensive biomarkers to help further identify the right patient for the right treatment. In addition to biomarker analysis, physicians assess the patient&#146;s
medical history, presence of <FONT STYLE="white-space:nowrap">co-morbidities,</FONT> and ultimately the patient&#146;s prognosis to help guide treatment decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximately 50% of patients do not have sufficient tissue collected following diagnosis to facilitate tissue-based molecular testing.
Conducting an additional tissue biopsy is costly and has the risk of adverse events. Blood-based testing can provide rapid, actionable, upfront tumor profiling from a minimally invasive blood draw, and eliminate the need for repeat biopsy
procedures. Blood-based offerings include testing of individual driver mutations in lung cancer, or broad mutation profiling, typically through next generation sequencing. The broader mutation panels often include genes that are prevalent in and may
be tied to therapeutics approved in tumor types outside of lung cancer. Single gene assays or smaller actionable gene panels may be focused more specifically on lung cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the tumor mutation profiling, the state of the patient&#146;s immune system has long been understood to be an important factor
in the patient&#146;s diagnosis, prognosis, and response to therapy. The causal relationship between inflammation and cancer progression is more widely accepted today as the immunology and oncology communities have continued to collaborate around
the advancement of immune-targeting drugs. However, recent studies indicate that less than 25% of <FONT STYLE="white-space:nowrap">treatment-na&iuml;ve</FONT> lung cancer patients were alive after five years when treated with single agent
immunotherapy and some patients do not benefit from immunotherapy in comparison to those treated with chemotherapy. These reports underscore the complexity of the underlying biology and the need for immune-related biomarker treatment selection. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Monitoring </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that there are over 1&nbsp;million testing opportunities in the United States for blood-based tumor and immune profiling to monitor
for disease recurrence and progression in NSCLC patients. Unfortunately, advanced stage lung cancer is often terminal, so repeat tissue biopsy to assess the evolution of resistance mutations or to detect disease progression is not feasible from
either a cost or risk perspective to the patient, which we believe demonstrates an important need for blood-based testing to help routinely monitor these patients. As a patient progresses through therapies, changes in their immune system occur and
blood-based immune profiling could help physicians identify these changes prior to subsequent therapy selection.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Platform&nbsp;and Technologies
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our focus on tumor and immune profiling is central to our core belief that no single technology will answer all clinical questions
that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and our proprietary AI platform, Diagnostic Cortex, to discover innovative diagnostic tests for clinical use. Through our
learning loop, we continuously revisit our technology strategy and integrate new technologies into our evolving platform, which ultimately support the addition of new service and product revenue offerings. We focus on developing technologies that
are capable of single and multi-omic research and development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Diagnostic Cortex Artificial Intelligence Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of clinical diagnostic tests, which we
believe overcomes standard machine learning challenges faced in life sciences research. Researchers commonly encounter issues with machine learning-based biological discoveries that cannot be repeated or validated when assessed in additional
specimen cohorts. This challenge, commonly referred to as overfitting, occurs when the machine identifies a perfect pattern in an initial training dataset but is unable to identify the same pattern in a new dataset. For over 15 years we have focused
on developing our platform to overcome this challenge through proprietary computational techniques to ensure each diagnostic test that is discovered can be further developed to perform consistently in the clinical testing environment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continuously evolve and improve the Diagnostic Cortex platform. These improvements range from basic code optimization to complex
improvements such as the incorporation of novel computational methods for the optimization of multi-omic diagnostic tests. Any AI platform is inherently limited without the highest quality data inputs. Therefore,<B> </B>all of the technologies that
we employ have been chosen and developed to<B> </B>provide high-quality data to enable our Diagnostic Cortex platform. We feel that this level of data integrity is crucial for the development of diagnostic tests that require the advanced pattern
matching abilities of deep learning algorithms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We utilize multiple technologies, including ddPCR, NGS,
<FONT STYLE="white-space:nowrap">LC-MS,</FONT> ELISA, and our proprietary DeepMALDI mass spectrometry platform in our molecular analysis of the tumor, immune system, and host-status of each patient. The data from these technologies feed into our
proprietary Diagnostic Cortex platform to discover clinically relevant diagnostic tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are experts in many technologies, but we are
a true market leader with over 15 years of experience in the field of clinical proteomics. We have been discovering and developing proteomic-based diagnostic tests and have a deep understanding of how to incorporate technologies that can be applied
to blood samples in order to extract important protein-based biological information in the form of clinical diagnostic tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our suite
of technologies that assist us in discovery, development and commercialization of novel diagnostic tests includes: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>DeepMALDI Mass Spectrometry </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed DeepMALDI, a proprietary high density matrix-assisted laser desorption/ionization <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">time-of-flight</FONT></FONT> <FONT STYLE="white-space:nowrap">(MALDI-ToF)</FONT> mass spectrometry (MS) technology, to produce blood-based proteomic data for disease diagnosis, personalized health care, precision medicine
for direct treatment options, and disease screening in lung and other disease states. DeepMALDI overcomes the limitations of conventional MALDI and other mass spectrometry methods to produce highly sensitive, stable, and reproducible data by:
(1)&nbsp;utilizing optimized <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">signal-to-noise</FONT></FONT> reduction and signal processing algorithms; and (2)&nbsp;novel batch correction methods and spectral alignment methods. The
combination of these improvements yields substantially higher quality data content and is thereby much better suited for the discovery of biomarkers with clinical utility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current DeepMALDI methods allow us to achieve finer mass resolution, greater sensitivity, and
<FONT STYLE="white-space:nowrap">20-times</FONT> faster imaging speeds than other instruments. Additionally, we believe enhancements to our DeepMALDI methods and <FONT STYLE="white-space:nowrap">MALDI-ToF</FONT> technology evolution will allow us to
measure approximately 1,500 proteins, an improvement from the estimated 900 proteins we can measure today. We intend to maintain our leadership role in the discovery of proteomics-based diagnostic tests. We utilize our DeepMALDI and <FONT
STYLE="white-space:nowrap">MALDI-ToF</FONT> technologies in our discovery and development efforts and as part of our collaborations with our biopharmaceutical customers and academic partners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquid Chromatography Mass Spectrometry MS </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use Multiple Reaction Monitoring (MRM) MS with triple quadrupole mass spectrometers and <FONT STYLE="white-space:nowrap">up-front</FONT>
liquid chromatography (LC) sample injection in the Nodify XL2 test. This mass spectrometry method offers highly sensitive, specific, and cost-effective analysis for simultaneous quantitation of hundreds to several thousands of targeted peptides in a
single experiment. We have since included the MRM technologies as part of our services for discovery and development with our biopharmaceutical customers and academic partners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Enzyme-Linked</FONT> Immunosorbent Assay </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ELISA is the most widely used ligand binding assay platform within and outside the pharmaceutical industry. Formats include direct, indirect
and sandwich assays and are typically run in manually or semi-automated modes. We use a semi-automated implementation of ELISA in clinical testing for the Nodify CDT test and the Platelia <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Total Ab test for <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The acquisition of Oncimmune USA in 2019 expanded our ability to conduct very high throughput and cost-effective ELISAs in our
clinical testing laboratory. We have now included the ELISA technologies for research and development both internally and externally with our biopharmaceutical customers and academic partners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Droplet Digital PCR Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use the ddPCR technology for multiplexed, semi-automated nucleic acid detection. This allows high sensitivity, fast turn-around times,
flexibility in our laboratory workflows, rapid scaling from low to moderate analyte complexity, and high-volume scalability. ddPCR is an absolute quantitation method based on the partitioning of circulating nucleic acids into up to 20,000 droplets
per reaction and is used for the GeneStrat test and Bio-Rad <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> ddPCR test for <FONT STYLE="white-space:nowrap">COVID-19.</FONT> We have included the ddPCR
technologies for research and development both internally and externally with our biopharmaceutical customers and academic partners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Next Generation Sequencing Technology </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use an NGS technology for broad genomic sequencing of clinical specimens. Our strategy with NGS relies on a menu of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> and custom research use assays, which we develop and make available as a part of our biopharmaceutical test services. The NGS technology integrates automated
systems to yield high sensitivity results with a rapid turnaround time. Since adoption of this technology, we have included the NGS </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technologies for research and development both internally and externally with our biopharmaceutical customers and academic partners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Clinical Validation Data </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
dedicated to continuously publishing and presenting new data on the clinical validation and utility of our diagnostic tests. We have participated in 27 clinical studies, 4 of which are ongoing, and have published over 275 peer-reviewed publications
and presentations. Below we outline our clinical validation data for our six diagnostic tests: Nodify CDT, Nodify XL2, GeneStrat, VeriStrat, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> ddPCR, and
Platelia <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Total Ab. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nodify CDT
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nodify CDT has been studied in 14 peer reviewed published studies and presentations. Here we highlight an overview of one of our
key peer-reviewed clinical validation papers. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Healey GF, J Cancer Ther 2017</I>: In this study, the objective was to assess the clinical test performance of
Nodify CDT (previously named EarlyCDT-Lung) and its clinical utility in assessing risk of indeterminate pulmonary nodules. A High Level test result demonstrated a 98% specificity and 28% sensitivity with a positive predictive value (PPV) of 78%.
With these test performance metrics, the test is most clinically useful as a tool to <FONT STYLE="white-space:nowrap">&#145;rule-in&#146;</FONT> cancer, which is can be defined as helping to identify patients who may be at a higher risk of
malignancy. Conversely, a result of No Significant Level of Autoantibodies Detected (NSLAD) does not help rule out lung cancer and therefore does not change a patient&#146;s <FONT STYLE="white-space:nowrap">pre-test</FONT> risk of lung cancer.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nodify XL2 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nodify XL2 has been studied in 12 peer reviewed published studies and presentations. Here we highlight an overview of two of our key
peer-reviewed clinical validation papers. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Silvestri G, CHEST, 2018 (PANOPTIC)</I>: In the prospective, multicenter PANOPTIC clinical study, the test
demonstrated a sensitivity of 97%, a specificity of 44% and a negative predictive value of 98% in distinguishing benign from malignant nodules. When compared to traditional cancer risk assessments, Nodify XL2 performed better than a PET scan
commonly used and validated lung nodule risk models (including the Swensen nodule calculator), and physicians&#146; cancer probability estimates. The PANOPTIC study concluded that if the test results were used to direct care, 40% fewer invasive
procedures would be performed on benign nodules. As such, Nodify XL2 may have significant clinical utility in guiding incidental lung nodule management decisions, potentially eliminating unnecessary invasive procedures, resulting in improved quality
of life for patients as well as reduced financial expense for both the patient and the health system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Pritchett M, </I><I>Am J Respir Crit Care Med</I><I>, 2020:</I><B><I> </I></B>Preliminary results from the
ORACLE registry study were accepted as a late breaking abstract at the American Thoracic Society conference. In the study, the Nodify XL2 test resulted in 46% of nodules being <FONT STYLE="white-space:nowrap">re-classified</FONT> from the &#147;low
to moderate risk&#148; <FONT STYLE="white-space:nowrap">(5-65%)</FONT> into the &#147;very low risk&#148; (less than 5%) category. This redistribution was predicted in the PANOPTIC clinical validation study and is now seen in real-world clinical use
in the ORACLE study and through commercial clinical testing. This shift in distribution may lead to a substantial increase in benign nodules correctly routed to CT surveillance, thus a significant reduction of invasive procedures being performed on
benign disease. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>GeneStrat </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GeneStrat has been studied in 30 peer reviewed published studies and presentations. Here we highlight an overview of one of our key
peer-reviewed clinical validation papers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Mellert H, J Mol Diagn, 2017</I>: This study highlights the clinical validation data for the targetable
mutations (EGFR, KRAS, ALK) in the blood-based GeneStrat test. The overall clinical test performance of the genes and variants in GeneStrat is 91% sensitivity and 100% specificity. Clinical sensitivity for each gene ranged from 88% to 100%. Clinical
specificity for each gene was 100%. Additionally, this study reported on mutation results from our commercial clinical testing. Mutation results were available within 72 hours for 94% of the tests evaluated. The GeneStrat test is a rapid, highly
sensitive, and actionable blood-based test that supports faster targeted therapy treatment decisions for patients with NSCLC. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>VeriStrat </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">VeriStrat has been studied in over 85 peer reviewed and published clinical studies across many different types of treatment regimens such as
chemotherapy, targeted therapies, immune checkpoint inhibitors, and combination therapies. The presence of a VeriStrat Poor result indicates the presence of chronic inflammation and a chronic acute phase immune response. Typically, patients with a
VeriStrat Good result respond better to standard of care treatments than those patients that test as VeriStrat Poor. The results consistently show the test to be predictive of outcomes, independent of other prognostic factors including <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression and performance status. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Leal T, Curr Med Res Opin, 2020</I>: Timely assessment of patient-specific prognosis is critical to oncology
care, however clinical prognostic factors traditionally used in NSCLC treatment have limitations. This meta-analysis study examined the prognostic performance of VeriStrat through a systematic literature review of 21 published studies. It was found
that patients who test as VeriStrat Poor, on average, have an overall survival that is less than half of those who test as VeriStrat Good, independent of treatment type and line of therapy, demonstrating that the test is strongly prognostic.
Conversely, patients with a VeriStrat Good test result typically respond better to standard of care treatments than those patients that test as VeriStrat Poor. The robust prognostic performance of VeriStrat has clinical implications for patient and
physician shared decision-making and potential for the introduction of novel treatment strategies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Mitchell BR, J Clin Oncol, 2020</I>: Recently, we published data at the American Society of Clinical Oncology
2020 virtual meeting on an interim analysis from the INSIGHT clinical study. The data suggest that blood-based VeriStrat testing can provide clinically significant information to predict outcomes and guide treatment choices made by physicians for
patients with advanced NSCLC who are eligible for immune checkpoint inhibitor therapy. Specifically, the study identified that patients who have tumors that express <FONT STYLE="white-space:nowrap">PD-L1</FONT> greater than 50% and have a VeriStrat
Poor result should not be treated with immunotherapy alone. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Biodesix WorkSafe
<FONT STYLE="white-space:nowrap">COVID-19</FONT> Testing Program </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Bio-Rad</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> ddPCR Test </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA EUA Authorization&#151;All
acceptance criteria for the performance verification of the <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> ddPCR test were fulfilled. The sample size used
for the clinical evaluation study of the test was 60, and included 30 negative specimens and 30 positive contrived specimens per FDA EUA guidance. Specifically, verification of accuracy revealed 100% agreement with the reference result. An
additional study was performed to confirm our first 5 positive and first 5 negative clinical specimens relative to an external laboratory with an orthogonal EUA test. Data from this study demonstrated 100% concordance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Here we highlight an overview of one of the recent publications on ddPCR testing for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2:</FONT></FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Suo T, Emerging Microbes</I><I></I><I>&nbsp;&amp; Infections, 2020: </I>Quantitative real time PCR <FONT
STYLE="white-space:nowrap">(RT-PCR)</FONT> is widely used as the gold standard for clinical detection of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2.</FONT></FONT> However, due to the low viral load specimens
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and the limitations of <FONT STYLE="white-space:nowrap">RT-PCR,</FONT> significant numbers of false negative reports are inevitable, which results in failure to timely diagnose, cut off
transmission, and assess discharge criteria. To improve this situation, an independently developed optimized ddPCR was used for detection of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT> which showed
that the limit of detection of ddPCR is significantly lower than that of <FONT STYLE="white-space:nowrap">RT-PCR.</FONT> Results showed that the ddPCR test demonstrated 95% accuracy vs. 47% for other &#147;bulk&#148;
<FONT STYLE="white-space:nowrap">RT-PCR</FONT> technologies used in other molecular tests. Results from this publication were prior to the Bio-Rad SARS-CoV-2 ddPCR assay receiving FDA EUA and reported results derived from independently developed
testing from a different ddPCR testing product than the Bio-Rad SARS-CoV-2 ddPCR test. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Platelia <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Total Ab Test</I><B><I> </I></B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA EUA
Authorization&#151;All acceptance criteria for the performance verification of the Platelia <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Total Ab test were fulfilled. The test is intended for the
qualitative detection of total <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-SARS-CoV-2</FONT></FONT> nucleocapsid antibodies (IgG, IgM and IgA) in human serum or plasma specimens. The sample size used for the clinical
evaluation study of the test was 40, and included 20 negative specimens and 20 positive clinical specimens. Specifically, verification of accuracy revealed 100% agreement with the reference result. Additionally, precision was evaluated and found to
be comparable to that reported by the manufacturer <FONT STYLE="white-space:nowrap">within-run,</FONT> <FONT STYLE="white-space:nowrap">between-day,</FONT> <FONT STYLE="white-space:nowrap">between-instrument</FONT> and
<FONT STYLE="white-space:nowrap">between-operator.</FONT> Finally, all confirmed negative specimens tested were within the reference interval. The sensitivity is 98% (49/50) (95% confidence interval (89.5%-99.7%)) and specificity is 99.3% (596/600)
(95% confidence interval (98.3%-99.7%)) eight days after the onset of symptoms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Case Studies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe every patient deserves a personalized approach to improve their care. Our objective is to empower physicians with swift,
comprehensive, and actionable insights to help address clinical questions across lung disease. The following are case studies provided by our customers from their real-world experience with our diagnostic tests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Case Study #1: Catching Cancer Earlier with Nodify CDT </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Outcome</B>: Appropriate management of patients with incidentally discovered lung nodules must balance between the need to
identify malignant nodules earlier and the potential harm of invasive procedures, while keeping patient preferences in consideration. In this case, a 90% post-Nodify CDT risk of malignancy result led to a decision change by the physician and patient
to proceed with an invasive diagnostic workup, which led to an earlier diagnosis of stage IA lung cancer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Case
Background</B>: A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">64-year-old</FONT></FONT> female presented for medical attention after falling on her right side. A chest <FONT STYLE="white-space:nowrap">X-ray</FONT> showing a
spot on the lung and subsequent CT scan identified a spiculated (nodule edge characteristic), 10 mm lung nodule in the patient&#146;s right upper lobe. Based on her clinical risk factors and nodule characteristics, a 39% risk of malignancy was
determined by the Solitary Pulmonary Nodule Calculator. At this estimated risk, the patient was not comfortable with any invasive diagnostic procedures but was willing to undergo a <FONT STYLE="white-space:nowrap">follow-up</FONT> PET/CT scan and a
blood draw for Nodify Lung testing. PET/CT results had a standard uptake value (SUV) of 3.3, which is not a strong indicator of benign or malignant disease. The patient&#146;s Nodify CDT post-test risk of malignancy was 90%. Through shared decision
making based on the test results, the patient proceeded with a biopsy, which was diagnosed as cancerous. Early detection identified the patient as a candidate for a potentially curative procedure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Case Study #2: Avoiding Unnecessary Procedures with Nodify XL2 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Outcome</B>: Traditional diagnostic risk assessment and testing indicated that this patient had a higher risk of malignancy,
but because of the patient&#146;s health condition, a biopsy was not preferred. A 6% post-Nodify XL2 risk of malignancy result led the physician and patient to make a shared decision to monitor the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
nodule with a short-term <FONT STYLE="white-space:nowrap">follow-up</FONT> CT. The <FONT STYLE="white-space:nowrap">follow-up</FONT> CT demonstrated a reduction in size, indicating a benign
diagnosis. Blood-based risk classification provided additional information that enabled a decision to avoid an unnecessary invasive procedure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Case Background</B>: A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">74-year-old</FONT></FONT> male with
severe chronic obstructive pulmonary disease (COPD) presented for medical evaluation. The patient&#146;s pulmonary function tests showed severe obstruction. A CT scan was completed for evaluation for candidacy of procedure which revealed a
spiculated 10 mm nodule in the patient&#146;s left upper lobe. The <FONT STYLE="white-space:nowrap">pre-test</FONT> risk of malignancy with the Solitary Pulmonary Nodule Calculator was calculated as 49%, however biopsy was not a preferred option due
to the patient&#146;s poor pulmonary function and the difficult location of the lung nodule. The Nodify XL2 test was ordered and returned a result of Likely Benign, with a 6% post-Nodify XL2 risk of malignancy. Subsequent PET/CT imaging showed SUV
of 7.0, which is concerning for a lung malignancy. Based upon the Nodify XL2 results and patient preference, a wait and watch approach with repeat chest imaging was pursued. A repeat CT scan demonstrated a reduction in size of the nodule to 7 mm,
indicating an inflammatory or benign etiology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Case Study #3: Biodesix Lung Reflex Results Changed Patient&#146;s Cancer Treatment
Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Outcome</B>: It is important for physicians to have a holistic view of each patient&#146;s dynamic disease
state to make more informed patient care decisions. Prior to receiving Biodesix Lung Reflex results, the physician was considering putting the patient on single agent immunotherapy due to her high PD-L1 expression status and potential for less
treatment-related adverse events. The patient&#146;s GeneStrat result came back negative for driver mutations, indicating to the physician that the patient was eligible for immunotherapy regimens. However, the patient&#146;s VeriStrat Poor result
identified the need to expedite time to treatment and be more aggressive, leading to the physician changing his initial treatment recommendation to a combination immunotherapy and chemotherapy regimen. The patient has been alive for over 18 months.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Case Background</B>: A 55-year-old female presented to the clinic with a cough, fever, and chest pain. The patient was
a former smoker who had quit over a year ago. Imaging identified multiple lung lesions and metastases, including in the brain, and was staged as stage IV adenocarcinoma. The physician advised the patient of her potential eligibility for single agent
immunotherapy based on her high PD-L1 expression status (PD-L1&gt;50%), but wanted to order molecular testing to confirm. A blood sample was collected for Biodesix Lung Reflex testing. The GeneStrat test result was mutation negative and the
VeriStrat test result was Poor. The VeriStrat results lead to the physician changing his initial treatment recommendation to a more aggressive combination immunotherapy and chemotherapy regimen, which has been successful for the patient who has been
alive for over 18 months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Case Study #4: First Do No Harm &#150; Biodesix Lung Reflex Supports Shared Decision Making </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Outcome</B>: Lung cancer is a deadly disease, and often patients with advanced disease on average live about 10 months. In
this case, an elderly patient was diagnosed with advanced NSCLC, but was hesitant to receive further surgical procedures. This patient received the unfortunate combination of a VeriStrat Poor and a KRAS mutation. The results facilitated a
conversation with the physician and the patient&#146;s family regarding her overall poor prognosis and short estimated survival. The patient and family decided to pursue
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-life</FONT></FONT> palliative care, saving the patient from unnecessary procedures and adverse effects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Case Background</B>: A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">92-year-old</FONT></FONT> female
presented with back and chest pain and recent difficulty breathing. The patient had also lost 8 to 10 pounds in recent weeks and had a productive cough. The patient had a 40 pack-year smoking history but had quit over 35 years prior. A PET/CT scan
revealed metastatic disease with multiple brain metastases, leading to a diagnosis of stage IV lung cancer. The patient and her family were hesitant to proceed with an invasive procedure for further diagnosis and clinical staging to inform a
treatment plan. Biodesix Lung Reflex testing was ordered to inform potential treatment pathways. The GeneStrat test result showed the patient was positive for a KRAS G12V mutation, implying a worse prognosis. Additionally, the VeriStrat test result
was Poor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Diagnostic Tests in Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the goal of finding solutions for clinical unmet needs related to diagnosis, treatment and monitoring in lung disease, our diagnostic
tests in development include the following: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Early Stage NSCLC&#151;Risk of Recurrence </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, surgical resection of the tumor without systemic or radiation therapy is standard of care for stage I NSCLC patients. However, 20 to
40% of surgically treated patients will suffer a recurrence within 5 years after surgery. From market research with pulmonologists, thoracic surgeons, and medical oncologists, we identified a significant clinical unmet need for a blood-based test to
help identify stage I NSCLC patients who are at a higher risk of recurrence and may benefit from neoadjuvant or adjuvant systemic treatment. With this information, we discovered the Risk of Recurrence (ROR) test, which is a <FONT
STYLE="white-space:nowrap">pre-surgery</FONT> blood-based proteomic test, designed with the Diagnostic Cortex to predict whether a stage I NSCLC patient has a higher risk of recurrence post-surgical resection. Knowing this information early and
before surgery may support treatment decisions such as neoadjuvant or adjuvant therapy, which have the potential to reduce tumor volume and address micro-metastatic disease as early as possible. Our ROR test validated in an independent sample set,
and we are currently working with major academic institutions across the United States to further validate the test. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Late Stage
NSCLC&#151;Immunotherapy Treatment Guidance </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, the first immunotherapy-based treatment regimen was approved by the FDA for use
in lung cancer. Currently, there are 9 immune checkpoint inhibitor (ICI) regimens (single agent or combinations) recommended by the NCCN guidelines for treatment of advanced NSCLC patients. For a portion of patients treated, these drugs can result
in significant improvement in overall survival compared with platinum-based chemotherapy options. The combination ICI regimens see some improvement in performance over single agent ICI, but side effect profiles are worse, and costs are higher than
for single agent ICI. In addition, recent data have shown that a subset of patients experience more rapid disease progression on ICI compared with chemotherapy. We utilized the Diagnostic Cortex platform to discover our Primary Immune Response (PIR)
test. PIR is a blood-based proteomic test designed to profile a patient&#146;s immune response to their cancer and stratify by who is likely to respond to ICI treatment. Our PIR test has been validated in multiple independent sample sets for
advanced stage NSCLC patients treated with single agent ICI, and we are currently working with major academic institutions across the United States to further validate the test in a prospective study called BEACON-Lung. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Monitoring &#150; Progression&nbsp;&amp; Resistance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Blood-based monitoring with our ddPCR technology may offer a feasible method to <FONT STYLE="white-space:nowrap">non-invasively</FONT> evaluate
therapeutic mechanism of action, disease progression, and the emergence of resistance mutations in patients treated with targeted therapies. Our internal validation studies have shown the utility of the GeneStrat <I>EGFR</I> ddPCR test in all three
of these indications. The test can identify disease progression up to 3 months (median) in advance of standard imaging. Using ddPCR for longitudinal blood-based monitoring of EGFR cell-free DNA mutations is a cost-effective testing method while
patients are being treated with targeted therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Trials </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dedicated to continuously publishing and presenting new data on the clinical validation and utility of our diagnostic tests. We have
participated in 27 clinical studies, 4 of which are ongoing, and have published over 275 peer-reviewed publications and presentations. The following are our ongoing clinical studies for our diagnostic testing solutions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>ORACLE Registry Study (NCT03766958) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ORACLE registry study was designed to develop real-world clinical utility data for Nodify XL2 and is titled &#147;An Observational Registry
Study to Evaluate the Performance of the Nodify XL2 Test&#148;. The study objectives are to show a reduction in invasive procedures on patients with benign nodules compared to a historical control obtained from chart review. The first patient
enrolled on October&nbsp;16, 2018. As of May&nbsp;1, 2020, 423 patients have been enrolled and are undergoing primary endpoint analysis, with <FONT STYLE="white-space:nowrap">2-year</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> estimated
to be completed by the first half of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>ALTITUDE Clinical Utility Study (NCT04171492) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ALTITUDE clinical utility study is designed to evaluate the performance of Nodify Lung (Nodify XL2 and Nodify CDT) in a randomized
controlled study (RCT). The study is titled &#147;A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Test in Incidentally Discovered Low to Moderate Risk Lung Nodules&#148;. We
received central investigational review board (IRB) approval in December 2019 and have an enrollment goal of 2,000 patients. The study objectives are to evaluate how the addition of the Nodify Lung test result impacts the clinical decision making
for patients with new, incidentally identified solid lung nodules assessed as low to moderate risk of lung cancer. The trial has an adaptive study design with a blinded standard of care arm and 2:1 randomization for open-label results for Nodify
XL2. First patient first visit is expected the second half of 2020. Phase 1 of the study with only Nodify XL2 is expected to enroll 500 patients. Phase 2 of the adaptive study design will include an open-label arm for Nodify CDT, which is aligned
with our commercial testing algorithm. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>INSIGHT Observational Study (NCT03289780) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The INSIGHT observational study is designed to evaluate the real-world clinical utility and performance of the Biodesix Lung Reflex (GeneStrat
and VeriStrat) testing strategy. The title is &#147;Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects with <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer
(INSIGHT)&#148; and the first patient enrolled was on May&nbsp;11, 2016. To date, we have over 3,500 patients enrolled with a target 5,000 enrollment goal. Final analysis with <FONT STYLE="white-space:nowrap">3-year</FONT> <FONT
STYLE="white-space:nowrap">follow-up</FONT> is estimated to be completed by 2024. Results of an interim analysis were presented at ASCO 2020. The study rationale is to guide the adoption of VeriStrat and inform medical decision making, including
treatment choice, and enable the validation of additional mass spectrometry-based proteomic tests. The primary study objective is to describe the impact of the VeriStrat test results on treatment decisions, including but not limited to the
percentage change in treatment decision, differences in chosen treatments between patients classified as VeriStrat Good and those classified as VeriStrat Poor, and the percentage of patients receiving systemic therapy or supportive therapies only.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>BEACON-Lung Clinical Study (Pending IRB Submission) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In partnership with ALCMI (Addario Lung Cancer Medical Institute), the BEACON-Lung clinical study is intended to evaluate the performance and
utility of our proteomic product currently in development, PIR, in advanced stage NSCLC patients who express high <FONT STYLE="white-space:nowrap">PD-L1.</FONT> The study title is &#147;A Biomarker Analysis in High
<FONT STYLE="white-space:nowrap">PD-L1</FONT> Expressing NSCLC Patients Treated With An Immune Checkpoint Inhibitor (ICI) With or Without Platinum-Based Chemotherapy.&#148; IRB submission is planned for the second half of 2020. The study design is
an observational, multicenter, open-label study to assess biomarkers (serum, microbiome, radiomics and tissue) as predictive of early progression in 390 treatment-naive patients with advanced stage NSCLC and
<FONT STYLE="white-space:nowrap">PD-L1</FONT> greater than or equal to 50% treated with two standard of care regimens, triplet therapy (platinum-based chemotherapy plus&nbsp;ICI regimen) and ICI monotherapy (single agent ICI). The objectives are to
collect biospecimens and evaluate candidate biomarkers, with a focus on PIR, to detect early progression on ICI monotherapy versus triplet therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our lung cancer and nodule management tests, commercial efforts are focused on the promotion of our testing strategies to healthcare
professionals actively involved in the diagnosis and treatment of lung cancer. Primarily focusing on pulmonology, the commercial team, consisting of specialty sales representatives, medical affairs, marketing and customer care representatives, works
to educate and inform the entire patient care group consisting of physicians, nurses, office staff, laboratory personnel, and administration as to the appropriate use and value provided by our testing. The team&#146;s goal is to drive test adoption
through articulating the scientific and clinical evidence behind our tests, how they impact the clinical care of a patient, and how the tests can ultimately help to improve patient outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with pulmonary nodules are concentrated in this <FONT STYLE="white-space:nowrap">sub-specialty,</FONT> where additional resources
such as lung cancer screening and nodule management clinics may exist to provide an increased level of care. We are also engaging large hospital systems in a <FONT STYLE="white-space:nowrap">&#147;top-down&#148;</FONT> approach, with a goal of
incorporating our tests into system wide pathways and protocols. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a physician orders our tests, blood is collected either in the
physician office or laboratory, third party &#147;store front&#148; patient service centers, or it can be collected in the patient&#146;s home or workplace. We have contracted with a network of patient service centers and mobile phlebotomy services
to be enable collection of blood samples outside of the physician office, at home or work for patients across the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our
Biodesix WorkSafe <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing program, we have a dedicated outreach team that works with healthcare providers and hospitals, and employers looking to safely return to work across many industries,
including food services, oil and gas, biotechnology and pharmaceuticals, sports teams, universities, and many small businesses. We recognize everyone&#146;s <FONT STYLE="white-space:nowrap">COVID-19</FONT> situation is unique, which is why we
provide <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> customized solutions to support testing for our different customers, such as risk assessment tools, physician ordering services, <FONT
STYLE="white-space:nowrap">on-site</FONT> testing, phlebotomy services, shipping logistics, and ongoing support. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business development
team is focused on selling our complete offering of tests and services to biopharmaceutical companies in the United States and internationally. Our team consists of customer facing business development associates that work with our biopharmaceutical
customers to identify projects, draw up statements of work and negotiate service agreements. Alliance managers help to manage the contractual obligations and scope of the project, whereas our operations team assures the project is managed with
adequate resources and delivers on time. We take a <FONT STYLE="white-space:nowrap">two-pronged</FONT> approach generating business in this segment. Primarily, we leverage existing projects and relationships to expand sales in current accounts. We
also actively map ongoing drug development projects in biopharmaceutical companies and target programs best suited to our platform for new test development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Coverage and Reimbursement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary
source of reimbursement for our tests in the United States is from third-party payers including government payers, such as Medicare, and commercial payers, such as insurance companies. For our <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing
program, the primary source of reimbursement is through contracts with hospitals, companies providing wellness testing for their employees, or direct pay from patients. We believe that our lung cancer tests can both improve patient outcomes and help
guide cost-effective treatment choices for patients with and <FONT STYLE="white-space:nowrap">at-risk</FONT> of lung cancer. Achieving broad coverage and adequate reimbursement for each of our tests is a key component of our financial success and
will continue to be important over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Families First Coronavirus Response Act&nbsp;(FFCRA) and Coronavirus Aid, Relief, and
Economic Security&nbsp;(CARES) Act, Congress has imposed a broad requirement that Medicare fee-for-service, Medicare Advantage, Medicaid, and commercial payers generally cover clinical diagnostic laboratory tests administered during the Public
Health Emergency for the detection of SARS-CoV-2 or the diagnosis of the virus that causes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
COVID-19. Where applicable, the FFCRA and CARES require payers to cover COVID-19 tests without cost sharing or medical management techniques like prior authorization. Medicare fee-for-service
does not require cost sharing or prior authorization for any clinical diagnostic laboratory tests.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Department of Health &amp; Human
Services&nbsp;(HHS) has indicated in guidance that the coverage requirements of the FFCRA and CARES can apply both to infection and serological testing, but that they are only applicable to testing that is &#147;diagnostic,&#148; which &#147;may
include testing of individuals with signs or symptoms compatible with COVID-19, as well as asymptomatic individuals with known or suspected recent exposure to SARS-CoV-2.&#148; Testing that is &#147;not primarily intended for individualized
diagnosis or treatment of COVID-19 or another health condition,&#148; including &#147;testing conducted to screen for general workplace health and safety,&#148; is beyond the scope of the statutory coverage requirements. We believe these coverage
requirements apply to the Biodesix SARS-CoV-2 ddPCR test and the Biodesix Platelia SARS-CoV-2 Total AB test when performed for diagnostic purposes.&nbsp;In some cases, we submit claims to insurance payers for the Biodesix SARS-CoV-2 ddPCR test
and/or the Biodesix Platelia SARS-CoV-2 Total AB&nbsp;test. In these cases, insurance payers may have a different position on the scope of mandatory coverage of our tests under the FFCRA and CARES.&nbsp;More commonly, we enter into arrangements with
clients under which the client pays us directly for testing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The payment rate for the Biodesix SARS-CoV-2 ddPCR test and the Biodesix
Platelia SARS-CoV-2 Total AB&nbsp;test depends on the payer. We bill for the Biodesix SARS-CoV-2 ddPCR test using the Healthcare Common Procedure Coding System (HCPCS) code U0003 (Infectious agent detection by nucleic acid (DNA or RNA); severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), 2&nbsp;amplified probe technique, making use of high throughput technologies as described by <FONT STYLE="white-space:nowrap">CMS-2020-01-R).&nbsp;Medicare</FONT> has
established a payment rate of $100 for U0003. We bill for the Biodesix Platelia SARS-CoV-2 Total AB test using HCPCS code 86769 (Antibody; severe acute respiratory syndrome coronavirus&nbsp;2 (SAR-CoV-2). Medicare has established a payment rate of
$42.13 for 86769. These payment rates may be subject to change effective January&nbsp;1, 2021, under Medicare&#146;s annual basis of payment determination process for new or substantially revised HCPCS codes. When covered under the FFCRA and CARES,
commercial insurance payers must make payment for the Biodesix SARS-CoV-2 ddPCR test and the Biodesix Platelia SARS-CoV-2 Total AB test at the cash price for the test listed by us on our website or at a lower negotiated rate. When entering into
arrangements with clients under which the client pays us directly for testing, we and the client negotiate a payment rate for the test. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with applicable laws and regulations, as well as internal compliance policies and procedures adds complexity to the billing
process. The CMS are responsible for overseeing the establishment of new Healthcare Common Procedure Coding System (HCPCS) codes for billing the Medicare program and other payers. CMS continuously evaluates and implements changes to the Medicare
billing, coding, and reimbursement processes. To receive reimbursement from third-party payers, we bill our tests using a variety of HCPCS codes or CPT codes, as defined by the American Medical Association. For some of the tests we conduct, there
may not be a specific CPT or HCPCS code, in which case the test may be billed under a miscellaneous code for an unlisted molecular pathology procedure or unlisted multiple analyte assay with algorithmic analysis (MAAA) procedure. Because these
miscellaneous codes do not describe a specific service, the third-party payer claim may be examined to determine the service provided, whether the service was appropriate and medically necessary and whether payment should be rendered. This process
can result in a delay in processing the claim, a lower reimbursement amount, and/or denial of the claim. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Government Payers
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicare is limited to items and services that are within the scope of a Medicare benefit category and that are reasonable and
necessary for the diagnosis and treatment of an illness or an injury. Medicare develops National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), setting forth additional requirements for coverage for tests such as ours using
an evidence-based coverage process with opportunity for public participation. Median age at diagnosis for lung cancer is 71 years old; therefore the Medicare eligible population represents approximately
<FONT STYLE="white-space:nowrap">60-65&nbsp;%</FONT> of the addressable market in lung cancer. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Novitas Solutions, the MAC responsible for developing coverage policies for tests performed in
the region that includes our Boulder, Colorado clinical laboratory, issued a final LCD <I>Biomarkers for Oncology</I> (L35396)<I> </I>that included coverage for the VeriStrat test on October&nbsp;1, 2015 (most recently revised effective July&nbsp;1,
2020). This policy provides coverage for patients with <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer whose <I>EGFR</I> gene mutation status is either wild type (negative) or mutation status unknown. The <I>Biomarkers for
Oncology</I> LCD also includes coverage for the genes in the GeneStrat test for patients with <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Palmetto GBA, the MAC responsible for administering the molecular diagnostics services program covering many other regions of the United
States including the De Soto, Kansas clinical laboratory, issued a positive coverage LCD for the Nodify XL2 test, known under the generic name <FONT STYLE="white-space:nowrap">BDX-XL2</FONT> (L37031), effective July&nbsp;10, 2017 (most recently
revised effective October&nbsp;24, 2019). The test is covered for patients who are 40 years or older, have a suspicious pulmonary nodule between 8 and 30mm, and have a <FONT STYLE="white-space:nowrap">pre-test</FONT> risk of cancer of equal to or
less than 50% as assessed by the Solitary Pulmonary Nodule Malignancy Risk calculator (Mayo Clinic). There is currently no Medicare coverage, and as a result, no Medicare reimbursement, for the Nodify CDT test, but we are actively engaged in efforts
to gain such coverage and reimbursement by Medicare. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our tests and those like ours are typically paid by Medicare Part B under the
Clinical Laboratory Fee Schedule (CLFS). In April 2014, Congress passed the Protecting Access to Medicare Act of 2014 (PAMA) which included changes to how prices are assigned to billing codes used to identify these tests. Under PAMA, entities who
receive a majority of their Medicare payments under that CLFS or the Physician Fee Schedule are required to report private payer payment rates and volumes every three years, or every year for tests with the Advanced Diagnostic Laboratory Test (ADLT)
designation. CMS calculates a weighted median rate for each code, which establishes the Medicare CLFS reimbursement rate for the subsequent three years, or one year for ADLTs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;21, 2018, CMS determined that VeriStrat met the criteria for an &#147;existing ADLT,&#148; meaning an advanced test that was
paid on the CLFS prior to January&nbsp;1, 2018. Assignment of this status meant that beginning on January&nbsp;1, 2020, the reimbursement rate assigned to the code used to identify VeriStrat would be set annually. Data collected from January to June
of 2018 was reported to CMS in the first quarter of 2019 and set the rate of $2,871 for calendar year 2020, representing no change from the rate paid for VeriStrat for calendar year 2019. Data collected from January to June 2019 was reported in the
first quarter of 2020 that will be used to set the rate for calendar year 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;17, 2019, CMS determined that Nodify XL2 met
the criteria for &#147;new ADLT&#148; status. From July&nbsp;1, 2019 through March&nbsp;31, 2020, Medicare paid the list price of $3,520. During the period from July 2019 to November 2019, we collected the required commercial payment data and
reported to CMS in December 2019. The data from this period was used to set the payment rate for the test from April&nbsp;1, 2020 through December&nbsp;31, 2021, which remains priced at $3,520. The rate for 2022 will be set based on data collected
in the first half of 2020 and reported in the first quarter of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medicare Advantage plans, which are an alternative to original
Medicare and are offered by private companies, such as commercial payers, also cover and reimburse our products. Medicare Advantage plans must provide at least the same level of coverage for Medicare beneficiaries as traditional Medicare; however,
reimbursement for our tests by Medicare Advantage plans can depend on our contracts with each plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">State-based Medicaid and Managed
Medicaid plans offered by private companies such as commercial payers, have limited coverage and reimbursement of our products. Payment by Managed Medicaid is also dependent on our contracts with each plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Commercial Third-Party Payers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are actively engaged in efforts to achieve broad coverage and adequate reimbursement for all of our marketed tests. Reimbursement from
commercial payers differs depending on if they have established coverage </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and if we are contracted as a &#147;participating provider&#148; or do not have a contract and are considered a <FONT STYLE="white-space:nowrap">&#147;non-participating</FONT> provider.&#148;
Approval of a claim is dependent on coverage, and reimbursement rate and timing of payment is based on the terms of or presence of a contract. When we are not reimbursed in full or at all, we may submit appeals of the denial or underpayment or seek
payment from the patient. However, insurance appeal and patient collection efforts take a substantial amount of time and can have varying levels of success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We bill for the VeriStrat and Nodify XL2 tests using test specific CPT codes&#151;81538 and 0080U, respectively. The GeneStrat test is billed
based on the genes that are ordered by the physician using the existing molecular pathology codes. The Nodify CDT test is billed using the unlisted MAAA code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the evolution of genomic testing, individual commercial third-party payers&#146; medical coverage policies around the CPT codes we bill
and their associated payment rates have changed over time, resulting in changes to our reimbursement revenues. We believe all of our products provide significant clinical value and reduction in downstream healthcare spend, as evidenced in research
studies and clinical publications, which we believe will continue to support and drive third-party payer reimbursement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy
includes educating commercial third-party payers and evidence review organizations regarding our strong clinical data, which we believe validates the value of our tests and will eventually result in more commercial third-party payers covering our
tests. The VeriStrat test is covered by many private payers including Aetna, Cigna, Humana, and various Blue Cross Blue Shield plans. We are actively engaged with private payers to expand coverage and contracting for all of our marketed tests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competitors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We primarily face
competition from lung cancer diagnostic solutions companies in the United States, Europe and Asia seeking to answer clinical questions in the space, all of whom provide cancer-focused diagnostic tests to hospitals, researchers, clinicians,
laboratories and other medical facilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Diagnosis&#151;Nodule Management </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not aware of any other company that offers two commercial blood-based tests to help physicians reclassify risk of malignancy in patients
with suspicious lung nodules. We are aware of efforts by Veracyte, Inc. to develop and validate a test that may be competitive to the Nodify XL2 and/or Nodify CDT tests in the future. Additionally, Veracyte currently markets a test that is used
post-bronchoscopy that is not competitive with our <FONT STYLE="white-space:nowrap">pre-bronchoscopy</FONT> nodule risk assessment tests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Prognosis, Treatment Guidance and Monitoring&#151;NSCLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are unaware of any other diagnostic test available, commercially or in development, that will compete with our VeriStrat immune profiling
test. There is substantial interest and activity in tumor profiling through liquid biopsy. Our genomic test offering, GeneStrat, faces competition from academic hospital laboratories, and companies such as Guardant Health and Foundation Medicine. We
believe that there are several companies and academic research institutions in the process of developing tests for monitoring patients on or following treatment for recurrence or progression of lung cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> Testing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our competitors include national and state laboratories, reference laboratories such as Lab Corporation and Quest Diagnostics, <FONT
STYLE="white-space:nowrap">in-hospital</FONT> laboratories, and a number of other diagnostic providers. We are aware that a number of other companies have announced development efforts to develop <FONT STYLE="white-space:nowrap">COVID-19</FONT>
tests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Biopharmaceutical Diagnostic Discovery, Development&nbsp;&amp; Testing Services
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are aware of a number of companies who compete with our diagnostic tests and services, including diagnostic research, clinical
trial testing, and the discovery, development, and commercialization of companion diagnostics. From the perspective of tumor profiling, we believe Guardant Health and Foundation Medicine are our most significant competitors. Conversely, in the
immune profiling market, we believe Adaptive Biotechnologies and Personalis are our most significant competitors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Laboratory Operations
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We perform the VeriStrat, GeneStrat, and <FONT STYLE="white-space:nowrap">COVID-19</FONT> ddPCR tests in our Boulder, Colorado
clinical laboratory. The laboratory is <FONT STYLE="white-space:nowrap">CAP-accredited,</FONT> CLIA-certified, New York Department of Health (NYSDOH)&#151; permitted and licensed, ISO 13485:2016 Quality Management Systems&#151;Requirements for
Regulatory Purposes for Medical Devices certified, along with all other states that require licensing: California, Maryland, Pennsylvania, and Rhode Island. All aspects of the testing process from receipt of the test requisition form through to
delivery of test results are performed in the Boulder, Colorado facility. The proprietary testing methods use semi-automated workflows that facilitate the successful delivery of greater than 90% of our tests within 3 days, and we believe our
existing workflows will continue to successfully deliver our tests within this timeframe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nodify XL2, Nodify CDT, and <FONT
STYLE="white-space:nowrap">COVID-19</FONT> complete antibody tests are performed in our De Soto, Kansas clinical laboratory. This clinical laboratory is CLIA-certified, COLA-accredited, New York Department of Health&#151;permitted and licensed, and
licensed by California, Maryland, Pennsylvania, and Rhode Island. Efforts are underway with the NYSDOH to become permitted and licensed to perform Nodify XL2 and Nodify CDT testing for samples from the state of New York. Receipt of requisitions and
testing is performed in our De Soto, Kansas clinical laboratory. Delivery of the test results is performed by personnel from our Boulder, Colorado headquarters. The proprietary testing methods use semi-automated workflows that facilitate the
successful delivery of greater than 90% of our tests within 5 days, and we believe our existing workflows will continue to successfully deliver our tests within this timeframe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Personnel in both facilities are responsible for quality assurance oversight, licensing, and regulation compliance and maintenance to ensure
data integrity and consistent, validated processes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Supply Chain </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party suppliers, including in some instances single source suppliers, to provide us with certain components of our diagnostic
tests. The number of suppliers feeding into the production of our diagnostic tests is in excess of 65 worldwide. We consider a select few of these suppliers, located in the United States, Europe and China, as critical single source providers of
components. <FONT STYLE="white-space:nowrap">Bio-Rad,</FONT> as described below, is the sole source supplier for our GeneStrat test and <FONT STYLE="white-space:nowrap">COVID-19</FONT> diagnostic and antibody testing program. Oncimmune is also the
sole source supplier for our Nodify CDT tests but there are known secondary suppliers for these materials. We have initiated the second source qualification process for the majority of these critical components. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we purchase supplies through purchase orders without long-term supply agreements with, or guaranteed commitments from, many of
our suppliers, including single source suppliers.&nbsp;Additionally, at present, we rely on contract manufacturers for the production of our diagnostic tests.&nbsp;We depend on our suppliers and contract manufacturers to provide us and our customers
with materials in a timely manner that meet our and their quality, quantity and cost requirements.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a nonexclusive license
and supply agreement with <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> in August 2019. We rely on <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> to supply equipment and reagents used to perform ddPCR testing, a service offered by us under a
variety of fee for service agreements and the core technology powering the GeneStrat test, but these supplies are able to be supplied by known suppliers. A disruption to this supply would negatively impact our ability to perform the GeneStrat and
SARS <FONT STYLE="white-space:nowrap">CoV-2</FONT> tests until alternatives could be validated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have initiated the second source qualification process for the majority of these
critical components, we may not be successful in securing second sourcing for all of them at all or on a timely basis. A disruption to this supply would negatively impact our ability to perform these tests until an alternative supplier could be
validated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All materials for our VeriStrat test and Nodify XL2 tests have alternative suppliers readily available, and a disruption in
any single supplier would not materially impact our ability to deliver the test. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic has allowed us to pressure-test our supply chain and logistics processes as we purchased additional manufacturing capacity above our normal run rates to ensure that supply to execute on tests for the foreseeable future was available <FONT
STYLE="white-space:nowrap">in-stock</FONT> and <FONT STYLE="white-space:nowrap">in-house.</FONT> Our suppliers have been able to allocate sufficient capacity to meet this increased demand with reasonable lead times and therefore we believe
sufficient capacity exists for all tests for the next 24 months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends, in part, on our ability to obtain and maintain intellectual property and proprietary protection for our products and other
<FONT STYLE="white-space:nowrap">know-how,</FONT> to operate our business without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of others, and to defend and enforce our intellectual property and
proprietary rights. We take efforts to protect our proprietary position using a variety of methods, which include pursuit of United States and foreign patent applications related to our proprietary technology, inventions and improvements that we
determine are important to our business. We also may rely on trade secrets, trademarks, <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and potential <FONT STYLE="white-space:nowrap">in-licensing</FONT> and
acquisition opportunities to develop and maintain our proprietary position. For more information regarding risks relating to intellectual property, please see &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have invested heavily in the protection of our key assets, namely the VeriStrat<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
and GeneStrat<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> tests, and we acquired a patent portfolio relating to the Nodify XL2<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and CDT<SUP
STYLE="font-size:85%; vertical-align:top">&#153;</SUP> tests in our acquisitions of Integrated Diagnostics in June 2018, and of Oncimmune USA in October 2019 from Oncimmune Limited (Oncimmune). We own patents and patent applications as well as trade
secrets relating to our products currently in development, collection device for whole blood, business strategy, client lists and business methods. Further, we have expanded our access to key intellectual property through license and <FONT
STYLE="white-space:nowrap">co-development</FONT> agreements, including our <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> License Agreement with <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> (the
<FONT STYLE="white-space:nowrap">Bio-Rad</FONT> License), which allows us to use the Droplet Digital PCR<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> technology developed by <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> and which we
employ in our GeneStrat test. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent strategy has focused on creating and acquiring protection for our VeriStrat and Nodify XL2
proteomic tests, while utilizing trade secret and some methods patent protection for our genomic test (the GeneStrat test) and ELISA test (the Nodify CDT test). We have entered into a non-exclusive license agreement with Bio-Rad, without the right
to grant sublicenses, to utilize certain of Bio-Rad&#146;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of ddPCR in cancer detection testing for third parties in the United States. For
more information regarding this license and supply agreement, please see &#147;&#151;Material Agreements&#151;Agreements with Bio-Rad.&#148; Bio-Rad owns patents relating to ddPCR and to which we have a non-exclusive license to utilize for the
performance of ddPCR in cancer detection testing for third parties as set forth in the Bio-Rad License Agreement. In addition, we have separately been granted permission by Bio-Rad to use the Bio-Rad
<FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT> ddPCR assay and Platelia SARS-CoV-2 Total Ab assay for commercial diagnostic services. For more information regarding the permission granted to us by Bio-Rad with respect to such tests, please see
&#147;Business&#151;Material Agreements&#151;Agreements with Bio-Rad.&#148; We are unaware of patents owned by Bio-Rad relating to its COVID-19 antibody test but acknowledge that Bio-Rad has know-how and trade secrets relating to this assay. We have
patent protection in the United States and other countries around the world for the primary use of the VeriStrat test for profiling of patients with NSCLC, and various other uses of the VeriStrat test, such as breast cancer, prostate cancer, head
and neck cancer have received patent protection. We have also received patent protection relating to our core classifier development program, our Diagnostic Cortex<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technologies and our
approaches to using mass shot matrix-assisted laser desorption time of flight <FONT STYLE="white-space:nowrap">(MALDI-TOF)</FONT> technology (DeepMALDI<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> techniques). Additionally, our first
device patent was issued in 2019 for our internally designed blood collection device. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;21, 2020, our patent portfolio includes approximately 48 issued United States
patents, 35 issued foreign patents, which includes 2 European patents that were nationalized in multiple European countries, and 38 pending applications (including 1 PCT applications and 23 foreign patent applications). With regard to our product
development efforts, PCT applications have been filed around our risk of recurrence and primary immunoresistance tests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent
portfolio can be broken down into 5 categories: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">1)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Issued patents and patent applications relating to the VeriStrat and Nodify tests and uses of these tests; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">2)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Issued patents and patent applications relating to methods for developing classifiers using the Diagnostic Cortex and DeepMALDI technologies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">3)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Issued patents and patent applications relating to tests currently in development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">4)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Issued patents and patent applications relating to our novel blood collection device; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">5)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Issued patents and patent applications relating to tests developed for our third-party partners. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents relating to the VeriStrat test are scheduled to expire between 2026 and 2032. The patents relating to the Nodify XL2 test are
scheduled to expire beginning in 2031 (excluding any patent term extension granted by the USPTO), and the patents relating to the Nodify CDT test are scheduled to expire in 2027. The patent related to the blood collection device is scheduled to
expire in 2039. Should our current patent applications in prosecution in the United States issue, the resulting patents would be scheduled to have expiration dates between 2036 and 2040 (excluding any patent term extension(s) granted by the USPTO).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending PCT patent applications are not eligible to become issued patents until, among other things, we file such PCT applications as
national stage patent application(s) within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to any such PCT patent
applications and any patent protection on the inventions disclosed in such PCT patent applications. Provisional patent applications are not eligible to become issued patents but can become the basis of PCT and United States <FONT
STYLE="white-space:nowrap">non-provisional</FONT> patent applications, if such PCT or United States <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications are filed within 12 months of filing the related provisional patent application.
If we do not timely file any <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, we will lose our priority date and any patent protection on the inventions disclosed in any such provisional patent application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the term of individual issued patents depends upon the legal term for patents in the countries in which they are obtained. In
most countries in which we have filed, including the United States, the patent term is generally 20 years from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application, assuming the patent has not been
terminally disclaimed over a commonly-owned patent or a patent naming a common inventor, or over a patent not commonly owned but that was disqualified as prior art as the result of activities undertaken within the scope of a joint research
agreement. The life of a patent, and the protection it affords, is therefore limited and once the patent lives of our issued patents have expired, we may face competition, including from other competing technologies. In the United States, the term
of a patent may also be eligible for patent term adjustment for delays within the USPTO. The term of a patent that covers a biological product may also be eligible for patent term extension when FDA approval is granted for a portion of the term
effectively lost as a result of the FDA regulatory review period, subject to certain limitations and provided statutory and regulatory requirements are met. Any such patent term extension can be for no more than five years, only one patent per
approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval, and only those claims covering the approved biological product, a method for using it or a method for manufacturing it may be
extended. We may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail
to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. There can be no assurance that we will benefit from any patent term extension or favorable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adjustment to the term of any of our patents. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products
similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to maintain and solidify our proprietary and intellectual property position will depend on our
success in obtaining effective patent claims and maintaining and enforcing claims that are granted. However, our owned and licensed patents could be invalidated or narrowed or otherwise fail to adequately protect our proprietary and intellectual
property position and our pending owned and licensed patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because branding is as much a part of any intellectual property strategy as patent or trade secret protection we have a number of registered
and pending trademarks relating to our company and products. We have received or filed for trademark protection in the United States for our tradename (Biodesix), the names of four of our commercial tests (namely the VeriStrat, GeneStrat, Nodify XL2
and Nodify CDT tests), and a suite of research tests (ImmunoStrat), as well as having trademark protection for our core development and methodological platforms, such as our Diagnostic Cortex and DeepMALDI technologies. In all, as of
September&nbsp;21, 2020, we have 20 uniquely registered United States trademarks 7 of which (including Biodesix, VeriStrat, and GeneStrat) have received foreign issuances as well. We will continue to pursue protection in the United States and abroad
for our branded assets and will continue to use branding to protect products currently in development, key Biodesix developments and <FONT STYLE="white-space:nowrap">non-trade</FONT> secret methodologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on trade secrets, including know how, confidential information, unpatented technologies and other proprietary information, to
(1)&nbsp;strengthen or enhance our competitive position, (2)&nbsp;protect and maintain aspects of our business that are not amenable to, or that we do not presently consider appropriate for, patent protection, and (3)&nbsp;prevent competitors from
reverse engineering or copying our technologies. We have decided that some technologies, such as our laboratory methodologies (including sample preparation and assay development), and some information (such as client and billing information) are
best kept as trade secrets. However, trade secrets and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> are difficult to protect. To avoid inadvertent and improper disclosure of trade secrets, and to avoid the risks of former employees
using these trade secrets to future employment, it is our policy to require employees, consultants and independent contractors to assign all rights to intellectual property they develop in connection with their employment with or services for the
Company to the Company. We also protect our existing and developing intellectual property expressly through confidentiality provisions in agreements with third parties. There can be no assurance, however, that these agreements will be self-executing
or otherwise provide meaningful protection for our trade secrets or other intellectual property or proprietary information, or adequate remedies in the event of unauthorized use or disclosure of such trade secrets or other intellectual property or
proprietary information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our trade secrets and other confidential
information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in the measures we take to protect and preserve our trade secrets, such measures can be
breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to pursue additional intellectual property protection to the extent we believe it would advance our business objectives, which may
include objectives within and outside the United States. Despite our efforts to protect our intellectual property rights, and despite the breadth of protection that has issued around our key assets, these rights may not be respected in the future or
may be circumvented or challenged (and potentially invalidated) in a legal proceeding in any jurisdiction where we have intellectual property rights. In addition, the laws of various foreign countries where we have received intellectual property
protection and where we may eventually distribute our products may not afford the same protections or assurances to the same extent as the laws in the United States. See &#147;Risk Factors&#151;Risks Related to Our Intellectual Property&#148; for
additional information regarding these and other risks related to our intellectual property portfolio and their potential effect on us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical laboratory tests like our diagnostic tests are regulated under the CLIA and State law. The FDA regulates medical devices pursuant to
the FDCA, including many diagnostic test kits, such as IVDs. However, most LDTs are not currently subject to the FDA&#146;s regulation (although reagents, instruments, software or components provided by third parties and used to perform LDTs may be
subject to such regulation) because the FDA has historically exercised enforcement discretion over LDTs. LDTs are a subset of in vitro clinical tests (IVCTs) that are intended for clinical use and developed, validated, and offered within a single
laboratory for use only in that laboratory. FDA&#146;s authority to regulate LDTs has been contested for many years, and there have been several legislative and administrative proposals regarding LDT regulation seeking to end or limit enforcement
discretion and to bring LDTs under new or existing FDA regulatory frameworks: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On July&nbsp;9, 2012, Congress passed legislation in the FDASIA requiring the agency to notify the Committee on
Health, Education, Labor, and Pensions and the House Committee on Energy and Commerce of its intent to regulate LDTs. This law, though enacted, had a <FONT STYLE="white-space:nowrap">5-year</FONT> sunset provision, meaning that FDA is no longer
subject to this notification requirement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In October 2014, the FDA issued two draft guidance documents: <I>Framework for Regulatory Oversight of Laboratory
Developed Tests</I>, which provided an overview of how the FDA would regulate LDTs through a risk-based approach, and <I>FDA Notification and Medical Device Reporting for Laboratory</I> <I>Developed Tests</I>, which provided guidance on how the FDA
intends to collect information on existing LDTs, including adverse event reports. In the Framework for Regulatory Oversight draft guidance, the FDA asserted that LDT manufacturers would be subject to medical device premarket submission,
registration, listing, and adverse event reporting requirements phased in over several years based on which tests posed the highest risk to public health. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On November&nbsp;18, 2016, however, the FDA announced that it would not release the final guidance and would
instead continue to work with stakeholders, the new administration, and Congress to determine the right approach. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On January&nbsp;13, 2017, the FDA released a discussion paper on possible approaches to regulate LDTs in which it
described a policy wherein previously marketed LDTs would not be expected to comply with most or all FDA oversight requirements, except for adverse event and malfunction reporting. In addition, certain new and significantly modified LDTs would not
be expected to comply with <FONT STYLE="white-space:nowrap">pre-market</FONT> review unless the agency determines certain tests could lead to patient harm. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In March 2017, the draft Diagnostic Accuracy and Innovation Act (DAIA) was introduced and outlined a regulatory
approach for IVCT tests, i.e., IVDs and LDTs, that was risk-based and flexible. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In April 2017, the FDA issued a document describing 20 case studies of LDTs that raised concerns about the safety
and efficacy of this category of tests. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In August 2018, the FDA responded to the DAIA draft with its own proposal for IVCTs, including PMA, provisional
approval, and precertification, in addition to authority to revoke approval, request raw data, and take corrective action against test developers to protect public health. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On October&nbsp;31, 2018, the FDA issued its Safety Communication entitled &#147;The FDA Warns Against the Use of
Many Genetic Tests with Unapproved Claims to Predict Patient Response to Specific Medications&#148; alleging that the agency was &#147;aware&#148; of healthcare providers making &#147;inappropriate changes to a patient&#146;s antidepressant
medication based on the results from genetic tests.&#148; Following this Safety Alert, the FDA contacted several laboratories that offered tests that made claims regarding drug responses for specific medications. While most laboratories addressed
the FDA&#146;s concerns by removing specific medication names from their labeling, the FDA issued an enforcement letter against a laboratory for making such claims without first undergoing the FDA premarket review. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In December 2018, a new draft bill which revised the DAIA and incorporated feedback from the FDA was released.
The Verifying Accurate, Leading-edge, IVCT Development (VALID) Act creates a risk-based regulatory framework for IVCT regulation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On April&nbsp;4, 2019, the FDA issued a warning letter to Inova Genomics Laboratory for its pharmacogenomics
tests, i.e., tests that predict medication response, among other things. In this letter, the FDA rebutted Inova&#146;s argument that it believed it was operating within the scope of FDA&#146;s LDT exemption and not subject to the FDA&#146;s
premarket review or labeling requirements by noting that the FDA has not created a legal <FONT STYLE="white-space:nowrap">&#147;carve-out&#148;</FONT> or exemption for LDTs and that it ultimately retains discretion to take action when appropriate.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On March&nbsp;5, 2020, identical versions of the VALID Act were introduced in both chambers of Congress.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On August&nbsp;19, 2020, HHS announced a new policy determining that FDA must engage in notice-and-comment
rulemaking before requiring premarket review of LDTs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently market our GeneStrat, VeriStrat, Nodify XL2 and
Nodify CDT tests as LDTs in the United States. As a result, we believe our diagnostic services are not currently subject to the FDA&#146;s enforcement of its medical device regulations and the applicable FDCA provisions. If the FDA disagrees with
the LDT status of any of our tests, the FDA may consider the test to be an unapproved medical device and may subject us to FDA enforcement action, including, without limitation, requiring us to seek clearance, authorization or approval for the
laboratory test. If the FDA were to begin enforcement with respect to our LDTs, we could incur substantial costs and delays associated with trying to obtain <FONT STYLE="white-space:nowrap">pre-market</FONT> clearance or approval and costs
associated with complying with post-market requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, the FDA has not engaged in notice-and-comment rulemaking or released
broad-sweeping guidance, but it could choose to do so in the future and if <FONT STYLE="white-space:nowrap">pre-market</FONT> review is required, our business could be negatively impacted as a result of commercial delay that may be caused by the new
requirements. The cost of conducting clinical trials and otherwise developing data and information to support <FONT STYLE="white-space:nowrap">pre-market</FONT> applications may be significant. If we are required to submit applications for our
currently marketed tests, we may be required to conduct additional studies, which may be time-consuming, costly and could result in our currently-marketed currently marketed tests being withdrawn from the market. Continued compliance with the
FDA&#146;s regulations would increase the cost of conducting our business, and subject us to heightened regulation by the FDA including penalties for failure to comply with these requirements. Failure to comply with applicable regulatory
requirements could result in an enforcement action by the FDA, such as fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal sanctions. There are other regulatory and legislative proposals that would increase
general FDA oversight of clinical laboratories and LDTs. Until the FDA finalizes its regulatory position regarding LDTs, or the VALID Act or other legislation is passed reforming the federal government&#146;s regulation of LDTs, it is unknown how
the FDA may regulate our tests in the future and what testing and data may be required to support any required clearance or approval. The outcome and ultimate impact of such proposals on the business is difficult to predict at this time and are
monitoring developments and anticipate that our products will be able to comply with requirements that may be imposed by the FDA. In the meantime, we maintain our CLIA accreditation, which permits the use of LDTs for diagnostics purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FDA Emergency Use Authorization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;564 of the FDCA allows the FDA to authorize the shipment of drugs, biological products, or medical devices that either lack
required approval, licensure, or clearance (unapproved products), or are approved but are to be used for unapproved ways to diagnose, treat, or prevent serious diseases or conditions in the event of an emergency declaration by the HHS Secretary. 21
U.S.C. &#167; <FONT STYLE="white-space:nowrap">360bbb-3(a)(1)-(2).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;4, 2020, HHS Secretary Alex M. Azar II
declared a public health emergency for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> under 21 U.S.C. &#167; <FONT STYLE="white-space:nowrap">360bbb-3(b)(1),</FONT> justifying the authorization of emergency use of IVDs for detection and/or
diagnosis of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> This determination was published in the Federal Register on February&nbsp;7, 2020. 85 Fed. Reg. 7316 (Feb. 7, 2020). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While this emergency declaration is effective, the FDA may authorize the use of an unapproved
product or an unapproved use of an approved product if it concludes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an agent referred to in the emergency declaration could cause a serious or life-threatening disease or condition;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is reasonable to believe that the authorized product may be effective in diagnosing, treating, or preventing
that disease or condition or a serious or life-threatening disease or condition caused by an approved product or a product marketed under an EUA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the known and potential benefits of the authorized product, when used for that disease or condition, outweigh
known and potential risks, taking into consideration the material threat of agents identified in the emergency declaration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there is no adequate, approved, and available alternative to the authorized product for diagnosing, preventing,
or treating the relevant disease or condition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other criteria prescribed by the FDA is satisfied. <I>Id.</I> &#167;
<FONT STYLE="white-space:nowrap">360bbb-3(c).</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical products that are granted an EUA are only permitted to
commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for
the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety, and we cannot predict how long the EUAs for the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> tests will remain in place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">Bio-Rad</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> ddPCR test and the Platelia
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Total Ab test have been granted FDA EUA pursuant to the current emergency declaration. We have completed all required performance verification studies to
validate the use of the tests in our laboratories in accordance with the FDA Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency, CAP and New York State Clinical Laboratory Standards of Practice (NYS CLEP) requirements. The
FDA Policy for <FONT STYLE="white-space:nowrap">COVID-19</FONT> Tests is a guidance document that explains the FDA&#146;s current thinking on the topic, is subject to change, and does not establish any legally enforceable responsibilities. As stated
in the FDA&#146;s Policy for <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the FDA does not expect a separate notification or EUA request from laboratories that are performing testing using <FONT STYLE="white-space:nowrap">EUA-authorized</FONT>
test kits purchased from commercial manufacturers or their distributors. According to the FDA Policy for <FONT STYLE="white-space:nowrap">COVID-19</FONT> Tests, a laboratory may make certain modifications to an
<FONT STYLE="white-space:nowrap">EUA-authorized</FONT> test if the modified test is validated using a bridging study without submitting an EUA amendment or formal notification. A laboratory may modify an EUA authorized test for use of a new specimen
through a bridging study when the new specimen type has been previously authorized for another test of the same technology without submitting an EUA amendment or formal notification. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal and State Laboratory Licensing Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biodesix Boulder, Colorado clinical laboratory is a <FONT STYLE="white-space:nowrap">CAP-accredited</FONT> clinical laboratory regulated by
CMS pursuant to CLIA. CMS has granted CAP deeming authority under CLIA, which allows CAP to inspect laboratories in lieu of CMS. The CAP accreditation program involves unannounced <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of our
laboratories. In addition to holding a CLIA Certificate and CAP laboratory accreditation, Biodesix&#146;s Quality Management System (QMS) holds an ISO 13485:2016 certificate. The Biodesix Boulder, Colorado clinical laboratory has received approval
from NYSDOH, NYS CLEP in Soluble Tumor Markers and Molecular, Cellular Tumor Markers as well as holding state permits and licenses in California, Maryland, New York, Pennsylvania, and Rhode Island. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CLIA regulations establish standards for proficiency testing; facility administration; general laboratory systems; <FONT
STYLE="white-space:nowrap">pre-analytic,</FONT> analytic systems, post-analytic systems; personnel qualifications and responsibilities; quality control, quality assessment; and specific provisions for laboratories performing moderate to high
complexity tests. Our Boulder, Colorado clinical laboratory is inspected biennially as part of its ongoing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certification under CLIA certificate of accreditation by CAP. The Boulder, Colorado clinical laboratory most recently passed its CAP inspection in February 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under CLIA, a laboratory is any facility that performs laboratory testing on specimens derived from humans for the purpose of providing
information for the diagnosis, prevention or treatment of disease, or the impairment of or assessment of health. CLIA requires that a laboratory hold a certificate applicable to the type of laboratory examinations it performs and that it complies
with, among other things, standards covering operations, personnel, facilities administration, quality systems and proficiency testing, which are intended to ensure, among other things, that clinical laboratory testing services are accurate,
reliable and timely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biodesix De Soto, Kansas clinical laboratory is a COLA-accredited clinical laboratory regulated by CMS pursuant
to CLIA. COLA Inc. (COLA) was founded in 1988 as a private alternative to help laboratories stay in compliance with CLIA. In 1993, the Health Care Financing Administration (now CMS) granted COLA deeming authority under CLIA, and in 1997 The Joint
Commission also recognized COLA Inc.&#146;s laboratory accreditation program. The De Soto, Kansas clinical laboratory is inspected biennially by COLA. The De Soto, Kansas clinical laboratory most recently passed inspection in August 2019. The De
Soto, Kansas clinical laboratory also holds state permits and licenses in California, Maryland, New York, Pennsylvania, and Rhode Island. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ISO is an independent, <FONT STYLE="white-space:nowrap">non-governmental</FONT> international organization that defines world-class
specifications for products, services and systems, to ensure quality, safety and efficiency. ISO 13485:2016 is a harmonized, international regulatory benchmark for quality management systems that addresses most or all of the QMS requirements in
markets including the United States, European Union, Australia, Japan and Canada. The ISO 13485:2016 certificate confirms that an organization operates a QMS that conforms to the standards established by ISO. The FDA recently proposed a rule to
harmonize and modernize its QSR, which would supplant the existing requirements with ISO 13485:2016. In March 2020, we passed an ISO 13485:2016 inspection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards.
Laboratories such as ours, which are performing high complexity testing, are required to meet more stringent CLIA requirements than laboratories performing less complex tests, and therefore our laboratories are also subject to random, unannounced
survey and inspection at any time. In addition, a laboratory that is certified as &#147;high complexity&#148; under CLIA may develop, manufacture, validate and use proprietary LDTs. CLIA requires analytical validation including accuracy, precision,
specificity, sensitivity and establishment of a reference range for any LDT used in clinical testing. The regulatory and compliance standards applicable to the testing we perform may change over time and any such changes could have a material effect
on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a
number of states have implemented their own more stringent laboratory regulatory requirements. State laws may require that <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-state</FONT></FONT> laboratories maintain an <FONT
STYLE="white-space:nowrap">in-state</FONT> laboratory license to perform tests on samples from patients who reside in that state. As a condition of licensure, certain states may require that laboratory personnel meet qualifications, quality control
procedures, facility requirements, record maintenance requirements or other state-specific requirements. Because our Boulder, Colorado clinical laboratory is located in the State of Colorado, we do not need a specific State of Colorado laboratory
license, however, we maintain licenses to conduct testing in other states where nonresident laboratories are required to obtain state laboratory licenses. We maintain licenses for our Boulder, Colorado and De Soto, Kansas laboratories with NYSDOH.
We also hold licenses in other states in which we operate, including California, Maryland, Pennsylvania and Rhode Island, that require licensing of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-state</FONT></FONT>
laboratories under certain circumstances. Other states may currently have or adopt similar licensure requirements in the future, which may require us to modify, delay or stop its operations in those states until such requirements are met. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with CLIA certification and state clinical laboratory licensure requirements
may result in a range of enforcement actions, including certificate or license suspension, limitation, or revocation, directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions, and revocation of the laboratory&#146;s
approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CLIA and state laws and
regulations, operating together, sometimes limit the ability of laboratories to offer consumer-initiated testing, also known as &#147;direct access testing&#148;. We do not offer direct access testing and instead require that our tests be ordered by
licensed healthcare providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Boulder, Colorado and De Soto, Kansas laboratories are certified and adhere to the NYS CLEP, based on
New York State Public Health Law, Article 5 Title 5. NYS CLEP is exempt from CLIA and establishes their own method of laboratory certification and assay validation approval. To process NYS patient specimens a laboratory must submit a robust
analytical and clinical validation package to demonstrate clinical utility of the test and receive approval prior to offing the test in the state of New York. Our GeneStrat and VeriStrat tests have received NYS CLEP approval. NYS CLEP requires
semi-annual inspections to ensure the laboratory meets all general and specialty standards. Biodesix passed NYS CLEP inspection in May 2019 and is currently scheduled for a routine <FONT STYLE="white-space:nowrap">re-inspection</FONT> in May 2021.
Although delays related to NYS CLEP&#146;s <FONT STYLE="white-space:nowrap">COVID-19</FONT> response resulted in the department&#146;s inability to complete the review of our Boulder, Colorado and De Soto, Kansas laboratories prior to the permit
expiration date, the current permit expiration dates have been extended until NYS CLEP has made a final determination of the application. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory
framework for medical devices in the United States </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to its authority under the FDCA, the FDA has jurisdiction over medical
devices, which are defined to include, among other things, IVDs. The FDA regulates the research, design, development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, manufacturing, safety, effectiveness, packaging,
labeling, storage, recordkeeping, <FONT STYLE="white-space:nowrap">pre-market</FONT> clearance or approval, adverse event reporting, marketing, promotion, sales, distribution and import and export of medical devices. It is possible that one of our
current, or future, tests will be subject to FDA authority and oversight as either an IVD or a CDx pursuant to the FDA&#146;s authority to regulate medical devices under the FDCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Medical devices are subject to extensive regulation in the United States and elsewhere, including by the FDA and its foreign counterparts.
Government regulations specific to medical devices are wide ranging and govern, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product design, development, manufacture, and release; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory and clinical testing, labeling, packaging, storage and distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product safety and efficacy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">premarketing clearance or approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">service operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">record keeping; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product marketing, promotion and advertising, sales and distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and
removals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">post-market approval studies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product import and export. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Device classification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the FDCA, medical devices are classified into one of three classes: Class&nbsp;I, Class&nbsp;II or Class&nbsp;III, depending on the
degree of risk to patients that is associated with each medical device and the amount of oversight needed to provide reasonable assurances with respect to safety and effectiveness of the medical device. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured
by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the FDA&#146;s QSR, facility registration and product listing, reporting of adverse events
and malfunctions, and appropriate, truthful and <FONT STYLE="white-space:nowrap">non-misleading</FONT> labeling and promotional materials. Some Class&nbsp;I devices also require premarket clearance by the FDA through the 510(k) premarket
notification process described below. Most Class&nbsp;I products are exempt from the premarket notification requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;II
devices are subject to the General Controls as well as any special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, patient registries, FDA
guidance documents and post-market surveillance. Most Class&nbsp;II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class&nbsp;II devices is accomplished through the 510(k) premarket
notification process, although some Class&nbsp;II devices are exempt from the 510(k) requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;III devices include devices
deemed by the FDA to pose the greatest risk: such as life-supporting or life-sustaining devices, implantable devices, or those deemed novel and not substantially equivalent to a predicate device following the 510(k) process. CDx tests are regularly
considered Class&nbsp;III devices. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Premarket submission process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless a statutory or regulatory exemption or enforcement discretion policy applies, before a new medical device, or a new intended use of,
claim for, or significant modification to an existing device, can be marketed in the United States, the manufacturer must obtain the FDA&#146;s: (1)&nbsp;permission for commercial distribution under section 510(k) of the FDCA (510(k) clearance); or
(2)&nbsp;approval of a PMA; or (3)&nbsp;de novo classification and authorization. These processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 510(k) clearance process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is
&#147;substantially equivalent&#148; to a legally marketed predicate device. A predicate device is a legally marketed device that is not subject to a PMA, i.e., a device that was legally marketed prior to May&nbsp;28, 1976 <FONT
STYLE="white-space:nowrap">(pre-amendments</FONT> device) and therefore a PMA is not required, a device that has been reclassified from Class&nbsp;III to Class&nbsp;II or I, or a device that was previously found substantially equivalent through the
510(k) process. To be &#147;substantially equivalent,&#148; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological
characteristics and not raise different questions of safety or effectiveness than the predicate device. Premarket notifications typically include bench, analytical, and preclinical data. Clinical data is sometimes required to support substantial
equivalence. If a manufacturer obtains a 510(k) clearance for its device and then makes a modification that could significantly affect the device&#146;s safety or effectiveness or constitutes a major change or modification in the intended use of the
device, a new clearance, authorization or approval may be required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By statute, the FDA is required to complete its review of a 510(k)
notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may
require further information, including clinical data, to make a determination regarding substantial equivalence, which may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device. If the FDA determines that the
device is not &#147;substantially equivalent&#148; to a predicate device, or if the device is automatically classified into Class&nbsp;III, the device sponsor must then fulfill the much more rigorous, costly, and time-consuming PMA approval process
or seek reclassification of the device through the de novo process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain a PMA, the applicant must submit data and information
demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#146;s satisfaction. Accordingly, a PMA typically includes, but is not limited to, extensive technical information regarding device
design and development, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial data, manufacturing information, labeling, and financial disclosure information for the clinical investigators in device studies. The PMA application
must provide valid scientific evidence that demonstrates to the FDA&#146;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once filed as a PMA, the FDA has 180 days to review the filed PMA application, although the review of an application more often occurs over a
significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the
applicant&#146;s response to deficiencies communicated by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to approval of a PMA, the FDA may conduct inspections of any
clinical trial data and clinical trial sites, as well as inspections of any manufacturing facility and processes. The FDA&#146;s review of a PMA application generally takes between one and three years, but may take significantly longer. The FDA can
delay, limit or deny approval of a PMA application for many reasons, including (1)&nbsp;the device may not be shown safe or effective to the FDA&#146;s satisfaction; (2)&nbsp;the data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies
and/or clinical trials may be found unreliable or insufficient to support approval; (3)&nbsp;the manufacturing process or facilities may not meet applicable requirements; and (4)&nbsp;changes in FDA approval policies or adoption of new regulations
may require additional data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable
letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval
letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the
PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when data is available. The PMA process can be expensive, uncertain and
lengthy. A number of devices for which the FDA approval has been sought by other companies have never been approved by the FDA for marketing. New PMA applications or PMA supplements are required for any modifications to the manufacturing process,
equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a condition of PMA application approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the
applicant conducts a <FONT STYLE="white-space:nowrap">follow-up</FONT> study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public
health or to provide additional or longer term safety and effectiveness data for the device. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among
other things, restrictions on labeling, promotion, sale, distribution and use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternatively, the FDA also allows the submission of a
direct de novo petition. This procedure allows a manufacturer whose novel device is automatically classified into Class&nbsp;III to request down-classification of its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medical device into Class&nbsp;I or Class&nbsp;II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the
enactment of FDASIA, a medical device could only be eligible for de novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent.
FDASIA streamlined the de novo classification pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent
determination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 510(k), <FONT STYLE="white-space:nowrap">de-novo</FONT> or PMA processes can be expensive, lengthy and unpredictable.
The FDA&#146;s 510(k) clearance process usually takes from three to 12&nbsp;months, but can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years,
or even longer, from the time the application is filed with the FDA. In addition, a PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any
delay or failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the device,
which may limit the market for the device. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Companion Diagnostics and the Premarket Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that one of our future product candidates may include a companion diagnostic or complementary diagnostic (collectively CDx).
CDx&#146;s can identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or
monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. The use of the CDx will be stipulated in the labeling of both the CDx and the therapeutic
product. The FDA may require an application for the CDx separate from the drug approval process, and this could potentially delay the approval of any new drug application or the CDx, or complicate the review process. CDx&#146;s are generally
regulated as Class&nbsp;III medical devices by the FDA and are therefore most often subject to the PMA approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA issued
guidance in July 2016 for the <FONT STYLE="white-space:nowrap">co-development</FONT> of CDx tests with a therapeutic product and issued another draft guidance in December 2018 specific to oncology CDx tests. The FDA finalized this draft guidance in
April 2020 in &#147;Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products.&#148; The guidance is meant to guide the development of CDx products, which are defined as IVDs that provide
information that is essential for the safe and effective use of the therapeutic product. A CDx is often developed and approved or cleared contemporaneously with the therapeutic, and the use of the CDx is stipulated in the labeling of both the CDx
and the corresponding therapeutic product. While it supports contemporaneous marketing authorizations, if there are any deficiencies in the submissions, the FDA may place a PMA review of a CDx on hold or request additional testing, which could
potentially delay the approval of the corresponding new drug application or the marketing authorization of the CDx, or otherwise complicate the review process. Some oncology CDx tests can be developed in a way that results in labeling for a specific
group of oncology therapeutic products, rather than a single therapeutic product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Market FDA Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if regulatory clearance, authorization or approval of a device is granted, the FDA may impose limitations on the uses and indications for
which the device may be labeled and promoted, and the device remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared, authorized or approved. After a
device, including a device exempt from FDA premarket review, is placed on the market, numerous post-market regulatory requirements apply, and the FDA has broad authority to enforce these requirements. Medical device manufacturers are subject to
unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers. Failure
to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions such as: warning letters, fines, injunctions, consent decrees and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
civil penalties; unanticipated expenditures, including requirements to repair, replace, and/or refund the cost of the devices, recall or seizure of our products; operating restrictions, partial
suspension or total shutdown of production; the FDA&#146;s refusal of our requests for 510(k) clearance, de novo classification, or PMA of new products, new intended uses or modifications to existing products; the FDA&#146;s refusal to issue
certificates to foreign governments needed to export products for sale in other countries; and withdrawing 510(k) clearance or PMAs that have already been granted and criminal prosecution. In the event that a supplier fails to maintain compliance
with the FDA&#146;s or our quality requirements, we may have to qualify a new supplier and could experience manufacturing delays as a result. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal
and State Fraud and Abuse Laws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to federal fraud and abuse laws such as the federal Anti-Kickback Statute (AKS), the
federal prohibition against physician self-referral (Stark Law), the Eliminating Kickbacks in Recovery Act (EKRA), and the federal False Claims Act (FCA). We are also subject to similar state and foreign fraud and abuse laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The AKS prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, overtly or
covertly, in cash or in kind, in return for or to induce such person to refer an individual, or to purchase, lease, order, arrange for, or recommend purchasing, leasing or ordering, any item or service that may be reimbursable, in whole or in part,
under a federal healthcare program, such as Medicare or Medicaid. There are a number of statutory exceptions and regulatory safe harbors to the AKS that provide protection from AKS liability to arrangements that fully satisfy the applicable
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EKRA prohibits knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in
return for the referral of a patient to, or in exchange for an individual using the services of certain entities, including laboratories, if the services are covered by a health care benefit program. The term &#147;health care benefit program&#148;
is broadly defined such that EKRA extends to referrals reimbursed by both governmental and commercial third party payers. EKRA includes a number of statutory exceptions that provide protection from EKRA liability if the applicable requirements are
met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stark Law generally prohibits, among other things, clinical laboratories and other
<FONT STYLE="white-space:nowrap">so-called</FONT> &#147;designated health services&#148; entities from billing Medicare for any services when the physician ordering the service, or any member of such physician&#146;s immediate family, has a
financial relationship, such as a direct or indirect investment interest in or compensation arrangement with the billing entity, unless the arrangement meets an exception to the prohibition. The Stark Law also prohibits physicians from making such
referrals to a designated health services entity. There are also similar state laws that apply where Medicaid and/or commercial payers are billed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCA imposes civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented,
claims for payment to the government that are false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly
avoiding, decreasing, or concealing an obligation to pay money to the federal government. This statute also permits a private individual acting as a &#147;qui tam&#148; whistleblower to bring actions on behalf of the federal government alleging
violations of the FCA and to share in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of $11,665 to $23,331 per false claim or
statement for penalties assessed after June&nbsp;19, 2020, with respect to violations occurring after November&nbsp;2, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payer knows
or should know is likely to influence the beneficiary to order or receive a reimbursable item or service from a particular provider, practitioner, or supplier, and contracting with an individual or entity that the person knows or should know is
excluded from participation in a federal health care program. In addition, federal criminal statutes created by HIPAA prohibit, among other things, knowingly and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or
property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these federal laws, there are often similar state anti-kickback and false claims laws that typically apply to arrangements
involving reimbursement by a state-funded Medicaid or other health care program. Often, these laws closely follow the language of their federal law counterparts, although they do not always have the same exceptions or safe harbors. In some states,
these anti-kickback laws apply with respect to all payers, including commercial payers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of states have enacted laws that require
pharmaceutical and medical device companies to monitor and report payments, gifts and other remuneration made to physicians and other healthcare providers, and, in some states, marketing expenditures. In addition, some state statutes impose outright
bans on certain manufacturer gifts to physicians or other health care professionals. Some of these laws, referred to as &#147;aggregate spend&#148; or &#147;gift&#148; laws, carry substantial fines if they are violated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs and extensive annual trainings for all of our employees and contractors. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to
significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm,
diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with
the law, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we
do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Corruption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCPA and similar
international bribery laws make it unlawful for entities to make payments to foreign government officials to assist in obtaining and maintaining business. Specifically, the anti-bribery provisions of the FCPA prohibit any offer, payment, promise to
pay, or authorizing the payment of money or anything of value to any person, while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to a foreign official to do or omit to do an
act in violation of his or her duty, or to secure any improper advantage in order to assist in obtaining or retaining business for or with, or directing business, to any person. In addition to the anti-bribery provisions of the FCPA, the statute
also contains accounting requirements designed to operate in tandem with the anti-bribery provisions. Covered companies are required to make and keep books and records that accurately and fairly reflect the transactions of the company and devise and
maintain an adequate system of internal accounting controls. With our international operations through our third party partnerships, we could incur significant fines and penalties, as well as criminal liability, if we fail to comply with either the
anti-bribery or accounting requirements of the FCPA, or similar international bribery laws. Even an unsuccessful challenge of our compliance with these laws could cause us to incur adverse publicity and significant legal and related costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Privacy and Data Protection Laws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous federal and state laws and regulations, including HIPAA, as amended by the HITECH, govern the collection, dissemination, security, use
and confidentiality of protected health information (PHI) and personal information. In the course of performing our business we obtain personal information, including PHI. Laws and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulations relating to privacy, data protection, and consumer protection are evolving and subject to potentially differing interpretations. Under HIPAA and HITECH, the HHS, issues regulations
that establish uniform standards governing the conduct of certain electronic healthcare transactions and requirements for protecting the privacy and security of PHI, used or disclosed by covered entities (CEs) and their authorized business
associates (BAs). Because we are a health care provider that electronically transmits health care information, we are at times either a CE or a BA, as defined by HIPAA. Our subcontractors that create, receive, maintain, transmit or otherwise process
PHI on our behalf are HIPAA BAs and must also comply with HIPAA, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA and HITECH include the privacy and security rules,
breach notification requirements and electronic transaction standards. The privacy rule governs the use and disclosure of PHI by CEs and BAs. The privacy rule generally prohibits the use or disclosure of PHI except as permitted under the rule. The
rule also sets forth individual patient rights, such as the right to access or amend certain records containing such individual&#146;s PHI, or to request restrictions on the use or disclosure of such individual&#146;s PHI. The security rule requires
CEs and BAs to safeguard the confidentiality, integrity, and availability of electronically transmitted or stored PHI (also referred to as ePHI) by implementing administrative, physical and technical safeguards. Under HITECH&#146;s breach
notification rule, a CE must notify individuals, the Secretary of HHS, and in some circumstances, the media of certain breaches of unsecured PHI or ePHI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Penalties for failure to comply with a requirement of HIPAA and HITECH vary depending on the number and nature of the violations, but can be
significant and include civil monetary or criminal penalties. HIPAA is enforced by the Department of Health and Human Services, Office of Civil Rights, and HIPAA also authorizes state attorneys general to file suit on behalf of their residents for
violations. Courts are able to award damages, costs and attorneys&#146; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit in civil court for violations of
HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic
compliance audits of HIPAA CEs, such as us, and their BAs for compliance with the HIPAA privacy and security standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI
may receive a percentage of the civil monetary penalty paid by the violator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to state privacy,
cybersecurity, and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. California, for example, has enacted the Confidentiality of Medical Information Act,
which, in addition to HIPAA and HITECH, sets forth standards with which all California health care providers must abide. State laws may be more stringent, broader in scope or offer greater individual rights with respect to PHI than HIPAA, and state
laws may differ from each other, which may complicate compliance efforts. For instance, the CCPA became effective on January&nbsp;1, 2020. The CCPA, among other things, gives California residents expanded rights to access and delete their personal
information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly
defined) and provide such consumers new ways to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches
that is expected to increase data breach litigation. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. Although there are certain
exemptions for PHI and clinical trial data, the CCPA&#146;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future and the CCPA may increase our compliance costs and potential liability.
Additionally, a new California ballot initiative, the California Privacy Rights Act (CPRA), has garnered enough signatures to be included on the November 2020 ballot in California. If voted into law by California residents, the CPRA would impose
additional data protection obligations on companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It would also create a new California data protection agency
specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. Similar laws have been proposed in other states and at the federal level,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and if passed, such laws may have potentially conflicting requirements that could continue to make compliance challenging and costly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the Federal Trade Commission (FTC) and state attorneys general enforce consumer protection laws that prohibit unfair and
deceptive acts and practices, including Section&nbsp;5 of the FTC Act, which creates standards for the collection, use, dissemination and security of health-related and other personal information. Claims of unfair or deceptive trade practices
regarding privacy and security can lead to significant liabilities and consequences, including regulatory investigations, penalties, fines and orders as well as civil claims, which could impact our data practices and operations or cause reputational
damage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be subject to laws and regulations in foreign countries covering data privacy and other protection of health and
employee information that may add additional compliance burden and complexity. For example, in the EEA and the United Kingdom, the collection and use of personal data is governed by the GDPR. The GDPR, together with national legislation, regulations
and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data. European
data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which adds to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and
compliance practices are often updated or otherwise revised. GDPR applies extra-territorially under certain circumstances and imposes stringent requirements on controllers and processors of personal data, including, for example, requirements to
ensure a legal bases to process personal information, provide robust disclosures to individuals, facilitate data subject rights, provide data security breach notifications within 72 hours after discovering a breach in certain circumstances, limit
retention of personal information and apply enhanced protections to health data and other categories of sensitive personal information. Failure to comply with the requirements of the GDPR may result in fines of up to &#128;20&nbsp;million or up to
4% of the total worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. To comply with the GDPR and other applicable international data protection laws and regulations, we may be required to
put in place additional mechanisms ensuring compliance, which may result in other substantial expenditures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cybersecurity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business relies on secure and continuous processing of information and the availability of our IT networks and IT resources, as well as
critical IT vendors that support our technology, research and other data processing operations. While we take steps to protect our systems and data, security incidents, data breaches, computer malware and computer hacking attacks have become more
prevalent across industries, including the life sciences sector, and may occur on our systems or those of our third-party service providers. Unauthorized persons may in the future be able to exploit weaknesses in the security systems of our (or our
third-party service providers) IT networks and gain access to PHI and other personal information, or sensitive trade secrets or other proprietary information. Any wrongful use or disclosure of PHI, other personal information, trade secrets or other
proprietary information by us or our third-party service providers could subject us to regulatory fines or penalties, third party claims or otherwise could adversely affect our business and results of operations. Although HIPAA and the regulations
promulgated thereunder do not provide for a private right of action, failures to adequately protect PHI or our IT systems could be viewed as violations of the HIPAA security rule or violations of other applicable information security laws,
regulations, contractual obligations or industry standards, and could further result in costly data breach notification obligations that negatively impact our reputation. Moreover, data security incidents or data breaches, as well as attacks on our
IT systems, could result in operational disruptions or data loss or corruption that could adversely impact our business and operations, result in substantial investment of resources to investigate, recover and remediate and subject us to heightened
regulatory scrutiny. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>International Regulations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries in which we may offer any of our diagnostic tests in the future have anti-kickback regulations prohibiting providers from
offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national health care program. In situations involving physicians employed by state-funded institutions or
national health care agencies, violation of the local anti-kickback law may also constitute a violation of the FCPA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCPA prohibits
any United States individual, business entity or employee of a United States business entity to offer or provide, directly or through a third party, including any potential distributors we may rely on in certain markets, anything of value to a
foreign government official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that reports to the SEC to
have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate information and control over sales and distributors&#146; activities that may fall within the
purview of the FCPA, its books and records provisions and its anti-bribery provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The standard of intent and knowledge in
anti-bribery cases is minimal. Intent and knowledge are usually inferred from that fact that bribery took place. The accounting provisions do not require intent. Violations of the FCPA&#146;s anti-bribery provisions for corporations and other
business entities are subject to a fine of up to $2&nbsp;million and officers, directors, stockholders, employees, and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United
Kingdom and other OECD Anti-Bribery Convention members, have similar anti-corruption regulations, such as the United Kingdom Anti-Bribery Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When marketing our diagnostic tests outside of the United States, we may be subject to foreign regulatory requirements governing human
clinical testing, prohibitions on the import of tissue necessary for us to perform our diagnostic tests or restrictions on the export of tissue imposed by countries outside of the United States or the import of tissue into the United States, and
marketing approval. These requirements vary by jurisdiction, differ from those in the United States and may in some cases require us to perform additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical testing. In many countries
outside of the United States, coverage, pricing and reimbursement approvals are also required<B>.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Healthcare Reform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the ACA was enacted in the United States. The ACA made a number of substantial changes to the way healthcare is financed both by
governmental and private insurers. For example, the ACA requires each medical device manufacturer to pay a sales tax equal to 2.3% of the price for which such manufacturer sells its medical devices. The medical device tax was permanently repealed at
the end of 2019. The ACA also contains a number of other provisions, including provisions governing enrollment in federal and state healthcare programs, reimbursement matters and fraud and abuse, which we expect will impact our industry and our
operations in ways that we cannot currently predict. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trump administration and Congress have, and we expect they will continue to,
seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. Since January 2017, the Trump administration has issued three executive orders and other directives designed to delay the implementation of certain provisions of
the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. For example, on January&nbsp;22, 2018, the Trump administration signed a continuing resolution on appropriations for fiscal year 2018 that delayed the
implementation of certain <FONT STYLE="white-space:nowrap">ACA-mandated</FONT> fees, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans, the annual fee
imposed on certain health insurance providers based on market share, and the medical device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. Concurrently, Congress has considered legislation that would repeal or
repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain taxes under the ACA have been signed into law. The TCJA among other things, included a provision repealing, effective January&nbsp;1, 2019, the
<FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment, or penalty, imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the
&#147;individual mandate&#148;. In December 2018, a federal district court in Texas ruled that the ACA&#146;s individual mandate, without the penalty that was repealed effective January&nbsp;1, 2019, was unconstitutional and could not be severed
from the ACA. As a result, the court ruled the remaining provisions of the ACA were also invalid. The Fifth Circuit Court of Appeals affirmed the district court&#146;s ruling that the individual mandate was unconstitutional, but it remanded the case
back to the district court for further analysis of whether the mandate could be severed from the ACA; that is, whether the entire ACA was therefore also unconstitutional. The United States Supreme Court granted certiorari on March&nbsp;2, 2020, and
the case is expected to be decided in 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since the ACA
was enacted to reduce healthcare expenditures. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions of Medicare payments to providers of up to 2% per fiscal year that started in 2013 and, due
to subsequent statutory amendments, will remain in effect through 2030 unless additional Congressional action is taken. In 2020, the CARES Act temporarily suspended the 2% cut in Medicare payments from May&nbsp;1, 2020 through December&nbsp;31,
2020, and it extended the cut through FY 2030 to offset the cost of such temporary suspension. The American Taxpayer Relief Act of 2012 made other changes, including reduced Medicare payments to several types of providers and increased the statute
of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the
National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve
R&amp;D, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Environmental,
Health and Safety Regulations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to various federal, state, local, and foreign environmental, health and safety laws and
regulations and permitting and licensing requirements. Such laws include those governing laboratory practices, the generation, storage, use, manufacture, handling, transportation, treatment, remediation, release and disposal of, and exposure to,
hazardous materials and wastes and worker health and safety. Our operations involve the generation, use, storage and disposal of hazardous materials, and the risk of injury, contamination or <FONT STYLE="white-space:nowrap">non-compliance</FONT>
with environmental, health and safety laws and regulations or permitting or licensing requirements cannot be eliminated. In particular, the introduction of our <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> ddPCR and Platelia <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> Total Ab tests requires that we maintain compliance with applicable and evolving
federal and state laws and regulations relating to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including the generation, use, storage, and disposal of testing materials and agents. Compliance with environmental laws and regulations has not had
a material effect on our capital expenditures, earning or competitive position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition of Integrated Diagnostics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2018, we purchased select assets and liabilities from Integrated Diagnostics, Inc. and IND Funding, LLC (collectively, the
Seller) which included CLIA lab in Seattle, Washington and all rights to the Nodify XL2 test and the intellectual property related to that test. The purchase was made for total consideration of $27.6&nbsp;million, consisting of $8.0&nbsp;million
(10,649,604 shares) of our Company&#146;s Series G Preferred Stock and contingent consideration with an initial fair market value of $19.6&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The acquisition of Integrated Diagnostics included a contingent consideration arrangement that requires additional consideration to be paid by
us to the Seller based on the Milestone of the attainment of a three </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consecutive month gross margin target of $2&nbsp;million within a seven-year period. The amount can be payable in stock or cash at our and the Seller&#146;s option. The total amount of
undiscounted contingent consideration which we may be required to pay under the arrangement is $37.0&nbsp;million. For the 6 months following the achievement of the Milestone, the Seller has the option to require us to pay the contingent
consideration in cash over 8 equal installments due each calendar quarter. If the Seller elects not to exercise this option, have 12 months to either settle the contingent consideration in two equal quarterly cash installments or in 14,959,114 of
Series G Preferred Stock. As of June&nbsp;30, 2020, we have not made any payments in connection with the contingent consideration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition of Oncimmune USA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;31, 2019, we completed an acquisition of United Kingdom-based Oncimmune&#146;s United States operations including its CLIA
clinical laboratory in De Soto, Kansas and its IPN malignancy test, then marketed in the United States as the EarlyCDT-Lung. We renamed the test and relaunched the test on February&nbsp;28, 2020 as the Nodify CDT test and the De Soto, Kansas
clinical laboratory will be the sole United States provider of the Nodify CDT test. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the acquisition, we and Oncimmune entered
into several agreements to govern the relationship between the parties and to allow us to provide the Nodify CDT test. The overarching umbrella PCA defines the general relationship between the parties. Included under the PCA was (a)&nbsp;an asset
purchase agreement (APA) whereby we acquired all of the United States assets associated with the De Soto, Kansas clinical laboratory, as well as the trademarks and patent application associated with the test; (b)&nbsp;an intellectual property
license granting us the rights necessary under Oncimmune&#146;s background intellectual property to perform the Nodify CDT test; (c)&nbsp;a supply agreement for supplying us with the necessary materials and reagents needed to run the Nodify CDT
test; and (d)&nbsp;a development agreement where Oncimmune agrees to assist us in further developing the Nodify CDT test. We were also granted an option through December&nbsp;31, 2020 to acquire the rights to expand the field of use of the Nodify
CDT test to include lung cancer screening. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the rights granted to us, we agreed to payments of $1.2 million and
further agreed to an option fee for the screening option of $9&nbsp;million due within 30 days of exercising the option. We also agreed to a revenue share payment of 8% of recognized revenue for <FONT STYLE="white-space:nowrap">non-screening</FONT>
tests up to an annual minimum volume and 5% thereafter, with an escalating minimum through the first four years of sales. The minimum sales volumes will be adjusted upwards in the event we exercise the screening option. Royalty payments of $0.1
million were paid for the six months ended June&nbsp;30, 2020. As of June 30, 2020, we have paid $1.0 million of the agreed upon payments. In July 2020, we paid the remaining $0.2 million. In September 2020, we notified Oncimmune that we would not
exercise this option for expansion of the field of use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Agreements with Bio-Rad </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2019, we entered into the <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> License. <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> is
a key supplier of equipment and reagents used to perform ddPCR testing&#151;a service offered by us under a fee for service agreement&#151;and the core technology powering the GeneStrat and COVID ddPCR tests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> License, we received a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, without the right to grant sublicenses, to utilize certain of <FONT STYLE="white-space:nowrap">Bio-Rad&#146;s</FONT> intellectual property, machinery, materials, reagents, supplies and <FONT
STYLE="white-space:nowrap">know-how</FONT> necessary for the performance of ddPCR in cancer detection testing for third parties in the United States. We agreed to purchase all of the necessary supplies and reagents for such testing exclusively from <FONT
STYLE="white-space:nowrap">Bio-Rad,</FONT> pursuant to a separately executed supply agreement with <FONT STYLE="white-space:nowrap">Bio-Rad.</FONT> As further consideration for the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, we
agreed to pay a royalty of 2.5% on the net revenue received for the performance of such ddPCR testing collected from third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">Bio-Rad</FONT> License expires in August 2024. Either party may terminate for the other&#146;s uncured material breach or bankruptcy events. <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> may terminate the <FONT
STYLE="white-space:nowrap">Bio-Rad</FONT> License if we do not purchase licensed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products under the separate supply agreement for a consecutive twelve month period or for any material breach by us of the supply agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, we entered into a Material Transfer Agreement, which was amended in April 2020, with Bio-Rad for the purpose of collaborating
to submit for an EUA for Bio-Rad&#146;s SARS-CoV-2 ddPCR test pursuant to which Biodesix was granted a non-exclusive license, without the right to grant sublicenses, to use certain testing materials provided by Bio-Rad, including reagents and
assays, for such purpose. The intent of the agreement was for Biodesix to create, validate and file Bio-Rad&#146;s SARS-CoV-2 ddPCR assay for EUA with the FDA specifically for use in our laboratory in Colorado. Additionally, under the agreement,
Bio-Rad agreed to file a kit manufacturer SARS-CoV-2 EUA with the FDA for broad distribution in the U.S. Additionally, under the agreement, we performed feasibility, verification and validation studies, including developing software for process
automation, sample accessioning, data management and reporting, all required to demonstrate that the test operated as claimed by the manufacturer, and further, to validate the test as required by our certifying regulatory agencies for high
complexity laboratory testing. As part of the validation effort, we agreed to supply the ddPCR testing equipment, trained laboratory personnel, extraction kits and process testing, patient samples and full access to all resulting data for use in
joint publications and purposes. We entered into an amendment to include additional materials that Bio-Rad had the option to purchase from us, including nasopharyngeal swab samples and other reagents necessary for the validation efforts. In a
separate letter from Bio-Rad, we were additionally granted permission by Bio-Rad to use the Bio-Rad SARS-CoV-2 ddPCR assay for commercial diagnostic services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, we entered into a second Material Transfer Agreement with respect to Bio-Rad&#146;s Platelia SARS-CoV-2 Total Ab assay for the
purpose of evaluating the performance of such assay pursuant to which Biodesix was granted a non-exclusive license to use such assays provided by Bio-Rad for such purpose. In a separate letter from Bio-Rad, we were also granted permission by Bio-Rad
to use the Platelia SARS-CoV-2 Total Ab assay for commercial diagnostic services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Debt Refinancing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, we entered into an agreement with Innovatus Life Sciences Lending Fund to refinance long-term debt carried over from earlier
loan agreements. The initial amount borrowed under the 2018 Notes was $23&nbsp;million and the maturity date is February 2023. We are required to make quarterly interest payments that began in June 2018 and outstanding principal is due in 24 equal
installments commencing in March 2021. The agreement has been amended multiple times to adjust terms to account for our acquisitions and growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loan may be prepaid by us at any time, subject to a prepayment penalty of up to 3% of the principal amount, depending on the date of
prepayment. Upon payment of the 2018 Notes at maturity or prepayment on any earlier date, unless waived, a 2% <FONT STYLE="white-space:nowrap">back-end</FONT> facility fee will apply to the amounts paid or prepaid. The 2% fee is being recorded as
additional interest expense over the term of the 2018 Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 Notes contain customary affirmative and negative covenants for a
loan, requires us to comply with a minimum daily liquidity covenant, and has a rolling monthly revenue requirement. Failure to comply with the covenants and loan requirements may result in early amortization of the loan in a 24 or <FONT
STYLE="white-space:nowrap">36-month</FONT> payment schedule. Further, we granted the lender a security interest in all of our assets through a pledge and security agreement, patent security agreement and trademark security agreement, each between us
and the lender. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Drug <FONT STYLE="white-space:nowrap">Co-Development</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, we and AVEO entered into a <FONT STYLE="white-space:nowrap">Co-Development</FONT> and Collaboration Agreement (AVEO Agreement)
whereby the two parties agreed to <FONT STYLE="white-space:nowrap">co-develop</FONT> AVEO&#146;s compound ficlatuzumab and our VeriStrat test. Under the AVEO Agreement, we agreed to use commercially reasonable efforts to continue to develop the
VeriStrat test and obtain regulatory approval for VeriStrat as a companion diagnostic for ficlatuzumab in certain major markets. We agreed with AVEO to agree on a development plan for ficlatuzumab and VeriStrat. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the AVEO Agreement, we agreed to co-develop their clinical trial asset, ficlatuzumab
(HGF-inhibitor), along with our proteomic test, BDX004 (a variant of our VeriStrat test), a test that identifies a subgroup of individuals who derive the most benefit from this drug. In collaboration with AVEO, we reported early clinical data on
ficlatuzumab in head and neck cancer, acute myeloid leukemia, and pancreatic cancer. Most recently, we announced data from our phase 1b study in pancreatic cancer, a challenging disease to treat, that demonstrated encouraging responses that support
the further assessment of the drug. We believe BDX004 could help differentiate patient benefit to ficlatuzumab across multiple indications and support decision making in therapeutic selection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the AVEO Agreement, we granted AVEO a perpetual, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free license to
certain background intellectual property related to VeriStrat, our interest in joint inventions developed under the AVEO Agreement and certain diagnostic data to develop, manufacture, seek regulatory approval for and commercialize ficlatuzumab and
certain IVD devices for use in connection with ficlatuzumab. AVEO granted us a perpetual, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free license to certain background intellectual property related to ficlatuzumab, their interest
in joint inventions developed under the AVEO Agreement and certain clinical data and biomarker data to develop, manufacture and commercialize VeriStrat and certain IVD devices other than VeriStrat. We solely own inventions relating to VeriStrat
(excluding ficlatuzumab) and AVEO solely owns inventions relating to ficlatuzumab (excluding VeriStrat), and we jointly own all other inventions under the AVEO Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the licenses under the AVEO Agreement, we agreed to reimburse AVEO for $15&nbsp;million of certain ficlatuzumab clinical
development costs. Additionally, we agreed to pay half of AVEO&#146;s clinical development costs above that $15&nbsp;million cap. Unless we or AVEO exercises our right to <FONT STYLE="white-space:nowrap">opt-out</FONT> of the <FONT
STYLE="white-space:nowrap">co-development,</FONT> we equally share in any income received from licensing rights to ficlatuzumab to any third parties. If either party exercises the right to <FONT STYLE="white-space:nowrap">opt-out</FONT> prior to the
first commercial sale of ficlatuzumab, the party that opts out will receive 25% of any such income. In September 2020, we exercised our opt-out right for the payment of half of the development and regulatory costs for ficlatuzumab. This opt-out is
effective as of December&nbsp;2, 2020 with remaining obligations estimated to be $0.3 million. Following the effective date, we will be entitled to a 10% royalty of net sales of ficlatuzumab and 25% of license income generated from the licensing of
ficlatuzumab. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any event, we and AVEO agreed to negotiate a definitive commercialization agreement for ficlatuzumab in good faith upon
results of a clinical trial for ficlatuzumab, pursuant to which AVEO would be the lead commercialization party. Such commercialization agreement would allocate commercialization responsibilities, provide decision-making processes, and include other
terms related to the commercialization of ficlatuzumab. The AVEO Agreement provides that under such commercialization agreement, we would share all profits and losses from the commercialization of ficlatuzumab, except that each party would have the
option to opt-out of commercialization activities and we would be entitled to receive a low single-digit royalty of net sales of ficlatuzumab made by AVEO. The AVEO Agreement also sets forth certain key provisions to be included in the definitive
commercialization agreement. We and AVEO agreed that under such commercialization agreement, we would share all profits and losses from the commercialization of ficlatuzumab, except that each party would have the option to opt-out of
commercialization activities and instead receive a low single-digit royalty of net sales of ficlatuzumab made by the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
AVEO Agreement continues in force until terminated by either party for the other&#146;s uncured material breach or bankruptcy events, or as terminated under the terms of the commercialization agreement. If we terminate the AVEO Agreement for
anything other than a breach by AVEO that prevents or irreparably disrupts certain clinical activities, AVEO will be deemed to have exercised its opt-out rights and will receive 25% of any income received by us for licenses under ficlatuzumab to
third parties. If we terminate for a breach by AVEO that prevents or irreparably disrupts certain clinical activities, AVEO will instead receive 12.5% of any such income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2016 we and AVEO amended the AVEO Agreement to deem our obligation to cover initial pre-clinical costs satisfied in exchange for a
one-time payment of all applicable development costs incurred to that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date, and to provide that we and AVEO would share development costs. Under the amended terms, we agreed to allow AVEO to recapture these costs that it otherwise would not have been responsible
for sharing, from any royalties or revenues eventually derived under the AVEO Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ficlatuzumab is currently being evaluated in
SCCHN, PDAC, and AML. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
of June&nbsp;30, 2020, we had 154 full time employees, 43 of whom were engaged in development activities, and 38 of whom were engaged in general and administrative functions. Our employees are primarily located in Boulder, Colorado, with additional
employees located in De Soto, Kansas and remotely across the country. None of our employees are represented by any collective bargaining agreements. We believe that we maintain good relations with our employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We occupy approximately
29,722 square feet of office and laboratory space in Boulder, Colorado under a lease that ends on January&nbsp;14, 2023. We also occupy 9,066 square feet of office and laboratory space in De Soto, Kansas under a lease that ends on October&nbsp;31,
2020. A portion of our employees are located outside of Colorado and Kansas, and others work from home. We believe our existing facilities meet our current needs. We will need additional office space in the future as we continue to build our
development, commercial and support teams. We believe we can find suitable additional space in the future on commercially reasonable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal
Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time be involved in various legal proceedings and other matters arising in the normal course of
business. For example, we have received, and may in the future continue to, receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. We have also
instituted, and may in the future institute additional, legal proceedings to enforce our rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. We cannot predict the results of any such disputes, and despite
the potential outcomes, the existence thereof may have an adverse material impact on us because of diversion of management time and attention as well as the financial costs related to resolving such disputes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth information concerning certain individuals, including their ages as of June&nbsp;30, 2020, who are expected to serve as our directors and executive officers upon completion of this offering. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Hutton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">48</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robin Harper Cowie</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">40</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer, Secretary, and Treasurer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kieran O&#146;Kane</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">43</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Georgantas III, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">50</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President, Research and Translational Science</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Pestano, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">53</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Development Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Patience<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">72</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman and Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean Franchi<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">53</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hany Massarany<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">59</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jack Schuler<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">79</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Strobeck, Ph.D<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">47</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Watts, M.D<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top">77</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Audit Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Compensation Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the Nominating and Corporate Governance Committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following are brief biographies describing the backgrounds of our executive officers and
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Scott Hutton</I></B> has served as our President, Chief Executive Officer and Director since January 2020, and previously held the role
of Chief Operating Officer from March 2018 to December 2019. Additionally, Mr. Hutton has served on the board of Eximis Surgical since February 2018 and was an Observer on the Board of Directors of Aqueduct Critical Care from September 2014 to
January 2017. Mr. Hutton joined Biodesix from Spectranetics Corp (NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions (now part of Royal Philips (NYSE: PHG)), where he served as Senior Vice President and
General Manager of the Vascular Intervention division from January 2017 to December 2017. Prior to joining Spectranetics, Mr. Hutton held several positions of increasing responsibility, including Vice President and General Manager, at Medtronic plc
(NYSE: MDT), a global healthcare products company and manufacturer of medical devices and supplies, over a period of 16 years. From April 2012 to January 2017, Mr. Hutton was Vice President and General Manager of Neurosurgery, where he oversaw the
operations of the approximately $1 Billion Neurosurgery Business Unit. From 2008 to 2012, he grew from Senior Director of Global Marketing to Vice President and Business Leader of the Surgical Navigation and Intra-Operative Imaging Business. Mr.
Hutton holds a B.A. in Health and Kinesiology from Purdue University. In July 2011, Mr. Hutton received the <I>Medtronic Wallin Leadership Award</I> for his focus on talent development, business performance, and his personal and intentional
demonstration of leadership. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Robin Harper Cowie</I></B> has served as our Chief Financial Officer since April 2017. She has been
with the Company in multiple financial and reimbursement positions since March 2011, serving as Vice President of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Finance from February 2016 to April 2017, Vice President of Reimbursement &amp; Health Economics from February 2015 to February 2016, Senior Director of Reimbursement from January 2014 to
February 2015, and Director of Reimbursement from March 2011 to January 2014. Prior to joining Biodesix, Ms. Harper Cowie held a leadership role in payer and government relations at Precision Therapeutics, Inc. Ms. Harper Cowie&#146;s background
includes corporate finance, managed care and payer relations, reimbursement and regulatory policy, and revenue cycle operations.&nbsp;Additionally, she spent several years as a researcher at the University of Pittsburgh Medical Center. Ms. Harper
Cowie holds a B.S. in Molecular Biology from the University of Pittsburgh, and an M.B.A. in Finance from the Joseph M. Katz Graduate School of Business from the University of Pittsburgh. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Kieran O&#146;Kane</I></B> has served as our Chief Commercial Officer since March 2020 and has been with the Company in multiple
marketing management roles since February 2018. From April 2016 to February 2018, prior to joining Biodesix, Mr. O&#146;Kane lead the Global Diagnostics Marketing team at NanoString Technologies, a biotechnology company focused in developing cancer
diagnostic tools. He is a highly experienced strategic and tactical global sales and marketing leader for both in-line and pipeline products with a career focus in oncology. Mr. O&#146;Kane has held commercial leadership positions and managed
multiple new product launches at Biotheranostics, Cell Therapeutics, Eisai, Cephalon, Bristol-Myers Squibb, and Roche. Mr. O&#146;Kane received a B.S. in Pharmacology at King&#146;s College, University of London. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Gary Pestano, Ph.D.</I></B> has served as our Chief Development Officer since October 2018 and has been with the Company in Product
Development and Operations since March 2012. Prior to joining Biodesix, Dr. Pestano held senior positions in Pharma Services, R&amp;D and Project Leadership at Ventana Medical Systems, a member of the Roche Group, from 2003 to 2012. Dr.
Pestano&#146;s experience in laboratory operations management and assay development for high complexity molecular diagnostics in oncology and virology include molecular and proteomic testing. Dr. Pestano is the co-inventor on multiple national and
international patents for diagnostic tests. He has also fostered many collaborations in academia and industry as a part of new product development. Dr. Pestano received a B.S. in Biochemistry from The City College of New York, his Ph.D. in Molecular
Cell Biology at The Graduate Center, City University of New York where his thesis focused on vaccine development for novel genetic variants of HIV-1. He conducted his post-doctoral training in Cancer Immunology and AIDS at the Dana Farber Cancer
Institute, Harvard Medical School. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Robert W. Georgantas III, Ph.D.</I></B> has served as our Senior Vice President of Research and
Translational Science since August 2019. From 2014 to 2019, prior to joining Biodesix, Dr. Georgantas worked at AbbVie where he served as Director of Immunology Programs and Biomarkers within the Genomics Research Center of Excellence, a group of
experts tasked with applying genetics, genomics, epigenetics, and metagenomics to inform the product pipeline primarily regarding new target discovery, biomarkers for clinical trials, and asset positioning. Dr. Georgantas is recognized as a leader
of immunology translational science and strategy. Dr.&nbsp;Georgantas completed his Ph.D. in pharmacology and molecular medicine at The Johns Hopkins University School of Medicine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">John Patience has served as a Director of the Company since June 2008 and Chairman of the Board since September 2020. Mr. Patience currently
serves as both a Director and Chairman of the board of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) and has served in that capacity since joining the board in 2012.&nbsp;Mr. Patience served as a director of Ventana Medical Systems, Inc. from 1989 and
as Vice Chairman from 1999 until Ventana&#146;s acquisition by Roche in 2008. Mr. Patience also served as a director of Stericycle, Inc. (NASDAQ: SRCL) since its founding in 1989 to June 2018. Mr. Patience is also a founding partner of Crabtree
Partners, a private equity investment partnership in Lake Forest, Illinois. Mr. Patience was previously a partner of a venture capital investment firm that provided both Ventana and Stericycle with early stage funding. Mr. Patience was also
previously a partner at the consulting firm McKinsey &amp; Co., Inc., specializing in health care. Mr. Patience holds a B.A. in Liberal Arts and an L.L.B. from the University of Sydney, Australia, and an M.B.A. from the University of
Pennsylvania&#146;s Wharton School of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Jean M. Franchi</I></B> has served as a Director of the Company since April
2020.&nbsp;Ms. Franchi is currently Chief Financial Officer at Replimune, a biotechnology company developing oncolytic immuno-gene therapies. Prior to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Replimmune, Ms. Franchi was Chief Financial Officer at Merrimack Pharmaceuticals from 2017 to 2019, Dimension Therapeutics from 2015 to 2017, and Good Start Genetics from 2012 to 2015. From 1995
to 2011, Ms. Franchi held various positions at Genzyme Corporation, including Senior Vice President of Corporation Finance, Senior Vice President of Business Unit Finance, and Vice President of Finance and Controller, Product Line and International
Group. Ms. Franchi currently serves on the boards of directors of Biophytis BSA and Visioneering Technologies, Inc. Ms. Franchi received her B.A. in Accounting from Hofstra University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Hany Massarany</I></B> has served as a Director of the Company since July 2020. Mr. Massarany was President and Chief Executive Officer
of GenMark Diagnostics, Inc. (NASDAQ: GNMK) from April 2011 to March 2020. From February 2009 to April 2011, Mr. Massarany served as President of at Ventana Medical Systems and Head of Roche Tissue Diagnostics, a division of F. Hoffman-La Roche Ltd.
focused on manufacturing instruments and reagents that automate tissue processing and slide staining diagnostics for cancer. From 1999 to 2009, Mr.&nbsp;Massarany held various global leadership positions with Ventana, including Chief Operating
Officer, Executive Vice President, Worldwide Operations, Senior Vice President, Corporate Strategy and Development, and Vice President, North American Commercial Operations. Mr. Massarany also held executive management positions with Bayer
Diagnostics and Chiron Diagnostics, working in both the Asia Pacific region and the United States. Mr. Massarany served on the board of directors of GenMark Diagnostics, Inc. from May 2011 to February 2020. Mr. Massarany earned a B.S. in
Microbiology and Immunology from Monash University in Australia and an M.B.A. from Melbourne University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Jack Schuler</I></B> has
served as a Director of the Company since June 2008. Mr. Schuler served as a director of Ventana Medical Systems, Inc. from 1991 and as Chairman of the board from 1995 until Ventana&#146;s acquisition by Roche in 2008. Prior to joining Ventana, Mr.
Schuler was President and Chief Operating Officer of Abbott Laboratories, a diversified health care company, which he joined in 1972 and where he held a number of management and marketing positions, also serving as a director from April 1985 to
August 1989. Additionally, Mr. Schuler has served as a director of Abbott Laboratories (NYSE:ABT), Medtronic (Lead Director) (NYSE: MDT), Stericyle (Chairman) (NASDAQ: SRCL), Chiron Corporation, and Quidel Corporation (NASDAQ: QDEL), and currently
serves on the board of directors of Accelerate Diagnostics (NASDAQ: AXDX). Mr.&nbsp;Schuler holds a B.S. in Mechanical Engineering from Tufts University and an M.B.A. from Stanford University Graduate School of Business Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Matthew Strobeck, Ph.D</I></B>. has served as a Director of the Company since January 2012. Dr. Strobeck is currently the Managing
Partner of Birchview Capital. In addition, Dr. Strobeck is currently a Director of Quidel Corporation (NASDAQ: QDEL), Accelerate Diagnostics (NASDAQ: AXDX), Tepha Inc., and Monteris Medical. Dr. Strobeck received a B.S. from St.&nbsp;Lawrence
University, a Ph.D. from the University of Cincinnati, a S.M. from the Harvard University/MIT Health Sciences Technology Program, and a S.M. from the MIT Sloan School of Management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Charles Watts, M.D</I></B>. has served as a Director of the Company since July 2019. Until his retirement, Dr.&nbsp;Watts served as
Chief Medical Officer at Northwestern Memorial Hospital (NMH) and Associate Dean for Clinical Affairs at the Feinberg School of Medicine, Northwestern University from 2001 to 2011. Prior to his tenure at Northwestern, Dr. Watts served as Chief of
Clinical Affairs and Associate Dean at the University of Michigan Medical Center. He has also served as Executive in Residence for the Health Management Academy, as an active faculty member of a nationally based Physician Leadership Program. Dr.
Watts served as a Director of Providence Health and Services (Seattle, Washington) from 2012 to 2016 where he chaired the Quality and Patient Safety Improvement Committee, and served as a Trustee of Swedish Health Services until May 2017, when he
accepted an appointment as interim Chief Medical Officer, serving in that capacity until June 2019. He currently serves as a Trustee on the Institute for Systems Biology Board and as a director of Accelerate Diagnostics. Dr. Watts received his
medical degree from the University of Michigan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary responsibilities of our Board of Directors are to provide oversight, strategic guidance, counseling and direction to our
management. Our Board of Directors meets on a regular basis and additionally as required. Our Board of Directors currently consists of ten directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with our amended and restated certificate of incorporation that will go into effect upon the completion of this offering, our
Board of Directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification
until the third annual meeting following election. Effective upon the completion of this offering, our directors will be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors will be John Patience and Scott Hutton, and their terms will expire at our first
annual meeting of stockholders following this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors will be Matthew Strobeck, Ph.D. and Charles Watts, M.D., and their terms will expire
at our second annual meeting of stockholders following this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors will be Jean Franchi, Hany Massarany and Jack Schuler, and their terms will be
expire at our third annual meeting of stockholders following this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of
incorporation and amended and restated bylaws that will go into effect upon the completion of this offering will provide that the authorized number of directors may be changed only by resolution of the Board of Directors. Any additional
directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The
division of our Board of Directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the
holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding voting stock entitled to vote in the election of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the listing
requirements and rules of Nasdaq Global Market, independent directors must comprise a majority of our Board of Directors as a listed company within one year of the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors has undertaken a review of its composition, the composition of its committees and the independence of each director.
Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our Board of Directors has determined that Ms. Franchi and Messrs. Massarany,
Strobeck, Watts, Schuler and Patience do not have any relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#147;independent&#148; as that
term is defined under the applicable listing requirements and rules of the Nasdaq Global Market. In making this determination, our Board of Directors considered the current and prior relationships that each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances our Board of Directors deemed relevant in determining their independence, including the beneficial ownership of our capital
stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Leadership Structure of the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate governance guidelines, which will become effective immediately prior to the completion of this offering, will provide our Board
of Directors with flexibility to combine or separate the positions of Chairman of the board and Chief Executive Officer and/or the implementation of a lead director in accordance with its determination that utilizing one or the other structure would
be in the best interests of our company. Mr.&nbsp;Patience currently serves as the Chairman of our Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. Our
Board of Directors may establish other committees to facilitate the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management of our business. The composition and functions of each committee are described below. Members serve on these committees until their resignation or until otherwise determined by our
Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of the date the registration statement of which this prospectus forms&nbsp;a part is declared effective by the SEC, our audit
committee will consist of Ms. Franchi and Messrs. Massarany and Strobeck, each of whom our Board of Directors has determined satisfies the independence requirements under the applicable listing requirements and rules of the Nasdaq Global Market and <FONT
STYLE="white-space:nowrap">Rule&nbsp;10A-3(b)(1)</FONT> of the Exchange Act. The chair of our audit committee is Ms. Franchi, whom our Board of Directors has determined is an &#147;audit committee financial expert&#148; within the meaning of the SEC
regulations. Each member of our audit committee can read and understand fundamental financial statements in accordance with applicable listing standards. In arriving at these determinations, our Board of Directors has examined each audit committee
member&#146;s scope of experience and the nature of her or his employment in the corporate finance sector. The functions of this committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">helping our Board of Directors oversee our corporate accounting and financial reporting processes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with our management the adequacy and effectiveness of our disclosure controls and
procedures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assisting with design and implementation of our risk assessment functions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the qualifications, performance and independence of our independent registered public accounting firm
and deciding whether to retain its services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the rotation of partners of our independent registered public accounting firm on our engagement team
as required by law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and
reviewing, with management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit
matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing related party transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving, or as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by an independent registered public accounting firm; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing, at least annually, the performance of the audit committee and adequacy of its charter.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of the date the registration statement of which this prospectus forms&nbsp;a part is declared effective by the SEC, our
compensation committee will consist of Messrs. Massarany, Patience and Watts, and the chair of our compensation committee will be Mr. Massarany. Our Board of Directors has determined that each of Messrs. Massarany, Patience and Watts is independent
under the applicable listing requirements and rules of the Nasdaq Global Market and is a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined in <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> promulgated
under the Exchange Act. The functions of this committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, modifying and overseeing overall compensation strategy and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation and other terms of employment of our chief executive officer, other
executive officers and senior management, as appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation arrangements with our executive officers and other senior management, as
appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to the full Board of Directors the compensation of our directors;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing and overseeing the work of compensation consultants, legal counsel or any other advisors and
consultants engaged for the purpose of advising the compensation committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adopting and administering equity award plans, compensation plans and similar programs, as well as modification
or termination of plans and programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing policies with respect to equity compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating with the chief executive officer the succession plans for our executive officers; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing, at least annually, the performance of the compensation committee and the adequacy of its
charter. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of the date the registration statement of which this prospectus forms&nbsp;a part is declared effective by the SEC, our nominating
and corporate governance committee consists of Ms. Franchi and Messrs. Strobeck and Schuler and the chair of our nominating and corporate governance committee will be Mr. Strobeck. Our Board of Directors has determined that Ms. Franchi and Messrs.
Strobeck and Schuler are independent under the applicable listing standards. The functions of this committee include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing periodically and evaluating director performance of our Board of Directors and its applicable
committees, and recommending to our Board of Directors and management areas for improvement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, evaluating, nominating and recommending individuals for membership on our Board of Directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with our chief executive officer the plans for succession to the offices of our executive officers and
make recommendations to our Board of Directors with respect to the selection of appropriate individuals to succeed to these positions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our Board of Directors any amendments to our corporate governance policies; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing, at least annually, the performance of the nominating and corporate governance committee
and the adequacy of its charter. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Conduct </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a Code of Conduct that applies to all of our employees, officers (including our principal executive officer, principal
financial officer and principal accounting officer or controller, or persons performing similar functions), agents and representatives, including directors and consultants. The full text of our Code of Conduct will be posted on our website at
www.biodesix.com. We intend to disclose future amendments to certain provisions of our Code of Conduct, or waivers of such provisions, applicable to any principal executive officer, principal financial officer, principal accounting officer or
controller, or persons performing similar functions, and our directors, on our website identified above. The information contained on, or accessible from, or hyperlinked to, our website is not part of, and is not incorporated into, this prospectus.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of the compensation committee is currently, or has been at any time, one of our officers or employees. None of our
executive officers currently serve, or has served during the last calendar year, as a member of the Board of Directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board of Directors or
compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019, none of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors received retainers or
other cash payments with respect to service on our Board of Directors or any of its committees. In connection with this offering, we expect to adopt a formal <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Director Compensation Table </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information for the fiscal year ended December&nbsp;31, 2019 regarding the compensation awarded to, earned by or
paid to <FONT STYLE="white-space:nowrap">our&nbsp;non-employee&nbsp;directors.</FONT> The only compensation received by our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors was in the form of restricted stock units (RSUs) and option
awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In respect of 2019 service, Messrs. Schuler, Patience, Miller, and Strobeck each received stock options representing the right to
purchase 35,158 shares of our common stock. Dr. Watts joined the Board of Directors as of July 16, 2019. The Board of Directors granted him a new member equity award and a pro-rata award for the term from his first board meeting until March 31,
2020, upon availability from the stock option pool. As such, Dr.&nbsp;Watts received stock options representing the right to purchase 26,368 shares of our common stock. These stock options vest in a series of twelve (12)&nbsp;successive, equal
monthly installments measured from the vesting commencement date. Moreover, Dr.&nbsp;Watts received an RSU award with respect to 26,368 shares of our common stock. <FONT STYLE="white-space:nowrap">Two-fifths</FONT> (2/5) of the shares subject to
this RSU award vest on the second anniversary of the vesting commencement date, with the remaining balance vesting in a series of <FONT STYLE="white-space:nowrap">thirty-six</FONT> (36)&nbsp;successive equal monthly installments measured from the
second anniversary of the vesting commencement date, provided that, no shares will be issued until the earlier of Dr.&nbsp;Watts&#146; separation from service other than for cause and the fifth anniversary of the vesting commencement date. In the
event Dr.&nbsp;Watts is terminated for cause, this award will be forfeited and no shares will be issued. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jack Schuler</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,689</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,689</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Patience</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,689</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,689</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark C. Miller</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,689</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,689</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Strobeck, Ph.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,689</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,689</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles M. Watts, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">20,348</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">12,517</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">32,865</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent the aggregate grant date fair market value of the RSUs, calculated in accordance
with FASB ASC Topic 718 based on the assumption that the value of each RSU was equal to $0.77. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent the aggregate grant date fair market value of the stock options calculated in
accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the award disclosed in this column are set forth in Note 11 of our audited financial statements included elsewhere in this prospectus and under the
heading &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Critical Accounting Policies and Significant Judgments and Estimates&#151;Stock-based compensation and common stock valuation&#148; in this
prospectus. These amounts do not correspond to the actual value that may be recognized by the named executive officers upon vesting of the applicable awards. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of compensation arrangements of our named executive officers. This discussion contains forward-looking
statements that are based on our current plans, considerations, expectations, and determinations regarding future compensation programs. Actual compensation programs that we adopt may differ materially from currently planned programs as summarized
in this discussion. As an &#147;emerging growth company&#148; (as defined in the JOBS Act), we are not required to include a Compensation Discussion and Analysis and have elected to comply with the scaled disclosure requirements applicable to
emerging growth companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current executive compensation program is intended to align executive compensation with our performance objectives and business strategy
and to enable us to attract, motivate, retain and reward executive officers whose contributions are critical to our long-term success. The compensation paid or awarded to our executive officers is generally based on the assessment of each
individual&#146;s performance compared against the business objectives established for the fiscal year as well as our historical compensation practices. <FONT STYLE="white-space:nowrap">New-hire</FONT> executive officers&#146; compensation is
primarily determined based on the negotiations of the parties as well as our historical compensation practices. For the year ended December&nbsp;31, 2019, the material elements of our executive compensation program were base salary, discretionary
cash bonus and equity awards in the form of stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following this offering, we expect that our executive compensation program
will evolve to reflect our status as a newly publicly-traded company, while still supporting our overall business and compensation objectives. The compensation committee of our Board of Directors (Compensation Committee) oversees our executive
compensation program. In addition, during the year ended December&nbsp;31, 2019, we retained an independent executive compensation consultant to help advise on elements of our executive compensation program. This section provides a discussion of the
compensation paid or awarded to our Chief Executive Officer and our two other most highly compensated executive officers serving as of December&nbsp;31,&nbsp;2019, the end of fiscal 2019. We refer to these individuals as our &#147;named executive
officers.&#148; For the year ended December&nbsp;31, 2019, our named executive officers were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">David Brunel,<I> </I>Former<I> </I>Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robin Harper Cowie, Chief Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Scott Hutton, Former Chief Operating Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective December&nbsp;31, 2019, Mr.&nbsp;Brunel ceased to be our Company&#146;s Chief Executive Officer. Effective
January&nbsp;1,&nbsp;2020, Mr.&nbsp;Brunel became our Company&#146;s Chairman of the Board of Directors. Pursuant to the Brunel Consulting Agreement as described in the section titled &#147;Certain 2020 Actions&#148;, Mr. Brunel resigned from his
position as Chairman of the Board of Directors and ceased to be a member of the Board of Directors effective as of September 14, 2020. As of such resignation, Mr. Brunel began service at the pleasure of the Board of Directors as a Director Emeritus.
He will cease providing services to the Company as an employee on December 31, 2020 and will provide consulting services to the Company beginning on January 1, 2021. Effective January&nbsp;1, 2020, Mr.&nbsp;Hutton ceased to be our Chief Operating
Officer and became our President and Chief Executive Officer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Named Executive Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Base Salary </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Base
salaries are intended to provide a level of compensation sufficient to attract and retain an effective management team, when considered in combination with the other components of our executive compensation program. The relative levels of base
salary for our named executive officers are designed to reflect each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
executive officer&#146;s scope of responsibility and accountability to us. Please see the &#147;Salary&#148; column in the 2019 Summary Compensation Table for the base salary amounts received by
each named executive officer during the year ended December&nbsp;31, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Annual Cash Bonuses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide our senior leadership team with short-term incentive compensation through an annual cash bonus program. Annual bonus compensation
holds executives accountable, rewards the executives based on actual business results and helps create a &#147;pay for performance&#148; culture. Our annual cash bonus program provides cash incentive award opportunities based on the achievement of
performance goals approved by our Compensation Committee at the beginning of each fiscal year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, our Compensation Committee
establishes a Company-based performance metric as a threshold vesting criteria for any payouts for a particular annual bonus period. In determining bonus payouts, if any, individual performance of our named executive officers with respect to
individual goals established at the beginning of the applicable year is only considered if that metric is met or exceeded. For 2019, the Compensation Committee determined that the Company&#146;s revenue would be the applicable Company-based metric,
and at year end, measured actual revenue against targeted revenue, determined in accordance with U.S. GAAP. No payouts were earned or made under the 2019 annual cash bonus program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Equity Awards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To
further align the interests of our executive officers with the interests of our stockholders and to further focus our executive officers on our long-term performance, we have historically granted equity compensation in the form of stock options. In
the year ended December 31, 2019, the Board of Directors awarded Messrs. Brunel, Hutton, and Ms. Harper Cowie stock options (Time-Vested Options) representing the right to purchase 45,485, 42,116, and 35,377 shares of our common stock, respectively,
on a five-year vesting schedule. Two fifths (2/5) of the Time-Vested Options vest on the second anniversary of the vesting commencement date, with the remaining balance vesting in a series of thirty-six (36) successive equal monthly installments
measured from the second anniversary of the vesting commencement date, subject to the award recipient&#146;s continued service through the applicable vesting date. In September 2020, the Board of Directors amended the Time-Vested Options such that
twenty-one sixtieths (21/60) of the Time-Vested Options vest on the date that is twenty-one (21) months after the vesting commencement date, with the remaining balance vesting in a series of thirty-nine (39) successive equal monthly installments
measured from such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the year ended December 31, 2019, the Board of Directors also awarded Messrs. Brunel, Hutton, and Ms. Harper
Cowie stock options (Performance-Vested Options) representing the right to purchase 26,954, 25,269, and 17,688 shares of our common stock, respectively, on a three-year vesting schedule subject to the achievement of applicable performance criteria.
One third (1/3) of these Performance-Vested Options vest after each of the first (2019 Tranche), second (2020 Tranche) and third (2021 Tranche) anniversaries of the vesting commencement date, subject to the Company&#146;s achievement of recognized
revenue of at least $31 million, $67 million and $134 million for the years ended December 31, 2019, 2020 and 2021, respectively. The Board of Directors has sole discretion to determine if the performance hurdles are met and to determine the vesting
date, and shall make such determinations within 90 days after the end of the applicable fiscal year. In September 2020 and in light of the impact of the COVID-19 pandemic on the Company&#146;s operations and other considerations, the Board of
Directors amended the Performance-Vested Options to provide that the performance hurdles for the 2020 Tranche and the 2021 Tranche are $28.6 million and $51.5 million, respectively. The Board of Directors retains ultimate discretion to determine
whether such performance hurdles have been met, and at the time of the amendment believed that such achievement was uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see
&#147;Outstanding Equity Awards at Fiscal 2019 <FONT STYLE="white-space:nowrap">Year-End&#148;</FONT> for a summary of the outstanding equity awards held by each of the named executive officers as of 2019
<FONT STYLE="white-space:nowrap">year-end.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2019 Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows information regarding the compensation of our named executive officers for services performed during the year ended
December&nbsp;31, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Brunel<I> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former<I> </I>Chief Executive Officer<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">343,750</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">41,157</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">384,907</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Hutton</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief Operating Officer<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">298,475</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">38,285</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">336,760</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robin Harper Cowie</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">263,525</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">30,150</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">293,675</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Brunel&#146;s service as our Chief Executive Officer terminated on December&nbsp;31, 2019, after which
he became Chairman of our Board of Directors. Mr. Brunel resigned from the Board of Directors in September 2020. Effective January 1, 2021, Mr. Brunel is expected to transition into a consulting role for which he will be paid a quarterly fee of
$5,000. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Hutton&#146;s service as our Chief Operating Officer terminated on January&nbsp;1, 2020, after which
he became the President and Chief Executive Officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on our 2019 performance measured against the Company&#146;s objectives, our Compensation Committee
determined not to award payouts under the 2019 annual cash bonus program. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts disclosed represent the aggregate grant date fair value of the award as calculated in accordance
with FASB ASC Topic&nbsp;718. The assumptions used in calculating the grant date fair value of the award disclosed in this column are set forth in Note&nbsp;11 of our audited financial statements included elsewhere in this prospectus. These amounts
do not correspond to the actual value that may be recognized by the named executive officers upon vesting of the applicable awards. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal 2019 <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding the outstanding equity awards held by each of the named executive officers as of
December&nbsp;31, 2019. As of the year ended December&nbsp;31, 2019, none of the named executive officers held any outstanding restricted stock units or other stock awards. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)&nbsp;Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)&nbsp;Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Unearned<BR>Options (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Brunel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/26/2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/25/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/22/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/21/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/8/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/7/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/30/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/29/2022</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/30/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/29/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/11/2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/10/2023</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2024</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/20/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/19/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/8/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/7/2025</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/7/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/6/2026</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/13/2026</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/16/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/15/2027</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/4/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/3/2028</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/4/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/22/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2028</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Hutton</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/4/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/3/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/22/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robin Harper Cowie</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/22/2011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/21/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/4/2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/3/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/8/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/7/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/7/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/6/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/16/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/15/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/4/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/3/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/22/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/31/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These stock options vest in a series of sixty (60)&nbsp;successive, equal monthly installments measured from
the vesting commencement date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Two fifths (2/5) of these Time-Vested Options vest on the second anniversary of the vesting commencement date,
with the remaining balance vesting in a series of thirty-six (36) successive equal monthly installments measured from the second anniversary of the vesting commencement date, subject to the award recipient&#146;s continued employment through the
applicable vesting date. In September 2020, the Board of Directors amended these Time-Vested Options such that twenty-one sixtieths (21/60) of the Time-Vested Options vest on the date that is twenty-one (21) months after the vesting commencement
date, with the remaining balance vesting in a series of thirty-nine (39) successive equal monthly installments measured from such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Two fifths (2/5) of these Time-Vested Options vest on the second anniversary of the vesting commencement date,
with the remaining balance vesting in a series of thirty-six (36) successive equal monthly installments measured from the second anniversary of the vesting commencement date, subject to the award recipient&#146;s continued employment through the
applicable vesting date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the year ended December 31, 2019, the Board of Directors awarded Messrs. Brunel, Hutton, and Ms. Harper
Cowie stock options representing the right to purchase 26,954, 25,269 and 17,688 shares of our common stock, respectively. One third (1/3) of these performance-based stock options vest (or could have vested) after each of the first, second and third
anniversaries of the vesting commencement date, subject to the Company&#146;s achievement of recognized revenue of at least $31 million, $67 million and $134 million for the years ended December 31, 2019, 2020 and 2021, respectively. The Board of
Directors has sole discretion to determine if the performance hurdles are met and to determine the vesting date, and shall make such determinations within 90 days after the end of the applicable fiscal year. For the 2019 Tranche, the Board of
Directors determined that the performance hurdle was not met. As a result one third (1/3) of each executive&#146;s award was cancelled, and the remaining two thirds (2/3) of each of Mr. Hutton&#146;s and Ms. Cowie&#146;s awards are currently
outstanding. Under the terms of the Brunel Consulting Agreement, the 2021 Tranche of Mr. Brunel&#146;s award was cancelled. In addition, in September 2020 and in light of the impact of the COVID-19 pandemic on the Company&#146;s operations and other
considerations, the Board of Directors amended the Performance-Vested Options to provide that the performance hurdles for the 2020 Tranche and the 2021 Tranche are $28.6 million and $51.5 million, respectively. The Board of Directors believes that
the achievement of the performance hurdles remains uncertain, and retains ultimate discretion to determine whether such performance hurdles have been met. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under the terms of the Brunel Consulting Agreement, the expiration date of these stock options has been amended
to be the earlier of (i) December 31, 2021, (ii) thirty (30) days after the termination of the Brunel Consulting Agreement, and (iii) the original expiration date of such term as reflected in the table above. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Matters </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Harper Cowie
Offer Letters </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019, Ms.&nbsp;Harper Cowie was party to an offer letter agreement with the
Company, dated as of March&nbsp;11, 2011, as amended (the 2011 Harper Cowie Offer Letter). Effective February&nbsp;16, 2019, Ms. Harper Cowie&#146;s base salary was raised to $265,000 annually, and she is eligible to receive a bonus of up to 50% of
her base salary if certain milestones and objectives determined by the Company were achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms. Harper Cowie and the Company entered
into a new offer letter agreement, dated as of February&nbsp;23, 2020, which supersedes the 2011 Harper Cowie Offer Letter (the 2020 Harper Cowie Offer Letter). Under the terms of the 2020 Harper Cowie Offer Letter, Ms.&nbsp;Harper Cowie is entitled
to a base salary of $290,000 annually effective the beginning of the first month after this offering, and she is eligible to receive a bonus of up to 50% of her base salary after approval from the Compensation Committee and Board of Directors that
relevant objectives have been achieved. In addition, Ms.&nbsp;Harper Cowie is entitled to certain severance benefits in the event that her employment with the Company is terminated without Cause, as defined in the 2011 Harper Cowie Offer Letter,
including but not limited to a termination following a change in control. The severance benefits consist of (i)&nbsp;base salary continuation for a period of 6 months following the effective date of a general release of claims, less standard
deductions and withholdings, and (ii)&nbsp;if Ms.&nbsp;Harper Cowie timely elects healthcare continuation coverage under the Consolidated Omnibus Reconciliation Act of 1985, as amended (COBRA), Company-paid COBRA premiums (including in respect of
coverage for eligible dependents) for a period starting on Ms.&nbsp;Harper Cowie&#146;s termination date and ending 12 months thereafter, subject to earlier termination if Ms. Harper Cowie becomes eligible for health coverage from a subsequent
employer, or if Ms.&nbsp;Harper Cowie ceases to be eligible for COBRA continuation for any reason including plan termination. Any change in control which results in a change of position for Ms.&nbsp;Harper Cowie also results in accelerated vesting
of 100% of all unvested and then outstanding options held by Ms.&nbsp;Harper Cowie. In order to receive the severance benefits, Ms.&nbsp;Harper Cowie is required to execute a release of all claims in favor of the Company which becomes irrevocable,
and to be in continued compliance with cooperation, non-disparagement or confidentiality provisions contained therein and with obligations under the Company&#146;s Confidentiality and Inventions Assignment Agreement, including non-solicit provisions
thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the 2020 Harper Cowie Offer Letter, in the event Ms.&nbsp;Harper Cowie resigned, or
if her employment was terminated by the Company for Cause or due to death or disability, Ms. Harper Cowie would be entitled to any salary earned but unpaid prior to such termination, any reimbursable business expenses that were incurred but not
reimbursed as of Ms.&nbsp;Harper Cowie&#146;s last day of employment, and, if applicable, all accrued but unused vacation. Any unvested stock options or other equity awards shall cease to vest and be forfeited on Ms.&nbsp;Harper Cowie&#146;s last
day of employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Hutton Offer Letters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019, Mr. Hutton was party to an offer letter agreement with the Company, dated as of February&nbsp;8,
2018, as amended (the 2018 Hutton Offer Letter). Effective February&nbsp;16, 2019, Mr.&nbsp;Hutton&#146;s base salary was raised to $300,000 annually. Under the terms of the 2018 Hutton Offer Letter, Mr. Hutton is eligible to receive a bonus of up
to 50% of his base salary if certain milestones and objectives determined by the Company are achieved. Mr.&nbsp;Hutton and the Company entered into a new offer letter agreement, dated as of February&nbsp;23, 2020, which supersedes the 2018 Hutton
Offer Letter (the 2020 Hutton Offer Letter). Under the terms of the 2020 Hutton Offer Letter, effective January&nbsp;1, 2020, Mr.&nbsp;Hutton&#146;s base salary was raised to $350,000 annually. Effective the beginning of the first month after this
offering, Mr.&nbsp;Hutton&#146;s base salary will be further adjusted to $425,000 annually, and he will be eligible to receive a bonus of up to 100% of his base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Mr. Hutton is entitled to certain severance benefits in the event that his employment with the Company is terminated without
Cause, as defined in the 2018 Hutton Offer Letter, including but not limited to a termination following a change in control or, following a change in control, a successor&#146;s failure to assume the terms and conditions of the 2018 Hutton Offer
Letter as it relates to Mr.&nbsp;Hutton&#146;s salary, duties and responsibilities or severance provisions. The severance benefits consist of (i)&nbsp;base salary continuation for a period of 12 months following the effective date of a general
release of claims, less standard deductions and withholdings, and (ii)&nbsp;if Mr.&nbsp;Hutton timely elects healthcare continuation coverage under COBRA, Company-paid COBRA premiums (including in respect of coverage for eligible dependents) for a
period starting on Mr.&nbsp;Hutton&#146;s termination date and ending 12 months thereafter, subject to earlier termination if Mr.&nbsp;Hutton becomes eligible for health coverage from a subsequent employer, or if Mr.&nbsp;Hutton ceases to be
eligible for COBRA continuation for any reason including plan termination. In order to receive the severance benefits, Mr.&nbsp;Hutton is required to execute and allow to become effective a release of all claims in favor of the Company, which
becomes irrevocable and to be in continued compliance with any cooperation, <FONT STYLE="white-space:nowrap">non-disparagement</FONT> or confidentiality provisions contained therein and with obligations under the Company&#146;s Confidentiality and
Inventions Assignment Agreement, including <FONT STYLE="white-space:nowrap">non-solicit</FONT> provisions thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the 2018
Hutton Offer Letter, in the event Mr.&nbsp;Hutton resigned, or if his employment was terminated by the Company for Cause or due to death or disability, Mr.&nbsp;Hutton would be entitled to any salary earned but unpaid prior to such termination, any
reimbursable business expenses that were incurred but not reimbursed as of Mr.&nbsp;Hutton&#146;s last day of employment, and, if applicable, all accrued but unused vacation. Any unvested stock options or other equity awards shall cease to vest and
be forfeited on Mr.&nbsp;Hutton&#146;s last day of employment. In the event that Mr.&nbsp;Hutton&#146;s employment is terminated by the Company without Cause, as defined in the 2020 Hutton Offer Letter, he is entitled to the same severance benefits
as provided for under the 2018 Hutton Offer Letter, plus an additional payout of target bonus previously established by the Compensation Committee. Furthermore, any change in control which results in a change of position will trigger the accelerated
vesting of 100% of all unvested and then outstanding options held by Mr.&nbsp;Hutton. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company participates in a multiple employer <FONT STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) savings plan which allows
participants to defer eligible compensation up to the maximum amount allowed under Internal Revenue Service guidelines. The Company does not currently make any discretionary or employer matching contributions under the plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2016 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, our Board of Directors adopted our 2016 Equity Incentive Plan (the 2016 Incentive Plan). The following summary describes the material
terms of the 2016 Incentive Plan. This summary is not a complete description of all provisions of the 2016 Incentive Plan and is qualified in its entirety by reference to the 2016 Incentive Plan, which will be filed as an exhibit to the registration
statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the 2016 Incentive Plan is to help secure and retain persons performing
services to the Company, provide incentives for such persons to exert maximum efforts for the success of the Company and any affiliate, and provide a means by which such persons may benefit from increases in value of the Company&#146;s common stock.
The 2016 Incentive Plan provides for the grant of incentive stock options (within the meaning of Section&nbsp;422 of the Code), nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units (RSUs), and other
stock awards. Only directors, employees and consultants who provide services to us or any affiliate of ours are eligible to receive such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Subject to the Plan. </I>The number of shares reserved for issuance under the 2016 Incentive Plan as of December 31, 2019 was
1,853,026, all of which may be issued in satisfaction of incentive stock option awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent an equity award granted under the
2016 Incentive Plan or the Company&#146;s predecessor plan expires or otherwise terminates without having been exercised or settled in full, or is settled in cash, or the shares underlying an award are forfeited, cancelled or repurchased by the
Company, the shares subject to such award will become available for future issuance under the 2016 Incentive Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#146;s tax withholding obligations on a
stock award, or are reacquired by the Company as consideration for the exercise or purchase price of a stock award, such shares will become available for future issuance under the 2016 Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, our employees, directors and consultants hold outstanding stock options granted under the 2016 Incentive Plan
for the purchase of up to 1,665,384 shares of our common stock, with 621,806 of those options vested as of such date, and outstanding RSUs with respect to <B></B>26,368 shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration. </I>Our Board of Directors, or a committee or committees delegated by our Board of Directors, administers the 2016
Incentive Plan. Subject to the terms of the 2016 Incentive Plan, our Board of Directors will have the authority to determine the eligibility for awards and the terms, conditions, and restrictions, including vesting terms, the number of shares
subject to an award, and any performance goals applicable to awards made under the 2016 Incentive Plan. The Board of Directors also will have the authority, subject to the terms of the 2016 Incentive Plan, to construe and interpret the 2016
Incentive Plan and awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Participants. </I>Employees, directors and consultants of the Company and any affiliate are eligible to
participate in the 2016 Incentive Plan, if selected for participation by the plan administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options and Stock Appreciation
Rights. </I>Our Board of Directors may grant incentive stock options, nonstatutory stock options, and stock appreciation rights under the 2016 Incentive Plan, provided that incentive stock options are granted only to employees of the Company, a
parent corporation or a subsidiary corporation. The exercise price of stock options and stock appreciation rights under the 2016 Incentive Plan must equal to at least 100% of the fair market value of our common stock on the date of grant. The term
of an option or stock appreciation right may not exceed ten years; provided, however, that an incentive stock option held by an employee who owns more than 10% of all of our classes of stock, or of certain of our affiliates, may not have a term in
excess of five years, and must have an exercise price of at least 110% of the fair market value of our common stock on the grant date. Subject to the provisions of the 2016 Incentive Plan, the Board of Directors will determine the remaining terms of
the options and stock appreciation rights, including the number of shares subject to the award, vesting, and the nature of any performance measures. Upon a participant&#146;s termination of service, the participant may exercise his or her option or
stock appreciation right, to the extent vested (unless the Board of Directors permits otherwise), as specified in the award agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Awards</I>. Our Board of Directors will decide at the time of grant whether an award
will be in the form of restricted stock, RSUs, or other stock awards. The Board of Directors will determine the terms of the awards, including the number of shares subject to the award, vesting, and the nature of any performance measures. Our Board
of Directors may grant other stock awards that are valued in whole or in part by reference to, or otherwise based on, shares of our common stock, including the appreciation in value thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability of Awards. </I>The 2016 Incentive Plan does not allow options or stock appreciation rights to be transferred other than by
will or the laws of descent and distribution following the participant&#146;s death. Restricted stock awards may be transferable by the participant only upon such terms and conditions as set forth in the award agreement, as the Board of Directors
determines in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments. </I>If any change is made in our common stock, without the receipt of
consideration by us, such as through a merger, consolidation, reorganization, reincorporation, recapitalization, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating
dividend, combination of shares, exchange of shares, change in corporate structure, or any similar equity restructuring transaction, appropriate and proportionate adjustments will be made in the number, class, and price of shares subject to each
outstanding award and the number and kind of shares subject to the plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions.</I> In the event we experience a
corporate transaction under the terms of the 2016 Incentive Plan, subject to the terms of the applicable award agreement or any other written agreement between the participant and the Company or any affiliate, or unless otherwise expressly provided
by the Board of Directors at the time of grant of an award, our Board of Directors may (i) arrange for the surviving or acquiring corporation to assume or continue the stock awards, or to substitute stock awards; (ii) arrange for the assignment of
any reacquisition or repurchase rights held by the Company in respect of common stock issued pursuant to stock awards to the surviving or acquiring corporation; (iii) accelerate the vesting, in whole or in part, of stock awards, and terminate such
awards if not exercised; (iv) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to stock awards; (v) cancel or arrange for the cancellation of stock awards in exchange for such
cash consideration or no consideration as our Board of Directors, in its sole discretion, may consider appropriate; or (vi) make a payment (in the form determined by the Board of Directors) equal to the excess, if any, of the value of the property a
participant would have received upon the exercise of a stock award immediately prior to the effective time of the corporate transaction over any exercise price payable by such participant in connection with such exercise, which payments may be made
subject to conditions or contingencies applicable to shareholders of common stock in the transaction. The Board of Directors is not required to take the same action or actions with respect to all stock awards or portions thereof with respect to all
participants, and may take different actions with respected to vested and unvested portions of stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control. </I>In
the event we experience a change in control under the terms of the 2016 Incentive Plan, an award may be subject to additional acceleration of vesting and exercisability as may be provided in the award agreement or in any other written agreement
between the Company or any affiliate and the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>New Plan Benefits. </I>The Board of Directors has the discretion to grant
awards under the 2016 Incentive Plan, and therefore it is not possible at the time of filing of this prospectus to determine future awards that will be received by our named executive officers or others under the 2016 Incentive Plan. Only directors,
employees, and consultants are eligible for consideration to participate in the 2016 Incentive Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination</I>.
The Board of Directors has the authority to amend or terminate the 2016 Incentive Plan, subject to any stockholder approval required by law. No amendment may impair the rights of a holder of an outstanding award without the consent of such holder.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated 2006 Employee, Director and Consultant Stock Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of the material terms of the Biodesix, Inc. 2006 Employee, Director and Consultant Stock Plan, as amended and
restated in 2008, 2011 and 2013 (the 2006 Incentive Plan). The summary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
below does not contain a complete description of all provisions of the 2006 Incentive Plan and is qualified in its entirety by reference to the plan, a copy of which will be included as an
exhibit to the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2006 Incentive Plan was replaced by the 2016 Incentive
Plan. The 2006 Incentive Plan governs outstanding awards granted prior to the adoption of the 2016 Incentive Plan, but no further awards will be granted pursuant to the 2006 Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares. </I>At the time the 2006 Incentive Plan was replaced by the 2016 Incentive Plan, 135,040 shares of our common stock
remained reserved for issuance under the 2006 Incentive Plan and became available for issuance under the 2016 Incentive Plan. In addition, from and after the date on which the 2016 Incentive Plan was adopted, to the extent that any equity award
granted under the 2006 Incentive Plan expires or otherwise terminates without having been exercised or settled in full, or is settled in cash, or the shares underlying an award are forfeited, cancelled or repurchased by the Company, the shares
subject to such award will become available for future issuance under the 2016 Incentive Plan. As of December 31, 2019, our employees, directors and consultants hold outstanding stock options granted under the 2006 Incentive Plan for the purchase of
up to 250,708&nbsp;shares of our common stock, with <B></B>247,277 of those options vested as of such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration.
</I>Our Board of Directors, or a committee delegated by our board of directors, administers the 2006 Incentive Plan. Subject to the provisions of our 2006 Incentive Plan, the plan administrator has the authority to, among other things, determine the
eligibility for awards and the terms, conditions, and restrictions, including vesting terms, the number of shares subject to an award, and any performance goals applicable to awards made under the 2006 Incentive Plan, construe and interpret the 2006
Incentive Plan and all awards granted thereunder, and to exercise powers and to perform acts necessary or expedient to promote the best interests of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Participants. </I>Employees, directors and consultants of the Company and any affiliate were eligible to participate in the 2006 Incentive
Plan, if selected for participation by the plan administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types and Terms of Awards. </I>Under the 2006 Incentive Plan, we were
authorized to grant stock options, stock appreciation rights, restricted stock awards, RSUs, and other stock awards. Stock options and stock appreciation rights may not be exercised beyond a <FONT STYLE="white-space:nowrap">ten-year</FONT> term (or
such shorter period as required with respect to incentive stock options held by certain holders). The terms of the awards are specified in an underlying award agreement approved by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Termination of Employment</I>. Under the terms of the 2006 Incentive Plan relating to stock options and stock appreciation rights, upon a
participant&#146;s termination of service, the participant may exercise his or her options or stock appreciation rights, to the extent vested (unless the Board of Directors permits otherwise), as specified in the award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments. </I>If any change is made in our common stock, without the receipt of consideration by us, such as through a merger,
consolidation, reorganization, reincorporation, recapitalization, stock dividend, dividend in property other than cash, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure,
or other similar transaction, appropriate and proportionate adjustments will be made in the number, class, and price of shares subject to each outstanding award and the number and kind of shares subject to the plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions.</I> In the event we experience a corporate transaction under the terms of the 2006 Incentive Plan, subject to the
terms of the applicable instrument evidencing the stock award or any other written agreement between the participant and the Company or any affiliate, or unless otherwise expressly provided by the Board of Directors at the time of grant of an award,
the surviving or acquiring corporation may assume or continue any or all outstanding stock awards, or substitute similar stock awards, and any reacquisition or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
repurchase rights held by the Company in respect of common stock issued pursuant to stock awards may be assigned by the Company to its successor in connection with such corporate transaction.
However, if a surviving or acquiring corporation or its respective parent chooses to assume or substitute none or only a portion of the stock awards, the stock awards that have not been assumed, continued, or substituted for similar awards, unless
otherwise determined by the Board of Directors, terminate if not exercised at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by the Company with respect to the stock awards shall lapse.
Notwithstanding the forgoing, in the event a stock award will terminate if not exercised prior to the effective time of a corporate transaction, our Board of Directors may provide, in its sole discretion, that the participant will receive a payment
(in the form determined by the Board of Directors) equal to the excess, if any, of the value of the property the participant would have received upon the exercise of a stock award immediately prior to the effective time of the corporate transaction
over any exercise price payable by such participant in connection with such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control. </I>In the event we
experience a change in control under the terms of the 2006 Incentive Plan, an award may be subject to additional acceleration of vesting and exercisability as may be provided in the award agreement or in any other written agreement between the
Company or any affiliate and the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination</I>. The Board of Directors may, at any time, amend or
terminate the 2006 Incentive Plan as it shall deem advisable, subject to any stockholder approval required by law. No amendment may impair the rights of a holder of an outstanding award without the consent of such holder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Bonus-to-Options</FONT></FONT> Program
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of the material terms of the Biodesix, Inc. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Bonus-to-Options</FONT></FONT> Program, as amended and restated in 2015 (the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Bonus-to-Options</FONT></FONT> Program). The <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Bonus-to-Options</FONT></FONT> Program was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011 and 2015. The summary below does not contain a complete description of all
provisions of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Bonus-to-Options</FONT></FONT> Program and is qualified in its entirety by reference to the plan, a copy of which will be included as an exhibit to the registration
statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Bonus-to-Options</FONT></FONT> Program is only available to the Chief Executive Officer, direct reports to the Chief Executive Officer and vice presidents of the Company. The <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Bonus-to-Options</FONT></FONT> Program allows executives to convert some or all of their annual cash bonus into fully vested, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock
options to purchase shares of our common stock. Executives must declare their intent to participate in this program not later than the last day of the calendar year prior to the taxable year for which bonuses will be awarded. For the first year in
which an executive becomes eligible to participate, the executive has 30 days to declare his or her intent to participate in this program. Executives may declare their intent to convert a percentage of their bonus, up to 100%, or designate a maximum
dollar amount of bonus to be converted into options under this program. None of our named executive officers received option awards under this program during the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price for the options under the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Bonus-to-Options</FONT></FONT>
Program equals the greater of the &#147;Deemed Preferred Price&#148; or the then current price for the shares of our common stock. The Deemed Preferred Price is determined by dividing (i)&nbsp;the sum of the products of (A)&nbsp;the share price in
each of the most recent sales of preferred stock of the Company and (B)&nbsp;with respect to each such sale, the number of months elapsed between such sale and earlier to occur of the next subsequent sale of preferred stock of the Company or the
final day of the calendar year by (ii) 12, rounded down to the nearest whole cent. Options issued under this program must be exercised within a <FONT STYLE="white-space:nowrap">ten-year</FONT> term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A maximum of 1% of the fully-diluted equity, as of December&nbsp;31 of the year for which the bonus was awarded, may be issued in any one year
to the executives. If the executive team has elected to receive options that, in the aggregate, would total more than the maximum allotment for the year, then a maximum percentage of each person&#146;s bonus to be converted to options will be set
such that the 1% threshold is not exceeded. As of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
June&nbsp;30, 2020, our executives held outstanding stock options granted under the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Bonus-to-Options</FONT></FONT> Program for
the purchase of up to 173,233 shares of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain 2020 Actions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Brunel Consulting Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr. Brunel resigned his position as Chairman of the Board of Directors, resigned from any committees of the Board of Directors of which he was
a part, and ceased being a member of the Board of Directors effective September 14, 2020. Thereafter he began his service at the pleasure of the Board of Directors as a Director Emeritus. In addition, Mr. Brunel and the Company entered into a
consulting agreement, dated as of September&nbsp;19, 2020 (the Brunel Consulting Agreement), pursuant to which Mr. Brunel will cease providing services to the Company as an employee on December 31, 2020 and will provide consulting services to the
Company beginning on January 1, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consulting period under the Brunel Consulting Agreement will extend from and including
January&nbsp;1, 2021 through December 31, 2021 unless earlier terminated by either party. During the consulting period Mr.&nbsp;Brunel will be entitled to receive a quarterly consulting fee of $5,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Brunel Consulting Agreement further provides that each stock option held by Mr. Brunel, other than those stock options granted under the
Bonus-to-Options Program, as amended and restated, be amended to provide that the expiration date of such stock option is the earlier of (i) December 31, 2021, (ii) thirty (30) days after the termination of the Brunel Consulting Agreement, and (iii)
the original expiration date of such term. For any outstanding stock options held by Mr. Brunel that remain subject to time-based vesting, the parties agreed that such vesting would continue through January 1, 2021, and that the unvested portion of
any such option would be cancelled. The 2020 Tranche of Mr. Brunel&#146;s Performance-Vested Option remains outstanding and will have the opportunity to vest based on the Company&#146;s recognized revenue in 2020. However, the 2021 Tranche of
Mr.&nbsp;Brunel&#146;s Performance-Vested Option was cancelled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr. Brunel is subject to restrictive covenants as set forth in the Brunel
Consulting Agreement, including perpetual non-disparagement and confidentiality covenants, and, during a restricted period commencing on the effective date of such agreement and expiring on December 31, 2021, covenants regarding non-competition, no
interference with customers and suppliers of the Company, non-solicitation, and no-hire. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Modifications of Prior Equity Grants
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, in September 2020 the Board of Directors of the Company amended the Time-Vested Options and the
Performance-Vested Options as follows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the original vesting schedule for the Time-Vested Awards, two fifths (2/5) of the stock
options vest two years after the vesting commencement date, and the remaining balance vest in a series of thirty-six (36) successive equal monthly installments measured from the second anniversary of the vesting commencement. As amended, twenty-one
sixtieths (21/60) of the Time-Vested Options vest on the date that is twenty-one (21) months after the vesting commencement date, with the remaining balance vesting in a series of thirty-nine (39) successive equal monthly installments measured from
such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the original terms of the Performance-Vested Awards, one third (1/3) of stock options vest (or could have vested) after
each of the first, second and third anniversaries of the vesting commencement date, subject to the Company&#146;s achievement of recognized revenue of at least $31 million, $67 million and $134 million for the years ended December 31, 2019, 2020 and
2021, respectively. The Board of Directors has sole discretion to determine if the performance hurdles are met and to determine the vesting date, and shall make such determinations within 90 days after the end of the applicable fiscal year. For the
2019 Tranche, the Board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Directors determined that the performance hurdle was not met. As a result, one third (1/3) of each executive&#146;s award was cancelled, and the remaining two thirds (2/3) of each of Mr.
Hutton&#146;s and Ms. Cowie&#146;s award is currently outstanding. The 2020 Tranche of Mr. Brunel&#146;s Performance-Vested Option also remains outstanding, and will have the opportunity to vest based on the Company&#146;s recognized revenue in
2020. However, under the terms of the Brunel Consulting Agreement, the 2021 Tranche of Mr. Brunel&#146;s award was cancelled. In addition, in September 2020 and in light of the impact of the COVID-19 pandemic on the Company&#146;s operations and
other considerations, the Board of Directors amended the Performance-Vested Options to provide that the performance hurdles for the 2020 Tranche and the 2021 Tranche are $28.6 million and $51.5 million, respectively. The Board of Directors retains
ultimate discretion to determine whether such performance hurdles have been met, and at the time of the amendment believed that such achievement was uncertain. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with this offering, our board of directors and our current stockholders are expected to approve the 2020 Incentive Plan, to be effective prior to the completion of this offering. The 2020 Incentive Plan, if created, would replace the 2016
Incentive Plan, as described above. The following summary describes what we expect to be the material terms of the 2020 Incentive Plan. This summary is not a complete description of all provisions of the 2020 Incentive Plan and is qualified in its
entirety by reference to the 2020 Incentive Plan, which will be filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purposes of the 2020 Incentive Plan are to align the interests of the Company&#146;s stockholders and those eligible for awards, to retain
officers, directors, employees, and other service providers, and to motivate such persons to act in the long-term best interests of the Company and its stockholders. The 2020 Incentive Plan provides for the grant of incentive stock options (within
the meaning of Section&nbsp;422 of the Code), nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other stock awards. Officers, directors, employees, consultants, agents and
independent contractors who provide services to us or to any subsidiary of ours are eligible to receive such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Subject to
the Plan</I>. The number of shares reserved for issuance under the 2020 Incentive Plan is 1,893,395, plus an annual increase added on the first day of each calendar year, beginning with the calendar year ending December&nbsp;31, 2022, and continuing
until, and including, the calendar year ending December&nbsp;31, 2030. The annual increase will be equal to the lesser of (i)&nbsp;4% of the number of shares of our common stock issued and outstanding as of the December&nbsp;31st of the immediately
preceding calendar year and (ii)&nbsp;such lesser amount determined by the board of directors. Up to 4,790,481 shares of our common stock that may be issued under the 2020 Incentive Plan may be issued in satisfaction of incentive stock option
awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent an equity award granted under the 2020 Incentive Plan (other than any substitute award) or granted under any other
equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Incentive Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares
subject to such award will become available for future grant under the 2020 Incentive Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#146;s tax withholding obligation upon the exercise or settlement
of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Incentive Plan or a Prior Plan, such shares will become available for future grant under the 2020 Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Director Compensation Limit</I>. The aggregate value of cash compensation paid and the grant date fair value of equity awards granted
during any year to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director will not exceed $600,000 for incumbent <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and $1,050,000 for
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors who are first appointed to our board of directors in such year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan
Administration</I>. Our Compensation Committee will administer the 2020 Incentive Plan. Our board of directors has the authority to amend and modify the plan, subject to any stockholder approval required by law or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock exchange rules. Subject to the terms of the 2020 Incentive Plan, our Compensation Committee will have the authority to determine the eligibility for awards and the terms, conditions, and
restrictions, including vesting terms, the number of shares subject to an award, and any performance goals applicable to grants made under the 2020 Incentive Plan. The Compensation Committee also will have the authority, subject to the terms of the
2020 Incentive Plan, to construe and interpret the 2020 Incentive Plan and awards, and amend outstanding awards at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock
Options and Stock Appreciation Rights</I>. Our Compensation Committee may grant incentive stock options, nonstatutory stock options, and stock appreciation rights under the 2020 Incentive Plan, provided that incentive stock options are granted only
to employees. The exercise price of stock options and stock appreciation rights under the 2020 Incentive Plan will be determined by the Compensation Committee, but must equal to at least 100% of the fair market value of our common stock on the date
of grant. The term of an option or stock appreciation right may not exceed ten years; provided, however, that an incentive stock option held by an employee who owns more than 10% of all of our classes of stock, or of certain of our affiliates, may
not have a term in excess of five years, and must have an exercise price of at least 110% of the fair market value of our common stock on the grant date. Subject to the provisions of the 2020 Incentive Plan, the Compensation Committee will determine
the remaining terms of the options and stock appreciation rights, including the number of shares subject to the award, vesting, and the nature of any performance measures. Upon a participant&#146;s termination of service, the participant may
exercise his or her option or stock appreciation right, to the extent vested (unless the Compensation Committee permits otherwise), as specified in the award agreement. The 2020 Incentive Plan prohibits the payment of dividend equivalents with
respect to options and stock appreciation rights and prohibits the repricing of options and stock appreciation rights without stockholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Awards.</I> Our Compensation Committee will decide at the time of grant whether an award will be in the form of restricted stock,
restricted stock units, or other stock awards. The Compensation Committee will determine the terms of the awards, including the number of shares subject to the award, vesting, and the nature of any performance measures. Unless otherwise specified in
the award agreement, the recipient of restricted stock will have voting rights and be entitled to receive dividends with respect to his or her shares of restricted stock, provided that (i)&nbsp;a distribution with respect to shares of common stock,
other than a regular cash dividend, and (ii)&nbsp;a regular cash dividend with respect to shares of common stock that are subject to performance-based vesting conditions, in each case, will be deposited with us and will be subject to the same
restrictions as the underlying shares of common stock. The recipient of restricted stock units will not have voting rights, but his or her award agreement may provide for the receipt of dividend equivalents, provided that any dividend equivalents
with respect to restricted stock units that are subject to performance-based vesting conditions will be subject to the same restrictions as the underlying restricted stock units. Our Compensation Committee may grant other stock awards that are based
on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our
obligations to pay cash under any compensatory plan or arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance Awards</I>. Our Compensation Committee will determine
the value of any performance award, the vesting and nature of the performance measures, and whether the award is denominated or settled in cash or in shares of our common stock. The performance goals applicable to a particular award will be
determined by our Compensation Committee at the time of grant. Any dividends or dividend equivalents with respect to a performance award subject to performance-based vesting conditions will be subject to the same restrictions as such performance
award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability of Awards</I>. The 2020 Incentive Plan does not allow awards to be transferred other than by will or the laws
of inheritance following the participant&#146;s death, and options may be exercised, during the lifetime of the participant, only by the participant. However, an award agreement may permit a participant to assign an award to a family member by gift
or pursuant to a domestic relations order, or to a trust, family limited partnership or similar entity established for one of the participant&#146;s family members. A participant may also designate a beneficiary who will receive outstanding awards
upon the participant&#146;s death. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments</I>. If any change is made in our common stock, without the receipt of
consideration by us, such as through a stock split, stock dividend, extraordinary distribution, recapitalization, combination of shares, exchange of shares or other similar transaction, appropriate adjustments will be made in the number, class, and
price of shares subject to each outstanding award and the numerical share limits contained in the plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control</I>. Subject
to the terms of the applicable award agreement, upon a &#147;change in control&#148; (as defined in the 2020 Incentive Plan), our board of directors may, in its discretion, determine whether some or all outstanding options and stock appreciation
rights will become exercisable in full or in part, whether the restriction period and performance period applicable to some or all outstanding restricted stock awards and restricted stock unit awards will lapse in full or in part and whether the
performance measures applicable to some or all outstanding awards will be deemed to be satisfied. Our board of directors may further require that shares of stock of the corporation resulting from such a change in control, or a parent corporation
thereof, be substituted for some or all of our shares of common stock subject to an outstanding award and that any outstanding awards, in whole or in part, be surrendered to us by the holder and be immediately cancelled by us in exchange for a cash
payment, shares of capital stock of the corporation resulting from or succeeding us, other property or a combination of cash, such shares of stock or other property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clawback</I>. Awards granted under the 2020 Incentive Plan and any cash payment or shares of our common stock delivered pursuant to an
award granted under the 2020 Incentive Plan are subject to forfeiture, recovery, or other action pursuant to the applicable award agreement or any clawback or recoupment policy that we may adopt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination</I>. Our Compensation Committee has the authority to amend, suspend or terminate the 2020 Incentive Plan, subject
to any stockholder approval required by law or stock exchange rules. Our 2020 Incentive Plan will terminate on the <FONT STYLE="white-space:nowrap">ten-year</FONT> anniversary of its approval by our board of directors, unless we terminate it
earlier. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, our board of directors and our current stockholders are expected to approve the ESPP to be effective upon the
completion of this offering. The following summary describes what we expect to be the material terms of the ESPP. This summary is not a complete description of all provisions of the ESPP and is qualified in its entirety by reference to the ESPP,
which will be filed as an exhibit to the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, all of our full-time
employees (including those of our consolidated subsidiaries, other than those subsidiaries excluded from participation by our board of directors or Compensation Committee) are eligible to participate in the ESPP. The Compensation Committee retains
the discretion to change the scope of eligible participants, subject to applicable limitations under the Code. The ESPP permits employees to purchase our common stock through payroll deductions during
<FONT STYLE="white-space:nowrap">six-month</FONT> offering periods. The Compensation Committee retains the discretion to change the duration of future offering periods, subject to applicable limitations under the Code. Subject to applicable Code
limitations, participants may authorize payroll deductions of a specific percentage of compensation of up to 15%, with such deductions being accumulated for <FONT STYLE="white-space:nowrap">six-month</FONT> purchase periods beginning on the first
business day of each offering period and ending on the last business day of each offering period, although the Compensation Committee retains the discretion to change the duration of future purchase periods, subject to the limitations under the
Code. Under the terms of the ESPP, the purchase price per share with respect to an offering period will equal the lesser of (i) 85% of the fair market value of a share of our common stock on the first business day of such offering period and (ii)
85% of the fair market value of a share of our common stock on the last business day of such offering period, although the Compensation Committee has discretion to change the purchase price with respect to future offering periods, subject to the
terms of the ESPP. No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of our stock or the stock of any of our subsidiaries. Except as otherwise determined by the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Compensation Committee with respect to future offering periods, no participant may purchase more than 10,000 shares of our common stock during any offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to adjustment for stock splits, stock dividends or other changes in our capital stock, 338,106 shares of our common stock have been
reserved for issuance under the ESPP. Subject to the adjustment provisions contained in the ESPP, the maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year,
commencing January 2021, by an amount equal to the lesser of (i)&nbsp;1% of the shares of our common stock issued and outstanding on December&nbsp;31 of the immediately preceding calendar year, and (ii)&nbsp;an amount determined by our board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the ESPP, in the event of the proposed dissolution or liquidation of the Company, any offering period then
in progress will terminate immediately prior to the consummation of such proposed dissolution or liquidation, unless otherwise provided by the board of directors, and the board of directors may either provide for the purchase of shares as of the
date on which such offering period terminates or return to each participant the payroll deductions credited to such participant&#146;s account. In the event of a proposed sale of all or substantially all of the assets of the Company, or the merger
of the Company with or into another corporation, each outstanding option under the ESPP will be assumed or an equivalent option substituted by the successor corporation or a parent or subsidiary of the successor corporation, unless the board of
directors determines, in the exercise of its sole discretion, in lieu of such assumption or substitution to either terminate all outstanding options under the ESPP and return to each participant the payroll deductions credited to such
participant&#146;s account or to provide for the offering period in progress to end on a date prior to the consummation of such sale or merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP will be administered by the Compensation Committee or a designee of the Compensation Committee. The ESPP may be amended by our board
of directors or the Compensation Committee but may not be amended without prior stockholder approval to the extent required by Section&nbsp;423 of the Code. The ESPP shall continue in effect until the earlier of (i)&nbsp;the termination of the ESPP
by our board of directors or the Compensation Committee pursuant to the terms of the ESPP and (ii)&nbsp;the <FONT STYLE="white-space:nowrap">ten-year</FONT> anniversary of the effective date of the ESPP, with no new offering periods commencing on or
after such <FONT STYLE="white-space:nowrap">ten-year</FONT> anniversary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_13"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of certain relationships and transactions that exist or have existed or that we have entered into with our
directors, executive officers, or stockholders who are known to us to beneficially own more than five percent of our voting securities and their affiliates and immediate family members, other than compensation arrangements which are described in the
sections titled &#147;Executive Compensation&#148; and <FONT STYLE="white-space:nowrap">&#147;Management&#151;Non-Employee</FONT> Director Compensation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below
were comparable to terms available or the amounts that would be paid or received, as applicable, in <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transaction Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
established a written related party transaction policy that provides procedures for the review of transactions in excess of $120,000 in any year between us and any covered person having a direct or indirect material interest with certain exceptions.
Covered persons include any director, executive officer, director nominee or stockholders known to us to beneficially own 5% or more of our voting securities or any affiliates and immediate family members of the foregoing. Any such related party
transactions shall require advance approval by a majority of our independent directors or by our audit committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Financings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have issued preferred stock from time to time to finance our operations or to make acquisitions. The purchasers of some of our preferred
stock are covered persons or their affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2017, May 2017, July 2017, December 2017, and February 2018, we sold an aggregate
of 35,496,613 shares of Series G Preferred Stock to accredited investors at a purchase price of $0.75 per share for an aggregate purchase price of approximately $26.6&nbsp;million, including conversion of indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, we issued an aggregate of 10,649,904 shares of Series G Preferred Stock to Integrated Diagnostics as consideration for certain
assets and liabilities. See &#147;Business&#151;Material Agreements.&#148; The shares issued at closing also include 2,129,981 shares that were deposited in an escrow account to be used to satisfy any indemnification obligations of the seller that
may arise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, February 2019, and May 2019, we sold an aggregate of 23,923,188 shares of Series H Preferred Stock to
accredited investors at a purchase price of $1.15 per share for an aggregate purchase price of approximately $27.5&nbsp;million, including conversion of indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the number of shares of Series G Preferred Stock and Series H Preferred Stock purchased in the foregoing
transactions by holders of more than 5% of our capital stock and their affiliated entities and our directors. None of our executive officers purchased shares of Series G Preferred Stock or Series H Preferred Stock in the foregoing transactions. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series G<BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series H<BR>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jack Schuler and entities affiliated with Jack Schuler<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,556,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,959,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Patience and entities affiliated with John Patience<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,668,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,182,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manlia Limited<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,913,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,024,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Strobeck and entities affiliated with Matthew Strobeck<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,660,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">996,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Life Sciences Alternative Financing and entities affiliated with Life Sciences Alternative
Financing<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,649,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,651,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lawrence T. Kennedy, Jr. Revocable Trust UAD
6/19/01<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,597,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes shares of preferred stock purchased by Jack Schuler, a member of our Board of Directors who together
with his affiliates holds more than 5% of our capital stock, and by Jack W. Schuler Living Trust, Schuler GC 2010 Continuation Trust, Schuler Grandchildren LLC, Tanya Eva Schuler, Trust, Therese Heidi Shuler, Trust, and Tino Hans Schuler, Trust.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes shares of preferred stock purchased by John Patience Trust, dated July&nbsp;23, 1993 and Patience
Enterprises LP, entities affiliated with John Patience, a member of our Board of Directors who together with his affiliates holds more than 5% of our capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Cawthorn is an affiliate of Manlia Limited, which holds more than 5% of our capital stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes shares of preferred stock purchased by Clajer Capital LLC. Dr.&nbsp;Strobeck, a member of our Board of
Directors is an affiliate of Clajer Capital LLC. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes shares of preferred stock acquired by Life Sciences Alternative Financing LLC and IND Funding LLC in
connection with the acquisition of certain assets and liabilities of Integrated Diagnostics, Inc., which together hold more than 5% of our capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lawrence T. Kennedy, Jr. Revocable Trust UAD 6/19/01 holds more than 5% of our capital stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, each outstanding share of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT>
Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;C Preferred Stock, Series&nbsp;D Preferred
Stock, Series&nbsp;E Preferred Stock, Series&nbsp;F Preferred Stock, Series&nbsp;G Preferred Stock and Series&nbsp;H Preferred Stock will convert into 0.1684664 share of common stock. Upon the closing of this offering, each share of <FONT
STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Preferred Stock will convert into approximately 0.196 shares of common stock. For a description of the material rights and privileges of the preferred stock, see &#147;Description of Capital
Stock&#151;Preferred Stock.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Debt Financings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, we issued $10.0 million in convertible debt (the March 2020 Notes) that was scheduled to mature in August 2020. In August 2020,
the maturity date of this debt was extended to June 30, 2021. The March 2020 Notes were issued in two tranches of $5 million, with the first tranche being funded in March 2020 and the second tranche in June 2020. Interest on the March 2020 Notes is
at 3% per annum and is payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the March 2020 Notes are unpaid, the outstanding
principal and unpaid accrued interest under the March 2020 Notes shall be automatically converted into common stock at the completion of this offering. The conversion price will be equal to 80% of the price per share paid for the common stock sold
in this offering. We may prepay the March 2020 Notes in whole or in part at any time with prior consent of at least two-thirds of the noteholders. In the event of a corporate transaction, the unpaid principal and accrued interest shall become
immediately due and payable in the same form of consideration and on the same terms and conditions as the consideration to be received by the holders of our equity securities in such transaction. The holders of the March 2020 Notes include a number
of our directors and their affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, we issued $6.0&nbsp;million in convertible debt (the December 2019 Notes), that
were scheduled to mature in August 2020. In August 2020, the maturity date of this debt was extended to June&nbsp;30, 2021. The December 2019 Notes were issued in two tranches of $3.0&nbsp;million, with the first tranche funded in December 2019.
Interest on the December 2019 Notes is 3% per annum and is payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date if the December 2019
Notes are unpaid, the outstanding principal and unpaid accrued interest under the December 2019 Notes shall be automatically converted into common stock at the completion of this offering. The conversion price will be equal to 80% of the price per
share paid for the common stock sold in this offering. We may prepay the December 2019 Notes in whole or in part at any time with prior consent of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of noteholders. In the event of a
corporate transaction, the unpaid principal and accrued interest shall become immediately due and payable in the same form of consideration and on the same terms and conditions as the consideration to be received by the holders of our equity
securities in such transaction. The holders of the December 2019 Notes included a number of our directors and their affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August and September 2019 we issued $10.0&nbsp;million in convertible debt (the August 2019
Notes) that was scheduled to mature in August 2020. In August 2020, the maturity date of this debt was extended to June&nbsp;30, 2021. Interest on the August 2019 Notes is 3% per annum and is payable in full upon maturity through the conversion to
Series H Preferred Stock at the original issuance price of $1.15 per share. On or before the maturity date if the August 2019 Notes are unpaid, the outstanding principal and unpaid accrued interest under the August 2019 Notes shall be automatically
converted into common stock at the completion of this offering. The conversion price would be equal to 95% of the price per share paid for the common stock sold in this offering. We may prepay the August 2019 Notes in whole or in part at any time
with prior consent of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the August 2019 noteholders. In the event of a corporate transaction, the unpaid principal and accrued interest shall become immediately due and payable in the same
form of consideration and on the same terms and conditions as the consideration to be received by the holders of our equity securities in such transaction. The holders of the August 2019 Notes include a number of our directors and their affiliates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the December 2019 Notes, the conversion price on the August 2019 Notes was amended to 80% of the price
per share paid for the preferred stock in any subsequent qualified financing or the common stock in an initial public offering. In addition, the conversion price to Series H preferred stock at the maturity date was amended to be 80% of the Series H
original issuance price of $1.15 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into an amended and restated investor rights agreement (IRA) with certain holders of our preferred stock and common
stock, including certain holders of 5% of our capital stock, and including certain members of, and affiliates of, our directors and certain of our executive officers. The IRA provides the holders of our preferred stock with certain registration
rights, including the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. The IRA also provides certain major stockholders with information rights,
which will terminate upon the closing of this offering, and a right of first refusal with regard to certain issuances of our capital stock, which will not apply to, and will terminate upon, the closing of, this offering. After the closing of this
offering, the holders of 20,090,745 shares of common stock issuable on conversion of outstanding preferred stock, will be entitled to rights with respect to the registration of their shares of common stock under the Securities Act under this
agreement. For a description of these registration rights, see &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Agreement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into an amended and restated voting agreement with certain holders of our preferred stock and common
stock, including certain holders of 5% of our capital stock, and including certain members of, and affiliates of, our directors and certain of our executive officers. Pursuant to the Voting Agreement, certain holders of our preferred stock and
common stock have agreed to vote their shares in favor of specified transactions approved by the requisite supermajority of the shares of our voting capital stock held by investors party thereto. The Voting Agreement will terminate upon the closing
of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, we entered into an amended and restated right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement <FONT
STYLE="white-space:nowrap">(Co-Sale</FONT> Agreement) with certain holders of our preferred stock and common stock, including certain holders of 5% of our capital stock, and including certain members of, and affiliates of, our directors and certain
of our executive officers. Pursuant to the <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, we have a right of first refusal in respect of certain sales of securities by certain holders of our capital stock. To the extent we do not
exercise such right in full, certain holders of our preferred stock are granted certain rights of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> in respect of such sales. The <FONT STYLE="white-space:nowrap">Co-Sale</FONT>
Agreement will terminate upon the closing of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contingent Value Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, we entered into a contingent value rights agreement (CVR Agreement) with certain holders of our preferred and common stock,
including several members of our Board. Pursuant to the CVR Agreement, the holders would be eligible to receive in the aggregate up to 15% of any future income and proceeds that we would receive, subject to a number of conditions and offsets, with
respect to ficlatuzumab rights under our agreement with AVEO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directed Share Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the underwriters have reserved up to 5% of the shares of common stock offered by this prospectus, for sale at the initial
public offering price through a directed share program to certain individuals, including our directors, employees and certain of our existing stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of October&nbsp;15, 2020:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC, and therefore it represents sole or
shared voting or investment power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they
beneficially owned, subject to community property laws where applicable. We have deemed shares of common stock subject to options that are currently exercisable or exercisable within 60 days of October&nbsp;15, 2020, to be outstanding and to be
beneficially owned by the person holding the option for the purpose of computing the percentage ownership of that person but have not treated them as outstanding for the purpose of computing the percentage ownership of any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based percentage ownership of common stock before this offering on 20,405,792 shares of common stock outstanding as of
October&nbsp;15, 2020, which includes 20,090,745 shares of common stock resulting from the conversion of all outstanding shares of preferred stock immediately upon the closing of this offering, as if this conversion had occurred as of
October&nbsp;15, 2020. Percentage ownership of common stock after this offering assumes the sale of 4,000,000 shares of common stock in this offering and no exercise of the underwriters&#146; over-allotment option, as well as the conversion of all
convertible debt into an aggregate of 1,848,280 shares of common stock immediately upon the closing of this offering, based on interest accrued through October&nbsp;15, 2020 and the initial public offering price of $18.00 per share. At our request,
in addition to the directed share program described in this prospectus, the underwriters have reserved for sale at the initial public offering price per share approximately 824,000 shares of common stock in this offering to certain individuals,
including directors, existing stockholders and other persons associated with us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below does not reflect any shares of common stock purchased in this offering by the
beneficial owners identified below, including through the directed share program described under &#147;Underwriters&#151;Directed Share Program,&#148; which will increase the percentage of shares owned after the offering by such beneficial owners
from that set forth in the table below. Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o&nbsp;Biodesix, Inc., 2970&nbsp;Wilderness Place, Suite&nbsp;100, Boulder, Colorado 80301. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Beneficially<BR>Owned Prior to</B><br><B>this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;Following<BR>this Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Principal Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jack Schuler and entities affiliated with Jack Schuler<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,704,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,670,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Patience and entities affiliated with John Patience<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,634,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,823,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Life Sciences Alternative Financing LLC and entities affiliated with Life Sciences Alternative
Financing LLC<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,072,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,190,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Cawthorn and entities affiliated with Robert Cawthorn<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,836,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,987,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Lawrence T. Kennedy,
Jr.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,111,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,245,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Hutton<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robin Harper Cowie<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Brunel<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jack Schuler<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,704,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,670,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Patience<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,634,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,823,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Cawthorn<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,836,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,987,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Strobeck, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,024,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Miller<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Watts, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean Franchi<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hany Massarany<SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and named executive officers as a group (14 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,054,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,468,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;58,596 shares of common stock issuable upon the exercise of options held by Jack Schuler
that are vested and exercisable within 60 days of October&nbsp;15, 2020, (b)&nbsp;165,029 shares of common stock issuable upon conversion of (i)&nbsp;49,975 shares of Series D Preferred Stock, (ii)&nbsp;51,317 shares of Series E Preferred Stock,
(iii)&nbsp;218,713 shares of Series F Preferred Stock, (iv)&nbsp;313,690 shares of Series G Preferred Stock and (v)&nbsp;345,906 shares of Series H Preferred Stock held by JS Grandchildren Trust, (c)&nbsp;165,029 shares of common stock issuable upon
conversion of (i)&nbsp;49,975 shares of Series D Preferred Stock, (ii)&nbsp;51,317 shares of Series E Preferred Stock, (iii)&nbsp;218,713 shares of Series F Preferred Stock, (iv)&nbsp;313,690 shares of Series G Preferred Stock and (v)&nbsp;345,906
shares of Series H Preferred Stock held by Schuler Descendants Trust, (d)&nbsp;344,932 shares of common stock issuable upon conversion of (i)&nbsp;83,085 shares of Series C Preferred Stock, (ii)&nbsp;99,950 shares of Series D Preferred Stock,
(iii)&nbsp;107,834 shares of Series E Preferred Stock, (iv)&nbsp;437,427 shares of Series F Preferred Stock, (v)&nbsp;627,380 shares of Series G Preferred Stock and (vi)&nbsp;691,812 shares of Series H Preferred Stock held by Schuler Grandchildren
LLC, (e)&nbsp;354,530 shares of common stock issuable upon conversion of (i)&nbsp;83,416 shares of Series C Preferred Stock, (ii)&nbsp;99,950 shares of Series D Preferred Stock, (iii)&nbsp;107,834 shares of Series E Preferred Stock,
(iv)&nbsp;437,427 shares of Series F Preferred Stock, (v)&nbsp;627,380 shares of Series G Preferred Stock and (vi)&nbsp;736,577 shares of Series H Preferred Stock held by Therese Heidi Schuler, Trust, (f)&nbsp;352,530 shares of common stock issuable
upon conversion of (i)&nbsp;83,416 shares of Series C Preferred Stock, (ii)&nbsp;99,950 shares of Series D Preferred Stock, (iii)&nbsp;107,834 shares of Series E Preferred Stock, (iv)&nbsp;437,427 shares of Series F Preferred Stock, (v)&nbsp;627,380
shares of Series G Preferred Stock and (vi)&nbsp;736,577 shares of Series H Preferred Stock held by Tanya Eva Schuler, Trust, (g)&nbsp;4,913,087 shares of common stock issuable upon conversion of (i)&nbsp;1,454,545 shares of Series B Preferred
Stock, (ii)&nbsp;1,250,000 shares of Series B-1 Preferred Stock, (iii)&nbsp;333,333 shares of Series C Preferred Stock, (iv)&nbsp;3,101,784 shares of Series D Preferred Stock, (v)&nbsp;1,759,853 shares of
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Series E Preferred Stock, (vi)&nbsp;6,273,780 shares of Series F Preferred Stock, (vii)&nbsp;9,419,362 shares of Series G Preferred Stock, and (viii)&nbsp;5,366,411 shares of Series H Preferred
Stock held by Jack W. Schuler Living Trust and (h)&nbsp;352,530 shares of common stock issuable upon conversion of (i)&nbsp;83,416 shares of Series C Preferred Stock, (ii)&nbsp;99,950 shares of Series D Preferred Stock, (iii)&nbsp;107,834 shares of
Series E Preferred Stock, (iv)&nbsp;437,427 shares of Series F Preferred Stock, (v)&nbsp;627,380 shares of Series G Preferred Stock and (vi)&nbsp;736,577 shares of Series H Preferred Stock held by Tino Hans Schuler, Trust. The number of shares
listed as beneficially owned after this offering includes (a)&nbsp;25,271 shares of common stock to be issued to JS Grandchildren Trust, (b)&nbsp;17,454 shares of common stock to be issued to Schuler Descendants Trust, (c)&nbsp;37,535 shares of
common stock to be issued to Schuler Grandchildren LLC, (d)&nbsp;44,239 shares of common stock to be issued to Therese Heidi Schuler, Trust, (d)&nbsp;44,239 shares of common stock to be issued to Tanya Eva Schuler, Trust, (e)&nbsp;752,829 shares of
common stock to be issued to Jack W. Schuler Living Trust, and (f)&nbsp;44,239 shares of common stock to be issued to Tino Hans Schuler, Trust, in each case upon the conversion of convertible debt immediately upon closing of this offering, based on
interest accrued through October&nbsp;15, 2020 and the initial public offering price of $18.00 per share. Mr. Schuler disclaims beneficial ownership of all shares other than those held by Mr. Schuler personally or by the Jack W. Schuler Living
Trust. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 58,596 shares of common stock issuable upon the exercise of options held by John Patience that
are vested and exercisable within 60 days of October 15, 2020, (b) 1,829,368 shares of common stock issuable upon conversion of (i) 1,454,545 shares of Series B Preferred Stock, (ii) 250,000 shares of Series D Preferred Stock, (iii) 809,200 shares
of Series E Preferred Stock, (iv) 3,205,681 shares of Series F Preferred Stock, (v) 957,114 shares of Series G Preferred Stock and (vi) 4,182,413 shares of Series H Preferred Stock held by Patience Enterprises LP and (c) 2,747,015 shares of common
stock issuable upon conversion of (i) 1,250,000 shares of Series B-1 Preferred Stock, (ii) 666,666 shares of Series C Preferred Stock, (iii) 2,932,534 shares of Series D Preferred Stock, (iv) 1,484,624 shares of Series E Preferred Stock, (v)
3,055,837 shares of Series F Preferred Stock and (vi) 6,711,816 shares of Series G Preferred Stock held by John Patience Trust, dated July 23, 1993. The number of shares listed as beneficially owned after this offering includes (a) 81,502 shares of
common stock to be issued to Patience Enterprises LP, (b) 64,338 shares of common stock to be issued to John Patience Trust, dated July 23, 1993, and (c) 42,496 shares of common stock to be issued to Patience Capital Partners LLC, in each case upon
the conversion of convertible debt immediately upon closing of this offering, based on interest accrued through October 15, 2020 and the initial public offering price of $18.00 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 1,794,150 shares of common stock issuable upon conversion of 10,649,904 shares of Series G
Preferred Stock held by IND Funding LLC and (b) 278,203 shares of common stock issuable upon conversion of 1,651,389 shares of Series H Preferred Stock held by Life Sciences Alternative Financing LLC. The number of shares listed as beneficially
owned after this offering includes (a) 102,224 shares of common stock to be issued to IND Funding LLC, and (b) 15,850 shares of common stock to be issued to Life Science Alternative Financing LLC, in each case upon the conversion of convertible debt
immediately upon closing of this offering, based on interest accrued through October 15, 2020 and the initial public offering price of $18.00 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 1 share of common stock, (b) 58,596 shares of common stock issuable upon the exercise of
options held by Robert Cawthorn that are vested and exercisable within 60 days of October 15, 2020 and (c) 1,778,169 shares of common stock issuable upon conversion of (i) 392,292 shares of Series A-1 Preferred Stock, (ii) 60,000 shares of Series
A-2 Preferred Stock, (iii) 120,665 shares of Series A-3 Preferred Stock, (iv) 187,273 shares of Series B Preferred Stock, (v) 312,500 shares of Series B-1 Preferred Stock, (vi) 233,333 shares of Series C Preferred Stock, (vii) 299,000 shares of
Series D Preferred Stock, (viii) 452,602 shares of Series E Preferred Stock, (ix) 1,508,529 shares of Series F Preferred Stock, (x) 4,913,376 shares of Series G Preferred Stock and (xi) 2,024,338 shares of Series H Preferred Stock held by Manlia
Limited. The number of shares listed as beneficially owned after this offering includes 150,709 shares of common stock to be issued to Manlia Limited upon the conversion of convertible debt immediately upon closing of this offering, based on
interest accrued through October 15, 2020 and the initial public offering price of $18.00 per share. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 774,044 shares of common stock issuable upon conversion of (i) 2,666,668 shares of Series G
Preferred Stock and (ii) 1,927,983 shares of Series H Preferred Stock held by Lawrence T. Kennedy, Jr. Revocable Trust UAD 6/19/01 and as amended from time to time and (b) 337,368 shares of common stock issuable upon conversion of (i) 1,333,332
shares of Series G Preferred Stock and (ii) 669,253 shares of Series H Preferred Stock held by Lawrence T. Kennedy, Jr. Perpetuity Trust UAD 6/30/16. The number of shares listed as beneficially owned after this offering includes 133,689 shares of
common stock to be issued to Lawrence T. Kennedy, Jr. Perpetuity Trust UAD 6/30/16 upon the conversion of convertible debt immediately upon closing of this offering, based on interest accrued through October 15, 2020 and the initial public offering
price of $18.00 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 90,268 shares of common stock issuable upon the exercise of options held by Scott Hutton that are
vested and exercisable within 60 days of October 15, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 106,931 shares of common stock issuable upon the exercise of options held by Robin Harper Cowie
that are vested and exercisable within 60 days of October 15, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 76,732 shares of common stock, (b) 316,709 shares of common stock issuable upon the exercise of
options held by David Brunel that are vested and exercisable within 60 days of October 15, 2020 and (c) 31,098 shares of common stock issuable upon conversion of (i) 660 shares of Series A-1 Preferred Stock, (ii) 110,399 shares of Series A-3
Preferred Stock and (iii) 73,540 shares of Series B Preferred Stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 6,704,263 shares beneficially owned by Jack Schuler and entities affiliated with Jack Schuler, as
set forth in footnote (1). The number of shares listed as beneficially owned after this offering includes 965,806 shares of common stock to be issued to entities affiliated with Jack Schuler upon the conversion of convertible debt immediately upon
closing of this offering, based on interest accrued through October&nbsp;15, 2020 and the initial public offering price of $18.00 per share, as set forth in footnote&nbsp;(1). Mr. Schuler disclaims beneficial ownership of all shares other than those
held by Mr. Schuler personally or by the Jack W. Schuler Living Trust. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 4,634,979 shares beneficially owned by John Patience and entities affiliated with John Patience, as
set forth in footnote (2). The number of shares listed as beneficially owned after this offering includes 188,336 shares of common stock to be issued to entities affiliated with John Patience upon the conversion of convertible debt immediately upon
closing of this offering, based on interest accrued through October&nbsp;15, 2020 and the initial public offering price of $18.00 per share, as set forth in footnote&nbsp;(2). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,836,766 shares beneficially owned by Robert Cawthorn and entities affiliated with Robert
Cawthorn, as set forth in footnote (4). The number of shares listed as beneficially owned after this offering includes 150,709 shares of common stock to be issued to an entity affiliated with Robert Cawthorn upon the conversion of convertible debt
immediately upon closing of this offering, based on interest accrued through October 15, 2020 and the initial public offering price of $18.00 per share, as set forth in footnote&nbsp;(4). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 61,965 shares of common stock issuable upon the exercise of options held by Dr. Matthew
Strobeck that are vested and exercisable within 60 days of October 15, 2020 and (b) 831,747 shares of common stock issuable upon conversion of (i) 100,000 shares of Series C Preferred Stock, (ii) 686,250 shares of Series&nbsp;D Preferred Stock,
(iii) 750,907 shares of Series E Preferred Stock, (iv) 903,516 shares of Series F Preferred Stock, (v) 1,660,268 shares of Series G Preferred Stock and (vi) 836,231 shares of Series H Preferred Stock held by Dr. Matthew Strobeck and (c) 21,973
shares of common stock issuable upon conversion of 130,433&nbsp;shares of Series H Preferred Stock held by Clajer Capital LLC. The number of shares listed as beneficially owned after this offering includes (a) 76,539 shares of common stock to be
issued to Matthew Strobeck, (b)&nbsp;18,692 shares of common stock to be issued to Clajer Capital LLC, and (c) 14,072 shares of common stock to be issued to the minor children of Matthew Strobeck, in each case upon the conversion of convertible debt
immediately upon closing of this offering, based on interest accrued through October&nbsp;15, 2020 and the initial public offering price of $18.00 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 61,965 shares of common stock issuable upon the exercise of options held by Mark Miller that
are vested and exercisable within 60 days of October 15, 2020, (b) 183,484 shares of common stock issuable upon conversion of (i) 726,750 shares of Series D Preferred Stock and (ii) 362,398 shares of Series&nbsp;E Preferred Stock held by
Tiger&#146;s Family LLC and (c) 11,230 shares of common stock issuable upon conversion of 66,666 shares of Series C Preferred Stock held by Mark C. Miller Trust. Mark Miller </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
disclaims beneficial ownership of the shares the 362,398 shares of Series E Preferred Stock held by Tiger&#146;s Family LLC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 49,806 shares of common stock issuable upon the exercise of options held by Dr. Charles Watts that
are vested and exercisable within 60 days of October&nbsp;15, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 19,576 shares of common stock issuable upon the exercise of options held by Jean Franchi that are
vested and exercisable within 60 days of October&nbsp;15, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 14,649 shares of common stock issuable upon the exercise of options held by Hany Massarany that are
vested and exercisable within 60 days of October&nbsp;15, 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The description below of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated
bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws to be in effect upon the closing of this offering, which are filed as exhibits to the registration
statement of which this prospectus is part, and by the applicable provisions of Delaware law. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our amended and restated certificate of incorporation will authorize us to issue up to 200,000,000 shares of
common stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001 par value per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;15,
2020, there were 315,047 shares of common stock issued and outstanding, held by 60 stockholders of record. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;15, 2020,
after giving effect to the conversion of all outstanding shares of preferred stock into 20,090,745 shares of common stock and the conversion of all convertible debt into 1,848,280 shares of common stock, based on the initial public offering price of
$18.00 per share, there would have been 22,254,072 shares of common stock issued and outstanding, held by 344 stockholders of record. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the
election of directors. Under our amended and restated certificate of incorporation and amended and restated bylaws, our stockholders will not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock
entitled to vote in any election of directors can elect all of the directors standing for election. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any then-outstanding preferred stock, the holders of common stock are entitled to receive ratably
those dividends, if any, as may be declared from time to time by the Board of Directors out of legally available funds. We do not anticipate paying any cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in the net assets legally
available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preemptive or Similar Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable
to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October 15, 2020, there were 118,766,273 shares of preferred stock outstanding, which will be converted into 20,090,745 shares of common
stock upon the closing of the offering. On the closing of this offering and under our amended and restated certificate of incorporation, our Board of Directors may, without further action by our stockholders, fix the rights, preferences, privileges
and restrictions of up to an aggregate of 5,000,000 shares of preferred stock in one or more series and authorize their issuance. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of
redemption, liquidation preferences and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. Any issuance of preferred stock could adversely affect the
voting power of holders of common stock and the likelihood that such holders would receive dividend payments and payments on liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deterring or preventing a
change of control or other corporate action. No shares of preferred stock will be outstanding immediately following the closing of this offering. We have no present plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Financings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have issued preferred stock from time to time to finance our operations or to make acquisitions. The purchasers of some of our preferred
stock are covered persons or their affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2017, May 2017, July 2017, December 2017, and February 2018, we sold an aggregate
of 35,496,613 shares of Series&nbsp;G Preferred Stock to accredited investors at a purchase price of $0.75 per share for an aggregate purchase price of approximately $26.6&nbsp;million, including conversion of indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, we issued an aggregate of 10,649,904 shares of Series&nbsp;G Preferred Stock to Integrated Diagnostics as consideration for
certain assets and liabilities. See &#147;Business&#151;Material Agreements.&#148; The shares issued at closing also include 2,129,981 shares that were deposited in an escrow account to be used to satisfy any indemnification obligations of the
seller that may arise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, February 2019, and May 2019, we sold an aggregate of 23,923,188 shares of Series&nbsp;H Preferred
Stock to accredited investors at a purchase price of $1.15 per share for an aggregate purchase price of approximately $27.5&nbsp;million, including conversion of indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, each outstanding share of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> Preferred Stock, <FONT
STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred Stock, <FONT STYLE="white-space:nowrap">Series&nbsp;A-3</FONT> Preferred Stock, Series&nbsp;B Preferred Stock, Series&nbsp;C Preferred Stock, Series D Preferred Stock, Series&nbsp;E
Preferred Stock, Series&nbsp;F Preferred Stock, Series&nbsp;G Preferred Stock and Series&nbsp;H Preferred Stock will convert into 0.1684664 shares of common stock. Upon the closing of this offering, each share of
<FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Preferred Stock will convert into approximately 0.196 shares of common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Debt
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The March 2020 Notes were scheduled to mature in August 2020, but in August 2020 we extended the maturity date of this debt to
June&nbsp;30, 2021. The March 2020 Notes were issued in two tranches of $5.0&nbsp;million, with the first tranche funded in March 2020 and the second tranche in June 2020. Interest on the March 2020 Notes is 3% per annum and is payable in full upon
maturity through the conversion to Series&nbsp;H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date if the March 2020 Notes are unpaid, the outstanding principal and unpaid accrued interest under
the March 2020 Notes shall be automatically converted into common stock at the completion of this offering. The conversion price will be equal to 80% of the price per share paid for the common stock sold in this offering. We may prepay the March
2020 Notes in whole or in part at any time with prior consent of at least two-thirds of the noteholders. In the event of a corporate transaction, the unpaid principal and accrued interest shall become immediately due and payable in the same form of
consideration and on the same terms and conditions as the consideration to be received by the holders of our equity securities in such transaction. The holders of the March 2020 Notes include a number of our directors and their affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The December 2019 Notes were scheduled to mature in August 2020, but in August 2020 we extended
the maturity date of this debt to June&nbsp;30, 2021. The December 2019 Notes were issued in two tranches of $3.0&nbsp;million, with the first tranche funded in December 2019 and the second tranche in February 2020. Interest on the December 2019
Notes is 3% per annum and is payable in full upon maturity through the conversion to Series&nbsp;H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date if the December 2019 Notes are unpaid, the
outstanding principal and unpaid accrued interest under the December 2019 Notes shall be automatically converted into common stock at the completion of this offering. The conversion price will be equal to 80% of the price per share paid for the
common stock sold in this offering. We may prepay the December 2019 Notes in whole or in part at any time with prior consent of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the noteholders. In the event of a corporate transaction,
the unpaid principal and accrued interest shall become immediately due and payable in the same form of consideration and on the same terms and conditions as the consideration to be received by the holders of our equity securities in such
transaction. The holders of the December 2019 Notes include a number of our directors and their affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The August 2019 Notes were
scheduled to mature in August 2020, but in August 2020 we extended the maturity date of this debt to June&nbsp;30, 2021. Interest on the August 2019 Notes is 3% per annum and is payable in full upon maturity through the conversion to Series&nbsp;H
Preferred Stock at the original issuance price of $1.15 per share. On or before the maturity date if the August 2019 Notes are unpaid, the outstanding principal and unpaid accrued interest under the August 2019 Notes shall be automatically converted
into common stock at the completion of this offering. The conversion price would be equal to 95% of the price per share paid for the common stock sold in this offering. We may prepay the August 2019 Notes in whole or in part at any time with prior
consent of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the August 2019 noteholders. In the event of a corporate transaction, the unpaid principal and accrued interest shall become immediately due and payable in the same form of
consideration and on the same terms and conditions as the consideration to be received by the holders of our equity securities in such transaction. The holders of the August 2019 Notes include a number of our directors and their affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discounts on the automatic conversions created a put option liability that was separated from the March 2020 Notes. The estimated value of
the put option liability as of the issuance of the March 2020 Notes at June&nbsp;30, 2020 was $2.5&nbsp;million. The put option liability was reflected as a debt discount on the March 2020 Notes, which is being amortized over the term of the March
2020 Notes. The unamortized debt discount was $1.4&nbsp;million as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discounts on the automatic conversions
created a put option liability that was separated from the December 2019 Notes. The estimated value of the put option liability as of the issuance of the December 2019 Notes and June&nbsp;30, 2020 was $1.5&nbsp;million. The put option liability was
reflected as a debt discount on the December 2019 Notes, which is being amortized over the term of the December 2019 Notes. The unamortized debt discount was $0.3&nbsp;million as of June&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discounts on the automatic conversions created a put option liability that was separated from the August 2019 Notes. The estimated value
of the put option liability as of the issuance of the August 2019 Notes was $0.5&nbsp;million. The put option liability was reflected as a debt discount on the August 2019 Notes which is being amortized over the term of the August 2019 Notes. The
unamortized debt discount was $0.1&nbsp;million as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the December 2019 Notes, the
conversion price on the August 2019 Notes was amended to 80% of the price per share paid for the preferred stock in any subsequent qualified financing or the common stock in an initial public offering. In addition, the conversion price to
Series&nbsp;H preferred stock at the maturity date was amended to be 80% of the Series&nbsp;H original issuance price of $1.15 per share. The changes to the discounts on the conversions of the August 2019 Notes created an increase to the put option
liability on the August 2019 Notes of $2.0&nbsp;million to a total estimated value of $2.5&nbsp;million as of December&nbsp;31, 2019. The increase in the value of the put option liability was reflected as a change in put option in the accompanying
2019 statement of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, accrued interest of $0.4&nbsp;million is included in the convertible
debt balance included on the accompanying balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have issued warrants from time to time to purchase shares of preferred stock in conjunction with the sale of preferred stock and debt. The
grant date fair value and fair value at each reporting date of the warrants was determined using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model with weighted average assumptions relatively consistent with those for
our granted stock options, other than term, which is the contractual term of the warrant and the use of the exercise price and current estimated fair value of the respective series of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the activity for convertible preferred stock warrants outstanding (in thousands, except weighted average exercise
price): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series G</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding - December 31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(902</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding - December 31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding - June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining contractual life at June&nbsp;30, 2020 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center">7.5&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October 15, 2020, options to purchase an aggregate of 249,370 shares of common stock were outstanding under our 2006 Incentive Plan. As
of October 15, 2020, options to purchase an aggregate of 2,473,941 shares of common stock were outstanding under our 2016 Incentive Plan. For additional information regarding the terms of these plans, see the section titled &#147;Executive
Compensation&#151;Employee Benefit Plans.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to an IRA which provides that certain holders of shares of common stock, including those shares of common stock that will be
issued upon conversion of preferred stock in connection with this offering. These shares are referred to as registrable securities. The holders of these registrable securities possess registration rights pursuant to the terms of the IRA and are
described in additional detail below. We, along with certain of our stockholders, are parties to the IRA. We entered into the IRA in connection with the issuance of Series&nbsp;H Preferred Stock in October 2018. The following summary discusses
certain material provisions of the IRA and is qualified by the full text of the agreement, which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration of shares of common stock pursuant to the exercise of registration rights
described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the registration expenses (other than underwriting discounts,
selling commissions and stock transfer taxes) of the shares registered pursuant to the demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registrations described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, in an underwritten offering, if we determine in good faith in consultation with the underwriters, we have the right, subject to
specified conditions, to limit the number of shares the holders may include. The demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights described below will terminate on the date five years following the
closing part of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of an aggregate of 20,090,745 shares of common stock issuable upon conversion of outstanding shares of preferred stock will be
entitled to certain demand registration rights. Ending on the date six months following the effective date of the registration statement of which this prospectus is a part, upon the written request of the holders of a majority of our registrable
securities then outstanding that we file&nbsp;a registration statement under the Securities Act covering at least a majority of our registrable securities then outstanding, or lesser percent if the anticipated aggregate offering price, net of
underwriting discounts and commissions, would exceed $5.0&nbsp;million we are obligated to register the sale of all registrable securities that the holders may request in writing to be registered. We are required to effect no more than two
registration statements that are declared or ordered effective. We may postpone the filing of a registration statement for up to 120&nbsp;days once in a <FONT STYLE="white-space:nowrap">12-month</FONT> period if in the good faith judgment of our
Board of Directors such registration would be seriously detrimental to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of registrable securities will be entitled to certain piggyback registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we register any of our securities for public sale, either for our own account or for the account of other security holders, we will also
have to register all registrable securities that the holders of such securities request in writing be registered. This piggyback registration right does not apply to a registration relating to any of our stock plans, stock purchase or similar plan,
a transaction under Rule&nbsp;145 of the Securities Act or a registration related to stock issued upon conversion of debt securities. We, based on consultation with the underwriters of any underwritten offering will have the right<B> </B>to limit
the number of shares registered by these holders if the underwriters determine that including all registrable securities will jeopardize the success of the offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of at least 10% of the registrable securities then outstanding will be entitled to certain registration rights on Form <FONT
STYLE="white-space:nowrap">S-3.</FONT> The holders of these shares can request that we register all or a portion of their shares on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> if we are eligible to file&nbsp;a registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and the aggregate price to the public of the shares offered is in excess of $5.0&nbsp;million. We are required to effect no more than two <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT>
registration statements that are declared or ordered effective in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. We may postpone the filing of a registration statement for up to 120&nbsp;days not more than once in a <FONT
STYLE="white-space:nowrap">12-month</FONT> period if in the good faith judgment of our Board of Directors such registration would be seriously detrimental to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any
business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before such date, the Board of Directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon closing of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the
interested stockholder) those shares owned (i)&nbsp;by persons who are directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or after such date, the business combination is approved by the Board of Directors and authorized at an annual
or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines a &#147;business combination&#148; to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
or any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested
stockholder&#148; as an entity or person who, together with the person&#146;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the
outstanding voting stock of the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision
in its original certificate of incorporation or an express provision in its amended and restated certificate of incorporation or amended and restated bylaws resulting from a stockholders&#146; amendment approved by at least a majority of the
outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Certificate of Incorporation and Bylaws to be in Effect Upon the Closing of this Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other things, our amended and restated certificate of incorporation and amended and restated bylaws will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit our Board of Directors to issue up to 5,000,000 shares of preferred stock, with any rights, preferences
and privileges as they may designate, including the right to approve an acquisition or other change of control; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the authorized number of directors may be changed only by resolution of our Board of Directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our Board of Directors will be classified into three classes of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, subject to the rights of any series of preferred stock to elect directors, directors may only be
removed for cause, which removal may be effected, subject to any limitation imposed by law, by the holders of at least 66&nbsp;2/3% of the voting power of all of our then-outstanding shares of the capital stock entitled to vote generally at an
election of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be
filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special
meeting of stockholders and not be taken by written consent or electronic transmission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates
for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of our stockholders may be called only by the chairman of our Board of Directors,
our chief executive officer or by our Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common
stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of any of these provisions would require approval by the holders of at least 66&nbsp;2/3% of the voting power of all of our
then-outstanding capital stock entitled to vote generally in the election of directors, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
combination of these provisions will make it more difficult for our existing stockholders to replace our Board of Directors as well as for another party to obtain control of us by replacing our Board of Directors. Since our Board of Directors has
the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it
possible for our Board of Directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions are intended to enhance the likelihood of continued stability in the composition of our Board of Directors and its policies
and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such
provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market
price of our stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware will be the exclusive
forum for: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a breach of fiduciary duty owed by any director, officer or other employee to us or our stockholders; (iii)&nbsp;any action asserting a
claim against us or any director or officer or other employee arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended and restated bylaws; or (iv)&nbsp;any action asserting a claim against us or any director or officer or other employee that is governed by the internal affairs doctrine. Notwithstanding
the foregoing, the exclusive forum provision will not apply to any claim to enforce any liability or duty created by the Exchange Act or the Securities Act and for which the federal courts have exclusive jurisdiction. Our amended and restated
certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Exchange Act or the Securities Act.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled &#147;Executive Compensation&#151;Limitations on Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is
currently not listed on any securities exchange. We have been approved to list our common stock on The Nasdaq Global Market under the symbol &#147;BDSX&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. The transfer agent&#146;s address 150 Royall Street, Canton, Massachusetts 02021, and its telephone number is
<FONT STYLE="white-space:nowrap">(800)&nbsp;962-4284.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, no public market existed for our common stock. Future sales of shares of our common stock in the public market after
this offering, and the availability of shares for future sale, could adversely affect the market price of our common stock prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after
this offering due to contractual and legal restrictions on resale. Nonetheless, sales of substantial amounts of our common stock, or the perception that these sales could occur, could adversely affect prevailing market prices for our common stock
and could impair our future ability to raise equity capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales of Restricted Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of shares outstanding on October 15, 2020, upon the closing of this offering, 26,254,072&nbsp;shares of common stock will
be outstanding, assuming no exercise of the underwriters&#146; over-allotment option, and no exercise of outstanding options. All of the shares of common stock sold in this offering will be freely tradable without restrictions or further
registration under the Securities Act, except for any shares sold to our &#147;affiliates,&#148; as that term is defined under Rule&nbsp;144 under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining shares of common stock and common stock subject to stock options will be on issuance &#147;restricted securities,&#148; as that
term is defined in Rule&nbsp;144 under the Securities Act. Restricted securities may be sold in the public market only if registered under the Securities Act or if they qualify for exemption from registration under Rules&nbsp;144 or 701 under the
Securities Act, which are summarized below. Restricted securities may also be sold outside of the United States to non-United States persons in accordance with Rule&nbsp;904 of Regulation&nbsp;S. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, persons who
have beneficially owned restricted shares of our common stock for at least six months, and any of our affiliates who own either restricted or unrestricted shares of our common stock, are entitled to sell their securities without registration with
the SEC under an exemption from registration provided by Rule&nbsp;144 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a person who has
beneficially owned restricted shares of our common stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the
90&nbsp;days preceding, a sale, (ii)&nbsp;we have been subject to the Exchange Act periodic reporting requirements for at least 90&nbsp;days before the sale, and (iii)&nbsp;we are current in our Exchange Act reporting at the time of sale. Persons
who have beneficially owned restricted shares of our common stock for at least six months, but who are our affiliates at the time of, or any time during the 90&nbsp;days preceding, a sale, would be subject to additional restrictions, by which such
person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of common stock then outstanding, which will equal approximately 264,207 shares
immediately after the closing of this offering based on the number of shares of common stock outstanding as of October 15, 2020; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock during the four calendar weeks preceding the filing of a
notice on Form&nbsp;144 with respect to the sale; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, in each case that we have been subject to the Exchange Act periodic
reporting requirements for at least 90&nbsp;days before the sale. Such sales both by affiliates and by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice provisions
of Rule&nbsp;144. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Substantially all of the restricted shares are subject to
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and in the section titled &#147;Underwriters.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;701
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule&nbsp;701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon
Rule&nbsp;144 but without compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees, executive officers or directors who purchased shares under a written compensatory plan or contract may
be entitled to rely on the resale provisions of Rule&nbsp;701, but all holders of Rule&nbsp;701 shares are required to wait until 90&nbsp;days after the date of this prospectus before selling their shares. However, substantially all Rule&nbsp;701
shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and in the section titled &#147;Underwriters&#148; and will become eligible for sale upon the expiration of the restrictions set forth in those
agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> Registration Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As soon as practicable after the closing of this offering, we intend to file with the SEC one or more registration statements on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to register the shares of common stock that are issuable pursuant to our 2006 Incentive Plan and 2016 Incentive Plan. These registration statements will become effective
immediately upon filing. Shares covered by these registration statements will then be eligible for sale in the public markets, subject to vesting restrictions, the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below
and Rule&nbsp;144 limitations applicable to affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and all of our directors and officers, as well as the other holders of substantially all of our common stock and securities convertible into
or exercisable or exchangeable for our common stock outstanding immediately upon the closing of this offering, have agreed with Morgan Stanley&nbsp;&amp; Co. LLC and William Blair&nbsp;&amp; Company, L.L.C. on behalf of the underwriters that, for a
period ending on and including the 180th&nbsp;day following the date of this prospectus, subject to certain exceptions, we and they will not, and will not publicly disclose an intention to, offer, pledge, sell, contract to sell, sell any option or
contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or
exercisable or exchangeable for shares of common stock, file any registration statement with the SEC relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock, or enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock, except with the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC and William
Blair&nbsp;&amp; Company, L.L.C., in their sole discretion, with or without notice, on behalf of the underwriters. See the section titled &#147;Underwriters&#148; for a more complete description of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements with the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the restrictions contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements described above, we have entered into agreements with certain security holders, including our IRA and our standard forms of notice of exercise under our 2006 Incentive Plan and our 2016 Incentive Plan, that contain market <FONT
STYLE="white-space:nowrap">stand-off</FONT> provisions imposing restrictions on the ability of such security holders to offer, sell or transfer our equity securities for a period ending on and including the 180th&nbsp;day following the date of this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, the holders of 20,090,745 shares of our common stock issuable upon conversion of outstanding shares of
preferred stock, or their transferees, will be entitled to certain rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely
tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directed Share Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request,
the underwriters have reserved up to 5% of the shares of common stock offered by this prospectus, for sale at the initial public offering price through a directed share program to certain individuals, including our directors, employees and certain
of our existing stockholders. Shares purchased through the directed share program will not be subject to lockup restrictions with the underwriters, except in the case of shares purchased by any of our officers or directors, employees and certain of
our existing stockholders. For additional information, see the section titled &#147;Underwriters&#151;Directed Share Program.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_17"></A>MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO <FONT STYLE="white-space:nowrap">NON-UNITED</FONT> STATES HOLDERS OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material United States federal income tax consequences to non-United States holders (as defined below) of
the acquisition, ownership and disposition of our common stock issued pursuant to this offering. This discussion is not a complete analysis of all potential United States federal income tax consequences relating thereto, does not address the
potential application of the Medicare contribution tax on net investment income, and does not address any estate or gift tax consequences or any tax consequences arising under any state, local or foreign tax laws, or any other United States federal
tax laws. This discussion is based on the Code and applicable Treasury Regulations promulgated thereunder, judicial decisions and published rulings and administrative pronouncements of the Internal Revenue Service (IRS) all as in effect as of the
date hereof. These authorities are subject to differing interpretations and may change, possibly retroactively, resulting in United States federal income tax consequences different from those discussed below. We have not requested a ruling from the
IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is limited to non-United States holders who purchase our common stock pursuant to this offering and who hold our common stock
as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all of the United States federal income tax consequences that may be relevant to a
particular holder in light of such holder&#146;s particular circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to holders subject to special rules under the United States federal income tax
laws, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other pass-through entities (and investors therein); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">corporations that accumulate earnings to avoid United States federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, financial institutions, investment funds, insurance companies, brokers or dealers in securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations and governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign pension funds; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accrual-method taxpayers subject to special tax accounting rules under Section&nbsp;451(b) of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who have elected to mark securities to market; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedging or conversion transaction or straddle, or a constructive
sale, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement that is classified as a
partnership for United States federal income tax purposes holds our common stock, the United States federal income tax treatment of a partner in the partnership will generally depend on the status of the partner and the activities of the
partnership. Partnerships (including entities or arrangements treated as partnerships for United States federal income tax purposes) holding our common stock and the partners in such partnerships are urged to consult their tax advisors about the
particular United States federal income tax consequences to them of holding and disposing of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>PROSPECTIVE INVESTORS
SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO THEM OF </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR FOREIGN TAX LAWS, AN APPLICABLE TAX TREATY OR ANY OTHER UNITED STATES
FEDERAL TAX LAWS. IN ADDITION, YOU SHOULD ALSO CONSULT WITH YOUR TAX ADVISOR WITH RESPECT TO POTENTIAL CHANGES IN UNITED STATES FEDERAL TAX LAW AS WELL AS POTENTIAL CHANGES IN STATE, LOCAL OR FOREIGN TAX LAWS. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of Non-United States Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a non-United States holder is any beneficial owner of our common stock that is not a &#147;United States
person&#148; or a partnership (including any entity or arrangement treated as a partnership) for United States federal income tax purposes. A United States person is any person that, for United States federal income tax purposes, is or is treated as
any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or entity treated as a corporation for United States federal income tax purposes) created or
organized under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to United States federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (1)&nbsp;whose administration is subject to the primary supervision of a United States court and which
has one or more United States persons who have the authority to control all substantial decisions of the trust or (2)&nbsp;that has a valid election in effect under applicable Treasury Regulations to be treated as a United States person.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described under the section titled &#147;Dividend Policy,&#148; we have not paid and do not anticipate paying dividends in the foreseeable
future. However, if we make cash or other property distributions on our common stock, such distributions will constitute dividends for United States federal income tax purposes to the extent paid from our current or accumulated earnings and profits,
as determined under United States federal income tax principles. Amounts not treated as dividends for United States federal income tax purposes will constitute a return of capital and will first be applied against and reduce a holder&#146;s tax
basis in our common stock, but not below zero. Any excess will be treated as gain realized on the sale or other disposition of our common stock and will be treated as described under the section titled &#147;&#151;Gain on Disposition of Our Common
Stock&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding effectively connected income, backup withholding and Sections&nbsp;1471
through 1474 of the Code (commonly referred to as FATCA), dividends paid to a <FONT STYLE="white-space:nowrap">non-United</FONT> States holder of our common stock generally will be subject to United States federal withholding tax at a rate of 30% of
the gross amount of the dividends or such lower rate specified by an applicable income tax treaty. To receive the benefit of a reduced treaty rate, a <FONT STYLE="white-space:nowrap">non-United</FONT> States holder must furnish us or our paying
agent with a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN</FONT> or IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> (or applicable successor form) certifying such holder&#146;s
qualification for the reduced rate. This certification must be provided to us or our paying agent before the payment of dividends and must be updated periodically. If the <FONT STYLE="white-space:nowrap">non-United</FONT> States holder holds the
stock through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-United</FONT> States holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">non-United</FONT> States holder will be required to provide
appropriate documentation to the agent, which then will be required to provide certification to us or our paying agent, either directly or through other intermediaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-United</FONT> States holders that do not provide the required certification on a timely basis, but that
qualify for a reduced treaty rate, may be eligible to obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a <FONT STYLE="white-space:nowrap">non-United</FONT> States holder holds our common stock in connection with the conduct of a trade or
business in the United States, and dividends paid on our common stock are effectively connected with such holder&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
United States trade or business (and are attributable to such holder&#146;s permanent establishment in the United States if required by an applicable tax treaty), the <FONT
STYLE="white-space:nowrap">non-United</FONT> States holder will be exempt from United States federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-United</FONT> States holder must generally furnish a valid IRS <FONT
STYLE="white-space:nowrap">Form&nbsp;W-8ECI</FONT> (or applicable successor form) to the applicable withholding agent certifying eligibility for exemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, any such effectively connected dividends paid on our common stock generally will be subject to United States federal income tax on a
net income basis at the regular graduated United States federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-United</FONT> States holder that is a foreign
corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year (as adjusted for certain
items), which will include effectively connected dividends. <FONT STYLE="white-space:nowrap">Non-United</FONT> States holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding backup withholding and FATCA, a non-United States holder generally will not be subject to United
States federal income tax on any gain realized on the sale or other disposition of our common stock, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the non-United States holder&#146;s conduct of a trade or business in the
United States, and if required by an applicable income tax treaty, is attributable to a permanent establishment maintained by the non-United States holder in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the non-United States holder is a nonresident alien individual present in the United States for 183&nbsp;days or
more during the taxable year of the disposition, and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a &#147;United States real property interest&#148; by reason of our status as a
United States real property holding corporation (USRPHC) for United States federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the non-United States holder&#146;s holding period for our
common stock, and our common stock is not regularly traded on an established securities market during the calendar year in which the sale or other disposition occurs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Determining whether we are a USRPHC depends on the fair market value of our United States real property interests relative to the fair market
value of our other trade or business assets and our foreign real property interests. We believe that we are not currently and do not anticipate becoming a USRPHC for United States federal income tax purposes, although there can be no assurance we
will not in the future become a USRPHC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above generally will be subject to United States federal
income tax on a net income basis at the regular graduated United States federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-United</FONT> States holder that is a
foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year (as adjusted for
certain items), which will include effectively connected gain. Gain described in the second bullet point above will be subject to United States federal income tax at a flat 30% rate (or such lower rate specified by an applicable income tax treaty),
but may be offset by certain United States-source capital losses (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-United</FONT> States holder has timely filed
United States federal income tax returns with respect to such losses. <FONT STYLE="white-space:nowrap">Non-United</FONT> States holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different
rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual reports are required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-United</FONT> States holder
indicating the amount of dividends on our common stock paid to such holder and the amount of any tax withheld </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to those dividends. These information reporting requirements apply even if no withholding was required because the dividends were effectively connected with the holder&#146;s conduct
of a United States trade or business, or withholding was reduced or eliminated by an applicable income tax treaty. This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the <FONT
STYLE="white-space:nowrap">non-United</FONT> States holder resides or is established. Backup withholding, currently at a 24% rate, generally will not apply to payments to a <FONT STYLE="white-space:nowrap">non-United</FONT> States holder of
dividends on or the gross proceeds of a disposition of our common stock provided the <FONT STYLE="white-space:nowrap">non-United</FONT> States holder furnishes the required certification for its <FONT STYLE="white-space:nowrap">non-United</FONT>
States status, such as by providing a valid IRS <FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN,</FONT> IRS <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;W-8BEN-E</FONT></FONT> or IRS
<FONT STYLE="white-space:nowrap">Form&nbsp;W-8ECI,</FONT> or certain other requirements are met. Backup withholding may apply if the payer has actual knowledge, or reason to know, that the holder is a United States person who is not an exempt
recipient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information reporting and backup withholding generally are not required with respect to the amount of any proceeds from the
sale or other disposition of our common stock by a <FONT STYLE="white-space:nowrap">non-United</FONT> States holder outside the United States through a foreign office of a foreign broker that does not have certain specified connections to the United
States. However, if a <FONT STYLE="white-space:nowrap">non-United</FONT> States holder sells or otherwise disposes of its shares of common stock through a United States broker or the United States offices of a foreign broker, the broker will
generally be required to report the amount of proceeds paid to the <FONT STYLE="white-space:nowrap">non-United</FONT> States holder to the IRS and also backup withhold on that amount unless such <FONT STYLE="white-space:nowrap">non-United</FONT>
States holder provides appropriate certification to the broker of its status as a <FONT STYLE="white-space:nowrap">non-United</FONT> States person (and the payer does not have actual knowledge or reason to know that such holder is a United States
person) or otherwise establishes an exemption. Information reporting will also apply if a <FONT STYLE="white-space:nowrap">non-United</FONT> States holder sells its shares of common stock through a foreign broker deriving more than a specified
percentage of its income from United States sources or having certain other connections to the United States, unless such broker has documentary evidence in its records that such <FONT STYLE="white-space:nowrap">non-United</FONT> States holder is a <FONT
STYLE="white-space:nowrap">non-United</FONT> States person (and the payer does not have actual knowledge or reason to know that such holder is a United States person) and certain other conditions are met, or such
<FONT STYLE="white-space:nowrap">non-United</FONT> States holder otherwise establishes an exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an
additional tax. If any amount is withheld under the backup withholding rules, the <FONT STYLE="white-space:nowrap">non-United</FONT> States holder should consult with a United States tax advisor regarding the possibility of and procedure for
obtaining a refund or a credit against the <FONT STYLE="white-space:nowrap">non-United</FONT> States holder&#146;s United States federal income tax liability, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding on Foreign Entities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FATCA
imposes a United States federal withholding tax of 30% on dividends paid on our common stock to a &#147;foreign financial institution&#148; (as specially defined under these rules) unless such institution enters into an agreement with the United
States government to withhold on certain payments and to collect and provide to the United States tax authorities substantial information regarding certain United States account holders of such institution (which includes certain equity and debt
holders of such institution, as well as certain account holders that are foreign entities with United States owners) or an exemption applies. FATCA also generally will impose a United States federal withholding tax of 30% on dividends paid on our
common stock to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless such entity provides the withholding agent a certification identifying certain direct and indirect United States owners of the entity or an exemption
applies. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-United</FONT> States holder might be eligible for
refunds or credits of such taxes. FATCA currently applies to dividends paid on our common stock. The Treasury Secretary has issued proposed regulations providing that the withholding provisions under FATCA do not apply with respect to gross proceeds
from a sale or other disposition of our common stock, which may be relied upon by taxpayers until final regulations are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors are encouraged to consult with their own tax advisors regarding the possible implications of this legislation on their
investment in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_18"></A>UNDERWRITERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below,
for whom Morgan Stanley&nbsp;&amp; Co. LLC and William Blair&nbsp;&amp; Company, L.L.C. are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares indicated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Blair&nbsp;&amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canaccord Genuity LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BTIG, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and the representatives are collectively referred to as the &#147;underwriters&#148; and the
&#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several
underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and
pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146; over-allotment option described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters initially propose to offer part of the shares of common stock directly to the public at the offering price listed on the
cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $0.756 per share under the public offering price. After the initial offering of the shares of common stock, the offering price and
other selling terms may from time to time be varied by the representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable
for 30 days from the date of this prospectus, to purchase up to 600,000 additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may
exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the shares of common stock offered by this prospectus. To the extent the option is exercised, each underwriter will become
obligated, subject to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of shares of common
stock listed next to the names of all underwriters in the preceding table. At our request, in addition to the directed share program described in this prospectus, the underwriters have reserved for sale at the initial public offering price per share
approximately 824,000 shares of common stock in this offering to certain individuals, including directors, existing stockholders and other persons associated with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses
to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional 600,000 shares of common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by us:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,040,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,796,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,960,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,004,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are
approximately $4,000,000. We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority up to $40,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have informed us that they do not intend sales to discretionary accounts to
exceed 5% of the total number of shares of common stock offered by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have been approved to list our common stock on the Nasdaq
Global Market under the trading symbol&nbsp;&#147;BDSX&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and all directors and officers and the holders of substantially all of
our outstanding stock and stock options have agreed that, without the prior written consent of the representatives on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, during the period ending 180 days
after the date of this prospectus (the restricted period): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the Securities and Exchange Commission relating to the offering of any
shares of common stock or any securities convertible into or exercisable or exchangeable for common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whether any such transaction described above is to be settled by delivery of common
stock or such other securities, in cash or otherwise. In addition, we and each such person agrees that, without the prior written consent of the representatives on behalf of the underwriters, we or such other person will not, during the restricted
period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph do not apply to us in certain circumstances, subject to certain limitations
and conditions set forth in the underwriting agreement, including: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the issuance and sale of shares of common stock in this offering;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the issuance of shares of our common stock upon the conversion of securities or the exercise of warrants outstanding as of the date of
this prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) the issuance and sale of shares of common stock or options to purchase shares to employees, officers, directors,
advisors or consultants pursuant to employee benefit plans described in this prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) the filing by us of registration statements
on Form S-8 with respect to the employee benefit plans described in this prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the sale or issuance by us of, or our entry into
an agreement to sell or issue shares of our common stock in connection with our acquisition of one or more businesses, products, assets or technologies (whether by means of merger, stock purchase, asset purchase or otherwise) or in connection with
joint ventures, collaboration or licensing agreements, marketing or distribution arrangements, commercial relationships or other strategic transactions, provided that the aggregate number of shares of common stock that we may sell or issue or agree
to sell or issue shall not exceed 5% of the total number of shares of common stock issued and outstanding immediately following the completion of this offering; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) facilitating the establishment of a trading plan on behalf of a shareholder, officer or director of the Company pursuant to Rule 10b5-1
under the Exchange Act for the transfer of shares of common stock, provided that (i) such plan does not provide for the transfer of common stock during the restricted period and (ii) to the extent a public announcement or filing under the Exchange
Act, if any, is required of or voluntarily made by us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such plan during the restricted
period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, with respect to our directors, officers and the holders of substantially all of our
outstanding stock and stock options, the restrictions described above do not apply in certain circumstances, subject to certain limitations and conditions set forth in the lock-up agreements, including: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) transactions relating to shares of common stock or other securities acquired in open market transactions after the completion of this
offering or as part of this offering (other than issuer-directed shares purchased in this offering); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) transfers of shares of common
stock or any other securities convertible into or exercisable or exchangeable for common stock as a bona fide gift; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) transfers of
shares of common stock or any other securities convertible into or exercisable or exchangeable for common stock to certain trusts; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
distributions of shares of common stock or any other securities convertible into or exercisable or exchangeable for common stock to limited partners, general partners, members, stockholders or other equityholders; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) transfers of shares of common stock or any other securities convertible into or exercisable or exchangeable for common stock to affiliates
or to certain related investment funds or entities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) transfers of shares of common stock or any other securities convertible into or
exercisable or exchangeable for common stock to any nominee or custodian of a person or entity to whom a transfer or disposition would be permissible under clauses (b) through (e) above; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) transfers of shares of common stock or any other securities convertible into or exercisable or exchangeable for common stock by will or
intestate succession; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) transfers of shares of common stock or any other securities convertible into or exercisable or exchangeable for
common stock to us in connection with the exercise of options, warrants or other rights to acquire shares of common stock or any security convertible into or exercisable for shares of our common stock by way of net exercise and/or to cover
withholding tax obligations in connection with such exercise pursuant to an employee benefit plan, option, warrant or other right disclosed in this prospectus; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) transfers of shares of common stock or any other securities convertible into or exercisable or exchangeable for common stock pursuant to
the automatic conversion of outstanding preferred stock or our convertible notes into shares of common stock as described in the prospectus; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) transfers of shares of common stock or any other securities convertible into or exercisable or exchangeable for common stock by operation
of law, including pursuant to a court or regulatory agency order, a settlement agreement, a qualified domestic order or in connection with a divorce settlement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) transfers of shares of common stock or any other securities convertible into or exercisable or exchangeable for common stock to us pursuant
to any agreements under which we have the option to repurchase or a right of first refusal with respect to transfers of such shares; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)
transfers of shares of common stock or any other securities convertible into or exercisable or exchangeable for common stock to a third party pursuant to a merger, consolidation, bona fide tender offer or other similar transaction made to all
holders of shares of the common stock involving a change of control and approved by our board of directors; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) facilitating the
establishment of a trading plan on behalf of a shareholder, officer or director of the Company pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of common stock, provided that (i) such plan does not provide for the transfer
of common stock during the restricted period and (ii) to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by the Company regarding the establishment of such plan, such announcement or
filing shall include a statement to the effect that no transfer of common stock may be made under such plan during the restricted period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representatives, in their sole discretion, may release the common stock and other securities subject to the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the common stock, the underwriters may engage in
transactions that stabilize, maintain or otherwise affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short
sale is covered if the short position is no greater than the number of shares available for purchase by the underwriters under the over-allotment option described above. The underwriters can close out a covered short sale by exercising the
over-allotment option or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available
under the over-allotment option. The underwriters may also sell shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked
short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering.
As an additional means of facilitating this offering, the underwriters may bid for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the
common stock above independent market levels or prevent or retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any,
participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long
and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or
express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing of the Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this
offering, there has been no public market for our common stock. The initial public offering price was determined by negotiations between us and the representatives. Among the factors considered in determining the initial public offering price were
our future prospects and those of our industry in general, our sales, earnings and certain other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain
financial and operating information of companies engaged in activities similar to ours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directed Share Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the underwriters have reserved up to 5% of the shares of common stock offered by this prospectus, for sale at the initial
public offering price through a directed share program to certain individuals, including our directors, employees and certain of our existing stockholders. The sales will be made at our direction by Morgan Stanley &amp; Co. LLC and its affiliates
through a directed share program. The number of shares of our common stock available for sale to the general public in this offering will be reduced to the extent that these individuals purchase such reserved shares. Any reserved shares that are not
so purchased will be offered by the underwriters to the general public on the same terms as the other shares of common stock offered by this prospectus. Shares purchased through the directed share program will not be subject to lockup restrictions
with the underwriters during the restricted period described above, except in the case of shares purchased by any of our officers or directors, employees and certain of our existing stockholders. We have agreed to indemnify the underwriters against
certain liabilities and expenses, including liabilities under the Securities Act, in connection with the sales of the shares reserved for the directed share program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Canada
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of our common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are
accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT
STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of our common stock must be made in accordance with an exemption from, or in a transaction not subject to,
the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of
a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are
not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the EEA (each, a Member State), no securities have been offered or will be offered pursuant to the offering
to the public in that Member State prior to the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State or, where appropriate, approved in another Member State and notified to
the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that offers of securities may be made to the public in that Member State at any time under the following exemptions under the Prospectus
Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), subject to obtaining the prior consent of the representatives; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(c)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such
offer of shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article&nbsp;23 of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the
representatives and us that it is a &#147;qualified investor&#148; as defined in the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any shares
being offered to a financial intermediary as that term is used in Article 5 of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have
not been acquired on a nondiscretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in
a Member State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer of shares to the public&#148; in relation to any shares in any Member State
means the communication in any form and by means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase shares, the expression &#147;Prospectus Regulation&#148;<B> </B>means
Regulation (EU) 2017/1129 (as amended). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each underwriter has represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(a)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the
Financial Services and Markets Act 2000 (FSMA) received by it in connection with the issue or sale of the shares of our common stock in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(b)</TD>
<TD WIDTH="2%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares of our common stock in, from or otherwise involving the United Kingdom.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No registration pursuant to Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as amended)
(the FIEL) has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the shares of common stock have not been, directly or indirectly, offered or sold and will not be, directly or indirectly,
offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or <FONT STYLE="white-space:nowrap">re-sale,</FONT> directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration
requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>For Qualified
Institutional Investors (QII) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in
Paragraph 2, Article 4 of the FIEL) in relation to the shares of common stock constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, Article <FONT
STYLE="white-space:nowrap">23-13</FONT> of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock.&nbsp;The shares of
common stock may only be transferred to QIIs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>For <FONT STYLE="white-space:nowrap">Non-QII</FONT> Investors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article&nbsp;4 of the FIEL) in
relation to the shares of common stock constitutes either a &#147;small number private </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
placement&#148; or a &#147;small number private secondary distribution&#148; (each as is described in Paragraph 4, <FONT STYLE="white-space:nowrap">Article&nbsp;23-13</FONT> of the FIEL).
Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock.&nbsp;The shares of common stock may only be transferred en bloc without
subdivision to a single investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (SIX) or on any other stock exchange or
regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss
Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other
offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares have been or will be
filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares
has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (CISA). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of
shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Sidley Austin&nbsp;LLP, San Francisco, California.
Certain legal matters in connection with this offering will be passed upon for the underwriters by Davis Polk&nbsp;&amp; Wardwell LLP, New York, New York. Partners of Sidley Austin LLP own less than 1% of our outstanding common stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_20"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Biodesix, Inc. as of December&nbsp;31, 2019 and 2018, and for each of the years in the <FONT
STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2019, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere
herein, and upon the authority of said firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom937421_21"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act, with respect
to the shares of common stock being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information
with respect to our company and the common stock offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to
are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not currently subject to the informational requirements of the Exchange Act. Upon the closing of this offering, we will be subject to
the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. The SEC also maintains a website (<I>http://www.sec.gov</I>) that contains reports, proxy and information
statements and other information that we file electronically with the SEC. We also maintain a website at <I>www.biodesix.com</I>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically
filed with, or furnished to, the SEC. The information contained on, or accessible from, or hyperlinked to, our website is not part of this prospectus by reference or otherwise. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>INDEX TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unaudited Interim Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin937421_2">Condensed Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-2</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin937421_3">Condensed Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-3</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin937421_4">Condensed Statements of Changes in Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-4</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin937421_5">Condensed Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-7</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin937421_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audited Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin937421_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-35</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin937421_7">Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-36</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin937421_8">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-37</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin937421_9">Statements of Changes in Convertible Preferred Stock and Stockholders&#146; Deficit
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-38</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin937421_10">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-41</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin937421_11">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-43</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin937421_2"></A>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Six Months Ended June&nbsp;30, 2020 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales, marketing, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,041</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(68.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(64.88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:300pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin937421_3"></A>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED BALANCE SHEETS (UNAUDITED) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<BR>June 30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="12" ALIGN="center"><B>Assets</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="12" ALIGN="center"><B>Liabilities and Stockholders&#146; Deficit</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Put option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paycheck protection program debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total non-current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.001 par value, 185,432,719 (2020) and 174,237,067 (2019)
authorized; 118,766,273 (2020 and 2019) issued and outstanding; liquidation preference of $202,582 (2020 and 2019); no shares issued and outstanding pro forma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 220,000,000 (2020) and 190,000,000 (2019) authorized; 274,523
(2020) and 254,918 (2019) issued and outstanding; 22,198,893 shares issued and outstanding pro forma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(250,564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(248,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(230,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(246,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(228,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock, and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin937421_4"></A>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT (UNAUDITED) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six Months Ended June&nbsp;30, 2020 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;A-2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B-1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;June&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B-1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series H Preferred Stock, net of issuance costs of $44</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;June&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT (UNAUDITED) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six Months Ended June&nbsp;30, 2020 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Continued from the
previous page) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;D</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series F</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;June&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series F</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series H Preferred Stock, net of issuance costs of $44</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;June&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT (UNAUDITED) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six Months Ended June&nbsp;30, 2020 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Continued from the
previous page) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series G</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series H</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-In<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">193,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(230,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(228,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance&#151;June&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">193,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(248,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(246,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series G</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series H</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-In<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">183,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(200,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(198,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Issuance of Series H Preferred Stock, net of issuance costs of $44</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance&#151;June&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">193,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(214,737</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(212,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin937421_5"></A>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Six Months Ended June&nbsp;30, 2020 and 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in
operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of convertible notes debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest on debt payable and convertible debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for doubtful accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in
acquisitions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(529</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash and cash equivalents and restricted cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent costs and intangible asset acquisition, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments to acquire Oncimmune assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash and cash equivalents and restricted cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(818</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(851</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of series H preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from long-term debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash and cash equivalents and restricted cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash&#151;beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash&#151;end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Continued from the
previous page) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Supplemental disclosure of cash flow information: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">There was no cash paid for income taxes during the six months ended June&nbsp;30, 2020 and 2019. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash paid for interest for the <FONT STYLE="white-space:nowrap">six-months</FONT> ended June&nbsp;30, 2020 and 2019 was
$0.9&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> activity (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value of put option recorded at issuance of convertible debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin937421_6"></A>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
1&#151;Description of Business and Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(a) Organization and Nature of Operations
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biodesix, Inc. (the &#147;Company&#148;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The
Company&#146;s headquarters are in Colorado, with laboratories in Colorado, Kansas, and Washington. Biodesix is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform
to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research,
clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, the World Health
Organization declared the outbreak of COVID-19, a novel strain of coronavirus, a global pandemic. This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads. The COVID-19 pandemic has disrupted, and the
Company expects will continue to disrupt, its operations. In addition, the COVID-19 pandemic also has started to negatively affect, and the Company expects will continue to negatively affect, its non-COVID-19 testing-related revenue and its clinical
studies. The extent of the effect on the Company&#146;s operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, and governmental, regulatory and private sector
responses, all of which are uncertain and difficult to predict. Although the Company is unable to estimate the financial effect of the pandemic, at this time, if the pandemic continues to evolve into a severe worldwide crisis, it could have a
material adverse effect on the Company&#146;s business, results of operations, financial condition, and cash flows. The condensed financial statements do not reflect any adjustments as a result of the pandemic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to various risks and uncertainties frequently encountered by early stage life science companies. Such risks and
uncertainties include, but are not limited to, undeveloped technology, strict regulatory requirements and approval of products, a limited operating history, competition from other service providers, dependence on key personnel, the need for ongoing
capital to fund operations, and management of rapid growth. To address these risks, the Company must, among other things, successfully develop its customer base, successfully execute its business and marketing strategy, successfully develop its
technology, raise capital on acceptable terms to the Company, and attract, retain, and motivate qualified personnel. There can be no guarantee that the Company will be successful in addressing these or other such risks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(b) Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the
United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Rule <FONT STYLE="white-space:nowrap">10-01</FONT> of
Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP, have been omitted. The accompanying unaudited condensed financial
statements include all known adjustments necessary for a fair presentation of the results of interim periods as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets
and liabilities. Operating results for the period ended June&nbsp;30, 2020 are not necessarily indicative of the results that may be expected for the year ending December&nbsp;31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements should be read in conjunction with the audited condensed financial statements and
the related notes for the year ended December&nbsp;31, 2019, which are included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(c) Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses
during the reporting period. Areas of the financial statements where estimates have the most significant effect include the valuation of contingent consideration and purchased technology related to the Company&#146;s business acquisition,
stock-based compensation, valuation of put option liabilities, and the valuation allowance related to net deferred tax assets. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(d) Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates in one operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold
improvements, and other fixed assets are physically located within the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(e) Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from <FONT
STYLE="white-space:nowrap">non-owner</FONT> sources. If the Company had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#146;
deficit. There were no elements of comprehensive loss during the <FONT STYLE="white-space:nowrap">six-months</FONT> ended June&nbsp;30, 2020 and 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(g) Concentration of Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to credit risk from its accounts receivable related to services provided to its customers. Reimbursement on behalf of
customers covered by Medicare accounted for 60% and 58% of the Company&#146;s diagnostic test revenue for the six months ended June&nbsp;30, 2020 and 2019, respectively and represented 29% and 18% of the Company&#146;s total accounts receivable as
of June&nbsp;30, 2020 and December&nbsp;31, 2019, respectively. One services customer represented 18% and 44% of the Company&#146;s total accounts receivable balance as of June&nbsp;30, 2020 and December&nbsp;31, 2019, respectively. One diagnostic
test customer represented 32% and 0% of the Company&#146;s total accounts receivable balance as of June&nbsp;30, 2020 and December&nbsp;31, 2019, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(h) Cash, Cash Equivalents, and Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The
Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally
insured limits. Included in cash and cash equivalents are money market funds recorded at $10.6&nbsp;million and $4.8&nbsp;million at June&nbsp;30, 2020 and December&nbsp;31, 2019, respectively. These money market funds were measured using
Level&nbsp;1 inputs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash consists of deposits related to the Company&#146;s corporate credit card and a letter of credit
related to an operating lease agreement. As of June&nbsp;30, 2020 and December&nbsp;31, 2019, the Company had $0.2&nbsp;million in restricted cash, which was included in other current assets in the accompanying balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(i) Accounts Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company provides an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are recorded
at carrying value and charged off against the allowance for doubtful accounts when it is determined that recovery is unlikely and cease collection efforts cease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzes trade accounts receivable quarterly and considers historic experience, customer creditworthiness, facts and circumstances
specific to outstanding balances, and payment terms when evaluating the adequacy of the allowance for doubtful accounts. The Company recorded an allowance for doubtful accounts of $0.2&nbsp;million as of June&nbsp;30, 2020 and December&nbsp;31,
2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(j) Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories are stated at the lower of cost or net realizable value on a <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT
STYLE="white-space:nowrap">first-out</FONT> basis. Inventory consists primarily of supplies, which are consumed when processing tests. The Company does not maintain any finished goods inventory. Inventory balances were $1.8&nbsp;million and
$0.8&nbsp;million as of June&nbsp;30, 2020 and December&nbsp;31, 2019, respectively, and are included in other current assets in the accompanying balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(k) Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost. Depreciation is provided utilizing the straight-line method over the estimated useful lives, ranging
from three to five years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(l) Intangible Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets are stated at cost, net of accumulated amortization and include patents, trademarks, and acquired developed technology.
Trademarks have an indefinite life and are not being amortized but are reviewed for impairment on an annual basis. External costs associated with patents are capitalized as long as such efforts are expected to be successful. Upon approval of the
patent, the related capitalized costs are amortized over the lesser of the contractual term of the patent or the estimated useful life of 10 years. Acquired developed technology is amortized over a useful life of 9 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets are reviewed for impairment whenever events or changes in circumstances may affect the recoverability of the intangible
assets. Such reviews include an analysis of current results and take into consideration the undiscounted value of projected operating cash flows. See Note 3, Business Combination, for further information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(m) Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the
asset may not be recovered. The Company looks primarily to the undiscounted future cash flows in its assessment of whether or not long-lived assets have been impaired. The Company has determined that no impairments are necessary for the periods
presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(n) Deferred Rent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases office space under <FONT STYLE="white-space:nowrap">non-cancelable,</FONT> long-term operating leases that include scheduled
increases in minimum rents and renewal provisions at the option of the Company. The expense associated with leases that have escalating payment terms is recognized on a straight-line basis over the lease term. Tenant improvement allowances received
from a lessor are recorded as a deferred rent liability and recognized evenly as a reduction to rent expense over the remaining lease term. The portion of the deferred rent liability that will reverse in the next 12 months is not significant to the
balance sheets; therefore, the entire amount was recorded as <FONT STYLE="white-space:nowrap">non-current</FONT> in the accompanying condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(o) Goodwill </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwill is recorded when the purchase price paid for an acquisition exceeds the estimated fair value of the net identified tangible and
intangible assets acquired. Goodwill is not amortized and is tested for impairment at the reporting unit level on an annual basis as of December&nbsp;31 and between annual tests if an event occurs or circumstances change that would more likely than
not reduce the fair value of the reporting unit below its carrying value. The Company may first perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value.
If it is concluded that this is the case, it is necessary to perform a quantitative <FONT STYLE="white-space:nowrap">two-step</FONT> goodwill impairment test. Otherwise, the <FONT STYLE="white-space:nowrap">two-step</FONT> goodwill impairment test
is not required. The quantitative <FONT STYLE="white-space:nowrap">two-step</FONT> goodwill impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. Multiple valuation techniques can be
used to assess the fair value of the reporting unit. All these techniques include the use of estimates and assumptions that are inherently uncertain. Changes in these estimates and assumptions could materially affect the determination of fair value
or goodwill impairment, or both. The Company assessed qualitative factors to determine whether it is more likely than not that the fair value of Goodwill exceeded the carrying value. Based on that assessment, there were no events or circumstances in
the six months ended June&nbsp;20, 2020 and 2019 to indicate that the fair value of goodwill exceeded its carrying value, and thus a quantitative analysis was not performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company did not have any goodwill impairments for the six months ended June&nbsp;30, 2020 and 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(p) Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is recognized when control of the promised services is transferred to customers, in an amount that reflects the consideration the
Company expects to be entitled to in exchange for those services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s revenue is generated from the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Diagnostic tests. These services are completed upon the delivery of test results to the prescribing physician,
which is considered the performance obligation. The fees for such services are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Services. These services are generally completed upon the delivery of test results for assay development and
testing services, which is considered the performance obligation. Customers for these services are typically large pharmaceutical companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2020 and 2019, revenue from these services consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diagnostic tests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diagnostic test revenue that were reimbursed by Medicare comprised 60% and 58% of diagnostic test revenue for
the six months ended June&nbsp;30, 2020 and 2019, respectively. Two services customers comprised 15% and 26% of services revenue for the six months ended June&nbsp;30, 2020 and 2019, respectively. For the six months ended June&nbsp;30, 2020, one
health care provider comprised 13% of diagnostic test revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from diagnostic tests are recognized when the performance obligation is satisfied,
which is when a customer receives results of the Company&#146;s tests, which is generally upon delivery to the requesting physician. Revenue from services are recognized when the performance obligation is satisfied, which is when a customer receives
results of the Company&#146;s tests, which is generally upon the delivery of test results for assay development and testing services. The Company also provides services to patients with whom the Company does not have contracts as defined in ASC 606,
<I>Revenue from</I> <I>Contracts with Customers </I>(ASC 606). The Company recognizes revenue for these patients when<I> </I>contracts as defined in ASC 606 are established at the amount of consideration to which it expects to be entitled or when
the Company receives substantially all of the consideration subsequent to the performance obligations being satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
determines the transaction price related to its diagnostic test contracts by considering the nature of the payer and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction
price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as
collective groups rather than individually. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(q) Deferred Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred revenue has historically primarily consists of research, development, and testing services fee payments received in advance. As of
June&nbsp;30, 2020, deferred revenue also includes $3.5&nbsp;million in a Medicare advance payment on testing services which can either be paid back or earned back starting 120 days from receipt. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(r) Research and Development Expenses and Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenditures made for research and development are charged to expense as incurred. External costs consist primarily payments to clinical trial
sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#146;s discovery and preclinical activities, process development and clinical development activities. Internal costs consist primary of employee-related
costs, facilities, depreciation and costs related to compliance with regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates and accrues its
expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment
flows that do not match the periods over which materials or services are provided under such contracts. The Company&#146;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each
activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(s) Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for stock-based compensation arrangements with employees and recognizes compensation expense for stock-based awards based
on the estimated fair value of the awards. Compensation expense for all employee stock-based awards is based on the estimated grant-date fair value and recognized as an expense on a straight-line basis over the requisite service period (generally
the vesting period). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(t) Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes deferred tax assets and liabilities based on the differences between the tax basis of assets and liabilities and their
reported amounts in the financial statements and net operating loss carryforwards </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that will result in taxable or deductible amounts in future years. The Company establishes a valuation allowance for all deferred tax assets to the extent it is more likely than not that a
deferred tax asset will not be realized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(u) Warrant Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently
redeemable are required to be reported as liabilities in the financial statements. The issuer must present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting
period, and any change in value is recognized in operations. The Company has determined that certain warrants issued to investors and lenders, which are exercisable for shares of the Company&#146;s convertible preferred stock, shall be classified as
liabilities due to a contingent redemption provision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(v) Changes in Fair Value of Contingent Consideration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the purchase transaction with Integrated Diagnostics, Inc., the Company recorded contingent consideration pertaining to the
amounts potentially payable to Integrated Diagnostics&#146; shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value
are recognized as operating expenses within the statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the contingent consideration is
based upon significant assumptions including probabilities of successful achievement of the related milestone event (&#147;Milestone&#148;), the estimated timing in which the Milestone is achieved, and discount rates. The estimated fair value could
materially differ from actual values or fair values determined using different assumptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(w) Fair Value of Financial Instruments
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of financial instruments, including cash and cash equivalents, receivables, other current assets, accounts
payable, and accrued liabilities, approximated fair value as of June&nbsp;30, 2020 and December&nbsp;31, 2019 because of the relatively short maturity of these instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of long-term debt payable and convertible debt payable issued approximated fair value as of June&nbsp;30, 2020 and
December&nbsp;31, 2019 because interest rates on these instruments approximate market interest rates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(x) Business Combinations
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be
accounted for as a business combination by assessing whether or not the Company has acquired inputs and processes that have the ability to create outputs. If determined to be a business combination, the Company accounts for business acquisitions
under the acquisition method of accounting as indicated in the Financial Accounts Standards Board (&#147;FASB&#148;) issued Accounting Standards Codification (&#147;ASC&#148;) Topic 805, <I>Business Combinations</I> (&#147;ASC 805&#148;), which
requires the acquiring entity in a business combination to recognize the fair value of all assets acquired and liabilities assumed and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets
acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in the acquiree based on the fair value estimates as of the date of
acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(y) Recently Issued Accounting Standards Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases</I> (ASC Topic 842). The new guidance
maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a
lease liability on the statement of financial position for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability,
subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning January&nbsp;1, 2021. The Company is currently evaluating the impact of the lease guidance on the Company&#146;s financial
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(z) Net loss per share and unaudited pro format net loss per share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of
common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common
shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the convertible preferred stock, common stock options, restricted stock units, preferred stock warrants and
convertible debt are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for
participating securities as the convertible preferred stock is considered a participating security. The Company&#146;s participating securities do not have a contractual obligation to share in the Company&#146;s losses. As such, the net loss was
attributed entirely to common stockholders. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands,
except per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,599</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following outstanding shares of potentially dilutive securities were excluded from the
computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debt<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,747</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of common shares that convertible debt was assumed to convert to was based on the Company&#146;s
estimated common stock price as of June&nbsp;30, 2020, as determined by the Company&#146;s board of directors with assistance from a valuation firm. The ultimate conversion price will be based on the fair value of the Company&#146;s common stock at
the completion of an initial public offering. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Unaudited pro forma net loss per share </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unaudited pro forma basic and diluted net loss per share is calculated to give effect to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> conversion of all outstanding shares of the Company&#146;s convertible preferred stock and convertible debt into shares of common stock in using the
<FONT STYLE="white-space:nowrap">as-converted</FONT> method as though the conversion had occurred as of the beginning of the period presented or the date of issuance, if later. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the basic and diluted unaudited pro forma net loss per share (in thousands, except for per
share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add back: Interest expense on convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss used in computing proforma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,070</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjust: Assumed weighted-average effect of conversion of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjust: Assumed weighted-average effect of conversion of convertible debt<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing pro forma net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of common shares that convertible debt was assumed to convert to was based on the Company&#146;s
estimated common stock price as of June&nbsp;30, 2020, as determined by the Company&#146;s board of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
directors with assistance from a valuation firm. The ultimate conversion price will be based on the fair value of the Company&#146;s common stock at the completion of an initial public offering.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Balance Sheet </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma stockholders&#146; deficit as of June 30, 2020 gives effect to the automatic conversion of all outstanding shares of
the Company&#146;s convertible preferred stock into an aggregate of 20,090,745 shares of common stock and the automatic conversion of the Company&#146;s convertible debt into an aggregate of 1,833,625 of common stock which will occur immediately
prior to the completion of this offering, resulting in an aggregate of 22,198,893 outstanding shares of the Company&#146;s common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
2&#151;Liquidity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the
realization of assets and liquidation of liabilities in the ordinary course of business. To date, the Company has funded its activities primarily through private equity placement offerings, convertible debt payable, and long-term debt. The Company
is still in its early stage and has yet to generate revenue sufficient to create positive cash flows and most likely will be dependent upon future private equity placements or additional borrowings to execute its business plan. The Company has cash
and cash equivalents of $11.7&nbsp;million, cumulative net losses of $ 248.8&nbsp;million, and stockholders&#146; deficit of $246.4&nbsp;million as of June&nbsp;30, 2020. Based on cash and cash equivalents on hand at June&nbsp;30, 2020, management
has determined that additional private equity placement offerings will be necessary to fund operations through September 2021. As a result, the Company has obtained commitment letters from two significant investors which requires that they will
provide funding to the Company to meet its obligations and debt service requirements through at least September 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3&#151;Business
Combinations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Oncimmune Limited </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;31, 2019, the Company purchased select assets and liabilities from Oncimmune Limited (&#147;Oncimmune&#148;) for total
consideration of $1.2&nbsp;million payable in quarterly installments commencing 30 days following the closing of the transaction. Concurrent with the Oncimmune purchase, the Company acquired an option to license rights within the United States to an
additional indication for their product for $9&nbsp;million. This option, which is exclusive to the Company, expires on the earlier of 30 days following Food and Drug Administration approval or December&nbsp;31, 2020. As of June&nbsp;30, 2020,
$1.0&nbsp;million has been paid with the remaining amount due of $0.2&nbsp;million being included in accounts payable and accrued liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the transaction as a business combination in accordance with ASC 805. As such, the assets acquired and liabilities
assumed were recorded at fair value, with the remaining purchase price recorded as goodwill. The goodwill associated with the acquisition is the result of expected synergies, an increase in future revenues as a result of the expansion of the
technology into additional markets as well as lower future operating expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes the aggregate consideration paid by the Company and the allocation
of the purchase price (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fair value of consideration transferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Company has finalized its accounting for this business combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Integrated Diagnostics, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2018, the Company purchased select assets and liabilities from Integrated Diagnostics, Inc. (&#147;Indi&#148;) for total
consideration of $27.6&nbsp;million, consisting of $8.0&nbsp;million (10,649,604 shares) of the Company&#146;s Series G Preferred Stock and contingent consideration with an initial fair value of $19.6&nbsp;million. The 10,649,904 shares issued at
closing include 2,129,981 shares that were deposited in an escrow account to be used to satisfy any indemnification obligations of Indi that may arise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the transaction as a business combination in accordance with ASC 805. As such, the assets acquired and liabilities
assumed were recorded at fair value, with the remaining purchase price recorded as goodwill. The estimated fair values of acquired assets and assumed liabilities were determined by management with the assistance of an independent third party. The
goodwill associated with the acquisition is the result of expected synergies, an increase in future revenues as a result of the expansion of the technology into additional markets as well as lower future operating expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes the aggregate consideration paid by the Company and the allocation of the purchase price (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock issued&#151;10,694,904 shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fair value of consideration transferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(877</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The acquisition of Indi included a contingent consideration arrangement that requires
additional consideration to be paid by the Company to Indi based on the Milestone of the attainment of a three consecutive month gross margin target of $2&nbsp;million within a seven-year period after the acquisition date. For the six months
following the achievement of the Milestone, Indi has the option to require the Company to pay the contingent consideration in cash over eight equal installments due each calendar quarter or to require the issuance of additional shares of Series G
preferred stock. The total amount of undiscounted contingent consideration which the Company may be required to pay under the arrangement is $37.0&nbsp;million. If Indi elects not to exercise these options, the Company has 12 months to either settle
the contingent consideration in two equal quarterly cash installments or in 14,959,114 shares of Series G Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value
of $19.6 million contingent consideration recognized on the acquisition date was estimated by management with the assistance of an independent third party. These fair value measurements were based on significant inputs not observable in the market
and thus represent Level 3 fair value measurements. See Note 4, Fair Value Accounting, for a discussion of the fair value of the contingent consideration and changes in fair value subsequent to the acquisition date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets acquired, amortization method and estimated useful lives as of June&nbsp;30, 2018 was as follows (dollars in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Useful<BR>Life</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortization<BR>Method</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">Straight-line</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;16,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The technology acquired from Indi consisted of the technology and related know-how of the XL2 test for which
Indi had developed. The fair value of the technology was estimated by applying a multi-period excess earnings method. The results of this method are based on significant inputs that are not observable in the market, or Level 3 inputs (see discussion
of the fair value hierarchy in Note 4). Key assumptions included (a) projected revenue and related profitable attributable to the acquired technology over the estimated life of the acquired technology and (b) a discount rate of 37.5%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company had finalized its accounting for this business combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4&#151;Fair Value Accounting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company accounts for certain assets and liabilities that are required to be recorded at fair value under a framework for measuring fair value that requires enhanced disclosures about fair value measurements. This framework requires disclosure about
how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped based on significant levels of inputs as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Level&nbsp;1:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quoted prices in active markets for identical assets or liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Level&nbsp;2:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset
or liability; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Level&nbsp;3:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop
its own assumptions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination of where assets and liabilities fall within this hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth by level, within the fair value hierarchy, the Company&#146;s
liabilities measured at fair value on a recurring basis (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>June&nbsp;30, 2020:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent value rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Put option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>December&nbsp;31, 2019:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent value rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Put option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the unobservable inputs needed to calculate the fair value of these balances, these liabilities are
classified as Level&nbsp;3 liabilities. The following is a reconciliation of the beginning and ending balances for the <FONT STYLE="white-space:nowrap">six-</FONT> month period ended June&nbsp;30, 2020 for assets measured at fair value on a
recurring basis using significant unobservable inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent value rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Put option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,944</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no changes to the valuation methods during the months presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 12 for further discussion of preferred stock warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the shares of Series F Preferred Stock that were issued in January 2016, investors who purchased more than their
<FONT STYLE="white-space:nowrap">pro-rata</FONT> amount in the financing described above received a calculated number of contingent value rights (&#147;CVRs&#148;), but only to the extent that the total amount raised in the financing exceeded
$20,202,323. One CVR represents 0.00375% of the Company&#146;s interest in the drug ficlatuzumab (see Note 9). In connection with the Series F financing, the Company issued 3,999 CVRs originally valued at $0.5&nbsp;million. The initial estimated
value of the CVRs were recorded as a liability and as a reduction to the Series F proceeds. Upon receipt by the Company or a milestone, royalty, or any other type of payment from the Company&#146;s ownership rights in the drug, the Company will make
a cash payment to the CVR holders equal to 15% of net proceeds, as defined. In addition, the CVRs will be adjusted to their estimated fair values each reporting period. During the six months ended June&nbsp;30, 2020, there was no change to the
estimated value of the CVRs. The value of these CVRs was $0.1&nbsp;million as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The put option liability was valued
based on the calculated returns as a result of the various discounts included in the Company&#146;s convertible debt payable and the related probability assessments of the various settlement scenarios that the discounts apply to. As of June&nbsp;30,
2020 and December&nbsp;31, 2019, the combined probability assessment of a qualified financing or initial public offering is 95%. See note 6 for further disclosure of the discounts and settlement scenarios. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contingent Consideration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the transaction with Indi, the Company recorded contingent consideration pertaining to the amounts potentially payable to
Indi&#146;s Selling Shareholders pursuant to the Asset Purchase Agreement (See Note 3). Contingent consideration is measured at fair value and is based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement
within the fair value hierarchy. The valuation of contingent consideration uses assumptions the Company believes would be made by a market participant. The Company assesses these estimates on an <FONT STYLE="white-space:nowrap">on-going</FONT> basis
as additional data impacting the assumptions is obtained. Future changes in the fair value of contingent consideration related to updated assumptions and estimates are recognized within the statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contingent consideration may change significantly as development progresses and additional data are obtained, impacting the Company&#146;s
assumptions regarding probabilities of successful achievement of related Milestone used to estimate the fair value of the liability and the timing in which they are expected to be achieved. In evaluating the fair value information, considerable
judgment is required to interpret the market data used to develop the estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market
assumptions and/or different valuation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
techniques could result in materially different fair value estimates. The fair value of the Company&#146;s contingent consideration liability was estimated using significant unobservable inputs.
The fair value of $ 19.6&nbsp;million contingent consideration recognized on the acquisition date was estimated by management with the assistance of an independent third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in the fair value measurement each period reflect the passage of time as well as the impact of adjustments, if any, to the likelihood
of achieving the specified targets. Contingent consideration is recorded in the balance sheets in long- term liabilities. The change to contingent consideration during the six months ended June&nbsp;30, 2020 was primarily due to $1.9&nbsp;million
resulting from the accretion of the liability offset by $1.9&nbsp;million due to the impact of the deceleration of expected revenue and decreases in expected costs. The $2.3&nbsp;million change to the contingent consideration during the six months
ended June&nbsp;30, 2019 was primarily due to $1.6&nbsp;million resulting from the impact of the acceleration of expected revenue and decreases in expected costs as a result of events occurring after the acquisition date, as well as
$0.7&nbsp;million resulting from the from the accretion of the liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant unobservable inputs used in the measurement of
fair value of the Company&#146;s contingent consideration are probabilities of successful achievement of the Milestone, the period in which the Milestone is expected to be achieved and discount rates ranging from 12.2% to 13.5%. Significant
increases or decreases in any of these inputs would result in a significantly higher or lower fair value measurement. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5&#151;Balance Sheet
Disclosures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,415</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for each of the six months ended June&nbsp;30, 2020 and 2019 was $0.4&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademarks (indefinite life)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded amortization expense of $1.0&nbsp;million for the six months ended June&nbsp;30, 2020 and
2019. Amortization related to the remaining net intangible assets is scheduled to amortize as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remainder of 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation related accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical trial expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6&#151;Convertible Notes Payable </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, the Company issued $10&nbsp;million in convertible debt (the &#147;March 2020 Notes&#148;) that is scheduled to mature in August
2020. The March 2020 Notes were issued in two tranches of $5&nbsp;million, with the first tranche being funded in March 2020 and the second tranche in June 2020. Interest on the March 2020 Notes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is at 3% per annum and is payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date
and if the March 2020 Notes are unpaid, the outstanding principal and unpaid accrued interest under the March 2020 Notes shall be automatically converted into, the earlier of, the preferred stock sold at the close of the Company&#146;s next equity
financing (Qualified Financing) or common stock in an initial public offering (IPO). The conversion price would be equal to 80% of the price per share paid for the preferred stock in the Qualified Financing or common stock sold in an IPO. The March
2020 Notes may be prepaid in whole or in part at any time by the Company with prior consent of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the note holders. In the event of a corporate transaction, the unpaid principal and accrued
interest shall become immediately due and payable in the same form of consideration and on the same terms and conditions as the consideration to be received by the holders of the equity securities of the Company in such transaction. The discounts on
the automatic conversions created a put option liability that was separated from the March 2020 Notes. The estimated value of the put option liability as of the issuance of the March 2020 Notes was $2.5&nbsp;million. The put option liability was
reflected as a debt discount on the March 2020 Notes which is being amortized over the term of the March 2020 Notes. The unamortized debt discount was $1.4&nbsp;million as of June&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the Company issued $6&nbsp;million in convertible debt (the &#147;December 2019 Notes&#148;) that is scheduled to mature in
August 2020. The December 2019 Notes were issued in two tranches of $3&nbsp;million, with the first tranche being funded in December 2019 and the second tranche in February 2020. Interest on the December 2019 Notes is at 3% per annum and is payable
in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the December 2019 Notes are unpaid, the outstanding principal and unpaid accrued
interest under the December 2019 Notes shall be automatically converted into, the earlier of, the preferred stock sold at the close of the Company&#146;s next equity financing (Qualified Financing) or common stock in an initial public offering
(IPO). The conversion price would be equal to 80% of the price per share paid for the preferred stock in the Qualified Financing or common stock sold in an IPO. The December 2019 Notes may be prepaid in whole or in part at any time by the Company
with prior consent of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the note holders. In the event of a corporate transaction, the unpaid principal and accrued interest shall become immediately due and payable in the same form of
consideration and on the same terms and conditions as the consideration to be received by the holders of the equity securities of the Company in such transaction. The discounts on the automatic conversions created a put option liability that was
separated from the December 2019 Notes. The estimated value of the put option liability as of the issuance of the December 2019 Notes was $0.8&nbsp;million for each tranche issued. The put option liability was reflected as a debt discount on the
December 2019 Notes which is being amortized over the term of the December 2019 Notes. The unamortized debt discount was $0.3&nbsp;million and $0.7&nbsp;million as of June&nbsp;30, 2020 and December&nbsp;31, 2019, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August and September 2019 (the &#147;August 2019 Notes&#148;), the Company issued $10&nbsp;million in convertible debt that is scheduled to
mature in August 2020. Interest on the August 2019 Notes is at 3% per annum and is payable in full upon maturity through the conversion to Series H Preferred Stock at the original issuance price of $1.15 per share. On or before the maturity date and
if the August 2019 Notes are unpaid, the outstanding principal and unpaid accrued interest under the August 2019 Notes shall be automatically converted into, the earlier of, the preferred stock sold at the close of the Company&#146;s next equity
financing (Qualified Financing) or common stock sold in the event of an IPO. The conversion price would be equal to 95% of the price per share paid for the preferred stock in the Qualified Financing or common stock sold in an IPO. The August 2019
Notes may be prepaid in whole or in part at any time by the Company with prior consent of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the August 2019 Note holders. In the event of a corporate transaction, the unpaid principal and
accrued interest shall become immediately due and payable in the same form of consideration and on the same terms and conditions as the consideration to be received by the holders of the equity securities of the Company in such transaction. The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discounts on the automatic conversions created a put option liability that was separated from the August 2019 Notes. The estimated value of the put option liability as of the issuance of the
August 2019 Notes was $0.5&nbsp;million. The put option liability was reflected as a debt discount on the August 2019 Notes which is being amortized over the term of the August 2019 Notes. The unamortized debt discount was $0.1&nbsp;million and
$0.3&nbsp;million as of June&nbsp;30, 2020 and December&nbsp;31, 2019, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the December 2019
Notes, the conversion price on the August 2019 Notes was amended to 80% of the price per share paid for the preferred stock in the Qualified Financing or common stock in an IPO. In addition, the conversion price to Series H preferred stock at the
maturity date was amended to be 80% of the Series H original issuance price of $1.15 per share. The changes to the discounts on the conversions of the August 2019 Notes created an increase to the put option liability on the August 2019 Notes of
$2&nbsp;million to a total estimated value of $2.5&nbsp;million as of December&nbsp;31, 2019. The increase in the value of the put option liability was reflected as a change in put option in the accompany 2019 statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of convertible notes payable is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 2020 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December 2019 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 2019 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,728</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7&#151;Long-Term Debt </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Paycheck Protection Program Note Payable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2020, Company entered into a loan pursuant to the Paycheck Protection Program under the CARES Act, as administered by the U.S. Small
Business Administration (the &#147;SBA&#148;). The loan, in the principal amount of $ 3.1&nbsp;million (the &#147;PPP Loan&#148;), was disbursed by JPMorgan Chase Bank (&#147;Lender&#148;) pursuant to a Paycheck Protection Program Promissory Note
and Agreement (the &#147;Note and Agreement&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PPP Loan matures on the <FONT STYLE="white-space:nowrap">two-year</FONT>
anniversary of the funding date and bears interest at a fixed rate of 1.00% per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (discussed below), will commence after the
<FONT STYLE="white-space:nowrap">six-month</FONT> anniversary of the funding date. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan. The Note
and Agreement provides for customary events of default, including those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects. The Company may prepay the principal of the PPP Loan at any time
without incurring any prepayment charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All or a portion of the PPP Loan may be forgiven by the SBA and the Lender upon application by
the Company. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during the eight-week period beginning on the approval date of the PPP Loan. For purposes of the
CARES Act, payroll costs exclude compensation of an individual employee earning more than $100,000, prorated annually. Not more than 40% of the forgiven amount may be for <FONT STYLE="white-space:nowrap">non-payroll</FONT> costs. Forgiveness is
reduced if full-time headcount declines, or if salaries and wages for employees with salaries of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$100,000 or less annually are reduced by more than 25%. The Company cannot assure that the PPP Loan will be forgiven, in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for the PPP Loan as debt in accordance with FASB ASC 470, <I>Debt</I> and accrues interest in accordance with the
interest method. If the loan is forgiven in part or in whole, and legal release is received, the Company will reduce the liability by the amount forgiven and record a gain on extinguishment in the statement of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Note Payable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
February 2018, the Company extinguished a Note that originated in 2013 (the &#147;2013 Notes&#148;) through the issuance of new long-term debt with a different private investment company (the &#147;2018 Notes&#148;). The lender for the 2018 Notes is
also a holder of the Company&#146;s Series G preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial amount borrowed under the 2018 Notes was $23&nbsp;million and
the maturity date is February 2023. At the time of the issuance of the 2018 Notes, the Company paid a 1% facility fee of $0.2&nbsp;million and issued a warrant to the private investment company for the purchase of 613,333 shares of Series G
preferred stock, which had an initial fair value of $0.3&nbsp;million. The facility fee and the value of the warrants were recorded as reductions to the carrying value of the 2018 Notes and are being amortized to interest expense over the term of
the 2018 Notes. The 2018 Notes bears interest at 10% with 7.5% being paid in cash and 2.5% being added to the principal value of the 2018 Notes through December&nbsp;31, 2020. The Company is required to make quarterly interest payments beginning in
June 2018 and outstanding principal is due in 24 equal installments commencing in March 2021. As of June&nbsp;30, 2020 and December&nbsp;31, 2019, the interest added to the principal value of the 2018 Notes was $1.4&nbsp;million and
$1.1&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loan may be prepaid by the Company at any time, subject to a prepayment penalty of up to 3% of the
principal amount, depending on the date of prepayment. Upon payment of the 2018 Notes at maturity or prepayment on any earlier date, unless waived, a 2% <FONT STYLE="white-space:nowrap">back-end</FONT> facility fee will apply to the amounts paid or
prepaid. The 2% fee is being recorded as additional interest expense over the term of the 2018 Notes. The 2018 Notes are senior to all of the Company&#146;s other indebtedness including any contingent consideration payable to Indi. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 Notes contains customary affirmative covenants, including covenants regarding compliance with applicable laws and regulations,
payment of taxes, insurance coverage, notice of certain events, and reporting requirements. Further, the 2018 Notes contains customary negative covenants limiting the ability of the Company to, among other things, to incur future debt, transfer
assets except for the ordinary course of business, make acquisitions, make certain restricted payments, and sell assets, subject to certain exceptions. In addition, the 2018 Notes requires the Company to comply with a minimum daily liquidity
covenant and a rolling monthly revenue requirement. Failure to comply with the covenants and loan requirements may result in early amortization of the loan in a <FONT STYLE="white-space:nowrap">24-</FONT> or
<FONT STYLE="white-space:nowrap">36-month</FONT> payment schedule. As of June&nbsp;30, 2020, the Company was not in default under the terms of the 2018 Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the 2018 Notes, the Company granted the lender a security interest in all of the Company&#146;s assets through a pledge and
security agreement, patent security agreement and trademark security agreement, each between the Company and the lender. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-term notes payable as of June&nbsp;30, 2020 and December&nbsp;31, 2019 was as follows
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Final payment fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt discount and debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(458</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current maturities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,064</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Maturities of long-term obligations as of June&nbsp;30, 2020 are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remainder of 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with entering into the 2018 Notes, the Company issued to the lender a warrant to purchase
613,333 shares of Series G convertible preferred stock, at an exercise price of $0.75 per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on February&nbsp;23, 2028.
The fair value of the warrant on the issuance date of $0.3&nbsp;million was recorded as a debt discount and as a preferred stock warrant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8&#151;Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
inception, the Company has incurred net taxable losses, and accordingly, no current provision for income taxes has been recorded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9 &#150;
Commitments </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases facilities under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases. Rent expense was $1.1&nbsp;million
for the six months ended June&nbsp;30, 2020 and 2019, and was inclusive of common area maintenance charges. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments for operating lease obligations, net of sublease income are as
follows as of June&nbsp;30, 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remainder of 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Co-Development</FONT> Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO Oncology (&#147;AVEO&#148;) to develop and
commercialize AVEO&#146;s hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company&#146;s proprietary companion diagnostic test, BDX004, a version of the Company&#146;s serum protein test that is commercially available to help
physicians guide treatment decisions for patients with advanced <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;). Under the terms of the agreement, AVEO will conduct a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> (&#147;POC&#148;) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects, referred to as the NSCLC POC Trial. The Company and AVEO will share
equally in the costs of the NSCLC POC Trial, and each will be responsible for 50% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC
clinical trials of ficlatuzumab in combination with BDX004 with each responsible for 50% of development and regulatory costs. Expenses related to this agreement for the six months ended June&nbsp;30, 2020 and 2019 were approximately
$0.7&nbsp;million and $0.2&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2019, we entered into the <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> License. Under the terms of the <FONT
STYLE="white-space:nowrap">Bio-Rad</FONT> License, the Company received a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, without the right to grant sublicenses, to utilize certain of
<FONT STYLE="white-space:nowrap">Bio-Rad&#146;s</FONT> intellectual property, machinery, materials, reagents, supplies and <FONT STYLE="white-space:nowrap">know-how</FONT> necessary for the performance of Droplet Digital PCR (ddPCR) in cancer
detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from <FONT STYLE="white-space:nowrap">Bio-Rad,</FONT> pursuant to a separately
executed supply agreement with <FONT STYLE="white-space:nowrap">Bio-Rad.</FONT> As further consideration for the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license, the Company agreed to pay a royalty of 2.5% on the net revenue received
for the performance of such ddPCR testing collected from third parties. <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> License expires in August 2024. Either party may terminate for the other&#146;s uncured material breach or bankruptcy events. <FONT
STYLE="white-space:nowrap">Bio-Rad</FONT> may terminate the <FONT STYLE="white-space:nowrap">Bio-Rad</FONT> License if the Company does not purchase licensed products under the separate supply agreement for a consecutive twelve-month period or for
any material breach by us of the supply agreement. The Company incurred royalty expense of $0.1&nbsp;million for the six months ended June&nbsp;30, 2020 under this agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10&#151;Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table details, by series, the Company&#146;s convertible preferred stock at June&nbsp;30, 2020 (in thousands, except shares and
original issue price): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Issued and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Defined<BR>Original<BR>Issue&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series H</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,031,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,923,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series G</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,464,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,146,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series F</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,468,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,468,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,972,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,639,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,781,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,874,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,356,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,356,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,641,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,641,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,432,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,766,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Series H </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February and March 2019, the Company issued 8,695,621 shares of Series H Preferred Stock at $1.15 per share for total cash proceeds of
$10.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible preferred stock has been classified as temporary equity in the accompanying balance
sheets given that a majority of the Company&#146;s Board of Directors seats are held by convertible preferred stock holders and could cause certain events to occur that are outside of the Company&#146;s control whereby the Company could be obligated
to redeem the convertible preferred stock. The Company has not adjusted the carrying values of the convertible preferred stock to the respective liquidation preferences of such shares as the instruments are currently not redeemable and the Company
believes it is not probable that the instruments will become redeemable at this point in time. Adjustments to increase the carrying values to the respective liquidation preferences will be made if and when it becomes probable that an event would
occur obligating the Company to pay such amounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conversion Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Series <FONT STYLE="white-space:nowrap">A-1,</FONT> Series <FONT STYLE="white-space:nowrap">A-2,</FONT> and Series <FONT
STYLE="white-space:nowrap">A-3</FONT> (collectively, &#147;Series A&#148;); Series B and Series <FONT STYLE="white-space:nowrap">B-1</FONT> (collectively, &#147;Combined Series B&#148;); Series C; Series D; Series E; Series F, Series G, and Series H
are entitled to convert their shares into common stock at the option of the holder, at any time, into fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock. The number of shares of common stock to which a
holder of the Series A, Combined Series B, Series C, Series D, Series E, Series F, Series G, and Series H (collectively, &#147;Series Preferred&#148;) can convert is obtained by multiplying the conversion rate that is in effect by the number of
shares of Series Preferred being converted. The conversion rate is determined by dividing the Original Issue Price by the applicable conversion price (initially the Original Issue Price for all classes of Series Preferred except Series <FONT
STYLE="white-space:nowrap">B-1,</FONT> for which the conversion price is initially $16.33). As a result of the reverse stock split (see Note 14), the conversion rate for the Series Preferred is 0.1684664 per share. Each share of Series Preferred
will be automatically converted into shares of common stock (based on the then-effective Series Preferred conversion price) if there is an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affirmative election of 65% of the holders of the outstanding shares of Series Preferred or immediately upon the closing of a firmly underwritten public offering in which the offer and sale of
common stock, voting together as a single class on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to</FONT></FONT></FONT> -common-stock basis, is at a <FONT
STYLE="white-space:nowrap">per-share</FONT> price of at least $11.88 (adjusted for stock splits, dividends, and recapitalizations) and gross cash proceeds to the Company (before underwriting discounts, commissions, and fees) are at least
$40&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series Preferred holders are entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT> cash dividends. The dividends are
required to be declared by the Board of Directors and are calculated at an annual rate of 8% of the Original Issue Price of the respective Series Preferred shares. Series Preferred holders have the following order of preference on dividends: Series
H holders, Series G holders, Series F holders, Series E holders, Series D holders, Series C holders, Combined Series B holders, Series A holders. The Series A holders have preference over the common stockholders. In the event that dividends are paid
on any class of Series Preferred, the Company shall pay an additional dividend on all outstanding shares of a higher preference in a <FONT STYLE="white-space:nowrap">per-share</FONT> amount on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to-common-</FONT></FONT></FONT></FONT> stock basis. In the event dividends are paid on any common stock, the Company shall pay an additional
dividend on all outstanding shares of Series Preferred stock in a <FONT STYLE="white-space:nowrap">per-share</FONT> amount on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">as-if-converted-to-common-stock</FONT></FONT></FONT></FONT> basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of each share of Series Preferred stock have the right to one vote for each share of common stock on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted</FONT></FONT> basis. When converted, the common stock and Series Preferred stockholders have equal voting and power rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As long as any Series Preferred stock remains outstanding, a majority vote of the respective class of holders would be required to amend any
provisions of the Company&#146;s articles of incorporation or bylaws that would adversely affect them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Series Preferred stockholders are subject to automatic redemption in the consolidation or merger of the Company or sale of all or substantially
all of the Company&#146;s assets in which the stockholders of the Company immediately prior to the transaction hold less than 50% of the outstanding securities of the surviving entity. Proceeds available for distribution from such transaction will
be distributed consistent with a liquidation event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the articles of incorporation, upon a defined event of acquisition or asset transfer, liquidation, dissolution, or winding
up of the Company, any amounts that are available for distribution are to be paid out to its stockholders in the following order of preference, in an amount equal to the <FONT STYLE="white-space:nowrap">per-share</FONT> Original Issue Price, plus
any accrued, declared, and unpaid dividends: Series H holders, Series G holders, Series F holders, Series E holders, Series D holders, Series C holders, Combined Series B holders, Series A holders. If the assets of the Company are insufficient to
make payments in full to a class of holders of preferred stock, in the order of preference previously described, then remaining assets shall be distributed among the holders of that class of preferred stock ratably in proportion to the full amounts
to which they would otherwise be respectively entitled and the holders of lower preference shares will receive nothing. Upon payment of all preferential amounts required to be paid to the Series Preferred, the holders of common stock and Series
Preferred shall be entitled to receive a ratable portion, calculated on an as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-if-converted</FONT></FONT> basis, of the remaining assets of the Company available for distribution to
its stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11&#151;Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2006, the Company adopted the 2006 Employee, Director, and Consultant Stock Plan (the &#147;2006 Plan&#148;) under which the Company is
authorized to grant stock awards to employees, directors, and consultants of the Company. The Company is authorized to grant incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, restricted stock awards,
restricted stock unit awards, and stock appreciation rights up to 831,388 total shares of stock awards. The award price and vesting terms are determined by the Board of Directors of the Company and evidenced in the award agreement extended to the
employee, director, or consultant. The options granted generally terminate ten years from the date of grant and vest over various periods as determined by the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the Company adopted the 2016 Equity Incentive Plan (&#147;2016 Plan&#148;) as a successor to and continuation of the 2006
Plan. As of February 2016, no additional stock awards may be granted under the 2006 Plan and any unallocated shares remaining available for issuance pursuant to the exercise of options or issuance or settlement of stock awards not previously granted
under the 2006 Plan will cease to be available under the 2006 Plan and will be added to the share reserve of the 2016 Plan and be immediately available for issuance pursuant to the stock awards granted in the 2016 Plan. In addition, all outstanding
stock awards granted under the 2006 Plan will remain subject to the terms of the 2006 Plan unless they expire, terminate or are forfeited, cancelled or otherwise returned to the Company and will immediately be added to the share reserve and become
available for issuance under the 2016 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2016 Plan, the Company is authorized to grant stock awards to employees, directors,
and consultants of the Company. The Company is authorized to grant incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, restricted stock awards, restricted stock unit awards, and stock appreciation rights up
to 1,431,964 total shares, plus any shares subject to outstanding stock awards granted under the 2006 Plan. The award price and vesting terms are determined by the Board of Directors of the Company and evidenced in the award agreement extended to
the employee, director, or consultant. The options granted generally terminate 10 years from the date of grant and vest over various periods as determined by the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the activity for options and restricted stock units (RSUs) outstanding (in thousands, except for weighted average
exercise price and weighted average grant date value per share): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSUs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Grant<BR>Date<BR>Value&nbsp;Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the composition of options outstanding and exercisable as of
June&nbsp;30, 2020 (in thousands, except price and life): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options&nbsp;Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exercise Prices</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Life<BR>(years)*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$0.42 &#150; $0.84</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$2.62 &#150; $3.74</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$4.40 &#150; $4.46</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$6.83</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total&#151;June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Price and Life reflect the weighted average exercise price and weighted average remaining contractual life,
respectively. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were 52,736 and 26,449 restricted stock units outstanding at June&nbsp;30, 2020 and
December&nbsp;31, 2019, respectively, none of which had vested as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option grant is estimated
on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions for the six months ended June&nbsp;30, 2020 (dollars in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Approximate risk&#151;free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.55</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average expected life</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of total options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates volatility based on the historical volatility of its peer group and average expected
life based on the review of historical exercise behavior of option grants with similar vesting periods. The expense recorded for options granted under the Plan is net of estimated forfeitures of 10%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the impact of employee stock-based compensation expense on statements of income line items for the periods
indicated (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales, marketing, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unrecognized remaining stock-based compensation balance for shares issued inside of the Plan was
approximately $0.5&nbsp;million as of June&nbsp;30, 2020 which will be amortized over the next three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, the
Company has issued a total of 205,199 stock options outside the 2006 Plan to employees of the Company. These options are issued at the discretion of the Board of Directors of the Company to the Chief Executive Officer and their direct reports who
wish to convert all or a portion of their incentive compensation to options. The value of the options at the date of grant was calculated using the Black-Scholes </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
option pricing model using approximately the same assumptions as in the previous table other than the term, which is approximately five years. As of June&nbsp;30, 2020, 173,233 options outside of
the 2006 Plan are outstanding and exercisable and have a weighted average exercise price of $11.11, a weighted average remaining life of six years, and were fully vested on the grant date. There was no unrecognized remaining stock-based compensation
balance for shares issued outside of the 2006 Plan as of June&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12&#151;Warrants for Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has issued warrants to purchase shares of preferred stock in conjunction with the sale of certain preferred shares and certain debt
issuances. The grant date fair value and fair value at each reporting date of the warrants was determined using the Black-Scholes option pricing model with weighted average assumptions relatively consistent with those disclosed for stock options
above, other than term, which is the contractual term of the warrant and the use of the exercise price and current estimated fair value of the respective series of preferred stock. The preferred warrants are classified as liabilities on the
accompanying balance sheets as the underlying preferred stock has a contingent redemption feature. As these warrants are classified as a liability, they are revalued on each reporting date or exercise date, and any change in value is recorded to
change in fair value of the warrant liability in the accompanying statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the activity for
convertible preferred stock warrants outstanding (in thousands, except weighted average exercise price): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series G</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining contractual life at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center">7.5 years</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 13&#151;Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated all subsequent events through the auditors&#146; report date, which is the date the condensed financial statements
were available for issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, the Company exercised its <FONT STYLE="white-space:nowrap">opt-out</FONT> right with Aveo
for the of payment of 50% of development and regulatory costs for ficlatuzumab which will be effective December&nbsp;2, 2020. The Company estimates it has $0.3&nbsp;million in remaining obligations related to the Aveo agreement as of the <FONT
STYLE="white-space:nowrap">opt-out</FONT> date. Following the effective date, the Company will be entitled to a 10% royalty of net sales of ficlatuzumab and 25% of license income generated from the licensing of ficlatuzumab from Aveo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, the Company terminated its option to license rights within the United States from Oncimmune to an additional indication for
their product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, the Company extended the maturity date of the Convertible Notes to June&nbsp;30, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 14&#151;Reverse Stock Split </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;19, 2020, the Company obtained approval of an Amended and Restated Certificate of Incorporation effecting a 0.1684664-for-1
reverse stock split of its issued and outstanding common stock as converted. All common shares, stock options, and per share information presented in these financial statements and notes thereto have been adjusted, where applicable, to reflect the
reverse stock split on a retroactive basis for all periods presented. The per share par value and authorized number of shares of the Company&#146;s common stock were not adjusted as a result of the split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin937421_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biodesix, Inc.: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have audited the accompanying balance sheets of Biodesix, Inc. (the Company) as of December&nbsp;31, 2019 and 2018, the related statements of operations, changes in convertible preferred stock and stockholders&#146; deficit, and cash flows for each
of the years in the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2019, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material
respects, the financial position of the Company as of December&nbsp;31, 2019 and 2018, and the results of its operations and its cash flows for each of the years in the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31,
2019, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to
error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included
examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the
overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denver, Colorado </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;27, 2020, except for earnings per
share and Note 1(aa), as to which the date is August&nbsp;12, 2020 and Note 14, as to which the date is October&nbsp;20, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin937421_7"></A>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Direct costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales, marketing, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of put option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,985</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(126.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(130.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (1.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares outstanding, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin937421_8"></A>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Assets</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Liabilities and Stockholders&#146; Deficit</B></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Put option liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.001 par value, 174,237,067 (2019) and 156,350,836 (2018)
authorized; 118,766,273 (2019) and 110,070,652 (2018) issued and outstanding; liquidation preference of $202,582 (2019)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 190,000,000 (2019) and 180,000,000 (2018) authorized; 254,918
(2019) and 214,885 (2018) issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(230,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(228,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(198,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin937421_9"></A>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2019 AND 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B-1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative effect of ASC 606 Adoption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series G Preferred Stock&#151;net of issuance costs of $11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series G Preferred Stock related to business combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series H Preferred Stock, net of issuance costs of $44</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series H for debt conversion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series H Preferred Stock, net of issuance costs of $3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2019 AND 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Continued from the
previous page) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series F</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative effect of ASC 606 Adoption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series G Preferred Stock&#151;net of issuance costs of $11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series G Preferred Stock related to business combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series H Preferred Stock, net of issuance costs of $44</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series H for debt conversion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series H Preferred Stock, net of issuance costs of $3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2019 AND 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Continued from the
previous page) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series G</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series H</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Convertible<BR>Preferred</B><br><B>Stock</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-In</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulate</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholder</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(174,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(172,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cumulative effect of ASC 606 Adoption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series G Preferred Stock&#151;net of issuance costs of&nbsp;$11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series G Preferred Stock related to business combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series H Preferred Stock, net of issuance costs of&nbsp;$44</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series H for debt conversion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">183,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(200,138</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(198,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series H Preferred Stock, net of issuance costs of&nbsp;$3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance&#151;December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">193,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(230,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(228,539</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin937421_10"></A>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in
operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of convertible debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on disposal of assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> portion of loss on extinguishment of
debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of put option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Write off of assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued interest on debt payable and convertible debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for doubtful accounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in
acquisitions:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash and cash equivalents and restricted cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,677</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(498</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent costs and intangible asset acquisition, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(106</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments to acquire Oncimmune assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash and cash equivalents and restricted cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,872</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(617</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of series G preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of series H preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from long-term debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments of equipment financing and debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,518</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt and equity financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash and cash equivalents and restricted cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash&#151;beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash&#151;end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Continued from the
previous page) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Supplemental disclosure of cash flow information: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">There was no cash paid for income taxes during the years ended December&nbsp;31, 2019 and 2018. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash paid for interest for the years ended December&nbsp;31, 2019 and 2018 was $1.8&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> activity (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued business combination payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value of put option recorded at issuance of convertible debt payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series G Preferred Stock in business combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of warrants issued as part of 2018 loan agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible debt payable plus accrued interest into Series H Preferred
Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:350pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See notes to financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin937421_11"></A>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
1&#151;Description of Business and Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(a) Organization and Nature of Operations
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biodesix, Inc. (the &#147;Company&#148;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The
Company&#146;s headquarters are in Colorado, with laboratories in Colorado, Kansas, and Washington. Biodesix is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform
to discover, develop, and commercialize solutions for clinical unmet needs, with a </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">primary focus in lung disease. In addition to diagnostic tests, the
Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to various risks and uncertainties frequently encountered by early stage life science companies. Such risks and
uncertainties include, but are not limited to, undeveloped technology, strict regulatory requirements and approval of products, a limited operating history, competition from other service providers, dependence on key personnel, the need for ongoing
capital to fund operations, and management of rapid growth. To address these risks, the Company must, among other things, successfully develop its customer base, successfully execute its business and marketing strategy, successfully develop its
technology, raise capital on acceptable terms to the Company, and attract, retain, and motivate qualified personnel. There can be no guarantee that the Company will be successful in addressing these or other such risks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(b) Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of
America (U.S. GAAP). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(c) Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. Areas of the financial statements where estimates have the most significant effect include the valuation of contingent consideration and purchased technology related to the Company&#146;s business acquisition,
stock-based compensation, valuation of put option liabilities, and the valuation allowance related to net deferred tax assets. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(d) Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates in&nbsp;one&nbsp;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment,
leasehold improvements, and other fixed assets are physically located within the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(e) Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from <FONT
STYLE="white-space:nowrap">non-owner</FONT> sources. If the Company had comprehensive gains (losses), they would be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#146; deficit. There were no elements of comprehensive loss during the
years ended December&nbsp;31, 2019 and 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(g) Concentration of Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to credit risk from its accounts receivable related to services provided to its customers. Reimbursement on behalf of
customers covered by Medicare accounted for 60% and 61% of the Company&#146;s diagnostic test revenue for the years ended December&nbsp;31, 2019 and 2018, respectively, and represented 18% and 44% of the Company&#146;s total accounts receivable
balance as of December&nbsp;31, 2019 and 2018, respectively. One services customer represented 44% and 25% of the Company&#146;s total accounts receivable balance as of December&nbsp;31, 2019 and 2018, respectively. As of December&nbsp;31, 2019, two
services customers represented 12% and 10% of the Company&#146;s total accounts receivable balance as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(h) Cash, Cash Equivalents, and Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. The
Company continually monitors its positions with, and the credit quality of, the financial institutions with which it invests. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally
insured limits. Included in cash and cash equivalents are money market funds recorded at $4.8&nbsp;million and $5.2&nbsp;million at December&nbsp;31, 2019 and 2018, respectively. These money market funds were measured using Level&nbsp;1 inputs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted cash consists of deposits related to the Company&#146;s corporate credit card and a letter of credit related to an operating lease
agreement. As of December&nbsp;31, 2019 and 2018, the Company had $0.2&nbsp;million in restricted cash, which was included in other current assets in the accompanying balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(i) Accounts Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company provides an allowance for doubtful accounts based on experience and specifically identified risks. Accounts receivable are recorded
at carrying value and charged off against the allowance for doubtful accounts when it is determined that recovery is unlikely and cease collection efforts cease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company analyzes trade accounts receivable quarterly and considers historic experience, customer creditworthiness, facts and circumstances
specific to outstanding balances, and payment terms when evaluating the adequacy of the allowance for doubtful accounts. The Company recorded an allowance for doubtful accounts of $0.2&nbsp;million as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(j) Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories are stated at the lower of cost or net realizable value on a <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT
STYLE="white-space:nowrap">first-out</FONT> basis. Inventory consists primarily of supplies, which are consumed when processing tests. The Company does not maintain any finished goods inventory. Inventory balances were $0.8&nbsp;million and
$0.7&nbsp;million as of December&nbsp;31, 2019 and 2018, respectively, and are included in other current assets in the accompanying balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(k) Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost. Depreciation is provided utilizing the <FONT STYLE="white-space:nowrap">straight-line</FONT> method
over the estimated useful lives, ranging from three to five years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(l) Intangible Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets are stated at cost, net of accumulated amortization and include patents, trademarks, and acquired developed technology.
Trademarks have an indefinite life and are not being amortized but are reviewed for impairment on an annual basis. External costs associated with patents are capitalized as long as such efforts are expected to be successful. Upon approval of the
patent, the related capitalized costs are amortized over the lesser of the contractual term of the patent or the estimated useful life of 10 years. Acquired developed technology is amortized over a useful life of 9 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets are reviewed for impairment whenever events or changes in circumstances may affect the recoverability of the intangible
assets. Such reviews include an analysis of current results and take into consideration the undiscounted value of projected operating cash flows. See Note 3, Business Combination, for further information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(m) <FONT STYLE="white-space:nowrap">Long-Lived</FONT> Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reviews its <FONT STYLE="white-space:nowrap">long-lived</FONT> assets for impairment whenever events or changes in circumstances
indicate that the carrying amount of the asset may not be recovered. The Company looks primarily to the undiscounted future cash flows in its assessment of whether or not <FONT STYLE="white-space:nowrap">long-lived</FONT> assets have been impaired.
The Company has determined that no impairments are necessary for the periods presented. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(n) Deferred Rent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases office space under <FONT STYLE="white-space:nowrap">non-cancelable,</FONT> <FONT STYLE="white-space:nowrap">long-term</FONT>
operating leases that include scheduled increases in minimum rents and renewal provisions at the option of the Company. The expense associated with leases that have escalating payment terms is recognized on a
<FONT STYLE="white-space:nowrap">straight-line</FONT> basis over the lease term. Tenant improvement allowances received from a lessor are recorded as a deferred rent liability and recognized evenly as a reduction to rent expense over the remaining
lease term. The portion of the deferred rent liability that will reverse in the next 12 months is not significant to the balance sheets; therefore, the entire amount was recorded as <FONT STYLE="white-space:nowrap">non-current</FONT> in the
accompanying financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(o) Goodwill </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwill is recorded when the purchase price paid for an acquisition exceeds the estimated fair value of the net identified tangible and
intangible assets acquired.&nbsp;Goodwill is not amortized and is tested for impairment at the reporting unit level on an annual basis as of December&nbsp;31 and between annual tests if an event occurs or circumstances change that would more likely
than not reduce the fair value of the reporting unit below its carrying value.&nbsp;The Company may first perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its
carrying value.&nbsp;If it is concluded that this is the case, it is necessary to perform a quantitative <FONT STYLE="white-space:nowrap">two-step</FONT> goodwill impairment test.&nbsp;Otherwise, the <FONT STYLE="white-space:nowrap">two-step</FONT>
goodwill impairment test is not required.&nbsp;The quantitative <FONT STYLE="white-space:nowrap">two-step</FONT> goodwill impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value.
Multiple valuation techniques can be used to assess the fair value of the reporting unit.&nbsp;All these techniques include the use of estimates and assumptions that are inherently uncertain.&nbsp;Changes in these estimates and assumptions could
materially affect the determination of fair value or goodwill impairment, or both. The Company assessed qualitative factors to determine whether it is more likely than not that the fair value of Goodwill exceeded the carrying value. Based on that
assessment, there were no events or circumstances in 2019 and 2018 to indicate that the fair value of goodwill exceeded its carrying value, and thus a quantitative analysis was not performed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes the Company&#146;s goodwill activity (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to 2018 acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to 2019 acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company did not have any goodwill impairments for the years ended December&nbsp;31, 2019 and 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(p) Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues are recognized when control of the promised services is transferred to customers, in an amount that reflects the consideration the
Company expects to be entitled to in exchange for those services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s revenue is generated from the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Diagnostic tests. These services are completed upon the delivery of test results to the prescribing physician,
which is considered the performance obligation. The fees for such services are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Services. These services are generally completed upon the delivery of test results for assay development and
testing services, which is considered the performance obligation. Customers for these services are typically large pharmaceutical companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2019 and 2018 revenue from these services consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diagnostic tests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diagnostic test revenue that were reimbursed by Medicare comprised 60% and 61% of diagnostic test revenue in
2019 and 2018, respectively. One services customer comprised 71% and 95% of services revenue in 2019 and 2018, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from
diagnostic tests are recognized when the performance obligation is satisfied, which is when a customer receives results of the Company&#146;s tests, which is generally upon delivery to the requesting physician. Revenue from services are recognized
when the performance obligation is satisfied, which is when a customer receives results of the Company&#146;s tests, which is generally upon the delivery of test results for assay development and testing services. The Company also provides services
to patients with whom the Company does not have contracts as defined in ASC 606, <I>Revenue from Contracts with Customers</I> (ASC 606). The Company recognizes revenue for these patients when contracts as defined in ASC&nbsp;606 are established at
the amount of consideration to which it expects to be entitled or when the Company receives substantially all of the consideration subsequent to the performance obligations being satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines the transaction price related to its diagnostic test contracts by
considering the nature of the payer and historical price concessions granted to groups of customers. For diagnostic test revenue, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive
in exchange for providing services based on its historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(q) Deferred Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred revenue primarily consists of services fee payments received in advance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(r) Research and Development Expenses and Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenditures made for research and development are charged to expense as incurred. External costs consist primarily payments to clinical trial
sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#146;s discovery and preclinical activities, process development and clinical development activities.&nbsp;Internal costs consist primary of
employee-related costs, facilities, depreciation and costs related to compliance with regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates and
accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result
in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company&#146;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the
status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(s) <FONT STYLE="white-space:nowrap">Stock-Based</FONT> Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation arrangements with employees and recognizes
compensation expense for <FONT STYLE="white-space:nowrap">stock-based</FONT> awards based on the estimated fair value of the awards. Compensation expense for all employee <FONT STYLE="white-space:nowrap">stock-based</FONT> awards is based on the
estimated <FONT STYLE="white-space:nowrap">grant-date</FONT> fair value and recognized as an expense on a straight-line basis over the requisite service period (generally the vesting period). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(t) Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes deferred tax assets and liabilities based on the differences between the tax basis of assets and liabilities and their
reported amounts in the financial statements and net operating loss carryforwards that will result in taxable or deductible amounts in future years. The Company establishes a valuation allowance for all deferred tax assets to the extent it is more
likely than not that a deferred tax asset will not be realized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(u) Warrant Liability </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Freestanding financial instruments that permit the holder to acquire shares that are either puttable by the holder, redeemable or contingently
redeemable are required to be reported as liabilities in the financial statements. The issuer must present such liabilities on the balance sheets at their estimated fair values. Changes in fair value of the liability are calculated each reporting
period, and any change in value is recognized in operations. The Company has determined that certain warrants issued to investors and lenders, which are exercisable for shares of the Company&#146;s convertible preferred stock, shall be classified as
liabilities due to a contingent redemption provision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(v) Changes in Fair Value of Contingent Consideration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the purchase transaction with Integrated Diagnostics, Inc., the Company recorded contingent consideration pertaining to the
amounts potentially payable to Integrated Diagnostics&#146; shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value
are recognized as operating expenses within the statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of the contingent consideration is
based upon significant assumptions including probabilities of successful achievement of the related milestone event (&#147;Milestone&#148;), the estimated timing in which the Milestone is achieved, and discount rates. The estimated fair value could
materially differ from actual values or fair values determined using different assumptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(w) Fair Value of Financial Instruments
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of financial instruments, including cash and cash equivalents, receivables, other current assets, accounts
payable, and accrued liabilities, approximated fair value as of December&nbsp;31, 2019 and 2018 because of the relatively short maturity of these instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of <FONT STYLE="white-space:nowrap">long-term</FONT> debt payable and convertible debt payable issued approximated fair
value as of December&nbsp;31, 2019 and 2018 because interest rates on these instruments approximate market interest rates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(x)
Business Combinations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the
transaction should be accounted for as a business combination by assessing whether or not the Company has acquired inputs and processes that have the ability to create outputs. If determined to be a business combination, the Company accounts for
business acquisitions under the acquisition method of accounting as indicated in the FASB issued Accounting Standards Codification (&#147;ASC&#148;) Topic 805,<I>&nbsp;Business Combinations</I>&nbsp;(&#147;ASC 805&#148;), which requires the
acquiring entity in a business combination to recognize the fair value of all assets acquired and liabilities assumed and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and
liabilities assumed in business combinations, including contingent assets and liabilities, and <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest in the acquiree based on the fair value estimates as of the date of acquisition. In
accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(y) Recently Issued Accounting Standards Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued ASU <FONT STYLE="white-space:nowrap">2014-09,</FONT>
&#147;Revenue from Contracts with Customers&#148;, and has subsequently issued several supplemental and/or clarifying ASUs (collectively, &#147;ASC 606&#148;). ASC 606 prescribes a single common revenue standard that replaces most existing U.S. GAAP
revenue recognition guidance. ASC 606 is intended to provide a more consistent interpretation and application of the principles outlined in the standard across filers in multiple industries and within the same industries compared to current
practices, which should improve comparability. The Company adopted the new standard using the modified retrospective method on January&nbsp;1, 2018 for contracts that are not completed as of the adoption date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised
goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606,
the entity performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to
the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies a performance obligation. ASC 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. The
standard also requires disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company examined its revenue recognition policies specific to revenue streams for diagnostic testing and services provided to third
parties and came to conclusions on the impact of the new standard using the <FONT STYLE="white-space:nowrap">5-step</FONT> process prescribed by ASC 606. As noted above, the Company used the modified retrospective method to adopt the new standard
which means the Company did not restate previously issued financial statements but recorded a <FONT STYLE="white-space:nowrap">one-time</FONT> adjustment to accumulated deficit and accounts receivable of $0.4&nbsp;million. This adjustment reflected
the Company&#146;s ability to establish a transaction price for the Company&#146;s <FONT STYLE="white-space:nowrap">non-Medicare</FONT> pay arrangements as of January&nbsp;1, 2018 as a result of having sufficient history to determine the transaction
price under these contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC 606 did not have an aggregate impact the Company&#146;s net cash provided by operating activities but
resulted in offsetting changes in certain assets and liabilities presented within net cash used in operating activities in the accompanying statement of cash flows, as noted above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(z) Recently Issued Accounting Standards Not Yet Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the Financial Accounting Standards Board (&#147;FASB&#148;)<U> </U>issued ASU No.
<FONT STYLE="white-space:nowrap">2016-02,</FONT><I>&nbsp;Leases</I> (ASC Topic 842). The new guidance maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability on the statement of financial position for those leases previously classified as operating leases under the old guidance. The
liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning January&nbsp;1, 2021. The
Company is currently evaluating the impact of the lease guidance on the Company&#146;s financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>(aa) Net loss per
share and unaudited pro format net loss per share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per common share is calculated by dividing the net loss
attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable
to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the convertible preferred stock, common stock options,
restricted stock units, preferred stock warrants and convertible debt are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the <FONT
STYLE="white-space:nowrap">two-class</FONT> method required for participating securities as the convertible preferred stock is considered a participating security. The Company&#146;s participating securities do not have a contractual obligation to
share in the Company&#146;s losses. As such, the net loss was attributed entirely to common stockholders. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common
share for those periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the basic and diluted net loss per share
attributable to common stockholders (in thousands, except per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">130.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following outstanding shares of potentially dilutive securities were excluded from the computation of
diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (in thousands, except for per share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,131</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of common shares that convertible debt was assumed to convert to was based on the Company&#146;s
estimated common stock price as of December 31, 2019, as determined by the Company&#146;s board of directors with assistance from a valuation firm. The ultimate conversion price will be based on the fair value of the Company&#146;s common stock at
the completion of an initial public offering. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Unaudited pro forma net loss per share </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unaudited pro forma basic and diluted net loss per share is calculated to give effect to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> conversion of all outstanding shares of the Company&#146;s convertible preferred stock and convertible debt into shares of common stock in using the
<FONT STYLE="white-space:nowrap">as-converted</FONT> method as though the conversion had occurred as of the beginning of the period presented or the date of issuance, if later. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the basic and diluted unaudited pro forma
net loss per share (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,726</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add back: Interest expense on convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss used in computing proforma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjust: Assumed weighted-average effect of conversion of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjust: Assumed weighted-average effect of conversion of convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,088</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding used in computing pro forma net loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of common shares that convertible debt was assumed to convert to was based on the Company&#146;s
estimated common stock price as of December&nbsp;31, 2019, as determined by the Company&#146;s board of directors with assistance from a valuation firm. The ultimate conversion price will be based on the fair value of the Company&#146;s common stock
at the completion of an initial public offering. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2&#151;Liquidity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and liquidation
of liabilities in the ordinary course of business. To date, the Company has funded its activities primarily through private equity placement offerings, convertible debt payable, and <FONT STYLE="white-space:nowrap">long-term</FONT> debt. The Company
is still in its early stage and has yet to generate revenues sufficient to create positive cash flows and most likely will be dependent upon future private equity placements or additional borrowings to execute its business plan. The Company has cash
and cash equivalents of $5.3&nbsp;million, cumulative net losses of $230.9&nbsp;million, and stockholders&#146; deficit of $228.5&nbsp;million as of December&nbsp;31, 2019. Based on cash and cash equivalents on hand and amounts raised subsequent to
December&nbsp;31, 2019, management has determined that additional private equity placement offerings will be necessary to fund operations through May 2021. As a result, the Company has obtained commitment letters from two significant investors which
requires that they will provide funding to the Company to meet its obligations and debt service requirements through at least May 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
3&#151;Business Combinations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Oncimmune Limited </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;31, 2019, the Company purchased select assets and liabilities from Oncimmune Limited (&#147;Oncimmune&#148;) for total
consideration of $1.2&nbsp;million payable in quarterly installments commencing 30 days following the closing of the transaction. Concurrent with the Oncimmune purchase, the Company acquired an option to license rights within the United States to an
additional indication for their product for $9&nbsp;million. This option, which is exclusive to the Company, expires on the earlier of 30 days following Food and Drug Administration approval or December&nbsp;31, 2020. As of December&nbsp;31, 2019,
$0.5&nbsp;million has been paid with the remaining amount due of $0.7&nbsp;million being included in accounts payable and accrued liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the transaction as a business combination in accordance with ASC
805. As such, the assets acquired and liabilities assumed were recorded at fair value, with the remaining purchase price recorded as goodwill. The goodwill associated with the acquisition is the result of expected synergies, an increase in future
revenues as a result of the expansion of the technology into additional markets as well as lower future operating expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
summarizes the aggregate consideration paid by the Company and the allocation of the purchase price (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fair value of consideration transferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Company has finalized its accounting for this business combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Integrated Diagnostics, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;30, 2018, the Company purchased select assets and liabilities from Integrated Diagnostics, Inc. (&#147;Indi&#148;) for total
consideration of $27.6&nbsp;million, consisting of $8.0&nbsp;million (10,649,604 shares) of the Company&#146;s Series G Preferred Stock and contingent consideration with an initial fair value of $19.6 million. The 10,649,904 shares issued at closing
include 2,129,981 shares that were deposited in an escrow account to be used to satisfy any indemnification obligations of Indi that may arise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the transaction as a business combination in accordance with ASC 805. As such, the assets acquired and liabilities
assumed were recorded at fair value, with the remaining purchase price recorded as goodwill. The estimated fair values of acquired assets and assumed liabilities were determined by management with the assistance of an independent third party. The
goodwill associated with the acquisition is the result of expected synergies, an increase in future revenues as a result of the expansion of the technology into additional markets as well as lower future operating expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes the aggregate consideration paid by the Company and the allocation of the purchase price (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock issued&#151;10,694,904 shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fair value of consideration transferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(877</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The acquisition of Indi included a contingent consideration arrangement that requires
additional consideration to be paid by the Company to Indi based on the Milestone of the attainment of a three consecutive month gross margin target of $2&nbsp;million within a seven-year period after the acquisition date. For the six months
following the achievement of the Milestone, Indi has the option to require the Company to pay the contingent consideration in cash over eight equal installments due each calendar quarter or through the issuance of shares of Series&nbsp;G Preferred
Stock. The total amount of undiscounted contingent consideration which the Company may be required to pay under the arrangement is $37.0&nbsp;million.&nbsp;If Indi elects not to exercise these options, the Company has 12 months to either settle the
contingent consideration in two equal quarterly cash installments or in 14,959,114 shares of Series&nbsp;G Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair
value of $19.6 million contingent consideration recognized on the acquisition date was estimated by management with the assistance of an independent third party. These fair value measurements were based on significant inputs not observable in the
market and thus represent Level 3 fair value measurements. See Note 4, Fair Value Accounting, for a discussion of the fair value of the contingent consideration and changes in fair value subsequent to the acquisition date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets acquired, amortization method and estimated useful lives as of June&nbsp;30, 2018 was as follows (dollars in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Useful<BR>Life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortization<BR>Method</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">Straight-line</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The technology acquired from Indi consisted of the technology and related know-how of the XL2 test for which
Indi had developed. The fair value of the technology was estimated by applying a multi-period excess earnings method. The results of this method is based on significant inputs that are not observable in the market, or Level 3 inputs (see discussion
of the fair value hierarchy in Note 4). Key assumptions included (a) projected revenue and related profitable attributable to the acquired technology over the estimated life of the acquired technology and (b) a discount rate of 37.5%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company had finalized its accounting for this business combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4&#151;Fair Value Accounting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company accounts for certain assets and liabilities that are required to be recorded at fair value under a framework for measuring fair value that requires enhanced disclosures about fair value measurements. This framework requires disclosure about
how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped based on significant levels of inputs as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Level&nbsp;1:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quoted prices in active markets for identical assets or liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Level&nbsp;2:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset
or liability; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Level&nbsp;3:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unobservable inputs in which there is little or no market data, which requires the reporting entity to develop
its own assumptions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination of where assets and liabilities fall within this hierarchy is based upon the
lowest level of input that is significant to the fair value measurement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth by level, within the fair value hierarchy, the Company&#146;s
liabilities measured at fair value on a recurring basis (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>December&nbsp;31, 2019:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent value rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>December&nbsp;31, 2018:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent value rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the unobservable inputs needed to calculate the fair value of these balances, these liabilities are
classified as Level&nbsp;3 liabilities. The following is a reconciliation of the beginning and ending balances for assets measured at fair value on a recurring basis using significant unobservable inputs (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent value rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no changes to the valuation methods during the years presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 12 for further discussion of preferred stock warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the shares of Series F Preferred Stock that were issued in January 2016, investors who purchased more than their <FONT
STYLE="white-space:nowrap">pro-rata</FONT> amount in the financing described above received a calculated number of contingent value rights (&#147;CVRs&#148;), but only to the extent that the total amount raised in the financing exceeded
$20,202,323.&nbsp;One CVR represents 0.00375% of the Company&#146;s interest in the drug ficlatuzumab (see Note 10).&nbsp;In connection with the Series F financing, the Company issued 3,999 CVRs originally valued at $0.5&nbsp;million. The initial
estimated value of the CVRs were recorded as a liability and as a reduction to the Series F proceeds. Upon receipt by the Company or a milestone, royalty, or any other type of payment from the Company&#146;s ownership rights in the drug, the Company
will make a cash payment to the CVR holders equal to 15% of net proceeds, as defined. In addition, the CVRs will be adjusted to their estimated fair values each reporting period. During 2019 and 2018, there was no change to the estimated value of
the CRVs. The value of these CVRs was $0.1&nbsp;million as of December&nbsp;31, 2019 and 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contingent Consideration
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the transaction with Indi, the Company recorded contingent consideration pertaining to the amounts potentially
payable to Indi&#146;s Selling Shareholders pursuant to the Asset Purchase Agreement (See Note 3). Contingent consideration is measured at fair value and is based on significant inputs not observable in the market, which represents a Level&nbsp;3
measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions the Company believes would be made by a market participant. The Company assesses these estimates on an
<FONT STYLE="white-space:nowrap">on-going</FONT> basis as additional data impacting the assumptions is obtained. Future changes in the fair value of contingent consideration related to updated assumptions and estimates are recognized within the
statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contingent consideration may change significantly as development progresses and additional data are obtained,
impacting the Company&#146;s assumptions regarding probabilities of successful achievement of related Milestone used to estimate the fair value of the liability and the timing in which they are expected to be achieved. In evaluating the fair value
information, considerable judgment is required to interpret the market data used to develop the estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of
different market assumptions and/or different valuation techniques could result in materially different fair value estimates. The fair value of the Company&#146;s contingent consideration liability was estimated using significant unobservable
inputs. The fair value of $19.6&nbsp;million contingent consideration recognized on the acquisition date&nbsp;was estimated by management with the assistance of an independent third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in the fair value measurement each period reflect the passage of time as well as the
impact of adjustments, if any, to the likelihood of achieving the specified targets.&nbsp;Contingent consideration is recorded in the balance sheets in long-term liabilities. The $4.1&nbsp;million adjustment to the contingent consideration during
2019 was primarily due to $3.4&nbsp;million resulting from the reduction of estimated time to first payment and $0.7&nbsp;million due to the impact of the acceleration of expected revenue and decreases in expected costs. The $5.4&nbsp;million
adjustment to the contingent consideration during 2018 was primarily due to $3.9&nbsp;million resulting from the impact of the acceleration of expected revenue and decreases in expected costs as a result of events occurring after the acquisition
date, as well as $1.5 million resulting from the reduction of estimated time to first payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The significant unobservable inputs used
in the measurement of fair value of the Company&#146;s contingent consideration are probabilities of successful achievement of the Milestone, the period in which the Milestone is expected to be achieved and discount rates ranging from 12.2% to
13.5%. Significant increases or decreases in any of these inputs would result in a significantly higher or lower fair value measurement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note
5&#151;Balance Sheet Disclosures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,386</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,568</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for each of the years ended December&nbsp;31, 2019 and 2018 was $0.8&nbsp;million and
$0.7&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchased technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(939</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase option</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trademarks (indefinite life)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded amortization expense of $2.0&nbsp;million and $1.0&nbsp;million for the years ended
December&nbsp;31, 2019 and 2018, respectively. Amortization related to the remaining net intangible assets is scheduled to amortize as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation related accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical trial expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6&#151;Convertible Debt Payable </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the Company issued $6&nbsp;million in convertible debt (the &#147;December 2019 Notes&#148;) that is scheduled to mature in
August 2020. The December 2019 Notes were issued in two tranches of $3&nbsp;million, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the first tranche being funded in December 2019. Interest on the December 2019 Notes is at 3% per annum and is payable in full upon maturity through the conversion to Series H Preferred
Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the December 2019 Notes are unpaid, the outstanding principal and unpaid accrued interest under the December 2019 Notes shall be automatically
converted into, the earlier of, the preferred stock sold at the close of the Company&#146;s next equity financing (Qualified Financing) or common stock in an initial public offering (IPO). The conversion price would be equal to 80% of the price per
share paid for the preferred stock in the Qualified Financing or common stock sold in an IPO. The December 2019 Notes may be prepaid in whole or in part at any time by the Company with prior consent of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the note holders. In the event of a corporate transaction, the unpaid principal and accrued interest shall become immediately due and payable in the same form of consideration and on the same
terms and conditions as the consideration to be received by the holders of the equity securities of the Company in such transaction. The discounts on the automatic conversions created a put option liability that was separated from the December 2019
Notes. The estimated value of the put option liability as of the issuance of the December 2019 Notes and December&nbsp;31, 2019 was $0.8&nbsp;million. The put option liability was reflected as a debt discount on the December 2019 Notes which is
being amortized over the term of the December 2019 Notes. The unamortized debt discount was $0.7&nbsp;million as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August and September 2019 (the &#147;August 2019 Notes&#148;), the Company issued $10&nbsp;million in convertible debt that is scheduled to
mature in August 2020. Interest on the August 2019 Notes is at 3% per annum and is payable in full upon maturity through the conversion to Series&nbsp;H Preferred Stock at the original issuance price of $1.15 per share. On or before the maturity
date and if the August 2019 Notes are unpaid, the outstanding principal and unpaid accrued interest under the August 2019 Notes shall be automatically converted into, the earlier of, the preferred stock sold at the close of the Company&#146;s next
equity financing (Qualified Financing) or common stock sold in the event of an IPO. The conversion price would be equal to 95% of the price per share paid for the preferred stock in the Qualified Financing or common stock sold in an IPO. The August
2019 Notes may be prepaid in whole or in part at any time by the Company with prior consent of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the August 2019 Note holders. In the event of a corporate transaction, the unpaid principal
and accrued interest shall become immediately due and payable in the same form of consideration and on the same terms and conditions as the consideration to be received by the holders of the equity securities of the Company in such transaction. The
discounts on the automatic conversions created a put option liability that was separated from the August 2019 Notes. The estimated value of the put option liability as of the issuance of the August 2019 Notes was $0.5&nbsp;million. The put option
liability was reflected as a debt discount on the August 2019 Notes which is being amortized over the term of the August 2019 Notes. The unamortized debt discount was $0.3&nbsp;million as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the issuance of the December 2019 Notes, the conversion price on the August 2019 Notes was amended to 80% of the price per
share paid for the preferred stock in the Qualified Financing or common stock in an IPO. In addition, the conversion price to Series&nbsp;H preferred stock at the maturity date was amended to be 80% of the Series&nbsp;H original issuance price of
$1.15 per share. The changes to the discounts on the conversions of the August 2019 Notes created an increase to the put option liability on the August 2019 Notes of $2&nbsp;million to a total estimated value of $2.5&nbsp;million as of
December&nbsp;31, 2019. The increase in the value of the put option liability was reflected as a change in put option in the accompany 2019 statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, accrued interest of $0.1&nbsp;million is included in the convertible debt balance included on the accompanying
balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April and July 2018, the Company issued $10.3&nbsp;million in convertible debt that was scheduled to mature in April
2019 (the &#147;April 2018 Notes&#148;). Interest on the April 2018 Notes was at 6% per annum and was </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payable in full upon maturity. On or before the maturity date and if the April 2018 Notes are unpaid, the outstanding principal and unpaid accrued interest under the April 2018 Note shall be
automatically converted into the preferred stock sold at the close of the Company&#146;s next equity financing (Qualified Financing). The conversion price would be equal to 100% of the price per share paid for the preferred stock in the Qualified
Financing. The April 2018 Notes may be prepaid in whole or in part at any time by the Company with prior consent of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the April 2018 Notes holders. In the event of a corporate transaction,
the unpaid principal and accrued interest shall become immediately due and payable in the same form of consideration and on the same terms and conditions as the consideration to be received by the holders of the equity securities of the Company in
such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company issued 6,086,941 shares of Series&nbsp;H Preferred Stock at $1.15 per share for total cash
proceeds of $7.0&nbsp;million. In connection with this issuance, the $10.3&nbsp;million in convertible debt issued in April and July 2018 and accrued interest of $0.2&nbsp;million automatically converted into 9,140,616 shares of Series&nbsp;H
Preferred Stock as a Qualified Financing occurred prior to the maturity date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7&#151;Long-Term Debt </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, the Company extinguished a Note that originated in 2013 (the &#147;2013 Notes&#148;) through the issuance of new long-term
debt with a different private investment company (the &#147;2018 Notes&#148;). The lender for the 2018 Notes is also a holder of the Company&#146;s Series G preferred stock. The Company recorded a $0.2&nbsp;million loss on the extinguishment of the
2013 Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial amount borrowed under the 2018 Notes was $23&nbsp;million and the maturity date is February 2023. At the time of
the issuance of the 2018 Notes, the Company paid a 1% facility fee of $0.2&nbsp;million and issued a warrant to the private investment company for the purchase of 613,333 shares of Series&nbsp;G preferred stock, which had an initial fair value of
$0.3&nbsp;million. The facility fee and the value of the warrants were recorded as reductions to the carrying value of the 2018 Notes and are being amortized to interest expense over the term of the 2018 Notes. The 2018 Notes bears interest at 10%
with 7.5% being paid in cash and 2.5% being added to the principal value of the 2018 Notes through December&nbsp;31, 2020. The Company is required to make quarterly interest payments beginning in June 2018 and outstanding principal is due in 24
equal installments commencing in March 2021. As of December&nbsp;31, 2019 and 2018, the interest added to the principal value of the 2018 Notes was $1.1&nbsp;million and $0.5&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loan may be prepaid by the Company at any time, subject to a prepayment penalty of up to 3% of the principal amount, depending on the date
of prepayment. Upon payment of the 2018 Notes at maturity or prepayment on any earlier date, unless waived, a 2% <FONT STYLE="white-space:nowrap">back-end</FONT> facility fee will apply to the amounts paid or prepaid. The 2% fee is being recorded as
additional interest expense over the term of the 2018 Notes. The 2018 Notes are senior to all of the Company&#146;s other indebtedness including any contingent consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2018 Notes contains customary affirmative covenants, including covenants regarding compliance with applicable laws and regulations,
payment of taxes, insurance coverage, notice of certain events, and reporting requirements. Further, the 2018 Notes contains customary negative covenants limiting the ability of the Company to, among other things, to incur future debt, transfer
assets except for the ordinary course of business, make acquisitions, make certain restricted payments, and sell assets, subject to certain exceptions. In addition, the 2018 Notes requires the Company to comply with a minimum daily liquidity
covenant and a rolling monthly revenue requirement. Failure to comply with the covenants and loan requirements may result in early amortization of the loan in a <FONT STYLE="white-space:nowrap">24-</FONT> or
<FONT STYLE="white-space:nowrap">36-month</FONT> payment schedule. As of December&nbsp;31, 2019, the Company was not in default under the terms of the 2018 Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the 2018 Notes, the Company granted the lender a security interest in all
of the Company&#146;s assets through a pledge and security agreement, patent security agreement and trademark security agreement, each between the Company and the lender. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-term debt payable as of December&nbsp;31, 2019 and 2018 was as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018 Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Final payment fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt discount and debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(458</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(602</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Maturities of long-term obligations as of December&nbsp;31, 2019 are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with entering into the 2018 Notes, the Company issued to the lender a warrant to purchase
613,333 shares of Series G convertible preferred stock, at an exercise price of $0.75 per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on February&nbsp;23, 2028.
The fair value of the warrant on the issuance date of $0.3&nbsp;million was recorded as a debt discount and as a preferred stock warrant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8&#151;Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since
inception, the Company has incurred net taxable losses, and accordingly, no current provision for income taxes has been recorded. The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax effects of temporary differences that give rise to significant portions of the
deferred income tax assets and liabilities are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,254</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2019, the Company had $222.1&nbsp;million and $3.0&nbsp;million of net operating loss and
research and experimentation tax carryforwards, respectively, which are set to expire beginning in 2026. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain
events occur, including significant changes in ownership interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In assessing the realizability of its deferred tax assets, the Company
considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in
which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any
historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the Company does not believe it is more likely than not
that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets. The valuation allowance increased by $7.0&nbsp;million during 2019 and $5.5&nbsp;million
during 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has concluded that there were no significant uncertain tax positions relevant to the jurisdictions where the
Company is required to file income tax returns requiring recognition in the financial statements for the years ended 2019 and 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company has recognized no interest for the years ended December&nbsp;31, 2019 and 2018 related to uncertain tax positions. As of December&nbsp;31, 2019, and 2018, there was no accrued interest related to uncertain tax positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions.
At December&nbsp;31, 2019, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s federal and state tax returns remain open for 2013 through 2019 to examination by tax authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9&#151;Commitments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company leases facilities under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases. Rent expense for the years ended December&nbsp;31, 2019 and 2018 was $2.1 and $1.6&nbsp;million, respectively, and was inclusive of common area
maintenance charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments for operating lease obligations, net of sublease income are as follows (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ending December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Co-Development</FONT> Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO Oncology (&#147;AVEO&#148;) to develop and
commercialize AVEO&#146;s hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company&#146;s proprietary companion diagnostic test, BDX004, a version of the Company&#146;s serum protein test that is commercially available to help
physicians guide treatment decisions for patients with advanced <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;). Under the terms of the agreement, AVEO will conduct a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> (&#147;POC&#148;) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects, referred to as the NSCLC POC Trial. The Company and AVEO will share
equally in the costs of the NSCLC POC Trial, and each will be responsible for 50% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC
clinical trials of ficlatuzumab in combination with BDX004 with each responsible for 50% of development and regulatory costs. AVEO may recapture certain of its costs under the agreement from royalties and other revenue received under the agreement.
Expenses related to this agreement for the years ended December&nbsp;31, 2019 and 2018 were approximately $0.9&nbsp;million and $0.3&nbsp;million, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2019, the Company entered into the Bio-Rad License. Under the terms of the Bio-Rad License, the Company received a non-exclusive
license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#146;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR (ddPCR) in cancer detection
testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement with Bio-Rad. As further
consideration for the non-exclusive license, the Company agreed to pay a royalty of 2.5% on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in August 2024. Either party may
terminate for the other&#146;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the separate supply agreement for a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consecutive twelve-month period or for any material breach by the Company of the supply agreement. The Company incurred royalty expense of $0.1&nbsp;million during 2019 under this agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10&#151;Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table details, by series, the Company&#146;s convertible preferred stock at December&nbsp;31, 2019 (in thousands, except shares
and original issue price): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Series</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Issued&nbsp;and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Defined<BR>Original<BR>Issue&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series H</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,836,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,923,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series G</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,464,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,146,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series F</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,468,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,468,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,972,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,639,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,781,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,874,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,356,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,356,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,998,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,641,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,641,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,237,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,766,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Series H </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February and March 2019, the Company issued 8,695,621 shares of Series H Preferred Stock at $1.15 per share for total cash proceeds of
$10.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018, the Company issued 6,086,941 shares of Series H Preferred Stock at $1.15 per share for total cash
proceeds of $7.0&nbsp;million. In connection with this issuance, the $10.3&nbsp;million in convertible debt issued in April and July 2018 and accrued interest of $0.2&nbsp;million converted into 9,140,616 shares of Series H Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Series G </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018,
concurrent with the closing of the transaction with Indi, the Company issued 10,649,904 shares of Series G Preferred Stock to Indi, including 2,129,981 shares that were deposited in an escrow account to be used to satisfy any indemnification
obligations of the seller that may arise.&nbsp;&nbsp;&nbsp;&nbsp;See Note 3, Business Combination, for further information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February
2018, the Company issued 2.0&nbsp;million shares of Series G Preferred Stock to the lender of the 2018 Notes at $0.75 per share for total cash proceeds of $1.5&nbsp;million. See Note 7, Long-term Debt, for further information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s convertible preferred stock has been classified as temporary equity in the accompanying balance sheets given that a
majority of the Company&#146;s Board of Directors seats are held by convertible preferred stock holders and could cause certain events to occur that are outside of the Company&#146;s control whereby the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company could be obligated to redeem the convertible preferred stock. The Company has not adjusted the carrying values of the convertible preferred stock to the respective liquidation preferences
of such shares as the instruments are currently not redeemable and the Company believes it is not probable that the instruments will become redeemable at this point in time. Adjustments to increase the carrying values to the respective liquidation
preferences will be made if and when it becomes probable that an event would occur obligating the Company to pay such amounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conversion Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of Series <FONT STYLE="white-space:nowrap">A-1,</FONT> Series <FONT STYLE="white-space:nowrap">A-2,</FONT> and Series <FONT STYLE="white-space:nowrap">A-3</FONT> (collectively, &#147;Series A&#148;); Series B and Series <FONT
STYLE="white-space:nowrap">B-1</FONT> (collectively, &#147;Combined Series B&#148;); Series C; Series D; Series E; Series F, Series G, and Series H are entitled to convert their shares into common stock at the option of the holder, at any time, into
fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock. The number of shares of common stock to which a holder of the Series A, Combined Series B, Series C, Series D, Series E, Series F, Series G, and Series H
(collectively, &#147;Series Preferred&#148;) can convert is obtained by multiplying the conversion rate that is in effect by the number of shares of Series Preferred being converted. The conversion rate is determined by dividing the Original Issue
Price by the applicable conversion price (initially the Original Issue Price for all classes of Series Preferred except Series <FONT STYLE="white-space:nowrap">B-1,</FONT> for which the conversion price is initially $16.33). As a result of the
reverse stock split (see Note&nbsp;14), the conversion rate for the Series Preferred is 0.1684664 per share. Each share of Series Preferred will be automatically converted into shares of common stock (based on the
<FONT STYLE="white-space:nowrap">then-effective</FONT> Series Preferred conversion price) if there is an affirmative election of 65% of the holders of the outstanding shares of Series Preferred or immediately upon the closing of a firmly
underwritten public offering in which the offer and sale of common stock, voting together as a single class on an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to-common-stock</FONT></FONT></FONT></FONT> basis, is at a
<FONT STYLE="white-space:nowrap">per-share</FONT> price of at least $11.88 (adjusted for stock splits, dividends, and recapitalizations) and gross cash proceeds to the Company (before underwriting discounts, commissions, and fees) are at least
$40&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series Preferred holders are entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT> cash dividends. The dividends are
required to be declared by the Board of Directors and are calculated at an annual rate of 8% of the Original Issue Price of the respective Series Preferred shares. Series Preferred holders have the following order of preference on dividends: Series
H holders, Series G holders, Series F holders, Series E holders, Series D holders, Series C holders, Combined Series B holders, Series A holders. The Series A holders have preference over the common stockholders. In the event that dividends are paid
on any class of Series Preferred, the Company shall pay an additional dividend on all outstanding shares of a higher preference in a <FONT STYLE="white-space:nowrap">per-share</FONT> amount on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to-common-stock</FONT></FONT></FONT></FONT></FONT> basis. In the event dividends are paid on any common
stock, the Company shall pay an additional dividend on all outstanding shares of Series Preferred stock in a <FONT STYLE="white-space:nowrap">per-share</FONT> amount on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted-to-common-stock</FONT></FONT></FONT></FONT></FONT> basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of each share of Series Preferred stock have the right to one vote for each share of common stock on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted</FONT></FONT> basis. When converted, the common stock
and Series Preferred stockholders have equal voting and power rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As long as any Series Preferred stock remains outstanding, a
majority vote of the respective class of holders would be required to amend any provisions of the Company&#146;s articles of incorporation or bylaws that would adversely affect them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Series Preferred stockholders are subject to automatic redemption in the consolidation or merger of the Company or sale of all or substantially
all of the Company&#146;s assets in which the stockholders of the Company immediately prior to the transaction hold less than 50% of the outstanding securities of the surviving entity. Proceeds available for distribution from such transaction will
be distributed consistent with a liquidation event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the articles of incorporation, upon a defined event of acquisition or asset transfer, liquidation, dissolution, or winding
up of the Company, any amounts that are available for distribution are to be paid out to its stockholders in the following order of preference, in an amount equal to the <FONT STYLE="white-space:nowrap">per-share</FONT> Original Issue Price, plus
any accrued, declared, and unpaid dividends: Series H holders, Series G holders, Series F holders, Series E holders, Series D holders, Series C holders, Combined Series B holders, Series A holders. If the assets of the Company are insufficient to
make payments in full to a class of holders of preferred stock, in the order of preference previously described, then remaining assets shall be distributed among the holders of that class of preferred stock ratably in proportion to the full amounts
to which they would otherwise be respectively entitled and the holders of lower preference shares will receive nothing. Upon payment of all preferential amounts required to be paid to the Series Preferred, the holders of common stock and Series
Preferred shall be entitled to receive a ratable portion, calculated on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted</FONT></FONT> basis, of the remaining assets of the Company available for distribution to
its stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11&#151;Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2006, the Company adopted the 2006 Employee, Director, and Consultant Stock Plan (the &#147;2006 Incentive Plan&#148;) under which the
Company is authorized to grant stock awards to employees, directors, and consultants of the Company. The Company is authorized to grant incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, restricted stock
awards, restricted stock unit awards, and stock appreciation rights up to 831,388 total shares of stock awards. The award price and vesting terms are determined by the Board of Directors of the Company and evidenced in the award agreement extended
to the employee, director, or consultant. The options granted generally terminate ten years from the date of grant and vest over various periods as determined by the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the Company adopted the 2016 Equity Incentive Plan (&#147;2016 Incentive Plan&#148;) as a successor to and continuation of
the 2006 Incentive Plan. As of February 2016, no additional stock awards may be granted under the 2006 Incentive Plan and any unallocated shares remaining available for issuance pursuant to the exercise of options or issuance or settlement of stock
awards not previously granted under the 2006 Incentive Plan will cease to be available under the 2006 Incentive Plan and will be added to the share reserve of the 2016 Incentive Plan and be immediately available for issuance pursuant to the stock
awards granted in the 2016 Incentive Plan. In addition, all outstanding stock awards granted under the 2006 Incentive Plan will remain subject to the terms of the 2006 Incentive Plan unless they expire, terminate or are forfeited, cancelled or
otherwise returned to the Company and will immediately be added to the share reserve and become available for issuance under the 2016 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2016 Incentive Plan, the Company is authorized to grant stock awards to employees, directors, and consultants of the Company. The
Company is authorized to grant incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, restricted stock awards, restricted stock unit awards, and stock appreciation rights up to 1,431,964 total shares, plus any
shares subject to outstanding stock awards granted under the 2006 Incentive Plan. The award price and vesting terms are determined by the Board of Directors of the Company and evidenced in the award agreement extended to the employee, director, or
consultant. The options granted generally terminate 10 years from the date of grant and vest over various periods as determined by the Board of Directors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the activity for options and restricted stock units (RSUs)
outstanding (in thousands, except for weighted average exercise price and weighted average grant date value per share): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSUs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Grant<BR>Date<BR>Value&nbsp;Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(224</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the composition of options outstanding and exercisable as of December&nbsp;31,
2019 (in thousands, except price): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options&nbsp;Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exercise Prices</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Life<BR>(years)*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$0.42 &#150; $0.84</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$2.62 &#150; $3.74</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$4.40 &#150; $4.46</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$6.83</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Price and Life reflect the weighted average exercise price and weighted average remaining contractual life,
respectively. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were 157,000 restricted stock units outstanding at December&nbsp;31, 2019, none of which had vested
as of December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option grant is estimated on the date of grant using the <FONT
STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model with the following weighted average assumptions (dollars in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Approximate risk&#151;free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.26</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.64</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average expected life</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.58&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.94&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value of total options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates volatility based on the historical volatility of its peer group and
average expected life based on the review of historical exercise behavior of option grants with similar vesting periods. The expense recorded for options granted under the Plan is net of estimated forfeitures of 10%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the impact of employee stock-based compensation expense on statements of income line items for the periods
indicated (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales, marketing, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unrecognized remaining <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation balance for shares
issued inside of the Plan was approximately $0.3&nbsp;million as of December&nbsp;31, 2019 which will be amortized over the next three years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Company has issued a total of 205,199 stock options outside the 2006 Incentive Plan to employees of the
Company. These options are issued at the discretion of the Board of Directors of the Company to the Chief Executive Officer and their direct reports who wish to convert all or a portion of their incentive compensation to options. The value of the
options at the date of grant was calculated using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model using approximately the same assumptions as in the previous table other than the term, which is approximately five
years. As of December&nbsp;31, 2019, 188,043 options outside of the 2006 Incentive Plan are outstanding and exercisable and have a weighted average exercise price of $11.52, a weighted average remaining life of six years, and were fully vested on
the grant date. There was no unrecognized remaining <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation balance for shares issued outside of the 2006 Incentive Plan as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12&#151;Warrants for Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has issued warrants to purchase shares of preferred stock in conjunction with the sale of certain preferred shares and certain debt
issuances. The grant date fair value and fair value at each reporting date of the warrants was determined using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model with weighted average assumptions relatively consistent
with those disclosed for stock options above, other than term, which is the contractual term of the warrant and the use of the exercise price and current estimated fair value of the respective series of preferred stock. The preferred warrants are
classified as liabilities on the accompanying balance sheets as the underlying preferred stock has a contingent redemption feature. As these warrants are classified as a liability, they are revalued on each reporting date or exercise date, and any
change in value is recorded to change in fair value of the warrant liability in the accompanying statements of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the activity for convertible preferred stock warrants
outstanding (in thousands, except weighted average exercise price): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series E</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series G</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(907</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/canceled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(902</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining contractual life at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center">0.46&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center">8.0&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 13&#151;Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated all subsequent events through the auditors&#146; report date, which is the date the financial statements were
available for issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the quarter ended March&nbsp;31, 2020, the Company failed to meet the revenue requirements specified in the
fifth amendment to the 2018 Notes. In accordance with the 2018 Notes, a cure of this failure can be achieved by receiving $10&nbsp;million from the sale of the Company&#146;s debt or equity securities, or a lesser amount if approved by the lender by
June&nbsp;30, 2020. If the Company does not receive this amount from the sale of the Company&#146;s securities, amortization of payments for the 2018 Notes will become payable in 24 equal monthly installments beginning June&nbsp;30, 2020.&nbsp;The
Company intends to pursue the equity cure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2020, the Company called the second mandatory closing of the December 2019 Notes
for total cash proceeds of $3.0&nbsp;million. In March 2020, the Company issued $10&nbsp;million in convertible debt in two tranches of $5&nbsp;million, with the first tranche being funded in March 2020. The terms of this debt were the same as the
December 2019 Notes (see Note 6). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, the World Health Organization declared the outbreak of
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> a novel strain of Coronavirus, a global pandemic.&nbsp;This outbreak is causing major disruptions to businesses and markets worldwide as the virus spreads.&nbsp;The extent of the effect on the
Company&#146;s operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, and governmental, regulatory and private sector responses, all of which are uncertain and
difficult to predict.&nbsp;Although the Company is unable to estimate the financial effect of the pandemic, at this time, if the pandemic continues to evolve into a severe worldwide crisis, it could have a material adverse effect on the
Company&#146;s business, results of operations, financial condition, and cash flows.&nbsp;The financial statements do not reflect any adjustments as a result of the pandemic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIODESIX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 14&#151;Reverse Stock Split </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;19, 2020, the Company obtained approval of an Amended and Restated Certificate of Incorporation effecting a 0.1684664-for-1
reverse stock split of its issued and outstanding common stock as converted. All common shares, stock options, and per share information presented in these financial statements and notes thereto have been adjusted, where applicable, to reflect the
reverse stock split on a retroactive basis for all periods presented. The per share par value and authorized number of shares of the Company&#146;s common stock were not adjusted as a result of the split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g04z61.jpg" ALT="LOGO">
 </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g937421g00b90.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g937421g00b90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g00b90.jpg
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M P,# P,# P,# P/_P  1" ,J G(# 1$  A$! Q$!_\0 ]@ !  $$ P$! 0
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M=([^66,KH(V G2"PZ)'4K0N>\$DTKITM-0T*5O\ 5S$3_P#F:ZK\G97O#_\
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MD#]5L8KRU#FNH_J8W>!FS[?L0=_F9+ATY X-C88Q7D'&1U.>@\E]/_R,^\>
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M@=RV8!.",F1K7<34L-@1F,M*O.ZQ$S6A/MNDB6 GFT6W.-['^H[:Y8M]L-Y
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M9%I]A&1!Q!!!Q"_GMNNV7NR[C-M>XQNCO8)"Q[2*$$&G:#P(J",02,5@]35
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M+2>WL+N:%[9Y9"Y\%O(]HG#ZM.+=0=$(6ZFAIC+7>[FV0P';SU$^DO\ *?\
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MSLUF<]J'?G&:Z#^3=QLE<"UDV74;#%1R9(D^7;7YOOK#:]PO]TNY;J^M-O\
M'=:W%I\)/'(T'5IHUK7V[G4:'@2EA%3*ZH"^N[QY)VW<=TV^RV>TBMMONMP\
M!MU!="Z@D8XLIK&N1S)VM)=H+H=8.$,="5%N@8;T6^JC>MJ]-?:KTT;)V1SS
MVH]U<IV*[\2N].Z[KNV6V'M1HFU;]#9[_:=GP#MT[A.X.)T^0Q,+78.$/7Y4
MELVRDLLN(=G>S>;O+=G%Y@W+<([R 2PBXMQ!&R-K9I&1GX9[?Q=41>"WQ72>
M( 0=)(I4V,'DKS/>S>7=KVZ2SN?!F=;W!G>^1SH(GR#XACOPJ2AE'>%'%X9-
M??:T@R1J7:K2N^,/\JSM[W @R\AJN4]"_K+V.3$A9&9B9)9+0^X?K1[@ZTZD
MZ ZS)!N+LNL0W7 0N5YL";-% R1:^YW.[VB3S)?V)#;EN\6#02 X4DBV^)^!
MPQ8]PZ#B,0K"#:;3=AY;VV_:76YVB_<0"1[T4NYR,-1R>QIZ1@M&.RG;30=A
M]+/JH[T[;K[^Q;)V6V?TIAK,1,WEL-CI.*[E;SN>,WO#Y$<4^RIIG\/K[4=M
M^ROPOB<843XUV.\;C?0>8MLVFUD$<%Y%>:SI:X@Q1QF-PJ#W7.)ID[(X+D-C
MVG;9O+VZ[O=QF2:RGM0P:B!ID?('@T(KJ#0.8X+Z<=^=4[$^I+UW>G?M?-[)
MLZ-@9'H3[=[AG'L'W*W_ "\S-1<+^7E$[E=K]<)S-9!Q<;$[:S=:B1!DQU&3
MFF (IRN&97^>[)<[UY?\F7^XMNS-.-YE8W5%& TNW0Q3.]T8F4/<ZAP8<&4
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M+:UNX?*?EFUW6\N[J.>;8_Y&W<((O$#9&NDDMVMB>]K:$!TCHR\,]YGOAH)
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M^2;9R,'E9E-/"VTK<'>?+<6ZW<6YV]S<V6[Q,,8F@+-1C<:F.1DC)(Y&:AJ
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M$ %I:(F/:220\5RP53:^<-WLI]MN+?PFR[6QS(O=KJ:^665[90XD.#C,]C@
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MGFKGC,/C7\)D<LYE!:F1$>%B,72"Q(TBM\[9&3KAOJ2H"BMD5/:J5BY[@\-
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M1Q'F,7!>LB2D*2 F\Z-V[ @BI7*W4[+M<L4GQER-) ]UISQS)Y88 =JY+?\
M>(IHO@;0ZFD@O<,L,0!SQQ)RX8K4*NG7))1$HB41*(E%XMANVJ"FL,V @(IL
MTC(@44=53#E,"5$1P>G9+I=.%O957=_O>P*_VZGPHYZBI"2HPR5B,U$'=-F/
M*EX9D),5J>W%E'T9#G15UAUUM&D%\TZ %U&SY4<($7C9:G61(:XT.FJI]S#7
M/8 0'T.>&'7]:P3I.X#6Y2OMDQD]G?7'M :<KK. Q;S,B>ZG&Z!E,HC+0DG
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M86S-6^<T3QLJVK5(:TIDK"SC+=3G=Y9V/@GZ/[E1SFIRP_=FVBQ<=TD3K-3
M!I?VN1UMSJBB_N_ B_JK;#741PHHE\ 80?M!RBZI*JDHBDK3%_AW [-OA_!+
MCLEJ>J*O EV#.Q7!R&09_I8/ *Z:$GS7GVO;4"Z_'FCLQW2=;_U6G ?M.IV
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M)Q%LBV05NEU\55?D2MC&5Q.2S8RN+E7*VVJ64!M[N5$M_)X5MT@X4P6TM;Q
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MP^OL5M$E$N;Q7CQ*ZWNBHJKQ157C61%11:T$^6Z60A+Q%;V6W@MT5%14H15
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M')BS56G.@)IZE]0U556Z^*U\[7TQ$546Z<%3BBIXHM$6@'=W84T?N%L&-U7
MZMBY1G%R<C._<[.3S12\M%:GR59<RQ3H6,5'GE5$C,-61;WO7;;7!\98QR7+
MY'-Q ;JHVC30=VA/:2N$W:X%E?R16K(FNJ"7:075< 3WJAN? !0-F,_G-A?\
MSGLQDLP^GS3R,Q^6C?R,MNF33 I[$ 11/=5S%!# -,+&L'0 %137$]P[5,]S
MSTDE6FMJTI1$HO4HO$HB41*(E$7(BI$(BER(A$4]Y$J(*?K5:+W-3[@\##PL
M4&P; Y9@/FI1"A...+8B "5+@R!<!%+>%UNM5\DAD/Z*OH(&0MH![],2KM*Q
MS,H>8#=A30NL;)073B3XCO[#C,J.3;R(*^(\W*J<%K"O @%O(X@]A61C#A4$
MM?P(P([0HT>[C;6TZ[C=F'#[DS$=<C&SMN)BY9].B:MKT<NB1\XQ?EX*,E%2
MMGP%O37!JB<?N$M']W%OJ4 [A<M)CN=$P&'OM#C_ 'L'>M>?G^V68^W8'8M.
MDEXR=<R#6Q8D27]I<1G5CY%MM/<$XU1/"O=&X1=Q\<K>3AI=_>;4?X5YKVV;
MOLDA=S8=3?[KJ'_$G\ 1\FM]2W/5MA(OJ\?,E'JN<6_@"0-A2+%><]EF9+MU
M\+UY\:Z/^)BDCZ0-;?2VI]("? -D_A9HI#R)T.]#J#T$K&,WJVRZV2#GL#E<
M2B_,=FPGFHSJ>PF9G*41\5]B@9(M28;FWN!6%[7=1Q[1F%&FM;FW-)V.;U@T
M[#D58/'BG&MRT+T::=?=:88:<???<!EAAD"=>>><) ;:::!"-QQPU1!%$555
M>%>$AH+G&C0@!<0UHJXY!;5:7Z7<ODHS,_=<L>O"\(N!AL>RU*RH 271)LAX
MO)PG;+Q;$7B'P*R\*YVZ\PQ,<66C==/M$T'9Q/7@NHL_+4LC1)>.T _9&+NT
MY#UJ77?3EJ8ZS/UF!F]@BL9#*8_,.RWR@37AF8R+/B1A1M(L4/+$&0-3&Z$J
MHEB3P6L&^7)N!</8PEK2V@J,"03Q.."MCY>M1;.MF/D#7.#JFAQ (' 88K5'
MN3V;V?MNHS9)-9C7GG199SL!MP&VG3^KCY**:FY ?<\!52-HUX"=^%=)8;I;
MW_NM]R<?9/M!X^U<MN.T7.W>^ZCX">\/I'#V=*B.K)52V2T(FH?8[N]F@CLQ
MW)(8[71-L50W4>5D20W#(C<(EGJJI>R7LB5S]]5^\VD-20*O_+T+H["C-DNY
MP "=+/R]*@*" -0LA/5MMUV.45B.+P"XV#DHSYGE;-% R!MI4&Z*B*MZNWDE
M[68@&I/8J!@ 8Z3B* =J]93;2N8F5Y5@UR#"*Y&4%&.4D9!Q%<1L"&PF2(2B
MBH/-\BVHTFCVU-&G/C2E5DX"K'@"KAEPK6BFCN)GLUA^[NVQ\5ELCCXF+%@5
MA1)CS4)U,9K\!$9.&A+&-HW1^)%!;I>J;;[>";:8G2L:Y[JXD"N+CQS5WN4\
M\&[S-B>YK&TP!P]U@X9<%8,=N+6Q-12VO4M3SY?>8Q)$MG&!KN4=CN1G)/"?
M@/(H3P*RJ(1M&JHO&];Y+,VY/PLTL8TU KK;6M,GU]1"CQ7K;@#XN&*3WJ$Z
M=#J4KFRGL*Y2+VNVN#-<CS<MH<Z*Y&-D,E#9S6&!N0X3/EUGXX(V0%I%LJ&\
MV1#;BJTU;G:O <UD[#7NDM=AC6AJ/04T;3=L):Y]O(*4J-3<>%10^D+-.VFB
M9C5]BC;6R>#V+$P(>PR(V;PLQC*LC(;U?,>0C)$5$ELRYL]QH!3IJ7-P1>-1
M-POX;F VKM<<KBVK7#3AK;4URH!7BIFW;?/:W NFEDD+0\AS2'8ACJ"F8)-.
M"UH)IUDE8?;<9?;L+K3P$TZV:)91<;<03 D7V*E=$"'#4,6E<VX%I+2*$*2]
M%A)*R3&7:18)8ME>@L)UYAPI3CIM@9OBYUCL $I(I6)51+6X5$N*:3&[W@[G
M0^I6%BS5()A[I:.!(Q]JG0V&OO!V!TQ06F'@1Q$^E)\8_7*0;G$C,G!]JVLM
M0 XZ \9D]E*THKHM&LQ\*>NF:Q#,=N96X9+'P<"S%7+>48F267"%AW+ 0MD3
M3,DTY0DL,.6;$E "1+*M[5DZ]9:1NFF)\/41SITD<JY\5&DVY]Y(V."GBT!/
M#5U'GRX%01F\/)P;S$&=&D0YXMO+,BRFC8?9="7(80#9<02"P-)[++XI=*LH
M96S-+V$%E<",1D%13PN@<(Y 0^AJ#F,:+C"(TZ^\PY'8=ZD28XCCHJ9M=&(\
MXB-"J\@JIBB\RHJI;A:O9JAH<"1B/65[#0N+2 :@^H*WP(Z2YD.*2JB2)##)
M$GB@N.")*B^^RUF]VAI=R!6MC=3PWF0KGT6Y[^406FV!AL%Y4&@0! &IK+"=
M2R(KID#BW(KJJK6O46!N-:G'T+86B1SJ4 :,/2N683*Y'*XY0YA:8R*,N%Q-
MIR"AN@:+_21I4+WHM"]WAMDZ1ZT$8\1T?('U+/\ ML 8AI_N+-)W'8O2)L8F
M7H3SD;(;'L4V-,7&ZU'D\RKTI0CU)O*G*U" U5+F-X5^3(X6+*.DE!SQ#6@B
MKB.C[/-U.2G[:!"#N#_=BA(Q&!>\@T8#TYNY-KS4]X;U6SH28>/L.EP\G,DQ
MH;CTG&91W'QWUEN&W<H<F).)HA&WS7%XI=$2J:7RVQ^MT$Q:T$X$5(IT@CV*
M]A\T/9H;<0ASB!B'4!KT$'VK$LUWNV#?YV=U_(X/7V]5"'-CR,(Z$J4]*M*:
M;C22R:/1I34R'(;%ULV4:$22RB2*M3+;9H+5K)FO?\14'4*"F&(IB*$8&M5%
MEWJ>^D? ]D8MM)!;B2<<#JP-0<013J4/9'4\CA=9=V6#"&=B?OD<7(G&#,M<
M8^D8)#09)BQ>6"9U4%ATQ1LU$Q%>>Z5:>/$^Y%LXTDT:@,JXTP/&G$#HX*HD
MM9(;8W$8K%KH3@:&E<1PK7 ]?%8;D(K?WC':9%&0G-X]X6Q^:TLT&U(11;J@
M"9+;W)6]CCX9)S%?4H<C!X@ P#@#Z5ZM0V2EYN'R72,Q/<CFJJI-%!=YA6]^
M*&V*B5_&]>%Y#6/YD5[5Z&-U/9R!IV*@<(#@L*+#31-R":)P$57'E5D34G3(
MB5>/@B6%/=6P5#S4G+T8K T+!@!0J],"U&EX?'^78-N8Q#=E.$T)/FY.)5$V
MGU17&5C(H\G*J<4XWK227-=)4U!-.6'1TK<VC7,CH*. KSQ^I7G$Y9ER4^U.
M9)PH+$U]Q0LH2/)"=N8>85%3(4543@O&LWNHP$9DCUK?%.TN+9!W0>VBHCRJ
M95X&6FU!IZ0V,KX1:(F"^<+0-+RM@?+RK[4NGOK)YTL-,P%@Z82G2W(G'JZ%
MCKSOG&GW598:Z!-])&&@906G#(4:) 1.?EX6);E\M -! J37FHQ=K!- *947
MC"02>1LFP/G%SB2*JCRM&7PI?ENJHG&U>OP%5XS$THKAKD5Z?EX4*-C2RCTF
M0PRD=N.]+,4<=!",6&$+F+E6R*2**7O6$[@R)SW.T@#.M/:L[9CI)6L:W620
M*4KZ@LYB]GMWEJ](E08>OP1=<O)ST^/ !L.H7*I,BKSP(B>PA&H3MULVT:TE
M[Z9-!*G-V>^=5SFB-G-Q ]6?J5SRNEZ-B)SF-R>_P'CALFUY;6<))RKZO@R+
MCKKL]QZ/'-PW!6URLB<$1*PCN[R5GB1PD5.;W #T9K;+96,,GARW#309,:7&
MO.M0%;B;[=Q9F.P\>+M.3;EQXO7D24P6.-UV>UU!? TCY*2TK'.G*@DB63C>
MLZWSF.E<8VD$X#4<N' +41M[7MA:)7!P%:Z1GQR)PX8K!79F)CN.I!@9!HD4
MV^:5E(\D5Y2M<@:Q46Z\/825/C\44+RTCH!'TE0B^)A/AM<.MP/^J%FPX."Y
MKRY:6<L6URV$PZ1(;+#S\IW,0'9Y.@XZ2*AQ^44$!^=?QJ/)>2.E\%@'=<ZI
M.6DTIV\U-\%CK?Q75IJ:V@&)+A7CR4H:5Z=9N7.)F<PN:B84&9<R3B9.+AQ-
M@=:CMH3"A'+)2FFV7S)%NX(N<J?5\4JGO-^9%6*'09L ' DMQZ:#'U=*L[+R
MZ^:DTQ>V&A):6@.-.BIP/3CT*8]BTGM7%TIO$-8!_&NN99DY<V-BI4C9VXT&
M([+FSV398?>ER.D'0!I!5CGD#<$1+I66=[NGQIG\0. 9@"1H))H >0XUSH,U
M<W%CMD=GX0CTG7B0"7T J2,,3PIECDM))D['0\B]&Q;$N1 2<38'FXC$;)N1
MD)L$"5&9-\(KJW);"=TX?HKM62R/C#I !+I^R26UZ#A5<7))$R0LB!+-7V@
M:=(QIV%9?*=*!V^R.%3'RT8R?<H)#>4)&R@/MZ[KTN.>.YN?J#*C'F6W;$-B
M%RZ+<5J#^^OFW.H:FV]"WB-3A[W4=)'0>M27G18.ATG2ZXK7@=#2*=8U J/(
MH"SBY4_IMN/++9@LJZ N"RALN/O.(!HHJX0B@HJHMN-N-2G&L@9PH3UJO:*1
M&3 NJ!U88KKDF&Q<@N- +0SH,62K8I8 =<4FG.1%7@)&WS6]EZ]C<2"#CI<0
MO)6@%I&&IH*[0B1T94!UIDP&-+=:<Z0(^V^P*NBXCR)U%%>114551LOA1^%'
MBN8ZJ%&8U80,CUU'2O2!':+)Q83C8N-RVVV'+I<A.0USHZV7B!MFJ*GZ+5X]
MQ$9>,QCZ%DQ@,H8<B/;Q5I$A9=YB;!]&B*[;G,@.*-TL?(HERW2]D5+UL.(Y
M+2,#S5XR0"SEU;;::%LFX1$P(\C)"Y%8=<'E"UA)25>'%/?>L8*N8,<23[2M
M\F$U&@4-,.&0602S<98C163./!D1X\QR"PXXW#<DDB@CYQD/I./(VV*<Y(I6
M1.-;6,8"30%X)%3G3KS4IWNM#6X,(!H,J\Z<^E4DN(T&-9?!EI9,AU\E<)L3
M7I1N4>BB*ED1TC557Q\*$:G$<A[5K?&/"#@!J)/JX+'^J,-V4K;+1'S-BTK[
M0/BR)7<.P.(0*2BB#=46R7K536!6M.C!1:Z": 5Z<5ZY.,VDN+T0%D9\2#*1
ML$L#1RA07!!+K8$<151/8BVKR-QT&N.DD>A92-&L4P#@#Z5G.M;QLNB;#);U
M:8./8CF^#\(VD>A9)(,=TE3)LDJ>95\FUN=T<"_P$-JA7-G;WL -R-3C3'B*
MGAR_*JFVU]<V4Y%L=+1F.!H.//\ *BW$TSN/H'>W&)K>QXF".8,$5_7,H74!
MUQ+<\_79UVGC-M$5;"H2&D\4(4YEY.[V^^V>3XB!Y\+@\>QP_(%=A9[C8;S%
M\/<,;XOW'>UA_(CI&*U=[N]L,/I6X2\7@LX,R&9/2#QS[2ED,(AN<S$22\V(
M1I*.-KS-K\+B!;G'BA+U.SWL]_:"6=FDY:N#N9 S'3PKD5S.[;7#9W9CMWU9
MG0YMY \#T<:9A8NF%"&\,%EMEX3@(VI$R 2EE/QE>.4$E>9Q#!"Y0%%$;5,J
M:&2IK7LI6E**+X C=H;0^[RQJ1G7V+!H@B4;((;0<[,17$-153$_,,!PNM@Y
M45?!+UM?74VG$_6H#*%KA3)OTJ]:ILDO3<Y@-HQS3+TS%9,9J-/BA-2&6>5N
M1"/@O*U+CNFV2IQ1"NGA6FY@;=0OMY*ACFTZN1[#1;K2Y=9SQW,8!>UU<>/,
M=H7U#U3==0W62VF$RL9#)YH96'DR&F<OCB<$7#C/Q7#%P^FA<J.@A-FB71:^
M=W-G<V@_%::4P<![IZ:_0<5],M;RTO'#P'"M<6DT<.@CZ1@J#=NY.I:>R4C,
M9*",A21J!A(#L=W*3#(^5EEN,T2N *D2(3SW* IQ5?8N=I875T[3$TZ>+C6@
M[?H"UWFXVMHW5,YNK@T4U'L^DKYQ;=L,C<-FV_*9&/';>DO39K*,MHAQ/).-
M,,L(_;JNM#%!&UYE6]D5+5WMK VUMXHXR:  'IKC[5\]NYW7=S+)(!4DD=%,
M /1@L4$6SPK[G1:%QK(QFD=0?I5%R.^1(1K=>55%."63A4@U$P%30M/M42@,
M)-,0X?2K8(7!PK_,Y.'OYBM6SBM:O6.BLODS(=;$P8BY!]QKP%]8+*.-(:);
M@1$B%[T2M4CG"K1F2.RJW1M#J.(P ->FBM<8$D2VT<1.5QQ2,03D&R7,A%!X
M"BHED1/"MCO=;@M;1J<*JYD03\=D'RCQV7(+T4V28:!FS$EPV2CGR(G50%1%
M%5N7CQXUAW)&BI(<#GCB.*V5#XW.( +2*4Y'"BL=;5I7?D^B1V_BX3=O[T )
M5_W]>5QIT)3"JN[V.;" DP55%6! ?Y;_ /&R);T<R_1RL7M[UK6)#XFC](CT
M 'Z5M,8#-?Z(/I)"N,#&#+:ARV8927 QN1>.*TV;J2)$!T&6#<;"Z\IJ^*GX
M(7+\JUK?(6DL)H-0QY X_0ML<0> \"I#2:<R,O:BX@8\5O)Y.;%@/CDE$H[(
MC*DKRM-R !(D->C')"%>!F%D6L]=7:&@D:?S<5YX(:WQ)'!KM669YY# >I3;
M@Y,7.^2>BN<[$MYL"\$<:(B1'&G115Z;H>U/UI=*@R Q@US 5W"]L]"WNDJ\
MRI$-N'F)DI&8L?'LC(%P40$;:;>1GI)[7#=%SA>Y$5JU@.U-:*DDT69<P,>]
MU UHKZZ46MTO/K+E27WL7B'Q??==%'H2"\@&:J"./QW&'#-!5+DJJJK5H(](
M !*Y]T^IQ<6L-3Q&/I"[PLEAUDLI(UN(YSN-MV9R&0: 5<<$>?I/'* E%%X(
MMQ^2O'L?I-'GT!>QR0ZAJC!KTG\Z\"76G",2CYJ-Q)$Y'X$T$XJB+RN,PR6W
MZ:]_%'%I](^M8UMR<GCM!^@+)<)M$_ BK6!WS/8N.7 X$N"](QK@KXB_CTE9
M''NBO@J*RJ5HEMH9\9HF.=SX^G ^M28;J2 4@G>UO(BH[14@^A9!]_:_F%Y=
MAP.A9ATU1"R&">R.A9HB);<RI&A)@GG55?VXBHJ^-1_AYHOW$DK1R=21OK.K
M_$I'Q%O-A/' \\VUC=ZAI]+5GF$U7!8%]96+BR0D*YU6)&1?8EY&$)"EF&Y4
M9B,R)LW5.HT *?C6M\LLC=,I!YT% >PU4Z&U@@.N,'5F"34CHJ*#M 4FX/:\
MS@Y#;S$M^1'0D5^#(><=8?;O\0H+A%TG%'YIC947WIPJOGLX;@:7 !W C,*P
M@NIH"""2WB#D5LW$E-38L:9'528EL-2&E7QZ;P"8HMOVD1;+\M<J]KXWF-W>
M:2/0NF:X/:'M[I%5Y9/&P,UCIN(RD8)>.R49V'-C.(BB['>'E-$O\TQX$!)Q
M$T14XHE>QS/B>)(S21IJ"L9(F31F*05C<*$="T%_]W[+_P#*W/\ 27_!G@GX
M#_TWX?6_)X5VG\[BY?\ E]?[7W5PO\BEY_\ F?#_ &?O+I!E>1],^:8Y% \S
MW(C CG-P=:8C8\U!!M?X"@$OBOC6+VZ_,3#P9;GUD_6O8W:/+3P?MW ]0'U*
M#8,UJ.$J-*9-^',!L70:<%IYMQD^HP^R9@X"&"JJ*A(J$BK5V]A=1S31X_(A
M43'AH+7"K#]&15RA/#E<_KL1EE68H9#$8^*P1]5Q&SR#7.;KB""&\\XZI$J(
MB<;(G"M4@\*"1Q-7:7$GL6V,B6XC8!1NIH [?I64]QLWU>ZNZY<&4-I[8LJR
MY',[H[&2\%UI3%$MSMMK9;<%M[JB[=#IVN&(G$1M->G-2]SGU;K-*!AXCA3H
MRHL/^]FHJ0V\7'<89B3//EYMT'W9#_*C8@XK3;((P#-Q1$2Z\RJJU,\(NJ93
M5Q%,,*#^U0O%#=(B% #7'&I7G*R$-8S\7'Q'HP3'VY$I7Y OE]"IDS&8Y&FN
M5@#<5;E<EX>ZO6L=J#I""0*"@IVE>.D9I+8P14U-37L'0I([39(<3$[CY)1D
M@YB]#R,V%*AR$CR(N3ES\9B(;H<[;K1$*SE(54>82&Z57[I'XKK>/ ATP!!%
M00 YQ]BLMIE\%MQ)B"V D$&A#B6M'M5[E=PX$W$ZR'<+6H6V_>N-F2I&6:%K
M'9Z,+.7GXZ.<:3&!D7/H(EU%5;YBXWK0VP>R60V$CHM+@ W-I]T$U!KSZ5)?
MN,<D,0W&(3:V$EV3A[Q&!%.2R'6]?U*6U)E:!L#N0 V%.1K&5 6<_%(7B=0X
MR?1K-;:!PD7E$U6W U7A6+[JYB>&7[ W'!X[O;R_+!;[>VLWM<_;I"X4Q8[O
MCJY]E>M7QS((KQ/] AG%&.,^1%\/45L6%?%KE0P>Z0JA(JV0EO\ )6T1G32O
MX=:CVTKR61DQU4I)2A]E5BTKNJ[I.;PTW$18L_+XSE9R 2"4HKN.0+!%(FTZ
MD>>J*BHX*D@B*7%;VKV7;FWL+XI"1&[$4S!^D="C?S4V4S'Q .E;@:Y4Y=!Z
M5,[Q=NO4+@FE^*'L6+BDV)"C3>QX?G<-U!=%+-Y?%=9Q;+Q;LO!6S\*%HO\
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M5.9&G6W%'PYD;,3M?C:]J\(J".87K31P/(KH2\Q$7AS$JV]UU5;5ZO%Q1%V
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M#P/2.U;'PAYUM);+S'L/,=!4.=R.[$C5L-FL1CV8N1W=B,C:-XJ2S+CXZ/)
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M5WNW3Q7%I'+" V.@%.5,*=B^;[E!+;7LD4YU2:JZOO5Q![:JQ;/^.3?T1/\
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M68[:K\#:>-3X;5I_%E>99",ZT:.AK1@!Z3TJ#->/9^% P0QCA2KB>;G$5)]
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M&9G$](=,#<.7CHCF4RLETB$0;6*O,ZXJK[$NJHB^.DM[-\DTE&QL:QHPZ":
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MZ0/<#I!- ,2,.KISQ5/_ "E\DCHV&-KQJ- 2< <>O/V*Z[!A]ET3M])GZ0S
M=R^+FOL[3+=@A*RB1Q!75FXQ5L+L5ED@=Z;@N*#)<R75"J-'+!?[@!>EWA/:
M- !HWJ/36HJ*5*W3Q7-AMY?8AOC-<0\D5=3F.C(T-<%J+(R.6VG[TR6P9?(9
M,H$$I(+)D$Z/F'GFX\8&FE7H,-=1VZH BEALGC72MCBMM,<#&M#G4PPPS/7V
MKD'RS71=+</<XM;7$]@Z@O1G$P9K<">+;C$-R%E'LA&;=(UZV( 5<&.ZYS&
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MJ?M-I0]H&?IYKE=WV\6;G3PC_+2"A ^R[,=A.7HY5B7$Y*&$_ 8II'WX!$]
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M@K/L2;C$)ORZJC+D;1(;(BJH!!-R4^9D>"+8NJ<(^I[T3CX5"E +SJSK(?0
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MED"TRX:HBDA =E KJE</XTEN\R6SG?#..D.%16N5>'Y57T#P8KE@CNFM^):
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M1;]PC:[<)Y"3X6LFO$U- .NJQ1,''==C/LR7AQ3^/E9)Q]UL"E1VH)JU+CD
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M49FP8K</#N2V3;+&9>),G-*3L6/+RI@XV@N"-W68ZQP0S%%3XEM=$H6/<3,
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ML99!=-EY(?5\PPKME%MSIHA#S61;*GC66Z$QVLDP!(\)S33IR6O:0)+N*(D
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MFX1W*RW%2ZLO,1<-/DQYL<U1.I%DMH)@7N6R\45*ZR^GCN=J=+$:L>&CIQ<
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MP2XH*K[?;6[XMFJE#3FL#MLVFH+=7+\ZCAUEUMQR.ZV;3P&3#C1BHFVZA<A
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M_$UI73R!YYGA3CJ;&S.2U[8G\MB9*Q9L3(35 [(3;@'(=1V/):+X'XT@%47
M*Z$B^^RUTSHHYX!%**L+1_:.D+E63RVUSXT)H\./]AY@\0MXNUNX07LQ(UB
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M2DU+G<^8 P]-5%N?,-_,0(M,4(% UO(\"3CCT45C#)N/]KMJ<Z(1VIVX:O!
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MGU+BMQWV>^<Z,"EJ373Q)YDCV9=>:AAS)R'<D&4<1LGVWV'P;05!@4C*WT&
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MT\45%I^'<1ED@PK0@\_RR* R6TK9(W>]F"/R](6S^R8)GO-H,+:\:Y&7>,#
M596/;0UE28K39R'\-.<04!)AM@4G'&O!X%)I51Q;5SEO.=IOC:R5^#>[ \ <
MM0Z.#N6!R747,#=ZV\7<1'QT;<6\2,RT]-*N;S%1FM4H$%S(/&V!@RVTR[)D
MR'N9&H\=E+N.N((J:JET1!1.8B5$KIGO#!4XDF@',KE&,+S3  "I/(+O.QZP
MPBR&I#<R',!PH\EH'&T4F30'V7&741QIYHE2Z+>Z*BHM>,?J):11XS'6CX]
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MAH<CGP5J6RQBP"$VN136F8_31P%O.#)EDSQZ.<W(KZ1RMRW^>G+XUMR=X_\
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MVERDY>+;:7^AP-==RB\E!$+?W;3_ *;AS/V1P'25\TN'-LXC90D&9W[QP_T
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MLN.?]J/_ 'A[N?#)2'J/^D_M_P#@7]J-=_!_L?XI'^N_PO\ XJ@W7_+9^_\
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M*]3&=W[7;FH,G?X9#++\N:N&)^R9'\!^K_\ 6WVKYJ_8?Z7_  K5A)WV]_\
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M_(+?MG\6,^Z?R/Y9T6U0?/#YOSP^?\SYR?/_ *'O^2J$Y=BZ49K93_\ -?\
2A_\ T=<C]?Y?M+J?J_+L7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g937421g04z61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g04z61.jpg
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M P,# P,# P,# P/_P  1" ,J G(# 1$  A$! Q$!_\0 O0 !  $$ P$
M          @%!@D* @0' P$!  $% 0$!              8" P0%!P$("1 !
M   & @$" @8)! $% 0    $" P0%!@<($1()(1,Q%!75E@HB5%475Y?7&!E!
M42,6,H%",W>W.A$!  (! P(#! ,)#@,%"0    $" Q$$!1(&(3$'05$B$V$4
M"'&!T3*24].4%I&A0E+2(S-CLR34%548<K*3L4-D=+3P@G,T5#87-SC_V@ ,
M P$  A$#$0 _ -_@
M
M
M
M
M
M                    '&:>23T^N>63U32R2^J:$OJGF^$LDOF,/,TT?HA]
M,1Y-JU_&F(UG3[Z"/:KW"^&^G>R:]KW+NG<R_5=FFH0QFWZYH<F2TBKZOES7
MU*GL=YF<;;WF0Q%O4^;<V=M+7O)*</,M*;S+YQ<^[Q;>T5R1;Q]L1K'[OO\
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MJ7YD))HQEEGC)Y]4))II8PA'QXC&#W2=-?8\UC73VN;QZ
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M2M3FC5EI1]-2:E"6:,:DM.;X31AY\1^E[-+1KK$^'F1:L^4QXONI>@
M                                                  -8#L]@M<]P
M_AK?^PW%^M4>/.[G3W9\IA^9-/UBI<6N:VK6M.S&0HVFPX6M1]&2O;[$4\)4
MOL1<31C>VU2SNL=&:I&6TGCI,W3O,=LU(Z=SCG2T>^(GSCW^^L_>?F)ZH<?Q
MWVA.S=_Z@]L;>G'^MO:&YO3D,&";1DS8<%[17+CF-,EK8XQS?#:=<E)QY=OK
M?3!9Y]S/5N/<*Z2:EW&TRI&W[;]0);' <US8"7ZKG-CU/"30S6.WJUEM?35E
MNL;+2^W[2I)"62E/+E:-/S\JG"%&3^][:-Q7^GQ^%M/;'GK'_-'WX1[O.V3[
M0GHIM/6+A?A]6^T.G%R/RXZ<N;!C^.FYC328FFD[BMHTBLQNZUUZ*1'V[)YO
M(=RNJW$'N-</UHX;LQUAN\-J_8*GKDE&AE[2.LW-OE,/R%1M+>'S9[/$9*I3
MR=&:,LTDN+R-S2GFC)830E]S3.YP5WF/PST\+:?1Y3][S^Y,J_4C?;GUD]*^
M'^T9V?/R?4KMBV/#RL8HBN2/DVB^/=16(F=*7TRUGQB,67)6TS&VF(R*=3K+
M2NZ7+_7KW%>-K_#ZQR9K&N;1Q'VQT"G5GDGO\I-HF2QF"R]E2IRS3_-I92K9
MU;6>M^C=8:I0E]<*UC-)-EX(KN<M-[72,D1-;Q][_P!M/?$OHGTGQ<-ZT=V]
MO?:([:R8=MW'MMOFV/.[6)\;W^JY,>+)6(]O7..U9M^/@Z*]47P6K:!/YIR;
MT=?^J,_CSZ.;=PF\?[^GCC(Q\?\ KX?7OV5(U[@Y:/\ P./^VAT_[0/APW'3
M_P"+O_92C!AORYFI<A=*M [#\2\]<@5.P>V\'Z?S-B-<V3$ZU+I&2S6P:3CM
MQI:1876)LK/:L#4]5W]2L\E-?74:=2$E2I1C+&,LLIS_ &D-YQW>^X[<Y?C]
MO^SV'?9-M:]+7^;6M,LX_FS%IG'?RZK4Z:ZQK$6U:'%Z)[?>]K8>:X[>9O\
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MV=IQ;;:XZTICCRBM?*(G7V^W6)F=;>.MIE,1#4F>?[3RSQ7H^1IX?=>3./\
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M!^D/[B^OG\=N&_YGZ3]^'U_8?G\/Y=?PG[<]D_ZQQ7ZW@_2']Q?7S^.W#?\
M,_2?OP^O[#\_A_+K^$_;GLG_ %CBOUO!^D>R,M*0
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M7%UKVP;OCIL?AY(7.'Y-J6=IA<A=V5G>W$E26$:=/ZS7IQ[1ZRTS;WT6IO\
MOK!ML'=U+8>BM)B>C<6R1%Z8IUMX6P]5LE*VM6-)\9Z:RYAZ9VQ[7U.OM.U,
MN;+VY:,O5-HF.K#%)FMLD:5_%R],4M-:VGP\(ZIA[1UI_P#Z?>4O_LWL-_\
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M+^L9/\,W*'7'ZG
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M(Q@JY+O3NSF.+IPG)\ANLW$8NCHPVO/RZ_+CIII3\6(K'A6--(]BG9=L=O\
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M-D@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MV:QX^/L5!;5@
M                 -'7]ZOO ?M_OC^&^5/N!QGZUW7_ !M]^3D_ _(K]H_M
M/_GN\O\ I;S]&?O5]X#]O]\?PWRI]P'UKNO^-OOR<GX#]H_M/_GN\O\ I;S]
M&?O5]X#]O]\?PWRI]P'UKNO^-OOR<GX#]H_M/_GN\O\ I;S]&?O5]X#]O]\?
MPWRI]P'UKNO^-OOR<GX#]H_M/_GN\O\ I;S]&?O5]X#]O]\?PWRI]P'UKNO^
M-OOR<GX#]H_M/_GN\O\ I;S]&GQ[9._>XOG>Y/'6,[!Y;M?=\55\#R%/GJ'*
M6%WVSTJ:]HZ;E:N#CD[C.XFTQDEQ+E9:4;:$\\)HUX2PE\Q^#=]N9^X+\OCK
MOYW4[7IOKUQ>*Z],Z:ZQIY^3L_H!S7KGO/5+8[?O;)W);MR<.YG)&[Q[FN#J
MC!><?5.2E::]>G3K.O5IIXMDGF6C/<<0<K4*5*>O5K\;;S1IT*5.:K4K3U-8
MRDDE*G2DEFGJ3U)IO$)80C&,8^(0=>X68KS&TM,Z1&YQ>/N^.K] .4B;<;N(
MCQF<&3_DEJ3<*]@^S-S[?6]\(3V4_.W%F@>W+J>:R^D<B=-,[J^'X"Y=U/;.
M.-<T+A>M+NF'N<1V$I[?IE:\RDT_U>[FDJ8V2]I3TJ-26A)]=<WV[VO7U"V_
M.1/U#E=QW)DK7)AY&E[;O;Y,>:^7<Q\NT6VGR\G3CTUKX7FDQ-HZI^=^-YGG
M_P!C\_%S_?-CAX:LS3)L[5C!FI?'7'AUO$QN>NFM]=+>->N)B/!DMM>Y7>6A
MW?S'%&)PEYFL;CN7M^T6SZKPZ[;)@];L>M^M\19#9>/^S]#M?4A)JE>\W3>;
M2SQ_V/"K&WDFO9K*2VIW%+YCF5NR^Q+=C4Y;-DK3);9XLL[[ZY2UYWE]Q%,N
MQG8?TD1CQ3:_S--?AZYM-9T3:O<_=<=U6X[%2;4KN<F.-I]7M6L;:N&;8]U&
M[_$UO>*UZ-=/BZ8K$QJQ_:'VH[L;%RON?9;%V^Q\W]FM&]M3DZ?_ *5D^I^^
M\/8WA#E'-]A>&ZO(/"]CCLC0MZW-5QQ+AZ5QDK?ZG6JW>2A9PDGJ5XU82R="
MW_:G9&VXG#VSEG%L>U\_<V#^=KO\6XMN<%=IN/D[F9B9^K1N+:4MU1%:=6L1
M7368;M.X.Z<W(Y>=QQ?=\]AX++\$[3)AC!EMN,'S,$1.GSYPUUM'3,S;ITF9
MUTB1&>[X^X3C^F?[VK'>L'>5+7LK>Z?B.4['@/:LCO.[\76/%MUL=;#5-4J\
M68SC;![5+R/+)C;+(5K.QQ&=MYY<?1OK/*2SU9HYM^P?3S)WI_E&3!>L3QD9
M+8)W=(Q8\\YXIU?,^?;-:GR?CM2+7R8IB<EL=\4Q$;S-W?WC3M?_ #&F6LVC
M?32N6-O:;WQ1BZNGH^5&.+?,^&MIK2E]8I%ZY(F9JN^=G^TFC4^VF_=>./*V
MO=DM[YQZ:1XRXQCUCQ./VGL#D-IZ?:/M_)>H<N22UXYG%_\ 3+>YR-W6R]7/
M5:NNW.,HXB-Y5A5A2JVMAVMVKOIXCC^XMQ&3MK!L>1^?G^NVFFTC'R&7'AR;
M?PZ;?,F*5C'&*(S5O;-T1IK%S>=P=P[:O([OAL,TYO)NME\K%]6B+;B;[.F3
M+3+XZUZ-;VFWS)G'-8Q]4ZZ3,O?N\O(&/Z3X;(\%9S>N8>R<G O"W+.U;YFN
MN>X2QPFC[OR/8\=\K\H3<9Z[K^"U[,;OQ7]4S=_5T&RNOM:A+CY?FTJU&6>I
M5A7']B\?D[WOCY['@V?;7U_<[?'BKO,?Q9<6&<V#!\Z][7KBSZXZQNK5^7/7
M.DUMI$2?>=U[S'VM6_%7R[GG(V>'+?).VO\ #2^2,>7+\JE:UM?%I>WR*SU1
MT^,3$3,Q7YK[N]L-0X>X*S?'G8S:=CTC;,3V(RE;M5'V\N1[G,<E\H:!E,);
M\*]?[O@:6RI7^E8[DJA>7OIVV2UMK/+QM82V<;2>6M%+.$['[2WG,[_!R/&X
ML>^PWV=?J/\ F^&*X,&6MIW.[C=:Z99PS%?[O-K6Q]6M^N)JC_)]T]P[?C-I
MEV>^R7VN2NXGZW_EV3JRY<<UC!MYP::XXRZS_/:1%]/AZ=).1>UGN<W^\Y[)
MX':,-PS0UO,^VUI>P<,Y?KQ1Y!M,7MO<75,=B.9;BEN,^3Q&<N,?PKN&3GOI
MJ$M>M"%2V^1<W-&A":2HX[M/TOQ[''BW&*^]MEIS.2FYKNYQ3;'QV2;;:/E]
M-JQ.YQUBNND>%NJM9MXQYO.X._,F[O?#DIM8QVXVEL-MO&2(OO*1&;XYFMM,
M%YFVFL^,=,S$>$Y6.@/*'-7)W".SR]@,C;[%R7QESUSWPID-VMM,_=]3Y#Q'
M%')VP:CKF^1U&E-4QV'J;+@[&A7FDLIIK*>/Z=&,99G)_4'B^$XOG,4]O5G%
MQFZX_:[F,4Y/G?)MGP4R7Q?,\[=%IF/B^+V2Z%V?O^4W_%9(YFT7WV#=[C!.
M2*?+^97%EM2N3HCPKU5B)TKX>Y-Y!DJ
M
M
M
M
M
G                                                 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g937421g18p26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g18p26.jpg
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M P,# P,# P,# P/_P  1" ,J G(# 1$  A$! Q$!_\0 R@ !  (" P$! 0$
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M'K2><>?;*X<=PS:;14>5Q!MOGN0XK&_5]E\.EW3)0Q[Y;Q1WO&RF^YS8R;F
MN7U%PUZ]1*N-PG<F3R^4\[19V,V00L9(3],BAP&O8LPU1;7 !'0 U!O//&'-
M^-^>KGQPS6=0SKW$[^9C#$F+.6JJY65QH#SL 2L7_P IL&K%YHHT;<A!R0X
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M8DN7'[;&!E>7P (.O^74U6O</U*[=@XR=.V\_!S><4[%BAFBE=&-[NR(Q.U
M";D6W6!ZUT/Z*]N>4,BM\[SC)KG.,PRF<[<9-F.46LN_R+(K>2Z3DFQM[B>X
M_+G2#(^G<7: ["""*(*0G:\V8QR"2^[QKP=]1^9Y6%WR)9)'S)6)9F)+&_F3
M^WA6\K#!(%S5 *1&76G&O8=:)L7!<^W;<Q45_F0M;)\1& VW!_&]43@=R<GQ
MV5^IAE?W ;]359_EOP&W05T;.H'Y8?L:-5UA <DO/Q(U+)E*C;L..X1MPRCS
M7D[^SM$FRZIN*:V_ Y3PYGZ+(L5DU5M+[AX$^-QT^(KVE] _JO+S&3-VQDJB
MSY +HP #-*JZW(U;<H-KW(8:=340L7O8%,\TIN".ZH'JG>G7H0(GKLJ>GUU.
M)%5X]MQ]M7AS7%9G(J2BL0 2?XWJ6-!R#6M16E_)5I]I&W$3[V9#9CL;3R%]
MCK1B0H0JFVR]4UIECR(6_I"X!N"#T(\C\/PJE<[M_-2<E%-KZ$?P\*O0\.N8
M,.\@_&2\XSY8YHC8B'_F"MQ]O&.*N(,5D9Q;8E;8==+:7<AN'07<J\O4O8 /
M65PS#*WC13=ED[V]JM^J^V,C.[M[=DY:>/\ 6<[^E*[GD:Z2JRKML3U=;E=0
MIT%AUK?YG&309\/<,6-))F' +,T\TGM+,CV %Y$55.@2(ML-PH'4&H.5B')^
M&81D'D=/O<(Y)PF%GUIPAD&)WME56'*]G,R?%'\L.\_#"J&WQVV:;<)MN8^1
M3EGM.LJ1 +R+AX_.\]P/*+A9T*3XT*6,)5!(5<[2NB:."3:]S;6_45;\.7AR
M947 B-\?)> 3*5%HE$;*I30V*Z] -NW7K:I*>!W$>3T/R,?&O@SO(N+Y17<Q
M<H^,G+$P>-[@ID^IK;>^J,UN<-SFSBR%ER+;'8M(42UAO$VR#S:MDTO15AG)
MY4.=P^;)D)M'M.X4$A@X4 &2W4WMUT'2WC6WX3,BS\UP(9(VQ\MHKN-&VVL\
M>FBL#I;XZ^%>KKJC*L:FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4J@7_ "+L_P ]PWPFPREQN395V$<A\YXMB/*MA7NO
MLM2<<3'\GO:7&[AUDA1*3(LKJ(8O >S;[C#;!;HZH%I.?>5,$;+^V7 ;_IU_
M FUZH3_D;-SB?3MX.&+JDV0J3%;@^UM<[3;^5G"@^?3QL>K R. W_%[S%VE.
M56Q4.$;-@U%.*R;#*NB;C4H585&7&D+[DVZ?PUHX_9,-PUI!:W["ORDB;D\+
MF(SA&1,SW-H*$APQ-K+M(;U7MIYU JSS[C.=FT&/Q](BO1W:ELK=:UD&JUN<
M!-BTC*, #'>8]V_9]$3?Z:Z6AFBM.ZLJL;:Z&_F =;5?&/VMW<.V)AW*CK*D
MUX1*Q:3:0=][DFP-MM_C4H,2OX@0D&08(G:A*2JG],D3U_COOK9HRN@-S>J1
MS<9X9FCL=#43/-C)Z2)P?R2\Z\T2RJ!VMA&JH+KUG8/QX<%&]EW]P9+@FGZ*
MBKKL@(?.A6/J'O\ (#7K5W?\>.*Y',^J'%OC!O;BR-[FQML12S7^P6^VU4C<
M5P+C+<B@H M._C2HX=SJ%[3CO<"]Y .VZ@/\VRIZZE<^0$@:27H ;U^D7>?*
M8G$\'*LEP9$*@+UM;XU.+R;X^S"+BN-9TRW7M1J9@JZ]<K0=9?)F>40:R2;3
MJDI1V7P4"^]5%747;;=4C/;/(I#/)BH7 D.Y=UB+B]_MMKT\*\^_1SNOMK-Y
M[,[6G+ODS-OA#V*AH]WN*"/YB#<: $*?&UY.?#3Y#\T8CRQDG"'$=1A&0\E9
M3(M.5^)8>>*ZW%LLMQ'!\BI\_P +BRV&'9 R,YXOL)1M BI_W-,RH?<JB?H_
MZ1=PP8V?E=N<DY_2YZ*8[L509$;*5+%?58@?RW)VA;:W%P?43A>+DX^/.R_>
MCP5"PRF( [$:0-'(5.EHY1ZC8D"0GPN-S>1F#Y1X#^25'RM0Q..N?+_EWA"S
MNK7'+2EDW>*53/+<=IS(:W$#JY$*TK<FQA^R]F!8$;A^XC@DR@ODTES=PKE\
M=RL/>>)'*>44R1F%A8621 _MFP8;P00[7)6^BAM-;P^9!W;PSX,AEQ(L?+"A
ME?U7A/I+DBQ#6]:VM?Q.V]9]\!F%SLP^7WQ0DV>..5)1\HS#,&XS[4EB9':Q
M/BSD*]:=EM.,,N+M(;;[35-E%L4)5U4?>HSQQV;RDT8AQLB-%"@G_7<7N &\
M0"+Z+4^P;-F01HP958^((T4G2WR^^O4XU0]3*FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K .4N*^.>;< R?BSEK#*#D
M#CS,JXZK)L2R: U8U%M#)P'FQ>8<V)J1%DM ]'?:('XS[8.M&#@"2<719%*.
M 4(L0:QLS#Q>0Q7PLZ-)<21=K(PNK ^!!_8'4:U7)C?PG_&]C&-\DXM$X"&V
MK.4,/R'!;<LLS7-LQET&.Y-#*'/;PE_*+ZU_M.V8!4*-911&RCF ]CZ)NBX6
M/QF#C2>[$@W^%R3;Y WM5?<5](/ISPV=)R>!Q< Y"0$>XUY&2_7V]Y;8?)EL
MP\ZZ0OGY\._DQ\8.1YAF#V/VO+/B=#G.2L:\@,;@C*8QK'I=@U#J*SFFLB)^
M1@F01G9D>*Y/)O\ 9+"08JP^#CBQF\'E>/GRR#'K^WE51=^_3KF8)7EQD?(X
M]CHRC<0/)U&H(\^A\^H%:CWDECE5&;!;:(X\ZK;,=D9+'WNNF+;0;^XB)N9)
M]R[(*=5UJXN*Y1M +*.I-_"J/7Z.Y/(Y)E3&FV@%F.QM  23T\K_ ,*Y7R#\
M9LVYQ\?Y698[DYV&1XN\>4.8H#S+%-;PHL5SWJACO[7"N8S)J[$<<)&WW45O
MM%3 DY\1DPX\_N2#^FPVECU77KY >8_PUZOI5]5.!^GWU)/;_(X20\'D 8WZ
MBQ::)V8%9FM>\3GTR*JDHEGW&S U:\79"7%UJW&R:JL:.:KS4T&KZ!*K'VO<
M[ 4G8\YB.ZC)$VG:6W:O7KOJ69$4>9BF.-P4/B"#^(KV+WIPH[OX\9/!SPY,
M"@J?:=9 2-;!D)%_,7OTJ57+?DS4YCQY)P:IVFR[=N,S.ECL4:)$9?9D'VDB
MK[KSBLH(HG\J*JJOIK1<9P,V+FKD3,/:COM'B38C[!K50?3[Z.9G!=VIW5EH
MT,4!9E4GU.Q!4:=0-;DGKTJ)N/2K''[.#D%#;V=#=5LA9=9=T=C,I[>NDH!M
MI)K[2O?C3X,A&W"'O:<$NTE3?9534LBEEAE$D+,DJFX8&Q4^8(U'V:U?V?DF
M:,XTB*R,+%6 8$>1!T.OG6\N(?+ODC@?D2FRJ(Q3\MUD:%;U%]@G+!VN4XE<
MTUW%E,264%R>,ZIN:^;*_<*Z='<1R!9LMRA$C#K)\7O3N6 +&^9-/CA@VV5C
M)8@@W4L2RWM8V-F&A!%84_:\7.<;)#EL^.[V,;QV5T8=&\CIZ2I_,I*G0UV<
M_P#'(Y:IO)SY5./>1K'$[],ZQ;@_E.?E>3W_ "+.RJ0[D<7$(&&MV;46;B\%
MUP+JIR20KJ%+(6W3107=#$IAW7W@>YNU3-D%I,LR1*P)L(&!9@J"WK1E!LQ(
M*G36LCM_ALCA>17$]U&PP'9%6)8PJ'^71ST)%K*#;K\/17U3=3VFE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*JK
M^</%DS'XC/D%I%:)U$\:L\N^P0=<5/[5CL92CG:T0ELRM-WJJ_:B#N2***FO
MJ_F%8V6[QXSR1@EU6X'RKQXVXC(OO!'^]DC7[E#M$EW5-P3U451=9T:L:P!D
M,(!)-Z6L-+WM5OWA%DEAF&/PJ;,<CDS:>CMX\)FI)PA9,(GMN0I-LB&BSW&&
MG$%M7$41047J7W:@O/XL.+R0C1=J2#>?(MXV'0#Q/F:_/_\ Y'\7A]O\M)G\
M#BI#D9<=Y)@-0&OO6,_R*3^:VNI%]NE;N^5/$N++#QN:R96JEG+\9R+' Q.<
MU[269K:3FX-K3B0K[CD.96FX\;:JHH3 GLBCOK*XUD3,1,8G8RG</D.OEU_P
MJ'_\1^:[DP_JE_9L5G/#9F+.<E 3[>V-"\4Q'0.DFU VA(D*WL;5UU*ZW<@J
MG<)."GIL6RHGIMUZ*FI0'\Z_3MU#C6N5D96^8*$=E6U)-E5PMT3?U5!';==O
MXZ;AX5TC'C#;B 37YQ\A: -GHY^YT4B;(20R^JKW[$._Z==<A(+:BNTK7;;_
M ,-5NPOODMYUG#[@U&.^'67S76E S;2QL^6N(JN&Y[@*+;3WXJR$1"W[QWV3
M[=T[#F3C&?$4_P#QY&5F%AU6]B#:XZD:'6^M=D42;Q*1ZP" ?@;7KTP]8595
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*5"7Y*\?#*OCM\[<?<:%]+/P_\ (]D628.2CKH<0Y<^R"1VR!QXR>:'
MM%%W4MM<D.UP?C77,N^)DO8E2+_97B\5\^-*C1WVE:)#9:-$14+92 57NVZ[
MHJZW"R(1=:B4N!E ;'9B/.LMQKE_)N+)YW&+W"P)KP=KD3VPE1IO;OV>_$-4
M'^GOT/<2'?HOTUKN2Q<+/C"92[K="-"/D1_Z5I.:[!X+NO$_0\_![N,.AOM=
M?^EO(^(((^%ZPGE3G3DWF=^"YGN0G81*M3.LJ(C(PJF$ZX/MG)"(V1>]+)O[
M?=<(S0=T'9%5%UV)@8N$#^G4[CU)-S\KGP^ K*[-^G?:'8,4D?;&(L$LUO<D
M)W2. ;A2YZ*#KM4 7U-R!6HM9E3:OT;8=>W1ILS5$W7M3T_U7T37T"_2G2OX
M(3 E$Q453U14V5-"+5](%J[K'^$W0#)\M/-K*?;W*F\=>/Z!'O8,E;3)>2W;
M$FOR4+VV?=7%$7VU12<[-T5$!=^#5W1=/V^%>C=KC7;32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E:(\I*-,F\9
M/(O&R;%X<AX(Y=HR9-TF =2VX_R& K9/ J$R)I(V4DZBB[Z#K7%S9"1X UX>
M$ZJ9K*&)([Q%/Q88"J;B1.$RVGHG7==9/Y1KI6AP>0&9(4L0PU-8/*D+)<0E
MZ"(H(HOKT]57^*KKK)O6TKY?_C_CKZ%TN:YJM]37ZMLNO'V- 3A?H*;_ /-5
MV1$_BNOECX5P-AUZ5DAUTUF,TC8M,H#(F8D8JX;RIN?VMD73?INJ^FNP"PKB
MKIT.IK&3(U)4/?<25%1?HOU3]4ZZX-:U=K;;6\:[W_\ A"4*.97\C>4*T*K&
MH_&+'@>]XD,?RIO-UFZU^/OV$!_B@7N*FZ*FR>JZZVKLBO:O0&UQKMII2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2L2SZO2VP7-*I6V'4L\2R.O5J2G=&<2;3S(WMR![3[F#]S8TV7<=^BZ5\874
MCS%>&O4?M5VU.C6A,$D4WH"Q]]FFDBN$T:M]R(0FIM_8J;%LB;:R=P;K4&Y-
M,WBQ&O&J2-VI&I)\+_ ?=YUPMOQR#%(_:USLCW(PF^3+ZH8O,"BFHHJ"*@\#
M:;I]%VZHFN.VON+W1'+R:\?.J@-87'^K_ FM2IKE4T&E?6U))HQ(=Q3_ '"*
M]%7]?UWU\KX5%K5]<FS<>;[$)479$5?3I_'7V_G7 1[3<UQ>ZDJJJ[[_ %WW
MWUP8WKXQ!Z5Z#?\ A#52-<9?(E>*W&WF\A^.M2#R"GY>U7BW*<QQIPNQ%2,B
MW J"=R_<I]$]5ZC7='^7]OC7>LU\KLII2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2OPE,-28TB,\'N,R&'6'6U[O
MZC3K9-N!]JH7W 2ITZZ4KP>ILV/CV=Y6T48AB1LKR.,+&Q=T8(MY8--#VN;F
MOM G:J+]W3]==ZC2L#,QSD0M$AVEA^^LVNN4V"HI=/5LHZ<Z.<=7G&5 8XN!
MV&Z*GL2NH*KLB=-_77%@N\/KNJ"X799CY-.0RY#_ $WW  ]2#< _"M'@/7M3
M?T5$^JJNW1/^.OH-S>K #>K7I7,TU05BZI.=PQFR1#5.BN%T56Q7Z;)ZKZHB
MI^NNU5+&ODL@B%_&MCM5L6(PGMQF0%>G0!W5$3KNJ[JO3]=97MHJGSK2C-::
M?VP3I6N[WV$D*C30-K]5 >U%_P!=MD5=M8;@&MU&MUUKT0_\)NE=A^+OFY=O
M5[L?]XY\X[C,3W&W &?%J^-W'6VVB/8'&XKMHXJ**?\ S?5>FL<D7L*^P9$$
MKO#&RM+&0' -]I.H!\C;6W7SZUW9]?*R::4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2O!YY=Z\N<KKOZ\G\@K
MO_\ W?<Z[0VE8Y:Q^.E:^T)O7 F_6B*J*BIT5%W1?XIKY7RMG8\(K51G1!$[
MCD*:IZ*Y[JH7_H*?Z:S(ORA_"M?D2[I6BOZK"N6F2D1KJ7HBH/7?_7IKLD=2
M++71B8GM.6\ZP^JJ!R/*JBJ7?VYTX ?VZ+^.">Z^B+]%)H%3_CK$<V4M\*R>
M7S_[7P^1G_S1Q$C_ *NB_B17?%^#OS_XY^.CP+YD2;A]AR+R=R=Y-C5<9\74
MM@Q1I8,4O$F!%<Y+D-Z_$G-X_B-'^7'9)UN-*D2)3[;++)?U7&8V_*+CJ\C#
M=(SV51\ -3Y ?Y5YVQOJSQ7T\[3S^?YH/D9DV<1%$I :1O;4DEC?:H)%S8FY
M  /AV0?"7Y9JKR3Y!HN(>5^,XO$V=YBU-+";&DRAS*,1R"Q@PW[)_&I,BPJ:
M.RI[TZZ*ZY&W!^/,5HP0VW?;!S+QLUY-HG387O:QN#\/@:QOI%_REX/ZD]S?
M^(<G@MQW,R[O882^[%*54L8R2D;))M!*BS*]B 0U@UQNMA7JRFE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*\)SR
M,99C>0_/T>.TVQ'8YPY<9889 6VF66N0<B!IIIL$0&VVP%$$41$1$V37,=*Q
MG_-6GVF77W099;)QUQ=@ 4ZE^J]=D1$3JJ^B)KD 2;#K7 FPN>E9?%Q+O!#E
M3%$E_P#EQP0D1?JBN.+LJHOZ#MK)3'!%V/W5B296QMH7[_\ *N9KS;HP=KY#
MY%"><]UA]T!%6'R1$,'"$E3VG4%.O394_1=<XR$NI_+71DXKSR)EP@>Z!8CS
M'A;XC\:^*WD"UW*!@2*G</:2$BB7^[<55%1==;5G0@D"]?#A5XU3YE0VTI>V
M-'G@,@E7HVS)$X[CB_HC:.]R_P $UTOZE*^8M6N[EP7Y'@<K!AUF>([1YE?4
M!]MK5W*/CZ\'.7_)_P '9GD%X]T"<A9EP[Y%9EB65\>0I$&+D&1X3>\<<47<
M*XQ1R?(BP[&XQVV9>%Z 3@.R8TKN84G&D:<ADW'Y#WFB6\L<C KY@@:B_4_P
MKQ7WI]*.>[][)?+[>0R\QQ^=(&@N%,B-'$?1<@%U(_*>H.FHL;IOC5\"_*W(
M/)?CGE;F3B7*^#^,N%[L<Q=?Y :CU&2YCDL"'*9Q_'L;QQ)#UF,!N?)&3-G2
M&V8Z1V5:;5QQW8<K"AS9ID;(5EACU]6FO@ +_>:C'T$_X[]Z8/?F'W9W/BOQ
MO&\=-[UI+"2:0 A$5020H8[G8V! VBY-=LC4BK]'*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*:4II2J+L\^<7C>!RWE.!<1\*9%RQA6#W5CCU_R>>:56(UEU
M;4TYZNMTP.H>I;Q[(:N-+CN S,E/US<L@4FD5E0>*V^S_H]S_=V'^MCEBQXB
MFY-X))OTO:VV_7Q-O"O,'?\ _P I>T>R.:?AL?$GY P2^W-(CI&BL-&6/<&]
MPJ="?0MP0&(UK,<X^>[X\>/'J>GR'+>3CS2TI(-U)P>JXHRF9<TR3/< H%A:
MOL0\0?F17VB;<6)9R6=TW0U14743Y+L?N#B>7?A<Z-4RTZ$L-K*>C*?%3\@1
MT(!J>8'UV^GW)<!'W!AS3OCN/4@B8R1O8$HX_*&%_!RI&JL1K6.M_/WX5RF&
MY4'#_(:7&<151Y,"Q-C;;KU!_D(#153JB;;ZD$/TF[GGA$R/B;3_ +VO_P#Z
MZB>3_P H?IYC3&%L?E2P-M(8OXSU@N:_Y)_QN\908MOR6OD'@]"]81ZV3?S^
M')%[6UCTH3_'>L PR_R>S"*ZX'MH;<9Q?<(1VW5-1GG>S^8[>C$V<(S$6M=&
M)L?C< CR^=3SLGZP=G=^YQXWA6R$S1&7"S($W!;;@I#N"R@W(\@2.AJ7GC_\
MT?Q:>3:5K7$WFQPG)LK5EMV%0YS?2>)\A>(Q5?QFJ7E.#AT^3*!442;9!Q>[
MHF_34;]B;:'VG:?MJPSRO'"<XS3(LZFQ5CM-_A>U_LO5F\.;#L8D:?7RXT^!
M-8:E0YL-]J5$EQG@1QF1&DL&;+[#S9(0F)*)(NZ+MKJK/!!%QJ*^G2OM-*4T
MI32E-*5X6/.K4:S\C_("0V\T_&+FWEN4PXV8N,R&7N0\A)IYLP4A=:("0D5-
MT5%1==J"]8DIVGX_Y5B;Q-"VGM;MDT)"BCLA]O:B+_IW)ZIKM!\16*M[ZZU]
MM>IHV31[]S:IU7U42%"%5]/HNLF)KW!ZUT90#6<>.E?!<B!,F)(B[[=-OX:X
M/XUE8Y.P5KMQTNQ&5_\ EDJ(OU[47H/3Z)K') K,) -_&D6)(G/MQ8C!R)#R
MJ@--IN1;)N2K]! 4ZJJ[(B>NN&K&U8TLL<"&:9@L:]2:],C_  U)%RG@!Y'U
M=[-:ERJCRULX\9M'?=D1JYWASBAR,U()=C(4<1Q )4ZB.VZ]NN#)M-[6)K#X
M6/C )\CC5"K--O>V@+[0"0/"X )^.M=OC7&MW32E-*4TI32E8)GG*'''%]:=
MOR+G.+857C%L)HOY)=P*HI$6IANV-F[#8E/MR9R0(#!O/(R#A-M I*B"BKK-
MP>-Y#E)AC<=!+/.?Y44L?P!K#RN0P,$7S9X8;V_.ZKU-A^8CJ2 /CI55/DM\
M[_Q\>+E?A-EF>1\TYA&Y*!%X]?XU\?>5\AK\T=**D]N+CM_:8WC^,V,N1!)'
MVFQF]SS*HX'<"]VLD\'R:[=\5BQL!<7)M>U@20; ];=#Y5JL/NSMOD)9X,+-
MQY9<7_N@-^07VDF]AM#:%A< Z$WK0/'_ /DN?')R7C.29#CS?-E1+PVFNLHR
MG%>0<2PGC?)JW$J%]B)89!!9S#D:LJ,F0)T@6?V^JF3;<'/^I$!%15W/%]E\
MKRB.Z28\.R%I+2NRDA.H6R-=@-3X 6N1<5U9G=6!AY"0&+)E61PBO$@D0NPN
M%)5BRW&NYU5+=&KX<M_R@?BFPODO)^-K7-.9+ <79;><S_%>(;7,^.;_ +5B
MI9)B-[BME;V.3M4OY)+*?B0G(R#'=)MQQ W74G@LX1/+Z#L0-8$W<$@'8+>K
M:#=K= ":S>/YO&Y#%3**2P;VMLE"JZ^6\*S;=W@";ZBX%63>+?R?>"/F7QU=
M\K^/_D1B>2X%C$PJW)\@R6!DG&D/';-N)&G2*^U=Y*I,3;:E0XTQHGNPC!KW
M0[B3N'?7+B9+Q^\D;-$3:X%Q?[/G7;-S?#X_(IQ&1DPIR<BAEB9P'8$D A2;
MFY! '4VTJ=L&="LX<:PK9D6P@36&Y,.=!D-2X<N,\*&S(C26#<9?8=!443 E
M$D7=%UT$%258685M*^K7RE-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*4TI32E-*4TI32E-*4TI5:7R ?+'X=_'-2-L\U9TM_P LW%:Y/PS@
M+C[\/(>6,H;[=H\^13K+C0\/QEQU40K>Y?@PE1"1DGW41DLO$PLC-D$< O?Q
M\*U7*<UQ_#P&;,>UOY1JQ)Z"WQ^-JZ3?GO\ Y#_R$^4C=[C_  OE)^&G$,]N
M1$BT/$4F)8<N6M>9JH.9)S-;52VM9,<9^TAQN)2=@JHJZ]_.LF';4440:=F9
M[>&@_<:K:3ZCY>1D^UB11QP_[KLWX$"_CH.OB:U/XZ>2^"W.&UC\+)*>OF1(
MC(7U'*G,M6E=8-MH$W\YAPQDF+A[D,C8A=$NY%5577IGL_O3CX./C7WDB**
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MW-R"<?QD>YW:Q8WV*.I+$ FRC4@ FWA6CYCN'C.$VIEL6RG%UB0;I& -B;7
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M'1Y64L:9Z)N8J2L+,M]Y7>VX;@&50PL"=IN+5W]G2\3D\Y/Q4:9I7E8BAGN
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M8LQ)/4DDD_PKC\)SMRJN+3*ELFG+.@DM0 I"5L"F5CX"Y-,7"^[\E=T)I25
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M(A_WC<6^.XS:.M&"HI5\F8VBILI(O36\XGL/N3F%#X\2QQGH9&VW^RQ;[Q4
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M @C_ "VZ?YU</T_2.+ADBQ(RF&1N!)N2QT8D_P"'06KV_>#.1XG,7"7#O+D
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M?ETPYW)Z!K-\<X?X0X)@7V%/6#E:SD=4_EF:\@76-NV+ //5P7U9>@R3H@1
MCG=LJ>OV&=8<E&E020(P8J>C6/3[?M^1JAOJ3DS2<[^FC-@N.H!ZV)W&]OAN
M!M53_D/*PJ(?->2>,<?B"9Q-SIQSAF86/'-3;XQG^3<+PV+RMR:MPB373Y$/
M)L.RO$K^+-KI,[V32:PB=K#4>6 #=&=R6)SG%Q_I)(A-%C)>- @]$;;MI3:
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M_$/%)R8Q0\2Q6-[G['21P: '9][9RMIUK(W4'IIDJ(C#3(A;/,=J_P#C'%G
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M%1<RD#X>VV(TJW! W;SIH>H'I]7V>=1=^!X=>0CY7:YSX$95)8[+&XOM_*6
M8A6'J )%R-*U;<LY,[!NL3NIC+SF/QICE3-KV)4$F,<N9 P;.K=%V+ DG%C6
M+S+I>Z"J8OO[JH&F^%GIEX^=-@94B,Z@IN3\MC_+>RGQUN+D>8-22 P/&LD(
MU!!()!U OYGJ.EJQ3B'D:1Q9=6M5E-=83N.,]A-X]R%0MLK[TRJCR2.%DE$W
M)]N,]DN'SS_,@JI"+VSD4S%F2[OI4&1A.K3(ZHP\00&'F+BQL?$7%=\^.F2R
M3(UIX[[3?2S#56^!L/B" ?GL7->)L@<SR!AT>TBV%?9L,6]/E41]7HF2XC.8
M&93WU(X1=D]BR@&BBJ[&B?<0BB[:9XCAB_5#2+Q^%^A'S_#[:C?)<GA=K\1/
MR!C)B#:(!H';2S6'I%^OW#6U;1Y(X\R^CD.<C/29&3_]M&=RMR:++EBH0X;$
M(K9QP&F&W@2)#:1]W_J"8^XJ$BFJ:W YF#/=L.;TR^'F?W:]-/$5 NW.\<+O
M)9.W.4*P<B23 X.U6\DM>^Y;^E?YUN+W%2.XUE<7Y;A+#62O5CU1?LA76,"?
M,_#!V5%4'D;5QI]AX'X,H!>!P23L(1/?M7KK(,;N2+FW_M,$V08EWLJ*SHT=
M_P#[@6UT^VX(N/4-*<YW'[^[6[CD;MV&:3D\0E_0C.K1'_4HZQNMP0=;Z"S#
M3]\/R#-?'F\/C?(9+^4\7VD2XL./,D<=B#)J7:]HI;]98D,I\:J/)(B0F72[
M Z/LHC1.",@BX2#O/(@?AY$BR990LAD('M@GU&47_,H!*'3W%'@;@=W<79W:
MWUNQ(>\^W!'@]X))%'GPMIHQV[V 'J9 -T;C65![;^L*1]7,S=C=8%B?+TS'
M\F:QBVLY.(X!S8QB=W5X0[;0@L7LXPB@MLCJX%B_E%&R_P!YQ15Y@)L4G6#4
M3(PNGB>V^V.V1#Q?'9N5+R0R;G(=61D!%C''%_\ ;*GU7U5W(;=XBU^P.U^/
M[-23MG"RGFFW^[+'(X+ 641M[:,41">I&K*XWZ@ [7GXUA'%7B'G;?-#V)U.
M4R+!)U+9X_87,OR J<TR;'XF>X!Q#+X_2^JV:KQNY.II<>^M[&5 8C1KHE;;
M4W=M;_D\[@H89N6S/U.2D,+V9-S0IDN3[0L5]*O<>Y&Q10V[^;2MNDF3R?<<
M+<8LKXZBS;K#&**Q224.02<F)KH@6Y*?S :53;SKS!F'-F:IEV8,T%8ZU6PJ
MRJQO#<<K<-PC&ZV V33%9B^*4P-5M5#;4R,RV.0^ZX;CKAF2KJ@N3Y+-Y25)
M<URYCC"*/Y44$D*H\ "2?MJR^,XW%XK%_2XN\H6+%G9G=B3<EG:Y/P'0
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M1WEW+)$,<SO)I92Z@GX>H6)^9N:JB+LGZ9Y/(JL>'+%(7]?LR;%/F0A5D4?
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M5B+_ "1;6^UOLJ4+GQV4D^M<6GSW*ZVP]KN9<L(=39PU/M54]R,U'KY"AO\
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M]H]^/64E9/M[%_92]B!6Q79LQ[M3J7MQV2+;Z[:\NQQO-(L40+2,P  ZDDV
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M*]4U!.0BR8LQBB%_=;TD#37P)\+?NKR1]=/I;W'ROU#GY [VXK-</')8L!<
M%.E@4M:WE8^-9;SO1\;\\8#5E;D[:WD]\9V.6U)8HU*K;*4P8F?MI[T21"C,
MF2/MN 2'V^J$B*F!B9.3@Y3FUG'Y]P-K ]/G_IM^ZM/],LCO/Z:]T3QX6V#A
M8U*S131W$J W!OHZR,1=65A:_B+WNP_QD*?$O'KY#<>Q&BC-QG^7N%^3,#M;
M)Y4*=:2ZF-3\CPQER2^XE)S"'5;:14 578136?Q_*3YG)!9#:-E:R^ \1]NE
M>@?I[]0>;[A^HR1\E+_\/(@F1([V12H$@V+\ A%]2?$FKA?\H/'<=Y"HO$+
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M^?CYUYR[WP\Z.-(6!6%20PZ>KP)^SI\JS[F?)\8DXH:O2FG+%Y02, N"KXO
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M8YG61SYLR3DU;C=?&:BTZ'[*0(@^T2.; 08D.S'+8N2"$OH/!#J20/,WUO\
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M_P#JL16S^.,@:@RHQNG]S1CW(J^O7JO5>J_76PP9%UC8]:C/=?&R9^ 3$+D
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M&;@TX&<K'Y4IM&X7N*)19+A"SO"[B$$*02IWM]!<+JFQ;JL1YO@<;/8.1MR
M+!AXCP#?P-:/O3Z>\5W? >379'R21FY(N&4"]F\=!^5M2O35;6G;&Y]#'VF!
MOHLR S)$/:EOAWPG5-$Z1Y;9.1R)%]1[^[^&H W S.Q$# N.J]&'S!L?PKS!
M-]-4Y9R^ !)(O55_,/FILP'QM:OOF^2=%#BD\EG&<!4W%5=;14Z;HJ=R]%V_
MAKC'P&=(^S:0:PX/I'/D9 08\ONWZ!34,N:?**UO(<NMQV2ZT+PN,G/7< :$
MT45_&[E[GGEW^WH@"O7KZ:E/'=N18?\ 6RO5(/"O0G8/T8QN,=,[FHU2);$1
M:%F(Z;_]*^8ZGII42\2N9$ZR6/,< G/8,V'%W1QPQ)%<[R(B[S(5[E7U795U
M+L*7W)P'Z[=/L\/NJZ>;0+@'VELF\7 Z =!I\.@K;\&F.Q(W6T[B$E;_ .*B
MA%LG7]4ULY&53N-5_E<DF&HB:^TZV_=66,8B(L(+H[NGN2(JBG\/143_ -=8
M;Y"_"U1^7GY#)>(@(/MKD(^(P1%2<( $ 53-53;NV+HGINNL-\M@;+UK#FY_
M,8V0FY/@*TSFE7&CV3+H=OW=S2J.VS@#]S:GZ;J'7;^"Z^.=Q#>-M:M/L_.E
MR,-XW)-K'7S.A^_2M<W;K3;*BG;UZ)M_,OT3_3?76YTJ91WOKT%83K&KZ=3>
MLKQ._P CI[*(U265M&9<F1W)D.!(D"R^Q[S:25=C@JM+NSNBDH[HGUU\**W4
M GY5J.8XSC.0Q7.?#"[B-@K.JDJ;&UF.O7PO;X59]S%CL;,^#!:BVUA>7U!C
ML3'\(9GWLJ<]5T@Y%,R,L?IVWY!)%K';*]GR/:%.P7)3B]$+47Q<[._N8BE-
MH+D$;0H L=2;>!KRUVGW1R>%WQBQ\L=O#1!@QV *HL_D/!C<?'I565[C-_C$
M@(E]4S*MUT5)C\AK9F0(^I1WQ[F7D'Z]I*J?5$U)U=&_(0?E7JSCN6XWEXC/
MQLR31CKM.H_Z@=1]HKX6$;015=D(A]5_C]/]>NNT=+5LS>VE?J;HMIU__!1%
MZKM^FOM? I-2'XLDPK)_"(5K$LY\>SOH<+(X4)QEM^[IUR*&JQ8IO2HX?D.U
MHN-HON,*CJ"HF);EJ9=OF25(\1F*I,WMZ 7VE@+ZZ:=0>NFE:;/"PNSQ[?0I
M.M[ [3;IKUK.<D\?L@L?)G,N.>*+ /Q(%_>0V;:R4ZUH\91]EH9CD.,Y(D/P
M;.!,:1MMHG5<;)%4UW4]1[N;=VYF/)-K(DFP[>C-\#9?2XU!L!8U&^Y>^^%[
M/[4_\DYP2?I;+M11=B[ D)KZ5(L;ECI;H3I6!\R<"93Q+R-8XID+C,6QK8T"
MR.;7C(CPK2'8QH\B-9T9RX\4WFE5XFGT1#('F74ZH!+K'C:+D($Y##)"-^8#
MJC>-[: 7T&NO7QKM[.[]X+O;MF#N7@V:3 FNNUOSQR+</%*+^EE(ZFRL"K+H
MRWX&QQRJMH[#LN.X8A&",_*%_P#K@ZHN=SH(V@$D'L%-A(20#5>NRHFML88\
MQ![NDP'7IH//X#P'G6P@Y6:5FAQ[)D@DA2+JPN/&VAUUUOX]*RKDWDO,L[S*
MOOLU?2VAM8=Q9QW7N$A27:+'>*>.L3XMQ(&_=9??D5\'&\39<.('8)23(PV+
MUQ(WDPG./)ZL<G4$7M\;>('7;T)UZULH,F/D8BUBF6HLR]/VOTW>6G2N=Q.<
MTU,89-UL/>%I^*?N"0/-F*.LFVXA;"\@;*H+LXV7VDB&BHG5R&&I@][%]4%O
M.Y'E\_,^*]#5;]V</*L+94"EHA?< -5^SJ1\>E;F@<;S>0SM+NEF,0+>J<#]
MU=AR*TY]C')MR5(EV-1*G0GI:FVV:!*'O63(1&2W<5M"WO;.!_?()8LZ= 4*
MV##<Y7JS=1HO^J][D D"U:_@.323$;C^9(FQ;#8'#%AX>EP#8+X^(!OHHK*.
M*8$?,\DDX [7YI,MK'#\AK< K,#QN-/E3<YKHEI98[*N**ZG5KYXQ=QX$EVP
MDPG5D5[0+);!X@5%LSBL267'BP\)!*BJ(A$"81?<P27U$$F8 N2A%K=2QO4J
MR<<X.#'+C&$8\<B^Y[C%1[=P&LRW_J"XMN%F)L; Z5HW]191\IOJB0['L;.%
M<V4*7)KK!NWAR9$66ZP[(BVX&;=A#,@W"1W*C@;%OUU1F1'+%DR0./ZJR,"+
MWU!(.OC\S]M3Z"5&QTE4%8V0$!AM(%NA7P/F/ U^O]IVB->X7XZ+_P#B_<)2
M_P!-Q;4=_P#37S]/*1K75^NQG?V]XW5R4? ;MQGWI/LPP_VB?<ZX2?0E$-A!
M%^FZ[_PUS7#E(NU@*UTO/\>DOM(Q=O$CH/M\?LJ2OCW<CB0V]3)D,I(_-&8V
MNWMDXP^R#1(*'U4A<8_7T76HY/"::,+UM54_57BY>0?&Y& %H#$5-O @D_B&
M_"I#WO*K4'M]MQ7W'4%IH!53?,S5!$0;%57J2[)UZZU.-PV\>K1;_956\=VK
MD9A("[474DZ #Q))K3.5Y7D3CXK809,<7A4FE5!<[!Z+L7LJX+1(B[JA;+K>
MXF/B1"T9O4XX/@>+>-CC3([KUUM]VZUQ\KU'[DN\-^# B,R7_P B3)-PQ:<,
M#6.RVH$+B-J*D!NN#L*]%[?X:SGM8*+;3K5H=H\4(,B65T7VU4 7%_43?3Y
M=?C6LX$:Y;;-IA9;+#J+WLMR"9!S?U0FD<%"1?KNG77Q0P&G2IY*N.[!Y%1F
M7H2 ;?(D:5\LV*(IVJRK#XINH*/8BHB;;**[)U^BIKXR^76N8L=18BN(372?
M*NMB;U)GPXP/#>3/)SA["L_%A[$K?)G'+6ODKM'N?VJJL;B%22.J=\>VGP&F
M7 _^:V1!_NU)^R\#!Y3NO!P.3M^ADG&\'HP +!3\&("GS!MXU7'U<YWENVOI
MORW-<$2O*PXP"..L?N2)&TH^,:N6!\" ?"NYXPF(-886'_MM,&,-PPA_LYPX
M@TJ1104&.W6(VD-J.R "C;8MH@]J=J(J:_0.%^)'#_VHI'^AV6*, $M;46Z6
M^%J_(29.7?F1R[2R?KA)N]T,WNW/4F2^XWUW&]S58F24V-X#E=([B=J^_ M[
M>RB2*N1);DC&%IV031PS04?%A&V]NPU/9-NNO.>5!@<'RT)XR0F"65E*$@V%
MS8KX@:6UZ::U>6'G9_</&Y,7)Q 300JRR*"M[V%FN;$F][BUS<6J0,>X:"J$
M")-T'H2KLB!MU1>OZ:LB.>/]/N8BU0$Q.6T'JJ)7/CM/9XU=1W$:)"8)]E21
M.])D9??CNA_[2 @V_P!%7]=5EWE/BOCL&M>X(JV/ITF;B\KCR)N WV(_VMHP
M/S!JN"?34>01EB6,)B3'<%4W($1YI2'H;#Z(CC+@*O117?5:&.#(&QE!%>H\
M7/S>.G][$=HY0? FQ^8Z$? U!SEK$UQ2V=KC)7FP]N76RS$1<D5\DB#M<[=D
M5UAT%$]NG<.Z(B+J&<SC''E]L^&H/F#_ (5>_;G+)S7%KF ;90=KKX!AY>-B
M""/G;PK*. /&?G+R"FV9\3XC^ZUU&XTU=9#;6$>CQNN?<!'6X;MK,,1>GJR2
M'[+ NNB"H1"B*F^7V[VKS_<S..%@,D<?YW)"(OC8L?&VMA<VUM6A[W^IO97T
M]BB7NC*]K)G!,<*(TLSJ-"P1>B7TW.54FX!)!MLK.^(.8N$)]?3<D4[N.R[1
MA^5438DV-;45O'BO$R^4"UA.$PZ\P0I[C1^V^VA"I B*BKL<_A.9X1UQ^6C]
MMW4E#HRL!H;,/+Q&A'EK45XGN_L?OJ!N1[9D7)AC($JD-'+&S:C?&XN VNUA
M=#8V:X-=P#_$7^4=R-R!R+\9/+=]VP,H=R'EKQCEV<Q.UG**YHI7+?&%<KQJ
M7M75;%_N:OCAV@#T:V+J;XIJ'YC^Y*6L 1IIXVJVN'PX<'#6'')]@^H ^&[4
M_MYZ^-=_+6'6UII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2O.;_ ,L/Y%(_-_E#AO@?AUZ\YP]XN38.4<RRJ979S=USIDM6
MJO07VHCC@20XCX\LR;V5$)FSMYC9[%'3;?<="D$/ZC(!]MR-1J0M]3;XV)^R
MM9ER,[^U"1O47L= 3;07KI97H5Z6]L=.CZ4QVMDM0,O=98U2S'UK4E*JDJR?
MPNSW.J_?OK6R^W[K>W<1;C:_6U]+_&U9D1<Q*);>[M%[=-UM;?"][5M/A+B/
M*.6+R?%I"8A5=3':.ZN)@F<>'^69C"BLM-J)29THF240111  B)4Z;ZK/Y*#
MC4#RW+,; #J?/Y 5!^]^]^)[(PX\CD-TF5.2(HE(#/ML68D_E1;BYL=2  ?#
M;N3<;U7$S]O6OS?[BR*PALA6S&V6XK-3']Y/S_?95UXO=F G8+@[KVH0[;*J
MKL>!ER.3*\A"FW'C8W#?S&VEC;PZGRTJ-=O]S\CWP\&='$,3AL>0F522QE;:
M?;"FPT0D,5.E[&]["N>XEL+AAJV:=[F*%Y'7P!1;=)+I$9:0&%]YM6F'6 W>
M78MNT>U-U74VQ>Z)N#CD!7<DINL=]=V@)OK86&NER;6'4UMN[>9P>(BC7_NY
MYZ*"1Z+G5C8V U \2=.E2<H.1N-HX8WCW+]*%KPQ@UG><E6_'L"PELWG,?);
ME"E3CE3;38:,2(M(;8!!4@*-'JZUZ8[[CTE]0=Z3W#!S#^_R42K@PHY6(.29
M)2!8L; E?L4 "UR2;U[!E<GR^6^9A_TLUU6)&%B((]VYFUZGJW2[/L%@JZ5[
M%G&<V?(E6],M9^22K5VM@0J*99O1JF,,)H(=345$8G6:^DJJIAIMF*RP++3,
M<4;1$'6GP<K-?E(@EY97<*$+;03_ "J#<!0/ "P TJZ1Q>#_ &X ((]@+;P/
M5<ZL6/5RQ)+;KDG7K5GWBCXQ\9>1'+%W3\E<YL<'!58S<7U)E=^_6OT4.9 @
MS)4J#:P)Q-?N,-R,T0N@RZTZB%W 6Z)KTAVOVC@92-SS9$XY6!P4 9"JJ2RN
M'1M' 7\QNI -PPL#41Y?F\SA.,6? Q3ELT@5D4'<038%2.A&A&A'G6O<M\@>
M5_(^'QQ*S3*8IXOXXMWN!\7CC2/0')\!RTB3;.WF3I;DN2,>S?K8SS#"" M=
MJDB*9*6M6W<W)=T\BW<L4L>+'@3O$A@N#,PV[I7+[MRMM4HGY1UU.M9J<7@<
M&\_Z)",C-VR3;M;&Q 4 6&@)N=;_ "%?*'.W.$+E-><F\GN\FNL8<Q=N)86\
ME+$<9"M&7$H(U>U8DL,*AM?=18OVBIN&:=5+?29',<_R?+9&1&[9 F5?<5K!
M5 ! V  !5ZW6PU-[]:PI^'XC-XM^"FC1,>=7#!1;>#8M?;KNZ'=X6 JYG)OD
MW\I^9_&OC?$,GH.#L]QOR&POE7ARQCI/<?S"XRJ?<.8+,DW&&4[L:#@:X_47
M,=R&AO.)-61^;N']-D-EPN+A\;QV5CS?U3E1B,*";1@WWJ/*YU:^HL+6O5:Q
M=A\#Q>;----EJN!+%.E_RI&BB0#W#K)=E;<; @6375C_ !Y,^&'@9XO^$D;"
MN?.-KG'/*Z]PPK+B'-N-RMW;7-,R5A?=D'=RY XK8XCBTPVF[^'9LMRVF'V2
MC KDAAU8?#Q&'R^>V-AK[>-[3!#TL4_,QOJWA;S^!K6]J\QW3W+W')RF!,#V
M\9@?;EMMC@MH"@!99'U92I()ZFRLHZWN*X%?!>T]K=44]RFAS EON-1_?7O9
M528<5@2)Q0!Y$)4'N)-OKJM,C(B8L ZDB]M;'X?+[ZLSGN[^&;A\CC>,R8QR
M,B;!<[18_F )T!(T%["ON\G,MK7*^CH*60)_EO+*FDRCC)"U"0.UIYLA;('%
MDFB]I(A)VZQ\AEVBP%] #;RZD'[NE:CZ3\/E+E9'*9JD>VNU+V.K=2#K_*#T
MTUJ)C=_;-@C:2^\439%=::=)$_\ OF"DO_%==:Y<ZBP;3[*NSVH]VZVOPTKC
MI$J1*/OD.FZ7T[EZ(GZ"*(@BG^B:Z7=G-W-S79^ZOY8D.Q7VI##BM/LF+K1H
MJ;B0KNB]>BI]%3T5.FOBLRD,ILPKB\:RH8W&Y&%B/A4D\0L\DETQ7(4TB-$C
MIWR7OY(\@=D[I$4#V=$5[?1=_P#[*KK:IDB0#W0 Q_'X@55_.8?#IG#CGR$.
M2^BC^93X*Q&G7H?O K/6\I"2TCH+L/8G<J;+MNFZ[KOZ+M]/IK@T0(TUJ)R\
M'-!*8F'JO7&3\L!EDD0P5$0MM^B#W>O55ZK_ *)KI*(NK7O^W[:UGX7;<V1*
M+@W)K4EN=G?MO6$4FC!HS!EMPU I"CNCBMFJ* H*]$WZ*OUU\"O(?0.E65@_
MH>$VX3W]Q@"QMH/(>=8"UCV1W#A&-7-%L$4B-8[W8@;JBN!]JD\&XK]P[CT]
M=?1A9TH#B*38>AVFQ\+C34>%QI4@;(A0>IU'VU_3V)36VU('VW7$WV:]MP"(
MO1!%5[NJKT]-=38SJ+FN"94#M:]AY^%6+\(< 55;003L6&Y%Q,"-(L7B!#+W
MW10UC-JNZHS&[NP4Z(JIW+U74/Y+FIHY#!C=-?MKRGW]]1,K-Y"0PNR<=&65
M%!MZ0?S'XMU^X5.S$^**2$R+$:O80R;W)Q&Q113;=4[E3?6H*Y&6=TSEC\]*
M\P<_]1\]IS[;$*#TOU^>M8;RYPMBF68I:4UM7LK'>CN(S(1L0DPY8H7X\Z&Z
M@]S4B,[]R*GJGVEN*JB\8I9N/E$L;,+'4$W!^%2;Z>?4WFL#G(<G&<F4-J/Y
M67Q1Q>Q5A]W4:@50O>5,K'[JUHYNRRZBPEUSY#N@FY$>-KW03Z Z@H0_P5-6
M%&XD0.O0B]?I/QN?#R6!#R&/_P!F>)77X!A>Q^(O8_$5\##,B8\W&BL/2I+Q
M(#,>.V;S[IKT0&VVT(R5?T1-<[@"]94LT4,;2S,J0KJ22  /B3H!4E<;I4A4
M4LE-S]ZQ5B)8L-H HPZQ7SHK5RCPEN9%&60);(B_:!*O3?:88R1P822;OZZ,
MMAYC4D_80H^-ZT4KK/*Q!_IN+CXZ:$?94]F_'+R#X^J\2\CG,=E4T2LQ2!RA
MBLNYL:C\ODWC6[6;+B/0(U?92@9CQ*2-+_(=)":C,-]JDD@66G)']0^'@DP,
M67.F1CGJ5A-T+[50.A<(;"2+<H:P-PRK>]Q59]RY?9_=>)-].>3R(_?Y,2P1
MH =RSPI[C$$@>I"!(MR Q!76]CQ/E3SUQ=S5A-%.D.?_ +]T0M-XP^PVR%HQ
M#FF!V-+:=X&7[2HF3I"JBK<@445W4A*D^"CYGBN1:#(1?TA)#W-P;=&7XGIJ
M.A.G2J;^AWTX[Z^GG=&5@DE^V,BXR%8-[>Y!:.:,Z#W= HM<-&2"-%(@?$D$
MV0;() O:O:2=[1BBH1,NBNR.M$J;*BIL8ZFY!@<,AO"VH_P^/\:](YV+^G<2
MQZ&]_M_QK\+>(DF$\D;<OL(P;^XCC/[ B=RBRV"-2I3B^S]RJ*#L75$4N4RI
MF(53_O#\?\23T\O&MCQTZRRK.XVSC1K=&'G]@&OX5B>+Y":N/U=BR^;93/\
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MC6^!(Z5,?Q-YIQ[CR/F.'9*]'K8^42J^WK;B0J-L-SZ^)(ANU\F2J*+'OLN
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M_02D$&POIHVC5H9N9[OSOJD>$XHQP=F\;CQMD,T.[WI9 #[*R&VUD1E8;&]
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M+2'%ANL&8/FXZD4/:D1_R8LB.[)'L$Q(@4UVWW79=Y/VOD#)3'CE3]2[$(K
MJ) +ZI("R$,?2"#:^E[U"L[M'D2QEQW1P@W>*]->O@;:'H1UK?MMP!;5E#7A
ME.)XABT";9U+\_+OVY_)8=(WE 6[=#B7+N'TLRXR'%)"U^(R[6O=@4SDR0W,
M:<F"D8FCU.^.XW!S^-<30XL4<<R*TBQ"0ACUCFCW%V0 762)?SM_4T&DAQ>8
M@GW.DDAF5+ ;@I;;MW-#(P42*&<(VYP 0=OJ!%20X#\>L9Q]GCKEGR_YLXNX
M XKR7$&,LXBLN0,(M<]P;E I\B'3XA@DJMH;<931TG]:1/A/MUTJEB1FGW3!
MDP[<.+D\;B(XN2F?%/M.5]LC:KWO[0,3HP.SQ&T6T)(L;:/EN;R999^.[6QI
M\KEX7*S /[;Q@ L9%)4@A_RHXW*[7&I!K5'S'XYXI\;9AQMQ+Q!F?(G(W)&)
M\7\7.VN0)S'@7-'#M'32*FW:E8?C618]96%Q7O4WLL?A5RBU&8A/@2"(J E"
M>[N8P^1A7&G5VY*/9[;J_P#32/U;XRFZ2Y/I*[2H4=16S^FTO<F9!D9_,1Q0
MXLD\EE,)AF+W4ER!Z&4W(+7W;@0;FYJE.!,EU4N//KWBBRHCHN1WFEV)LT1?
M1-ME%4W147HJ+J!;?"K-R,6'*@;&R5#PNMF4]"/VZ5M:3S+G-Q6)0(<=$E(3
M+K[ O_E.BXFQH*N/&TQ]N^Y(G1/3;72F/$LN\* U0S%[ [=PN0'(!'9D((4D
M;01\@"?D3\[U]G'>#2;W(JVJ]XFD>>63-D,H@FU%9["=$2V55,^@"J]$4M]9
MT=RVGA6P[KY^/A^&FSF 9[;44]"S7M?X#5C\K5:K@W'-3!@L Q&;9:99;5?L
MW79$Z;JNZN&6W5276SCA!];ZW^^_\/WUXOY[N7,R9V:5B79C^WP'RK^<]QJ"
M=>Y'-ALV76U104!V-%[AZHB>J*/K_'7*9 HW+I_ C_$4[?Y.9<@2JQ#@_=4
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M"7T1=1/)./B<:[Z!]ME'Q(L/\:X=KX.9W!W5B84 8PK.KL1?2.,AW)^P6^9
M\:IO%.T4'?T%!W3HNR)MZIUU !I7L0G6]6_^*7D1#/C^EHI\P6[7&8C%),:<
M<1'#8B"C4"2(JO<3<B*(IOU^\23U35E=K=TM@XRP,UBFGV?^E>0/JS].Y/\
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M"(^0=9$Q"?BF,C51<IL<2@O4<K&79[K<2(Q>U+Q&Q-IYDQT6&IK!E[4AP!,
M1Q%6@W[:YSAD&=(YGXHD*Q:X=2?ROM)/I8Z:'2XN!7+Z9<]W1_=H^#Y[+ES<
M3-EM_4.YD9KV())((TO8D$7'4 U3-Q1XO\@^5,F/;4UG1X=BL99-?!O+P)4E
MRVEM&B2OVZNB^V\<1AX4;)YPVP4T)![MEVT^9RD$,WZ>Q:4"Y \/F?/X59??
M'U=[4^C*CC,R/)S^9E(=HHBJB,$>G?(^@)&H4!C:Q(%Q?4GD5XQ<D>-%_7U6
M;#7V-5>#(/'LII#?.IM5B(VLJ*3<EMJ57V,471(V7$7<5[@(T1=NW$RXLJ^V
MX=>H_;J*F?TO^K/:OU6P)<O@?=ASL8K[^--82Q[K[6!4E7C:Q =3U!5@IT,<
M_76;5JC4U_JZ^4-B*V=QQGO*."/RI''>16U$-AV#/:CDRY6S3;%1;.1"G-2(
M3[[0JJ":![@ITWVZ:Q9L"#-LLT8>W0]"/D18U$>YNU>U>YH%C[GQ(,F.*^TN
M"&7Q.UU(8 ^(O8^53#\?/)KR!QO,#I;"9%R:/DK\B5*DV"LQ;*+):CDH$U-@
M-,^Y%% 018<;,&T5>Q0]%UG(<'CQP>ZA,(0=1J/D0?$^?6J+^J/T=^FO+<"O
M)01MBRX:JB")B496;H4<FQN;EP021Z@:LFXUKI-D]+L\P<9L;"^G.RK<AB!+
M'LE[ \$>$ICWA#C;(T'<BKV(F^_5=!@30_KUF0#V5( !\1YFWB2;FU>3N[,^
M'B9L/C^#4Q86*%5 6*C0Z;F_W&Y8_$^%16Y%LY/C3Y(AGN,?D3\:!Z=8>R]
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M7ZKJI.5B6.2Z] 37HSZ <YD1\E/PSL3C3Q%@#X/'8@CX[20?.POTJL/;K_\
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M^I'J-=P"W OJ+"VGB37?]-.;CS_U>)QL$LN3%&9'DN!$64'9'TNN[4"[-XD
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M]2^6.*2IF,P9DAEJ)+Y5XYC6N64I"HMM1V["YQ1[(F4!$0I!MQQ$C(.W5/\
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M;[XA7-F]S'S ;%H[%6\MR'2_Q!%^IN:XG,/+?-<H:=;KZB%3.O"0K).6_9/
M1I]QLM*U%9[NO120_P"*+K%DRY)-"*X\-]&^"XMP^3-)D*IOMVA ;>9NQ^=B
M*BW/ESI\M^?9/R94V6XKK\F6ID\^XOJ1$:)OLB;(B=$1-DV36*VXF[7O5L00
M08T*X^,JICH+!5T %;#XEPV+FF70J^Q;<*K P62J(8LN.D2>U&=?3810T15[
M>Y")$_3?77+)[4+R_P"E2:C/>?.3\#P<F5B$#,(LO0D#Q8#QMYV(%=DGP4^
MG-_D<C'84<C'^!^$\<LVZO)N?;>G*>\];-+$*5BG'&*QY=8[R'E##4QI)(%(
MC0(1/-B](]]QI@]5Q^5FY$IDDM^G(T_R_:U5;],^9[W[BY-^0:>0]OQN5D,Q
M)5V%KK$IU+C35;*MP";G:>TQ\<O'/PA?#KR1GW W"7/.6<G\_P"89CPUPOS)
MR/D%O?<F,S>:L@R:QI>*N&:JLX_IVL A\HI;W=Q-.FQ^OGWN-U$>;*O)$2&U
M[Q[8W.IKT1TKLMOT;W'_ !_*I.'<(Q 9=%62APW"'[$L!PYV>Z\Y)&),MJ7&
MLF=H84J9(<=?D,U<UU3,C]HS)=^-?>G2LW9)[\=HI0-A(]D"D!')Q]H'NQ%>
M!@R::=>;$]T%5 2)-OM1>FE*QXFJ[,:JHMX%A<PFG!9M:F?"<L:2:"/-?:DV
MLG,L^\V;9[.1+"*X"%_,TABBI]!M7SK7-P&93$-EJ:]'DRP$OR)$6*L)E]TC
M(B>&*K\GV2=5>XD[R13553UVU\K[7V:4II2FE*:4II2FE*:4II2FE*:4II2N
M A4\R)D-[<G>V4RON(=(S&QZ4D<Z^DFU?[DW.GU;HMC*#][CRHZ/M&1MB<1#
M#M5QS=2HP<"\:\BM<V>6_-'*L :K_P F\A81@O%&,%81;5F!PAP7C9P<1R"6
ML929C6^;<DY9E=ZC*I[D>!,A-N?U6S1%*H\_RV<BQ3$/B7S1B;&@AE/+W./C
MKQQ6R%]L;">UB687O*348=U1QV/5U]!:.)MT;62?IW]>R(7;X"N#Z"O+VH[%
ML3FL&B"O<V8)T3[=B$D3_CMK.B?:2+7K#R(&D"E3TK,8UFTRJ+N/;T5-]DV7
M_7;6;'D[3K6@R^'>:[H;/^^L[J[]HA%LB54547N1>J;JGT]$368NR0 BQJ$\
MCPTL3EF6S>7@?MKC^0K<J['DFP)A1ISTN/&C.M]J/;%W./J**A=NS *F^W3=
M-M8N2S0Q670DC_/K7/M7CQD\H<;*C#8RQEF!O:XMM^>IZ?"M M7EZ+YRDM)9
MON)L;CKJODJ?Z.H8IM]-D36M$D@.[<=U6H>.P/9&/[*"$&]@+"_V6KX)SDJ0
M\LF6\[(==1-WGC(S7L1$[=R5=A%%Z(FR)KHEW%MS&Y-?1#% HC@4+$.@ L!7
MS--./NMLL@3KSS@---@FYN.N$@-@*?4C,D1-==<6=8U+N0$4$DGH -23\A4R
M>/N%QKH34RP8%^R<$'),@A0PC]PJJQHWKLV'HI]%-?X;)K4Y'((I*J=:HKN;
MZA/D3M!@DKBJ; =+_P"X_'R'A\[UG<O%8S%E7QU9%&_=>05$-D,T;10WZ;*O
M8);=?UUL^&R=YD?^;9I]^O\ "H[B<W//C3.6/N6%_E?_ -*D;QE8)@-HU.;7
MLB2P;9GHJ_SM[[@JC^K)$NWUZKJQ>TN:?A.0&9(;8\@VM\KZ'[/'X5#N73^\
M0&.3\P)*_/\ SZ5/.FM(U[&C2XKPF#P";1"HJ)"J(7VJ.VZ:]-<=GQ<A LL3
M J1<:U5.7C/A2-'(MB.OV5FA6D.IAF]+DB#,=MQY\5,6P: !4B<=<-1!@! 5
MW(E1$%/76W&5%B1/-*=MAU^76Y\JT_Z67+D$<2DEC86UN3TL/$^0\:HS\L?*
M$\\Y5B?V*_#E8MA+,JNC2R;5Z'?6LAULK&>RX)-NN0HZ1VV&'!)$=[3--Q(5
MUY3^H?=Z=P\W? L<"!2@-M'8GU,/AH #XZGH:]E_33Z91\1VNR<ZKKR685<B
M]FB0 [%/4!C<LP(TN%Z@UJ_&?+_FW$9:O4UM2C![4$*:72MR:YI4W_J-'[[=
M@#A*O5??[5_1-17C^X^6XMKXDED_TD7'V>/XUON2^C_9'+0B/,AF,_\ ^8LI
M#GX'380/#T_;7$Y]Y0\M\F-N1,GNX\6O?11?AT$)*UMX2W0A>=-Z3+,"1=E%
M'114^FOG(=P<ERC[LU[_ "%JV/;?TQ[-[7<2\?C,\X-PTK;R#Y@6"W^.TU,/
MQ2JLHY-J*)_(+J;<4U#82@IHDTT<&,#)I&5QTS_JRG61$@:)Q2)MM5$51%U;
M7TTXK/[E]C&G=GP89"50]!K;[3X7/056/U.GXO@<Z:+C8$AR)XU,A46N3KH.
MB@WN0+;FU-73XU2UM;30X;3;*&0 CNVVY(G^P>G;VHB?\5U[BP\0<;C)B8X
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MX+E\3>>WL3+F3("]$DF1/9D8#PM'(@-O26 TW5/'Y N0HU+B^%\:MU\25?\
M+5M-H5FSP0V*&@C#&"UF P) 3UD^MDVW%15]MLNYPD+L05Z>%XQ>6Y#W\EBI
MQBK670[K^G7R%OM&E4?_ ,5^P5[G[NEYR3(DAX[A_:F 31Y99&;VU)(-HQL9
MI/%M%%KEA$SF'XSN3N"ZOA#F&@S+&[?"\O<@6U5:#)BSLFQ[*XB.W%/57U;
M>5HVGOVMQYAY0;0A9(#'?;??YW=#8*--"C-+#.JZZ>K5@=;7'I-[=#8'0BO?
M'U [QQ^S>"&=EQ%ER=RK9ELH!LVX:L+J2 /\*JPY<\5\[X^_,N6I$:^K3><D
M.>R#T>P:5TR<<4VG!5E[8R7JA(J_IJ.87+P9LAB *3]=K>/R(KJ[+^L?;G=1
M3&(:#*.ER0T9/S%BOV@CXU'_ !:K;EVHI/BNG"CJ[^0KH$#(R0%598>W1/N4
MT15%>J^BIMJ08$22Y ,P_HCKY7\ ?F:MG(<K%>,_U"-+>7B1YU-OQNX%<YUS
MU[&CMI%/C517G97[]>43]Q!@Q<;A,5;4IIUGND2FD!Q4%?9!>]!7;;6TY/(/
M&XKY$! 46])Z7)L/C^(%5/\ 5;ON?Z>=C9/=6/!#/GQ211QK*6",TCA/5LLQ
MVB[6!!;;8D#6KL6N,J7&Z*DQ^IC>U7TM9"IXK;ADZ;4*#&;CQP<=-%5TU9!.
MXE1.XE5=DU6,ZC*E:62QED)8_?Y>5?EGR'=7,<OS&1SF=+NSLJ=Y7(&T;W8L
M=HZ  FP'@+"HL\K\+U%DS8F_%8:!H#<=D&  (M@BDKIF:(B-BGJJ^FL*.3*X
M^8'')*7_ "^=_+_"KL[!^H^8DL.*[,V42 NV]R?*PU)/PJF]^%5U%G;/U$8P
MB3YCI^WWB2BV#KGL*T"=H W]ZDHIZ;]%Z:N#&@_MZ"0 LSJ-UO/X?#K7Z/8*
MY,F###F.&RDC6[6T)L-WQ_;6M?WL\+EI8U6KB@V\KDZ1NXQ')$$A:84=T5\N
MY5+J*HB(FWUUJL[)BG-H;]=3T!^%;>)&C%G(^%8&8]A$.Z+VJJ*J>G3_ %VU
MK2"*R""*R*LQ6VLVA?!L8\<T16W9'<*NBOH;;:"ID'_VEV1?IOKNCQI9!<"R
MUKLGE,/$8QR->0=0-;?/PO\ "I"<+<D\D^/5^MIC+[-O46SL8+O&'W7XK%FH
M%[3,B(]L?X=HT)J(.HA(0KVF)(B;8V?Q0FC#.=LB]&'A\#Y@^(JMN_NR.T/J
MMQ1P.7#19L"L89P 7C\6!_U(;7*DZ'4$&][J;GGIW$\72WRFL?@U[,5B2X44
MFIQM'($-FR;W:=<)'2[=NSUU#(,F;)E&/$ TC:#6W3Q^ZOSRPOI4_-<H>-X+
M*26;W"H#J4O;QO8KX7ZU%G-_(&7G,5V-0-/0X,M#%R7)[1D$V>Z*C3(*0L*J
M+MNJ[I]$1=9R\9)[H;.(.WHHZ?:?'Y#[ZN+MGZ7X?:<PESB),Q?+H#\]+U%W
M)HP-QR=)1Z(NR?1%_7?Z[ZWV(Y+V'_K5P\/*S.(UO:HW9-ATK(XDN\:>]F-7
M&XR!*'<#[G> $(]4)=WC$!VW^[?6S""5B ;$#]A5T<5SF/QLL'#R*3D2@,?]
MH(OK_P"T%C\+5L'CWB-"C1WW8J$XZB&X^8[N?\"5%]L4^B)K(W0XJ^!E_;I4
M5[J[Z"S-!C,5A4V \_\ &MLW'%U8[7&R_"8-KVBW5YL5ZHB[[*>Z)T^O37%<
MSW/^Z+K?RTJ#X/>&;'DB1)7#7\_WU+*L\1\M\>N!*O/N9LO\<N%(')>$CR#Q
M;@')O*D6)SAGV"V\=Y_&\SA<1XC1YIG%!1Y&C/O54ZY8JQGL]C[/<T0FNKY#
MC7R<A)<5B(UZC6P/B/(_'\:W_.]J\YW7F8_,KD)'N53M=]54]&""_H87(4[=
MP^!O5L?R%?)SF_AAQ5=^('C3;6&&-<7>,GB#POQSG=/,>AR(\OR%X$IN<>3^
M3L3D-$RZ.56\6YNYS]TG:^Y;9'5/MJV[11B3FL$<1](M:^G0 7/05<'$]N0\
M<81 X&%# J)&@LH/YF;YNY9F\22MSZ!4A?\ %(XAXWPW@OR"\P,GQW*.3?(A
MS-N1>%?$;CS&(..7.?4[]%@?&N1\VYAQ37\A3*S ZO.<D/DS'6;2YM9<80I:
MKVW7BAK);++BB63)2&4K'&2+E]P6W77:"UC_ +1<^&M24MZ"RW)\A:]_AX5W
M7.'FL<Y_\7:W!2Y,R9UZ!6!QMG&6<6^1+N6\D4658BY#:MZZQY^XV:QB2?(K
M0M,K=R*P8JLS'WV )6T0SY\GB2X68R21O&K .H9&CNK:@A&)8*?Y22218^-?
M()4ECNC!K&QL0=1U!(\?.MG\'^/F!>/U%)I,)L^3KYRR_&<N<AY8YCY5YHRN
MZE11<0)<_(N5,PRVQ!XO>+<8YL,]=D!$1$37DWKNM6\-?*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI32E=?/Y\_AWYS^77COA'%^)/(S">(&N#K?-LN8P
M//<+OK7&N0\QR:KJZ6HM+C,<=NCLL8#&JB--CL(W26:E^YO$NVR"O-'V&N)%
M^O2NASR%\#GD;XNW]ICGF$4SC?(S2<[B<G#)%=DF#Y;617.P+3'<U=BE$O$>
M%0-V)[,2;!%P$DM-&NVK%[5[+B[CP),\Y:QE#8HH!8'6VX$@B_A86ZV)KS9]
M6_KES/TZY^+A,7B-\$@!6><L$FZ;O9]LVLM[-N.\'JB@@FICFOA3)^'\S+'Y
M$Q+ND>3WJR];CG&:?:[U!8LYK=QN+.:5$W%"47!5"'ZHD7Y/C9^,S&Q9"&"]
M".A%6GV%W[QO?/#+GQ+^GSQI)"6!(/7<IT+(?.UP00? G&FF9J"V[&;9!6T3
MW  E%"1!1%0$[13NW_7IKXB3 !XP 0/OK<Y&1Q^YL?+9F#'0D=-?/J!6N<FM
M;"QFHS.:<BMQ$46(SGJ*&J=SQ*FX&3O8G5-TV39/KK!R9I97M)IM\/XUM.,Q
M,7#C)QB#OU)\_(?(5PC)HBIW;+]-EW^GU_XZZAJ*VIU%?M-=$T;$5WVW)?X;
M[(B?PU\>S6%=)&EC6SN#Z)F^Y$J69 B3,%F38J))NBN-(##'3K_(Y)0D_B.M
M=G2F'&=AUJ"?4+D9.-[7G:(V>5ECOY!B2?P6WVU;17X>#,-"9:1!-@2_7<.W
M?_5-BZ;)Z:KN7+=W]1\:\>3<Q'[VQF]5[?;6CN3:QZ(S[D1%;D1GFY$<D15(
M76T5-^G^TMU%4_1=2?@,PQRAVU6Q!'F#^WWU-NV<B)LD+-K$ZE6^1_PT(^(K
M$,'FW&>W"TCDQVFCQP:*7)<5H3(G5- !HWD1LD5&R5=M_35@Q""0JL; ACXF
MUOG^ZI#SF-B=O88SE59V<G:!?0#J3;4=16RF\KS+B?)EQJ'D3[K)Q6+".@]I
MMDS(-UH%6*\+S0.J;"[*VB=R+OMJ08?,<SP!_P#@9#1QC6UP4M\F! ^RM)'B
M<9W'Q@Y)X OK*,#?J "==--?'I4:/*/GK-\E<3CN5:W#$4!B6%^)JE>$\9#
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M"F1WF+2.+@17%=0E#:Y/-\)QN T_<$V/'BY:^RLHO_2D.JE-UQN!4;@P_*"
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M"B;KK3G&R&RXAB"^07 4#S\K_P ?A>HK]*>5Y*3GH.'P5:7+GE544=2Q.GR
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M D3D$  [6N0;'SL#8GS%Q?6K?_Y$]WR=I?3R1<+/?%YW(R8TB$,XCG(*ON(
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M#7UN#?K\ZTV1([3&1P1N.ZQN#8ZC0Z]#Y?=6TJ63G^=40\'87=I-BUF74_(
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ML;=^!=P*RVK;*V_MP)<F.^R)M/2"1%,>UPJYY+#.!F/C%UD46(9;[6#"X(N
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MW9'6G%$D)40A6ZN;^F''R<'+F\2GMY6/"SW!T;8NXAKZ:@'7J#;6U>5_IO\
M\@N]H.[L3![BR7SN#S<N.%UDL6C$KA%>)OS HS*2M]K*"+ V(Z^3+1,/"_-0
ME;<;5Q#)%57MTWZ*753+ITUYW&@NU?H:PV@K?U U)+QTJ(^1!=58.63DZ#)*
MT>KX$B;V'2E#[9DV1$B["<:*ZTGN.GN+:*F^V^ZSKLI8LO=@R,RVD+D!B+JR
M@&X&A (\?$U&^;E: *Y*B-K+<V_-?0 GQ/@!J:DX& 5U?95TZL?<I71D,@L^
M"@^\Q'?=!N2OM+NW*16E55:/<35-OT75AY'!08,J96&QA=3^=>H!-CIX_P#2
M>M1Z;)R!CR%!O<(2%)L"0"0"?"YTOX5)?+^"KNI6*\N0979O$/=!E4U1C5=5
M1S:! >=EM6HR79XFNVX_<VTI^NZ(J27E>"RXG'ZC)LR:@E=JGX@!3>_6WA5/
M8'U/GS6W20XF%$ #MR/?9Y+VO[910+ ]#U.GG>M89MQ;#MJ\6;0R?DL--"-T
M+$2-/5YL.Q732,PS'/W57[@04!?HB;(J5SR$$N1*9I3ZQITMH/A\>I^-=?'=
M\\F.1.;&?S&WM$DQA?( DD6\&ONO]U0_R3 Y&.S4:4WI=5^2P;TQ@&TEMQ?<
M!92JSNHB\(*O:J;HO_IJ-R*%7V_C^\_OJX^%[GP^5C4RVBRSIM-R"?#:WC]M
MJ]%7_%=\E.(\X\;>:?&;CB&W3R>$\KQC/Y$-^=(E6-O'Y6K)U?8W3XRE5T7!
MN\$/WNW8$*0'3<E58MS4#ID"5FW*PL/A;P_&IQQ3G8\;$:-<:6T/_I7:IUIJ
MVM-*4TI32E-*4TI32E-*4TI32E-*4TI32E00^33EJ[X2\&/(GD'&+R'CF35F
M"2X]';3G!:8C2)LB.S/5'"<;]M_]D_*5LD7<#1"V7;75,ZQQDNF\6/I\].GR
M\ZU'/Y^3QG"Y7(8:A\R&!W12Q4,ZJ2J[@"1<BUP"?(5YCW/GE%,OXF5<@%$N
M<EE27Y=G:V<.&[^WK+GR&VQ3\PA2,#2.N *[$:@'5?3457%GY#)6.8K%O/Y2
M1NMY!>HTTUKP1V[V'R?=??$O+]R9&-'SG)Y)E*EK6)!-E3\Q"(NU >M@+WUK
M5'QV8'QGS9Y!0G?(N"W#I<SDQ#FV-I7O^TVPKKNR4S[S;9.)7"VV#9,FACVH
M6Z*2ZLR+'_0\*1@(/U2)H"+&_P!O\*]LX/&X_"8$7%83%<&(!;BQ)%[NY'3<
MQ))^X=*X'Y0<J*OY\S7QNX[Y/M,YX#XBO()X/!E/B4.NN)U!#.V&QD#W/V=A
M2.S78C9/$9QP(VD^]#5=8)IIT$N0H6<CU  =?CYULH###(TBG<I-E-K%@.AM
M\1J:K$Q>H?A9!%M8-D]&GT,N%;PI,<1 V["+*&3#<;[^_86GXZ$N_JB;?769
MA87ZQRI-E O]_2LK/]G)PVQ,E ^/,C(RGH592&!^8-JF)XP^0^9<!<GT^0XW
M.9AG)?.%806\5C9;(R&!)0EG4E?5RVRBLR9D8"V=D.QX["(IDZ*)K8<GEI#B
M-#E1[CX$':+^!)ZKKUM?^%:/FIIN/XN7D,)(Y)8UN/=D$4:GP:5R&.P&UPB/
M(W14)-8]S^66\W\O7?+F35H19-E-@+6XQ"4"@U--4N^[!JWY8M#^2^XJF3Y@
M ![CA("=J#J*8D<,4!7>#(26)Z>IO\/#X=:J_L+D.$[1[;/;N/+NDEDR)I\B
MVTR9.4S/+*D=_0@9K1H22$5=QW7K\.0,AR7.L;>MJO$WH5+0R""UGMRV'H87
MDIDFH+$IE1:11 R4FB0"55WW1.NM_B8LV#"TTY4NZ:$"UCX>>I\;::5)>R^T
MH>V&DS\G)69Y555)7;M2^[0EB=S:;E&FGC47X'(.>XG4WN*1K0XE?>L!'M8T
MF#!EN.M)OVE&?EQWCC$2+LCC?::)Z$BIK$7-RTC,(<[/L_ U9P2":TRV;R(_
MRK7[;;CK@-- 3CCA(#8"BD9F2["*)ZJ2KK% +':HN37<3XGI6R:*@;K 9GSP
MWF*1[#WH8Q 5";'M$%4''>NY>O;OLG5%UN\/#]D+D2B[7-_&PZ>'CYUB22F0
MF*/0Z?;XUOW!.,+?((A91:5]@Q@+1.-K9@XW$2SL3-R.S!K'W6WG3$9+9+(,
M6U%L6R1"0U'4U[:[<GYK* ;<G#D,2^FMO!+_ !T.FGSK69F>D ]M2/UX'3K8
M=;L/W:UFN4\ASHD*#@>,QPJOQ&7&0=K)"C$8J&FB9)A67'W922'E>^]3(O<(
MU-2ZKK9<E 1R,?!\>%2)%)#7N @ZW'4MK]I-ZCV/Q<.3D/RF=9TN-&&I<Z@W
MZ6T^SI6CK%DIDYEF[<FO'$=;>62CJ.NN>T!(,9]'S$_;(41%]41.OKTUJ>>:
M+(A''9>[W(C='6VMO39@;$?/7SJ0(1'BL,/8F\6 M8 G^86_RKZSG$\S%9V%
M&&0=9#L;'W!%PR-$(Q'O-4,ME^G74>)4111L%V1J5!L 1ZB3<^-R36O_ $JQ
MDMUF%C<^-<R&%6+D8)4W>,RXPCD)QAQF0;Z%_*#S(FKC*$/ZINA)Z:QF)8A5
MO?<%4_RDGH+]#\;?.L!^X<7%E]E/5(S6((( /P;H?\*QZTCS(,9([2K"!]H@
MD%%%8[KP$G8;<AP"[U DZJ.Z;+_PUG-Q\ Q_<=V]YEN0- #Y6_;X5N,7(QLB
M83RCW'\ QNH^*@]#\:UW69]<XC>UMYB]I84EY1R6I=5<54AR+.@26=T!V+(
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MN(#X2HS*FTMB'</8('V/(8DG:/=VQ[^S9CYJXF.DCASZ3M-R/D+ZU8>%]5^
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ME2-1VF,Q>2L"Q'/8N/791#N:2)E]! R"+5VI07I$/]QA,6 MO>V9 C@JB+K
M.FE7I6Q-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5T]
M_P#)IYZY6QOASQJX;RFGQC%8'+'*',>;9P6,V/YIVM'PO?Q*[A.BN;(VFGI+
MR8KR Q=V#9*C#-LH@T" TAGO^$$2S-)<[P !]O4_A:J:^KF1DG QN-6RQ32.
MSD>/MVV*?AZ]Q^-JZG$BYM,:C08V54M[C?[C#&RJAR*GLJ0K*N/M0+&O_=(L
M5)\$^Y-GFNYI=TZ]4U.(>33V]CD$ ^!_8UYLS.WLA9A(RE=POJ"MQ\+^'Q%?
MVY8TTULGF_9>=<!$,E[5Z[?[/]=O760TN-)ZM"QK!CQL^!A&VX(IT'P^-5V^
M6$ROHLTX[MHS0I(;9N5FMM_]1RO5^ ! J;;K_P!5WL_^UJ"=P"(3H4ZV/[]*
M]$?2J#(Y#@N1PY"=C&/:3T#V>W[EO\*W/Q78,HS$D17P>B.LQI$=X#0@=8--
MVW!457<2!4_C^O75:\RID!/B;U5_=,$B9<D,RE9@2K ]01U'WU,.OLU.,(BZ
MJMD**B(NR(JI]41?3^.H:RV-CUJF<[C]LY8#UW\?X5DL.\"*((B*HBFRJA;J
MB)UW1.FZZXZW-JCV9PS95U;K7*V'*M/C5/86UO/"- @17ILM]_M_[>/'!3-1
M$C13</;M 4W4B5$1-U37.+'FR)%@A6[L; >9-:O$^G?(\MR$6%Q\;/E2R*J@
M>+,;#[/$GH!<GI77RY6SR;R?R/F6?3VU8>R:\E3F8J]%A5S?;$JH.R=$6)6Q
MF@+;HI(J_75I8>,,/%3%'\BV/S\3]IO7Z<]G=LX_9O:V!VQC'='AXZH6_P!;
MZM(__OD9F'P(%:])$(2%?14V7_CNFLH GI4F6X.X>%6;X;Y<TLWBZJH+FRCU
M5_2U\2!,AS$<99GA 9!D7X;XB33C<MMI%447W!)53M5-E64P]Q3'CUP78#;I
M\+?MX5Y=YOZ.YT'=<W)X$33<?/(SJ5L2A<DD.#J"I.AZ$ &][BK,? [E# .7
MW+[(DCMK=0K,*B.Q+:%IP6(\=EXRB-E]WLN./?S#_,B==77])N0XODLR:7*"
M?KE("W\@!TOYG]PKSC]:NU>:[.R,;C)B?T4D1DNINI<EAZK>( Z'SJ9_DQBN
M)-<1Y)?V]E%BV<1IA['W'" 9)W(R&B@Q8+>WNR"D]0(1_P#ED73IJSOJ%QO%
M_P#C.1R&5(B92@&/7U%[^E0/&_0V\+FJN["S>1_\JQL?$C9XW)60"]O;(]9;
MP&T>H$]"!44\#K9$ZMC/2VR(RC"+B+LJ]RCT]=N@ZK_@,=YL-)9A=ROC4U[@
MRX<3)=8C8&0VMY?*H+_(-05-+B&*Y20"EC7Y&_4,+_O>;M*N4^4?K_.@R*UL
MOJJ)O_'4'^HF%!AQ0YB "7<5^\$V_"K^_P".?)9F;R^9Q:,1BS8HD8> ,<BB
M_P +AV'QJJO$X!*0&J(9.$BJOU4E7<M]_P!57_UU5.''ND!/2O7?-9 APVL;
M$Z5-# *$':J4TU['Y!HVOM')C1D-Q 7VT0Y;K#1.=Y+VIW*N_IJW.P^)?E(<
MDP#=.I&EPNEKC4D#4WTOX:"J\XF5IFFEU)#VZ>%OAX'7[JQ6]JW&J^LN*?V6
M;:NEC+"GDM6+$J__ !I(E+B5TQJ(<*=*- )5:4_N^BDO34UY[ FFX./)XY/_
M -8H5(A(<-+M(W*C*I5VT(VWU\[Z5,T:.0;) =C+:^AVDC0G6XU\:SNJSUNT
MM8='!IK0;V5V>U4S(#\2<VIH)(BM/LH:D7<B!L*]Q*FR*FHU+R\D^4G'QP2Q
MYC#5)$9&4>-PP&O[=*U,V))#&TLA7VA_-<$?OJ8W%#_CM*OY%-S_ (=R+Q]D
M(PDQVCY:P3,[.>_@M@S)D.MR<FP2P1NON:-B=),I;<-8TH04E;,21%3NDXO'
M;(&:Z-'R"IM#[BR[;WVZ6V@DG47%[:6J&<M'W&B#,X*7'R<:Y9L:2-5]T$#_
M +<PU5K#0/N4^-2*C^5/*6-^WP#R5R#9YW'P;(6F^(.0:^^E)EN 9)$LV&1#
M%,X27%M9>!9A0DX1Q9+WM!O'>3L)O64S>R5,M][';KK=CX$=#Y@ZGS)'303=
MM<9E0KSW%P+!'/&3/ Z7C=2IZQ$$)-&]M5&IW+8D@U'?Y@N"/(;,J/ACRJRW
MCN5F,-ZAEX)R)Y"8@YCN45%U'9EU9\;ARO=X5.LX$'+ZYN;.K1LIZ-',C-QF
MC<)QL!6MN_.-#9$6=BQ,+@K)H0 01M)OJ ;D7MM%K ]*WWTGYKBD.9P>/D;(
MQ('BQY-RNALWNB)9 'V&RN$ZJ2UA8U"7P#Y[D>+7FQX<\Y.61JQQ;Y!\2WF2
MNH78+N*NY774F:-DJ&VHM/XC:36B[B3N EW5.NHQD.$Q!#OWL5L?N_A5K8>,
MLN4<@QA$5KJ?'[?._P +6Z5[52*A(A"J$)(BB2*BHJ*FZ*BIT5%34:J0U_NE
M*:4II2FE*:4II2FE*:4II2FE*:4II2O-S_R<\\@<]?,32\33)(.X]XO^,W'%
M%-AJ:DRWE7(MM?<G63KK?\HFYCMW3J>VZJC (OIMK%S\E\3#,D0O*38?,U5W
MU7[@R^"[?"X)(RLE]@(ZA0+M;XFX6_A<U5AXA^/'(_D_RPWR%P1CT)T>-V)
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M5SN&./:&+48C7S(:53&57+,MPC6J43E'"<1D\YDKA\<A=_;4N%*@@ D$W9E
MN3XD54/U+YWANV,"/F^=FBAF7(>+&,BR.IED"L&VQQRN2BH;60@&Q.H%3P\3
M_!O),R\;.5.'^1/)?BOSVS]D,NY<XLYPYEM!\@>0.%?(*VQN+5XBQ6<9<WXM
MD&'T>$Q/Y["NDNJI2WG D-"C@>QMNZ.!@X&&&7]/R>-D2-:T\4:1.HO=HY(W
MNWJ&GIL5U#&VNA^G?*97=?ZG!S,[@>5@B0R"3'GEGR()FML62#(C*HH0^KU
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M:?$231PP9N8L#B,O$BB,N>BJTC*7'FRJ0-+7N+_7YN_X_7EYX;<4V_-<'*\
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M<?O5BKVDT;CXJGNH!_:?;=7;'>\[/!#SD;KQT6.R0RJ&&VY4AE)0#U*+$AB
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M9=VC@%E87&NAJD7R"X+<P?+LRC\;9!(S3CQFYLEPV\=:_%M['%77"DX],FM
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M<P=K<M@9G 8;'(1\<I*4T6,2 J-2/SG4J-O\I/05TY?!X787$/S^"B-F(I>
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MP=PAB<BON8M&W86-8(K'DW5B_:[R4!15\X+Q?@D\A?R=S2H"]4ZIOK?QC%2
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M64_E%U%@/,Z"K(M5)5\TTI32E-*4TI32E-*4TI32E-*5C.:1+Z?AV60,6EI
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M%,AZKV]/75=869-.Z2%U,)LEB+;1?J+?$DGK>Y/6OT'QN-Q>#XZ/CH$M'!$
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M.TUW+N#^INJIK??3KG..XK/S,#E++!DK&4<"[+LW [K:E"6&H&AZCQJ ]O\
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M'<; LDS,"^ZQW&P5K%O"P  .EM>MS4%[FS>XL3/Q<*+-S8.W\6/VPL;N#9
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M'C29!(:YB4M?PNWB1YD7T\]:T'@@V,'*Z*-50K&TE65BS#6GJH<BRL+1R4I
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MDT:2_P"X]3_C:NP?6>/?AO6?#WR1Y))QSAF+<Z4'"-P]B_+M:!T.>UG)JDU
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M2Z^XB[=UBE]VZW0 7.ENM3L8\9<4XRI6%N(L;(,D)A')ME-:1R*DL@$GFZV
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M];R+,FF%W)O6HL\K8[T4_<$244=:1%1.J=I$AJO1=Q)/^6H1W#CPB.X%BO\
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MD*TH*^\.Y=R;(BH/3[A%5U3S9R9O)&$7W&]OC7HH<-D<+VQ^K>WK8%AX@:@
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M>J<;QLX&#*KY3,;@$$!-;WMY^'CXUD_\?<;N;,Y*?,SX98>%QX6C)=64/+N
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MY=&M_P"TDCY6\JV%P[5KRI@F:<+./MQ[I"C97@[TQPD;'(J]8D"KH6R!"/\
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MN,RHIMNMF2*8AK<J,!B\!!@9C;RTZC[+U6G+#-QLMA&7%I#M)T)VG0C]_G4
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MMOLK>V!XJ%5EF-.1%CFQ72VY$IF<^RTPC(DKCW<4PT95$%S?M(DWZ[:W0XR
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M+[YQN]\(RXZF'E(2%R,=CZHG\QTW1-U1QU&ALP(KB.,>3[S 9\ER,;[E+/>
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M;:;*"0+G=?I6FL)O)')/*>,U65Y"L0LHFG&H;N)!CC!K<C1I9,!Z<Q%8:BG
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MC< 1Z;WOK8CSTJOSG7(H^4<FWUI&,'0%FL@./-KW"[(@066'B[DZ$H&G8O\
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M%-N_N]QQOHJKL.L_,GR.6EWQHIS% #6  <>!/2[?'J1U-:3.X7B\J$1<BNZ
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M?&;K;"+038!*M*W+:<3\^.=AVN--BIIW;]J)W+J4KQ7]JP<ELF9%@VW1NEK
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M.(PZ;TJ-0TL!AJ'7L.&2@RTKA;.NNJOG'O7NS)[PYIN2D4QXJKLACO?8@\_
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M*Z/<V]X_YP!BO7=%A@NW_IK%S7,>)(XZA340[_D:+LODY%T9<20_A7F@MX_
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MU[E)"5>[9476IQN.Y'(<OQ$7ZOCIVWIM(!7<+V'F/W517)\9R_:7*3X;P2O
MLC+&Z(7]!8D*ZB[*P&G0@@ WUJ8?QH^5>,>0?RB\SX5@^75N1XKQEXCE8@5/
M*0V2N<DY1P=BSCRT:)69S4$(C1L.*G<R;[HBO:XJ:CO?F-E\?Q<>)R("9[9
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M514V'JFM F-(\1F4'8#:]C:_SZ5)IN5Q8,I,*66,3LNX(67>P^"7W$#S M7
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M5 Y-)6D[RAG3+:[$0G%II-5AT5Y47;=+>4@KZBNIAR'U@XC%TXZ&;)EMU/\
M33[S=C_](K3<1] NXLT!N8R(,*$G51_6DM\E*H/_ *S\JN3X7^![P=XU:B2>
M08.=\]W3+8_D'R%DS]7C+CZ;*IL8EA0X[#)C=/\ I3'IR+_N4M0'E/JSW7G
MIB-%B0G_ /+6[?\ UON/VJ%JT^%^A/8_%[9,Y)\Z<?\ YKE4O\(X]@^QBU6<
M\-^-/COX[P)-9P/P;Q+P[#G&X[8CQMQ_BV&O6S[KA//2KB90U<*9<2WW24C>
MDN.NF2[D2KJM))9)I&EE8M*S$DG4DDW)/Q)JXH((<6%,;'54@C4*J@6"JHL
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M#S<HC2,^[N]N#<NY"+!4-O465F:RV N+5!V'Y96%WS@F.>*'CI2X5Q';^4^
M\RU?%D.F@8SR?&R_#HV/Q"K4R]JQ8"OHK6%#)V3'&0VU <)Y_P!T6Y!GK9<5
MW1G1X>=Q*X3-A.$67(DLLKS!U>0[':UK!3[MBY)-C=KU*H^W9HN&<]Q9;S\L
M,"6'WBS21;9&=@ EMS-&2 KD7;0  K7[9/B7D/R'SA<</\KNY3RCF#N,U614
ME!!RNUSC.+R$ETS+RK^R'J>\R*OY$"IQN2\$EU9+01*MB1(;W$RVX#O>#!>#
M$XR7,?CLI7C<0QE$A8:N96#"\;#^EN('J-K6:]963!@]L<:O(8R)B(Q/N-M5
M4UC/MM*; H"P!Z,2Q53TJ0G#/CISY*\4\PM,!X0N8/!5KRW<Y# N)\F#CN9W
M/'G',')Z:YXN''WK,;\HT+.TDV1Q66V$G21[-G'H31+M.VNY)^3RXN'R,,IQ
M6/*\6)$=#+>_N,RG1&#75"3<I;H.L4Y/N#CVY['7DY@>0$"QJ0"\1GEV,)0X
M4J/Z7I#-?:OJN Y BOQ+XR\A>2/-.-8UQCBK-S6YW(J\ORKCO&IH4$NII9H2
MKJ;7K-OWHK6$?V'3R2J9;Y$ZL<U-&R<?]LBF;<UQTTQCAC&%QLD#Q92M:27W
M5#JMK$^V\?\ VVT8ZL;7 -3++[AP^+P)/UA=)XM\:NX+;F4[0UE!WB0@2*-+
M@@D $U>O\H/"'C%Y"AA7%7!7'.)<G<U\:XWFN4R^*,.OHN%O5^"8G$_!R&WS
M^WIY=-)"OQ/(I<=Q4>E?GS9N\?N4GS+4#CX67G9CBY!+0RA"BE]GNR!@!MW'
M_2?6W2Y !W$53G:?(\M@99S_ 'I\;@YO;1YG0NHEW HL2LI7<PWJ;+9(SN;\
MJUC7/GCIB=?\9>/R\'Y@R&H\&BH(4]KQ_P "QFAJLGO^/KJS<?R%JXS7*G\D
MF6O)%;R$I6861PX<]68IPY#QG_6#IP,+CL;"C[<Y?%9HUFF]UT<^_&/7[BJ3
MN0A;=+ *R@*=2:S.-Y;-C[OCDY3&B?NI\M@LTDC'VY45@A]N,* AB]++<IZM
MX&FT]+Z_\=N:K&MSSDG%>).3<EXCX\?;#)>3:O#KFRQ#'8$@B=K3R+):Z&]2
MUTO\)UHI *ZGL*7<?:"BJU!RO%S8N9-^F25^/5CL<KU0W*%K7&[;^8 Z&_A7
MJ2+G^(5X,/(R8(^0GT2)G4.S>(52;G7IY]!<UIB+<2*P#=C/JCI)L@DON 9)
M_(I 6Z+V;[ZU2S/%JAM6?E8D&4NV=0R_<1\B.E<596]C;N [8RG)*MHHM"6P
MM,H6W<C30H@!W;)NJ)NNVNF2624WD-S75C8F-AJ4QD" ];=3\SU-?$TTZ^8M
M,MN.N%_*#8$9K_H(HJZX %C91<UD$A1N8@+\:^M6;&N-%-F1&[T1"1>YM#%>
MG:>R[?7Z^FN>UTZW!KDNUQN!!7[#7SRNKBIV*&R=1).O7U55ZHNZKZ_77VNX
M:"IT>)W*6?9!=L<:65VY)QJMI),R#+D(KUI4,1Y$.)&K(LIPE%R"3DM$ 74(
MFA'8%0=AUKIN,?,?_P"(/ZY(ZMM!'0D_']]>=OK#VCV[@<>_=6+CJG+2SJKJ
MMA'*6#,79;:/9;EE(W$W8$ZULSR8Y2O>&LAJZ''[AV^_>*Z1/=6?[;90?:>!
MD!4XPI[PNJ:[=$7[5ZZ[AQDF!*T.9&1(+6L]P1]A/C41^E79^%WOQ<W(\M#^
MF,,H0!-=]P3?7I:P\^M5X9%D^3\AY Q*MI$FVMY[[4"L@L XZON271"/ K8;
M:&X;C[Q(B"*$XX2IZKMKO N0JBO3/$<-Q?;V!^CXZ,1XR^ICXL0/S,?$_@.@
M%=A#P,_Q??DB\TXE'F67XY \2N(;48\M,XYYJK6NRVTJGT;<_*Q#B",3&;61
MN1G4<8.W&AA2!ZMR21=]<W2-%_->3R _C6PQY)IY/^T5@_U,;$_);7_;K7<O
M\(O\53XO_%$*C(^6,1O/,WE& C#[V1\]&P7'<>P:45-VCX5HC8PU8#B@FS%\
M61.!UV>ZZZ+UL @%=CG$L/Q+ <>K,1P7%L<PO%*2,$.FQC$J2LQS'JB(VFS<
M6LI:>+#K8$8$] :: 4_37RN=9'I2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4K@\DQC&LRI+#&LO
MQZCRO'+9@HMKC^25,"\I+.,?\\:PJK2/*@36"^H.-D*_IKZK,C!E)##Q'6OA
M 8687%=>_P U_P#%]^+GR\G3,OQCCV\\6N39!N22R;@2P;J,1LY1$1MAD/%-
MNW8X2]7"1+W-U+5*^:=/?1-=LV1/D'=,Q:0"USJ?M/C]MZPY\,MC/#AO[$K
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MY_-1<S/QI4#2R:>R;#8S2JRF17T58R/2RWOM(4P\Y0Y*Y"X8BX'X!SN,,O\
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M;FN0 !ZKVOM6PT'32PUKS]] ?J%RG=?)<EVQW/GSYG,Y<XGC<H[[B%(DCWA
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M'N;&$Z0X2E6"OZ5B9K !&Z*"PN%8B]] P)K>\5BO)%.)\N;.QY1;;*=Q7_4
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M55IKZH#BH^Z6Q.'!7&Q\>*)E/594!]U3\5<D>1ZC2K X/W6PO?D?>LKET/\
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M'S9;>E0Y-+%A-P3:4ME;;8$G'"5501[E+=%%%25]M<<N3QEXTWY+3FUA<BP
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MZ_\ ;.+]623JW@OQ^?\ #XU=_P!&_HXW(B/N7N="O$#6& C7(/@SCPB\A_\
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M89;W!/C<]+Z6\K>%5K)VAWKD8WO<EQO(S<D0+NZF1KVUN06\?+2JOO)+PFY
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JI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g937421g27r95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g27r95.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  I .D# 1$  A$! Q$!_\0
M'    @,! 0$!              H'" D&"P4$_\0 /!   00" @$"! (&!@L
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M)WIKFGU"[3\AMBJ:_<A[JJ93#HCI^!M\L0<C,%(QAOUK#U=&:9PHG+'MOO\
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M&1FBFF210RD,I*@,""-P>I@BY2,G(R.FH21 F(:8!$E(F6BS!Y",E(R0';+
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MN9)N,/!\CEK@>:.LLK/X*E2LC1J6(60P58F@KQ11L2\>Z![+=I7232NO7C9
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M;-*(/ ^KASWS7(V1:;PI!@C,C)C-KQCV9 A.<Y2GM=ZHAUAGWS<%26DLM.I
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M-9DZ_:#6T2FN-THC$M(BVX^-0X3+23^0 SX^(3=*V3'RL00-7_+4+V+R$+5
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ME*L9QG./$V.\/;Q2&71]D,""",7@P00=P019W!!]@CV#TZCV:[D,"K:TK,K
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M:SL<5%Y[$K3RNP$T1\9E<MX_-X]CP*E/E-;H]P^Z:8VK@,94M*M2I7Q]9JF
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M3\9?X7'?G>3\I^HO[94_T3_N-U^>7VPO[PM _@%C_JECI@#@G^R=IK_ #_\
M/Y;RQX[^Q0?Y/_N/UL?M)_=WIC_R<W\[:ZMOYV],;H\.CH\.CH\.CH\.CH\.
MCH\.CH\.CH\.CH\.CH\.CH\.CH\.CH\.CH\.CH\.CH\.CH\.CH\.CH\.CH\.
3CH\.CH\.CH\.CH\.CH\.CK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g937421g45j20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g45j20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2*V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (IJ^B%@X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             @@   =E          $                          0
M           '90   @@                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   @@     4F=H=&QO;F<   =E    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   ((
M     %)G:'1L;VYG   '90    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    "3A"24T$#      89@    $   "@    +    >
M %*    82@ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN
M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M           !  #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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M/6$]H3W@/B ^8#Z@/N _(3]A/Z(_XD C
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:SCU"@VLM,C1IBCEBY8<0C1D'JCR2:[,\\-+#)45$BQ0Q(7DD<V55',D]IT
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MI!;]H]8.P@%1E5.0\0J#N Z\5';C/+?:I+Z:BGT%[:WWK:].G?TQ'Z=-O?\
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MMOCCZZ]%_P#>1DO3^[^>O_G*LY\[]FOW:X^;?2%_?5F&AMN4@OT_N6$XU9@
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M^_$?CY\C3"!D!VZ!W'& U /'73?.NNX<3I;GU-^AUM:^O*XN>SX88.VXYSL
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MMW_7G;X_=Q)L  ;$6TU_$]-VW0:D6[GGS^S\\&O81R =-?AX= Z#\L1>UB+
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M3Q8F.^%:^W_BIDH^@H!%%/335F:5<4B[JRYA3" U5)2O(I#'=WA&5-B>$5
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MQ!$17@B /.GE$J+)NB_V)(W5Q:]P6%@VF,2FJYV>DCE9BS"60\OKHC&Q3>T
MWD=64\K$ Z@@F4$-Z>8%BY-+7>DM)YTIW-+OSF?0@7/E?,41"NP<H"9W/1PU
MUY<8;;9*Q!)V><1=E5J2*)"E?W&5@YQUS<U_KISCER>T8:<UDN7>J(L*(]JJ
MSB==R/?%2\A;<,;FQW2H4JPW>^OBRBGCK/66:1G0F"Z\(AGW3"$"[P=0>8.]
MO*;Z$@RD9=J^T4Y[5BV[5_+RHK63;F[5V'M:]6@E-H+F<L -;[%021OEWNA;
MA X)+F6AOPVN_M3W6X#BC=JD[[0E$UJ^@C#G<;0BA:BM%!"94I!-*LJS15(9
M7)>HC<CA30%;!8U(]C6Y;3%TR2K5?622+&\QB0HT;PV9;+$Z#VXY=Z_M&^HM
MRQ3L$>O-")_Z4PL><3FQEJ+DOM4G56I;)C<:/N;>Z.5P^3]YN H=IJ2CA394
MYN47EKG0\Q$]F,C]+:J:VDQ:6YUIC:U$L87CRP^J4R&KD82E$92!'5B,!/;-
M@R#=:^]<$VM?$*LJO6WJ)V%,@X>\XL2U-ODN OM$,=X<K::8O%L)Q>CFWN/8
M2P4PYIKM<O\ '6/T>_+SS"J'&US]'8O=B_\ <.XZ ]#*9@JFC^PR$TZ(P@UK
MH(=V)M1IC%TA>#USJ:>BI2TIHD2"D2:=*:&H9JZ>G"RAWB@CC-U4*K*-^2^C
M,6LJD*+W.)C>2=HXVG>("EBENA"O*S7!8LP8%5L+@#4D;Q(MC+;F?O-<KEL]
M&^^W(M]?!!>B>,;-"HNCYDW%HBC@V4IIG<AA@KG=MS:(B4;%%Y<#9GY4Z&4I
M$RU I6,1:EZ3KJ*G.DW%I8HZFO$;PF*,F1_5E9KDI&TBPAG]L<0J%%_: ;V2
M3;&1-(\-(7642. J\8JI WG"&0JOLG=!N0-"1KI?$$7S471Y%.7B_-WK=<\5
MSN8J7EV.:']E@M[':W5P?H%QD4\BD74\Q$9*8F)K?T,&B38^.+C5&R272%G"
M474O/6 024%V'AUM13PO1Q4Z&<J7A$J%PJ,QIVWG*EV(%FTD N!BU*9*:&5T
MJ7F81@A9-QRI9@O%%@"$4$G='L7'9?'V:G"Z'*SS+\H$.C_./<WFOC7-@W7&
M;Y_#[HO,0EBA"DC=MW*>ME]K3JHLRLYT-AZ-U;2F=<S5J7:.*VQ]()1FJ'-,
MG6)9(CJJ>J=J2*E:E,91H5=!=I5C-/+ONV^UB2#HX*F_LDX R030 5#SB<.'
M5RK$;L9<2INJ HWK!A]FS"P!Q@IZ-N]?,AS,7!M9;DKF"YNU82SEYNM(^:QT
MN>_0! T1YIDA[I%K*W&Y2UZAN63"MY1S!'4C='Y8V/,?0*4+@D< K4%%(N,W
M,8:>G25^!2C=J(EI1$K[S%0&FCJA?=W=T@A;JY)%AN[V,:DEFF=$$LYWH7:<
MR% %#$K$T!MO$@Z7L1I[5B1AX.,CY@+<\G/I0+UI>;GF<D\RY>[\W9Y<+94R
MV?-#DV,\9AEP[."T3$2$45;%87$J0N;LT*GI(N1M!C6[+TY3 16<!U% 6"2K
MRV(TM.J3P15$FY&RDLT<N\I)8WCNH8K8FXT/3%1:5*>LEX\S-%+)$F\P("J\
M=CHH]JQ()[] ,9'S9YNU:?T?]ZKUKKP<Y=D+G6SF\?G-OQYL9U:ZX+_,7R.I
M&#Z MT2V6=K<V9[MK>5W?3H)]6G%14^?6>@'DPA.@0)ZUN.BPRU\,(BI)XY$
M9']526-45BV])]=NL)(0!)O ;N[87N3:ZS2)2RR%ZB-T<,O&='9B H" 1%@4
M=B5L1O;VMK6Q+G(ZZWYYH[!4WG>>8J0L5UY)S"S)RNO;JE$N):;$!#W=7'J.
M7-LBCG[HO9#XDW$-[L\42!.8?+%CY]).ICBVUL:NBS7)#33\%8%,2P((I+^U
M/OC>]8+*=U@Y)5=W[(6W,$8N4IDGA$C2L)&E<N@ONQV)7@@&Q 4 7OS))OR(
MV]<:S&?@X88.&&#AAAHSV>Q"V$/?Y[/7]!&8C&&\US>WIR,J+3(TI6*0 *:*
M3#U"E0=66E1(DI1RQ<L.(1HR#U1Y15=FHJ(:6&2HJ)%BAB4O)(YLJJ/O)Y "
MY8D  D@8P\PS"BRJBJ<QS"HCI**DB::HJ)6W4C1>IL"69B0J(H9W=E1%9F /
M()S[\^TOYOI?]#LXKXS9&,N%9L/AYE=):IY5D@:11+I?22::2I>SR33J&]!0
M8:BCZ(VI(EJ/6GN3BN\6VCVCFSN8Q1;T67Q->&&^ZTI%_KIN8+6)"I>T:FPN
MQ=F^)/23Z2:W;:M--3&6DV>I)=ZCHV.[)52+O**VM"D@RD,PABON4\9L-Z1G
MD?7CUR/7YX'0=]QWU_7QS)[>=M#<6UTM:PT&@%KW%[:'7'EV*I!136N14&!3
M676J3TUTC@::J*CJ*:J1 < (5 (@(#T'7KQ4A!=!VN+W',7%QW7Y<R3U.N+L
M(!FA5@"&EC!!MJI< @]Q&AOVXWT7OY6^7^+33T@#PPN%GEJF,6*1ND6L^R1A
MT3/MF'2EN@ A*2?>&)+'$)RVH]2J+/C[FI6?Z( $VB@RM7ZGIE?E.615.T<D
M;T+,F6[R4"T^ZU RQ0$3@[O"4M]K>CLUY-3>^/I':#8[9FDK?2/44\V1R/3;
M/12TN204DB5&0R[E!_+!O0K3Q&2[.&IW+_7ZZEK6,R!6CB_--!>11+RG0.8V
MODS##T*Z\ZEH?#KS24B40]$^.]WX]<1(X4I6E@87-6K,K;T"$]D)3LCBCJ$D
M:_<DEGU:C@S:GV>7):>>CFAB#UY20ULO%@XDE9'4@V5(G)NH!4;I4%=%%ALM
MR2BVOR[T=IL5E]=D]72T<<F>O#.V=U*U5$L\V=4^9H^Y%!3R,Q*(C1*L+Q@H
M;1)8K>6GLO(;)!:&V5M[032[E;'?.AV(N_%YI%;DW6^JKT]51^XG+[>8E&LB
M-:)FC;>4?1&4WNR ]4G,I?%"<D%:M9%+0T#4'J5+1T=15F.OWQ6PS0557P9&
M$53E]?NM#NI$ 1$NZNHWV4!B;659)D%3L^<CRC*\CK\YX&T"S)GE)74>9YP:
M2HG%+F6S^>+')2%(*9%9:5-V,N+3M&-]VAZ:W$A2KD&C-S4W+;RSM4VFMU9C
M9%;(6FV%2-S;&%LM^B7(Y.QK/IPQ6BG!2U76LI>33E22E104;0U4U4#ZVOJ:
MVG.S<58,HRE)ZBJFR]G2C4-&BTY(FC;?WA.K$D,21O6LH.IYROS;+W]&U+FR
M[*[*PYA79S6[//40Y64EBIHLK21:N!^/OI7AW+F8ED#6(BT)+VY-K+6OE?+A
M$D,P9+5QN=\P5^'^V$6F]T+>R"Y[[((H5&VML.+M&FC:D"X/)(G)5JQ;6^R<
MML85*NBGZ4>1;T_L$][(*"CERJ$314<=1F682TL<]73/522PB(+:D,1M3RQ2
M$L))+1E@=YK:8VFP.09/6;*425]-D]-F&TFT-5E-+7YMEE1F]3548I(XMW)U
MI9 ,NJ:.I9Y14U8BIV=/K)>':T#\HMF[?F<\RVT,B"/7:A<>07K;?>'1@5TL
MSTJB]O)<J0KC&.0HDRI.J;'= 6;30I24B2X(O;I:C"J23J]?DE!3+M%-0R\.
MM@ACKE#2Q?5R&*%]UVCE%PZ,+7(T*[RDBQ/+[%9#EH](LF1U/JV=4%+'GT6]
M/3.(9WI<KK'B=J>IC5D>*:-2-Y+"1 Z$KNDY*0_DHM]?+E(Y6XW$"F&,<Q;H
M2Z75EKZH)3(54CL>^W9<H;(GMQ65B4#H;;I"LB[VE(55^T)9$SDE:_;GKQ)#
M:19!39CDN3P0\*',6WJN62P5I:"6K:&5W86+FG5XF4'[**RK?>QV%%Z/LKVB
MV*V0I*-:6BVFE$N<5E0RI')59!49Q)1U,TKW^M;+HI:66,-;=BC=$N\H4S/7
M8SE''FE8YVDMZQJN5M+R"/-[UC=]!D5T+B6%^7P]5)C$=(T5'2NMN.1.E"_V
M@.-;I[)7[:A;^G1G_1^3?3$=2M-#]$C9QZPJ8EW&"2-$9BMK&7AE6#-=RQO<
M-C>G9S8O^.,&8IEE*^R2>CJ?/9(_5E*.*>I:B>K9!H]6866427XC2%7N&%Q$
MSUR36VLIRR<U\<EE$?F-[SXTXW@M6_DE(G)5';"P"X,>:&67(%H5#6T+;D$+
MGH]30B RE:R):$BDP@Q+40?A/D%)E^59S#*8IZ]HFK*62P=HLNIZB-8Y5?E&
M:B\A8+8%18Z+;&GJ/1[E.0;);9TE6*6NS]Z>7.\GJ0J2RTNSN7YC2Q4U7%(!
M>&3,E>8R".XDB7<=EW-T_.Y%C+6M7,+S[MR2V$400V$\C::<0%,5'$9+!'9F
ML@UIE"22QSU4X(D3VJ=54D,3KT=5*@]88[>RKJ-I4A2JLOI5S+:$+1P+!#L^
M)H ($$<<IIZ<K+$-W=20N'(=?:+;^MP<6LUV=RF+:7TCQID]''04'H^CKLM4
M4J+34M<]!E#+54IW1&E0TQJBLL9#,_&L;[^)_>N4WEU<HD\W!C$-A13[ _1^
MKW&XT'/9FZ@LN92NUJ:86UO.R(Q"HOZ9,<&>9LSN[E4%KZ7)$W'>RHIJ.6*M
MK-D^6&.HJ8J>F$E/L_)ZQ3F*, 2RTPFI:U%W2!(#'/&T@ ?>5;$"Y/4U.Q6R
MTM'49G24.7K49=Z.II,SR]H(@!65>3BMRK/(8S_S@RPUT$LX'$XD:&PL7?&#
MFA9+26YY8[6((Y'^5%DE,OY8[+REP:72VDE-YA7Q]E%29(\RZ+S-LH)B*,JH
MLDY<<8[&5N9@-S^-=)U:M 77JLY2@I<G@2*'*(YILJHI3&]$_P!(2/*%5YHJ
MB/=C7D6)8%_8<EB2N.2VPI<DRO9#*A2TVQU/5UNRF25+P3Y34G:.HGJS%%-6
M4E="5I(QN[TC&8-(>%/<L608]\ET+M/3RF(+@SB-\IX'G\V1\,E\MYFB!2F#
M;(NWD7>G>/V_=D@4+JIK16*MQ8&^HP4OJU.J@2AK !"G9ZGHOH..HJ(<FUS5
MX9YLU5032B&-Y(Z>2V\:@ LT2$[OVR;'7$>C_+\E_B5%F>8TFQ]SM<]%75NU
M2!?^*104TT]/E\RV<URW>6FC8M'_ #K%>HRHM%9/EJD%LHO+81;'EYD5EE-S
M^9E\G3_=6/29?=M38""3(XE YVO4,24Z5+'*-M"Y+13[_36X)$9[(!GLE59U
M7&YHJ#*9:*"6EH\KDH&J,SDGDK(9'JVH8*AP&I3&AE<QH1;?NRIPA]J^.QR3
M9_9.JRJEK,NRC9FJR%\VVIGKZK-Z6IDS9]GJ"K81RY2U.AJI)*:-U X@,B0M
M!KOWMA N_)7RZV,L5.[=<MT#Y@*>8:3705N4GO#''::"T-,=G*B-Q2V451-B
MY*FCDKJ8BB5KFXA2J>5;J:H.1T*TA19"#G":+*J#+JFCRJGS,9I-5%IJR%IR
MD25!BAI(0I BFX>I8W8N";&P"^?M]#;+;/;.YCE.R67[3KM/5YL9JO.:::N:
M*"GS!J6DRFECB<"EK#3@,[V>5I2Q D"J(\L2;!<O-EE'.(JIC=A6='$9;R]*
MHX=S(P^07*8+7_E-B"F02& GA'"E$GK5)EZRE"W&%G&@504@!V/.-(.-JWL>
M797EWTR>%ET:13T+1G,X#51TAJ(!+)3W4\31F(2S "XWMZUSV*;-;+9#)MN_
MJNSU-%25FS4E*=J**?-*;*#FM$]14Y:13;U5O+(V[&0QW (Q*6W"QCNQUK[/
M7*=^0.1O=J+4F%W>N]SHTSAOC\0(1Q21M<:0/JN)-=#6X I5&1R.&%D5Q=M<
MSE!C404GHIJ TL1XQ:"EHJN79V5Z.A/K=9GIE6.G00RK$LW"&XP):., <%7)
M,8L 1:^-9D.49'FTWH[JI\ER4C.LZVW]>CI*%(Z.IBI!(:.-8I-^0TU.+>J1
M2LYA7=ZWQA'86!PU\Y5.?*5/D69'.202KEO^ICVO;DRATC%,CNZX-#^+&K-+
MJ/;Z7AK+H;W 4M5 *DM%)!OK44@''.992PME.T4DL$;RT[99P'>,%X1)6.KB
M-F6Z;R@*VZ1O#0WQY]LYE=#/LAZ1JNIHH)*O+Y-EQE]1+"IFI!59Y+!4>K2,
M-Z,31 1R;A = %-QC9US/<I7+NR-7.7<BVT3AB!MAMK8Y#WB,BT(4_Y)KM)G
M& O::119!30 MS9,;?29*KI6M=(E?2:"1%*#2E"JM*7UV:Y-ED<>>U5-#3(J
MTD4+Q<)!ZE5@Q/Q85"VB$U/,C,4L2RL3JUL>N;6;%;*P4NW.:Y71Y?$E)E%)
M0STW B7Z%SB*6BG%521A;PI6Y=5QR<2/0RQ3ERK.5$:RJPT>/N;.N3*T%D^4
ME(2R0B+H8C.[YKYFVWKNFZRF%52)7=.!R^-T+37!M8U:=P-5M3>4E86_V1"8
M[*8T]N18LF6Q&HJ,CHLOR9%C@B6&;,&G6OJWEA,AK*>:)69DC8$E%LH*V.Z/
M9765FS=(<TS'8;)-GMC4CI\OI(Z/,,_?,(\[S>>LH#4-G%#6TBR\2*F=9"T2
M;L2$!+A2T<>BEP1U-R]<@K/3*:T*M0CJ4(S!.1J*DQ]9 G)3JJ2ZC4YHE^T(
M,J*HJK+JIKJHH$1 /-W7<=TNK;KLA922C69AO*2-0UO9-@;6[2,?-TT9AFEA
M+(YBD>,O&2T;F-BI9&(4E&(NI*@E2"0.6-W7HGO[GST@(?\ D-!M? 8_=T0T
MZ?SZ\>E>CRW#S4?YU%V=E4.GASZBW/'T[_!S_F-KO];DG^YFN-OG(S_K&69$
M,9#&<!_?T=P'OQZ/I?OL/AK;\<?2Q]Y\#;\1CCN]-0&?28<RX;Y4VL\,C^1.
MV^O4.F<8'Y;_ %WZ+_[R,F[/Y?I;E_QE5Z=#8W^=NF/FST@G_E7F/<E(/^Z0
M_GC5F(#@,9SG?X".@"(CY]<9#4-./0 1?4"W7O\ "VGAR'+J <<7B2&*[EQX
MU;>=VA8I4M;K;W-<8N[SN*E)VXQ%(W*%+#UT75*U!Z0YQ(K:%BA0<12B6I:#
M*C*J%%)U'Z :^?+*&>OI,SEIU>OH(YXJ2HWY0T452H69 H<1L)% !WT)%M+8
MS(LPJX:.IH(YBM)62125$.ZA65X"6C8L5+J4)T"LHU-P0<2^DYW.;!!8\_EN
M1WUG)-E#VM0Q&P:A6C$@8ZLJK%7&BGJI$,D(BRJDPTE3&B'FAA.2F&I#6ZM*
M;60.M?9/9V3-AGC953'-!()_63O_ ,^@&[/P=\PF=2 PF:/B;PN&WA?&P3:3
M.UR\Y4N93B@,9BX/L$B!M#$)=SC<(@6X8DW=VZ@!=,1Q)[_WHF-,9H?KD2@Z
MB'VF;K#L%+<N!AI26<::#Z$=NU5+ 6UTNL:JH5'4KD3N"^IT"L =#%@ET#1F
MT^1Y52\<PT,%ZK,'S:;B*9]_,I6NU8HF,G#F! W3$$5"/8 OKBS9QF51P>)6
M3?R>B7+XMPB+=HUN! >$$WT(/M;UV;^D3;#UCW.'S-1&46RFL7O)+F"4V=M^
MAM7;IX:#&] H8+;MQQYZ*$FEI4!:9]CI1ZDTVIND9#P2=5ZE1])HD$>SQ)=E
M\@J:>NI)\MIY:?,JU\PK(Y3(PDK7"AZE&,A>"4JH7>@:(@%@+7.,B/:'.H9Z
M2IBKYHYJ*F%'3.HC&Y3*=[@L-S=E2YN1*'N;$\AB^R'GHYM99>6(<P,BOE+G
M:[EOTZ]'!I6J+91*B*1U;UC6YIHY'*&FB*-)"]"Y+"59:)C)I4UG H-"M242
M<7;@V1V<I\LJLGARJ!,OK61ZR!&F#5#1.LL1FJ!)ZP_#>-64&6RA;#0L,5R[
M39Y-7T^9RYA*]92JZTTI6+=@6161Q'#N<%-Y6(8B,$Z$FX!Q#TKO1<Z<P* 6
MSE\M62"#VL!]"WK.Y(VLXV)D21<+F]H6IX!!2^T-;@OJ]\K:#G,YK)/H*K2H
MR/8E!1LJ;*,OHZVMS"FIEAK,PX0K)$DD"SF)=R-Y(BYAXBKIQ1&)-6WFNQO@
MU.9UU734U%4SF:GHR_JR,D9,7$8LZI($XFX22=S?*<K+[*VH[D79N)=]9&%]
MR)0LE:R%P:-6TBYZTA GJ:(+#B%":-1TBEN1HZ*TC20I/+(.4TGK#*3!%0I.
MJ"@::J#*J#*XJB*@IQ3QU55/6U"AY'XE54%3-*3([D&2RDJNZ@')>>(K,QK,
MPD@EJYS*]-!#2P-NHIC@@N(D 15!W+FQ:['JQQ)DJYO.9";D752RZZKY($5[
M6^&-=TF]R;X^>W2Y-;Q&C;X08J;19P0H7",I&]$2U/#.G;W<D$Y=8KJC0JJ'
M7T^R^0TK9<]-0)#)E4E3)02)+4!Z<U;L]2HDXQ>2.9G8O%,7B]HC= )QF3[0
MYQ4I61SUC2QU\<,57&\<)25:=0L/L</=1XU"A70*_L@EB0#AW'\_?.6JLY^0
M)1S#W#.M/]!A&!C-2]%[P9%@(]T"+FR>E $N.C?N/^=XQ\U],9Q;?\[11B@_
MJ;C'&QNRXS(9LN34@K^+QQ-NON"<G>XPI]_U82A_;$G"#;X#$W%\7CM3M :$
MY<<TJ?5>'P2EUXG"L5X1GW>.4W25W3(1;2UA;$"3*Z]Q+@QNWD0F<H6OT;M/
M'UD5MVU*2&\DB,1YP<CGA:UHS$:1,H/)4.9YRNJM><K/I,,&F@VDO] -Q2Y9
M0T4]=4TT CFS*85%<^_(QGF"",.P=F52$ %HU1>P7UQK)\PK*J*CAGG+Q4$9
MAI%*HO!C+[^Z"J@M[1)NQ9N^UL9&1?TA_.?#)O<&X\9OS)6J;74(B":X#\6S
M0Y0HDQ,"9QC\0+6)UL;4(2 9&>H427W%(CJ-+_35"H-"DWC1U&P^RU324=%-
ME,<E+EYJ321F>K7@FKD$M00RU <\20%COLP&H3=%QC;1;6[0PSU%3'F3K-5+
M"L[\&G.^L"&.(%6A*C<70%0"="22-&\=SQ\UQ\IALU-O,_URBWZZ[3E#7<&J
M+4'L*V^K@Z.EVE"0FA@I2F535>].:AQI5$'EIJUE=+72WE4%447UV1V<6GJ:
M49:@@JURY*F/CU1$JY2D<>7J29[CU=(HPI4J6W;R%R3>T^TV>/-!4-7OQJ9J
MQH'X4 ,;9@S-6$ 1;IXS.Q(8$+>R!188CHKF,OFGB5JX.DNC+D,8L=(G676B
M0M[C]'*+>2-[7%NCFZQAW0TIWIM/4.)=*ZDLMP]W3*ZCCTA1!AYU=>;] Y.:
MG,*MJ"G:?-8(Z;,6=2Z5<,2A$CFB8M"P5 !<(&( NQL!C%&=9H(:*F%;.L67
MS//1!"$:GD<W9HI%42 $WLI8J+D!0";ON^G.QS4\RL=:(C>^]$JGT89'"AW0
ML"TIF:6HQX*(-2%/+FBCS4T$/CR4E/4$$N[W2X.1):E324IH!0?Z^+E&RFSN
M1SRU.5Y73TE1+&8FF#32R",G>,433R2F*-F +)%N*; $6 &+^9;1YUF\*4^8
M5\D\".'$>['$C.!8/((D3B,!R9]X]1KKC%SJ/E\0U^[X8T$=.O0^?S_#]N-)
MY[L)KK@-- R&NW@&!#'B/@ :\.P?"_QO[_=T)P\?/WX-!TQT\ \,Y >W;0=M
M,#PUYW]_?S\3;Y'QP[>7AXZ>ZW>0>HP;#I\PSC7\".X &>H[CT\.EOCIUY7O
MJ>T:8=/V:WT^6ORU[@<CGMKU'OU#&N= TZ9P.O <QX@Z6\BPO?IVC3# &N1#
MQ --NO4.PZ!H&-/'AX]O,W^?[-=<,)CH.WB(9SC<=? >OAL&>)O;6YTTTT%A
MT&GOU]]R<.W\NG?Y_:HC@-?#7L./+7QP&V/T<<1\M._M^[ESTN.>)'/07[O/
MD8!U\=<;=N@AD,Z[;:B'QC$ V\Z@^>G4>XXZ9O1+^EK2H$T7Y2.;B4&41N@U
M&T63O8\+ !7#5=(4I6B%S5V4UB/U>UH11N2KJC*&:BLMA?C!CHI5C)X-Z1_1
MOQ./M!L]!]8 TV8Y="GV^;25='$H^WUG@3^<%Y8QOAD?V/8?;FW!R;.IM/9B
MH:Z0\KZ1TU2YY#^C#*W<CGDV.KQD>U)2D&)]$NASH+$Q&K+T2.Z,,!2K2U"(
MXJ#(4J$]0^T3F#@?7*K*--^?QKS%B.8.GRN?AS&/9/NTL>?GQOK][PXG$X.&
M&,4+K\C'*)?6?!="\-@;>W'G8I&E 8_RML/=3%*%B&H6I$M0'JA:ER-)Z]=-
M*58A/(-HKJH/+-HJ&D<J*MJH(S%#/)'&2QW4;=%V^T01J">I!Q8>F@D?B21(
M[Z#>87-AR!Z$#L(P\[A<K?+Y=98[KKA6IBLG4OUN6ZT+Q6M3J22U]L6F6(YR
MW0<Y.A5)4_U>2RMO1O-""@J@NH\BDDSUT@UIZK<=3/%;ARNN[(918\I"I0O_
M *14D7[#BIX8G)+HK701FXYH&#!?#> -L.^1V9M9+IA'9])H+'GN712+RJ$,
M3TX(P/.20Z;D(TTLBQZ<:@1.+ ^DMZ*E<TN:98BJJ3EF%DEF@-8TK+(J,BNR
MH[*[*"0"Z7W&[0RW-F%B+\\5&-&8,R*6564$B]E:V\O98V%QR-L1%9WD>Y2>
M7^3ODTLU8.WMOY3(6M8QN+VQM9H+2V-Q/I4KV-HK6*55$=95I]!9JIHC]#8W
M'UE$B:FJ]B5ZEV:LJJA%2:>215(8!F_I 6#-:Q8@: L20.1Q;CIH(F9HXD1F
M!!*BVA-R!_B@G4A; G4ZX=T<Y7.7N(J;-+(U::(LZWEZ;Y*TV66I$1M*RW37
M,4)[;)V^/JJSZU!:-Z1*3R%J=28I*K]H)E--!H4F!2U3._%#2N1.5:8$Z2%#
M=2W;NGEBH0Q+P[1J.$"([#[ 86(7LN.>&8U<BW)^QWE-Y@VCEWMB@O$:[J9$
M$V3Q\JE61)5@C6KDZ-M&L6)!*%1M59ZF2(FM.^'J33E1J^I0<:;76:VK,/JY
MJ)##8+N%M-T<DOS*#HA.Z.S%(IJ<2<81()+WWK:W/]*W+>_SK7[\74>3+E8J
MO?\ G(C8R #>[Z0I>/R@"TB+I].T(_H^B1^Y^V^AOK/2B_J<)+]&_3P4:_2/
MK?I<4^MU/!]7XTG!M;AWTW;[V[V[M]=V^[W8GU>#B\;A)Q;WW[:WM;>[-ZVF
M]:]NN)$-L;:4]9>-P-@C(8MY@FY"TWH454*/:7#;6V(C D"-_$%  82EAXBP
M% F!,((1&D1$S^$XHXTMH1OM: DPC_HR7XA*^+^UXXKX:7D.Z+R_SG^?9=W7
M_P##IB+[H<DG*=>B'V^@=T+$0.8Q>U+.CCUN$+DWJ"U<.8$"!(UIV)C>D*I(
M^)&:I @1)E36#E4A7T(TU2XA360573<BK*J%Y'BGD1I26D(;[;$EB6!N";DD
M&UQ?2V+;TT$BJCQ(RH $%K;H M8$6(%M"+V/7$S-%I[8L%MR+.LUOH:VVH3Q
MU1$BK<)8XTEPGZL*R#DRUA,C7NHM)[6N)4**%R,Y*82M]X45*J3JSS:J[+22
M-)Q6D<RE@_$+-O[P-PV]?>N"-#?%T(@3AA5"6W=P !;=EN5L0M9[D>Y1[!#+
MZK1<OUMH;7/FA5'9@8E8J',U]C2[5;%E9KX8Z&4158/JBJC">HEA4#06)S=6
M)18TWI:RJGW.+/(_#.\EV(W6_P 86M[0Z-]H=#BU'300[W#B1=X6:PO<'^B;
MW]G_ #>7=C[V2Y*.5'EP?W^4V/L/;^W$DDZ$YJ=WQ@:J_I0QG4**%:AC0+%Q
MZP]F83U11"@YC9:V]I-/3)3:T=5:5/46GK*JI55GGDE52" S7%QH&(ZL!R8W
M//7".F@B),<:H2+$@:V/2YN0+ZV%A?7#EA?*WR^VZ<[:O4%M7&8J[6?B\AA-
MN'%FH6HUD9A\J7FNK_&"3RUGM'!B7NIQKH+6[BX(TSG74X(RDZP?;<4O4SR"
M0/*[B5E>0,;AW0;JL?\ ."V%Q8V !N ,5+!"I0K&JF-2J$"VZK&Y [B=;'KK
MSQ4N/+-89V@]T[:N-L(VK@M[9@]7 NO&32U8MLXF4B5M2][D+U32JI-K7N*Q
MC:5"BI.:06)B$CU"Z0"H*H%1,'CD$C!XE"1-I=%4$*%N"  ";:=<288BKH44
MK(Q9UZ,QL23WD@'QUQ'<-Y#>4"WS<U-$.L)"&-I9+B1V[+8UIRG0]N37(B*5
M6CB\Q%$L<E*8]Y8$ZY90U'J2CJ$5:@PXDNDX0,"X]=5R$EZB0DQM$3< F-S=
MDN #NL0";<_"^+:TM.@ 6%  XDM8D;ZBP:Q)N0.5^6)SB%I;;P&57$FT,B+5
M&Y/=EW;9!<9S:J3TWUL?FAN!I1/3FB \6_Z5!OII3JG!,D(5N(44&.!JHZB@
MP++RR.L:.Y98@5C!UW%)+%0>=KDFU[#IBZL:(SLJA6D(+D?TB!8$]+VTOSMB
M1>+>*\'##!PPPT)[/8?;"(/\]GS^@C$1C" UR>WMR,$M,C2EC32 !3136>I4
MJ#JRTR)"E*/6KUAQ"-&0>J/**KLU%1#2PR5%1(L4,2EY)&-@JCMZDD^RH +,
MQ"J"2!C"S#,*+*:*IS',:F*DHJ2,RU%1,VZD:#2YYEF)(5$0,\CE416=E4\@
M?/KS[3#F_E_T0T_2$9LE&5]9L/AM=8$JW=650813+I=20>>G4O:DLTZAO0T&
M&HH^A.J2):CUI[BY+_%]HMHYLZFX<1:'+XGO%$;!I6&G&G .K6ONK?=C4V%V
M+,WQ)Z2?216[;5IIJ;BTNS])+O4=&3NO4R*"HK*P E3,06$,0)CIXVL-Z1I)
M'UYZZ#KG.^_EC[<:CG'3CE]+<A;6W,:ZZ<_]'F=+^\>7X TZ#CX=-?$-\=]!
MU#B3J+ C4Z&YU%SSOV?G;6]V/19E91E!M C28772875@!&FNBH*J1P(8'U1I
MSJ&!' #U#B1?F"HW2-==+:BS&_(].WGSL95BK!ET*D%3V$&X/N(ZZ8F5UYA[
MT/;_ ',E#K/G18_WBCQ,3N8YF)6BDZ6QT@EL():UU!3?00G(H)96N@*VXI&?
MA&6(G#548->P?-LPDFJYVJ&,M?%P:I]R+ZZ(!%"$! %T1/:01L>9;0D[Z?:G
M/ZFHS:KGS*62HSVE6BS:4Q4X-92HL2K"X$(5%"PQ"\*QN=P78W-W@T\X_- Q
M6U_) T7KFR"W@-IC(4PD+4WMTC(;2)1C*@?ZTM4E;V>HD:DWT2A>$S?2E'W6
ME,"?!87H\]SB*D]2CKIQ3!-P*&4,(B""B2E.*B6TW5< #0:8SX-O=L*;*OH2
M#:#,(LL$)IU@5TWXX&&Z8(JHQFKBAW?9$4<ZQA/8"A=,6V*<U_,7"+;*K012
M[4J8[=*DSJC&.(S46$:%\K-->4#0['(C7UC0.IIYYR]$S.:!(J.4*#CR:S%!
MU==,&=9K3T9HH*V6.E.^H0;ET$FKA)"ID1')-U1QJ21J3>U1;;;59=E+9'19
MU5T^5LDT8IDX1,<=029XH)VC:HIXY2S&1()8U8LQ(NS7C!3<>;++?MMJE4@5
MG6]9Y0NF;;&*BD@(TDH<F\MJ7/%!]*8%U2A0WE%)JRS%5:8** JH)IK$:N,,
MU54:..B:0FECF:H2$J@"RL-QG#V#BZWN"V[K< :G&F?-<PDRR+)GJ6.605DE
M?%2;D81*R6(0R3[X02%FB 3=9R@ .ZH))Q)5M^:?F&M!#G2W]M+L2J'1)V7*
M')4U,YZ0JM,X*TQ216N9G(U(>[1U6J3DEE*E,>7-ARFFG)]=8Y'C*I<YS2AI
MWI:2LEA@=BQ1=T;K/S,;LIDB++:YC=;G4GMVV5;9;49'02Y9E.<U=#132-*T
M,)CNDKJ$>2GE>-IJ5W4 .U-)"6UWB23>Q$<P5XTMU%][4\[="[JNA*\APFGN
MS76Y+"W1AJC#@!I%:"IO&I6PUUMYQ@(@-K+JJ.&OWJJH_BA<UKTK7S$5)]=D
M5D:;<B+.K1B([R[A07CL"; _T@;@$XZ;49]'G4FT*YC*,ZF619:\QP-+()J8
MT<F\C1&(EZ8F)CPP2#O7WR6Q9W6\=TGI+%$:Z=2&A/!H6;;J+4-RP6:IH@Q]
M:FM5&:#6>E <J;%@JU(+B5QBJM?0;46M,.*"FD*),QKI! K5,@%/3FD@*$1;
ME.><9,80LK!KMO%BP(#7M;%B?/\ .:A:)),QJ0N7T#971\)_5S#E[LS/2[T
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MHJ (JA1;&,^_VXZCX>>=N-/R[3>X.N[KIH>_GXWYDXY'&\7T3W]SYZ0'8/\
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M$'EW<K_!Y\^?S)D?M'(CO@=M-QSH'?(8QIH\>7CSU(TYCG?Y]N'G\_=WX3Y
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MQB.V_P"[Q\C!G3.<ZZ#@=_U@(C@, ./,,\+:VM;MY<O@+:#4GGSY'# &=,:
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M%EPVBC%?5Y)2YVU/#EKS1QQ5II8Z6F2KEK*6GEGEEJ&*C?16AC5HC+43)2C
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M2Q *QD9%O=M,=<AS%IX*9HDBFGJZFBW97W1%+1I')4/*UBJ0QQRJYDNP*!F
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MKE\4@C&MDTUDK%$HZW4!6O?)([(65I24U#BGWAP<3TZ4H:Q_1HIK-"JNK%-
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MU8]E&&DF%G$F&$G$UTF%&E5U%F%&T5!516690--19E%0!515353534 #2("
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MY)6T@EQ;#R5#<  36974IF<>ZSU$]1&:7ZN>.::6$TK.T;*&-BD6_&R/&ZH
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MW/)9=)J)L3$%)E)20DNFFRS9D\BHYK&F#+.J$SF4-&H"3 -=O8C"JL@%U0
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MON ;X^?77&, [#?7[K<CYUTOUP[]=;<SRT^'GF<+X[9QD,#G4 VU#4=LAN(
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M*0 *2PI  #QLDNSO(YD=B69BY9G)U+,Q)))UN3K>YN=#CT\  !44(JK8"VZ
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M[NP5$4%F9F("JJ@$LS$@  $DD "^*7945G=E1$4L[L0JJJ@EF9C8!5 )))L
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M;9KM\V+.DF%PW(@IR8;1+0)61F)EF4EF$?6=%_")9)(2P_U:E65'QIKJ,K2
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MEG%"TY*1AHE22215#K(ZRG'K"V!D=Q7J,-9TS7Q9FO"IMF\/M5V+<LZB-Q!
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M41 -1^[? _+3741WXD]!>PT(Y?'3G:W77NP\^/+]AP=Q$,Y'0.@=-<X !SX
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M;/4]<4J92ZK86PI$4P;(HJ<HE*5KHP."VM(0PY\\M'0TM'-E](K/7++))+F
MI\P:'@5$D IXT:FBI49A&M3(6IY)E2:!4E50W$Q(4J:J:HBJZ@@4K1JJ4G%I
M1()85EXK.)7F8 L8EW94C9HI&:,EK*PHE.N5>T#)S8VKY@)W;%V2PVXSR9,W
MNYJV/.EP[K124VXAEQ2UDQ:ZB =9J[1>B4N-M&DMA9U!)4?@S$U-B!$J1&MJ
M3.FI<YKY<CK,KIZM7JZ:,4T5$)8Z:CG@JZBCW(&!X=.DW!2K<NX)>HD=F8$,
M<:*HRZDCS."NG@9:>9S+)4-&T\\,D,=1>0?:D:+B/ NZNBQ*H52"!H.Y"O2U
M<S[GS5Q^ W!ECW=3EE?Y'7&5I<KB[6K?K60$U6:VQB<.4QC[*G>2_JRD^B:I
M<Z2U>\H7) 6ZJUQP/!Q;P3ZWM9Z/<AAV>DJZ6&++\ZA@$R\*H?A5]4%5ZBEC
MIYI60F5N)ZNL"QLIW% ,8W,>8[-;;9O49[ZK*\E9D\LSQ!G@7B4=.6*03R31
MI>R+;C&8E6N['VQ<=:*,B.+$2:1,"QFE,#F#;12K,0G(WN.R"/NA TTK2#4]
M2EN<D)J8\:@,*%0F5HC#B@]>@[3YZ99()2K+)#-"Y#*P:.2.1&U!!W65U8=0
M&4_''M:LLBZ%9(W4%6!#HZ.--;D,&'B#?LQP">E#Y2TW)?SDS^V,>1FI+:R@
MA%<VTM%==1GN\(EIZZD&6@RH:ZAHBDD;9%%4PGFFJU#<RH7!5748M"H?K#8'
M:)L]R.FJ*AM^KIV:CJSU,\(0B0@#G/$T<K$:!F86TQ\Z[;Y&N59K,(1NT\UJ
MF ?^CD)!3PCD#H/\T+S-\;7O1+^EK3,:6,<I7-O)C?J<!J-ILO>MV5X6P!9B
MA*TPV8NJFJH?JM2(THXY)%E9@1RBNAC?*ZXG6D4QSC/2-Z-Q.)MH=GH+2G>F
MS'+85MQK:O5TB*/YV^\9Z==)?:DB7BAEDZC8;;G=$62YU-<&T=%72'ER"TU0
MQ_H](I2=-(WOHPZRF1[4E**6-]J*!Q H#4*XK1&\H] H5):A&H ,#UJ04)QJ
M$P@P0UK)K).-^?K\^VYTT[OSU%A;'LH^(/(\_GK[CRZ=EWCPQ., N>]U1R4B
MQ?+HZO)#!$;\W+5U7>=%3B4SI"K$6EC+G<NYR!:\&G)Z6IOD8-$>B3HMJ/)H
M!HD#B16912<-0=?LG&T!S?.DC:6HRB@7Z-14,C'-\QJ(Z"@=(P"9'I^+/51J
M 3Q8(VL0"#R6U4BSC*LF>58J?-JUSF+LXC493E]/)75RM(2-Q)N%#32-<#AS
MN"POB\)>>+D4D*0FW?Y6K?JHJZIZ8@G(=8Z])+6.:$TKZ+H8"90[1Q/;E:V'
M$ "$M)0\F-YY%5"<L*RZZ*!QI-F-J(&:J?+ZQ9T)G<K+&U<C@F0RM!'*:Q'!
M^L+&,,+AC:X)NKM/LK,HH_I"C-/(/5U$D,JT$B%=T1+420K1/&RG= $I1A[(
MO8C%KDO*SRGV/3-EU(=RG++CN;6](%3'&[<MH3$UF.5":I+D<>A4LF#?#VY.
MW5%4'4*&-*6O2FFIJVU-55FHNVF<YSF#/2U&<^KK(C+++5.8>(!:\4L\,+3R
M,_(B0D-8[YM>]$V19!EBI74V0&M>.6-H8*.,5'#9C<3PTU14)31B.P;>B4.O
MLF-20+4O(]+H[<24<U5P%13@VW.DE]G!._1F6MAT?G\5MS'(\R,5J&5]C2\"
MW%G0?0R1R<DE%98I5#HXO=9*A2;0=6%.>0R4T>4TX*-3QY>I22%Q+!+422R2
M5;I*ETD8.RJ2#<(L8(&@Q:V6J(*VHV@K#Q$KILV99H*A##5T]%!!%!E\4L#V
M>-.&DDBA@5:629@2Q;$.16V5V)7>B\EQ[/J;>_6>T/.1=-Q%HN0ID:)C>T\R
MY<+0Q0U/2LC+>XKDJA.0J4'E'5D5%4'4D55E'EA64,U$\,=+20SB7=J,KI@&
MB"EE,5;4R V<@,#R(!%^T8U-/09E49KFM=EAHC49;M17R<*N:=(IEJ<@RRF*
MAZ=)'5@&+ E2 0+@\L90-MVY9=8F7V#E2>0\L7,7]7#'R.JD*MGF3,[-R%<F
M$N96YD2AOH:9C'R%U"=%)F!R;&>1H$*T]$L1(JS"W0K4R0I%NS1LM33EK7LT
M;*=?8E2^\C6U!!9#S#'EC?)F53F/K.35 FV?SPP<:G=&AJXY8T=;U5#,R".J
M@23=2HADCAG1'W71-Y9,2-R\W5>[DQE_:)VV(F"[ELI*I@5U6-N]<&RF1HDB
M1>WR)A]O4*DV,3*/KFN2,!Q_K5%IEQC=6:><W'FU6)556!0DHP#(3SL>A[U(
M(/;:_7&;D>935\$\59&D&9Y=4-19E"G\WQT1)$J(;G>--5P21U$!87"N8R2T
M9)C"_P KGD\O%;[EQ32Q3;.VURH%,I/(I=&R@KG<P-B3@THGRVD?=5(5HH:4
MJ97]&\KY 2E<7E8@*<$+:#6)!JI3;/+G:_Q]V--M U=F&;T&S2U;99EN9Y?6
MU515TPO7UAI)8(ZC+*>5CN40D@J5FDJ DLSQB5(>"RF0Y812+L4(C$>AT7;R
MVJ-Q5F;8^PMA1AQI:!H:$A*%O24&J##E!H)TI!17M5!QIYGJ^N::89556+EC
MK*2EIZ&EIJ*EC$-+2014U/$I)$<$"+'$@+$L0B*JW8DFUR2=<7_AC(PS;A7!
MAMJH;(+@7 ?T$8B,80&N3R\N-=5)"8@O%-!9995!BA6L5'5%I4*!&2>M7K#B
M$:-.>I.**KLU%1!2025-3(L4,2EY)'-@H'S))L%4 LS$*H)(&,+,<RH<HHJG
M,<RJ8Z2BI(S+45$ILD:#P!9F8D)&B!GD=E1%9V53Q_\ /ESXS+G F0MS?[]&
M+*QA<89"X56;[-0XGE :0$NEH$FF)U<A5DFFT(TE%1J&.H#A0(1/5G.KHZ>*
M[1;1S9U-PX]Z&@B:\,!OO2FQ FF -B^I"J#NHILMR69OB+TC^DBNVWK>! 9:
M39^DD)HJ$FSSNN\HK:T*2KSL&811@E*:,[B[TC2RR9*>AVY<V><W,EO,/-4!
M:R+6/(341=.IH"LA9<9S),4IE])=05%'5Q5G+J5DE&XK(>7I@<"! U%2(;C8
M7*EJ:J7,95#1T95*<'4&I<$[VI(O"AW@/Z+R(PU73K_03LG#FF;U6TM;&)*?
M(RD5"CBZMF<R[PFMR8T=/=E!'LRSPR*=Z/3=E-YXS)S%$QGCK6TQZEQ2(!4T
M(7)Q+),6G>P0)2TS6D7*:2QKQ0!@D^SI'-9U=-57K#ZM-/%31<68[BFPT5G)
M)L /9#'4Z\K<@= ;_5.89E1Y7":JNE,4'$2,,(Y9#Q)&LJA(D=[W.IM8:DFY
M PU[-71D4MN9<I@MU4S3%C<6R//<)7REU0QQ@C"%N4O,>E0$-:%K.GCRX@M+
MCB]2PJFY,F2@M(5N4DC),DCU+QKH*N6>HJ!$1(C!&B:0B-$"[\<EE"\9F#!"
M5*A0""9$+KO<GE6?5V8YKFD% T59!)'!44#5<J4U-2)&]13U(6*.)J^:7>%+
M+)3O&%3B!Y:BE%3 LK=AL<O#;NXT[NDV0.%S&-+7Z0,[>;&8FYMR:/UQ]Y7Q
MZ>T(F1#,I3,H=3)94SJ'8#8I#;SJY$0-*Y2WPZLVMBJQX4J8IYJ@)'+&SLB[
MD3*$,;-'-91)+)$))4+?5I5%QNDB,[R#79?3YU09EF.;1T5%6TLM544\9IJ.
M6):9J2>6DS I!'6U=92+4U=/)(/5:3.9)U<2&.CN].;I >;J%US>\#[=*6&L
MT)=@B!UM(^:#?)"T"9E9%C;.53-7$$KDN5MJZ1)QK(5. B>J4%J$%"%N>&YY
M9&Z8LS19JEJB3<A;A&G71Q94(F*\(,2I>UBUKFX 5@RBO+=M:6/,LYFS:L>G
MH9O4?HJGW5JMQ8*=HJ]XC1+-(T3U0TDE(9G#1A(Y8IH8\T3V)O1":;6E)7Q>
M2(A0/K4M3@<A6MC@2)-8JT*B@:*Z/8GUEJ2#RA U(:<0:5^GZM.X*JZD$ JR
MD,I&C!AKO C6XT/=>XQZ.PCEC*.BR13)NLKK='C=2&1D8:JRFS*PL02#I<8X
MN.>KEWIY4>::>6M;23RH0Y>Z3>VIA]8FU50J3U'FHD0&U"-9@1]V2O$6$\T1
M-4U,8JC!'VX#5XGM)E:Y;F,T48M"X$T -OYJ2]U\(W#H+ZD+>VM\?"_I*V57
M9C::NH8$*T4V[79>"2;4E26(C#'5A3RI-3AC8D0AB==<7P$! !TU^S4/GU#'
MZ^.9-[\N1OIH>H[;ZCD?<.F/-"+<^VWGQZ873^G;[ UP&^PZ_,2>0 L0/F/&
MW30Z@ <\,&1# AIOC/SQX[@.<!J/@'%.ECU-OAJ!V']WCA@$<_9V - [;?M[
M< #H1;G8C7MOSOJ/#IKVG#"<5=;B^M[$D$D@'L/=^9MH6%Z]\]OEIG7;( &@
MXWTSFD:VM[R=!RO8]O+R ,,'WCL&.G3OJ/;]0\23T8=3J"--23;G?]EK7&&#
M.>OZ_ <COIVUZ_$0/#0D:$<N5P>VQUU-S\6F%$<^8:YQOMN&O37MOWX@:=H!
M[;W!'9:U_P #:_>\^;83.@8TU'7X!U^(_/AIV]!T[C<<AK?D;^_3#!MG?MII
MJ&P]]!WV$,[ZX%W"Q/3IS!OH-!;XZ=18!@[]-M/Q^O[^)U&IOXVUL/'7KJ3<
M<A>VN&#MVU^/Q'X?LSNYDW%[V.G0<@2 ;WMKH3SPP>0^6=/Z-QZ]\AQ&OQYZ
M'F3^%P.W70'F6#IT_&H#J AI]NVFH\56^USN+].V^FFIO?0D:<^T8'SY^["Y
M''3QZ9WSKN.?/.HAJ&U!L.AL>6O?S&@Z=W6^'GSV83RT_'VY#R[ '%?(6TM<
M:@7N;Z @6Z:];\P22,,&H8'XAUP ?9\/#IU::@<K'K;Y'6_(7-NS6VK .NOA
ML   >.>PZ"/7(=.T#M&A-]22+:K;J>V^OSMJP;?M#KL/PQX8'OQ '(D]NG=K
M?7ET-AK?WG#!V_7X_$//I\N)/6PY,-+&_0=+C4C7ML->6&#0=.O;SSC?QZ>>
MO"Q'+2P)Y=EKGML2+CKTM;#ST^7=X];],;Q?1/#_ *7ST@.H_P"L6#:[?[7[
MN^>GZN/3?1Y?<S;_ $J'_=JN[MU[.SM/U#_!S_F=KO\ 6Y)_N9KC;WR-" 09
M9GN&F*1_OZ._Z]>VG'H_4^ _'W:?CCZ6-_)(^8_+]O'=Z:@!_=,N9C4?]4VK
M#0,CC\B=M]?#J&=@UP&1X^N_1?\ WCY+U_\ *&ATL?I*KOU[P="3[L?-OI!T
MVKS#_0I/_"P\^WD,:M,Y#L/CO@,ZZB'ZPU$!TSQZ -#]W47-NX@VZ_?RQQ79
MU\]Q_(XVAV8Y*;)3)LY8X)<&X5TFJ^G.6R.K]9Y7#HU'':TT#2C+Y1 HF1<L
MQP642E_/>Y'$7(]_&*&-H0QG6(E*JAU/+5$4^>9KM7F]-+GM50T>7/E.S,T4
M.8K53S1YA6,8(:BH:C"#@0B.*>,0BH4FHE#*IN0!W.7;.99-%D]/5U-:F99_
M%+-0M3Q1O1TP#R1P"I)^LD+O$QE,941*5O:S'$,13T?G,5-'E@86)NB![A)F
MNQKPU4FRM(628CYAW%]:K;UUG@GK+IK5*HZY [  UTMA5)!E=1M)P8VD^VN3
M4\,L\@JPD+YHCV@%PV4)#)5V!D!MNSIPKV+D,"%*ZZ^/9#-Y9A GJN^11L+S
MZ$5\DL4%B%(/M0OO@?9N.8-PX>5GEFLQ<'F&D-@;VS&5K5Q$4D[]'Y3R^R&$
MR.+^_06V4ENA*FQQ?']O5I'426]@KC28^/EG(BY,6NIJ7*FPHI<;8V@VAS2B
MR2GSO*J2G6)YXHIJ?.8JF"IW:FMAHZ>1(HF!C#,YF82D.82EE5RP%W)LCH*K
M-:C*<PJ9'E2)Y8Y\MDAFI_J*>2HG1I'4%V7=$8W/9WP]R0%)O)WHU>8>8M44
MN%:&$J5MMKJN[ LMHW3"41M'.T%O9ZY+T]OI?< Q,""(MR)T1HJE3HK:W4\Q
MH(K3.3JV-+8XMIZJVFWF34TD]%F=0%KJ".=:UZ2":2CDJZ-%-73T=V:HD=&;
M=0/&@D*NL;LR/:M]C<TG2&JHHE-)621-2QU4\:54=/4,5@GJ@ (45MW7<=V4
M%2R*2,7Z%^CI=[B6EESC!;E6QF=W&6]C';^,EQN[416VRN!'W.SDIN:8TPQQ
M,;B7)XN6H5L1:)"R*%S70G3IW1.ZMJ4R@I?39J=N(Z/,:5:K+J^FRV7+)JNH
MX^75"U]),F8040DJ$$ACCHE64LTJK)O.R<-SJ@O0[&RU%#4-!64<U?%7)3Q\
M*LB:BFB-&]28XFX8D>K++NB,E0H#;P &]B/$OHY.9)S:K>N;*1;E],N.JMP4
MD:6NX\=,>HFANQ:URO-"GVX"%2<E^I[$X6^8I*^'+',VFM(3&G6L].!!K6>Y
M9AV[R)9*V.45\(H4K"99*.015+Y?7)EU3%1NI;UF1:J6%%50 >,@+*5=4Q/X
MF9R5IBOJDC5#TRF)*I#)3K5TS5<4E2I X*&!)&8F[#AM96&X7DA'Z-:X:JVR
MM0E7,K_<M^NA:9KMD]1J=Q=9925V:G5L;[7 D=S:Y2J1$'$-T=ILPZ5JURU>
MT&-*1GDR-?'U3B"'V6"VWM$M:N\DL%!#09A)715%).N:P9I25N64L-"(%D*%
MYAF";JJK[YEB82HH:V8NQ54:-B)(Y:R2KHUI)8:F)\NEH)Z:KGDJFFW-X)&:
M5P6++8(_L-=3ALQ_T87,I)'IL:D3G9HEOE;O"F*U\L<+LQQ%$KRN<_:%$ACB
M:U;I7D^2G',*-:Y*R#43:I1BC-;#20?#$K6?D3>D+(8(W<Q9JTD$=1+74T>7
MRM49<E)(L,IKD+*L(XS*@(=U)96N([OC'BV(SB60()<N5)9(8Z6=JQ>!6M.A
MD04K!6:0B,%B&53I87:P-Z;/1GWPN8WPEQL[&#ZT;K:2VLI>EDWE\>H2/EP+
M@KYVD;(]#C6AN*I;TCS1!W$UL*E=24AEI35&2F4(0=&B@ZP=O\JHWJTS28[Z
M9E6T\*TM-+>*BI4I',]2)93O-'ZT@?@7=[VAIVX;G&0=B<PJEIY,O151J*FE
ME:JJ$W9*N=IK10<.(E0PBN@FW54'ZR07 &+UY.5RZMB8/:F?7"3Q]*SWC8")
M)$TK<]%+W4IL5MZ%V2BYI:2"B0K,0.*:I14TJG9.TN'O3"]GMDB0+FA-T>5;
M19=G%9F%'1<<R9;*T,[R1<.-W61HR8V+%K!UT$BQ&1+2Q!XB'QH<SR"ORFFH
MZJKX(2M4-&L<N_(ET#VD7="WL;'<9PK H^ZX*XQTWR&NFF._7KC<0QJ.!#/?
M/&]MUN-?ETY?D.\8TOGSV_+!L.^_0=1SN.0#<0TVQ@/ -1_.WAW=VA^)OK?#
MSY\_/!I]NN0V .G30,^(  ]N(Q-[_/X]NODZ6UUP8P AI\>O<<[Z@.HZX\>)
MUZ7[NMM3;W_OQ& =\^6X[9ST#.!S@,Z_?P'9^6MM3V<AK:_/QP\_=YZ?AA,#
MK_&V[_;D-,ZX  TTUW#A\.SET[>7Q//7 ^1V84<" AD0SKGI\]L#N(9ZCP\\
MOO\ )[.6'GOPF,:!U[= ' >8AUSC'D(9 ;GF3UY]2+].ENR]^RX-L+]U_P .
M?>/Q^& ,]1$-M\::!IKGKWUQYB(B+:#6^O72U^1TOWFUOAAV?MU\^>W  Z:[
MXZCD<#KMVQOW  ZZ (L;?#OMI\;BWC\<+ZGIU%O.EL Z8Z?$,CKW'.VX].G7
M0/>=-.Z]A?KX=_/0XFWX]OY=?WVQVG^A3BZ6'>C-*?T5-%*RZ-Z9X^N)X!2!
ME0MBIKA9!-58!ZWLZ$\'+JH*$1II%0=52 >UJS\I^ENI>;;&:,\J.BHJ:,=@
M*O4OI8:F2=R3KH ;D  ?1/HX@2+9B*15]JIJJN62UKW#B%=;F]DB4Z@&Y;2Y
MWFS?D[ QRZY%JX9,)4OMY$8PPS:^BR7-$BJA3VK=HH8PVZ3L:"9EFIE4;9:6
M:ZC_ %R]8T+VM^/(7L3>B=T3>M>"U7(9>TE-15M53PK4U$\U/EHA>,5$:),L
ME69&IR"LTADHHN LB/$'65WC9UC(Z>K59JFF@FD:"*..6KXJOPG9HRL&X)=#
M&H6I;B%2KV9-QP&>V%MS^:3D2MKS3/4&N5SF3M0V)+0KF2.2"(3ZX=4C@4C>
M'DIP50Z27MM<@*D<X:4S?4CDD :KBS23HH:_N,V!_4+:WN+(8[V%%L_M/79)
M'646SM/<UZO+'-24O"J8HTW5G@R^M9HX'+AHJMZ.GB,\24YC5!%*TG-5F>;/
M4F:-25>=NK>K%(S'45 D@E=KF.6KI[&0;I1X%J)GW&,F\6WXPN3:B"7TC/+%
M$E=RVNW3/9:+L1TROG:VWM,MC=VY;;\QF=WF?*7FXJB4/297*9&K7F3FYT-9
MZ4RZ6.!#]#"[O/Z5Y5.K]HQ49=+G$XHY*M\PFF$&75E289:*"J$D<=,$IA"K
M"*$)ZO1SO=80T4YHHC$%3<O#5+01M4K3BCCC,E9!$)5J9:<QNTH>4R$%WWA)
M41C60JZ"=@YNY(##[*\N5V&<OD?MY")"R74A$K?[G6RM-)H>B:5)4%6QE%%I
M\W.+@OJ9&9W(4/CI#J&6MY8VJ4'O-*Y342HC#@Y%6ZVKS/-Z-VVDK*I9:*>&
M*BJZ^.H>1?6%F>:E957B/&=R.?B<.1X0I4765$*EI:#+*A5R2DI^'512RU,%
M(T2(QB,*1S!K[BR69H@I=%?F=4+#(CE7KI?H-<Q_2L:V(1B4WMN@XQ:W;N0A
M2O-OBF]U)C4O97I V*U[<WNC[=%@GUP%*%$N5DIPFE%'MQ-$RFG4YR E12PF
M1)Y8<MHHYZJ-F>.J+1F6"6-W57=(Z.2FI5=E!/JU[8V.7>W%42;AC1ZNH:.!
MP ].%8)(C@%E5GG26<@$@"8#4<^=O_-+\.1%&\G5QBZ**792WW4A+@;@/:JD
M+?7!GMKIKJP%0T(U+@]5%TY$*:G T<9JR/J?H@J'#YU3Z[B^ISKV*[&=#UYL
M$77_ #?AP/I'@5X<LF-M\^L1:@DE;1./@WQOKRQR]DCZQ8;#IG.N.PCC8=L@
M X#MIM]$PM=%(N1I;74W'+37MU[^>/"I!:1AV'W>?']W3AZ'OTIKF<N@_)3S
M)K7F0-#NX-\9L#<XHM4Z22(/)]5*1C@<@,)*5+5T>-KJI11A\,H4&1X#*6-Y
M]I$JDAT9\)])GH]A$=3M+DJ1PF,&?-*+>5(W NTE92@[JI)K>> &TNKQCB;R
MR^P[![:R.\&19JSREB(J"K(+OR]FFG(!)  M%*>0LCFP5L=8$><%]9S@R.XD
M5NC10D,K/(KI$M:A7"II1+0*]:HQ.)PHU!9A)N*J#23 IJ-* LXSP''LG+&M
M[FQLS&>8#GMY.('<"BMSM_&[5\PEQWV)'5U_1$V.8G^S2)NCK^EIJ IS9*'I
M<ROC@U*Z#43B6RTHEA)J8\V@>^V>S2?)]D=IZNC(2LJ,QR2ABJ0!Q:02PYH[
MSP/SBF,220I*A#IQ2R$$:\-G^6P9MM3LY2U=WHX:'.*R:F)^JJS'+EJ1PSK>
MTD0E:*5XV!23A!7!&F-E+K$XN^QM7#GF.LCI$E[;4SK8RO:T*MA5--97L*FT
M]I/(K0&(1)_@O=:B!) L H"@   XX9)YHY1/'+*DZOQ%F21EE60&^^) 0X>^
MN\#>^M[X[22""6%J>6&*2G=#&T#QHT31D;I0QD%"EM-TBUM+8Q)Y-D3A!3N8
M.P="AS70JPUYOJQ:U4Z&*E1K;;R7V_A5RF>%EN2VHU4XIH,JESC'VTY0H4&I
MV,AH;_:>S1E@&[SYUJOHS,R$6HS*@XM:$ 7?JX*FHI)*@JME5JE84E<!0#*9
M&_I8Y_9Q9*5LWRJ[M2Y5F7 H&D+,R4=124M;'3;[7:1:5ZB2&-F8D0K$A^R,
M)>E$CC/-KRD3&-EEI9E/%]S[63.A* 4'R2UZ*W;].@^EZ:<"H2Q&9L<?7-B@
MS(H5#TI3T5!2Y5EUX]&S297FL,ES# M-5P[UB(ZEJF.G.Y?53+#(X<#1A&I/
MV!:C-%6#:+9RI@&[4U;YAE]5NZ&:@6AGK/K+?:6GJX8&C8_8,K*"!*P-SY5?
M]?'.?_\ FP>__P#'K-_CSXM9C_-97_\ =R?^)J?QN?"V)V>_NS:K_P#R.3_]
M*RK'OG#1IVUDLQ<9" $S*W_,/9VF+*"0"A>M33V:-5NY=&BCJ0]M4C?HI)G,
M%J2BKV9]2!*<;35[I1C%IB;RQG5)(9=X=Z(9$/B&46/?;KAM0JQQ937KI546
M>Y4*8C1W6NK(J"J@!Y[LU+4R[ZWL=Q6(N@(]-1I$<YW[DDI:J4C;+.6.W\RE
M5-.*2C7N*W"F\:;'=2 !D5%<>4&-X&#FJI*T%%Y$":0IM'6)==1(P ZVW5/W
MD^)\,4Q$0;89@JG=BJ=G:"JJ!?V>-35]=!'*W8Q@8H3U6( _9%GA*X';?FCB
M5K[D,LVF[$C;R39K;BX%O'E7"Y$0@E3$8W*3BSG-J,5$(G5H5"6L0+VXJNN@
M*2U)0 %98VR.8-P1<=X[?NQ>K,ORW:>ERO,8JVN@6(-6Y;F&75#T50J5=.T3
M$-)&6W)87(:.2/73>72V&/R\.$G9;R7\M,Y74EUUXQ!&:T3W''><+(T[2)L6
MS1'-*G]M/>(VPL!:Q*%3 VF)R%R4U0E'VH@:/MS!JH4G>8$D@6M<<M-;GK?X
MXUFS<U7#GFT>32YM69O29?!DM12S5[TLM3"]>E?ZQ"T]+3TPD0&FB*+*CR(=
M\ESO8REETK8X+%I#,Y.KK01V*LSB_OBXM*K75I&IJ2FK%RFA&@(4K551*<DP
MP"$J<X\WU?4**KK$*1B65(8I)I#NQQ(TCM8G=1%+,;*"QL 38 D] 3CK:RK@
MH*6HK:IS'34D,M1/($>0I%"ADD;<C5W;=12;*K,;6 )QQW<^'/E,^<&9^X(
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MPZW-CIJ1V&UASUMROA@SG&P>'Z\X#?O\]@XC0$7L1J;GY]M^1MW]HYL&NFH
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M^Z^#OT$<!G?.^WB Y 0T  #.VG#N[+G[ORPPF!# :8SOXZ],XQ@, '300QC
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M1X=VNI[OM=+"CR?/[\59[>N2IT*I4C5)DCF2:J;E)Z<XE.X)B%9Z ]0A.KH
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M(OU!*YB<:A3N+:O1**:%28/:@!J4ZNDJJ@PDVD:BU!5)*L@1HJ$"_:=X.O\
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MJAADDG;J]+ ,M>YQ=:E>7=O8;HJ6V;NS='@UL"0-5.9)9FCED/ 9PL?M KQ
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M"T;=07[6MR425M3H*2PW,J5'GEIZ2^OKB:%(AUZ\:44\[-NK!,6ZJ(I&:_\
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M1J;@ J>\8^E<KVQV2VB@(HLWH)A,A26CJG2GF97!62*6EJ@AD#*Q5P%DC<7
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M3M0?)2JX0WEHKC)FQU.*)D:U#2QNSR0VKVQ*JK17#L_&IC7UN0M/,D$'\B<
MR/14E8IJ29CZN@%4$>PD8;C. 4#;MX["1K+3PG,ZKB5U7!0T)^AY5035.49=
MFT39DS58.7Q*F8"&;V:B2/@RSK')%'(5\2'EUB\G64TV^DBM*_E,=G&LZ%&1
M8\4KA.;B6!<;CL+1&WP9,O7/*^8/D,?&8XM2QM-""4R1B0M1#JT'*%S=$^40
MS2,*2=EE6.AC-.824-34Y>:J)(Y>,Q=IW@D0EHTW998U4.I+A5[)T5;+NY76
M/'5BGR6 Y<:)A'+F.8[.29I3P4U2:R1YI*V>BGA.]!$$JJJGCA66(LZ-VWMI
M+=H;C7?BMS'OZ1C=N8,I3NDG:JE21+'ID[2^!VP!]**2GG5OC7 IE.:UIR:F
MOV,J;& ZHLI+2X%T$6*.@I%JZ^&KE+PTE.0\R701U$DM/2\3<!8R1T\\[$CE
M,D=["X P\JR+*8\WSVAS>HXU)E67.DU9"7C2ES">LR[*A4A4<F>#+JVO9V&J
MU45.3NH)%W9+26,MU#6N%HY9'G"036(/5QD-Z2TI[W(H\WN[E;HN8VW;UK;"
MG1O>E,1@:-D<'BX"V+N220&"JE"8HU6GCB%,=FIE5)3)3K41--40R5*UX7BR
M1"1Z7UBD5XH&1V@IU1GJ#$ZR$F0 D(!C<Q[,91009?'6TLM9F%%49I'GXC-3
M54L4\N5BORJ.2&@FBG>BRZ."2?,'HY5J7+U*!G6F5,16OM_'F6Y=S%2^,,1K
M'#+8(+FLL0:7F7+HN^!)6J%!'#$RQ[H8)X1&ZC9PCF-3&]U)9,@9T5<<>7$]
M42K=3L)Z2&.MK6>"(Q4U&*R.F229H9.)'3B,AI E2L1,XFX4MI$5>&[,06;2
MR9524V=9R\M%3-39=DR9S34$,U;)15/K,.7^JE7J/5\Q6D+9@M<U-4,E5'!&
M:6:5V5I6OCO;*+1F8W8<$L#,E2"!V^@$GCL)6K9+2T+S) W0*F12)Y/:7-ND
M[HP,-<A6JU2!C?6H\AP=&E8I6EQUK=&]5>DH:>&HS"1:0S+34U++3TK&81.9
MEIQ+,S(XE>.'BL[(LBD,Z'>$:LIOR9+1TE=GDZY6];'EN6Y;6467.U8L$YJ4
MR\5=5,T,B54U-2&I=Y(H*F(B26)FD6GBDC:%7F&NLA5K7Y!&8K $IZAE(*@_
MUM(1.Q1CJC:*DJJ/16;2=?<1U9W;Z23NC>HH^FB*DRDRI.XJ$B,PPK624KS.
M94IX*-6,2BF-0%ENXC ,4%1,U2RR\0,I D 4G=8[IQH*C+9JN5ZF.BH\I1Y*
M9!EAKA'4!IT@W)*6BS"IDS.6"?C+-$UIQN.V[*Z(2,LI-8BS:24W6?68FLV"
M/##=^/68C=,E4*7MDN3;.+39\?SGDRFNM8XM4>/@J*M.B6UTU+FZ[ENEAJA<
M*=W3AO),KRY9ZV5-::6*MAH(3,Q>*KI(9Y)3)S=DB:G4J&-BM937WO:QV]7L
MQL^E7G53!KEU12YS2[/TBU;O/#G&54E=/5&8DB22&F.7J422^_'G&7.S-N3*
M*=RM3;IR7QML9+=-K,QO;S7;!R<719<IEN%"Y'((@6_QQVFK+(EQ\7=7IN6,
MR]^,?H$O/ABV+*G)N>8LQ*G.*J4E4E!1,88THE2.5S1L[O515=/+)3F:-YH9
M6,4DB/$TAFIW>!H&=6C0O"539'E$KT<5/E$,%-53MD\TLS9M39I0551EZU5-
M-6T]9(U)-40R4\E2:O+Y9*%Z-YHIJ.$S4KIK^'IG7(!C0>H?#;;KIY8XY'6Q
M_?O7Y:ZCOY VU',G'E.-XGHGM>7ST@.<_P"L6#;;Y^K]WNOGUX]-]'GV<VMV
MT'^[5#QZ=ITY=_U#_!S_ )C:[_6Y)_N9KC;[R,A3]1E>>X &_2NCM\>_GTX]
M'',CN'X_ECZ6-^GW_L...[TU&OI,>9<!ZJ;6?_XE;?IM\,^.^H?7?HOM_$?)
MM.0K^W_*=7U([.I_9CYL](/]]>8_Z%)_X2'XXU:8[?(<CJ&FH@./O'3.X:=_
MW>;&Q[+^_7NTY\7A-,:8U'YY$ JQD0S\,>&NO ZBQ[!^SY?,D]3A;M&G7SW^
M;XO=4DD9ABHTU^>S#5Q[<J6UUNRZNI8I9Z1H:%"JJI0-1Y[51550VFG#74AI
M&H$M105#FQZK2@(%IX J+*B*(8PJ+-_/!5"[JB;G(JV5R27!-CB^*FINQ]8F
MN[1,YXLEV:$6B9CO$DQ#^;))*:;MK8OKI<VY+X["_OEPIP\/M3BE=Q>G66/S
M@ZU.R%&#<A=!<5:\Y74XHV_*%(M$[WE.BPD*,H(_0"U'EV7PQ<&*@HXX=PQ&
M*.E@1.&S\1DW%0!4+D,RVW6?VC=M<77S"NDD$LE95/('$@=JB5F#JA17#%]X
M,$)4,#=5)"D D8; NSJ+@E=:G-P%S04MM*)RJ7*17HJ6=.G2,]*58)GO*>EJ
M2(D:5N HVBE"G2IB$H%ED%TTW^##PVB,49B<R[\1C7A/QF9I=Y+;K<1G=I-X
M'B%B7WMYKV#-*9%EXLG%3<W)-]N(G#4+'N/O;RA JA+$;H4!=T ##O,NS=4Z
M7E7#/N;<$V?IR?=D\Y,F<CKEY*?W:M)[$F3U.-3T60"0TU,!=*T"P3&&$^J!
M==5(XWT9EOJYHUR^C%&6#-2^JPFG9]Z^^T&YPF:X4W*\P+=N+_TA7\=:KUVK
M-2J[BU!J)C,J:C<$A??"V)]D'=L>7/#8-D<B. :3GY[,IJ1+&RH#71<8%38X
M.)SNX-]7K'U4BA7.RE2ZK$@Y(5.)YRPXNM2;6;5D"FIQ]F&$6=);K$@/$CC$
M43_9'MQQJL2-S2,! 0BA1:-34L26GF8E70DRN24D<R2*;M<J\A+N.3.2S78W
M-T?I].Y76)LIFLNDAHM#>P"9()(]/)@L32>6K:V2JIQ6*!%H;%192AO;<BC1
MGET')B2C:*:@MPT-%3 "GI*6"TKS#@P11?72*4>8!%6TDB$H[@!F4[K$@VQ5
M+65D]^/55$]T6,\6:23ZM&WDC]IC9%;VE3D&LUKZX^KA<6X+HA;&MTGDS<6Q
ME;/H1F;ETH?%:%H90;W)J!H;$BA<8G0-GT4\/#;[@EH*2 @=G)&!()EZHLVE
M,OH(WDDCH:1))9!++(M-"KR2<1)=]W"!G8RQ12;S$L'C1P=Y%85-7UKJJ/65
M3JB<.-'GE95C*/&40%RJKPW=-U0!N.ZGV6(/S*GT[(:'J/$3:7$,$D):4TB8
MBI*\E,[\0Q)R$C&0]-E"T$3H4RI4J9,T%+B#J&XA,02CI)*)+IIDT%"98IS1
MTIG@:1H)^!%Q87E8O(\4A3>C:1V9I"I!=F+-=B28%;6+&\2U50(I0HEC$T@C
MD"*$42)O;KA455&\#95518  69>_/CM2KI<WEV<:5KF:\K*5[BL5@L>#R_9F
MNRJE0<8![D?0(T&+S?65&4"-%9M5(U -Y(((BAAAAB,<0B3A1HFY"IWA$@4#
M<C4@$(+*"+@:WQ:>>:0'?FDD#N96#NS!I""I<[Q(+E38MSL0+V&'2%U;H [Q
MA_IN1/J7Z%H"VN&O?UPD(.\3;"J#"BFZ,N0./OC"A**--++1-1R1,66:90!0
M4UU .-]&9;PIX?HZAX54YDJ8O58.'427!XD\>YN2M>UC(K6(N+'7%_Z0KS)#
M*:VK,E.NY!(:B8O"EK;D;;]T0C0JI (TL<7:)7JN9#"Y*D;)>_J&F9-DX02>
M/.;V]JX^^JI_"I# WM_=6>AR(1N4F)9).XFMCRNH4J4KF"949[R6480;:JLF
MR^KX#/2P))3/2&":*&%)H4HZF*JBACDX99(#)"JO$I"\,LJA;@B]39M74K2[
ME3*Z3"HXT<LLS12O4PO!)+(@<!Y0KEE=KG> )O8#%KINS=0M9&7&BYEP2W&%
MD$)X<OIF<C!;$4R1**%*1&E0.7MV$E.CJ%(04U&)"R4HBGH"DG- W?HK+"LZ
M?1U"4JB34J:6 BH9FXA,P,=I&+@,2^\2XWM3KBU](YAO1-Z]5[U/I WK,UXA
MN[EHR7!C4I[/LD>S[)TN,-LZ3R52><I42)]/4GFOIYZD]V7FJ#SY.GJ1R8XX
M\Q14:89(4E525\,KJ&IV3UU$.%1Y0^SXOBDI4 "TT"J!  JPQA0L!WZ< ;A
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M_B?=^6.U) T'+77J>OX:6^&-S,%@K+ V1,T-*8HH"BJ*33:**::C*@I !R(
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MFJ8)5:*JI7=5=H9 "KJ'CDC>['$LWDAO;[95*"K_ $)KN6X75N=<5QE!MHG
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MFBW@(I9!$CR!"D3E:(6>YZRM92C2S=Z3N[JZI3%K>FDJU%('.M,:<Z5TF>Q
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MTRK&Y<[FJF^*O*4@L4JP51]9ZPEJ<D1=1I92@_V!Q91U8CE0TN9HLDD,=6G
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M7IWE+!I;L\98'<C4%0N11[9T]#'EB09?F#KEU;25,453G/K$=(E()@RY0TE
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M$U7:$A$Q4EIKJ* C#6E+G;V*^6O:IQ35>Q;C/HU)2C5TKJGAA45+!7"Q3")
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MF=3=AR1"(2B?RAAA,(8'24RR4NJ-DCL=8T9K@ZO#LO-H(2(4*1/348<<<94
M"& HHH"HTRJ@JFNNG&JJJGHJ>:KJYHZ>GIXVEFGE;=2-$%RS$GH.0&I-@!<X
MOTU-45D\5+31/-/,XCBB07=V;D /&]R= !<D 8Z[^4#E MYZ+>WB6X%P4K!<
M+GBN"PU>Z)0$MT8;,L;F346<VM9Y=7Z1U6*TL@?TIA*R2J:3F%C-3QLAR<W#
MY6V]V]J-J*@T5$9*?(Z=_JHB2LE:ZG2IJ1V B\,)TC!WV'$("?1.QVQT&S\
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M8<8NC9=3I!W%0B:G1-"&V/FM=,AC2L]J8V-X(CWT6B-.9V]I=RTE3<6B5<5
M5*LR#B!G&^XWM'&OM$WW6U8B]S8DCG<8@\"RL=RR^RIMJNEPHZC07 [!?EBX
MM%O>4&=JZVICB5DY0MFJ>B\M2!N;(RXJ)"0J=7Q"-QJ$Y!9E:JHU[D4B1*)
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M//L(T!\?"]L,'3KO\-OU?KZ"(<1U/9J;VL;&_6VM]>AL.HU(8WB^B>UY?/2
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M+W'(=>W7M&IU%KC0'XL+D.P!X?'4:>P^'8!XBUA<'KJ1?W^(Y:]^O2S\?GA
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C:(9'&P!@>M(:]QQKIVU>^_GIJ?WWPY^&H[#S[1X<O>>[_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g937421g67y30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g67y30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>84&AO=&]S:&]P(#,N,  X0DE-! 0
M    %WR^8!(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             "0
M!V0          0                         !              =D   "
M0                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M0     !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   D      4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   !.$))300,      V"     0   *     Q   !X   6^    UF !@  ?_8
M_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,
M$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  Q * # 2(  A$!
M Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !
M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M$<@V,_\ )+GK[3USKQP,BPLP:7/ I:8WFKVNG]Y[W_YE/\W[_P!(M@?5OH0
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M.!TK+SJ>FTV6XU+[6,()!+6EPWP[Z'[ZET[ZG_5]F'5ZM%>;8]H<_(<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" "X ET# 1$  A$! Q$!_\0 'P !   & P$!
M  0%!@<("0$#"@(+_\0 :Q    8! @($!P<+"P\("04  0(#! 4&!P 1""$)
M$C%!$Q05%E%681<9<8&5U? *(C=35Y&3EZ&QTA@:(R8G-D9'6,'6)"4H,DAF
M9W>&AY;1U^'Q-3A"4E1E=K8S-%5SA::RM;=$161TI/_$ !T! 0 !!0$! 0
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MO/L3X.-_U(O"WN&P_J=L+;@ ;  ^YQ6^0 /8'HU\K<5#'%'$@'7&_;P,^O\
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MU6S'P_96.>O(T4R"62*&3DD0AUYXI'0E2#RL1GKKQ<RBAU,7TPRBAU-L@Y1
M#',8P@ UG#8[;B(CSW$0 =@W'< [M?0L8 W"T H \SH=P '[?N/J]6OR!MR/
M)PMLI=W<^^/BL9=F8X]R^"3@%B>G7/3IDGQSJ%E  *#3P$=M[!=P_P#\U.^
M-MO8&X<@[M5IGSNQ_P"PJX_CV?Z<_IC6)/\ UDVS_P!Y;Q_V?9=46 =FP!N
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M?S^G+50\FW#9_=;GWX_JN'U$_:OLT.^7QW"OW _M3^(S^_#]/5J'-TW?&B4
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M9M>416)]:OX7;</K.MY*^ JT1A'#\,W.A5Y;-J_/,V1@LKO9Q$_B&A$1!^M
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MY/P)V;[^YS9/3_C!_+V:@>1C@XC]LWKO^WZ_Q_VCW_H>_I9/EAXQ!^LV(_\
MW=<]O=^R?S]1_/KN#I[>.OOC\!\^8?N=63LY<OLA?3EJD^1K@X9]/>NAQ_5]
M?\QZ:MMY9.,E_L>P]<_W.N=W3_A37T'3V\=(EW\G8%[=OL=63NWY_9!]G9I]
M)K@[IZ>]=?\ 'Z_YA\_X#JR?+1QGR@]EL&23_<ZYC_O3/]&NXG3T\=)MMX_
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M],/ GD[L,$K[XT\C'"QP[]M<LAZ@#")7+G)Z?6]?9JS<\KOEKH(\MSA!*D2
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M]PD^V6_DQ^/[==)NA2JH[_N_V -PV_>!'?TH[?SZGW_3=/V,CZ C^JF\>_\
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MY^6[*G[Y68GU$QR1\OAW@2/WGNSCQUZ##=;JCU1 #;#U1, F*!MN0B4#%$P
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MJQY7)S(?--EA6('T39M2.[#P)6**-4/<>4,^/LCWZW2<+H5^K7'YB!GLHE4
M@YP"[/D>WE4GV=VJF/\ 4_F&S#N7B"R>&_;UZY4SCOS[! B>P=G(0'?;MU:7
MRN[D/[CT3W?V>QX?'J3PI6/]MSX_XD?J(]7MU##]3Z8<,("/$+D[EO\ P9J?
MT#;5P>6'<AW;-0[\_M]C_P /FU0>$:Q[KE@?_!%T^4:Z3?4]V&Q_NALG]@_P
M8J??MS^+;_7JL>63<@"/<6A@_P",6/5C]/\ RQ;/!M8X_7MCIW?4XO7G].GP
M8U"J_4\^'CB'4XBLF%  V$#U2JGW]&PE63VY!W@/Q:J'EEW+QV6B?@LV!_\
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MYFL12PQK"[A"RKG9+T'$_P '$4_N52QK07]9SS-0#Q\?($_?2Y)1R11X.2C
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MW-7%""63IR&Q+#:EFDB3JQAC:'M'Y1([1!XI-J2TGPH<*<.WCEGV"< 17@"
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MUL=E*\3LJL[3;2$OJ@CB8:MBUZ3X+(4UZ*4$E#IS608YN+L ZIMJ:XJSV93
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MGV[;>8 ]BJ1HURPF<^G+VJ5D=<%52RG=)KYU\MO$<O;4N&*\A2!88]SW/E;
MF9Y)%HUWP?K(>PEM2(_HL[U)!UB!UL(Z)3@&JW#%A2M9:N,"@ZX@,L5QC8)N
M4DFH#(4*K3K9O(0]!B"+=88MPFQ.V=W!=$J;Q].K+QKAPXC8>,(3BO*7QG8X
M@W:QME68KLFV3O!#'&V$NV869);LI'[8I<,M4,2B0A9%59)9,]OY,."*W#NT
MU]VMP!M]W2ND\LDJ_5*%6=5DBH1 _M3A"C7&&'DL%HV9HH8@-ONO,->IZ:::
M::::::::::::X$Q0[1 /A$ _/IJ,@=Y ^/7G:XCNB SUFWB6RCDYCES'*5*R
M!:I"T,I*RNK0YMT.TDUA51K9H-K!+1[AI7$!3B(@Y+*@BK$LF.Z;0_A&R7JV
MT<?;9MNSTZ3T+9LU85A981 L$A0=9>U:4.&E/IR#L20[-U;ZX_ WE"^A0XVX
MS\HO$G$D'%?#Z;-ONYS;C%8W&3<Y=VJ1V&YEV_S*.DU>2';UQ5J,-RC5JL4/
MH0G,:SB#Z!JM)MB><O$I,/'8E)X0(+&["-;E-U0ZY2&?W&544 IMP(H8J0B&
MPBF7<2ZHD\ITY/U':(E7P[2V\A__ *8(P/@Z_#K+I?00[6L8]T?*)=GEP.;S
M+A^O5C#8ZX[?=;C$9[B>4X'4=>EIN(7HA<@X7H?EW!,POQ%-#2S9:VXQL, W
MAY86C9NZ393U;<PMC8RSUXR4<KMWT;"2,7).VSE(2I2J"!VB>;M?'E3<;0CW
M-%VEA&RP7H)2Z LP+Q3++#)&%8*I5I4=%92<H2#KF.//H5-]X/V,W."+3^4"
M!K<4F[<,[E2CJV3'%%*L-_;I:6X5K<DT)EDCF@I6:]F:.5<+92-HAK%-A+*%
M7EC-GG#[Q0T"75-U3*1E?LJZG6ZXE,DQC5Z-!/E&X'^M0!6R/5!+L!EUA'P@
M]C[I4IH\C=MDM18Z"22%?#.7=;,B\W<6Q"@\0%Z8^<#P7Q)MEMDDX \I^PW#
MWR4Z.Y2G(;E*05WV.E/V0)98RVYV&[LN^23E)AC@4XG,U3(UI+'N:*G6+4C&
MQ=GR3G 5:?%5NOM9R)FW3^,J<N1Q.V6:(,8",$G'NSHIO''7<IM6XJR3+2;C
MQ+LVWQB7SK;9I8&>2&GMGZX>:5HI(E5[$?+%#'Z8,O,.8JOHDD!&].X/\B_E
M(XON-M_N#QGM>W[JE:KN?$/&S':JVV[?#>JW9)JVUVTDO;E=S5*41 _9QRRA
MI%2,M9ARDX\^C;L6-+5FWBKHMLK\AC!_ Y!MULK<TYD&]RAK#=X28BI$(<$8
MYU&3T8\LD^64\*YD8=VP;.UV@-7@,DW+K3<,\7Q7(-MV.S!*MQ)JD$$T80P2
M15I8W3M,N'C=88^3"I(K%0W,O-A?2?+;]#U?X>W7C;RH;+NM";ARSMW$6Z[I
MMMR2Q'NU3<-ZH7*U@4^SKS5KU>;<;WG/-+/3E@CE>(1S=BLDFDB1#]RZFAM_
M&#E+E_DQAKV=N_/L#G^7T=/ZX6O\CH?]?N/Z?@\?C2S_ +E=E_Y1\5_]U<$Z
MH0?;L/9N'(.0#V\Q[.>VPCV^S<!S-:#7/,.0<]MM@W !V#D/L$!_G[A --->
MGSH)/L%YM_QO,_\ R3 =N_?].W7C'E,_KIM_^0'_ +1+K])OH)?]PW&'_*]?
M^Y-LUO.UYMK[2TTTTTTTTTTTTTTTUI+Z7K@FK.1,6S_$W1(9O&Y0QI'DD[SY
M.;@F%YH+0R:4F\DTDA(D>;IK0QII&7.7QA:NLI2,=B[%"%*P]&X"XCFJ78=F
MM2,]*X_)6YSDUK39[-8R>Z.PWU,Q]%$K)(O+]4Y_DCZ*#R1T-^X;O>4'9JBP
M<1\/UUL;OV"!?=C9(6469+"C"FWM4.;:6C]4>C#8K2=KRTQ!Y7>6W<(CV (]
M@?D]O/</SAKVY\EOBSZAWGXA\VOS4D #=P)P!W] !X_'[3[.O76PKHUN*F0X
M8.(VMFDY)5'%^37L;2,D,3F#Q-NVD')F]?MABF,!$EJE,/"/'+L"F5\WW$^T
M23.H\3$G)<8;(N\[1-R)S7:2O9IL!Z1*CFF@/K$\:D*O=VHC8D!3KW3Z'SRD
MV/)WQ[MZV;#)PYQ'-6V??H21V4:SNT=#<SU 5MMM3"227!;S)[L:J6E4K[3-
M?/&OUNUHXZ8'(3HS_$>*6ZPE9IM);($J@ CLNZ665KL"H8.S=LDA8BEW_P"U
MFUZ!P167%VZ0"V4K(>F5  ED^)LQ_P 77+<1S'FK5QW -,W7Q/H)T^#M._UZ
MTG\^W\^WL]/PA[-O9KO^G=^'V^KX#[<^W7,:W)=#P[C"77-S!44PF7-6I[MB
M!A#PIHQE+3*,J*8;[^#(Z?PWAA NW6.AUAWZH:X7CA7,&WL,\@EG5O5SLB%/
MCPLF.I\>[QZ3APJ);2GZ\QQ$?\56<-\A9<_"-;Y=>=:ZS333333333333333
M3333333333333336B#I5<,97LF4:WDZOTJ<L%#88\A:R\F81L,KY-F6]EL[Q
M5"08,A7DF2*B4PP\"_6:$8+*K>+D="X*9(/0^#[]*&I+4EG2*R]F254<\G.A
MAB7*L<*Q^IME02PQG '77)[_ %K#V$G2)WA6!4+H.8*P=R00N6 /,N"1@DX!
MSTUIM.W<)+&05063<%,)#(*)G(L!]P*)#)& % /N/]J)=]^6W=KNN9< AE*^
ML$8P,GO[L#&/9KFSTZ'H3W ]-;&>CJPCEM]Q&XYR:WHL\UHE/>6%:?M$FT-$
MQ:"<G2I^);(,E9(6RDLZ6<3#(@MHI-ZJDBN#EP"+4#+EY/BK<:7N58IBQ&UF
M9H.SB0\[8CLQ.[.4!5!R1O@L5YCZ(R3C6XV>K8:]7G$+B*)W9Y&'*H#0R( "
MV.8DN!A>8]>N!DCTL:\NUW&FFFFFFFFFFFFFFFFFFFFFL3>.^'E9[@TXF(N%
M356D5L.799)% #BLNBQB%W[U!,I $YS+L6SE("  ]?K]0>1AUO\ A:2.+B/9
M))<!!N-4$MT +2!5)/AAF4Y\,9UA;DI>A<5>I->7 'CA22.GK UHYZ R0B$L
MJ<1$4N9$)Y]C^DR$60W5\8-$15BEV\\9+EUO D>3-<!?8=NN=OU@ 0((^H>5
MA)#1V>1<]BMNTDA'=VCPQF('KC/+'/CIGHVN?X<9>WM*<<QBB91XE5=P^/8"
MT>?A&O3QKQ#76Z::::::::::::::::::Q]RU@_"T]6LAV:<Q!BZ9LCVL6-\\
ML$KC^IR,V[?(P;HJ+QS*O(E9^NZ2*BD5-PJX,J0$DP*< (7;>[7O&[PV*%>'
M==RBKI9KHD$5ZU'"J&9246))0BJ23E0H!R<CJ=:VYMVWRQV)I:-.29HI&:62
MK \C,(R Q=D+$@  $G( &.X:U><".'\3I\%'1W95F,7XV?*-UH^+OU@E*367
MLF]:7QM=J=6G\B^<QBCI^\1R:^QVBB\=K*J,$%5W15$P1$Y?1.-=UW/WX<=[
M;%N6X(#VDE*".Y82-&IO3M6$C19 J(=O2\2B !R%4@YQKC>%-OI-PWPO;>G4
M=@JBQ(]>)W<3"Q#$SN5+.ZV6KX9RW*,D8(!&\77CVO1->([I?N&&>0Z0[+<^
MQ!I6J'>JO0\JR]QFC$95R!1>P#6HS0BY4.DF^E)&SU2160C4%"JJ/YAH+]:/
MCUE)1'Z]\EO$<'O%VN!N>Q>IV;NV15(1SV)RD[6X?14%DBCKV8PTC>B$B;D$
MC@1-X!QML<QXHOS)RP5+$%6_-9E]"M"IB6L^7Z<TLD]=RL*9D>20$@(6<:U7
M&6Z]C)-6$P.P!L]!,6DGEB?8(.K;.B517Q@:^R?MS-JM".^N9-- [,LDY8H1
M3AVTBYQJ]<O?0$VJ?<")M[D+)S<\6UP2,E2#('+V[HW/:G3H2W,8UD:1$:2%
ME5.4-^"B.SVF,HP'+)N$R*UN4GZ_L58,M6!AT"JIF90AD='5AJP$Q-3%B?*R
ME@EI*=DU" 120F)!U*/CI%WZJ:CMZJNN8A ^M(05#$*&Q0*!>W>Q115T$<$4
M<$8)Q'%&L<8)\0B +U^+OZ]>[42.\K]I*[RN05,DK%W;/K=R68'J<%OCS@:[
M$YR;38C%IS,J2,ZHI^3R2#PK$2&,(F3%H"P-^J.X]8HI[& =Q W<,,)<2F*)
MI!U[1HU[3)Q@AN7.?@ZYZ#'702/R<@=@F,<F3RX/+T"CT3UZ_6]_3IG.M@'1
MG9,=XCXD\+6EK).8MJ[XH>'RG31FSA1LBX@K[ 9QI<JT>$(8B;AD=O/>%.BL
M!T@.@DL  J@D8O$>4+;TW3A[=ZQC61TX<WRW#S*&99J-C9;<;(2&97#0E<C!
M(9E)P6UT7"EQZ&];;*DC1QOO.SUI0K<JM'9AW>LX<<ZJRCMLX;.&"L%9E4:_
M06U\.:^G]------------>)'IGH]Q#=(Y>9"T)JJ0,Q XCG6*:A3&*M5T*A#
MPKX$"CMUD32T%8$1 @@ KIK%W P&$/K3R5.LO M)*Y FBGW.%SD=+)MS3)D^
M!$4T!Z]RD'NU\B^5E##QS?>T"T$L.VV(UZY:J*,$#\N< *9J]A>AP65CT.1K
MVQQ[EF\8,G<>JBNP=-&SEBNW,4[=9FNB15LJ@8@B0R*B)B'2,01*)!*)1V$-
M?)KJR.R."KJS*ZMT964D,&!Z@@@@Y\=?7",KJK(0R,JLC*0596 *E2.A!!!!
M'0CNU%ZIU5IIIIIIIIIIIIIIIK3%QJ=%YDKB@SG+Y<K?$&E6HJ7AX..1J5CB
M)N01K9H>.0CU6\"XC)A! L7(*H*3"K<S)NJE*/Y%4RCD%RG)Z#P[QG4V7;4H
MR[5VSI)(YL121HTW:.6!E#QD\Z B,'F(**HP,=?D/RQ?0V<1^4KC2SQ5MW'J
M[;6M4Z=9=JW"G<L)MQJ0+"T=&2M=C05K#JUMXS#&RV9YV+2=H"OGHS/C!M@K
M*EYQ#=,AY#-9J%.N(.2<1]'CE(U^4B:;IA+1BCS*[-T>,F(QRSE8X[EHU<G9
M.T#+MT5143+ZGM]Z3<Z5:_6I4S!9C$B![3!T.2KHX%%@'C</&_*S ,IY2PZZ
M^#>+^&:_!/$V\\*;SQ'Q'[I;'=>G9>OP_6>M,.5)8+55Y>+X97K6ZTL5FNTL
M,,AAE3GC1R4%L0=TT.W(>3]]NT:'#; '=O\ NP\M^?MW[?0&;BW]HT?#^VY/
M]7^'Q:YSGV/^$O%'A_O>I?[9^'3^CNZ\BZIN^_NB9/V#??\ :'#?E_=@'?M
M?O\ PZ8MX_J&CX=/.W_U?X'^CXH[38_X2<4?Z/4O]L_#\'Q/&Z: ;>Z'D_F.
MP?M$A=Q[0#^.'MWVY\]MQ[.YBWT_6-'[[DZ=W_!Y_0?!J>TV3^$O%'^CU/V?
M_P Y?ICX-/&J;MSR'D\-]M@\Q(8/S9@W^'M^(-,6_M*CC_*Y,_)[G_TCQ]F8
M[38\_P"Z3BC'K][U+^;WYZNMC&DEN<;EF>JUIO<VVQMAV]W"QH3=281D8$0[
MC2TU$%'[/(EB4(Y\IVEBY01&+6!1!J[5,=!-N=9/ NV6KR4(K%:I$;FXU8(3
M%8:23M%?SAB$:I$.4)"P9NT&&91UYM=7PSLL>[UN+;^U;MOM^/AW@[?=UW".
M]L\%2KYM/5]R$!GAXCW)A*+.Y0R(AJL&2&5^9%C+"S<A]B^F[!M^Z%E'D/\
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M"(" @(#MK\]9HG@FE@D&)(9'B<'H0\;%&!!ZC# C7US&ZR(DB'*R(KJ1W%7
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MQCEUSN_<66.(HXQ?V[;5F@R(+==+<=B)696= 6N/%(C 8*S1R*O,SQ\K^F,
MJE.5R#<NU;%1HJ\(K()IMFLK,VJ%38*E.)CN$U*M-0KA=14@@D*;M5PD0H=8
MB93[FUV]J&Q,J"O<EILK'F:.&M*7!P.4BS#*H"X)]$*Q\21W\W%)%&29:Z6
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MG_EXOS76?'"-TAV4N#:HVJG8YIE!L4=;K(E:)!Q=4+$\?-WR44TB"H,SP4]
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M)U&/^$'(M?>=2YSE.I<4PAKA8+589UY.'BJC$U"_&QN=:1+&0$A(2;BRV([
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M4:*D->O$OH0UJ\<5>% $BC11C5#!^4>8!\7/N#LW^#?M$!'EE:TFOGM[>?H
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M5N&[;ENCB3<+L]H@DJLC_4TSW]G$H6*/X$11KZ&X7X'X1X*K&KPMP]MFRQN
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MH81GEEVJ<DLY4L2J#%FW/'.$Y EH5 TIC69 !#!*799,?5^P 4!49OKIUZD
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MRRI',%$T:2,J2A"602HI"R!"25#@\I)(P=&C1F5F1&9"2C,H+(3T)4D$J2
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MA/8<8::0*1S2,.A8]3K"N;%LVXF)K^UT;9@C$,)L5HI3%$#D1Q\ZGE0'KRC
MU>NGTVI8]K$+2J)68*G5"N,B1T#6:S%,H2"AV*9C'*UCHN/1;LVB/A#J*F(B
MB0#JJ**GZRBAS&T]JW:O6)K=VQ-;M6',D]FQ*\T\KG +22R%G<X &23@  =
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M2C7AEE GD3G)63*EUYVRW)RZT4>Y64"O*JD-4HE>TDC2'GG:;FLRR(A,:-R
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M,"0QR'!'*#T(/<P)^1XJL))O7"CJW5EK2FU4@K"PNJLY%"P?NIVR6BIEKC.
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ME]N?Y^OPZ8'J&ODK5J0A4B-FY$R$\$1,J*92%3ZP'\&4@% I2=< -U  "]8
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MOVP\-;]=1R302-(H>5$>&.2=>6-G:("1%970M:M\4;#53< UZO/+MT<\EJI
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M#0,1$(B!EW!#IOG;IVM9FWBU-9EM,L*RRU7J-R*^.S=2I?+2-(\O7(DD=SD
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:::::::::::::::::::::::::::::::::_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g937421g71s23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g71s23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &":^88(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #U@
M!V0          0                         !              =D   #
MU@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
MU@    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ]8     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M?^W6_P!R5*MOI*A]JZM_W";_ -NM_N3'J6300[-Q3343!M:X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M^-<?3/X7V_;WSG^G\'P_;^UC&.9T+^OUX?\ CFGW_A^5??3??[*_VY_V=_\
MY?![>-"_'UI3TS/M]_V>_P!\^]_1G[><?T_!CF-"^>,].GS\<_T\/ORKYZ;]
M_.?Y_P#G_9_PYG0OZ-/O_#\J^^F?PO>QW]_.>_WN_P!KWO;[_MSV^WCLT+^7
MAY_KY >1RKYZ;]_/O^]W_P"/?VY]N?\ RXT#X_KIZ>'A\*??^'Y4]-S[?;GW
MOA^]GV^_[?A[?>^#/&A?T?C^A_SK&/B?Z?E]_P#RVK[@SO\ ^UG^G./AQ[?S
M_P V,_AQH7]?=Y_+'GOZ9^_\/RI@S[^<Y[8]G?/?VYS\'WNV<_!CC0OR^_\
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M$UP&*C',#LG(+ 9E5">LFYLS;<YUX"P.O3=:.]6SD !)]29FI!C:ULPS9,[
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M)R^8.+X<KG&H(H.,X'05=B./V%C:V2\*X?<"V@C@YHXS+$)!&NG7H/"6*:L
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M5%OL/@*SV[-"9C49SE2N5M_"$D$BC"R9+8\''O>&!JSG;QS5E8S&2,HQRT>
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MK\^=FDER]AGI5U7B5(2\D9GV]\82^6\XA"?;GZEM"DH1COVPE.,8]F.>G P
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M+))=5A:F\>Q"U#(00E(^,I)4WGPJ<92G/56W!(.Q!Z>&^#MMJVW.WCN*="/
M X\?'[O/&#TZBJE)E+\C 32D9--;6PVTZXIO#*6D^-YYIW/GK2G#.<Y;2VUW
M]K+7A4IQ",ZJ.A.=/G@$DGSW&^>F=ACKMDOAUZXVVVQ\,;=,[X^\BN"PY!P2
M;BH,AF(-]"C'!2\8>>:94X^6MS*&FVDH0E3",>#+3BR5J<SY^,>!.59!4,C2
M LI9LKL"?=QN3UR#U&,=/(8()!"G'3!P2.I\L>N=_';<\GPE9A P; EHLMH
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M%$[.!*1.K2-'S=3?42$.5*@2+U3ZY#VCT^[9J[E<=M,Q] =ODZ=$B^EY/7>
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M[*7O8E^%6"BX>6?AMO<<-ML6-[P".-A=*]S:M"5@:VFMHK.2T94432B%GC8
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M$?*1S0_II&(QP.1)#]-23&^>H-UQ"XP5;)A8+C@^'7VXY[+AKS+L"-V$8"D
M:E8G2-6I V,-C4 -39 8 [%AA5(D. 7).=@1C.V&(SE0<'.!N0<;X(RV;:^A
M]YIAP=0 C< [ZZA$ BS,\G!-9/8R:ZXF*:'C1FYQ<DV2*P:UZ25B)2T\/)..
MEN99Z\S)#:FYG<D):./"RH=(&HECR]."0<+KR"N%&=-'48 7O*,,Q[A&?=&
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MK*N,L6R-^<R899"9#I8JJ+LHU(R'4 1D;GKGK@8J3*7/,EV^7K<6XAB-J*6
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M+/@(3[^?=8G R-.P(/O9.^V,;U:=&VFW:]I,Q0K=4#B9"'*,!(S)Q\E8)QX
M@5#*HY0#J/0Q\1Z/3BXPU!A#"59);?;9=961TN;3E6A<B8R+(BL-#+'&&!)U
MEAWFU=U64@'H5SG&L4NN=5!0*5)4Z@7;!'0 @ 8R2I!(W(.-CE3RIJ?6CR]V
M>=IN]K[9*W(OQ<S%[&MSXA;&<=\9]?2"7&7FU8RV0*0WE3)(KR5L$,K6TZA2
M%9QST,2+);1HPRK0Q@@_[*G;Q!!&01TVQ7GI':.X=T.&61L=#X_@?PK:-HS>
MT%N6 7VPS%W"+&QF?@/,Q[V/"WZUBO&K+I$20XI&,Y5XG@"',!E97W&)+I[F
MV:!O%HV/=;_V6\F'H1N/$"XM[E9UZ@./>7Q^8\P?Z>-:62OW<C\:]_;5ST Z
MC/F*H6ZGYG\:V>"_8P_XAG]&GE>>IQYFKY>@^0_"N_F*S3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI7K ^SPOY6-^F1S#=#\C^%*S5Y45(IQ2G%*A2"Z<](UN
M3EIJ'US!#2LW.A64\][TX\G$Q'W)O8@A "Y$POU0.W>66;6J.B?08UZ=88D'
MPW'V6U)[-<3, #(V%4J , 8*<LY  R='<R<G3MFN0@B4DB-<D@G.3N&UC&2<
M=_O8&!G?%>:&Z9]$5\B1)B=:0 RI%0&,,.9D# (<6-LD5<0XFIQAII,=2H!%
ML@X:RO5RH"P<"5.18$H7'/F"LO(RUS.P :1CC/D"Q*E"SD %VT,RZG+, Q .
MYK MX5SB,;XZY.,$-A020@U '"X!(!(R!5;3HC3B)",ED:YJJ)2'"CHV-D41
MK:#A8Z(OX.TXH!):<X?<#C=BQH=P &=<<9$G&W#&$-J))P]KSYL%>8^"22,G
M!)C,1./,QDH3XKL>@K;E1Y!T+D8 .-\!^8!GX/WAY-N*3^B]36B[![#GJ3&2
M-L#?AS,G.O2#8,E(5MY)%8E;! ,&-5ZS3%4)2@FIS%BBI23JQ+;1$ 7'/--K
M26>54,:N0A!&,#(#;,%8C4@<;.%(##(8&ABC9M94%L@^."5]TL <,5P-)8$K
MX8KE%Z,U%"2D/-1.OZZ!)U_$7B(+&$4A0686.O$3$N);\S++KT?%[)O4>*^^
MVZ\T)9I)A*_+6TEH9I2"I=B#G(SUU%"?C@F-"1TRHK/+C!!TC(Q@[^ 8#YX#
MON?YC7LC=-:IA[!!VF(U[4XF;K-4C*-6RHR&# 9K]0A<2J(>OPL<(VS&Q<=%
M,SLR+',@AL9""E#P1U-AE/,+&:5E93(Y#,7;+$EG;!9B3N2Q4$DG<@$[BL"*
M,$,$4$*%&   JYP !L  Q VV!(Z5PAM,:KKT0' PE%@(R&CE4)0$:*+EL0/]
MBU\$G7:1FO,REENG/1L>J":1V:!2&.VVCRVDHP,TK$DR,2>9DD_:C$G_ .,$
MZO/)H(HP,!  -&P_^KW3_P##X>566GI7T$V%,QP^NP@@YH@$G#,?,V:.Q778
MV07+ XH"P9H=W6; THZ[(H&UVNKC9.>>*4TIYUQ:M_:I\J>825!&ZJ=61@\S
M*GFY&V9-1Q6O(BPPT8#$' 9AC!R-&#]6,[X32,D^=316ZY T^OPE4JT1'P%:
MK<4!!P$'%#-AQD1#Q8K04=' ",I2T.(&*RTPPTA.$H;0G&.<&9G9F8EF8EF8
MG)))R23XDGK755"@*H 50  -@ -@!5:YBLTXI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5CKU8_O!7S_NQ][_Z85_\
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M.)&UUI+<7*0RF:*8RQHEM#J]FN)'*B)R767N'3^:BS;-O>R7JE7=/R=\;@X
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M-J*-2X^*C+S#3@Y+W=(TZW81:6= X(!49!*]XY<*226ST4#)QD%01F+*&?4
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M'U9PK(JG$C##K6TMES+IC+*L(!!H9!I+:EQGWB6 POQ'O=21D'89%9.VY)P
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MYD=!.76V9);;I 2L$YK[:GG0I(IK,JWB9V1$_M;AA#'LQT*QTR2D*"=."4R
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M4(\?(G$90E:\,B!L//NY0A2O VKPI5GMC.54LP51EF(4 =22< ?>:P2%!8G
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MC?ID<PW0_(TK%'K&]F\IG./?]25SVX]_':.1^;W\>W[?.MC^[+_M/^-5=_\
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M'#>IK8LJD)NCLLC%9(KB=2(P6!RJS9#;@LV5(U8P\MJQ55!;+;,H*J"LD,3
MN<$'48\%>ND8.<9OBC[C]SM?N6L)&A.UF-M9LA&UN@$P^OMB5UAC)$3K:GU!
M$QC%9C8>-KLG$7W54?K*6N2!JW*,W:I%4(TARR!$&:/#Q 1RA]10 M)F2-NC
M2.^GODE@8Y3*L>6&AQ(!H(&RRV1>,I@,3A"$=<9"*NK*@!2'C"%NZ=:Z#W@3
ML;Y75-J"^ICOC1>Q<X[]\1(G;M[,]_7$;[V?A^#DJS_>H>GO'KT]UNM<+K^P
MD^0Z]/>%8X],74[ZQ]7ZXV1(=I'&&@ZO:37L=I#&$X;8AIHAW./^L/8EN/D7
MEJS(JRD4M6#O)=.DW=GC,L0VZN@\/$LOP\U'3J-MA"M+O.(I3OT1SX^2L?/R
M/CT._78%RLJTK%3JJW;:-2P-/A-;6304+MG9%@?@J#&]0=PL=2K%A* $P49&
MQ"JW$FD2L\0\_&QP )LK6P5E28R<RKA3@L>9!OKEX$C6%[1;B9RD*W<KQH[
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M(*T9F'4Q<,#ZI*R]ZKM/PSLYPT<)/9_C4G&#=6(FX@'B$?LEP=&$&E5TZ\R
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MW]UQ"8V\G#KBZM)(KJ]DN)S+:W4@@Y:2QP2V]S-(R&2*$BP*)L"S72F1T[=
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M73TU&TN3$6Y@#/5I>(1,"97SS'17#*P9GD+$ ^(:12Z:L ,-:@$9KFL=E(I
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MTJX4$DDD@;DYZUP^AN/_ /KEE_\ &=Q__?N9Y[_RP_\ JUO_ /"K')3SE_\
M3S__ !*?0W'_ /URR_\ C.X__OW'/?\ EA_]6M__ (5.2GG+_P"GG_\ B5]Q
M6XSQ)RX[-$H2I*LL'6>S2 ;OA5A6$D!'2Y(9+?BQC.6B&'6E9QCQ(SVXY[^
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MH;FYXUP_L;P^T[3W<4B2\6-Y+-"DLJZ9;F.S,"@22C.L"5';)$LTP9P]%_\
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M^Y)2]YZ8ND_HVL_4_*_2[Z"D!9+:]2KNLG*_,=12X^T'6&,BYFPM[,,52:^
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MBE[LV?::[$5NP[%SI?4]EV;&ZI@K@66+5S[^17VW2 B9Q$?(20->@A)^U+A
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MN8Z\RA*2;*)07M4RFNUZ1DM.?L8LWK-8047H\J1H7[)["6;.T4<N<0'Z*C,
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M[%R!8H^5?D[84NM3IRY%DL6B,J60I.]P\$S3A9X\$ Q:S*P 60DJN+=>62I
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MX[ YA)QV2G'P8QCV>S'LQV]['L_HY3U.KJ([>0_WQWQY+O?'O]\>!7L[??\
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M%_:1OJS/,=5JSROJD9FB6Y5I$$S$CE<V)D1B [*<Z1BLFTN77&(HABX"(FE
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MX4GOAHH$G+)PTFW8@D 9V8Z<G!;0=&P9<DOC&/+<,.Z8\PWVR"0 3\-0SX'
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MJ<4IQ2G%*XK^L5_%5^;/%*_.\5^[D?C7O[:N>I'4?,5YANI^9_&MG@OV,/\
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MV*ZP-2"=L(9&+:G7E1D'*ZF9@#I!.I6Y'?!);)10V@]US&,L$&G"D.X.=6
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MM#3%WISU2U1;-JTT[6.YIRPQU8CC77&K;3XZNS-#AVI&-KT^2S.W,I,I4H
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M2 3MI"Z03@$')(.5&^,JE_6*_BJ_-GD6I%?G??<5YSW=>>_FN=_JL_Z>?O\
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M6O*>^6\-!8'4KPI<)9QG*\1I+N",'OAV\%C(;?XD'2!]Y/PJ3'9SR$=PHO\
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M,A'7)/-=M9-H\J0EA;&,B#WFXPTP?5  6-SW@^^)WMV0-W.\8DMUB#;:D"[
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JBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g937421g74k22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g74k22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1;X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %MR^6%(X0DE-! 0       \< 5H  QLE1QP"   "J   .$))300E
M   0,L2PA>$<H?HA5!(#(,% K3A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              ZT   =D          $
M                 0             '9    ZT
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   ZT     4F=H=&QO;F<   =D
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   .M     %)G:'1L;VYG   '9     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      ,=@
M  $   "@    4    >   )8    ,6@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M76@>W)L<?"7CM_61/V9U5I:!4!,Q^D_M)?LGJ?\ H6_YX2L*HH/M&3_IK/\
M/=_Y);/0\FZZJUECMPI<&M)DF"-WN<5F_LGJ?^A;_GA:?1L/)Q67?:&AIL<"
MT SH!"!(2 727,=>R,AG4WMKNL8W8P[6O<T?G?FM*Z=8?6>C9.3D_::"'%P#
M2PP(VS[M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 1$  A$! Q$!_\0 'P !  $$ P$! 0            @%!@<) 0($ PH+_\0
M>A    8"  ("!0\0%0<'!PT  0(#! 4&  <($1(A$Q05,5$)%A<805-4559A
MD9*6T=89(C925W&!DY6FL=+3U>'P&B,D,C,U-SAR<W1U=Y27H;*TM<'7)31"
M=K:WU"8G0T1%H_$*1F)C9(:G.4=E9FAXA**SPL3&XO_$ !T! 0 " @,! 0
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M3R[NY/0-%^H<K\(L>M]O^^^_7]73UPG[H_>M^E3R[FY/0-%^H<K\(<>M]O\
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MPS:OX4T_Z&I\4BX@_2W6GN:F_A5CV7/2G^!['_!&I?3=/8M]&WX9M7\*:?\
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M) @PN_-!'(^XI)(7>8[JDL0N,D\S\ :C#':7]];1ES%;7EQ!&7XL4BF>-"Q
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MS6_O=A_P\O\ 2*>PXZ*/P_;/X7TSZ#I^2)^//U,<.7\GMT_Q.R/L\USQ-/\
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MFG_\/+_2:>PXZ*/P_;/X7TSZ#I^2)^//U,<.7\GMT_Q.Q]GFN>)I_P#P\O\
M2:>PXZ*/P_;/X7TSZ#I^2)^//U,<.7\GMT_Q.Q]GFN>)I_\ P\O])I[#CHH_
M#]L_A?3/H.GY(GX\_4QPY?R>W3_$[)^SS6_O=A_P\O\ 2*>PXZ*/P_;/X7TS
MZ#I^2)^//U,<.7\GMT_Q.R/L\USQ-/\ ^'E_I-/8<=%'X?MG\+Z9]!U^BKQ)
M[C;V5QI\-]BVONU*D1-MC-MV2D,FU)B9*#B#PD16:9+M5E6<K.3[D[XSRP/B
M+."O2)'2(W(1NF9,YU?0-EM6NM9T^6ZNQ"LJ74D(ZE6C3<6*%P2'D<YR[?=
M8QPSDGXP_9!='&S_ $7;;VFSNSDVIS6,VSUCJCMJEQ!=7(N;F]U*W<+);VMF
M@BW+./<4Q%@Q<ER" NT])9)<@'14*H0>\8H\PSLA&*\,!!&16IWC>_5CCO\
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M(9INJC#/U44LF[N1N1Y<UJSTQ2NQB'(82'*8A@Y<RG*)3 !B@8HB!@ >1BF
MQ1Y<A*("',!#+.CQL5D1D8 $JZE6 8!E)! .&4A@<<001P(JJLKJ&1E=3G#*
M0RG!(.""0<$$'N((/$5Z 8OA8JR@,GAHQ%V@P6D@:KBP1?ND7#ALQ5>@GVLF
M\<-VCM=!J=4%UD&KE9-,R:"IBYTL[R2UDO4M;A[**>*VENUAD-K'<SI++#;R
M7 7J4GFB@FDBA9Q))'#*Z*5C<C$;FV6Y2S:X@%W)#)<QVIFC%R]O%)'%+<)
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M4MO:B3!7*JA62=DII44Q530V'"M).-KKAQR 11:D0L$BY<+ )0Z;)J01$PD
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MN-06687TJ,")+OK7:X;,K'><U;&8JY"F*4Q2F*4Q2F*5O0\3+_4A=_PG3_\
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M%O++'%"KB%+/SK%=@IBE,4IBE,4IBE<#WA^<.*5);A^Z[:P_=*7]V?MYH?\
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M>RAXC SQ[<' 'N\SCY^%2[ .0 '@  ]C(JU<XI3%*8I3%*8I3%*C#NC2H;!
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MYP/L#[^,-W#R>$.7'/ 'CR]'<0:C>'?\1[>795JUO@U1<25^0*ETCL+LBW.
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MF*4Q2F*4Q2F*4Q2F*4Q2L7W_ .2O2'\*$M_N6V]F:+VEQ_J5_G$%89?;V_\
MKF_F\]90S#6:F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F0>1\QI5"A&;4T-$B9LW,8T<R,8Q
MD4S&$PMDQ$1$2B(B(B/,1$1',CD[S<3[8]OEJ <C/G^6JIVDS]"-OI"7VF5R
M>\^FIIVDS]"-OI"7VF,GO/I-*=I,_0C;Z0E]IC)[SZ32G:3/T(V^D)?:8R>\
M^DTIVFS]"MOI"7VF,GO/II3M)GZ$;?2$OM,9/>?2:4[39^A6WTA+[3&3WGTT
MIVDS]"-OI"7VF,GO/I-*=I,_0C;Z0E]IC)[SZ:4[29^A&WTA+[3&3WGT]W+T
M4IVDS]"-OI"7VF,GO/I-*=I,_0C;Z0E]IC)[SZ32L%R.X:[4K-+U5TH@DZ;2
M*B@H@8A! 'B:+DG(G,.0"54#!R#EU\\ES[7.2=T?(?K\0';5>/'B/;=WF&.S
MS>?MSRS'!S;2=9$>M# 9,X /4/,.L.?KY4^?/U^O?YZD$\CS'US[O'T=F<56
ML5-,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4K3;QY^)X<3W$%NC6>R^&KC2W#H6#<V1DCMVGDV5?_&[ Q243)1KG8.I
M8-A*BSBKBO$N7%<>U4IX:N2H2II@'\2L$Z2>Y>PO[6WBECN;*&X.Z3"YCCWB
MQ8'JY6(R8^&\&XLN, $$;O&7=E<32I)!=2P D"10[;H''+Q@9 <C@01NG@>!
M!SM>US2&FMJ-5Z*QGK=:6]8B&T6%DOUGE;E<YY5$HF<R]DLLTNX?RLK(.3JN
MG*IC)-43*]JQS1C'H-6:'%R.9'9R$4L2=U%"(O<%50 J@< ![N3DUR**$55!
M9MT8WG8LQ\K,>))[35Z92K4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F0W(^8_)2J5!?I+$<^_W
M,8_U9++O[=ORF^4U Y>Z<>;)Q55RM33%*8I6K?9FR-X:YW3MQI#O[31-<W#<
MK0Z^TU=*[ WDTADH+ACTDK5ZI6Z?6#%.UA[U=C6UI(6A!)S%ISM:D*6T.QN]
MQBI%CR*)#)##D*\B0D=6)8X22US.6=V?@2D>Y@>VW6#'*(16BS2I+(!O*CRC
MPRC2!<01[H50?NW#;S 8RI'!F!J/?"YNOC(JA.$#3;S7J]<J++2_#/$2\%;M
M8;*2E)^+F-6Q#S:MEE+6A 2C>GV/7\\23A$*]/O(=.+D:\WCKF7I7^N2D;GN
M8;-O54PDWFZVY.\CQ[JL)6$2*N5WDD3#;PSP;*9ZME.*"6Y @C*;H$<60R29
M(*#?);#896R "1RRY\,$7NRO?'A>=?ZF;6RPO8*PW6&\3[W;,2E2T?:*HZI4
MGLK<K6)W9IR79GM+Q1W#TZ&:0\_<4)A9G+,80EHC[8U0K=@;I05"EBCR[NZR
MJ;^%0\R.'$4),$JG<'%WRJD#&=TKX0R;;UVR1[QP6%G(2D97=+R@3(06;(5,
M,0>/,'(/#'S>D;SE-G5K83JJNP@ZQ#\)D)'T1_JVZO&D;'7GQ0:X1FTU*Y/N
M+(2;KTS%5BO4_;-QD2'>HG@XJI*6>.\9,:V3=6#V_5E-_+%KEBXDCR66Q0Q;
MPZO# N7C4</#9BIWR352)MX/C( MUW-QB 'NV$A4[^0=S=<GCP4 ^""*KD+Q
M:<=\I5MJR<]5H6ERT,C6UW46^TUMM=YJZ==[4804Q3(J39TB9K=RZ>OPG%F%
MCDG4C$(3S&#N3]^VUQ=&CJN1ZEL@T05V8'> (EB'6A8BP?!96C'68!7&2I*
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M5;=,4K0_Q3?KM[K^V5G_ &<B,LWW/Y(_/0>CG\OY^=;7^'GEXSFO+S6R'L]
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MOM>VD81!.LU&3MNC+C2[,9NDD2GN5V<TPI<8VGR-(I[9ULY9 S21*$""0!Y
MK(MG$B+%O99@LZ.I^Z *EB5R1"&YC0J$D)8N4RJ$AFN9&)?!*J3"R' X$[V!
MO8!\T@U\4$H-ZH-3UA"6JOZW>7_8$ZQ3C(6MRL-(3]NXT=S6&YCM0LC2K&^9
M5%QI>7HT] N"W75Q!B9:QN:[,6"[HQ$,RN382)([LKR;D:G)92 EI B]5AU!
M83B16&Y+P5<@+EC %XK(J JF^[# 4@E[F4D/E6.Z8BK#!3 )(.\ !+/AU7XK
M+E2N)RL;$GMC56X*RMAC]-[-O%7HT06$D)N.GTHQ2OT5A4$&)6- D"P*KCMN
MP[>IMF!1%Q7[]-I+349%Z<_J96MVC6-EW5,L2.[$@%<[[[W.3PL;JQLN"&0>
M"6V(NO99U9F#9(C<A1@D'VJ[HP%\'FSAN8;B0(N/Y'Q2G9M2V$UOU";0$!<-
M3[+V[&T5:K:XN*,18'4),:LI/"?+1DU$S#"SI=LI1G$#)6.11>+/9EX>E+/U
MJP@:*5V@NG(\>Y*6*RQ1%]Z1,J&$LET",%<',"H,$ ;^Z&Y82;QU?*8#(\@0
MB-L''5I;GQ@?VXMWG=WL<*KI^&WB.6W9<K-";*W=2R&O'&C:*W<HR+U/*.6#
M&UP_#LMKFMPR=CUY,Q9*[9YJN29D4WT8^E7C6D'CPE&1'TLO)4%S;BWW.KA<
M[MHI0]8H)0W'6,Q5P2RJZXPP'AYQP&Z,,W6E@TH\*X(9>K) 80[@4,I #%2>
M*D^#Q."<[5]92%LE];Z^E;['A$WF3I%3D+G%E0!J6-MCV!8.;%'E; HL#<&<
MPJ\;@@"RH) GV,%#]'I#QT@42.$.4#L$/>H8[I[.8QV"M]"Q1"XPY52P[F(&
M\/<.:O?*5:F*5H?XIOUV]U_;*S_LY$99ON?R1^>GU]%;7^'GY#FO[F0_H$_'
MYV0.1\X^0_7ZXJ#[8>8_F]'U';4@<BIIBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4K%F\-50N\].[/TY85UFL+LZBV:DOWK8 ,YCTK%%.HTLB
MV*)B%,YCE5TWS<IC%*99N0IA HCFI?6B7]E=64A(CNK>6!F'-1*A3>'E7.\/
M*!7.[,:]=;+;1:'M'9*KW6AZK8ZI#&YPDKV5Q'/U+G!(28(8G(!(5R0,U^$?
M9G"YN3A/V*\UMN*JO(9\U=."0EA11<*U2YQC94$TIVI39T4F\I'KIBDJHB'8
MI&,45!G,,H^036:I_#W2#L]JN@7<L%_;2(AZSJ+H*QMKE,C#P2D ,"#X2'#H
M20ZJ<BOU]V-Z0-E^D/1H-9V;U"&X1@C7EB[QKJ.E3NAWK74;56+V\J/D*XWH
M)P.MMI9HBKG/FKIJ:B4G3>)EY2+0EV8QTLA'2#MBC*QR@ 95A))M5DB/F*@@
M!E&CHJK<X@'33'/G#7;Z_LX;R.RO+JUCO;>6VO$M[B6!+NW;):WN5C=5GA;C
MF*4,AXY7&:SW]E97<D#W5I:W4EG,MS9O<6\,[VMRK86XMFE1V@G7ANS1%)%[
M&%;G>!3A4OM[L;"_7!&<KFGVCJ.F%8ITJ_CF^SW\0X![!-!BQ402E*W'O^B_
M<R;Q!PR7,F:-C065=/7,=Z[^QRZ'-IM<U.#:775U'2=B(I;6].GS27%K'M;=
M64O7Z<CV6\BW6E6MQBY>ZGC>&9D]36HD$MQ+;_,'3]TM[/:)IT^SFBMI^J;8
MS17-F+V)+>YDV5M[N/U/J$JW>Z[VNJ7-OFVCM8)(YHE;U3=F,0VT5SNBVA7&
M=BCX5FO0ZS>U3RRB*;6TUZ/L+&,3[CRKT'PIR3AH@R(H]8L&*SP7(&3([Y(M
MWKD6[-;]"M4T'0]>B2#7-(TO5X(6,D46J6%K?QQR' +1I=0S*CE>;* 2  3B
MO@[3M:UG19'FT;5=2TJ:5>KEETV^NK&22,98+(]M+$SH#R5B0"<@9YT1O.6F
M :O(B*IK.(BXE\]:03./K$@#!>/:J3A8^/9-(1ZNW:)2G:#,C>;6+'MV:KA0
MSROHMW<.O);]K:6EE!#:V=O!:6L"+'#;6L4=O!"@^XBAB1(XT7/!$4+W'GC2
MN;JZNYI;J[GFNKJ=VDFN+F62XGGD.26DFD9I)&; R[L6X<>&*HYJA&QTJ]7+
MK"@.%[.XM;2>=L=<-VCB<CV3MB5A'R[X[Q<KCN^*BS@[R0!RS6,@58&"A45%
M X==D]E8Y;ZXCV<T%+C58VCU.8:1IPEOXY6WI8[YUM@]VCN TB3F0.V&<,1F
MN6.T^TKQ6<$FT&MM#IKK)IT1U2_,=C)$I2*2SC-P5MGC1BL;0!&1250@$BO,
MXEI=!2%70U;%RJ];9+LZ;+(4F18&AE3LX8RJ<6P>)J/ZO&HQ!)^)722=-NZ+
MV%C&;<2DF630O('1](ZS3Y3IVG];I*-%I<GJ.V+Z9$\8@>/3W$>;1'A6.)DM
MNK!B5492B #0&JZIN7\0O[X1:JZ2:FGJNY$>HRK(9TDU!.LQ=ND[/*KW E*R
ML9 0Y+5?\#TW5Q>RSRK147+*QZ\8>6\;+Q.<?13==%=N*EK%/M<(X7/-$M><
M&[,9=L$HBH*(D2+<:=IZ7KZFEE:#49;=;674%MX1>R6JL)%MGN@@N'MUD4.L
M+2&-6 (0, :J=0OVLETZ2\NCI\4[74=@9YS91W)0HUREL7,"SLC%#,L8D*DJ
M6()%1MK\%>-P<3T%M&SZXGZ!2]/5.?A:R-I!F1]9+?.NG<>XE&+9 YSJ0I(5
M8ZR"RHE[&Y1:*$Y+KK)MO!M,T[:';GI?T[;#6-E=4V:T#8/1-4T_2#K(MEN=
M6UW4YYK26]M8HGD8Z>NG,[Q2N5(E$++X4CI%[7J.H:%L9T5ZALGI6TNG;0Z[
MMMK&FWVK#2?5#6VEZ+IT$=S%:7$TBH@OFU!%22- =Z)IE;P(T:21#BQ7AJX1
M:.(YBZ(LUNJIUTJO8 :F4A7:S.!;J@WE)-9$LLDD#\QDT'RSYLN1)@T 2E66
M^A0!WGFO:,\>>.7+L^,UX3D\<CL.!CGC([SPY'RY KS42&0:S)))I2JO6ROH
M9TL]>Q]'+7I==\28<LA14?IOUR@V<MVR$B1J<JZBR2J3GLPD4((69F(P79L'
M@"Q8 8[,\.=550#D*HR"<A0IY_GYU>7C HG9)!7QE5,5)?EW54&N0XGDNBNF
MZ+V^86?-WR=(HN0[8%3\T))K_HI"F"N^_#PV\'EX1X<^7'AS/+O-3U:<? 3C
MS\$<?/PX^[51FJO6K(FV1L5>A)Y)D<56:4S%,9--JH8"E,=N1Z@L5 QBD*4Q
MDP*)@*4!Y@4.0,RYW69<\\$C/GQSJ656&&4, <X(!X^[5=         .0 '4
M  '>  \P RM6IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4ID-R/F/R4JE0?Z2Q'/O]S&//^+)9=_;M^4WRFH'+ARX
MX])^HJJY6IIBE:YKCXI'J[5=JV[6-LT^Y5%>@[D?ZKIPE/5Q/L9A!ZKH6R[-
M:XU:<LL!%L&\ UN[ 5HMU)=TI.-G*1W!0EK)9EZS$;R6$TB1/&58/$LCY)^U
MEI9(U0[H9B6,9P0N 0V\552U:C7<:,ZN&7=D*+R\,!(W+#)  7? ()!Y  D@
M5][SXH]J=E4MN3FI:Y;MOR.K==479920K)I'05CK^PXW7]@KKEB^D'Z4VR:.
M:MLJN6%"2E*ZQC9=H2=:5MW.2M4M;"%)82EHUD98NLD>/PCEE:/K P(X*3F)
MA@,2/!WL;Z;Q[R,+(4#.8U5^6 0P0C!SGDZ\2,$G )(;$@]E<4%!U1-5B"N$
M'>VSF=UU;=N3CIG74'<7KG6M 3A#7BW;"DBR9&L0QJZEAB6[]I&GFI=VLX4[
MC1TFFU=J(8([>2569=SA(D(!< R229W%C!QO%MUB#P  XD$XK*\R1D*P;)1I
M#A<A43&\S'D,9 QDDD\ <'$>(/Q4/A@L47$O8IQ<GDG+["KNNT:NSCZQ)3R#
M^V5N:MU>E5SQ-ND()1G+05<GU6$ QFWE_>R<-)5MI2U[.S7AB9SIURI;(0*L
M;2%B6 PK*C#!4-D,ZY;&Y@[V]N>%6(7L)Q[;)<)NX&06#,">..(5L+G?R"N[
MO#%9!W1Q@5^HZRL-@H"1WUR38;N7K32QPSL81=SP\[GK6DMEED^U)%DY*DC:
MK&W+!=B<I#*LN;\#)$3,@>D-JTDJH_!#U6\RD9'71-+%V'.57B,<.1P>-7EN
M%1"R\6^V8!!P>J<))GEP!SV\1Q&:M^D<>U-F[37Z+<=>; IENNN\]T:<I4<J
MRB'Z,NTT]>XBCO[>JH6:0=*,U'=C@QEXJ#9SDQ!%"PS#EDI3*K.6MG+V<BH7
M5XV5((9GXD$&9"X7 4@<B 6(#94 [[*AA;E2P5E96:62-1@'/5L 6Y^4<!E@
M,DC"L1?&P^+"$U;LN6H4O 6^^RTA/4VHT2DZOHSN9N;ZQS>N]A;,E$Y&0DK(
MPKSB/\:VOYB1;/#=P&L4+%5G(.WSF09BE1+9I$#@J@ 9G>1PJ!5=(\@8+9WI
M%7 #$DY "AB)><(Y0AF.5"JBDMDJSD$DA>2D@Y4?<\6(!D3KB_UG:^OZ3LZE
MNW#ZH[ JL%<JT[=L7<8\7A+'&MI:-.\C7Z2#Z.>=JND@=L'B"+IFX!1LX2(L
MF<H871HW>-P Z,48 A@&4D'##@1D<".!YBLR.LB*ZG*NH9200<$9&0>(/>#Q
M%7IE*M3%*T/\4WZ[>Z_ME9_V<B,LWW/Y(_/2MK_#S\AS7]S(?1^,)_X94<CY
MQ\AY_'YQBJGVR^8_FJ0.*M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*MNTTZI7F)6@+I6*];H)P8IUX:S0T=.Q:QR@8"'582C9TU.<@&-
MT#F2$Q.8B40'-:[L[2^A:VO;:WN[=^#P7,,<\+\"/"CE5T.,\,K6[I^I:CI-
MREYI5_>Z;>1Y$=U874]G<(#S"36[QR*#V@, >VL3UOA7X;:?)%F*SHO5L/)I
MJ LB\:4N"!9LJ \RG9B=F<K,Q1ZR"U*B)1ZR\AZ\ZS;; ;$6ET+VWV3V?CNE
M;>6?UJLFD1QR>,O"W5L.QH]TCLKM-]TD](&IVQL[_;3::ZM67=>"76;\QR+@
MC<E F'6J03E9-Y3VBL]@ %     "@   !R  #J  \   !U9VX #@  .X<.7
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MBRN1G&>+(IY\QW9JW5H7ZS'A @@^4*R#_E9A[M770J-6-94JJZ\I<<,14:5
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M<Z32(\@B9T2-"#(68 LPXA #S'(MRX9Y\C-R*?Q\I&1TG$KI.8N08M7L:Y0
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MU:-44FS5JV230;MFZ!"I(-VZ"12)(HHI%*FDDF4J:9"E(0H%  #4Y\ZV0 .
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MZ;J-]%<SV6GWMY#9)UMY+:VD]Q%:QX)ZRYDAC=8$PK'>E*K@$YX&KI 0'O"
M_.$,R5I5SD9'>/32F32F*4Q2F*5HILO"W$R4SL/;2FQ+^V>L/%$Z+$&UVW)2
M?&4[:VCBJU?*OR.%%JBM;P*[C+:\E5R(6I$BCLP!V,&1U&1^E/IJLUQ=FXN
M1K\(%N#%U1675+=C_HNNPPE9B.L'D\'@?IRRVWG@ATC04TC1FBDZ(-5G]>)%
MU'URCEL=@]=@B*[FHI8;T4UC%;H6L7.X,MO2XD&VO<.G:SL=FUGUGLW5+_4(
MF<3H^PZE9G]1LM96E$6ZCA 9)FJ$?*P#U['1;F5K5LCI^HR:D>T5E8)Z+9+H
M=JNK6.X <L\4T2OU,\4C121E@">(.ZZ$JI>.57B;=&^AP*\%T#:"]T=WM5CM
M;_2K^>U.IZ1J%G%J%E?+ SJC=1(O6P7<<<TZ6]Y82VM_")76"ZC#MFP>'CB%
M+?HN%H.RXR6HN^*]1:E*7VMV-&NH,IJ3=M.YDY8J3,U.PVBHS]>6M#"5220B
M; O)Q2"D<,Q&1A)&.[:U["_Z]4@N%:&]C@B>>.01A78KNR20M%))%)'UJL,(
MY* KO*H9<\MM=LGZTSW.JZ--!J6RMWJFH0:5>VK7C26\,4O6VMIJ5O?VEC?V
MMV+*6W<M<6B0SMUGJ>:8Q3".5.<G71Z8I3%*8I3%*M:[7:JZYJLW=KM.,:[5
MZZR._EY>15%-NV0*<B1"$*4IUW3MTX51:,&#1)=](OEVS!@W</'*""F.66*"
M-YIG6.*,;SNQP .79DDDD!5 +,Q"J"Q .[IVG7VKWUMINFVTMY?7D@BM[>%<
MO(V"S$DD*D<:*TLTLC+%#$CS2ND2.XUY,=RU;9,G(;OW"UL*)]:;!+3=(\)!
MH9VWV@CLUPT7=5.QW*BRA(Y:;VW<8912>U^R666H.M:*9Q=U;"#MK8[76>"6
M[CN6:\NUD MYQ%9Z64870N""8I)H&W2UU,A+P(V8;>#,Y?(DEC]7FV=O=&AA
MV:V>DM)/7G2?7':;;Y;F.31&T5)$6^LM.U.#KEMM TVY M-6E15U76M4":8+
M1HWLK&]E1JK5-E5LRF[-V*1LIM^3CW,; 0,8Y5?U+2E1D3(++T>DK+I-@DIA
M^9NV4OVPE6+*5N<DW1;-V\34XN K\=R5M;2&0W=WNM=,I5(U8M%9Q-@F&$G
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M!I6M89G+%W4JI,F<H)&!;&X%!(CU84)1D>1A))DJK'$8GDC7&XC L AR&*#
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M*W82,"@=N OW#QGTBYZ>-4$NAR66S-H]EM +S4=';4-632KC5M'3:'UBL(;
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M3L92$[(H(  J'Z(!TCB!2@)C<S"   CR ,R*B)O;JJN\Q=MU0-YSC+-@#+'
MRQR3@9-59F;&\S-NJ%7>).ZHY*,\E'8!P'97TYAX0]D,M5:<P\(>R&*4YAX0
M]D,4K1EQA#SXL)[]Z:KR]?\ R*T_\,NW*/\ (/N?;'_ZTK:!PW_(<U_<Z/\
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MY'";G5H7DWF *E4(D;K 69SE/ *)UC94%,!\NXK<HI;>WV")NJ3D,X* *=T
M8?P@S[H*L=X97")LXHL%,5>E5&MV&S2%UL$#6H.(G;C*I-V\E:YF.C6S64L;
M]LT(DS:NIM\DO)+M6:231JHY,W:I)MTTR%T6(9F*J$4DE4'$*">"Y[=T<,]N
M,UN*"JJ"Q8@ %CS)QQ/NFKJRM6IBE,4K634]$[_U?M*Y7J@4ROM*\K>I"=DH
M$;51EK+?X:P;,M]IDXNIW9O0ZQ8V]<=MK@[N\[7=RS-CD(N\%6K5'L36KMS2
MT]O//#)&$=V+!  =QPJ%8E4%DWRI?>4(K1A04\)U)W<::Q2HY9 H7>R06!+
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K*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g937421g75x09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g75x09.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1F 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &62^90 X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #SP
M!V0          0                         !              =D   #
MSP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
MSP    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   \\     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   &.$))300,      ]J     0   *    !2   !X   F<    ]. !@  ?_8
M_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,
M$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !2 * # 2(  A$!
M Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !
M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M>UM%CK&[?3LAQ?8RIV_=
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M9X27*$1%2&2"AL+$8V5F=8>BI:.GP\?7_\0 '0$!  ,!  ,! 0
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MCTT2BWA<&+A,-KI9#@!G!,$&,D4^>P!]S:U;5&EFS)GDA="RM92-6$H,Y((
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MO/@<]\;9@S()!RH7/C<R1C9()'L5['L>U'<VN:Y$5*NJLK*XE&5E8$P"I!#
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MN_JK_;I\O3M?]:^>_:6/?E'I]77_ +UK]9_[%/K&Q]V[^JO]OYGTT^7IVO\
MK7SW[2Q[\H]/JZ_]ZU^L_P#8I]8V/NW?U4_MT^7IVO\ K7SW[2Q[\H]/JZ_]
MZU^L_P#8I]8V/NW?U4_MT^7IVO\ K7SW[2Q[\H]/JZ_]ZU^L_P#8I]8V/NW?
MU4_MT^7IVO\ K7SW[2Q[\H]/JZ_]ZU^L_P#8I]8V/NW?U4_MT^7IVO\ K7SW
M[2Q[\H]/JZ_]ZU^L_P#8I]8V/NW?U4_MUSB\<&VYI(X8F([@$%ESQ###Q@X\
MZ2<B>1L4,,:>R/M?+(]K&)YW.1-/J^\))>T  23F?0#_ '*D<0LDA52Z22 .
MRNI)@?IS[JO\G%KCT4BPR[9;K12HUSECEI*2-[49$3.O2:[(4<U5A"-D8U41
MTC0RUC1WBTW0K]"?6+U@[?I-'+GEY2-IW$Q-6^F+,=5=D_S1SD[3/([]U?$7
M%UC4STCAVUW5F>Y4:C(J2DE=TW(.Y(U:S(7*DBH6-RC7E)TIF-Z/27EI]!?^
M.L^MB._^;X?CZPQBG:U=/^Z)_']OKKZCXN,;E&\<9MMNDHB-:]2EJ*%@_1<X
M=$7KGY&V-4;XT.^1>E_2HI632]")5>CZ"\QUMF>[,TSX#+KS]>F]/IBG:U=C
M36!&OC,>/@-3IK7([BQHF]4KMKMVD29L3XU6AIN2MF(%$BYK[(.37/*.$'1C
MU:])IV1JB.YHCZ$W\=9T,'M'30G[NT#?;QI],7^*N_J^('?WD5\1<6V.3R11
M#[:[IDR31K-"@M10E)-"V&0A\\3X,CD9+#%#&Y\TS%='!SC29S'2Q(]]!<3-
MVR(,&6.AF(,J-9V'/<4&,4[6KI]"@\ID:Z@<SR.A@UBZ<=>V"HB^Q;/N2IS3
MD'CJIR7N_P"<FK_5U[F]L'TM_9%4^L+7W+GL'QY57Y>K;#ZUL^^TL=_*33ZN
MO??M^UO[-1]8V?N7/8OQI\O5MA]:V??:6._E)Z_A?5U[[]OVMO\ J>_W4/$;
M/W+A]2_F13Y>K;#ZUL^^TL=_*33ZNO??M^UO[-3]86?NO[!\:?+U;8?6KGWV
MECOY2:?5U[[]KVM_8I]86?NO[!\:?+U;8?6MGWVECOM__B/X/=[>6GU==^_;
M]K?V:?6-G[K^P?&GR]6V'UK9]]I8[^4FGU==^_;]K?V:?6%G[K^P?&LHPGB^
MV_SK*Z/$*S'<R$L+\YH A!XM&P.*5T<DB/(>->DSMCZ,;D58X)7<U3YGES5*
M7,#=MH]PM;(020"TQ('-0.??5[>-M7'5 K@L8$@1L3.^VGI\*WANS]"O<S]3
M_,_VN67H[?@UQ5V5!7P>GSLV?O\ XL7K\.@W;^B/^KY[MAO-0=U]/Y&O2K2I
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MKJG#1F!%ARJY(BA2!I58J(](YXGQ/5BJCD1R-<O156N1%Y*J*G9J08((Y$'V
M5!$@@\P1[:\C;F@;C!5S6Q;0\3-PS'K J>G]B.98$?'>T-=.12!WU&*7<5$P
MMB4@+V TME#73LJ'A$+8,A*AAUYL/F"GK<."X&8/;<%2=2KD(T@3)()&;E(F
MO%FR%D9<00ID9774#L@K)$'D!IV8\!6S\-VIH<X"-/O:[?3!UK+6"*N#SK**
M-M@9$L%78PVXJ4TUZ",UMI&@[8_*"EQEU0Y3VQJX5&9M=*:#J&!&I1#'-8.8
M*2<NNT0Q &\W&'5A):^(.@9Q/(SI/,"-=Q-9XO#YBK2%)]ENY;27J/SG]EZM
M(>HTJ3"HLB5W6.4>?E*/S<O4R\GQ=%_)=5%]H\RU&NR C70CN[YT'C,"I^C)
M_&7M8G[0\MN7+E1W#SBCH)!'95N2X6:)D,HSLM11Y86-:C(9(75O5OB8C&(V
M-S58G1;T6]B:=>VAR6Y!,$()F=Y'CK._?MI)PRG0W+L=V?3V1%<)7#EAIT+Q
MCLEW%,&EZ'6#EY4TF!_0EZYG3AFK)(W(R;^FL16KT)/FVHCNW4_2'&H2V".8
M10=HW$'7TU!PJ$07ND'<%YGTR-8Y=U6GY5/;#L_JK+?V7K_Y%]?P3]*N:Z+Z
M8,_C^WU;U^A6>]_UA_9I\JGMA^>LM_9>O_D73Z5=_F^S]M/H5GO?]8?V:?*I
M[8?GK+?V7K_Y%T^E7?YOL^)I]"L_S_UA\*?*I[8?GK+?V7K_ .1=/I5W^;[#
M\?GPI]"L][_K#^S3Y5/;#\]9;^R]?_(ON^[W<M/I-W^;[#\?13Z%9_G_ *P^
M%/E4]L/SUEO[+U_\BZ?2;G\WV'XT^A6?Y_ZP^%/E4]L/SUEO[+U_\BZ?2KG<
MOL.OO_"GT.S_ #_UA\*?*I[8?GK+?V7K_P"1=/I5W^;[/V_/*GT*SWO^L/[-
M6/)^'/!<3QN_RFA%S:[O,;I;2^IZ8++*2B,M;2H"GL *X6[/J(P:<@TH>(>&
MT,D8*!)(TN=[8HG.21B'9E5BBJS!68HS !B 25!E@)D@:G4#P@X2TH++UA90
M64!P#(U$&!!D0"=MZTNM3-7QU_CFR_$N >DC:F=T&?;<.IQVQC3C50]+=NM!
M7709<-M(P2,6O&2*K*NT2!3!Y:DV^:9B[AB-6UMW)8R,Q*Y94Z:DDZA==0U5
MZH""5Q .W\(A @& #.H[1C00"T:Z':^WNVXV8I80VN.\1FV[1(X%ZO,,OQ18
MS7,1D3(!O8O99$Q'"1Q1*U"T%8L#890EGA1)&4:[E(@X>X=9*VSH2>>=5U)G
M:>8.FE:)8!!UQ";:-<77T92VVQV\)%;!9P^8=XK%)'F.XR!0+'+!)'E\*"P.
MBZ#8I87MK$BB='RC;'(Q6JSDQ&JG)J:I](8GS;4C?L DSO,D[B/"=8UBI&&3
M2'NZ'3M\QIW<HCPKM,X?,;<R-\>8[GNC=$R.)[<P1T;H.3'1LC<E8K71(UC'
M1HU58C6M5O8B:CZ0?NVM(/\ !CWZR"1(TCT$[S]'7^,O?UG=ZJXXN'C%85C=
M!EVYD+H%:Z!8<M9&L3FMF8UT70JV]!S6$D-:YG)S6D3-3DDLG,;[<TM$$R90
M<M==>?J&W,"7T9?XR[^OZ?#Q-6/Y5';'\^9>G+N3RM6? G]8]7.*N\@@]1_M
M?/O%/H5GO?\ 6']FGRJ6V/Y\R_\ 9:L_D/3Z5<[D],'X^NGT*SWO^L/[-/E4
MML?SYE_[+5G\AZ@XJ]_,_5;^T?GNI]"L][_K#^S3Y5';'SF9?^RU9[W_ *#U
M/TJ[RR>P\_7W3^=/H=GO?]8?V:?*I;8_GW+_ -EJS^0]/I5WD$]AUTY]KOUT
MCNBGT*SWO^L/[-5^51VQ_/N7_LO6>G_\C[?>YZCZ5=[D_5,[?TM/&0->X$4^
MA6>]_P!8?V:I\JEMC^?,O_9:L_D/4_2;O\S]4[^':]QGTT^A6>]_UA_9K--O
M.'+;_%,VQS(JPK)WV%18M+%899 2C+*V*5B)/%%402/9T7NYM;,Q>?+YKLUE
M>Q%QK3JV6&$& 9B08F>1&\>KNTM86TEQ7!:5,B2(F#X5)O=KZ%>YG;R_W/LS
M[?1_M<LNW7C*[Z@KX/3YVK/W_P 6+03KW0/Q_P *@\O3I[#^4UZ5:5--*4TI
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E?+_S#
MO[UWX%TI7F'D>:<%\F8WXN5Y5B0>:NR&PI\@?>6V34MI%<4JV8I"3&&%@-%J
M@"C+"OK+(>>+'&7#XZVG+6X8(.WS"+B\@*H^3*&7*%9<K09 $ZF 6$%B-6[,
MQP%K!8YF4-)4R2#*^F-!, [$Z R *M\]YP10V]:(^\QJ0V\R*UHZ:<:US8NG
MM,CH(,9H;"IK+4(V;'29ZYN5XQ2PA"F.':?:C5X,:V3"(HF7%D$Q< "*S:((
M5LQS$,,PG*S2>T0I)TRDQ.'D"1)+ :L02N4$ S&F90 .9@:S69XIMSPM;UU9
MV38O7U^<!>7;=IUJZ^S66R!R%QM@MVV22SNH+JFLC"#SGGHQH4UB$:U\J$5Q
M(ROJSXBT<K2ARJ0H5 "L C9<I&@@DL 1 ((JRK9N#,H#@DZR=YU&ID3S&DSW
M&MFXYL;M7B5I77..XW-5V-7)+.%/%?Y1-&TB>(F @H@0J^G#.,*B+(C*+/')
M*):]J3RR=7#T*-=N,""P(.\JH[B "%F-!H# C0;U=;:*00(C;4^.L$P3J=3K
M6V?F/2[[!/;\_2]?>UGWQOXDQR^?\:O3DSZ9WV/I[.WYKS>J]VDGWP-M>?>-
M]M_&-Z5BN:9OB&W6.'9=G%^)C6,UDH$5C=6+9&@A.L[ 6J#>4^%LSH8'G&CQ
M3$O8@XD3WE&2CB0SSQV56=@J*68@PJZDP,Q VG0$\B8  )(%0S!068P!$D["
M3&OK._+GI6I4XL>&=Y 8T>^6W$DM@$38@K%DM;+ 8()&+-+(.3&0\:9[HS6*
M*.V9Q)RCV3 HB'5-JT+7Z-B!,V;NA@]AI!VU$:;:Z "1,9A.?76C$7$,B1VA
MJ!'CX[;G6-C&_!21311C1)TG%,'@+%GC;S9.,3$V:"9BJ_\ ,21/;(WFB*K7
M(O+T8F08[M#X1^/X:=^^M=CYGZ9W;_U47E[7YM>7<B>GN[>6H]7/Y/COZ-3N
M12G)OTSOL4\W_O\ NKVZ>KG$^F/V#2>7J4Y,^F<O8O\ Q4_==[_N>=/,U]&H
M^?'703'HTU4^9^F=Z/S*>?G_ -?^;T]^FO<-YW[H\(GU^@Z4K$L]-Q.MP;,;
M'.9WP86!B]\;ETZ1V3G0XT+5E3WDK6TJNN'+'6,)>B5+762JU$!12>J1;('9
MT" %RRA02 "Q("[B-^^!W^%7*A6+:*%)8ZZ* 9VUVG;7NJ)LNY? ^1[%L>=D
M&+G0QQ7U/C HP^86(0##%FKKZ*(@2*<:KD>VR)GG+*F&>,*9/>1SP"SR'NZ.
MKQ@SL%8:JSR5'B-"-1IL))B-]*Q+X<95S*=PH@Z3((D3&AG4C>=M3NP#938K
M)@A+RNQ&N- /EN+0,L0V^%@GEOGALM#(X8K49J.(\D@Q#N6)$"@"'BK4&@:U
MBXF[>4QF@K (T_1D@&4G](DZZEC,S6G5VV@Q,R>8$MN8GF (,:<M*[]AP^[-
M6SA5M<)%LX@AF!"BV%E?F 0!Q1%PQB1UI%U)7^+(AYDRCJ-U3C")+![''JA*
M!=O"<KY23)(R@D]Y(22=-^[3;2I-NV=UF- #)$=T3 ]F]6\;AHV+$EC(&V_"
MBGA2)K"$L\B<0V.%K&PP+,^\=(X6)88I(Q'.45L\;"$A0AJ2:DXB^3J^\Z=D
M ]_Z&OX^H5 LVA$*/:?#G.NVQK=HPPP8\ @S5B'%@B&@B1O22.""-L44;5=(
MYRHR-C6HJN5RHG-55>:ZRDG6/>?'?3\?QBM*YOF?IG?8IW?9Z:\P/;^RE/F?
M2[[!/W_PKW_"NFO+\3\#^,>Z%/F?2[S?\5$]W_C]B<O;[?/RTU[A[3\-]!&E
M*<F_3.^Q3]_IKW#VGX?)I3YGZ9WM?,HO_P _9V\_PIIKKH-^\CT;#U>Z32GS
M/I=]BGI_OO1Z^?37N'M/PII\C]O?\?"GS/TSOL43L^S[>WU[-->X;]YT/LTI
M5WH>CY8 [5YI/]*G+\R_SHY?P+JCSD;0;=Y_ @59?.'SRJ_[M?0KW,Y]WR/L
MS_:Y9:XZVJ"O@]/G:L^_O7\6+N]>_GJ1^EZ!^(^?54'=?3^1KTJU%332E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI7R_P#,
M._O7?@72E0AO-K\QM+PRZJ=W[N@A))8^&G@Q';ZRK0Q5(=.2.B'T<A111$4C
M@W'F$S2*-$$XF(LL* I/)BY;@ V5)@@L#<!)VW!B!O  DS! TKD*,22'*@\L
MJD>,R)D[3/MKE&VTR.#(*_("=SK&P"&CB6PK"*H$86TZRBKZRUL735]@(-66
M%D<$_(TGJ@0Z\&V4.82N8X<Z6UC.I4C(!.Q&8D',S;$20 <HDDD;GS0H*T@E
MR8Y$#70#PY@G0 ;::$GZ@VMR" 5?$MW,UC,<.*HQZLQR:)"X1L=;X^17^36@
MGH615W1<XD[%#<F6'BPQQ"U6/1UD]8N_5K$ZB'[V,;@Q! G?LJ9DMF93]]I[
M^SOIW"#J#X0Q')8V\/#+%!!',0XJ6.**.4J7Q>.4F1C&M?/(P=L4#))G(Z1[
M(8HH6N<J11L8C6IG(Y:=P@Z>W6!WSZ35ZY>BOI;]FS]]I(\?8?A2G17_ *OG
M_P".W]UW^O2?3[#\*59,CJ+"YIRJVLO)\=,(>(Z.W$"I[,@5HYHY,S6!70EA
M6R^,PPR"N?.*]X[9U(&=$3%#,P& (+"==NT 3!$2L'?TR!MK4$$B 8\=/STK
M3!6T&XLL$D 6^]S5M8D+*Z,;;_ 2V5<, X34AA*N0K.Z.8XX/QV1;BXLGDLG
ME"/>="B/UH+J2)L*>^6NB=3R&508,:  0(BJ%'_C2-H "F/:"QU!W),&"2=3
MMO%:.]HPIA;W+C<OF?*.X8L^JQVF>'#$ */*-$/CU?6C.AF,A)/:LT4DD/C?
MBD4B#CPMU1F4D%5RC4$ N1(._:+$::$S!B=3,7 (&K9O$P.[N 'ND>JLHZ+O
M2W[-GM?];L\R?>U$CQ]A$[GNUY^OQJ:IT5[.U%_]]OQKR]W2?3["?R]U*=%>
MS\S]DWE^'UY^VFDCQ_5/PI'S(^>?S!JO17M7FG/^_9[??\UZ]NHG8<O0?=I2
MK?:BSEUEB*-:3TA! )<$%R&VLF+J998)&1V0T-L+85<LX+E0F*.R!-!>^)K2
MQ9X%DB=(8:$B8B00P!\"1#0=B001R(,4.QUCQ$2/'4$>T$>%:/.VJS*TZP(7
M?K+H&^/3%VE=Y%P2\'+&+AF@+!-"R&EN?ZBLA#)%*KI$6ABFE9-2TM1' # -
MJ+B ZVE/(0UQ8,S(RL-01O.;<LQ!-9%&,_:L!)TA3OR,@[@ZC;F -(N*[9;A
MJ7/%-O;ELM)(#T@QTIL2$N +J"[!LJ\N.T IQ&E54 0<M6;46 I<5L,<4TF9
ML:,8@7$C2TN8&"<SD$92"""3K)F01E($#OG*\G[1HY#*H(,@@R )$"""-037
M9#VWSL8RLL)MZ,M/)"> RPA(J,5BJ[D,>WB*-B*JQJN(<0D^H4BG\>J?)Q$$
MDL-DQSI1DA>SIJ.J43,07D'*0()8Z ZP00=JG*T@YV,1H0L'63,*-2-)$=\5
M; ]J=R@61PQ\1.?S00/Y#M,QK;(TA\*^+<VV!A>(SDE3<X2.4T<@C$:6]$A5
MT44C766S/V"21K#70)@ZK#CO'?L!X5&1_P"-;P[*>_LZ^ZMS5 1E?5UX)]L7
M?'"!CCEW5A#6"FVA$4;63'E#U =;5P3$R(Z5\0((HL:NZ,4+&HB:S)U)@ $D
MP)( )F!)8P-A))K0;;SXF)/B8 'L 'A5QY>Y[7S3?O\ :OP:?)_9M[:57EVK
MRY?9)][MY^XG?Z>?;J.[7W?,>)]D2*4Y+W]G9R_XR?NKV_Z^SEW/#OGYTV_P
MUG=1$7O[/-R[6]_M]NI/NY^CU4JG)?:^%/CTI3DO;W?9-^]V_@T[OV^_]M*K
MT5\_+W4<U?=\_;YO/IZ/?(_P]E*N]"U4N0.??UW->U%7\PY?3S]WW^_5'CJV
MC:/SJ5\X>FK]NU]"K<S]3[,_VN66N*MZ@MX/3YVK/W5_%B^/0?I?T1W=X]?S
MZ:@[CT_D:]*M*FFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2OE_P"8=_>N_ NE*\ILJX:U*W)R+,JC9W!K..^N76TLQ>\V
MZ^/QF69K<DCN,@LJ:G@2D=-=BW/*RH&U!-=$7.7U)!KSRK2+S*XC[,6S=<90
M%$6K+$!<N5 2<T+E)#%@8&L1%>/-KMYPBDDR?M+B_>DD $:@P5@@^\<>.</!
M89%E)'L1MM01PS&2U2$[O[G7T)1;LC! M2#:A8DKXO91AI-],+:MDEL8.C75
M5]6D V5A65TF_($WKC2(,6K:_HDKJ#/9>)&@W*D,%)+:B8MJL'2;CGF 9$1V
MDF#N- 002!V,2V'RG [KV2XMM3@HUXZU+L0)3MY=QCZO'XK5OC)56!C<=!7T
M/D>I)CC'H0E$G?7P<QA9Q0>I8'5KRN,K7&*P"0+5L%H,ABV<M)W)S0>X\Y6V
M4:5103WW'($C4 90('(1[)TFE5OM):VOEN@P@+:0,9]H%6'$6M<(>Z%KBQ@;
M(FNIR; 2&=9(QS)ZJNF(B:V60,9SEB9SDC7*9&L$P#$P"1+ >.I VDUL)C6
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M(P<W)FT$%BLA(0K2#1!,?>QHMA'%"KSG'3L<;6-UVS>$@HAC()529\S,1H3
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MV"HS-]X^T_/,^VJ>5+/SV)Z^Z80O_P#DT@=P]@IF;[Q]I]OI\:KY4L_T1/\
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M+W! QV>F$E."A93(S$D+R" 4V-P5?(7'86\SJRN($DY\,.%7,182_BKMJP<
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M_P#C7#\#P2X<'CEMWKUG#V\=CUX_A\(;UVT,1:&$N8>ZX:RU[S6/SS*"3C2
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M6=G=;%A@B5^?6A$\HV,<V!;7YU6[8Y[*D3!73/DQS<2YJL)*&BC>41DU@)3
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M74%?0$UTHK<*R?<625I0P$L:+#A.%Y9D1,3E;*,%C]HV=D9(LD"1EQF8K_G
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M==TDXF'L6,%CK?#,5>NVUQ[7+=NSQ"];PCNR!>O8("2#&[?E$N"K^Y,X=/\
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MK%_9KQ3_ )_WD_8W)_;3\X^G[_N:OU6$^[A_;;^-9]9C>^_^JWPI[->*=?\
MS_>3]C<G_B.G583[N']MOXTZS&]]_P#5;X4]FO%/^?\ >3]C<G_B/M_@]K3J
ML)]W#^VW\:=9C>^_^JWPI[-N*?\ /^\G[&Y/[?\ [%[OP>UIU6$^[A_;;^-.
MLQO??_5;X57V:\4Z_P#G^\G[&9/_ !'3JL)]W#^VW\:=9C>^_P#JM\*I[->*
M=?\ S_>3T?\ !N3^[^<OO]ZIIU6$^[A_;;^-.LQO??\ U6^%/9KQ3_G_ 'DY
M=O\ Z-R?W_\ S+_5IU6$^[A_;;^-.LQO??\ U6^%9OX23*^(G'.#;9J[V6FW
MQ9GQ.Y6S46X$FRE=D!NY[\+*Q>^FSG^DTM-=V(RN(C&<2075$C06J!(7!(]6
MPR?.NF-S'VL"AX9]-ZSZRLK<^KEN-B/HI%[K<HM*Y"Y0L$J5#9)&U?HK]S]A
M.B>-Z88ZSTT/1D8']Z7%KF!/2^_A,/P<<;5\ ,!US8S$X.VUS,UW[);]NZ]K
MK@C+!9?#F_W>X\8<>>5CV3>%6,R.>ID=!5%XEN<P4"XGPC(RH(S"7;/C,*&K
M]P1<;JYE%(:EGC5J29')7& S.U\^N8GI"MMFMW.E;.;?95K.*A;AL73#,<(
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MOK)'1>=7#W&8J&MR+PL 2QSW20"%*J1"9AG)@'_1EZ^7&^H$Y7(ZLW3H 50
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MVF_L4O\ @W_BKJ:GW5XNYWOSOX-G^X^(X5O-PE^.5N0YG585C5_FM6-E8Q1
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MRESNEER:2C@EIX!8L#%P2#(QL92QM&Y9(0?1^6F36(E@4X?HL,%-T',2I*B
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MHV2"!:NG:U<TRR ATSE0LZ:9BZY>\E0-P"ZRW_&)KFW91YLEN?Z(5B>X DZ
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M+BSQ^@LK8TALA-C845,:9+.35@2P.LN:'/<) "CMM(500H':T !(4" H8@
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MJYSG2B23#RNDAFE8^>OOG>]=.Y@W&.LDDC7O,CN.L U LVAM:MB.Y%[@.[N
M'H$;5LS&=N<!PR>8G$<,QG&2"/'NOFHJ6OJY)?*9D=C8H]P4$+G(:;#$42B\
MVRS11/>BK'&K:,[-YS,VWG$GP&YY3IX;5<*HV4#T #??:LRU6IJON>O\WF[5
M_#J/3\_MYF!^%*>_W]_KWK[?9\.II3M[4[?;3S?!III[OGT4HGN<_P";M]>[
M4'TQ^W3YWI5-32LPSBFJ,CP.3'K^L!NJ*]KFT]S3V@L)U;:U5E5D!V%;8!$L
MD'+".$FE&*&GC?#/!+)%(QS'*U>:R2MTL"05D@@D$$,"""-01N*NX!0 @$$
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M2=;V,X*CVUUB6& QN.N[:]FTV@/. >K%?N7?*CA[9>T.CN.8#2SA.+W$N-X
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MW9F9F/,FOTW9LX?"6+=C#V;.%PV'MA+5FS;2Q8LVD&B6[:!;=NV@&BJ%50-
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M;#,=0F=816%OC29*Z\J26#W&/VC8G-E?5W8%?8LB<R5PR1O8YWD.'\2P'%+
MQ/#\5:Q5K0%K;=I&(D+=MD*]MXUR7%4\XB*]0Z4=$.DW0KB;\(Z4\%QW!<>H
M++:QEJ+=^V&*]?A,2A?#8S#E@5&(PMZ]9+ J'D$#;'K[GF[?7[^N[Y]//3Y]
MU>MUIC?'>RBV'Q2NS')*/);BG*R>@QX\G'ZHJQAH1[NR'K6W%Q,/#,@XJ$DC
M5M<.C'S6E[8U0"J%72V=W3Z6K1O,44JIRLPS&,Q D@#>8U)Y $P3"M2XXMKF
M()$@&-8GF?#EZ2)@21MNO.%M  K,&19@K$08\.5T4L+I12X&$#RK#.R.>/K(
M9&/Z$L;'M1R(]K7)R3,Z&#RD;Z3,;[;Z?A5]Z[GM_'V>W\7MZ4J-7%Y_:^9U
M_C&'_MXQO6=W^#;_ '?^H59/.'K_  -;2X/OH1UG^2_$?KC[_3[=!^P>JM3'
M=/L_,U+:;^Q2_P"#?^*NI&X](\*'8^@UHO\ <_U_NZ[_ %1\^%8517M1S6JY
MJ.>KD8U7(BO5J*YR,1>2N5&HKE1$YHB*O+EI2K?<7%9CU397MT;!6U%0$58V
M1Y+^@.($)"^<B>5R(J\HXF.=T6HY[UY,8QSW(U>'B?$L!P?A^-XKQ3%6<%P_
MAV%O8W&XN^P2UA\-AD-V]=<F2%1%)@ L3"J"Q /9P[A^-XMC\'PSAN&NXS'\
M0Q-G"8/"V5S7;^(ONMNU:0:"7=@))"J)9B%!(\)N(??Z]WQRI\_3)KL)IYY8
M\6QYSU8C(DZ4:W-I&Q[XI;L^-565R.?& .YH KWM:029_)7RT>6'BWE5Z0.X
M>_@^BW#;UQ. <(9BH"2R?66/169+G$L4A)8RRX2RPPMDD"[=O_U \D?DJX9Y
M,^!K;*V<7TEXA:1^.<65<Q9SE<<.P3LJW+?#L,X&4$*^*O*<5?52;5G#]G8/
MALR_?$]QD+UH,) )2"VR@F!TJ2S,Z#I:VD&58TLK)(WM=*JR1A@1N20N=)GC
M"%='D?\ (;TC\JV+.*1CP?HMA+_58_CU^T7ZRXF1GP7"[!*_3,8%<&XQ9,-A
M5(:_=ZQK5B]CY5/+)T?\F6%&'N*.+=)<59ZW \$LW0A2VV=4QG$[X#_0\&70
MJ@"/B<2P*V+75K>OV)([T\47@_\ P:0+ ,RNQK#=5M?"6/A^-AC9UO5:PDL1
MT)94;Y@:S# #XVK.-)=V>&TMA'#(ZM::0SJW?TO\G/D1Z%]!K-K][/ ,.<=;
M06[W2+BBV\7Q:\\ .?IURWFL!R ;F'X;:P^&! )L!I)_GET^\L/2[II>N_OB
MXY>&"=\UK@'#B^%X59691?H5NX>O*2<F(XC=Q.(@L!?([(\D]RO]DH9%+8SP
M[/<+]*)4L<Y![3<W.S["Q*;TOF9)Z#%:JK& <J=CH(LELT:Y>23O1.:_9;?1
M\1]MB3/=:MB)_I7"21SDH#L/&ODUSCAG[+#Z<C<?7]51I^L:Q#%/]DF[Q#6$
M#LZX9=LKRKZUJ$Q8AF658I8)#SY.6">Z&S0=TK4[4;(.QCE145[$7FEVZ/VH
M.3$W0>6=$<?^'J_V51>.7 >WAT(_FNRF/6&GW3X5ZJ\.OA=N WC,+K\#S99=
MH=P;58:NMQO>2&LK:ZV++EB<P#$=RZLV6F28@Q!H A+4[$;JV.6 >MJ2YU:W
M7AL3P*[AL0F/&&L7\19LW+"8RU:5L5:P]QDN7;.8IURV;CVK=RY:1GM,UM'?
MM(I'EK'&;6)P[8$W[UJQ=O6[SX2Y<9</=Q%M'MVKQ0-U+7K:7+ENW<8"ZJW&
M1##D&1F[O#A88C 5D6&O*N<>':^<^MGY2W%/"U'/D(:Z-C&V-= U.<LC&-,$
MC_IA$4\$1!L:SB \*\ G9N3? GV'E&@.-_"% 7MRRC=3YRCO'>!SYCQ$D1^Q
M'+;S"+T/(<?+<*<([DYJ])PQHKW-=. ="CFH0&2C&I+$JHYKVQSPOB)AAFCZ
M'17!5A(]X.TCN(_89$BN6W<:TP93!&X,P1W, 1(\/SKT*Q;'=JMYZ+*\J(HA
M[ ;<K&FX7N#C!SVSU4W41SML!S@&L8R6Q*',%8EJ_P#I\E>)4D!M!(4MT_CV
M-VRRK.MM@]MAN"=F![@03 V;,#.@'E[9MWD+@2'7*ZGEIJ#XP1KW01%;IQZA
MJL5H*3&:,9P=+CM374=2*\@@MX];5"0@@PO*,EG,*?&-!&R0DJ>8F=Z++/+)
M*]SW9$EF+$R6)8F(U)D[  :G0"/#:M0   -   !X#05MJ_\ G:KO^X?YH_U[
M=<MK^$;T-_U"M6\Q?5^!K7W+L[O-[_>B?A_=[U371.N_/\B?P_+8&LZ^6O:]
M7HUS7*QW1D1KD5S'=%LG1>B*JM<K'M>B.1%5KFN1%14YS2M<[I;C5NV>+SW9
M36$V,ZJ'1UBN<UUC9.8KFI)T5Z3 A&<R#ITZ"-B:V"-WC1(L<E[5MKC908&Y
M.\#V#4[ :ZZG0&LKUT6D+'?91WMR'HYGPKRPR'(;C*K@Z^OC9#[,^592)Y%1
M&M1$Z,<$$:<F0##QHV(<>)&QPQ-:QC41.WRBJ% 51 &P^=R:\,[M<8LQEC\@
M <AW"I/;4<-<UR+!DVXKB*FH?&A0M R3Q2Q+&1J2H1;$.1'U8;X^;O%XU98.
MC57R2UZM:LG+=Q.4Y;<$S!:) (W &Q(U$G2>35V6,)FA[L@:$)S//M'D.\;^
M(J(?$'X:7@4X49CL!VI%*WPRNMDF&.KMGHZF'!PK =RL=#>;G6$WDZUG5R*U
MYN+C9PZ.5CX3Y1YV*Q.JQPC&XK+<NGJ5:-;Q/6%>];0$@$;!NKT@B1%5O<3P
M>&E+8ZQAH1: R@C3M.8!/+LYCWUY?9)_LDS>X@Z5^(<-.U%+6=8[J!\ERS,<
MI/ZKG\PDQM2W#A^LY=BJP#H])%Y(NO(KT?L_IXFZ3_,1$'L87#[Z\>W'+I/8
ML6P.69F8^T!?P\/&ME;6_P"R3S4L81=Z^&$;R6]S$(N]JLYF\H"MYITY(,6R
MZM4<YR)S5L<F8UR<^7.5$YNUG<Z/Z?98F3]V[;T/I=#I_5GWUI;XYK%W#P.^
MV\GQ[+ <^68>FO0Q[?!G>&5QB2:@NH8]WJ:A58WPHS ]_,$"0EY#E/HBU*K<
MPQX4X]S3"HH\SQ,<FP?$'< VI+)X_1>D_0S"<54#BF&=;R)U6'XA8<Y[:@LZ
MHKPR,F9F/4WD![3LJJQS#[7Y+/+=TO\ )KB'/1?B-J[PO$8D8OB71WB-D7N'
M8VZ;=NR]Y[8*8C#8DVK5JW]+P5^S<(M64O->M)U)_.-QQ>#]WBX(,L''RQC,
MMVQR(V8;"-U*8.:&EMY6LF(;27@CW3OQK+(@X9"9:8D@B P>(@JEL;480V07
M\]=(^B^/Z.WPM\=?@[K$8?&VU(MW-R+=P&>JO  DVR2" 3;9U!(_J)Y)/+1T
M7\K7#'N<-)X;Q_!6E?BW1W%74;%85250XO"7 %&.X:UQ@BXJVB/:=DMXNSA[
MERTMS:/@U?"#W_!]G[<-S@HR_P"&[<$_Q3<#%9F26+,8*L(XP79WC@+G.1I@
MT#(8,EK(6/BR2AB>/(/-: TLXG=T/Z57^C^,6U>=WX5B+@^D6M6-AC &*LB>
MRZ0.L4?PJ"(SA&7USR^>1'A_E2X%<XAPVQ8PW3?A.&8\)QW9M#B=BWGN'@O$
M+D0]B\6<X*]<,X+%,&#KAKV*2Y^QZCVEVAN:;;"YJ 0\AJ,+N"]P]K[T:UG+
M@#;E3#;.&2HL@2(F'XJ1%;"G5]/(\JC(DJL:MIAC+*DK+"']'6\3UUOK;5Q7
MM8FTASH0R7;94%'#:@YE@AU()#$ A6(K^2^)P5[!XF]@\9A[N&Q>"Q%ZQ?P]
M]&M7L-B+-Q[=ZQ=ML%9+EJX&1[;@%'6&&91$@:'_ (8K_P##I^(Y?A]5UG<\
MQO1\_A55\X?/*L@W9^A7N9R[_D?YG^URRUQ5M4%?!Z?.U9^_^+%J1^E_1'_4
M/C4'=?3^1KTJ[^_45->'/'SP#^3O+6^6QM+SK^9%IN#M_5#JJ@*JNF-RK%0H
M&]H//K"+RD'9_47],LJV/Q-"11/?^CG2+/DX?Q"YV]$PV)<^?R6S>8_I;"W<
M)[6B/VH9O5N+\)C-BL*FFK7K2C;F;B #;<NO+=8&E>F7!S_:M;#_ *FN-_YF
MW7JG&_\ ]7XA_P#U5W_JKSG#?_D,)_\ 03\/F/"MKYOWU?N'>[WAZX['Z?\
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M"^#SN]-,W <23@5V%'4XT2="ZN\5=QN(1KZBT/L[BJI-MBJ6RSCK+C=:N8W
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MM6;-I%MVK5JVH2W;MVT 2W;MH J(H"JH"J  !5PHZ.YR6V!HL?K#;FXLYT&
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ML$$ %&CZRP>4 <1NR 06-AR3))F#AR 1( R@#28DDF?H&+DDX"T1.@ZY0
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M6%PV(P5_ XI+RWL/P["#'*SWK(O81R^/2+&*O#+,3^@6@_X8K^_^S?\ R/\
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ME\;%+BV6W-1=0D\)?'0/L$DBVQAU(!^QZQ "RR!-X+)[14'.H*QVA,$3_#.
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M)J ?%#+G'[J./'793&:;'E5*B/A,#M"(SY1:B&>PBZY!M DK]&MJ67,&Z\@
M-G"LIS98&1MP1I+:5 >-3><A3!!M@;9208$R9$008, :U>:NVK<HS@C&*O>G
M<U1LDLK\EV&Y;MB7<X_52VXUV0#6&76:TID=1)1V$=:52U5L?&R4BLHHJRN2
MJR:-+JI!6V&-BU*A1G2Z%8Y8!8*C"0PD,P'-B3F7LV!ELHN7(:3E9"0)DQ+
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M@PGK$/!+-/"UD)39AFOBF)G='.V%"$ZQ&]8K6L:W,7'52 [ :DA21OIK$;@
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MT=Y6--R(S$QX&=P8+W8'8M@SJ#<VWT[IF(]8\:YZ'<K?$[((?+NV&&4.+O\
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MJS&MUY $Q:<@ J(.N4@,QA9 \8D&I#W)TMH 3_&+.^H,2) U,$CQ-?+-U]^
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M5S2>1",?(L:V:GFAFE,\KP1.LA(Z^8DJHO)&4W[X7,I RJ1"D, 1/G!@"#,
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MMA<MTDVR<S.V91 @$*@$*#))HN&Q&8=9?+(#9;5V+9K>C 0$$-J28S,3+'0
M9+O)PD\2^:6>79;AN_#Z_,#LYW!M<))LLMR6KAP? [T?$A<9P_$+ 3%K\C Y
M'C Y@)FEQB@$5]<@WP8T-]SJ:.:@K9Q>&0(CX>5"6P\*K9W4N7=P64/NA16.
M52ID:MFF[A[[%F2\0Q=RLD@*A"A44Y6*[',5 +!HG18Y=A^%CBIVMI^).#)M
M[L8NKW>FEK;K$;2A-S&O$P3<]U VLS&R&KK(:P>H>:6<<-JN73F6F;4'4#C=
M9>Q" -#7\5A;IP^2PRBR65PV4FY:S$H"1 !M@QD "-S"ZRM6,1;%[-=4FZ R
MQF 2Y$,0#,AH!S'M+MJ*V=B'#ANM31;WY,=N"X7<G<G8YFUV#7<6;YQE<VW)
MM=F&_>0XHB9)D8D%A?18C6;DX+7!Y>72QY/;&XO;VMD&A1[Y+#)L1:/4H+<V
M[>(-UU*(O6 K85NRLA<QMN2@)50X4$@::+9N#K&+]M[(MJ<SMD(:Z1!.I@.@
MS0&8J2=:Q^\X;^(L+QV/#]\+\^H-R&^,*Q[)MV]T0B2:)+7==F!5H.<PB9'D
M^,OQ*HRS;6QNO)3)G[@6.VR466EG@7UC<S2N(PYC/94$*!F6U:(S1:SDVY16
MSE+@$QU8NYD@J!4-8O $)=8]HF&N7!I+Y1F&9ERYD)(G.4@Z,:T!G7#QQ=;9
M8;=2X/E5IGF5YE6WE=U> 99=X+8B;E6Q.\N14>Y61Y2*&):65;49!FN/HN)V
MC)<+N[*0LO+R::KK(#"M[5_"7+B]8H1$*'MJ+@-L=4K6E4R 2JMVP0X&BRVV
M3VL0B'(Q=FS>:62'.<ARRZD!B.R1E)U: #6^<^X=N*&PDRV7"M]3T'R6SOK:
M*FM=R]Q,=;5VEC9[_P#L=.I[^EJ+FRQZIP^KS78^9,&HQ1,6RLK:LROO(F0V
MQ]I=X)B,,"N>R(4*)%NVT@"SG#*Q4$N4NQ<)+(+DKJH U:S?@Y;I[18D%W$2
M;F4JT,5"AK?9 "MD(.A,WD[8'B,@M*^U#WBL<B ,RF\NLXP^SW2W'Q '(:U]
M_N?+AM7CN4X_4VUQMZ+C-+E. $6@&*5H@68F8 RCR!"*ZS+LYHZ_#F1U06$5
M4<6K;%3EMARR$@7"S*X!=B4%S,O: %3U5T#^$+$L2P-QU!&9RH# $H%!60H&
M;+E)@DUE%'MKOED.&[EU^2YG/#;3[[T)6V3\AD6=*K9W;/>&FRBJ\?@@99MD
MR?(JBOR(43('*ZQM*A^$&6SZVR#(0.C7+*O;*H"!8(N9=)NW+3*==.RI*DC8
M'.!(.MU2Z5<,^IN@I/*VK@@'?5@")WB#H=!@U;P]<3E(')7#[XGWO3P^RK:.
MYO-R=PV6.$;@6>V>%4INX,P:U5F/NF'-N-6YCD-?@&9%UN*XO7W(LF/1"JK*
M6IT.(P[&>I"]H2%MVX>V+CL$W'5$(44W$!=\L,3))H+5Y=.M+=DY6+M*N4 S
M$01<!?,<CG*H(RP0!5BNMBN*(&BR:SCW&O;<TVUV8J\&VYI=[MSV!8GCZ\0,
M-MNZ'=;HEU5?EV20V^TIC*OV=VE'89CC@$-N#CE>V6MJ"["RWL,6 -M0,MXO
M<-FW+,,.5LY;4E%B\,Q0$(Y(+&) HUF^%)%QB9MA4%UX4=:#<FX1F;-;D9B"
MR@$*-=;@+P\<5Y1-<-<;^$"ULAF%>7+&GS_.W6C\)K[K;6;)-LJP!]($'#9P
M56/YZ\/?EAP6Y67DY1#59!74X"N,KX&(PHS$6),/E#6T(SE+@6XQS3&9D^P@
MVT"2I)T,]3?,3=(G),._FAE+(--X!B[H[%B" *X3N%[B'N\ML;2PWI+KJRGR
M>SR7 36;B[D9(4!>(-O?7XQDA>+68U=25C:6ES_;JCL,$@M+W$LCBP NUN9"
MK&\-0A])L!% L@D@+<'5VU!7[(LH<$L<S)<8/"NF?*IRJ*GJ;Q9B;A"R"O;<
MZCK(8J8 @,@*258IF.I,Y1LELGQ/X1G6%7FX&[$.4XG7U.0A9-C9VY.>9E$(
MXY+N2MBQUMKBV-3Y"9+8STE@9DNXEGD)U+7BF8UC%8 (Z&Q=6]>PSHXMVBCD
MJ4(MVTVB2T,V720%MA0Q(=C.E3:MWU9"]P,H5@P+LVIF,H*K.L',Y) E0.=3
MJUQ5U4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5B^<6A]'AF67543
M2A6E3C=W95QF22$0X\*<%6DDB$7DHB*5'40SQQR6+QD6=HC970HLB-1;( SH
MI!(+*"%\X@D A>4D;>-5<D*Q$ A206, 0)DGN'.HOXWO7NO8T!MT4?PY60\@
M@3**PI]R#HZ\\H$@^#)CS6DBN4"OBG=4C0P^-3.K6>5"BRC)!Z\*XZFLV@V6
M,0NID&V)$P5&^NDZQ+&  ))&*W'(F;1!&A#:&)!/HF!X"3RUZ+=\=\X9:^"6
MDX?+/II8F71E1NQ*L5#7A5$MW(EC7%AQW+"!X@[0)OD\&UF,CJR[HD&F@AEK
MXW4V-8.(&P4-: S$L%&H)7FIU(U(43.:G67=!EMG<DA]@!.HB>1 ]!) @@<X
M_$'N#$-D;K";8*>2N#G?3FU&X5^>$6?!9XRV>"UCAQQZU8XM5873IG1E&D1V
MJXJ!/%$N1@/*'#VY7+U\$B0;:@Q#ZCM0=0L;",QGLFG6OKI:D QVSN"H(/9.
M6 3.YG+WUD?R7=UIZL JO'V&+-<7,791.W+LAXH<4*=5#4-VV">ECL ISK#V
M0BFBGC-'!6N8GCLLL1$3J]59D@F^ - >K!EA)9?.C092"#.NT&1/6/II;U.H
MSZY3 4Q',S(V\=-;&'O;NI<%U+*RPX=$",C#M7S2[B&R$DT!559G0FP0Q,<)
M$XF0:"9T4!]E((' :YZ2P.CL(K=1: :1B)$@#JQ 8, 0=CIJ)C4D;$14=8Y(
MR]40=1V]2(,<HU,>B#O5PI]Y=U[4@@,D39.H/K[:^%-"FSYUB^>B\A4-CBV4
M5+ZZ260T,LP^R8772C"VDXC:"=1:F&]0H.#9M  S>((4@BW$-F8,C9@(( !#
M;3FC-EUE;CF=+8()!&:21 (((Y$DZ1,1][3@9O'NN+6"06=IPUI>..H8O'8]
MR[2.JL1)XLE(R!1Q?)L\@5@+$%C_ )/%?9%03#D7=D24/"%".]U-HDP,1$-
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MJLFC!$@'M[>NR"W78,,(LEDS E&+Y5#=0+F0+<7M%4N $ZZJ9D*17JL20?M
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MR('.B,%N*NQO3KS)YY'F6UEOX15*]6W:4!NR8.7(4#CK06*N'9F5DSJ0H"@
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M EZ397$&3Y#FU\VT;8XOC\F+Y-<P L7%MVCUS6@@9\Y[8;",;@)8A6D8H2H
M*A 5AC.BIC#=0O<'5BX6(7*.P5Q"Y" LLNN'(DDALYG18]+->.KMII2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4JBJC45SE1K6H
MJN<JHB(B)S555>Q$1.U57L1-*572E=0FP "?#&8:((\A5:.PDF&!\[FNC8YL
M+97L656OFB8J,1RHZ6-J]KVHJE=O2E-*4TI32E-*4TI32E-*4TI32E-*5K_=
MGZ%>Y?ZG^9?M<LM*5!7P>OSLV?O_ (L6@Y^@:=VN_K]6U0=QZ?R->E6E332E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*58<I4I,:O_ !$!+0Q::R8-7.AB
M)8;,\25D8\@T_.(F.1SD;(,]'(0Q70]!ZO1JJ5I$2TS(O*L?VVH0#JBHQF>/
M);/(;*4/MQT(1T53B5J+063YO+)UK8UME"R8JM6SQ^J,?;CJ]\T%LI6N0"\N
MS++*2VO'5EZ($*'>XX#7]9>26TTMG*QMM25BLHA0L69D58ZUI,@LK/Q>>AIL
M-DM2D)O)'2J@>[E_C/LJ2H^299#;R!6F!V+*7QR( 3(@+FFLY9NNLY:^&PL*
M.*08P !\31[&>45UE*$(6QQ8\"#'N#5-9XJHB*JJB(B*JJJ\D1$[5557L1$3
MO72E0,J.)O>*QJI!XL2X?K#(AA:N0X@;?T, ,1<ANZ&GI;":BDH+&5M?)-D
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MUA5Q#.Q9QA\3;8JBQ=:[;<^%=W3S>BV0LLAV^V>Q:#=?>=-L[-:+=+#\WR\
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42E-*4TI32E-*4TI32E-*4TI7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g937421g76x01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g76x01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &,:^8T(X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #Q@
M!V0          0                         !              =D   #
MQ@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
MQ@    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   \8     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   $.$))300,      [+     0   *    !2   !X   F<    ZO !@  ?_8
M_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,
M$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !2 * # 2(  A$!
M Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !
M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#TJ[.]+,9BBBVPOK=:;6M)
M8(+6[/4^AZGN^BBU7EY -3F3R71 5?-M>VUC&T^HUS=7F8!G\_:U^U!:ZYXE
ME-3HT,N<W_JJDVIV3N.@V7W"@*(/4[NG 2@*EZ_4N?1I_P"W'?\ I)+[1U+_
M $-'_;CO_22?2QNP%"QMY_FGL;IIN87:_P!FRM46]0RS.Z@5Q^^'Z_U=M;MR
M)]ISR 6U4D'Q>X?AZ:5*9$=5 ('V<D\$[Q'Q;[MRA<_/KH+KC6UWJ4AIJGAU
MC&6!WJ?R7)_M'4O]#1_VX[_TDH9%F2_&/KL8R+J-NQQ=/Z6OF6L24Z*222"E
M))))*4DDDDI22222E))))*4DDDDI_]#T'JK-]M7Z,V>T\5^IW;_PE:GBO>ZI
MH<Q[=HC<]NT'^JQUEEG_ 'Q"ZOD8M5U0OJ982PEFYKW'0MW1Z;7?\&JS>LXU
M;6UL%;0-&@"W:/GLV[=4[HIM[Z:K['-Q[38XQ8]K1#OY6M@;_P!%6FD$B"#K
MV,_D62+6W?IQA,?ZAW;_ $KS/??_ #/\E7,1^0\C9CUT,W@/TLJ=_68Q];-Z
M2D6-4Z7AK=H<XZAEC 3X[L>U]?\ ;?L5MHN:&@FO;H/SY^3GN^DL1N?DUG]'
M7@MLDD 67@;A]-WMI_Z6U%LS>IV-VV'I3FP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" $U ET# 1$  A$! Q$!_\0 'P !  $$ P$! 0
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M?,F2;LN.<O(C EF9C*5E@2-EBWCIAB62PF*%+=;T.'PX91Y8F4@EFZJX"IS
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M\1>2[<M]""ZV\5B,/]78QMR#AK^/P]VT[)T?:V<6]S!!;0P[XC9R-?5<=M/
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M%%Y(W%''98PXEQ:$N%/69L;"U(:(7AO#V7.B.2KH=$=_+;-BS$==KR0[OU/
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M/XL:C3C[?5[?;/*E1W9MM(BTRK,R58+K&F#HZ#*8&V2\0./A3*6'E",CN9P
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M(N?E<[Y%3-FJ*(X"Y5KJ*I*2LTPZ*8#"SJ[".Y#- K8M,B.\%+/%,*EX65N
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MJ;KV[=DVXF"51K=MR!7,NP$U7GHZ/R_/OE.S&#)IAPPH-)M6/S'"245M:N%
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MF_\ D4]7EP4_Y5_#[_I8I?\ /&GY5V9_K#!?[U9_;I_E2^C?_;OHG_Q[9O\
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M()SEAE<,0+BE>MS?GFU23"D<U T (&\M,29($?FF+=6 8LI&?F#R)&\J2!H
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ML+DMID!"P#$R9))))/P72?9VUML=(=L[2V=T7VM@MG8K'XFYLW"6]@/@%PN
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M["0:RD<\-@A?\[Q.PMH7L5C+RX'"XBWB+SW+3W+UI'"MD .J,P@*X )CZPF
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M&Q!K5*M;O5Q?7D0L$S'*6Y'/T9T%P:9EV$SDT(2@ILSKB@$J9P]@MN#T=VA
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MLKD2,=<MM;P]QE3/E5&(0K;22HS/VE* S"C4$Y*\FX&+./)$97NHK,5$LH+
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MJC>8Q_BM[CX=W"I7>/$>^M5>!OG\#ZP__+>Q\=!^WX\^'\NN:S^<'I!\(/\
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MC<7?N8C%-D"(K7;^)NW;UY\P=[CEVG/FJPE\6W%:+7H.6QPE6LJ2DZ;?9ER
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M T%;&)@4'$*+:"#+Y+]TNP<G&BR1 4:!%44U#A\=#4"K"21O6U:^AMM;&'M
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MN#C8!NX#U)D$&;@1%@)DJY$/6E!,MM9V/C4O6[GE]VZMN]=#6M2KR!:[9S,
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M(GI.O.Y0AQUUQ:LH8%$&:>,.+=8#"8?+?9979%9W5$!9W(55&I)/+\3N U)
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M">CA*L\SHUMVMN &4P1OX3H1H94@B/;6RL'4,ID'=P]AUK92 _6<#Z3GUO\
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M#]*G^''CNVR9WEX?+C#2CQ:NYRY$)I0$E%SR!VR'ZQN-65I3(0TVRA]I3CI
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M\''2-D?3SQSZMU9BZVPVO'@5EI93>,_J5+QVY_1NP?W&/2?$A'Z1]+]C;)!
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MV+:"9-W&^1H #,:3\ U\FHQ$75C1"0)&-8[KFQ2VECD-S\LADJ10^.ZE*V"
M1TQ\&ZGGE#O>9!",\GM?OK]S]T";Z/OHQV'LW%6&P^V-JAMO[=MW4-N]:VCM
M%+97"7D8!DN[/P5O"8*[;,Y;]B\T NPK\-_3OTW7IW](VV,?A;ZW]D;+(V%L
M6Y;8/9NX#9]RZ'Q5EU)6Y:QV-N8O&6KH\ZQ?LKN05S:_M=?QRM@=HM^9S;YT
M>'F%$3=/RM*,A*5APZ&0K/Q3T.ZZI/-I//IKC'G,"KY*R.H1U;CCF%VPMS58
M5^>L-W'OX2/3758Q+6X5I9-T<5[Q/#^+NY1K.[]LF+)8:,S:-GY*/EI)G(\U
M% .MC*#M; 3V'2*PZ8<;&-P3\IAIV,>D"G.G#NN.J?#P2PGJ>%0%?+=! &AC
M>I(\^!)8"<P \Z-"0=?3+%DS6R&G4<F WK,B"8@D[C,B=VDDI$/W:CV[<'AL
MB:MLKQ/Q=<Q'S\A!46O2TM.4(B[.2UN>IU0S8V8,N0LMGJ\N+&G70<R48L<3
M9*^XW$R4VNT)Z0V1U2^6O8>255G90&" (6<*2,J,I(0Y2I5M0,M81F5FM1;N
M@"2%#$KFEH3, 98, 6UD,-#K6X>PF]=9WYV]CKK77DX+;4U%6R'P-)#NU:VL
M@!'2]7/1)A E,R<4@\7NT(AAD\'KVF9(4(SK!F^>]::RY1N4JVG:4DA77@0T
M&"-#&DBMK=Q;JYE/<1Q5H!*D&"")$@@$<0#4@WC_  )NG@_P1LWC_P"8SL^7
MS\'AUB_F-O\ -/#N(Y?._=6J[QXCWUJMP-_L?6#U^YO!SSG/Z:#\7@\?].-<
MMJ,XF(@[XY>_U>.\5H^X>/X&MT//[WGYXUV?/O\ GY-957R>?/P]OXM.?S&@
M_P ?32G@[/%V>7&,^/M\&?/LU&GOUY<-.5*IY^?WOZ=32JXY>/S\_#V\O!J#
M/#Y^=VD[Z5J_O5Q BTQ1-7J"AY"UXPIHX]6$/@5Y>>:5-J1G*D&3".7/N1>,
MC!JRG)F'G$K"STV;!>&>0F\#BV_3N7=KO/#G7)B,4+<HD,^XG@GCS;NX<>1\
M_).3D9D\J4EC29&1-=4\4:6ZMXA]Q7^,MQ><YY8QR2A&.2&T82VVE*$I3CO
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M/&X?4I\M[D5*'N&3DP^1)'%DN?L?#8:UA+(M6E@#5FB6=H$LQ&I)C0;@(50
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M7&"J))^23W#>>ZO4;;O;RM;2U=UIMX5)"!5'V>RFJ:$P1D5I;Q#[[[Z\(!B
M&TNK896ZE@5A*R"'%D.$$+\NY<:Z\G=,(N\#6!'\8R >).@T KV+5I;*0(F)
M9N9YZG0#EN],FOR^^B5^CF6&=DY_8_@DGG(&KA.DQ-KX@@>AW]L[S:GAS =J
M%K2M,)7<83E*;YE.)V86K)%7Q!@C"S<[]'L_8R@"]C5S,89+!T"[B#=@]IOY
M/S5TSYC*KX>.VL26M80P!HU_B>8M\APS[S^C&C'\S,A(2$L>9*2IQDI*2);Y
MTE)2)3YT@><2XIXHPTPE;I)99+RUNOE$../ONJ4XXM:\]+/T(      T
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MN8RQ:SYV(R D]DZE>M#!9 D@V;@GS21"LQF.JW@[]S)E4=LB.TN@86RK-!)
M/6IH 6$RR@$$\VT%)XG=N_3/N;M==IS99$'$7J+G;W5]UV:7(%LTV*G;-+U1
M@BFV+%EF6I\J@R@5?0&(36[).P)"1))UJ!E3(R+SX:X4M746\6-LK;:UU@'6
M$(KD.N491<&?])%;4=H K5O$H&NVW-D*'!N+<RSD#,4&1BS3D(70JQ&^ 2-^
M@=]?13(C</<;=V3@J1;;-NK*L[O/E7E>QFX</3+ILN^12H>^[:@3]MF1:!>]
MNB+0=5Z]%Q669)PA<G#"UV7(K1@\+P&SLLV[=D,Z+9!LPG7VRZ7NVR7"JKUE
MN[D#$F1H#F7,">WK-I![EPHC-=^LENJN!&M=D/;!8A'22 !J2",IRF(4K]&X
MZ-C3KMMC3@*M-!2TE9]NYD]-IIK =@L>[,'$6&3FN=RL53L)CL_$4V.C09*Q
M1":=+%UQV"[BE9IM;#VS7,#?"7;A92 MU1D<E5LE@!-M'7L&X6(5LP#!@0((
MS6WCK.>V@4@ED8YDAFN@,6[95NT% &8!25*P3-:JM\(7$2L4<Q&WK*F"HV$F
M&?[NMMNO3&V"R+J(+[XGIR[M"4+8V78NQ"FCCETUUIQ^XL00;:B<=7EF&^]X
MLI.2Y *J'.N2-5(*03GW)F.E<OD>)T^KWP?/M\6RC3/(AA# ZKO:!42W7;:[
M;>=X<W&&1$M6F+7.ULAJ8@Y@2=A4'$QBIF).@924#.B4RH4A#XD1WW E341.
M0J7E2T#,A@;)<2YFR-FRG*W992K$ Y2&52&@@P1.5E:(92<7MO;RYQ&89E(*
ML&$Q(*D@B01/,$;P0)\X*N,#<G@EWSKV\5 (>-CD*:B-P*2\6X/$W^E/OH7*
M5Z0QC"FVBV^CB0KTJIIQV%G!@S<-$"X,",QQ>%MXRRUE]#OMO$FV_!AW<& \
MY9$@P1MA,4^$O+<22NZXDP'3B#R/%3&AYB0?Z%]#N^VO$WLM6+_4#DV/;;=B
MI!3D,9E*62>XI%K"^I*9PIW,;/P,BTZ'(A.*61#ST:2&_CN@-Q.OA'2[A[K(
MXR7+3E6'(@\)WJRP08[2D$:$5]DK6\1:#*<UNZ@(/<=?0P.\;PP@ZBO-.XU<
M^EV>9K$E\43$&K'P]A"D(+&5A+P1S259SE+1HCC!3:<YRI"7<(7GIH5C'I(P
M=5<:9A,<N!!\#(//PKQ[B&V[(=ZDB=TC@? C7V&NI7)X^KST388Q?0.ASASA
M^WDES+*\9<'<[,\V2FLN#/IY?%LNN)_QM2RAE*G<P(\)X^(WCO%0C%'5QO4@
M^,;QX$:'NKV%A9<*?B(N<C5Y6!,1X<D&I78O(YH[9+6'$XSGHNI0YA+J.WJW
M,*0KXI.=>005)!U*D@Q&\:&/\=?#2O=5@RAAJ& (/<=15HO'^!%S_P"B-F_B
M0[57\UOYI]QJR[QXCWUJMP-_L?6#_P"6QR\'_&@_Z<^OC&N6S^<'@9\(/XUH
M^X>/X&MTO/[WY?+[.,>/L^??\.7@3PRK6?BVLEZ@=F)6.VTBCI&\7NP57;F
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MJ+):W9>W'6%F# "VO:;6;N[+EE@I!/4PV@UL6GS7+8?K8>ZCR4 7*Q-PG*#
MZH_I$PLR1:M_MI>.G<TN VLOT=7MP<;97B9KL59(RU4Z*<L%RW$":FBI%]5P
MG:Q,J:L U2=%$E\UROP,Y.PLHA3DI<BY(H^</=P-L-=MEK?66U9E*.<J6R5
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M8,DXZ\UR,S&S1S1+86!F!A3W+&$=4,!X?'81!G&-8(93EN-ZE68M[&V*H_\
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M<N@(GGP[XMJ]UMX3ECL1E VVC3L2T[ OA2F[D5)H-F@ 'Y "+"*BP&"AY++
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M@H3#+:TJ2VF'BDHPG$<)ABIO88[[V',3$W+1B29CM<9.[?).XFK"UBQH+6(
MY!+@Y<AW#U#D*XR-C.+$IHADK9KB*)9+.D9,IDC;K<UYHJ3F&VFI:1(;<AUM
MOG2C333<D6[A9!S;3:"G'4MXQAUV%D'K</(  /66@0!) \[0 R0.'#?4=3BC
M,VL09))^KN:EO.)TWF!)X\:[36S/%\ST\L[3\2;/6#G"N=50]TF^D-)NI?DQ
ME]")3TF9%Y*'CFL\VRW4X<(0ZO&%9=;A3$W<.=1$W+6A&X[](C0\*D6L6-UK
M$#>-$N;CO&[CQYUDCE'XW7JLBEN;:\2*JWBU(O"@?@:[@X>>MC<7F$8FRI1-
M>3+&%BQ*W0@DDG/#@LO$9#9962^MRF;!A\_68;/DZO-UEOS)S91VLH$ZF -=
M^[2V3&9.KZO$9,V?+U=SSH@-YLR 2!KI)BL:SLSQ>9R'TMI^)/.8X>.$C\YH
M6Z.>X1(=\<F'&"_M3CN4>**%%(C66,-MA/C,.BI:=9;6F_7874=;A^U)/UEJ
M#F!S3VH,@D&=\D&J]5B]/J\1I$=B[IEB(TTB!'*!%<$WL;Q6V5<8N?V1W[E5
MP\:F'C%F;57QQ0<<DXZ54,URKR<\G9.5E),EQ?3>*DI$T\IU\HI]Y87L,LY;
MU@2<QBZFIR@3YV^% C@   ( J&LXEHS6;Y@0)M/H))CS>9)/,DDU8O4T<1_/
M]K[O@KGS_P#9+?L>7/+MK^>7;[/;X>7+MMY1A_O[']-;/N:H\GQ'W%[^B?\
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M&C<.'E6&3BHV/ E 8Z<> B2PW98P<>=4T<C$*"<IIK)9[621=>I026ME9S9
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M3+98X::3Z)@^V)?Z"_W57UJ/>ZQK2#S/L^%.@O\ =5?6H][I2#S/L^%.@O\
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MYV&1UM2C<F&'G"NK='DW.X'VT$8Z.JG"8@&VO5L6NFX$189R;9(?LB2(@GO
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MLT$&H6];;.0P(0J"1J.UYL<23(@ :R")D5DM6WTV?O$YBMT_<2L66;5!-65
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M_DG$BDO;NRQ,G#%8R^<:0E)0A0,17B6>PG'V#=12Y"LXN%+>9 PBV224X=4
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MIU N;B%6WJ V\*JC7\:R(JF\#4"S \-KMVH%<)JDG*UB#VF8WQD8*QQ;6Y^
MWY+;)N!8O M@])UL'FH=D;:UYM=37'EUH**KK ;< RU&;&MFQ.2XP<!VNFR"
MI-N0+F;)ESH0WUH[4AB6G-4Y<,,MC.@*DJ+8N00'U-O*&!R$$=@Z1E $9:[L
MA=>#>X,@T82UT6ZQ,JQOQ+#KK.X\9(0^9JX]Q8W1K;TV%;V$L6JYB[W.R$-"
MNDHRW%R9<E%+B! (Y[%0N+MG/E=".H':MD&%UM, 4/90V0"P&\ &22*DG#-"
M2K#ZX]EM):!<$AM["[(' $D1 K&)B*X!["[9;'8MP=NXYP=V8<W B"=_WHB+
MBYS=$?=$64]/%?BMPT5MJRR ^XVZ48&7(,.E ,E',0I30];AUQ-P<<,JK;N&
M0.K(L22MKJXR$V\V4&W;)C0D"9+--6&%,EG492Q8=:0 UP/.9<V7,0[QII.F
MBB,2F=H^&(/B$VZ;F;JR-$6@^GV_:_;P*S2BJ];=S+%7+(76;6V\)N <V>]B
MJ['2I,7)OTN&9EUL!0[%WLS&?2J#(O8@V+@"25#+=N%5S+;5D!3\V"H#75!&
M<@23D4RU0;5D7;<M 8AD0$PSE6AM&@DJA(.77+ 8C09O9*EP*IQNK=I.U50U
MC9R2M6YN[T9![OV61 I=E-$NT)8;9;J+7[@\&';3!%W*J#%'PF)EU$:_5XS'
M2@QH\*!<QOU:!7!O!+=HM94%U!0JB.4DJ"$: 8DACYTF2F%[;EE(M%G<"X2%
M8YLS,H:)(++)&Z0-VGU<Z)PD7BC[S1]<W)K@0MY%NM<W!<J.ZY<H)FR6*W)<
ML1_I78N:*ZC=(&X7\&-K$V^%B?J]JG*9' 9;5'UJ*9A'Q5M[):VQ*%&MY[<'
M*J]D!BN;JBJ$D Y64,3H6-2R6'6Z X[09;F5Y$DB9 :.LE@%)U!( W 5GSV.
M$RZ5V&W7E96AQ<%4]M&CTR)]T$K,=1-O!8+<&@$)GA@K +"UV-@ ;EN)49)\
MWJQHB4Q)@K*;D8 94?3_ #I&-L"X6:YH A8O<S(\J2I9B2EMP!O$&(8S>+!&
M8Y0%0 G- 1(=8,&  &=3R/>!$7)8]#ZE@ 1&-Z]N"8:PUC<+<&)C0N)^21#2
M6VQ9D[([N'14>+N2@![:F4D8*PR&Y,<(RJDG%UHQ^Q#+55F^]FO^?@DFQ<E6
MMVR3A1(N *+4GJYZT!E%LDYP&&4]O7,>2& +J00[@"^8*=KK(&>,A(8W -)4
MEO-TQF3:]#UGIN<N$[Q"[,R5#12]IMLCZ:O?^)$H3*R;!NEN-15VE@2^L1ME
M/N#]XE9VG!VE@Y3.:WB=JRL+:)?8L/R@ $6Q>SY[MT.,.3<T6U;N%3U>8!0J
MJY4QVLK:G6#Y&3F-VV5"HA7K1DU+NH89\I)DLH82(D;M,K+-]#YJX>YV)??#
M:N-, M5-J^[%HG^)E[TWP-_K%ID;%1(VVW.6W%59:_=XBQTR2S",GRH4WABF
MDPR4.1-<> $KEQ[=5%BZ05=K2+ANPR,H5RB"WE9&5Q, @YP=[ D3A!GF[;D,
MJN3>&8.K%DEBV8.I5HUD!2#H#$2B67T-FP&$5VUR%7I0>V=Q&C8>T;H[L(K(
M%ALR[)?*&(# V:9W)<F+>U9R=J;$>V-(K>&MH$6+,+1(2(!>(S0KM!!F7,YN
MVY*V[98JF1+DLJVP$*BX!IJAD:")IFP3:-E46W@,[0"V9D@,6);,4._SH!U.
M[+MP+AZ'AMELM:90W<ZEF4VM;FW>>='I._;Y5ZDMZ&Z/)0-RJ-7EP=Q@;$;N
M')426DX62I8DXP><!,DOFAY+D73W:VTQ]V\JBVX=K2++6(062X9&8=65%L7%
M!#E2 5$&%@2[X.W:8FXN57<]F[V^LRD.JG.&SY"05F2#J)->C$)#1M=AHBOP
MXV XB"C (:*$PX\]@6-C!&@@1L/$..ONX8%8::PX^ZX\OH])QQ:\J5GSR2Q+
M$R222>9)DGUUV@   ;@ !QT'>=:N>HJ:X$_'+WT@?\(5J> \3[EJ.)\![VKG
MU%332E-*4TI32E-*4TI32E-*4TI32E-*4TI32E:I[Z;5V6Y63-DC-L-HMQX^
M/JT:#WHN9,Q$6B=,#.M!SD*//BI?BHV''<,BGPDR4?)M$%2$VR0T(PM+ZNJQ
M=5%RF[=MDN3F0 JH(43E.I)@@P5("J1)TK"ZC,V8);<!0(;1CJQ@-N &D @@
MR08WU@4]L?;[$ML^6V)V+EY9UWI$]^+1:RQ6\]TX,9+;*4.M_#[9B72B641V
M>N<4E?=KSDL?F(T6^BR!?OJNL954$\-TC2-!)TUT$ -5K;$2;5HG^,Q,:R-8
MYDG0=Q)DQCZ^&B7'9AXB/V+V8<B4N)D9\B>L%FLDDT>Q9YH@4B".**!(EC78
M= 19P$JB B6I"30ILT]M!H L^4@EF-^]FDA<JJH(*B<P&@&:8*YF@$$"0:CJ
M3  M6^&:6+'0DZ3O, ;X&O'<+TYLO=H92K)G9+9NT3<!"PQ%3CHU9P)S-EK(
MD)7 4XEYRR=SL@,P"C1H)A26^[P8I)EA/BI58X!D=>A[/77E5B<Y,$96+,>R
M%U,P3R+$*"NH=6XENKML0!E&XY@ !J3I T&IF"20=]H,V#O*7&1H?A_V!8C'
M"DDDB2MPN$DP@IA",C&N)[B0P;AIXFPN*#?CE)=<E12W'\$E2>0["^FI;$8@
MM&\(@D<CK(W*)!W C<%F#:?<+5H F2,Q.O,:0=YT([QOJ]"</<ZV_P!>SLGL
MK7S83HR4)(Q5LMIF)LS,A7%'P<^.Y'QQ&(D^/<LK@N'S940.;CH"4>CB$I?#
M=J<0.-^\P;1@449=&AEU(S#L@F 2I82-]2+1F1:MJ1J"&,G4$@Z#0B>8!@P8
MBKW)[&2S\-5@F]CMCB\1D;W.H!^9L*VZV2NS3<XTQ#DN MKDHL=P@0EYEY4;
ME!4K($B,.,PPT+-0+XS,3?OB3((5>UV562),'2!$Z*-1F)6QM:#ZJV=!I)T[
M3-IH)X<1J=) @XJ9L)<)5J0)DN'KAO?DB[$1./E/S=F?(D7%FXD6CR$(CF<Y
ME5.Y)P>T]*K$FI,AR9.)%<,.9788A! &(Q( $#LH($1 U.G+3L@!0# -5-IC
M,V;)),R6)[YB-_/774\8J]2&SMLA\JL,3L#LO/V*,&Q)@-(L,NRE!1 :7Y&'
MA@Y1MB,R6F=)E#QB328.-E!WL1Y3L0Y(ERP=1=1NRU^\JG0DJNX& 25EH@ $
M#,1H>UE"U/5L((M6R1J-3Q$D"=)DG>0#Q(S$UU+/L7:IS"BD[%[,G2!Z WG)
M&>NMND)@!:,1 BV72W1G7'C&  ,M,F#'=2UTL/I02N*2'9Y2^BB.OO!1/95$
M ,SKR ).HCTZRL-:9M>JM3IJ68GA(GG W^_]*];:[$24(77H><V:VB@*C67Y
M$Z-)C9V?MDZXJ6CZ_$/C%,S+(0_?/,>$TS)V,@Z6<DD0"E-QPRYMU.*W+X(9
MEO7F=X!E551!9A$$F).B@ #-O[-2EHB ;=L*NX@DF" ./&!J9UC<)(J:B>'?
M90V67/';>09\X\P@8F8/R<=)FLMN"N(Q('%&/$R"T9"%;2Z:Z0[@=E(V%]S9
M4TK$8B^!E%Q@LSE$0#KN$0-YW1KKOK4V;1,E%)YG>=V\[SN&^IHUC6E-*5Y+
M;S_MY&OWBJ'^H9U)W+X?B:@;SX_@*]81/C4;ZG9_!IU'S\S0;M?GU5V-*FFE
M*:4K![[M_![AQL6!,$2\>3!3@EEK\W7Y)V)G(*<#&.CT2$::VEQ"''HN4E(H
MIHA@@<B/DC&'&<Y<2M%T=K9)$',I5@PD,I@P1X@'AJ*JZ!P 9$&008(,$2/0
M2-01!K6^-X$N'R$CG(B%A[,#$EPM"@9B&<N=F+B+/';61+4-MT/:!7I/NB49
MJPJ2UL(:-"7(D29Y,NZ>3W"\#T''8@DL64M-Q@V194W23<RZ0,QU.AB!$"0<
M!A+(4* <L("I8D,+8A PF2%Y3K)F:ZE"X+*?'0UK8W:L)V[EAN<^/+S<R]B?
MKH*P(\38X6-@V(TJVVB0R&QGA\V])*>,GS"#'695K*F1)(@=4OC')0VE%H(I
M  RL9/72Q(11/U]P !0 ")DB:+AE 87&-PL023($#JX$9B8^J29)DSP)%7XG
M@JV2D'Q3)9JYS$@UF?[MDY*YS#TG,(L%%A=M'F)20;<:+6('1ZW7H1D(-T(,
M]<'$S-@8FK!'BRS51C+R^;D &6!D$+E=KD@;I+LS$F2)(7*I(JQPULZG,3K)
M+:G,H0@]V50($3 )D@$9"SPI;4"57%2 Q;(P-B_3>Y$9(QMID0I:"LECI\EM
M]-JA"&,H&CPI2D34W R [0>5G$3<O:S'G[U)%VEVOE-TMG.4DH+9!4$%58.N
M8'>0X# DZ0%'8 6IZA,N7M#M%I#006!4Q' J2"(XSYVM7XSASVR>ID#1HT2;
MK<15+;8;M5BJ[/R4?,5V?M8UNCK"_%2*W2'&QY*$O=N@5"/H(9%BYIY(*12Q
M8\L2!B+N=G)#%T5'S $,JE"H($;FMHT\U!,ZU/4IE"@%0K%URF"I8,#!Y$,P
M\"8C2(4SLWP3$0D_3^_]!<K]J+B-N9: 1NH-W,2?"7R8LL=1F$-V+!(\FBW3
M\B"Y"C/-RKV'FX9QM6&6F4ZB[BP0P6X&4-<#=69 9,K/NW90#FW")K,V\,00
M2A4D6XSB)5I";]X/Z._NKN;5TWA9VV*WMKVV-DK,7,1E&JL+NY:^_4&Y#PXI
M%BW>$KK-B+CW(VM1UDAY@BYB3,>IN+DA@6:\)*H0VF,5B;MS%7!8-U69>L=K
M2PV8G+9+99EBI4(0=1)8CC4(EA#=",H.15N-*Y0)N 3$*&!SYAH=T\(PNI;$
M<) U>J1WP9@K.1'2VWM6,N3>] 2D72<AP-K)K;^E2CX\Z0.2UEK:_;B=K58'
M*S,280:WRBYP:V6E^Q6>_BB[?5% 1=8)U1["L;BW7$C3\XZNT!03H%*KEA;6
M'RK-P-!12_6 9R AMJ2#K&5"JR20));,V;J+VNX&R[S'5G)D*?-;'#1,T?(D
M6 >=KE2'!@H*M(B[38I)V2BJ\=$"<,-:+F623(>=C"JT.X66R-9I866GKL:$
M+:@7R0!E*LY+,TJH@L#Y2X&C*0QT)4$0+>%S@#*3: ))(95@!>T3.4CJ5F,I
M!4:B2#?YW:K@W/@&Z8/9(F51)PVW=,9BZK>P[-.#P%X<X?Z/1)3,8@V74S%R
M:-IMG,@64D!P9+0BYH0K#TH06]07<6&S%2,IN-VT*J2G7NXD@21UUZ5!G7*=
M!%6*8>,H82P1>R\M#=4J&).D);@D1QWFKA:*IP;[KWB/NUJ?BYB[[92HVW!1
M4A:Y5J0IV=G[;<;<,]<P\S']JH1Z1V^N2GK+:FF@K?6U2L2>=(PLP2(^5\7:
M3(LA+H-P (L/UR(IRF-3#I"J95H( 8"A7#W&S$RULY#VC*]4S&6 /9$JW:,!
MA,RIKXJ&WG!8I ]-JMSJA;L2]3MO08YO<[+Y11KM%X?+!3X:)<?F.G.F2E'V
M1V;F8]R)6<J2#C9$AMQUV1GL*AGQ?GLKP0]PGJ]  ]]7)@=D![UX&8@L/XM2
M$PYT#+,JGG[SEM, -=25MVCI,P>;5?B=@^%G=2YR^XC-@CK;-6NXUV;>57MR
M&R(E^W5& N%?CLC 0$DD4V51#NVP<M)G=\BH2&="2XS&5D8*.KUV)MHMO*55
M48:VX;(S*^I(D+FRD1 DSJ6)-A;LLQN ABS R&!&8!ET T)@L#,G2!   S>2
MX2]D)>:S/R%:.)D%*"4OI3\RD9SN#=.?WE80X*@M+*V\WRS3$@\C*>3P1"(I
M?,!EIA-!B;P7*&TF=PF>K%KE]A0!RW[ZL;-LF<NL1O.HS%X/_P!Q]6FZKSME
MPX;:[3SK5FK2;,;/CPTC7!Y6S6B7L)3$!(16V<#B);S(/K;P.'";04".%=4V
MHQ>(<@\XHV7F)J1D%S$7+JY&RA<P8A5"@L#<,Z<2;MP\NU @!0"640YA)8 J
M"228(01KW6T'/LR9))..RG")LM*$!DJC+""Z/2&MLB\QMKFP\3.W&9:6FY*D
MS&$%*P7"3LC+O/32D=1)EI&"91(L-,90Y(Q5X<5/;-P2JF+D!0XT\Y0--X$G
M36H.'MS,'5<A@D2DDY3W29T@[M=!6/F\$>R)T:3$N>GQH)R$C*B"V+>YX=4)
M0HBM[D4Z/H,(XV_A0-6'JV[-YA$,\W91(\H*0B53(0\0:#88R].;L$R6)**<
MSEK;EVYMFM(W(D0002#7R:W '; $ 0Y[*@.H0<ERNPTU@[Y -)7@;X=Y:4L<
MR_4W$R5H;+7)%K=#DGDRIL@R<_.C.S<?*NMGY9&8BLB.+>@G(E"Q'X9W)!3K
MP8W$ * ^B[AJ!&O9.4C223/G Z@T.%LDDY1+;SH3/,$@F8 $>; W:F=IX*&#
MKL)#U^.4:N/@HJ/A@%2,B?+R"@XP1D(51\M*$&2<H;EAA&2I&1+*/-?RX280
M^0ZXZKF9BS,QB6)8P !),F   !R   W 16X$  3   DDG01J3J3S)U/&KKJ*
MFH)W6V$K^\%IJDS9YJ>&@X"G;A4R7K,*>7$LVZ)W"EMN9*1CIR1#*:?5!Y8V
M_P  GQ;3&'Y%N5Z;4E'X#6T=O:OM:1U55S,]MPQ )0VUN %01$_62#PC<9TR
MN6A<92Q,!74J- P<H2#W=B".,[QQPD3@RV-%!8C%QMG.C@(>*K,(&?;YU]FO
M5.OU:Y4JMU2&Q@I"AH2OUB^6.+C6W5$&Y22R6<::>,T7BQQ=[4RH))8D(H)9
MF1V8Z><S(I/"1  &E5\GM<B= !))A5#*JCD%5V XZZDF#2M<%G#Y41)L&!J#
M@ L[!V"K$H%.<#<9J]A)KY9$ T2 @0H@,!^MQ^8DN3>D)@)+AK??-U!CN,RV
M,Q#D%GD@AM=98!AFUW$AC.6 8&FE%PUE9"H!((TT[)(.73>.R(F2-=:D+X .
MW2)/:658$E12=E<SF*/W/+$HR.U81VQY,:0*5TY P5_#+*WA<&,L&]4@>2;-
M#QD;.?7W"+H,'KLN<D#>NXC@#J=8.\D03-6ZI ;<2.KG*)TUX'F/@)FH[E^#
M#8ZP2!TE/ 6N7)?LMIMD5DRZ6#*:K,7*0W%FIYVK88+95%-$6'=*VV$9'3?4
M!)N0J0G&(^MP($?H,9>40I4=A$;L+VU3JPN>002%M(I,"0#,EF)J<-:)DYCV
MF<#,84OGG+RU=F'(G30*!V%<'>S*UND.L6UPZ3Q9&;5(YM\PV5=0+K86K;>8
MJT89=:%)C+E9AQ9B<#CAHQ&%C-1T5F,A5/1CL>57?XD#+E&40AMKD0KR*+H)
MGF9;6IZBW_&_2G7S@[9G#::AFU(TW0(&E03CA)VRVM-I=JW5W5KK==I>Y6VT
MC0H>8%.KD5&UO:2J[DQ^TFU-=>G]P9V1/,A)>YMSV&TD2+=C;J$5'HJ;<AAZ
M:QOY7=NATM6FSO;N"XPAV9KKVFNW6BV ,PMQ.A3.QSD&*Q\G1"K/<&570J#(
M %M7%JV)8DD%I._-E R3)K);%8>#&P35*G)ZS1ZY?>JU1!PHYE@-BBXB<L=%
MHO$!"IW A## CMO&YBJ\*]1DA ;6%$K??A787 _=$\<P_5%Q@6XJJ<ME&!(4
M$,H>Y8;JV@AX;%."5)T8-^B(ECABRECVKK#]+<Q1+PSB3DE<.IU '9CB9^B.
M'K@WHU@ 8L-YCXVZ;90!,I&N6W>? UJHM(-J-;H[N5MR,X,;'5)_;N@@4\DV
M486Q)0#4\_*'G2TI,2Q#K\9<7LHQ2XP!R6NQ<=7:X)A89Q<N%X!T8@  !0)-
MG#*PS,H=%)EK@S*C*J'>=%*(%F-0#))+$V7<;9CAPDJK"1FWV].WNV5GV^L!
MP=>N,A=L6)ZK2N^8M@=)B\A";CU!WOYN'$VZ98K#<E*//$1,H^NO ./=P' S
M;O8@,Q>S<NK<&9D"90XLE=2>K?LVV49H U$,=X,/;LD+DNI;9#"MF!*FZ#H
M'7M."<LG<25$ZU+T'6N&*O3]"FD;ATXBU;< P>V4":7N1"MD=\-BZ/NA!D0I
ML8Q*L!/V&JU7=^_GVR.[C07',28\E*BC,Q4>X/BQQ+*XZMPEPFX0+;1]<]L@
M@QYK-;0*9@D0-36BBR"ASJ64! <XD]6K @B=2H=BPWB9-8W#5;A"C8C>F2%W
M:J)]9O-*8H.XKYF\\09 52B6.S;CJC*^&3B=P+3XZ0MNX.X0L,2X0T>](%K@
MPCG!J_$QL7=FQ;&R.J<,CE[<66#/<5;<L1E[9");D 0  Q$L2:@8<"X1<4JR
MY6)N A5):%!GL@LSP3K)(F  +=N'6N#DB1JU:M6YT%$R(FZ;\2/6HG<] YLI
MN'NSO WO6%5[+&QIY$@VN<W7HO?Z& ,Q'(RY 'P:'EPRY6+)6SBP&*VV(-O-
MF:WH+=JWU)920 <MNYE)$^<#YT&H<8<E5+@$/ERJ_P"D[]8 P$Q+IF$QJ#KO
MKNSG!)1SMKN)?;6"F%UI/$9"Q-6?FQ8\XHFH52OT6&IL)#"-.6)E^04,:-9K
M<4:+(03AMEND[)+:;.?>,))C'6[AKA7-Y,2P4D#.Q<N23ETD94$AH5%$P!!L
M*K)?22.O&4G4E5"A0!J..9C!$EB3J36/.^AH\)A<I-SLI3K!.3UIJ6X51MD[
M.7&>E9BS-;H8W.3<9^2D2R7"A[/(-;R;DCMR\.Y%Y8%LF14L9'AX!N*O^4L6
M JAU54:VR*J* O5=5D4  #*.IMF#.JSO+$QY#AY8E6)975B78EL_69B3/G'K
M;@D1HT;@(O\ ??0^.&K<BW7Z\6.$N+=BW)D6)"T%P6X5MKC)&%42X;8S08X<
M+)A"M"VC;Z^VNHV%3C3QI$+(BC F1^8.O+BJV]H8FVMM%9"ML0H:VC1VTN*9
M8$]FY;1U (&8$D',P,O@[%QG9@V9S+%79=,C6R(4@0R.RMQ((@C*L<-I]#OX
M8;6\0656[5$R+[UC<Q*5N_6R DAV;A-[^35L %*CI-E;(%B3Q-[S0\@.G&>C
M"VE@0)8CL# $QI=H8I! =2.SHUM&'8%@(8*[U\FLD'FFLAF!AL%AVF58$YM0
M[ ]HW2PD&8/7W1X-S (XG_0[.&A9&"0XJ]P[N;'3[22F'W(MP(\A+T*U[A7F
MI.2@:9)0<F-"6[<ZT6((,YA\9B91 RC3:#ZU!$@/RAB>+(W9=-;:$A72W;>#
M$C,EM5)!$C,#HS3/D=B9 8=I6T=@"49W60" 0&=F .DP=X!%A8]#$X10:SFI
MQ%.LM?B,YLX3GI>O%D@Y FIVT"OQ\QM_(2<::,?+4A;-3K+C$/+$'/-D0P[J
MC7.Z9%)MCM/%EL[.K-V#VD5@'0L5N!2,JW.V_: 'G& -(KY!A\H4*P ##LNP
M)5@ 4)!!*=E8!XCC)GT$UP5V4TI7 GXY>^D#_A"M3P'B?<M1Q/@/>U<^HJ::
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*\EMY_V\K7[Q5#^+\ZL=R_S?7VF_PJ!O;Q_ 5ZPB?&HWU.S^#3
MJM!N^/S_ &<M*[&E332E-*4TI32E-*4TI32E,XYXSCR]FE*TR@N!?9V$$,!<
ME;Q-#.[=YVHBD2Q]8Z=;H0P,?$PD+#/1=2BWG2:Y#Q845%V"<<F;*2*VIR>F
M)DUUTM78V-O,080'/UA@-VGDEF(+$#.Q)95"K.BJHTKF7"VE$2Q[.025E4T
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ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5P)^.7OI
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M3SB>N,2;5[S0T=62=RDC?YVI$<U(WB#< ^)%1DJF,QL3Q&CH5(A1F#RMJBF
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ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5P)^.7OI
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MY 0VT,O#JT.90A6/47I(-IP0I:"I!*A@I(GSAF('9G6M>MMP#G6"<LR")()
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0TI32E-*4TI32E-*4TI7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g937421g77b20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g77b20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1N@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &X2^<$0X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             $$0
M!V0          0                         !              =D   $
M$0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $
M$0    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !!$     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MYT 5%]5P$ES9>[;'T*O4]GY[U(XV27NVLZVUCC+)9<7,$N]CO])[/3_2[_\
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M $5W_;3O[E920U38[?BU>IX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- ET# 1$
M A$! Q$!_\0 'P !  $%  ,! 0            @%!@<)"@(#! $+_\0 91
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MPXXGUT^B?^IV/S;]O-W&GGH.I'\X</V5TU[/L>*;@#WB_*66^?4\..)_?/\
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M[9X]&V&)E!E4^2+6N/IRV[3D!L":'V-1-AN],C807M6E96$9)[&IGW1K"6U
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MH-R;#V0<)EX<4;!,@9<U<Y6SMD$%L9[5L5;"YNKJY1[AHTA2WE@GB(YI<3Q
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MY8M;R03)=M:+:/=QY2^AMRJJ%,WT.C9(.<Z:K(Q=D;5MT94[#7H5U68U'YC
MKHE'$.$S/DE$JP#4;U=>[1E["=)8REA:Z$H74F#D,[A%F.9C:E"=([R3N7?R
M@T <69"@9T[@E-:;-Y[&EQ/:WN)MN*;RTX?NLB<I%B/H=:SBWN'NTNWB-V98
M[B:T$BEXH-T6R79*[RLC<V[!QA%%/;7TN%MY\I%:"RDO^US1&6)8# KBW$;Q
M1SE" \NCZQAD4(K+LC?5W.APK..<*X\56B-X#PXMFQK30JS)8>A%8!UA2-HD
M)K(K)#'E>HT4U#:0I2UY)KX)8$_9PD:;9>BQS^2X-3(7'%TYR#Q>%6,L,:Z"
MV5^PBQ@E@$RMST[09!(6*$0A=--S:ZB+M.('M(<%"+19!A+RXNU;GE.TF>1)
M.6R\IA%MV;0P,FNNNU>ZK1<^7JURIJ65!N!)22)3S'%R[&_ZDAHS42T4971O
MW!A;=L@ 'I= 6[5^Z/:XHWPB]$>1.P6S=94?"J1Y:VRO;6+6_"@X7Y/9P Z"
M>.87IDYQT;R-O9]A'7=SCW59?-L]C/9&V4"7.'-&7FGR6,;+V?9R^J^5KS=P
M.HTY6E3%8^KU*4TKY *I!4[X? +RMM-=B:*5]R L6G)?")P7%F:'KP)K0K]"
MW.LBC+TRL#62Z1QR94R,:A*0O3#3+B0'[U2;V++9K;!K!DX5OL-C&Q#7-]A+
M#*VMY9FYFNDW8Z^=XX+B&6>4QSQS,P#,K!E)%347&LPFR1DLF:WR%X+X0VV2
MN;&>VN!#% VEW;*KRQ.D2;XFC4:CH0=#469_SBDMBU=R5K=^B*A2=R*MZ"6D
M9)G6PI;+'*&HJ]2*FQAAQ*F:"D4CDZ%*S&(FE(YO,J I0(FU,G)3"3!)(3[)
M8\&V^/R/#]_!=*HP.*O,:+>.QMK:.[>^99)KMEM.1!;NTP>5XXK8K(\C,S!M
M6:(NL]-=6F5M9(-3E+VWNS*]S-,UNML"L<"F?F22JL>V-6>8%54 +IHHO^T>
MHJYV8#D@$VI4+-^R(I&D*75;!-5"_P!R:>EU;&J(D*?PHND\LFR+;( !S69Y
M, V>,"&!>N[K01X6.X#CQ_T TRCR_0',9?+KK:*G:FRRR@P-^Z7Y0@YQTD',
M,FT HFI(R+OB9[HY4]B5#E+"PL3I.6Y(L6320'DKS#)L&J'9L!U#-6$.%?+:
M0\,KF]]=FB;78#:OBK[$)1!'Q=Y.:),TNGBC@W@5K/)KQH@;)*6B/2-.,+<>
M8::T:1A,3!5C4E3'%W"]OQ;B?H9-=26+I<P7=O>0IS);>6+<CE4YD6X36\L\
M##F* )=^C; IPL%F9<%?F]CA6X5H9();>1@B2H^UUU;9(5,<J1R@[23L*C:'
M+5DVQNH=9UI4#2=&RUB1KS:IM9?:<CGHG8S3_9ZD,CD\BB[*_DZ; ^)(XF.:
MRA&A-VN="CRUR0_2%*H0C&LC;'@/'8[-YC,6LSH,GC%QEO9<H<C&J;>VM[B:
M F0[WN1:6[.-D9!1UWLK@)E7/$]Y>8ZPQ\\88V=XU[)<<P\R[;FRRQ1R#80J
MP]HE52&D'53M4CRO"V^>3C:S)S:9CJQ1,>N9MB5+8"Y05+CW#=>FU6\N#N2U
M)"A1Q'J3EO8EXB#5AQC$) $K1@4RS8]@#5B^"DQDW"$RY%IO!.QREDBFU$?;
MQDHDB,C$7#]G,.S<$ F#DD%E%>7G$3WD>>C-HD7T=N;*X<\\L;8V;EPB@Q+S
M>9T!8F/;U(##2KK>.HXZ.][75=XJD0$*+DXG.'%D^-AFJ@PF/HU\,BD.W-B7
M7<7 -S4E%Q8#AI@&WH"AC6C3>6 A3Z/.QHN HXL-B,/]%'9<3Q-'Q(MQV-09
MW2[N;OL9C[21&I-P8^>'<@)NY.K:"Z_$SOD+Z_[$H-]AFPYB[0Q$2M!!$+C?
MR06($(;E;%UW:<P: U&7CC>,#IQ=.$%H4#!.0D L..$1]]C$I6*8S)64Y"NT
MX-S]7]C-2%?((*]DF[-(7*6D@9;N@-\37E#"2F,(V'/X:]RR6;XW.7N"O;"X
M:>&XME6XMYE=-DD%]82.D%["P 9%E8&)QN0C<P,7B\A;V+7"7>.MLG;7<7*D
MAF8Q2IM;<DEO=(CRV\@)(9D&CJ='U(4U,!DZHTDC')FK[KC=,1AJJZI*-#QP
MC5 #ECP\-3C49"5Q-0L<IG<@;79WD#BFD2EL?QN:MFT6H%'VM'M 6+QI8HU6
M;V.+>XX>R.'N,M<29'*9CZ/7&;%M%%(F4+1AYK:R@DBB@C:!9(!&DVJB>1A(
M?)59N/BZ:++6F0BL84M;/'_0R+&\^1T:R 8B.6YD1WD<3%)=[1]>4B[==SMC
M*TNHE:MO<=8?0<P9T2I0PW,]6Y)[# Y""_SPE?*9G-F>&O24+8'8&6-2FPI:
MZ-@S'-<6 :Q 6G0(]MXC%<AC> \9BL]=YNUE=5GQ,6+MK$QCDV3);6EG-=PM
MS-.=<6UC;1R:1H2%D+.^\!<2\XGOK[&08ZX16,5])>RW.\\RXW2S3QV\B[==
MD4US*R'<_P#  52O7Z;5Y_N5H.'.I>=5J%EWS<%2PEY9<P/7ZKCWG'=N=B-(
MQBC:3<I]T F_1!NS@L'DP)NS :7;#H O,;P1'CDX,1<D\PX/^BPC)M50W_T5
MBDB._2X;LW($FHV\_F$:'9K2\XC>\?B%C9K&<\;#<.>Q[+V!U<;3R5YW,VZ=
M>7LU_A^? -T<B%-PU=QKK,^)D1\KCI )%!$KR4]&.1DM+D$M62H3F>A&UH0L
MIB4Q8)#I(6K= G!+THVI*V+9(9S$X%<5DN(,B+IISGKV"]:(PB,6I@MEMN6K
MB1S,&"[]Q6/0G;M.FICKW)->V>+M#"(QB[>>W60.7,PFG,VXJ44)LUVZ!GU[
MR1H14P*<ZDT5@+/QO7V-Q2AEPVUQ31I(W4%JK+)E\..;X.A>%3JV,3Y$&A O
M8']VCP7!<GBS^OV(AF.,2N9K&XK4RD;AJN5]C^YO9<^EAQ-=XK&<2NUQE,:F
M/M;L27CQK')-#=2R)/!%/L1KF!-#,H:,31HRA)NRXIBMH\8UUAK>^O,.JQ65
MXUW-!LMU<LL<D"(T<KQ!F$4KDB-B'Y;-NW8BFO.5?,F*!L@ZU1MX8-R^L3ED
M4I#+#U0G)78$F:I(;!1E"CQ&DB9J$UA1ER()B@U8$[9XF5-LO10Y2SX.2TGO
M9AD&<WG"UAPR5-L%$:V-M);B]UY[%VEYA<P:*$TT$S$[A@W.?>=+=&M43L^;
MNLT#SR=S7,R2FV(,8VJA&T2C74'4Q@]#EAVZD$4L,-P,E[<5HE<4#GO("2\D
MH%%'"S9?%%=8V!*D13<[(#I)%VU$JFT/6HDJ8I='U:%BTL,VK/$J*&<FTAC(
MN +JP.+FPO$MUB;ZRPD& O;J/'VMRN1L;=R\3BWN)'6TND=B4G1YB@" *0K;
M\UN*(;D7L60P\%_;7.2FRMO"UY-"UI<S *ZF6) 9X670-&R1AM6);JNW!5W\
MOF^^>9X.6\QJ)OTVG2:LY"[5"GEQPFEV(KB/Q=C"QFR@R-Z/*;7[W,%&KM>Y
M\T9"1:>W@[[8 JQ3.'X5DPO"1X7M,I)S!;Y&"+*M:KS8C?SW,W.%MVC:9(>T
M$(>> 619#I]34??YM<CG!F9K)-AFM)7LA.2D@M8XHS&9N4"$D,0+?2B0I*#7
M76L_$]6_D<^6A:K]:R][M*C[;:[4C;YQR=Y>8@AC5%+'1.J%N96!VW'W,QO.
MA)2U"%H==,IBE44W&%FEIQKSC2H1O8OP$..QL.,2+&YC%R8VXAS\5KONY;JP
M>-Y)IXA/&'6[9',L7."H7&A8( 9(<9Y1[N[DO&>\L+U+N*3%O,$@2"Y5E6.-
M^4S*8 RA7V:L =P!;IBJRN:-=W/5;0SVQQ8B$PY 1VJ([3K%R%#9<_81D1R(
MD%(8P_.=8,AJ2.O,W:6TG273XI=BT"\0M:<614W%@:\DL?PC?XC)22XSB2[M
M<)/DY\K-@CC[&<-/=,7N((\C,&GBLY9&+<E8C(F@Y<RR$R5AW>=MK^SC2]P\
M$^2BLXK&+)]KN8]L<6BQ2O:1Z123JHTYA<*VOE1[/(%:BW4)<HQ9O'"R 52A
M6&\>.)I_%=,T"F1Y!<L1G16=QC<V/7:C)HF52$$X,6^0"TCH5L3:!/Y8[%8C
MD]JXX%CN,?GL?]$G09SB9>)&E%H";9UN;.X[&J=I'.7]R!!.7C/TPMRO)T:Y
M%Q*\5UB[L62L<;B#BA'SR.<IAN(>>6Y)Y; 3[N7HXU4C?UZ795O4F;H''J2>
M)-QG@UB\@^,\#'6M"WFZ3F7LI46B:,IV*BR65UHU@%'9TKAI3VXE,2Q4X-.P
M%FE&G%#7DC7'XN2]C^2]N,Q';\0WEA@^(;T9#-8:.SM9C<7+F-KEK;(2GGV:
MW311M,JQRZD$ A"%%ZTXI6WBQ[38JWNLEBK<VN/R#W,T?)B"NL0FM$!BN&A$
MC!"60Z$'3<"YL&/\_GUGD7!^3+J[3/3EPQ735RT:HEIR<RTELUGBF=K3W$P$
M<-U%3"%:HQ'O:<M_THUO:KP2-[\6UFS\#P2V_&%LE^T,?%BV::+:AAC4L[1;
M1%C!N!VD,JAO*,&WZG5OJJQDXCE27 2M:B1\&]P^IG(-XUQ.9V+D1?2=K$CH
M) ==1H>E9 AW4>BQ$;KUJM[BO#+I?*,M:<6A0$D=K%EL3'7PI].@6([QR0-4
M>0:26$VI90 #BV"=AMQ)!R=*%2A5I"STBK"NN ;@SWSXOB2[Q$&9QEGCLW;Q
M6%M<B^[%9]ACN())Y-UC(]N3'((N865FVNK$,N5#Q3%R[87N'M[^2PO+F\QL
MKW4L/93<W':7BE2-"MRB2G<I?:-5753IH:JKZDT F;'><-N;B/'[5@UY<HGK
MDZXL2BX)7$G**/3G&44>2,<<DD9C:5P*4-^D9FSI <#93FTN3HSG1X@:DIR3
M6E]C^^M)L-=XCBB;&7N&X=BX=CF7%6UU'<PQW+W#S7%O<7#(1)O&D(.L<L<<
MHG8*8VJ/%-M,F1AO\+'>V^0RS95XNW3P-#(T*Q!(I8H0VJA23*= RNZ&,:[A
M95@=2>;SI)R/2$5S'HD5=+5QFC->IHX\'E-M&Q+BU+C)5 F)F0KFA8.6[4"'
MHE8L<5;0 E:-2O)1[2&DM"7+L?8_L[)\ YOY[HXF3B&XOFN(5,F9NN([86UY
M-,Z2J+7:!JJ1K*2@5"X8&5K%QQ5<7*Y11;10B_3%16PAD(7'PXB?G6Z1AHSS
MR3T9G*:,20NW1!=?)WJB2KDK6LJBBJ 2^%3&Q"V(J?R!MY+7>\5RK):Q)QNJ
M6(44N>T\#BS=)A)@ <VMP%*F\@D9PT*<AQ$6YE8W#WL<6O#^0MKI;ZVO+2P,
MS6-O)@,1%?J90PC:ZS*1->W+VP8\J1!;.2!O8QZQF]E>+I\I:S0FVEMIKD1B
MYE3*7[VQ5-"ZPX]G%O"LVT"16:9="=!N\NHU4)S"FG'BE[SJV!MRINDEP2FC
M9<SV6VR(YJ=J^=J/F:R9-IJ%H U*R7S3VH5:1*2U3BWITQ!8N^3N9)YJ3-@S
M?"MIGLOALE>R+);XJVS%K+CY(!)%?1Y>U2U</*95:'DA-ZE4=F;3:T94-45C
M<Y<8RQO[2V5DEOI;"9+M92DEL]A.TR[4",LG-+;2"ZKIKT<$BI1Q3JCK(A=U
MR6TQT:GC;1R3AT:;K\A<"MR95XKD-D1Y:J=#+5KJ>11N02>KW1U=%R]>X,1
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M5O6NSR\NRQ.W-32U-R8Q8X.;FX+#"4B%O0)"3E2Q8J.*3I4Y1AYY@"P"%KT
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MT0JC4 DIRM(@:WN4B-+C#4X(W5,>4":-YA)JH#D0A7U7*[KV$"3E*T*!90=
M.LW13N #,"%!!&N]0-QT!J]C3*06OL%\87=SPXO%N2Q?%EQ>Y/A^[BD<7-Z\
MF'=+O)6BJ\DUO: =JFB>!E8V,BLJF)I(Y,]/:U;DI3J8W)P%'RAEW,FC6JJE
M$_;YK-GWW92BM94@]S!RMG<Y6)<\&]I)KX='GIJ+=/)@7)4R'D-S*Z =D!MR
MV=TNI+?FM,@4G<QW%&79T))/=NVL-0-VFBJ=0=3]DS#X//\ L4X/V2/!&RX&
MXAES(QDN/L+?L%IE;-S=*D\-ERX!U%NMQ#,8>:8TN%:6>$PR#)'^Z$;.G\)X
MK51#(W*G>!0*X[T8H%<$Q9PJ>_2PK;$].XV948DV!3MM<3D!CJX(2#B3'=-'
MC&@X1J!:M3**LBQ$*J"0KR!7T!.JA6;:=.\$@$CH6TTZC4&+_P#1HQ&,R'&&
M9O[NS@R62P7#UQDL'83[-LE^+B"$3H'!7FPAQ#$[*PA:Z$R@21HZZ7.IWPLX
M3\2&+B4LXGW&X29RL:;1E7)H?NS6R?MTV8&I.$;%<QB9H$%&V*?&G-:RHU20
M@AB7D/ZPJ.HT 43N%5AW$%O"(N2^N\JQ&X-N4 A9?)&FAU*@C13J=@ #5W?V
M)././>-+CC1.,L%%:18S'72VE]]")<9+87$S$3X,/,-\R;(8YW1V:XC:V0W+
MR;X=DY.4<$K[FOUM9/QFYG6&\Q&A:KJ)A<*1@NY4*&,U@2-TB4+?UJ1"Y'F%
M$%NSPXR>9*UK@UB)?75'!$<>(7!(;MD@O3(D]\8IVT14 12= S%5.U=>YFW,
M21Y3!0NN@ '/>$<ADN ?8#L^+.!,9!>\1YG-W,6?R/8^WSXRVAO;ZVC9XE#-
MR88;2Q1(Y0;>*3(O=-&6DU.(^"7'.@4W5WY=\5X1.5ET<>/V)EDU:@6.L@*E
M8FZ,/ZBH0/\  T4B*[Q&M*@CN\O,=;EB((=(E+8'0^US2J3A4011=JEA4AXN
M3(@Z@C:>7JH(Z>025&G=IIW@U-^R)Q/Q(_L)\%<7Y#'1X'B;PTQ>7ECAMFLA
M+=VR9LVV1DM3M>,Y&&""YECD)YB2G3Z4ZJ(EN%A\@HM3TIZ$9*=S666LYH-L
M%9I,(@P+2HI1V=@RP!2<GO=*T;,NEQ+/:PCC Z+%$7QR*-WW03-!M%I5C:QT
MU?GJ-?-H2&'374*7VR^YL8UN<>,X:O,Y9_\ I$EH$Q,? DN1GM-1SEX@AA-E
MJYV['G2S:;$  D]LMXBNI()FCU#.&)J/DW6L0K.%P/F;3_'CBG'Z]/X<-?(=
M#75U5$RQUDTE46>5$6UZ2R(T;H!U899[IDS#)_+KRY!(DD=5(2650HNW$ $J
M(B+<)'"$Y/-19(U50"=NN\:@J^]5<L6T92 FNA>QEQVLG">6O<M?9#@7.<3\
M8W.33CF;AE\I@<W<7,^X8AKZ:W>V A,5Q9FU>XM3!!&6M;E)6G1=S71FL&IK
M X)0#=,NUP+HA#I%*(68T7<_L4JF,,=T)Z-X60]')8XPQML>HFUIWQ$IBJD#
M.A-(:%Y" Y&WB1^346;8LAMP$,A"LRZ2%693T;0%54%=&!7H" =-!IH.%^SG
MC,SC/9#R8SL6$2^O;:TOQ/@+:>SL;Z"57A2]>UN;BYE@O)F@=;M#-(&FC:17
MD#\U]JF9E<?IBE8%M=?R?2/3<"C8M0[['1-81.RFUIY8$4>B7KQM3H1+<BB-
M<S%"H:](=(S-*E*],KVK&I*VCT244<;;<S:CEB,C3KO9E.OP;58:::>>MBP\
M?";P2GB"\XBM[D3:0IA\;C;V!H-B:-+)>Y6PD6;F;QL2)TV!&YFXE5Q;Y8ZA
M7H[X:_;)=OL*RC6Y_BP>LD_X=2_(]C3WTXY_H+ ?\QT\L=0KT=\-?MDNWV%8
MUN?XL'K)/^'3D>QI[Z<<_P!!8#_F.GEGJ%>CKAK]LEV>PO&MS_%@]9)_PZ<C
MV-/?3CG^@L!_S'3RQU"O1UPU^V2[/87C6Y_BP>LD_P"'3D>QI[Z<<_T%@/\
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MB"W03*ZQ[E/+TMYXFD"KJ@9FD3R%.FB;R=S%:P74G3]Y-1.O[!:%+::T.CE
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MQ2F*53"&1F2NBU[3-#8G>G(DA.XNY"!(4Z+TZ778F(6KRR@JU1*?7Q$%'FF
M)U\180Y[N8@*22HZ@:G0$]Y [AK7F@U)T&I[SIU.G=J?@JIYY7M,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE0OYS<Y:<X
M&TVNM*T5VG!Z7^,MM<URVJB"Y18LG+* ,#8UEF^'XFTH.^(5221J"AH&)O&
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M>!5SZ?;^JEKSPCB]%D]8OR:>=]KGT.S?U\P?@QX%7/I]OZJ6GA'#Z-+^&O\
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M1(6,:[=_U.YBX4 :%B)>;'PQ7"P!;YB92@;DQ(DBJK$F%VD =M=O?M&W<>\
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MT;JY@==Z[?I$22$ DA=1Y>IUT.@ ^&TG3BI<S4TKWPQJBR]L2199-4*AEL2
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MSJI6,J@I4\-ZU ]+4SJTJ3B-JNTHXE>E.!L8[5S8M--%/!<O:R1PR6[%(HY
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M8VE!L)MT8#0NDB22<U908D6(@2EWTT7EEE#=""67:6W#7ZD?%&R5KTO;RWB
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M0]3Y.@,/B<3V8"XN%!N"-43741 CS^8R>Z>H7N'7K4U>4OR:K]^AZQ?NHZY
MXGVTQWW=:_IT_;_"I._^LKO[FF_1M7(AG:*YU3%*8I5?BDA5Q&4QJ6("4ZA=
M%Y RR-$G6:-$D/5L;DF=$Q*H))A)PDQIZ4!9X23B3=E"'HLTL>]#U;FC6:*6
M%B0LT4D3%=-P61&1BNH(U 8D:@C7O!'2JXW,<B2  F-U< ]Q*L& .G70D=:D
MHY\MG\QU2NL8K.LX,8;:L;N*4@CJ:7J#)O+XJZ+GEH#(%<AESVI):"G!T<E(
MFUC,:"]G+#!@&#80:#%)AH]C)-=W5Q^XY;&$R&$"W@F14?EK%#&"Y5$&^3>=
M% ]W7/;).6#)!!%K<)<R!!(3+*C%EW%Y&(75B2J[1UZ:53F7E5*V=*UJ#(9
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M(3=$P*!(-&*3I;)E3R]*P&A98RS :6X"EX>5)0![*(+V()29,#6U3@L&2C2
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M+I]4%*]=X4@BJ;-Z"9X'1Z^7ODJ;2K-8+RF=5OL6)&_*"=;B:5G(4MB(T,8
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M5>5BTCI%IJ"S%FV[C&K,S(BDZA+=R31A)$A+!43G<L"8I&-$4OKU   UT#$
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MIM74=--=?*U/6L8YE5CTQ2F*4Q2MCG2S^5.5]',Q_IV3-8XN]J#]TP?[]3>
M^OS_ "$G]I*Z3,Y=6ZTQ2HC\\/DD79^KK;]YV+)GA[VYL/Y5OT4G3[]1V6]K
MKK[1?TB5RGYU^M IBE,4IBE,4IBE,4IBE,4IBE,4IBE=*G2Z^2HV?KU,_P"M
M),Y;Q;[;M]SP:_S-_LTK=L#]8#^6D_W:TU\^OE?79_/4>^Y$8S=^'/:6Q^TE
M_3RUK>7]LKK[9/T4=0_R;J-IBE,4IBE,4IBE,4IBE,4IBE,4J;/3I^6/3_\
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MSEU;K3%*B/SP^2/=GZNMOWG8LF>'O;JP\WTUOT4E1V6]KKK[1?TB5RGYU^M
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MP3.;<9^V-M]Q)^GGK<>'?K.;[I;]%%6U/-0J?IBE:5.L3^]./?\ E-I_%_\
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MARE4J4-QAZ@\XP0AFG&F#,,'O8ABV+>]YDK>7:*$2ZN550 JK/*JJ!T  #
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M*5:,^@4-M&&R.O;"CC7+87+FM0S2*.O*<*IN=&Y4'6C"3B][T,LPL80'I51
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MMP%;TO"ZDHB)T*Q)!.$%A-;HJ[(3NP2CSGEG0,6FA:>\! 66G4*WP/C*MV\
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M[ &)5ML",S:KMVHVFUV^'F%8FY%O>&U$W-UMM.0'+[=TFOU +:>[YO=K)NQ
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MCT))T/FJS.DY_P W;Q:_45S^^<GS+]DS_P =\1Z>F1_W2WK'X-_\,8C[G?\
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M9NSQB42M;0A(AR7"GZ4S2<R81:*0LBOM7?M$HYESE<J\Y_U[PNF=9(6J+6S
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M5Q1+/>3XS-8\XB_AMWNU4S+/#+;Q@M(RR*- R*KMY+2(RQR$.&1DJ,1O6'Y
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MV9L=(ZJFS;';%>43?69#BF>VM\D[:L(+"*]';1["CR6O-$T$A8W,)7LY$PE
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MD*AL$;36:#Q*,PUG/7*G0]JBC"U1UM.<UP@C6N)J%H2(TIBY8, !*E8RMJ%
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M&("C0*!#(&:!,J$1"X'A7/<3=K^@=@;XV*Q/= 7-G T:S<WE$+=7$!DW\F0
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M"[ZT((1:TYN:OL%KPM=@M[WO6\OQ%G,](LF8REY?E.J)/*3#'_)6Z[8(N_\
M\N-:F+#$XW&*4L+*WM0V@9HD D?3NYDIUDDT_P#C=JSMD-4A3%*8I3%*8I3%
0*8I3%*8I3%*8I3%*8I7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g937421g78h00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g78h00.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %BZ^5G@X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #K@
M!V0          0                         !              =D   #
MK@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
MK@    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ZX     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#T7.LZDRYK<2S$946@G[1O
MWS[]Q:&.:US/YK_P1"P<SJ5F0T9OH5TEKI#"W=O]GIM_G[O;_.INJ-O.2W8V
MKTS6)?87@@@G_0O;_8]B",7J;H?4W&#@1]/[0WCW?1<YN[W%.H=U6';@)0%E
M"SZPNG:_!,:&!:8/GJG+_K$!.["TUXM_O0X?$(OP=2 A6UY)GTK&LX(#F3VX
M^DU9U>9UM[=Q
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4E-5L=/P%4)6DM+A!U1B<I.5U"0S0X*CLO$TPB4U1'0F-F.BLV1S@[7#_]H
M# ,!  (1 Q$ /P#^^SBN.=?NIU]-D.)0E+;JVTV3Q#*[\R;VM>]U+5??>V_M
M;]UK6M.@&EQ.@.TC;X*NI<+VC:1J.Y?7)$]<5[I=\*DGNX#DI@=_$\TY(GKB
MO=+OA4D]W <D@=_$\TY(GKBO=+OA4D]W <D@=_$\TY(GKBO=+OA4D]W <D@=
M_$\TY(GKBO=+OA4D]W <D@=_$\TY(GKBO=+OA4D]W <D@=_$\TY(GKBO=+OA
M4D]W <D@=_$\TY(GKBO=+OA4D]W <D@=_$\TY(GKBO=+OA4D]W <D@=_$\TY
M(GKBO=+OA4D]W <D@=_$\TY(GKBO=+OA4D]W <D@=_$\TY(GKBO=+OA4D]W
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M:XO:(AQ&A(&U=^%P1Q0>1B<%A\A C%8AM ND3+ X',!M(T*BG]6"+Z6G;!^
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MO'H]CDP^[^VI.C?#WE5$R[=(XP)]RB+6C*I'#H *:"PHG.@V3K=GXP$^/#/
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MX-94;E)=PP6WSI_!9[:?MHDF4PQO.\FR_P I19\0*T0UD&C\'IZH5,D-%KD
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MV;F;OS4/'3\O)XV.N%F)%HC*@HW%IXM_%65KR)+4>K_%EU/BI?-H!PD8?$P
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M%P2%<.HN (%0@Z=IOO9*]GB<P^R6-?R)*?*"HG#_ $*W^*S\%3-+Z-3]YO\
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MI4C=7.<#!@C%BX$G"L O$&3BH@R(.AD0MNOP43\(<=;"E3)M)(@5]1!]((7
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M '?_ '-4'5OC[BIBV9?J2X[_  9G^@;JHYZ>/YGO3:? ?>5/3/TPK[NGU_\
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M*2M;C2E+(&)D#R&'E7NXR^:6ZVI+A+RE\F=XT>X:_K';$[=L"? ;ETY6_1'
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M!,FP@29V*KY#'EC07!KBT1JX P#XFWI5.Q]H?7>*:Q^-<V9\GSE10V/V/S%
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MD.HI83.&FJ\-< 6D5J9(AKR0Z6AK2XM8&DO:.W+FM(+!F7X@-):QA+21!IO
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M)AL:V8HXC$\I)GLNQ^'B<;*C)$'*"H?2I-!+<3G<' 9(:V6?-@G.*M1H=+S
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M(FJ429CQI;*778PEXB/C";O,<*UG$%1P)3*KW9*$8?;<:3RU!DJ/:VIG:UQ
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MY06) *C5HF)?(\!IEP^5WSI+@XY?F\N9L-@EN1P!DN&4O(@%TRUK:E)K2)8
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MSC)ETDF3<R9-S+G7-[D[2I  T:! @:"UK"!80!;N BP7M\-_J+=^MX-1;>>
MYJ9.X<?Y?G=N<-_J+=^3X-+;SP'-+[AQ_E^?N<-_J+=^3X-+;SP'-+[AQ_D4
MX;_46[\GP:6WG@.:7W#C_+\_<X;_ %%N_6\&EMYX?S2^X<?Y<?9*<8_U%N_)
M\&EMYX#FE]PXGDG&/]1;OR?!I;>> YI?<.)Y)QC_ %%N_)\&EMYX#FE]PXGD
MG#?ZBW?D^#2V\\!S2^X<?Y)PW^HMWY/@TMO/#^:7W#C_ "]V[T.&_P!1:_\
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MBW"[N*1#.I;L.@V[UUW:R+'W+)X'"XN=AE[N!)A7?@,>1(:XV)LTFP#B3IH
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MRH8U+H0<HH4@II09=G&&W$W&?M?BEV:6AS2\$L#@7 6);(S '82) 4.G*<I
M=!RDZ Q8GNG54T)Q+:93/<NQI>H$='-8G'MQ@65ZIX9*-,RHR-4E97'SEV(F
M99*D,H/D=.'L3FVXR4MB[4:Z2\8%%AF8',=>;#Y8=U9)>9+:3VVBED+;B W+
M4#VR"_-H20]O/%;-8/ #;9GM-^W(,3<RS*;P&Z_JF2M*H#::A+3$-J_DN-Y>
M!$SVG8>%Y5C1J!IW(X"*$<#S.>SF*9Q7% (F9R(X9K(#(:&>EH6/3+.8[%7>
M&A$RTX+L(22QKFEU&OF:]LM;4</FA3.=Y(;H'.RF1F.N4=&&S--45RQS13>*
M3KDN=D(#G#* UQ?!$$M;H#:70E&8)MJMM1;#V7%)R$8R11&9/(Y- E8P"I<O
M@Y,I)9SC ;%KY"%-10N? 8X#$1CJ0RI*+E@(C2<0H3%<*L7X.#V!!#9:&N#C
MV7PUCS9L.R%Q.H!!-6[G<P;7D7.V'%P(':$E[9O(S90-+&&6:V5<>C-IX3(L
M$$;'#$TQ9C,Q5J*O-M0 <HU6/R8O&7V8%R#7"86/CS6*LY0,B2%0QD47*N=G
M'+=B\7A((/%7Z X4RYWGYJ>0,ID4LF<%^?,XN+@R08:0<NKB2Y:T^M%6E('4
MAQ-4O=F>=T -(R$B8F8,0 ,IZTK#;2T=GL?/1#\G.84QC6GO+\;3/8Z.<_(
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M6KA6OPBBB2+[W7W5JC.[7,^0  <YT: T#30-:&C<  + !6(+C+B'& )(DP!
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M^Z7U*LR*(PZ^[=*5*X"%<%*K[K7D#,0UK7$N(  (DDF !;4FR$@ DF  22=
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M7ZE[VJ?#HHGQX'DG'7ZE[VJ/#HDCOX'DG'7ZE[VJ?#HD^/ \DXZ_4O\ 1O\
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M)/CP*<=?J7_:I\.B3X\"G'7ZE[VJ/#HDCOX'DG'7ZE[VJ/#HD^/ \DL]>_\
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M23O/$I W!.3C]0SWI'@TD[SQ*E.3C]0SWI'@TD[SQ*)R<?J&>](\&DG>>)2
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M/6<;M=-W&'QVWQ5J4*]PW65N*Y*D->]K'E[6N(:ZXS ;=3_/5=#>TQI<W*2
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M.9+(;W.21KQ9L8*_-Y0TRVW=Y@>\ED+;#:>42R$$)Q;0&_[0T& &@5&@Y6P
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M(T=]S5'%)4W((UQN$<FE8L5#PZ'A1Y*9D&64D20;$DZX*-:0QAIPT I7:ZF
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M4(F9XQ$8$06S0,Q+B6@5B1F)!S?JF':[03!VYB!J0%8OH@9I9%A-OUA(TT!
M)W0"= 5Z2=HO0MWC^2ZJ86?R<">DEVC)H:4NX+B]I!616&['J)Y65#)BS52
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M^F%?=T_DP_Z?I>I.C?#WE0/.=Z/N_/YA5_VEY/)(S!H56.!YP<DW,XN/R$?
MM-X;5.6OC!$7.7E5FXO-#ELJB6^+'6^4(,0?<NP4<..0F1=9<WPS6N>[,6"&
M$M-2H:0S@M@!PB^MB0(DR(!6=:<H@//:$Y&AYRP9D'9WB\Q8Z*FI)F=E$GE/
MHVAQVABS8N(E;[%N"FSG$-,PLZ60(X)'()$#FIZ+;44\Y#,<M/'AR8\R))C'
M#&NR&  ?[.9ASA\-?$W:)O<M:2 ),-)!#I"Y^T3_ ,802 ?@[)CLDZ"P)%SE
M$F""(*D.:+RN,G\Q0UYOCDR9(0DE'2(VS%C.18V)'#$93$.1SJA>$'DIA9A
MIDW+L'1V3KB8F =9,:AS5/$YM#'-9_Z> ' @XIS720QP(GS( (:(+)<X1F%K
MG,"Z]6>R0>I#A$EI%K$DD$DP[*T7B2=*@GLLA)\>=DHS:!-$O)XX[*PWZC[$
M$LR*XB;BX<:+6[!&&/BC,X\P.H4^/3: @A^7SP9#,K8F.1=V4M+0Z@##LKOA
MC[2"XN , DNV'M.D-((N*B6F2*Q$B1\';!@@7B3YHUD ><#-EV<(-SHG.L9C
MI\+7:;BVLZC!#HO(=DV#Q/#IR+R.!;A9"7G)N*<8 APX=[(CBY&3OQY+BH"X
MYPYT:IBR50,ZMQ:: /5D@MQ;GO:6N!#6M,EQ(;86':U!!"-+L[9ZTC, 0<.U
MK2"V"28  !,DZVA3N%LS:@1^.#P#&O\ )7>&-MQ<ZK3+"&IIR">M(.R4,66#
M8.Y3DC(NPLDJ3=M=X,F!'4 R.IZRQ\#B:9=F^#BX\WK'ELV (!F !F$#7,9.
MQ:]2^(ZTZZY&S&I!(UDP9UL(7J%;-V3EN1;+FL1K<1!1,7&PD:-I]AX;P;HL
M'' RAI$L(VQ(2+DM.Q@>3<46ZMH(L4)E''+#:,O Q+0'?,B7$EQ-1Y!!)( !
M,"&DMG:-UP9ZIUOG#    8T1 @F8DDD WT@:ZKZ?T#U2)@[13^O0JRGERJ)"
M21HIIV,X6#(!XT*&,RR)8=0+\*[%SYL<<.1RBY>1,*,L4W B-D0*],&>HL((
M'752 07$DR3.:6@@B(;:,Q0TJA$=;>]^K9M &R(B"09U-Y A9E] M5)V$O%R
M>T;,%D#-M+AW7M*]-%Q,6:P*.PR[Y7NQ=HXX1MQLA:12^&0D<QX!!Z!+K;<"
MO2:9&&;K?YVK)U_6F0;@R-H!B4-*H1'7&8MV&0#X1I[;ZKDA]GS.(V7AI,G6
MXPY@"7D2Y*,\S+ 1P)")DR2U$Q@ EPWP\>,?CRW8PJ8C!+.$,%R[O)&W9@R]
MSL0P@@4 ) @]94)#FB 29!=>X!, QN"D4G @]83!)(R,@@DVTL8,$C6]A)"\
MNVSKJ)"0<\'B>L@2I20A;@QC^1Z5X$6-'R[,_!R\9+NV#C&KDHAQHEX(,!X=
MVRK/@.*)1>!@>QL_"*3G-+Z!RATD-JU 2,K@6R3:29)&EX\YTP:3P"&U+Q::
M;#!D$'38! MXZ"-TQ#1G-8/) YK)]5(_.(]01HT[#':1Z?0BIIUVPEXUWLQ"
M"#28C,4ZT:4T*XZ<@@F0<4ZNS+3;%Z/K,<TAM(L=(+7"M4=E F1E<2#(@3:
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M\&ID[SQ3*-PX)R4;T.QWEOP:A,K=P3DHWH=CO+?@T2!N' )R4;T.QWEOP:)
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M38D5ZRR3WEE@RWYU\D=J A(R9\J4BB%BG#K2+F39E$L7BIU[@F!"/$!V&&H
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M*N(NYQ7"397 WVM>H+WN$.>XB9@N)$[X)B5(8T&0 #$2 T'C$^Y;+P7.L_\
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MK:7UC+F!VFW)C2]]0I6X2NK7[+?AUDM%FU[WZ4J3Z]T__BI5$5-MO7ZW*?\
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M^<:97;CP*2-^FO<JC;;^>8-/[/T[&P69XG-2+N18@XV!$Y'$2)KC;,^(MUQ
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M2/3N_P G9];K;]OG_%ZM0 2-=1W[YUD;+=_L18OL::>[M_9*1[=OI#/J;_\
MI?5YNY4WWC;L//\ .ED6;[&FGMO^TI'IO;Z0SVMW/]-]7]+\]1E._;W\/._)
M43>.X'C/)8_4:Z>_9*0]SL_C_7?[JF._[]T;_OF]U*6V--/>?_&4AS<_^3L[
M^FUNM_LI'?\ ?'W_ 'D^THOK]1GI[PN#V3D-W\'9W]&_KJ1WW].XC?[[FZ@&
M0#O7S?8TT]M_VE(]J_\ D[/;W7ZWN<WX_4J!)F_=MV2-^^]O"^JE9_4::>[K
MW[)2&_G_ .KM;NFW^V]7\7/OZ++@@3N^X_PW\;09)+%]C33VU_\ TE(]%O\
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MY]_)V>??>W-].[6_].;<@S).R($CTZ_FRB=._D3[DOL::>[M_9*1[PSV]_\
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8E$2B)1$HB41*(E$2B)1$HB41*(E$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g937421g78x08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g78x08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1-04&AO=&]S:&]P(#,N,  X0DE-! 0
M    $S2^218X0DE-!"4      !                      .$))300Z
M  #E    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O
M9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O
M;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R
M;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T
M3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--
M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             ""@
M!V0          0                         !              =D   "
M"@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M"@    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   @H     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( *<"70,!$0 "$0$#$0'_Q  >  $
M @(# 0$!            !P@&"0($!0,!"O_$ %X0  $$ @(  P0% @\+!@L)
M  0" P4& 0< "!$2%0D3%)06(3%5TU%W%R(R-3A!5'*!L[6VN-+P&",V.6%Q
M=GB2H=$*)#13D9,F)RA"1TA76,'4U3=T>9>8L;*TM__$ !P! 0 " P$! 0
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MF8#$<):?))UGL@9E*A<MX<6A9%5:P\PXIS#8I#/O!SG4/M!.D.#D):=E]VW
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M0UA"/*WY4)I/3O4))(T'7#DGSTJ_)))]3\GY)/G]M3&MZ*!@ZOI0V@DXU&S
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M :G>YP<X)/8 QC&3@'G(!X!#I#0./F9\G@_X6/=SQO)&3G&,XP1GS-?K.N=
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M9:77TE(#':;'00E]Y+R6\.8=<PK"\\UB69B3DEB2<8R222<<8R><8K?4 *H
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M.&Q@@AV!F&\9SA#32$^/U<Q$Q:5V8DLT5RS$^9)@E))^TDYI* L:*!@"2W
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M#_:[>NUT_P#V2_M)_P#60U+_ $1=!?V_M]4^IO\ $'0?^0M3_P YM:JGIO\
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M %*"$1)ALB#]&94&7&D:4.B1DY>0>#II4"&8=-3AAK!!$W*N&!<SKMQ(? "
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MIUG"+?9/>&='P0]%!@O-A8:<$)+&-<6X>.\E0(GBIEFF150[0) P/*R(%(&
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MD,EQ?P:@]YI[&Z^4+<Q06.HJ$"RQRD$6XC%[=WM_*H73HB?T/U\/DKK/$5>
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MZW5&A;6Q)W'8I>/<QE7YDL+8M'M/+8,LR[B#_%Y_W-\X,]P!D#<0KD#ML.Z
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M7E42 J-A##DKBJOEB=E)BDBJ_<P#MSB-))"W#%2&6,E""=V5]#FO<B^]N@Q
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MYV>FSAHR(AXJ/862=)2<B8XR(""&.VX^242ZVRPTA3CBTI3G.,JK,P5069B
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M&=2!.T05T +F9S#NYY7M[<AL*0?&-PXBR_=?.X5,:M2-1E[4"KUT[ ]E;_.
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M#%H[E^XI$WB2Y5R94[;;@PM^VNXLH P#PG/\9O/B&WBF0?T8J-8KF2),K,%
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M:W1CB[+FO4Z9,D%3]2MEBI@9UF&E^CIBRHCQ2,S(I",Q*B6)IXW;*#PO"C.
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M9[9;YB>E27M0667I+(IT@_' Q[PQ4>&+)QD8:'AKN=L>-5 01JJ1QHJH)EN
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MIW"?.^^XYE2\QDD>5WD<[G=BS' &6)R3@  9/H !]E21%C14085 %49)P ,
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LP%^WS.3DU:L2(=RK@X89R3P[F1O,GS<D_9Y# XJ3N5593BE.*4XI3BE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g937421g79j23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g79j23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &$*^8A X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #K0
M!V0          0                         !              =D   #
MK0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
MK0    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ZT     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M5&_)Z^\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" $M ET# 1$  A$! Q$!_\0 '@ !  $% 0$! 0
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M9?\ VBH^RG%_Q[GZ.GZNGLVN/;YLLL_@KP_\AM/L#T=_)[/Z9B/VBGV4XO\
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MC(N_WW2?[?@3P3N36=SE[?HJ5C7OV.ATCD/K.LG4UQ'ZHMW;0X(OHW>H5_\
ME7--9[@CO$>K4:_1[:D^D/4?;M_O[*Z0X>/E58U]*1_>H]*FMWZ4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4JA#\D*7_
M +]G\6'_ )]2=E]7TFJC=AXCY0/A6G]Z\QOL$QX;)*3$8\Q@!)FDR$)V54F(
MRUN.0@&EG6XA^2.&HS#(B1@0H*VSM:$.93U)(NP8A'];OAT6XQ5GR$@93E+
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MEJGT5>^O[4;/6$&SQ!O@4>"0^>EJ)#WCLC[:ZN$4OK^J:FG779S=8\B!.8S
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M"A5=- (TJUDJF"@#RH039HKYII%ZB;H7*<*H@A9-EPP9C(!).K,3IFDD0!H
M*RFV>UU["0Q_E$B% GD8 B3'B2*O*"OVA .>YO$M<9")FH"VX%58;R4\L1U=
M79*'DTAV-FU1%?905L;.=*>^L.6*>A.+'DF;)/,0Z&-TC_JX4H<I(LMH2N6&
M# C,=Q.N8"!H!4 *"?OI(:3K<4_A9I!$F-AH!I COS]%5[559M%95.^EZ>0/
M!(?$A6\7KD"O:ZF!QF"UDL0+0ZSKBJ]$KFGVQPHPD@1>579 YE>VT#:)2X[*
MI-RVB*62V";>2+EY\EI08!S.[JB+)S$((,:R#;4ANL8:[FX&! R@R#(U($QS
M=H.H%;-AW9VJ(!@M8-S-OIJTH$2R&L(\RQUP9%>>,26"?"4VP6"0,P0,PH4E
MKW0D#B$31/?'!*YE>JN@D&W<!!((R-((@$$1(()$CQ%7-Q"!]\0*=9S @B)W
MD$S$@[G4["3G:;,<1R,LD#'\JQV\-#$&/*$IKFOLR10C)21Q"YX0IYWQ#DSA
ME012O1&2302L8O2:J)5D=0"RLH)(!((DB)B>Z1[Z J=%928&;4'0F 3!F)4F
M8$@23O,E3ESY\T]'/EX\U]Q._O\ /W>/OKJM29V'=MK.G@9@P=@>6AU$VY#H
MF#$.FFZB!D$SIINL6#J(48Y7R]?S18NJ8CG]:BHK%3I<T5O- W'/P[ZD@'4D
M:Z2/#?E G3P&\FN0J@K8._K(3\>XJ[*6MMWK,A=3OECH\]FZ *:4A9[*-K;D
MLE1:TLJ8T@QUM $%)#"8/3UPXHG61?5B&PPD;@V6[.ND#8#4"(RF1(),U@#:
M([-XY3W75G0<S((B)DDD#F (K:HFRU3)5U8XFXNYTP8,0TE)9)G!-J;$*^M>
M*R<:ULQK-ZS$LG[0EH$HIJC_ *AB*\E&V@=ED;QDS;MB?2 0 $S,$"-NXSKJ
M=0(OD6 ,[D08[>OC)),3R(U.TQ,RC"=MAL'*-+AS+<+)5-4MZCYEEIE\$*\M
MX,I#P@GP0##2/G!<0U[8U?#,?:]4K(C98]5>X7CL6UB/04*3$[G4\^^-!SJP
M0*(#.9T[3%AK F-!H1O!WT(G38W@O+I)SYIYE7OYJB]W11>]/0GU>_6=7(\-
M@0?<.>HT/>=-8VKWHHO?S\4Y>?ER[E[T3EYE[DYKW<M*@DZ]P,[:SK$:$;C4
MP-9BO%3GZ/2BIX]_>B\D]WW_ !\>:<U4$#8[Z$$&"=HU'P]1$ 0;'MS]MLM+
MBKL9S_#+ZRG>;'#65.1U)MG*M>R.8U65PY<AKNRP30E2N0=6L%)'+5>S$0RR
M:-:N("61U C4J0-=M8CE&^^FX,55T:"K@\X# D0#( D$@:3WCGM4Z7O14Z2)
MYE7D[P[_ /W>_P %Y\D3X$7GG5@((,;Z@:#7Z.4:F/617G)4\Z<_#P7SKSYJ
MJ>'F[EY\N2)X+WJ:'3EO&VVA$$<M9.DDD[C0BIR3O3EW<_%/@Y(B^=/!/<[^
M?-%"-3KKK'.? DR/P3N?&!$5[YTY*B]WN\_<Y\T[N[WN?-?!5[E-(,P#)WV\
M8 &NND:Q',;D:G_N]W>BISY+YO'DO=Y^7C[G=WJ$]Y.Q$:2/6/'W;\FTSU#^
MS)\/V$/@BIYY/%%1._GS]_6=SE[?HJPC6/GGOYS.H]@]<UQ)ZHM\J+ _\KU#
MYN?]ZN:?G]SSZSY'U;=^HT-3S'J/T5TAP\?*JQKZ4C^]1Z5-;OTI32E6QO[3
M+^EI_O3]2NX]8^>H;8^H_-7+/&SE^3X+PY9IDV'WEECE^"?B48=O4D/%.'89
MEE,(4R*:/XYK2!9YH)43]G%(]B]RKK\L\L_%^)\"\G?&^)\'QM_AW$,/=X4M
MG%X9\EZV+W%<'9NA6@P'M7'1M-58BOGNE>)Q&$X'B[^&O7+%Y'PP6[;8JZAL
M3:5H8:B5)![P2*_(8C<+C.%#?8S[PVK (Z(;)9#4WDP*06.E-)0($N2>/*WQ
ML?8%JX:N#<Y#K">(B,,:=PQ"1?R9<X]Y:[5EL1<Z6WUL+@+?$VO?;7T=-L8&
M_<ZJQ?+KQ$K_ !B[-O#VYZW$.CK91V1POYDV-Z4*I=N*7 @M"^6^RV#*BTSA
M$8L,40"[G+;2<]Q@P16*M'S'N)QGOGD%?N[>"E0X^W*"1K'=K"ZH@.F4:,U\
MYL%GDPDHA(X4PYAE<0V.Q"&)&F+$AC(B<\./>6S/U;=*\7:NCAXXI<M8CI-P
M/"W+.#-M+Q>_;Q..M/:N6[-RW=NV' OVK=Q'N6U#"0QW2@DK]D[RL+ Q#+<X
MGA;3):*A\SK<Q"%&5"KO;8"Y;5E9U4,)ML?W,XT<IK*BXH=SLT/"O"XA*[EN
M!0C&O6:Z;CL9A569<CV=?4+>OCJ5O+ ,6F8=+".\YKYHD?CPSI'Y;>,83"XW
MAW2/BV(L8V\MFQ'&N&6[QS8OS!;US#7L3;Q%C"^>%<,<9?M6\*+SHAO2Z9HL
MX_I3?MVKMKB&*9;S!4_CUE7.:]U =K;WEN6[1O1:ZZXBV0Y"EP2)^A-R^,RP
MC%EK]V<FL&'Y)'B58X#<_%C6VUY))40N@IW"W\K+8,>>_IQS+:N<34A3G1PE
M&PR1$-AO:Z1>6O$*CX?I1C[XN\23A-CJ.D'![WG.-=L,A3"FUBW7$VK;XS"V
M[N)LE\/:N7@CW59+@0N/Z3N$*<2OOUF(&&M9.(X=^MO$VA%K+?/6H#?LJ]VW
MFM(SA6<$,!CX=WN,24>E,7=7-!0LA(IQ:DVQSRGK IY[\.R/IV3%V-J*."AP
MU18.C>?*+&R2%H\KXR"!XI>9>E?EH9,#<;I-Q6U:XE<P=K"7L1QGAN'LW'XA
M9Q5_!JUV_B+5NP;]O!X@KU[6P'06F(NW+:O1>)])F6T_V1Q:I>-I;;W,9;M(
M3>2X]J7N755,ZVKA!<J 0%)#,H. R7B%XJ<0N"Z*^W>SD:P!FF'G03+1[8)T
MPTKQBF"VM06?5'*&7%. 8H1I#0[$4NO)6(T0F"+S>*^4+RL<$QMW <1Z6<9L
MXFRS(XM\0P^*LEK;&W<6UBL(U[#7C:NH]F]U5ZYU5^W=L7,MVTZ+C?XUTAPU
MUK-[B>,5T)4Y,4+J2I*L%NVG>V^5@R/D=LEQ7MM#HRC >RLXC_GT9_\ Z^)_
MGUYOW6?*1^>7&_TD?Z*Q^V'CG]*XW^_?XT]E9Q'_ #Z,_P#]?$_SZ?=9\I'Y
MY<;_ $D?Z*?;#QS^E<;_ '[_ !I[*SB/^?1G_P#KXG^?3[K/E(_/+C?Z2/\
M1-/MAXY_2N-_OW^-/96<1_SZ,_\ ]?$_SZ?=9\I'YY<;_21_HI]L/'/Z5QO]
M^_QI[*SB/^?1G_\ KXG3[K/E(_/+C?Z2/]%/MBXY_2N-_OVI[*SB/^?1G_\
MKXG^?3[K/E(_/+C?Z2/]%/MAXY_2N-_OW^-/96<1_P ^C/\ _7Q/\^GW6?*3
M^>7&_P!)'^@4^V'CG]*XW^_?XT]E9Q'_ #Z,_P#]?$_SZ?=9\I'YY<;_ $D?
MZ/KK3[8>.?TKC?[]_C3V5G$?\^C/_P#7Q/\ /I]UGRD?GEQO])'^BGVP\<_I
M7&_W[_&GLK.(_P"?1G_^OB?Y]/NL^4C\\N-_I(_T4^V'CG]*XW^_;XT]E9Q'
M_/HS_P#U\3_/H/*SY2>?3+C?Z2/]'P]0I]L/'/Z5QO\ ?O\ &GLK.(_Y]&?_
M .OB?Y]/NL^4C\\N-_I(_P!%/MAXY_2N-_OW^-/96<1_SZ,__P!?$_SZ?=9\
MI'YY<;_21_HI]L/'/Z5QO]^_QKG_ (IN,_BLQ+8#<G(\9W\W+I+VKK*N:NM:
M_)"AS Y9<CI1I'P3-7FQ7CSS0O7SQR/:O<JZ_=/^&?IQTMZ5^73R>='ND?'^
M(\9X)Q/B/$[7$.&XZZ+N%Q=NUT>XQB;:7K>49@F(L6;JZB'MJ>5>=Q?I1TAP
MW"\?B+'%\=;O6<.7MN+Q)5NL02 P*G0D:@C7:OR/VPXU_5:]Y1;PW;;B<W[R
M47&20A<@FCW.KJUM.EAC^993 <>ES:5JCT\-#@&5G6%X]$IZKR;"-9G!F6M.
M-8?['\0Z+^3KA;6EQ_!.%8=KZNUD'!WKG6Y+V'L%$ZI'S7#=Q>'1;0^^OG+(
MC*EPI\+POI1Y3N-+>?AO&N(8E<.Z)?(OX*WU/66K]Y7N"Z$*VA;PUYFO$=6I
M3*S!BH.Z@MU?5N;+)[;"JSB2W'L<MH:[%S[G'0.*398RVKI\ULHJ?$,>*$@W
M*?)%F^3VDXX%#M^Y/7Q:E$BPA8_,\H=)/+? >2JWA[>*N<'P:8:[<OV[=Y^"
M<66V_FR&YB+JN<$%.'L(K->Q0/FUH*Q>ZH!KV4Q7E>N7VPJ<8OOB+=FU>>RO
M%>#-<1;S!;*.@O%EO76(%JPP%VX?01H,127B+]64$PV'<"VXG=U,;Q E=O.R
M7>6\0VW&(B'Q[H8I@><XF0#ZY<TJI2A4P_<[!,DR<F%BP8-3Y% =FKZ" &V>
M!N.#>3%L4<';X)@;V)7SS/:P_"<?B"AP-_%87$!^IP[Y3YQ@L59L@ZXFY:*X
M;K2]O/A]D_*R,(,;<XUB;&'8X,(^(XAPNP'\^MV+U@H+KH".JQ5BY=/_ &*O
M-S+D?+(LIW?]6TPT+<(^\XC]T%CVL)N@LX%I>)G:+)[:J/QG&4S3*:X2DQG<
M.VN<@LL4Q'I9)E==C8%N=C-(R:RO!P!8)I8\;'#O)9B'P=NUP? YL>+384W>
M#<3L6[B7[QPUAVNW\);M6K=_$#J+%R\]M+UTA+3.2 =+V.\KMBUC;S<7Q+IP
M_K!BNIXEPB^Z-9LC$7D6W9NO<NO9L,+MU+:LUM#F8 5BUWX]6CAK+FWL^)7=
M3'0J'9_%=_+)<NXCMKL.*CVCS6P2EQ[,AJ[*<\J+&Q&GR"07%SZVM%+NZ/+K
M&IQ.^K:W([:LJS-!PCR7M<M6[?!<#>:]Q'$<)M^;\(XCB5/$,,G6WL,7L8:X
MB,+,WT=V6U=PZ7+]JX]FW<=<CQ3RLJEZY=XSBK"V.'V.*W/.>(\)P[# 8@E;
M=\)>NHS#K%ZIU49[=YDM7%6Y<16A@7%QZKS88I@F7!\4>\<P^Z%K3U.W&,KO
M9B<6Y6<OR#)2\,H[+%=IYLDCW,O,?M<M /QT#):[%"* BU -'CL7=EG='TOT
M>\FR8K%X1N!\.#X&W=N8V]]CL4<%A>HL#$WK=_'BT<%:O6\.RWGLO?%U4924
MEE!PM\<\J=[ X7'V^-8UK6.N64P=CSO +C<2,1?.&L7;.!,8I[%V^&MK>%KJ
MR58YLJEA.TWR]6>6X=5)Q2;@J"S'_7*_.6\3^T;MIXP/7,F$]CEW@;N [:]F
M0>O56XDF,.RU,B6_D8$E8J/;(O)]B_)?U0N?8/"9S>ZD87["\2'$"W4><YQP
MXX48XV?-OXQU_4=3U7:ZS2*[?/?*WU_4_9N]DZGKCC/LGPK['@==YMU1Q^?S
M48CSG[QYOUO7&[V<D"1&\RXE_5FMOL%L=Q<RXA=^J+'*0FV&R 4K=W&I,QQI
MM'N-:[0VEAD^W V13[AXW1";H4=G@3\BN\7 H793#%3QV3S#0(B=\+P/R8XW
M%VL%A>$<*O7KZH;#+@,4,->-S!V^((EG&-:7!WKK8*ZF*ZFW?:Z+)+E %:.3
M&<9\K& P5['XOBO$;-C#$C$(V)P#8JPJXE\&;E["*6Q5NR,4C6#>:T+?60,T
M&:YR_13?5%>_GQC[[^[^O8[FGN\N2<_!>7H\5\->Y]S_ *%_FWPO^X_YJ^;^
MZ/TX_.3B'OL_JJ\_13O5%N_EQC[[^G]VQ_A\"HG^WN7FNGW/^A?YM\+_ +C_
M )J?='Z<?G)Q#WV?U5/T4[U17_''WWY^?GFQR>=?JK]3ERY?5T^Y_P!"_P V
M^%_W'_-3[H_3C\Y.(>^S^JI^BG>J*_XY&^_V['?45.[G\*<D\^GW/^A?YM\+
M_N/^:GW1^G'YR<0]]G]51/53O5%?\<??=?/^[8[S<^Y>7U/]NGW/^A?YM\+_
M +C_ )J?='Z<?G)Q#^U:'S6J?HIOJBW=SXQ]]_!5_=L=\/W?J(G-4]+[G_0O
M\V^%_P!Q_P U/NC]./SDXA[[/ZJGZ*=ZHKS_ 'X^^ZIR[D]>YO/W.?)/3YD[
M]/N?]"_S;X7_ ''_ #4^Z/TX_.3B'OL_JJ?HIWJBO^.1ONG?\VQW+_R]WO\
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MKYH"T(-AS8Z$>PELE%L!2Q (0Q!F%@3UAREP& PS6B#DM,IU@F[F ,R-,@T
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MJGQ!M\?G-;J_P>Y=_5'Y\]/N?=//S*Z5_P#E[BW[)3["\8_HKB7A_$,5K/\
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M=(1$G"[N(LH;IFEQ)-.L@KAPX;$AI,:8ITX%@KR!SIDE1G5!SPE/Z,$K'N^
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M)Q0!$)EY^JE"P905F09!:,Y[,KW(20V4[  DP->L 8*%:"1!@$20OI',(DL
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M]MC*8&VCEK3@,OL'%T?.VJ18[X* NOMFGQW6-27N-#F70[S9H)SV]%+,)>0
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MG5,,I9@K,C.TLZY59CD3+23A(XL.M#G=9[0.E NJO(@WM+)@:/>4SP_)MDR
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MD$)VE!T!8'T6RW.4KHU[T2H)DD@ @-IN06.4@:PL;RV%"APTPCRDF<\8;;2
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MK"[*H*N#^=FZ9Y3)L@UN1*'+F4[@G)F+$&5!+0<I,@$ "-HN0_>,V4@1,!B
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M"J"@VPV$.!S0*7,W(ISG.!L.KMV79"I F)#9CE.XT"1F!_#F.S%(O$  J&S
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M]GJV^L^RM=[GXSD&6T;:;'<PLL'))0^$NZJ*X&PL>Q&5%C7]4$XUS$KBQCC
MK@2R&<A$)55# J2#$$QOUL,J,2RJWHD!B0)# ZP#((!!!T(.X,&J7%+;%@8(
MD"8T,0>1!,CU>PZBEVRWH;(00-OY8OD<1%,..3MQB/94''L@S65TO5/:K6$!
MPG519\,33'06*%-Y35XD:= N6# ZI=HTN/.Q!.Q$@D$#:5C8FLLCC7.VA)U1
M8.H(!V@;CU'F:O;K;+="V/N9H=[[ZMJ;.RZX2A%PC$D@JZ=T\,LU3#9HV.[E
ME=#$X4>T\HQ$#QRODEA*F59'0+ED  VT) $L;CZGO@2H[\L$'VP!1Y/;:)&F
M00/ & 3W R-:^*W:_=&M?"QF^F2E!0UUP&P([#,1-<A1M)-74Y[[$N*>V(DH
MK:2/($B+.(2S(A;7%2,K'.'63<LF3U=N9!)#N-,TD " ,P!7;0:@3K3(\^FV
MQ@9 =8@$DZF#J==]Y!BL=/L]N@D%:^LX@,S MA:NQ"LCYL6Q:U#MSK3(+&[G
MM74MDR< "86 T6GK!@D9!75M6,,+T()B8)9ZVSJ3:M$$@@9W7* H 65WDB23
MJ229IU;Z#K'TF>RIDEI)@CD( @"( BJ<VV6^T5L.0#OZ9/4,;5M) LMN\,<2
M0K;$!+EZEB!0LCDGIV6*@=1!!#!9O!ZR%1XS'EQUEC*0;2 ]J"+ESN[.FNQW
MDDD=Q(RQU=P$$.Q C0VUUUUU\1IMH==8@Y6XV?R^8P,_'-Z-QZ"8(-PK(#4I
M\FKB>N)+E((L:^S%C',*C&E#$K2.44HG8E(,=:2ED(L"[;B&2T9,S+*=--"-
MA,DC8S'9BI*,3(9Q C0 @\Y8$:F(C4>LUAF;/[QL'-A3B/RQSGR(ZJDDP#!Y
M5KFL8SHM+D?"I=PJSQJ]Z$F0PN@FG'ZCIK"1#;K;.GWJWMK]\N=KQ[ET[@>_
MF13JWUBX_A][0QWSH"=N_OVWK,W6U>Y-M=E6L.]^55(B7!%G3T]?BN*QB5(C
MIHI!*267J>MN:R%D$;"O+"%F&JXA>UCQR0Q#0MRT  ;=LG+!)9Y/>>X&9C+
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M30VW))SN 3,9%,228D@DP( UDU2$V=W"'!&BGWVSPJSCR"IOB[5U-C;6EL#
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MH]M&0AKI*H!<MD%E +]H.57+.I8@+KFV,<HOX=E8AR0@!8Y6$!B0O9*@F8D
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M(K,%4O)X\?HL_P ,M,N%Q>"Y.PP3(JZ3+!:;K'HR/-\7-M86;KE$F]9U:64
MGK(66MN$+$!R(4MI+KK';,L @S/V+F@ #$B5!8PRE@H8I/:C>L41QK\*HN0#
M8G/N:,S*2<LJ<%?C:89G\E[69?>$;ABUN/Y!4Q8F\_&K*:3:K/7S0Y"/5]B%
MH4..<,%:TA%E(P^,*EA;.7*7#%TRE!DDALX##[Y;C+)8MI,$4-VP"!GU)"P
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M8, 5(#KK _";8F2CJND3)*@*#F6,Q$R,I,U83<=?"/"T*1=TH9A["QV_JA#
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MT?&8O&$-BVNED&53<N+<(!U(!!T$]\=]7NX#A^ A.'W[.(2YVKAM8>]APK+
M4,+R*6)&H*@@1K!-<L93PYW5E:'%)P7[5WKK>26PE-)W^R<%63$EPSS#VD:
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M]4JJ-&*"O)FM4T0ZQDCD?A=Q=S VKF)MV;-_JPK7;5ZVEU6PX=#B8#LA6X+
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MU<"DHDAP[;UA@==.57"P.#&.N116\_6W<.RKB/OEILP7$(CE@P@HM^W;MLB
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M3CSSUMKB%Z"=%"8-+"0*L@T[V++ ]D['.CDBECDC:[7'<MI=MW+5P2EU'MN
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M&BEEGEK:A#[ 2MYC1W!@H]3/85D!LEB+:PR)=1WG*I),"22%,#P!: 3J5!+
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MCNVN75Y]<Z<8O(+OKK7%]N<FALQ3Z$ZGR3(:P&[L4I3<65792%C=7[3<,'$
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M 5%P^!QP@$ G.+>#Q<A@"%3"8D,@;S:\C/BO)^_\/C^6Q>"@ DD7,5A3)!(
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M2=-9J?8-!NG=2&,WIQ3:T?R07666)E85<WF31R6,4MLV:SFCR?&Z.>BL A)
M8!6A)8.1939V6SFF* !G<%GL]4UP[YA<55C0;%6:1,ZF#L(TDW3K-<X0;1D)
M/?,R!X?7;9]C6UUN'+7VH =F!,Z%\P1XT)8LKQYXR1W2#SLDB>Z B&*>)SF*
ML<T4<K%1[&N3*KU>Z4K@#U1;OVBP1/3N]0I_\JYI^??_ +>6I'/U?2/KI\TU
M',>H_172'#Q\JK&OI2/[U'J*FOS1X^. ?ROY:WQV.IO[;?I]GG^W]7 Y5MU5
MSYC,IQ8.%CO[:_'.GNZ2!K663&26-='Y4[2-:?<]'.D63J^'X]^QHF&Q+D=C
MDMF\Q_ Y6[A] D(YR04^:XOPC/GQ6%7MQFNV0/2C=[8'X7-EV,2O:D-^=_ 7
MS]EWLE_]_P!US^T_(_'ZOW=?3=(?_8O$/_JK<?W]JO&X1_[2PW_B?_\ 2>>[
MZ]]?U2&_M,OZ6G^]/U^0KN/6/GK[UMCZC\U<F<=95&SACSZJO*];UN3'87CU
M;BH\F/MM<NLS,VQ\B+'**#)ZC(*@NX,%#+G&AGHK9\48LYD04CQ>FSJP.;SF
MV5.4J'8N<T(,C LQ4J0!(US*)(!(FL,41U+@ZYBJA=)8EAV0&!!)$QH>^-*Z
MXB3E%&G15O*-B=%>CS;R:B=%>BB-YIX+T41O=W(B<DUR?+71\E0#:KH>L6IZ
MOH+'VO(.KZJ=Q,?0]<EOT>K)>B/(9RY=&9Z(Z5O)[D17*FE*PUE29/AN46F4
MX/2"9#1Y3T#<SQ"*Q#IK9^2C1U]<-E>,$'Q15!1Y],-'7Y%4W%M3!ELJ:BR
M/'L6VD-WY=RSB<)B;F)P=E;]G$P^+PHN)9N^<+D08K#LZBT[O:4)B+=Z[95A
M:M7$<7!<6[]IA<?PGCG"<'PCC^/O<,XAPC-8X'QM\+?QV#'"KK8G%7>#<6MX
M9WQMK#X?'76Q/"\9@<%C[]EL9C<)B<-<PK8.Y@)'BV<XMGL%A7B=IALPP@7Y
M'A^2U)E+DE,-=0D(-'=X[<#P%M".4:P$&L(XB:6UD L&5IY\8L[V]6$QUG$D
MFRURW?M"W<N6+J/A\5AR\FVURTX6X@+(X2XH-MVMOU=Q\A(\CC?1OB? NIN8
MM,/B.'XN[BK. XOP[%8?B7!^)-@VMC$+@^(82Y=P]R[96]A[F(PEQK>.PEO$
MX8XS"X=KUM6U\5L)245D7D.S=O+LG?G0Q-M1</H\>FP3*I@U#2O?F&!'5RUI
MD@T :5[[?%B\.S":J)(KVY5#"T11/I5XW>OVUL<6M#C%E">J;%WL0,;A@V;/
MYIC4N=8N8MG%K$IB\*+BJYPS'-F^:\W5"6L'J&,9@BKU;Q$9[9$: 1*&VY!C
M/M6=L*W?J$ Z6KS3:(^SB#)DK@#]L<RJ033V0O<&(9:P;NW,]8(20D<)%A#4
M6LH<+WDQUISXVBRXV[G!#<07<'Q6W:+J+CV^)82ZZ6RP#NEIN%65N.JR5MM>
MM!R IN(#F$D8D E;E@D P#9N*"8T!;KVR@G0G*T;P=JPJ[ZUN.J-!NGC-YMF
M]]X90%Y#;,<3MN,6PL^&H);N!./55R5V0CB#359-B%5O0NR$J2X![)RP:V^P
MKW\S<-Q-CB(%E+Z6+1R\09"MLW5.!!N/UEAG874MO=&6V]Q&:V :@8@+ O(U
MDYBI8ZV@9(4];"B'@920-6"D Z5O?7B5T4TI5G8V(%/7GVUJ:+6U=6$58V5B
M=/&*$  %!(28:83,YD(XHH\4DY$\KVQQ11OD>YK6JJ2 20 "22  -R3H /$F
MH) !),  DD[ #4D^JN5>!,(8'A.V<B#H#L:%(J+VR&J["&A'G=#<9AD5M';1
M0XS28]2,K\A8:F052!547.KLPW$E69BD6AG5CB3BKV9@Q!4$@L1*HJQ+EF)6
M,ID[@P ( PPH L6P! AB! &[,9@ "&W$#8[G<])5?0\OY1T%:KNLIUE1LSI5
M;)Y-:B(]B]P[^J2)R0L^-5BL(7X^=VN2M^9[]/W3\M2-S6N:K7(CFN16N:Y$
M5KFJG)45%[E14[E1>Y4[ETJP)!!!((,@C0@C8@\B*U;8X1>TEK89%MO;!U1%
MK,&1=8;=0(["KLH860&2RBD"%?<XU>SB-KH9K"KD*JRHJD9IV.EES26+.%\-
M=MW&O8.XJ%RINX:X!YO<95*FX"JF[9NE0@+(6ML+8S62Q+CZC#<;P.-PF'X;
MTDPE[%6L*EZW@N,X)R.-X&U<NK?7#,M^\N"XG@$NG$NF&Q2V<59?%W#8XC:L
MVUPS6-INI;XP).1E6U>X$#08%G..Q46HS:H6&"$B0\RO?46K,B)#'D'1((S<
M8K+HV L.:&E21+ >NK<QURPI:_@<5""7>P+>(MP 2[+DN"\54C0&RMQE*D6Y
MSJG1A>BN#XG=2WPKI5T>N&_<%NQ8XK=Q?!,9GN7+:X>SB%QF%;AUJ_<6Y-QK
M/%,5@K#VKR/CBOF]S$Q7+J+AXSVZK[R_AJHLLBL:GR9F%21?8;EL%C"LU92L
MBS#'Y:2Z1(W6DP8HD]FX-_:U'= ]DG07UL+TBNX2V</8QX\WNS;;#7U2_A7Z
MUTE3A\3;N6)=U3M9 Q8"&FOGL3T)XCB"U^[P>X]RPCX@W\/<1<5;3#VKCW+B
MW,+>&(*VK(N,P4D! 21 TDE/A&Z.+1R@5.\OKIK7Q1H)+NOA-9DN1 E-E*=)
M%#=8);[6#G5?97!Q0P6]/97C9A222LB-0ML(O==QG#L00]WA8P]R2".'8RYA
M[+B%@M:QEKB++<S!R3:NV[.5@JV$RRWS]K"XZRK);X@V(7T@V.PR7[J:GLBY
MA7P(-L J!UJ7+D@EKK9H%Z+FF:41B4^8X3:WCYK:(*MS#;ZN@,QJP",*!AC)
MM*,N_,R/$RZI"RUMXBEN*EX5/+8U][.=8P8Z)5L+A+R&]A,7:M 6RUS"XRX5
MQ".@?,MN\ME,/B5<JHME>JO![G5O8"VS>>POXFTXM8G#7')8!,1ADFRZL%*L
M]IKC7L.1F.;-UEHJH=;Q+]6NVM>;7=32E<?[#R5%GQ&\9-_354JQ297M+C!^
M6CKCDE+>W&);>J+:T(Q%52BW4MUAI9SP<@BR&^NWARV (E>+2,A*B,Z[^88?
M!JQ_!NNJ'-*J]R0T$P%>.SE G*22TB.>U!O8A@/PD4MV8)5(@$ $Y><DQ,0(
M,]*WG5^N#"^:MZWRG;=6BS.:]6>MVTZQ6P)\;*U%ZOIR.[X55J-^3.UR5T5]
M9IB@^:XZ5CQ-C85+9S*:Q'LZI 5L #Z"[KL@K"AV685E7R+#8U8KY(3 2AYH
MDDBDB5KU5,<18&(M-:+O;EK;ATRYU:U<2ZC#.KH8=%T9&!$@BO5X+Q6YP3B-
MKB-K#X?%FW9QF'N8;%]?YO?P^/P6(X?BK5PX6_AL0H?#8JZJO9OVKB.5=6!6
M#&,5W!#EQC')<C==QY#+0T\E[')B&2COCN7UX[K1CQX:5(H'M.6=KH8D2.)R
M*QB(UJ)K&QB0;-DWC<%TVK9N@V;H(N%!G! M@ YID  #85Z?%>CUY.*<23AO
MF+\.3'XQ< Z\9X7<5L$N(N#"LMQ\<6<-8%LAV)9@<S&2:SWK^QKVVX^U;*?Z
MEUKYS:[W_NKW^BN#[ <2_%P7^+<)_;:>O[&O;;C[5LI_J73SFUWO_=7O]%/L
M!Q+\7!?XMPG]MK6&78ML9G!LUKD6+$37<X4M>_(:W&LVH<B0:3FK.A?T-?6V
M[)Q9%6>O):8A%<2JD RCS*KU]##<=Q6$06K&*O"R&#BQ<LO>L9AO]YO6KEN&
M&CKEAU[+A@ *X<1T-N8I^LO87AYNP1UR<6X79O>!ZVUCTN9E.J,6E#JI!UK&
M4K=TJ:<ZIVSO:[/\>AAG)BBWEFSV@N<8D.)&;3U]=ER8?<$9U600!WBFPW,[
MLF DDJ'G7DXQD'/J3&\(Q\MB+.)P>(MBT';A^$08?$ BZ&=K-^YAK=B\66V2
M,,6LA<TX>T60MY^*X/QO@XMGKL#B\/B;E\6DQ'%,+B,3A^KZ@E2V ?&7FL 7
M3U38Q+376SK:Q%XV+RV^E->96M-*5R!N9-2V?&-PP53*V6XR/%\(WSR@DBO?
MCSYL-H[RIQ[' [B_B-I+'(!J7);" VBK)J6UQR,NZ#ZLPFS&$(K).NUF&$Q1
MG*K/84 YH=E9F(6&"EE$,9#0LQ$S7.^4XBP(EE6Z=,LJ"  6D%H8@@05U!DG
M:NF\K5C:ABO5B-\M8PB+)*L+>D[)JAK$1Z(JN>KU:D4/<A$BL@<K4D5R<HW]
MA^8UN=O:/G%2345--*5&<EPS$\Q'8-E&.U%XV&$R 2:P"@F,KFGLCC+DJK!6
MH=4DRI# [ME:2*7'*./-%,R8>&1F-[#V,0,MZU;N@!@I=063, &*/Z5MC [2
M%6! (((!'I\,XUQ;@UQKG"^(XO EWLO>3#WW2SB389FM+B\/)L8NTI>X.IQ-
MN[99+EQ'1DN.K8#XEF*_^U9S_"GN?^6&LO,;'XV)_3L;Z_RCZ[;5Z'VU<5_F
MN!?^5>B__H]8%^TLE/>PY)@677^.64@M@%<C9';Y9N%274)J4_43S5.29:K0
M;*L\BPQ@6%>0,]HQEB.1$0TI'1Y>8]7=%[#7[UIRK)<%Z[?Q=NX&ZN"4O7R%
M=.K 5T(,,X(.;3O'2U<9@'X;Q[A'#^(X9;N'OX.YPW!\)Z.X[!7+/GG66TQ?
M#>$ W\+BO/7;$8?$6[@-VSAKEMK9M0V2EQO=>1XSV;GT,#8)W2RQ1;;,<PR-
MP\\"#$K/E\TC86231F-<'((0I(@[73N$<4*3H;6-)'\<MB#) P@AA!$&;Q,2
M0W9*F5&N7,IYDXET35;H/1CB%PW$"HS])2&LD7+;]9;%O@UM2Y5&LD7ENV^K
MNW"MM;PM7;>PJH8P*LK@["REN#Q  QCK><84.:U,@'CB)LIA 8H0A93IF/*D
M&#AB%@?*L0\4<36,3J0,J(KN;C*JAKA"J78  N54!5+&6(4!1,  5\[BKEF]
MBL3>P^&7!X>[?O7+&$2Y=O)A;-RXS6L,EZ^SWKJV$*VEN7G>ZX4-<9G))O\
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MZIC<+L,7GLV^N*JH5;I6V&8EV:%T>QQ+(>K'28W H@/AL0$+Y3,LMUF52\0
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MBLW;>N[9UE,.Y2NT&BV4R$*J\YDDL 0S7))TD[4-#.B)(QKDGK;OX[:;:G2
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M:?H6FY_A\4O OL7(?#S?W!Y^2_\ '3^"WTA_.C@WZ)COA4?<^XA^78+^S?\
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MD$:Y&1M)D=H:@3-6=<ZE1<:V9';ME<P@@P,RNNL094Z$C>H=ZS9_GIY]W_\
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MPQD16$$$0\;4%%:8EB2T2-B&F'F]<=-3.>MZUK:O+%BCABK3^-E*L>\P5UV
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M+0A7HT(0;)'55I/<1!1027XT+A2K(6K8.6@H<%B#WV9<K"(B6#$0:VKS6I
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M\%.<^VIK:-],:8(,ZR&'C%G,B@:)*4H$YHA=+5SJFS9%?LLL/) S J6$$=H
MF"9@ZQ(!%W3.(S,FH,K$F#,&0=#S&D[;2#G<)Q^OP?#,1PH$HHP+$,8H,7#+
M*@5I10N/U0E2.22V&%D+9YX1&2S)$QD:2.<D;6MY(D7'-QW<@ N[.0-@6))
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M3&\X<2RN;"N9Y,B='0U2B)=EPK#05E-6N;U<0U<$"." %6[=:ZTM &X  TD
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MU]+F'*M9M$A;26[F8* F8 LYN 6O4QW#>BEKHK@N)\/Z08[%=)+O2#B&!Q7
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ML5(H"RHF,GD7,F=^KG)F;).^63EG;6(Y#U#:BYLJYO2@9H[XU^7U^LU;=NW
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MH_PE9QDE3C-%N/:23W&.QY-!9S41_D<6M?B=5F,JV)8T!,H+@*VW&K[>><9
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M>?N7NU,^ [_1'P\-13L]_P#F/QIVOCX^;TS[5L*_)S49I_\ ^8^CZ\J:=_\
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ML(SWB>45J[6[=&1("$:@0T%326M@58'=FKPQ09Y2BH6HU77MVKEUBMM2[ 3
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MN859NJ;RF!U%H#M3#&3*A0=7([)!<:$9CK*@+4BV09ZRX=OP0-B3R4;@Y3X
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M*]LLL=0PB5[IK ]9H%U1$V;9[_OCB=!.SZ202?61W4-LG_M'&ICL Z:P-5V
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M+"#LB*:SKZF<FABF8995#K11Y@NH?8AZV+=NXS"XSH L@HAN$MF492%U ()
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M)*D"1N-1N*D,IV8'U$'YJD>JU--*4TI32E-*4TI32E-*4TI32E-*4TI6%O\
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MNZ$N0Y%D-"S-URZ427'=S+*@RN2CQ/G/%^BHLW.JPMK"WS<XT+2X7!ED*8W
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MM'+G&_B1W>%/84[6^VF_6V_AM10-,:;DC?N /=XT]A3M;[:;];;^&^#_ 'Z
M;^ GY0/I_P!JF=M-VCY2)^2GL*=K?;3?K;?PVIRQ&NXS;>LQOX0/IIFT)C8Q
M\WQI["G:WVTWZVW\-J<NL3\G];+]?J:KGTF.8&_?/AX5Y["K:WDJ]:;W<_\
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DI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g937421g79k19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g79k19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Q\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '&"^<F0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4
M @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              .T   '9          !
M                          $             !V0   .T
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   .T     %)G:'1L
M;VYG   '9     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   #M     !29VAT;&]N9P  !V0    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M4]@KJ)K%;(KW5OII:QSV>G6[^7O6Y]7NF=/ZET9@S:&W"J^TL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0)9A7=66\27V<^D;1[BT[)74!@NO:XENHG2983$SPB2-@ZH\H<,>5\15-N.
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M02:_K6IZR]MJ\JVS:E>W%X;<2V:-*L GD<0K(41G6,*K%5XPJ@0R;_:SK/\
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MXYE^XL8!^,3R<#^U![_^4^ZJ_'I_8P^N8_7TB]:ZU>6"(XQW_8_POH_KG/\
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M ) /+_G?]?.@UO)XMA^[D'R\NY]_'/-=*O+F%4_ZV>!GOG.,?UW)&._;'?\
MO<?)]GMY<?!HAZ:RWNSIX&?_ +9Q]-1\>=?[6''7Y<^N/\QZFJ?/ETRF._\
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MM"DO+Q.ELYSG*2A=X@4QC*D(E(8PTRCZ7I^D66FIBVA!EQA[B0!IV)X^?C*
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MY_QL77/._P#D Q]7V5U+\BEU!*_[*.G_ '>V3<_=CM_L4_+RP^$72Q_D-_\
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MJ^1\O+W5VX\@=U&X\,[DTG^/S[U[.V/=\4L>_O[_ &=ODY4_#+HA.3I.J_\
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MCQ6GF7I<QC"I+ZTL1VUI[O/+2VWA2U8QDL>K6S!DCU&W?DJRI<Q/A>6(("G
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MWX2-S@CD$%6"NI4?O+LQVGT?M?H]OK>AW2W-G/E64X6>UG4 RVMU%DF*XA+
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MSX/4'')\CZ_D!)]WX@(Q[\^['U]0?HXP1[\@;S] G5(2Z:=V!UDB#R=7WV;
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MBM:-<1I\CN(%H]U(Q9B=JL<C%>:T30=(FTO1;R:RBDEE8&XF+2C<S"=8F.)
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M<XSC.,XSG'CS\)RQM#))"X*O$[QN"""&1BK @\@@@@@\YZU^BT8.B.IRKJK
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MLK[CO6% 6#@G+[2054'"DE<OPI_ ':?<_;M\'&D]W=VE_+=WVF-?SRR7T$L
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M$F-+$OO*RI;[X2<.5*<SA4S$GS$XQR=1T:QU++3QE)\ "XB(27 R '."' &
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M\T/:_P#]K'<O\8P/W_\ BQQ]XO4?](++]Y3_ .^I]\2V_:R;]\IC[>Z]U/\
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MF8^J&W$?[6J=B;[6M5U-]5U'3[W0KZ.;V>PFTF$WVGSO;".*2TU)62YB[BX
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M L?Y_C/U7QR/N"N/VRA_>K_[ZGZJW2O]#=0_A>V_H5/OUU2_O 6/\_AGT_\
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M,R([R$N(SG&4N-JQC*'6EH>:6XTM"U=Z*6*=%EBD26*3!21&W*P..C#'09#
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M'F17GXDIE^,^\RO5O;*TU&UFLKZWBNK2X0QS03('C=3Z@]"" RLI#(P#(RL
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MT@\;KKJ2?D#CZB7./RYSGT%/B2^](OW0?S4SY,KJ?SC./5*%X^/^F_\ %_\
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M_P"@7C_[L9]G'WY>QGKJW[P3^DT/837OQ;3]]'GZ?DN?3Z,9SBGWC'KN\/\
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MJ^$K\30?X5;^BT^])]7G[QUS^>Z?\E<?=KHWK=?N!_GJ/U-7PE_YO0OX5/\
M1J?>D^KS]XZY_/=/^2N/NUT;UNOW!OYZ?J:OA+_S>A?PJ?Z-3[TGU>?O'7/Y
M[I_R5R?NTT;UNO+_ !!_G_KSG&*?J:OA+_S>A?PJ?Z-3[TGU=_O'7/Y[I_R5
MQ]VFC>MU^X'^?K[O*GZFKX2_\WH7\*G^C4^])]7G[QUS^>Z?\E<?=IHWK<_N
M!_.I^IJ^$O\ S>A?PJ?Z-3[TGU=_O'7/Y[I_R5Q]VFC>MS^X'\ZGZFKX2_\
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M!6$Y7#Y6MP@=T%"C(DD+DSZ:1/1_7H3[#;BUX3A53#( I*CQLJKXD)W, 5#
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M"6JQ>#;1XR16'DEN7]EN,9[L@>(G+*,!02Q(+9"C:P+' # KG<,57VB'\?S
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M!GC /)\.XD;6SA0Y)'AY_6VZ9Z>O%3-?5SHIM<ME9^WIEQR: L4?G4>WL$[
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M/,H 6]U*V:[UL5 +O1.L0&+W5@NN+AKH7"ISMA&5@M<!]>#Z[BC2XH/.-OB
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MXYN?3&@LAV2^]82W'SP6P#\Y4 4GQ EL+M9CN8,6R7SXL\54Q0_,('/."QW
M<8QDY 7:-H'"XXQS5KM%&Z0Z2+M$6RS\UFM@Z>($G9$G=-R" 3KR2EN&"O6E
MJV+#9L.WPAC7QJ- N19M_9(DF&A,B[,B>&P@65IF(*^)BY( C4LIP,X\!(0A
MQE =A!Y7!Y%(E# \#: <R$ \D#\+Y^5^=C=D<'(X0--]&ETKI$7%R-=Q!J3]
MBN<-G;]TAWV#3KW%,6PXSLJ>.OB+D[7[>BVE#%K%VTA)#V=^3'FF6"2QHIZ(
M,EPK DL"&PN8UV[D(5=N4VY3: I7H <>=!' RD8&,$L-[9PV2=V&SXLDG/4\
MG) J;!K_ -)!S6\...V)JU.O3!*O;8;BS[] $8;*WVW)W-6[ 28+&H1D/)L-
MME?&H>.)IA>G?4N$W Q#:7!10I.&)*R[UW(3M8GPKW;+P.0%\)QG'TU<-%M
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M( \G(SR"#DY!X.>15B@:MZ.8INOQXA^J.&JY56CPX0YN^Q353*[&$F"3-[L
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MF.H/V"S&I(^.J0F#%AV6R6B=*@L(R?+')[TN=)EYF:3O%^3.P1C9A<*,<#:
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M ?,LIEV\!0N>@')8Y))"KDGCKD\9)))-1'$(]V"3N()R2<8 4 9)P,#H#CT
MK9'F*LM.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE0S85%#[+IINCG
MW9K(@^S&8FNCG([4U"(LZ*0:S'<E1IC"%>GB-85ER,[CS,JPG"592M-T<QN'
M7&5SC/3D$>1'D:JZAU*G.&&#CK^4'^*M?:ST;ZSK5[JE^P<NADA0[,[8J4++
MR*NH/7F71^Y820*4CJH.*&QL=_>=S*L$K,4-6M)-D.^NQN(:*ME\C7$A5D&U
M0Z[7P&RW,9SRQ /R2CP@#'45C$"!@QR=K;E!"X'#C'"@GY[$9).3UXJ\WSI0
MUML%VXR"\L_&E7?8TW9YAZ,U4YS6;#-Z>7.FA43$"PU4X,FA&*"XL@P.,PB>
M4V?/KKC[@ON&R6XD4*HP56/NP#N'A[_VCJK Y+\$C!V\>^A@0ECD@LY<GP]3
M'W>.5/ 7G!SSG.1Q5#J;I$UYIZQVFU K-L4Z9O52#4R\2K98H)9VU"JW60%5
MKCQ&2R%@S8I()!#3WXDX/*&./RK0=^$\3XL>M1:]#SO(%#! $8LH5<!=S%R
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M^'ZQ^:)7]=N,#U;[5_,I7/JER_#U9_-(K^NO&!ZM]J_F5'/J/L/\]<>J7/\
M#]8_-$K^NW&!ZM]J_FU-<^J7+\/5G\TBOZZ_B_G[&!ZM]J_F5'/J/L_3]/\
M7J]4N7X>K'YI%?UUXP/5OM7\RG/N^S]-/5+E^'JS^:17]=>,#U;[5_,ISZC[
M/TU4PX]F1);60+@I4/'G^F8AUPA!DKQE"L-^CEOVDBTUYKF4+7E4)[ST)4VG
M#:EX=0X]_P!9'\@%3_7^O6K[Q2G%*<4IQ2G%*<4IQ2G%*<4J$[+M$ND:YO\
M<X$>/+G5&EVFS0XDS+F(DJ4!!SBD>/*RRMM[$=YZ*AM[T3C;GHU*\Q:%=E8S
MVL(N+JV@+%1/<0PE@,E1)(J$@'C(#$C/&>M8YG,<4L@&XI&[@>I520#[N.<<
M^E:GU/K0'E2A.*7I5O5W%ZKC5>O"J8='W2S6^\ [H>-PQPBT/B67@ X=3YA
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MAGCEJE3K-#BD H=RS0%3'Q.1A%<>?#$#!!4FVY*>6^E//':R[TABE"&2264
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M&K6N#(?E/O2)+;ED9:-.KD.NNND$)?<<4KEC>W9;>;F7=O[W(;&).[[K> ,
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MMJ=3ZKEFN6*8&CN^/:&66S_92$9SH>UZ@DMTXGNDFO=\=XX,@:Y#3I<NDI&
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M!'8DT&.5Q4VW;:T,;MC86*@JA^0-(2I\QUF(T-@F1M<E30LGT,/;/5HM*O\
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MSDAY2G9#CTA]^1)>>DR9,AYZ3)DO.R)#KCSBUJUI)'F=I)&+NYRS''/&!P,
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M.ILT1(F'44#S=EF>>VRVI@T>MA&-7HC.58)^K!L"D2W(V(Q%4UQQ<Q>[;Z[
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MI\TLF>Z4*JC"J0!BLBV9$$4+2 ]W,9<J@48)?P  ]1N^<>2>2,UCH9T-DYF
M+.P;_6;D/!A0M=0*30)4(?,&575%KUA6G9;$VWF$NDXCIP7:I,S&$-K*"5M0
MXT+#T:1#V&UP*9#;6\D+2/)(7]H!8-->07<@4K F$(B:$#D['.2<$-B33FPH
MEE5PH50HC(&$@DA0G=(Q)&\.3P"R]!U$1H73/LNH]1NNBLF"[8:_22,4N;VH
M:#@HQ8[&B:08UXD;#/M;!,V*8*58V,31=3(TZ!D-F87GO'IB/5EDL\VJ6TVF
M7,8VQRS1F..T1Y"J%M0-UO:/V5(@XA.QYEN&+JL:"(<A<4=G*EW"WB98WW/,
MRKE@+;NMH<2LY4MRJ-$ "6.\X&<EVSHH18)]S,#KQ# FKL7VA.,E(U8?<D%A
M-YM=0M8*JV#+5AANF*X D5B8/(CUOL-&(%B*IBX#N//+?U8=;,2PHUN9$@2U
M5$[U1M>"&XADF3,3!)9>^5U?G8T:%Q(  ,[Z?N,K"7:\C3$L$R2LKQ.L;>(;
MD7NRI&>5<@8J$G^@<N;%#X'W1:@RKU4NP]"=UM-DU^D9)7W-[2WIL3\>&E4*
M/G':K3FGY1OUP!EUM/JZ7<149X^T"Q,S"VF/B1@PN@LDY2V]G'MK]P1<<_+#
M BVR9ZDEJQMIC,JCO8^C9!A.V/,IE^0 D'=C'R9!W93BIE'Z-[+BS1"4O:0U
MP""L#I*L#8M,EQB\0;)WZ&WM)C%3*[9(C3R7KD&;78L^((&L1XST.>J"^Y'?
MC2,!UE.Z95M")98]DSF8%68:=)IX,:"%61=KB5E9WW-D948(N+!]^6G!57W(
M!&0P!N5N"&8R$,?#L!"J ,'!P<P!/D^2B*;.K6-G@)!)RRA3$0U-H)"4Q(;"
MBK8,9-6*O.W==?LEVDKM2Y)$Z8'3&23<!$27#<=R-(!=G[H5[]9?9'5.ZD1X
MUN5!!D>%V2&7V?O(8 (MJ11LNPL6#8+K)C&ED1[._!(=6#F,\A5D4%U[S8\F
M9,EV7R'&0I7>+7^MV:<<OEFG*#$K'=CL>6^>AC2,0JL -%0( 8(3DDSAS+J!
MC[1*2PP'P# ,Y(N+A@(DEV;)F<.>Y,T=O$.\6.",J(V=602.[-(Z!8XP-XV
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MO^7BG/J,?1_+G^2G>W?)7/K$_H]WF_C]_P G%3S_ %'Z?H_J>.>]M_<UWO\
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M%JEN8Y8()Q/+)<1C8\2%68#Q*P>LEQO*,=-\B37&,O;$BMGI4>!-G3-=6*/
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M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI5FL1.OA:^<,6R>(%U84()$K(3L$F'#
MC@,&&])+SC4P@MN!%$Q![4B01DSG$0V(;;SLE:64K5B5#%E"ABQ8!0N=V[(V
M[=O.[.,8YSC%0<8.[&W!W9QC&.<YXQCKGC'6M1;EL_I*TWK_ %]($5G71RB;
MC+P[128E!9U<W5[7@-%@6.'>X),\?K-0+QA*$ '@LF 7GG)DR4"AU4:2E*CL
M-[ADOII6:2>X[Z)&C=Y))N]56#*T61EUW@N&4@*07W8R:U\6R(@6.(I*P=0@
MC"L1@A^2 <<'.2>F*MA'=6CJ/<#\=SI\NXZTP[L.+3)PO657DSIYX\JV Z?<
MD.BS<B=$*768NRBZU +M"K[*9L$DQ/K8\ >=+RH+74D:@W3-&(C$J--(<1JT
M;-"%88V*1&QP>[RB^+*<2!"KG$.U]X8D(N=S*^')'0D%QDX;DY&""<X6B?T[
MU$PU4+<UK8(;O LA"<KY,<&3*.";38IDZ=$)1L1G$.0+7<B$[T31#S8]FMTV
M1&AX(')2FG,8ENF D66=NZ9'5A(_@>.-41E.[ADB55&.5C '"BK,D()#+'EP
M5(*CQ*S$D$8Y#,2<>;'UK7ZN;AZ2I0'I_P!E&J!3J $OM$M-UU5:;8!J$155
MJ],.5TA$4]/ANS\UV1+C73XZI4Q)S&K<1FSSST\8ZQ/=>SE]1/M,7M-Q)F0)
M<()I&[Z20%"&YP^1$$&3E\*!G K"HM3W,ABC7*%XV*KE54AA@XR/G;O=D^^I
M\_>.C\:Q+"V=&FJED4.NL.:%/MT5N,.K=!@7ZC',S) ]^>$@#DTJFWYIL-+G
M,$V:4'M<(@)@M@K..%XQ+?EMPFNF9F5@RR2DL[2),&&2"6,Q1\XP90C=2I-]
MML!@I$ %(P0N JJR'/4<(&7DYV9'3(KKE;-Z0P[)JVB'-5$K!-;LMSE0QK-2
M&6,L5UH(E'2DLA(/NA(04P)'S7IL<E;"8*,TT4^$E$6HDU<Q<;[PA8VFG"(H
MB56DD*HCD#8 "<H2B^$ _-Z<#$D6XRX6/).\X"@ED!.X],$!B<GGGWU-0VV^
MF2D3)E>KUNUG6)K1X-19(D+D:+=>,BH!D$(#,Q8+#7KS($;1+('R_%2^.K\2
MD6.!+D06JJ7:'TD%S( \IED!#.&<EL!VWNQ)/!=WW'/+,X;G<#5E:%,A-B\J
MN%&.54JHP!^"J$#R 7'EQ<I741KT?O!G0926D3<)HP;,$R"INGCXQTF6'FS4
M&N@0<JS-WHP0<!5JPEUDH%1>JS+0:? >L*#+6!JZ=TYB[X#*9.<!CM"D*68[
M=JC<RKRP;)'&#FK=ZO>=V3AN,9(&20QP!G).%)Z8X/H:@.PNLC66L[/<J?9Q
M-CCGZ=.ID)<91?6(V&81>HUIG!IK)H_L4,#JT; ^EV4BXULDE1B,X>.]=!0#
M$>5"<DW2W=PK KM;?SB0XV;00<(23EA\P, 3@G(-4>=4)!#$@CH4&<Y.068
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M=L[:UXPED 'B%Q"B1>5EB!#?+B8;[Z)A."Q(PB.0Y(1CM8(<#\-L[5'J6VG
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MY]S2\6MEU-5RRVNM["-DKD<=)F;)L+4=($DL/G58C*<QG5)ZB!&)5,D#1DJ
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M!'7$]6=?CP127(PTD360L#/K#[D@Q*=4A:(>XF<@LV2"K9(ZLK;@Q\LEN3C
M..G6I6WB7.U<9!'U$;<>O X&<D8'/%6,KT&].9:5:YBZR3A/W E)*E5CBRHS
MB910@\6L*F9&8[DIY1XL^X8<D$GR$VNFVX!ZD2JJ;#A2 Z?:IL*"^=O SSP
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MN=H"]<8 XSS48%=(.E!+Z7FQEBEXAC7J^!CD+8<E1:M4%5G8]3B4RN,9E(1
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MR8MIW,9D;:V4UL,KL%^W2HTF TZZ2&:O$X 8AF"EHGH$H:TY0ICBV3#$M,F
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MY!&-*GR!CSHLA(CP(LNT6R0=LUU.RA6<D#<.?1PZD8Z=)'YQGGKBH%O$IW!
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M";/<KSF\UZMV\K:J]3#%* (@XR;MFR[V0C6*3AUZ*=DHMFSB,T=+C!PL4?!
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M<0B]8CV%XF6 3/4XT.':D 0M6:/*L#)O5=O(&#$92,E0I8+@DAB,!A^*3!N
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MSTD6KNM/7VVMH1M8UND[5C*G14R1]Q+T]R+39>)5)$;+#*^%V9<G$6.?H%A
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MQ8$R\$2]9A6&]8U]7)UKB#QL,V:R++EO2,2(Q6>T.8:8#2(Y"$=4)/A2$H5
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M\JV)L6M-+:OITLR8:F@ZM7;R*V-Z$3')$9"+.D-!H $6$KU=&SBQ54V.L<#
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MQA/X#D,0 @H2/BY3=L0P"8W#!\2G<2I5MW@QLYRJ!55",@9P:H+8 J=W*GC
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MFI=KUFZ&A]:L"IP1$*;L0CIBSUMK N(BK,TT].KD ',+FQ]MVS/ 2<P+LSX
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MDAU6&V8[+CB\X2G.>2JLS*J@LS,%50,EF8@* /,DD #S)Q4,P52S$!5!9B>
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M<YQC:V2?%G QXL;&R5R!M//%9OK-D"7&MU^W5D@R7K=J""K)7RL=+J&"80Y
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M(DCJ-@)5B%4!AR00@PI.2,D+N *@X4GH*L7C4D' (Y)VG ZMRV,9QEL9R>2
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M>4VY&+LNM2(VO+ 6 1WFG$.1W)*#3*D'XD(K'A9I5)*N02,'@'C>),8((P7
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M&\)!&""<#R.#],-K_1)KL)L /?I-HMAY=9,RRE9KQ:#1_@<6Q,L-[MJATN1
MJ$(Y8$,V78MB*1B!\N1*-.I'N^N*GH)3RMS<N590%7>,,RELG 51@%BJ\(O
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=IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g937421g80v11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g80v11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1FD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &8B^938X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #=
M!V0          0                         !              =D   #
M=                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M=     !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   W0     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M8XUNT!=^ZBUM+&-87%Y: "]T28_.=MVM]RDG"^I7@2ZD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 1L"70,!$0 "$0$#$0'_Q  ?  $
M @(" P$!            !@<%" 0) 0,* @O_Q !:$  " @(" 0 '!00& PL'
M" L$!0,& @<  0@)$1(3%!76%A<95Y<A5EB6&E24E9C7(B4Q"A@C)#A!47%V
MM;<G,C8W.7?P)D1&875XD;$H,S12969G=(&AMO_$ !T! 0 #  ,! 0$
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MQYUUY5CI4C.\Y=+Y5@'5>(ID[\*'.#)HXR9@#M&O?:^!;/%SJ>(=B=?HNRO
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M1RL]GTM-PR5=>U',K[&PDBDG9CS>^CZ]WEZL8PY,"NTX? K1\PLP#@@KD5#
M$KW[>D#TQM:U^MQ;M^'Z=2O,9F"OF&4/@K*N2W:VS>-E;KON+BT:RM37;]3,
MLSH%=%;Z>,LD:'I\NLA7")A-D-GU+U%''%(:B9Y1>R8/")"6O.E[[$'[7]=2
M==Q+1IIV1XRV+$BS=5M;'?K8@[ W(MU(M;XAY:NQ\,G#HNTFB4C5</(AUFUG
MFT+R*L;M:Y+Z:6167Q6%YB[L$C"_:IZ*SR9/\F_$6GN;,?,RO^MC2-67H\N;
MN8ULPK82\E)8"I),NYR"7=69)"&1DO\ ^U/8W&6/??L=]8_1^SVO;B'#8GD8
MM/ 3IYB3<LT8!1R>I+QLA8^+Y5^I/(5VVE[;^3[AVJULK3<6X/(_ ^*2.Q,D
M\VCCB;3:MR>\SZK0S:9Y9#</J1J+$E2!V/\ .\K['7$)/!#F!&*+''(9D9B+
MH)I<,)3BHQ2#9(!8\N^LYY8PQ"2L\(^LN\(()9<NNL,,N^I )!(!(47)]0)
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M61'C%,5E!#UC#'EGCA'CWCAUZ\NL.LI<Y9LI)I.SCB5(RBF][Y, !<L-S8;
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MYJ?GCEE N7#]Y8]SE3]X]]_M[QB@AQD))DA&AEEP^A11/,X1!<GJ?!1XDGP
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MUL?$M%IM8^HB7E<M8F4&;><+ H5K0#ST_&N+)H^ MQ+B7$>'Z;4:OC"2:V*
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M9'MW4-OIH#Q7@.V>JHHL6B(XQ=*Q4L6$'4@S7M6  .-'$=(PZ[1\.X!VIT/
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MK%0P#2:B.$Q0(I8G%')('>**&4]S6RO_ %=7[_L5:O\ N(_GR&'^EB_YQ/\
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M$.FB,/F_ X7'3/3,7GX@5(N#J7CTSC:31-U/>&,,,$..&&/ ((+#$,**-%'
M.,/!AC%# /!%CA%###'CC'%%'CCA'ACCAACUCUUUUZL      "P V  Z #P
MK].HB1HD<:+''&JHB(H5$10%5$50%554 *H      %>[DU:G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*K&Q[:K=7<%)&"/9YA8?4'<I-<TYM>V)Y.B!XB</A7U
M8IK9*;WAA-CA/T(?-V,1C**1U&1#+%ASX.'3ZB)94ET"JV5EGXGP[32C%BIR
MAU&JBE6Y%P60!E(9200:XTFJCB<HR:EB+;QZ352IN =GBB=#UWLQL;@V((K!
M_?U3OW9W5_AYWM_EWS7V(U7W_A?Z:X/]>JGGT7WO6?F&M^KT^_JG?NSNK_#S
MO;_+OCV(U7W_ (7^FN#_ %ZGGT7WO6?F&M^KT^_JG?NSNK_#SO;_ "[X]B-5
M]_X7^FN#_7J>?1?>]9^8:WZO3[^J=^[.ZO\ #SO;_+OCV(U7W_A?Z:X/]>IY
M]%][UGYAK?J]/OZIW[L[J_P\[V_R[X]B-5]_X7^FN#_7J>?1?>]9^8:WZO3[
M^J=^[.ZO\/.]O\N^/8C5??\ A?Z:X/\ 7J>?1?>]9^8:WZO3[^J=^[.ZO\/.
M]O\ +OCV(U7W_A?Z:X/]>IY]%][UGYAK?J]/OZIW[L[J_P /.]O\N^/8C5??
M^%_IK@_UZGGT7WO6?F&M^KT^_JG?NSNK_#SO;_+OCV(U7W_A?Z:X/]>IY]%]
M[UGYAK?J]/OZIW[L[J_P\[V_R[X]B-5]_P"%_IK@_P!>IY]%][UGYAK?J]/O
MZIW[L[J_P\[V_P N^/8C5??^%_IK@_UZGGT7WO6?F&M^KT^_JG?NSNK_  \[
MV_R[X]B-5]_X7^FN#_7J>?1?>]9^8:WZO3[^J=^[.ZO\/.]O\N^/8C5??^%_
MIK@_UZGGT7WO6?F&M^KT^_JG?NSNK_#SO;_+OCV(U7W_ (7^FN#_ %ZGGT7W
MO6?F&M^KT^_JG?NSNK_#SO;_ "[X]B-5]_X7^FN#_7J>?1?>]9^8:WZO3[^J
M=^[.ZO\ #SO;_+OCV(U7W_A?Z:X/]>IY]%][UGYAK?J]/OZIW[L[J_P\[V_R
M[X]B-5]_X7^FN#_7J>?1?>]9^8:WZO3[^J=^[.ZO\/.]O\N^/8C5??\ A?Z:
MX/\ 7J>?1?>]9^8:WZO3[^J=^[.ZO\/.]O\ +OCV(U7W_A?Z:X/]>IY]%][U
MGYAK?J]/OZIW[L[J_P /.]O\N^/8C5??^%_IK@_UZGGT7WO6?F&M^KT^_JG?
MNSNK_#SO;_+OCV(U7W_A?Z:X/]>IY]%][UGYAK?J]/OZIW[L[J_P\[V_R[X]
MB-5]_P"%_IK@_P!>IY]%][UGYAK?J]/OZIW[L[J_P\[V_P N^/8C5??^%_IK
M@_UZGGT7WO6?F&M^KT^_JG?NSNK_  \[V_R[X]B-5]_X7^FN#_7J>?1?>]9^
M8:WZO3[^J=^[.ZO\/.]O\N^/8C5??^%_IK@_UZGGT7WO6?F&M^KT^_JG?NSN
MK_#SO;_+OCV(U7W_ (7^FN#_ %ZGGT7WO6?F&M^KT^_JG?NSNK_#SO;_ "[X
M]B-5]_X7^FN#_7J>?1?>]9^8:WZO3[^J=^[.ZO\ #SO;_+OCV(U7W_A?Z:X/
M]>IY]%][UGYAK?J]/OZIW[L[J_P\[V_R[X]B-5]_X7^FN#_7J>?1?>]9^8:W
MZO3[^J=^[.ZO\/.]O\N^/8C5??\ A?Z:X/\ 7J>?1?>]9^8:WZO3[^J=^[.Z
MO\/.]O\ +OCV(U7W_A?Z:X/]>IY]%][UGYAK?J]/OZIW[L[J_P /.]O\N^/8
MC5??^%_IK@_UZGGT7WO6?F&M^KT^_JG?NSNK_#SO;_+OCV(U7W_A?Z:X/]>I
MY]%][UGYAK?J]/OZIW[L[J_P\[V_R[X]B-5]_P"%_IK@_P!>IY]%][UGYAK?
MJ]/OZIW[L[J_P\[V_P N^/8C5??^%_IK@_UZGGT7WO6?F&M^KT^_JG?NSNK_
M  \[V_R[X]B-5]_X7^FN#_7J>?1?>]9^8:WZO5O@&Q,@0F,$9<,!X@QL,1X)
MBP^*(J'">.,U:Q@%8+R\,,^L203AAS!)NLX"8(IH\X\>M=#&[H2I*,R$HZR(
M2I()21"R.I(NKHS*PLRD@@URU(958 @, 0&4JP!%[,K ,I]:L 0=B :CELNB
MJFQ!3-%UN88GR31PXU.C7*[RQ908QY9]FPT]$[F7QY=28]0RG8#QD98R809R
M912=8XR2+';)9&O>W+BDDM:W7EJUNNU[7WMT-<+7<0AX>L;30ZZ42E@HT/#=
M?Q%E*@$F1=!IM0T0-QB9 H<@A22IM"OOQJ7[M[C_ $#W9] \S\Y3WFH_-M1^
M[KKO;'H?@?'_ .K/:'^&4^_&I?NWN/\ 0/=GT#QYRGO-1^;:C]W3VQZ'X'Q_
M^K/:'^&4^_&I?NWN/] ]V_0/'G*>\U'YMJ/W=/;'H?@?'_ZL]H?X93[\:E^[
M>X_T#W;] \><I[S4?FVH_=T]L>A^!\?_ *L]H?X93[\:E^[>X_T#W;] \><I
M[S4?FVH_=T]L>A^!\?\ ZL]H?X93[\:E^[>X_P! ]V?0/'G*>\U'YMJ/W=/;
M'H?@?'_ZL]H?X93[\:E^[>X_T#W9] \><I[S4?FVH_=T]L>A^!\?_JSVA_AE
M/OQJ7[M[C_0/=GT#QYRGO-1^;:C]W3VQZ'X'Q_\ JSVA_AE/OQJ7[M[C_0/=
MOT#QYRGO-1^;:C]W3VQZ'X'Q_P#JSVA_AE/OQJ7[M[C_ $#W9] \><I[S4?F
MVH_=T]L>A^!\?_JSVA_AE/OQJ7[M[C_0/=GT#QYRGO-1^;:C]W3VQZ'X'Q_^
MK/:'^&4^_&I?NWN/] ]V?0/'G*>\U'YMJ/W=/;'H?@?'_P"K/:'^&4^_&I?N
MWN/] ]V?0/'G*>\U'YMJ/W=/;'H?@?'_ .K/:'^&4^_&I?NWN/\ 0/=GT#QY
MRGO-1^;:C]W3VQZ'X'Q_^K/:'^&4^_&I?NWN/] ]V_0/'G*>\U'YMJ/W=/;'
MH?@?'_ZL]H?X93[\:E^[>X_T#W;] \><I[S4?FVH_=T]L>A^!\?_ *L]H?X9
M3[\:E^[>X_T#W;] \><I[S4?FVH_=T]L>A^!\?\ ZL]H?X93[\:E^[>X_P!
M]V?0/'G*>\U'YMJ/W=/;'H?@?'_ZL]H?X93[\:E^[>X_T#W9] \><I[S4?FV
MH_=T]L>A^!\?_JSVA_AE/OQJ7[M[C_0/=OT#QYRGO-1^;:C]W3VQZ'X'Q_\
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ME^[>X_T#W;] \><I[S4?FVH_=T]L>A^!\?\ ZL]H?X97G[\:E^[>X_T$W9]
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MC]2I^*CZ/_\ B4JG]P7OZ4X]G^#?#X?FD_8I]G/R3_CKPWZ#B/U*GXJ/H_\
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M)^Q3[.?DG_'7AOT'$?J5/Q4/1_\ \2E4_N"^?2G'M@X-\/A^:3]BGV<_)/\
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MCGUUEUUECCWZ^NNW!# ,#<$ @^L$7!^:OJD4L<\4<T3!XIHTEC<7 >.10Z,
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M8W9G=IV9F)))-]S6&_!%](Y^2Z#]6M5_5_-?LO\ 8+\+3_HSB7U6J>T/M-\
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M58"Q7_D]XZ5E;\W;[OU?&!T11A\I0;HB<2X?>6WK:.B%R")C3S(E=E/M]:R
M<R08J>ES@1T0; F[S/PS73:AC80RWLYW1E!Y88O8L "5"-<7O=2H!;:KM/"H
MN98_N?N@?3*A-@2;,66QZ;@WMO4$<^9VET>JV&Y2,;\?155X@U^P,K^O+39F
M(;PPN!>N()45\!DP'3,6):]<(UGAC'[8,UH,_N"C(8LM!HIFE$/N8=HS( TB
MH"H%R 6(&0%R5ZV!(N!69U40C,G?*APALC,;FP&P!-B2 #XD@>-6R!O/3YP4
M1<FR:2IF[<IJL<H?6A$D?([F_"Z/642Q)&+ =BBO4X_O/73V< U@QE@(B[7^
MW!+UCB8)@?Z-R,2P*HQ5D4V+JP%F3_7!*_'6HEC/W:@W"D%@&#$7"$$W#_ZI
MW^*L]K?9=#V_2TNQ-9VA7<Z38HRI$MC32YS+S\0C25Q?NLI8XI<<QCA"19HY
M8HY,)8<\<L>OV=]UDC>)S'(I1UM=6%B+@$?."#4HZ2*'1@RF]F'0V-C^L5.>
M4J].*4XI3BE.*4XI3BE.*4XI3BE.*57F&IM9Q[2GW='1JUAMTFD1ZV(V+BK&
MZMDU"B<_:&.IYM_8^)R2XN_4S^#[R]CLK"//+U^[CZQTYLO*Y&;<G/F<NYPY
MF..=NF6.U_55.5'S.;@O,*<LO8987OC?K:^]JU;:>C]TPVR!((L.QH6M92(:
MKK=^*PID+_6-/K9DLZFIUYKW1LRK.F$7R8(1LMK9;%: J((\5S()C(4Q(Y(U
M\PO98[,2TBD/C*[#=V&?=8GO'E<L%NH(VK Z2(VN7NH"HUUR11T4'#O #8<S
M/8"LW8/!723NOU) %-;ZIW0\GDE/;U9DD!9H9[ QK9ALT$)U<9)3.H@ZR*A!
M&:)SP0DIAL4(N)V"T]="ZZ<,S'!\\0X8$A@H8 &S C=BQL02?&UP9.EB*A1D
MN))4J1<$D$VN"/ #<&PZ;[UG%GAQJM98('\;&VS=+4=+K5>42$5<=?6T%$>T
MZRI$P!BZJ V%DKA;T=1,&NL[VP UD8IVMI ]66.CPY:MJY67$A-V=F8!KLSA
MP206*@V=@<%7+8OD0#5AIT!N"VP"J"1954J0 ;9$74;,6MN%L"16*9>$.I&4
M"Y7\XO0-86U7[,QU(!A68DLI&.BWOCC'9\R9:G/8H'L.J'TR2(0!Z'4\30P7
M7=8[:=&$F2-;,,C9"S-EF0Q8#GKJ<?2Q(YRAKE2]B5RM8"ITL9MNP4 @("H6
MYB:&_HW!Y;$;$+< VO4XV?XT5;:-R&O9MPOM2L2]">F3L*,13TK-&:?5[O3/
MM,HLA5,9V\5T%7-A6@-<)W89*L&:4*^CK?VB7AMH:Q:EXD*!(W4L&(?-@P#H
M^)4.$(+1H2<<B!CEB2#=X5=LBS*;6!7$$=UEN&Q+7 =@!EB";XWL:Y4'C#J&
M7#3>-FK"F]Y:'J[.KZWZM]8I!@:*)@923!W0*5;55*!-84?5 0"5YG6E*+Y2
M'\=%!![17O(ZG42^ZXL4YSAY,6>Y($@L69F8J1(V08M?;>I$,?N=P&,:%%R"
M[!BA.P4+>Z+8@"V_KJNDW@[J)2,[#G<7IX*TU25I)= X85GOJK:SS6G)UE>0
M2JZDL(DFKZMB4&KL%AF?V6>//WCQPXG]J;+5M;,Q!M&")1,;*W?DN&+,"Q'>
M(N57%?>A:H-+&+B[$%#&+E>ZA%@HLHZ#H6R;UDU:UAT'663 )[5;)==86H(F
MUR=6ND,U)38@.\=)L[6H)%OR*\U_)8W-K59:>Q$DA,6L:^NG3F+L<CHS<5G8
M JRI(A"]QP0 4OBP*,C74,P]*Q#$$':US"MPRED89=Y2";-;)>^'%B54[ $%
M18C>]=K?#/5X-[COY3R]/& 3:QM4RIR?694J/*UY[<*>!"8A5,%LP$*:;MOC
MC"2PMW3 8XL",<Z)<OB RT.KD*% J*"%#%0UVP,6)-W*@@0QKW5 (!N+F]4&
MFC#!KL2"6 )6P+"2_103?FL>\2;VL;"U1BP>!NK+'5PZ07<]H04Y4Z8/$E<'
M.H<P2@BQ(K"@NXN!++7S!JW7WP:T."+")9F+S ,@C"*J95I?%@#U9==*AR"Q
MYD %[."<2IC.T@53'B N(6_W88DFH;2QL+%GQN2%!6PR!##="2&R-P2>O=L*
MN1MX\T\VLH*ZF<VBGDU/9]TV_5K-79:Y,]1778+#89EJ,@&LM:L578",1-IW
M9/B&\K;7 8!K&4/E&\  <#Y+J'#,S!7SC2)U;(!D01A!=&5@08D-U8&ZV.Q(
M.AA4J%%UL[2*5M<,Q8L;,&4WS8=X'8^L C+DZ/I9>->ZFD==]UK8%^V4OSQ-
M'PRDLNQZWL"K6/LOV0NL90/EFRK'D -'C#F*5BNERGFC%SBG@3N,K8]^..([
M'T8VC=;;];QK?P()VWV<E.Z=^Z[R#INTBNK7VZ6<V^.WJJAIO1^>.I.#88@&
M[=JW"*9.0E%O#M4H'.GJ*NE36A>(FD7?!6*=0 QG+S@DQ3'.K;=7AR8EI9V9
M,NPU^H&-BET8,#@I-@Y<*20<E!L!>Y"HB@XJ!69TD)+$AN\"",V W4+< $6-
M@>EA=F8B[$U8.P_$[5FT+$=<K;/;3+@4 L4BV#!_UWBJ4+JM:Z=(K%K!015&
M/":HM@;%$:X6&K.Y)X[_ &H>"44,T84/--5+&H1,0@)../5BR/EE?,$-'&5(
M86Y:^()-V@1VR;(M8"Y/@%9;6MB00[WNIOFW@;5!!O!K7P3(!Z'LG<L-A49+
MRE+S-_3321'0E894@RQE ,J$8BL3UM273:H2EVM0^A2(#<0J>-6>UZF1?IYZ
M^XY4.))NN+@$9!@MQ(&50ZA^ZREF%W+7-5&F0&X>2XM8DJ2" 06W6Q)4E=P0
M ;*%J?:-\9ZEHVUW^QU_+*7"S*=:U)!!-+//,HJ6M]?UZI#]$Y39?#8O["S6
M%,K(8H&6@-XPZ]*4#DT"+-*I/J7G5%;[EI':PM=Y)&?;QQ4-9022+M8V(%6B
MA6)F()W"* 23940*/BNUKM8 &P\;D[+\XU;4XI5>634NLKA>]>[.M-%K#_86
MI\K)EK6Y-%(I=@I.5P5X);1W764N&1"[YXJPP!8>YRZ]_!CUCWZN_P!O-%EE
M1)(ED98Y<>:@)"O@<DR'0XMN+]#5&CC9TD9%9X\N6Y +)D,6Q/49#8VZUUF7
M_P 4?!/8.T+W#:K)L\]M8@]X "JU]>;RT_4Q]KMG37=EUJVQ M6$S5U9AL-H
M\-;=7C8CW42&[,[V(!70&75G"'[*/5ZZ.)"BQ!5,)+%E#RA$M"C1F49GE@ <
MN,3,@0EB"I/ ?3:1Y'#-*2W-LJABL9=KRNK",X]\DG-VB#%K*-P,&W\1/ ^T
MT.I*'!.^2H+-88U%;<P:OO:.Z6ZT_=?O'"6S")T>D561@)R/>&P;^S?KJP/0
M3+2*K-/[SC"8)F%QK-<DC,/-P57)E,L915YL)QNTYL;P)&%+<P)D!O9@.ETC
M( >=8G$$(X9FPE&5EB!((E=R0N&5B1U!Y0GBUX+7^N0V"?9NU&-9U1JRV54W
M)PD'I_<J;R!"V[1'FT!<9M.5E^;UL G86QN\RZ%F-J"T6Y:+9V=2;V>H+FJZ
MIU6NC8KRX@TLJOW3GWM.87$9M,RCE\J/9QS50E0P1R"&GTCJ#G(52-E[PPN)
MA(ADWC5CGS'W7W)FLQ4E5(FVWO&#PE.*<T:R[$M-.?51AM'85S JDZ@A\Z5[
MYO\ K2RVZLLXIM?V7)C%/<H--])EU6@&V,@")HJH=I"CMV MAK#JM: '6-'5
MQ%$A8$*I@CD1&%I%M[F9@Q<\MO="1DEUM)I]*;JSLI4R.X6UR)F1F4]QKW81
M$!>^.Z <6LVS%/V#XQZ.4%UM59>@BA [7MN< VLV$ZZCJ]Q[,RN;,:).OJ\=
MB]]-;]E*(!:5$LRLRU>XK.+%3W@0(81Q7CU,[ E0?1B!#H$O#%@#<OCLD1NY
M.)(:Q\*W1X(5(#$6RD-U8M[K(6(L%R/>< *!D!C<>-5$/X5>*^W"ZIN8%M<B
MEM?LVZ7!HSG%8(G<,KAO.X;8N".\U?8-'D:(\]>[D86$Q0+ -5+$A,61*K$8
MV' ]QWMY[JH@\%DNRPJ,;D@1PI"C(T;V;F0A03WU8$E0":S&ET\A67)R TK'
M*V+%Y6D8.K)<82%B!W2I%FO:U2KQ\TQXX^,:$R]5+8%OL8G527ZI-L-];#NV
M':*I[PVD8&.,K55E'\""NV/M:R5D;M,G"K :,"N!K0QEZWHXJFHGU.J8(\:*
M<C,%C&(R:"($DEVN3'$KF[%BQ8G<V$PQ:> %T=F!41W<Y;++)L %! #RLNPQ
M Q'07.QE:\@-,7%\BK-6V+77SJS!G'(1EA$I,#6)>58A28A&&$':W,_+*GVP
MD17V7BR8+:Q8&P A*M.P,'X[03(K,T;*JD!B1TN%(OXV[ZW/0%E!() /(66-
MB%5U):]K;WM>^_2_=;:]R 2!8$UD[#N;6%3(8C66XK4>:BP$59I*RC-&#7/!
M-:L-P%B&L)!>@1HAM;*F%JG82D8KH0Q9!I"\6/> 64+#*P!5"05S%K7*F40@
M@7O_ $I"6ZWWM;>AEC4D%@"&Q-[[-@9+7M;T 6OT\+WVJ/@^1.J#<AXIG%B1
ME&3!P KK=KK9%*:L,S[#1:F'FO56ZI)6)\!%BV91%6!(8LX^)5C#QDDPQA-R
M%DP2C?%6%B24DC<"RNQN49@.['(;$@V4T$T9MN1?8!D=";E5V#*"=W4;#[H5
M;^;57&5T%FR P-[SBCZ$S,'Q*[DFP*EACZ'[DZE[SEC",DBPZP]J3 0K/'KO
M&"7O#+%K7L;=;V-K"US?XKCYQZQ5[CI<7Z6N.N^WZC\QJ+6/9%'J35*DL5A#
M5L[$.62D%FQ(D[9]!.*F@D'%D@AEAD/F<7BJ@ KO>='L9G$'P Q.$1.<-UBD
M<,RJ2%(#'86N';>Y&UHW)/0!3<BJM(BD!F + D==[%1X;7NZ@#J;BP-<DJ^5
M0)>K9&->A8'!E57AP$!GPL\#;JS&35H9@FE%Q;*9F+0N('+!J$'V$1B1@PZ%
M[$*]S'+<DC'H&)-Q:R LUFOBU@+[$W'2]Q3-  2UKE0.M[N0%!%KBY(&X%CU
MM4C&8KS,(Y!#PBHYN^^HLQBH)\)>^LR(^^H\HI,L<^^I!"L.^L>^_5F,1CW_
M *4,G6-2".H(^46_SU'SU:X]8^?_ #ZC\U<SD5-.*4XI3BE5WL;4>L-NC543
M:%#J]]%H]T1;%J ]I4"-XJY>JSV3V@M2G N.3H-RJZ,+P$,BZZSPC)(B[]J*
M:3#+2.:6$N8I'C,B-&Y1BN4;>DAMU4V%Q5'CCDQYB*^#ATR .+KT87Z$7-C6
MMVWO +QVWCL,_:&P5%C.MK'"W"SF /NUN.*B]Z/9Z M:*#L8/HJ%4WI#&(R6
M/ KHN&RJ5348N&& @$KDP\0U$$8BC*A!@0"M^]'.-0C'?JL@L/#$L+;W&$NC
M@F?F.&+]X7#6V>(PL!8; H;^O( @[6JK>_1;>/TK7)\=;]OL737/ N\,B7=$
M@EV(X"=7YXB>6(9=KD%>C.KQ&S;F, +KD.BI3Q&D?5C4O2EZ\H77V4U%L0L0
M"[1@+(>6"L:LJDR$L&$2$F0R,"O=*@D'/V/AO<M(2=V)9>^07*DV0!2O,<#
M("#W@Q (FV7@7K4'96E[BBFGA3:PVA>-ON0FLLIK:SV:P4RF5E$BR)#Q7 =5
M!78:)2]F%+V(C C*_:]I#8.:'(&3O"GG\ICF1MVEB2$$;!5#N[-8W.;*[QW!
M'N<CJ;WJWF<8>)AL(Y'E(.Y9BJJJW%A@&1'L0>^B$$6K(V_P%U#;[#LJXR6[
M;B*Z[;>(;#>[:CMZSYHX9438='V1J3/L1U6W*""#2[*AK4FLAHDW4*FM.+6O
M;XO2[(S8RPFOF18DPB9(598T9#91)')'-NK*WNPD+2G+=@I&.(%2VBB9G?*4
M/(RL[AA<E'5XMBI7W(H!&+;*6!O<FK/U3XU)M5[.OFW/O+VIL*X[&K%,JED*
MV,QI32+M=0PO@Z_\KD046M,%,,4A#EK*D"8157Y_:+78!J^,YL#(V;*74M+%
M'#RHHTC>1U$8<&\ANU\G8'HH!(RQ55+%5 &D< CD>7F2.TBHK9E2 $%EM9%(
M&['&^.3,P +$U^-_>*NL/)#'/[P9[0/-UKRT:X$)K;85;,O66B^:GV5FX%Q*
M6,AY'R>WZ7H[%1(? :G[A'8@-TS8%C*/BT^KETW]'C_2+(<@3<K'-%8V([I2
M>0&UC<@@@BDVGCG],L.XR#$@6#/')?<'</$A%]MB""#:J7K?HXM#5AXH=@N-
MBY]*EFLAI4F+*GJ:Z\>ZMV51-J*+Q8D];I",9S<W-EUVB'>M"O6+@C)>*:ZN
MKT+@O/+9N(SLI4B/<R&]G+ 2121%%+.<4"R-BH^Z"EBUA60T4(8,,[@(+ J
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M@USY$6.6G'%#, 0Z_8J?8@VI->;&]6;,RSQQO'- <&5%D/>%D7EA4S!(CO)
MH< @Y*RD9 8W$<3LC)+WPS%.@NQ#,6Q(!:R2MC>XL58&Q[TFW!1_'*[V:LMM
MA;C:HZQO; RY5VE]YKDRZSV!SJ/+Q]BN [TVNYOT,>%)VBA4CKCV:Y?U<2:F
M3AA@=,:K<2/.],TT)@ FT;F"4WR,1CG,S1V5RC$2PN<ERN@>Q(LP'S>81RF0
M\O4*)44]T/E$(@_>4,O<D48DCO%38&X/#EM/CW<"M&; NWD8_OY-?V:S*UV\
M^S(29/>IIZBGG'HTPU9H0(M@KT;<6D[E$+"DPF.O-25.5;6*JII:T%3#4()T
MCTXC!C',7(LR#,W<%W)!L7A.VR,5(S.526B8PN\Q8A^X0H"O=?1-EL5R"R#<
M=Y5(-A:LU>-!>+$%ELVSKB]45MZ%L-T99+@T#K"<R"SYM=1[Q(7SV5C7XS9(
M$M>T\GC#+Q8R_+ZFSM G1W1'44BZV>M2.%,#A- LD*@E@T0.ITN856-KRM*"
MK $NJFV-KP4TS/(Y8!HY660D!2LEH9K9$7-D1"""0%8B^UA6R+4WBO)B_BL^
M^B+>PU!&1?;*;:QZ<GBJZ;7"KQZ2'MY8.Z>L!Q&IJWQ^I =H:@>])3M+38X6
M<RO-PB6JI:;4BQ2 ()B$4*78LSG4&P(<GOG4.0#L0JVO9B8$<&X:;(Q#)BV(
M"A.2-]@+*(4#;[%FO:X PM$\4=!=6UCKAGN#XZUO0;"XKZNEQ5E,[,I=ALNO
MKBMG:7Q940F3^S25K6E,8"K2')3!$K+=N4<.5=SK9->F353E1((B%! 8OF5#
MA9$(",Y"KE(X)L 2 K=[+*$T\5S&9;D[@*%5L24<$N%!+612+DD DCNV X]>
M\>/'?3C+2UBI6^BZGLBQHGK'2+JUITK56PPV0J44PNP3J'B#,W$L@:S:_7UZ
M-D^2R+;%ET@19+0-F;"K=LTG?5YZK3SZ?^AE,6J16&2/IV<L@=&*G!DER*YJ
M5[Q)Y<;K$:Z<+#)%-8RH'A9@UF695 ;%Q<9 I8-8@["V3 [Z(/(W1=H1=69)
MM&HEHLGU1K,;*5EB!!.[O[,5-10QL6. DI.%R:F0 U<P>.0%[/W)BL))Z@G[
MBZYM/.IQ,3WQ=K!2>[&,G.UQW +OXJ.MJY@FB(N'6P*KN;;N0%&]O2)LOK.P
MW!K)*=Y:H>V4BHJKFO+?"V<^E2"]#,X1<[:J^T/3*N"MB 8E!K@&2IV6 H$,
M^>>$E(Q%SPZ(&SBZ@PRJN10A<0][CT&QLQ%[@');7'W0/0U(D0MB&%\BMM_2
M%[B]K7V/CX&K8YE5Z<4JH-PI-V.PZ)AI*]4NB&KMEU1KL.>ZT\RX0V/5@<A?
M=OJB" -PGR2V5QAF%TM?32$Q!8P$1^XPS(P*'VA:!2_/C>0&-Q&$<)C*;8.U
MP<E7>ZBU]OD.4HF(3DNB$2*7S4ME&#WE6Q&+':S&]O556MW&^*?>-HRU_6=T
MO%?:[(IEK0FA636DBLNA]:\UU3K+4*R!;MDU]FAL8UK76&V30'J$]:)71-CA
M7A=@:C+#] ('CCRD1&$3HP*R7$G-D=7;&-E92A5-F+7L"H4950F97DM&S*75
M@;QV*8(K*H+A@V0)L5"V!()8@&B;!<_,^@T?N^;*,C 69KZP-<EE/6:L+=T[
M/+/1J\YC2)W;'*OF.6KE]NGIH5>6A=/5):^A+%@72CQ9VW=4T<CX1 DW8H7:
M0!_Z8@/B P "PXA ')9KWZ+B6U2*'D-A89A A*'W('$DV)),I)8E0%7I]UF9
M->>1'D)6O$2YM[DVU,QZT6;8=S3"BVQ"V!V392-"OP@%M1KNS*:.ILP\*?8H
M0<]O5[%K%:'G;)7-698.?ARZ<S3P/JE5!*O.QAW4J8UYP)9FB<LINA(1HV;8
MAA:XN%FE2!F;EMR\I38W#GEFP =0K;-;(.HW!4WWQSA?Y\L:FLKTAYT-GLFC
M)I;)8D6&GU22K[3=:XV*0\3KC>VF-F"?US9N&M$U /5KWM1ZJI-B86:Q,W&0
MS1#*G1!@Q%E69;*W,9FC62.Q(M@5:/F%[D-D%"HJ[-##5$%03<Q-=@$"ARC]
M#<,&5P@2V2XEBS$V(X[?#T@A]SM, B)!@CK]]>]4.Q''4.48BL$5O<*6LV-4
MN6O4QL\W01&LI;D@OBH[UV]HX-JV8: 7 =%(\P"QDE[LB\Q0'N&!B+*205L3
MS,#&190H?O$DCYT6?NKW2V!NI%B&"E?1/3#(.#WBV)M8"<[7TWY%[9K.K*QU
ML0FFM$ETW,);[Z/.V%.GIW>%UKNJ+5*FU=L;5&!-R-225.RX=B%9U]):I)RS
M:3 /#TK I%-!$\C\O,%(L8[BV=T:1;R1R]P$,N]F9-L[FYO)'-(BJ'"MDX9K
M&^/>"-9'2S6Q;Q4-]Q;81CVO/U@WLZT7UH%0Q?<BYZR"TT9&2:!7_(@G$.EX
M".V!\]#</U?C2O\ C;^F6WOW%AODV6*3#U3U2W\Q"H2,F(LR@RBP)T_>>X Y
M@!U.T9*76,][[JO\[+. ; ;J2L>Y FV6S'N$\G=@&W?I]SFJD'YEV/?B4S9"
M45)J:G;?L;D.52]J>*YM2#-=;YK57R!&3-H[,<'%DYU;/;$EU7M"\;[-*]K!
M0]>59#+(<Z-8"(R6E>)0;JUPXDA9KDW4$VE"E"!@ &&1N94:@R@N (U<G8K8
MJ5D"V WVNF0:_>N5-A85+;JEY7,DB"/6*S:X-S[I^U$>WK&=>9TZ-C;GV-U&
M)8T-3:-J* YG:2R2)W6KIU]&0(#ZP=4U@&[Z&@JC*N%ZH^E#-S#'AG$T0"!F
M"+@<7*QL0"N2R7=F#!B8'9E89%=00N&88*XD)<@%B&%U4N-PUBO=4%2MI5 (
M,@U%1_,9=N333>[$;!QH*-.V268)Q<TK-&16,#M_Y*2[L-CN.TL2MCS#.=)^
M_CA0;0FBPKP>'WR^OJX0GQ*^C,,RI@9&(*D)B0UH+A+0J.5=9K'*+9C>&Y6U
MHUU(DC+%L "#=K@K[I8L.83F;Q[$/:W](;$'/42R><%Z* /'&^S=3,LTQ9C2
MYJ-;+RLP5JC>LHZVL@HV;MO!K]R^3Z 5LSK6CQV7#%8;X6K@!%S!)J=9%T48
M(ODX0 !#(0&)@N7+*H+JIGL$8QW5+W-\I1M4]CLJEB26"7L.98)B3W6(BW89
MV9[$;8X=G'Y_2I8+6F'L?;=:J>J,:8Z-T4GL3,9J\\?22F\T2<^S:XQMBS&'
M>\%!*(8&*0Z>%7XK**;9VA73N0=!D5:V)(.:B8J"%U   .,F+>X%]@<BV-E
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MD+!")@"]XR@('*,3(C%6+-(AM85_G++:12#@A(3"Q88$A>^";G/F*S*+!0C
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M82I:YLC;],VE=JWDM'S'=@T>@4>IK:/*7D1[72)B^UU5['8,I!YL72K!O33
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M4!+\_9!PYD$461)N,;(0T@D:Z)@"[%8T9[W9(U5@=R;'1J1B9)+>O*[ A"@
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MJUMMU>+NN;_6-/;TZHVB*NJX[,8GMVWZ$FS,E6IHI\',QV<0D2&UQU^1I9&
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MG@5E,T.\;E1)B\98N4R+,X"*BJ5-W-A!U&L*#&&S/'*581R;.H8IDKV"!K*
MI+%F/@N]=G>IZGM.N3W9GL_9\>P)+:]!>5Y*'4U]74ZZ7XHER\RK)LH"#&3=
M?FQ#G9QFN2Y#<<R\XY>I"/B33>MF>)L!%'A@I5F+%C(<F(<^ [I"V'JZVL!S
M8UD&9=\LF!5<0N Q *W&YW!-SZZN'F-:TXI3BE.*4XI3BE.*4XI5=GJ=4'F/
ME#-?K\QA;G1B&S+#AJ[.;9+&VU\%"P3.@Y\,B&SIEJM(NP,7&1SG%T%2'[Z&
M2OA0]Q: R@*07 0!E(RLJB0V(\ HE)L1MS"?NC5"(SD#@2Q*L#:Y)074_&4
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M0XA,H49@RZ>6%3+&/C(97/,E,C%B5#OD;LMBRACU*Y L+W&0)&XOH@C48I@
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MZ-J8E)%\K*S,5W"A653?XB6ZBXV.^U9.G>56F[BKOSN-_G7E&N(UI]A867X
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M$0H]>DF8"1-S@0LH\#30UN<V)A0@F<T.!1$$.<(^4L>,N>'>>/7;%K%K'$$
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MSF02ETYHP56<)F^K!9%6J_>:-T:>#GBA5B=0_!PY#22NHE1F=6&3D.Q*(W?
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MY$6%HV*Z9V(^"1_9C,)\9[+;63ZXO<V%JL;]PRQDE>5@TC9, %!LHLH]$64
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M ==R/ $_EV!/R"]<&#86NR%T[>&Z5#M8$O5.S#LGZB(9>LL 7;%*S/DD*PQ
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M2; FP%KD[; 7%SX7%^M3DNVXWL!N-R;V ^6QM\A]5?L&QUYGG/&M?)6$@I6
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M ,6[^+CFDFC'ZSEQ!&+,H4Y*&+#Q 0%G)_\ 9 )/R4+* "2+,5 /K+$!?G)
M'RU@V>SZ2F?=UIJV(!<8XLINX"$=@P'["3"54UNUQ9?*^UF2-7#=:U@Q>XF=
MI@BCY0"3HSEK4<*PB=ER"W787!7JQ8*+7OD<&LMKV%[6()@R(#B38[[6/@%)
M/2UADMSTN;7N#:;BE#'"C&ASPE!F00E"E#R8RP$C$1XRP3P2X=Y82PS19XR1
MR8=]XYX98Y8]]]=]=\SZ=:OUZ5[^*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE5KM_3NLM^:\L&I]Q4Y3?M
M=6KI;U8*H[Z([6L_D[<!\L[F[$(%*PR";K #X<X"(L^IAH_7EWAWEAEK#-+I
MY%FA<QR)?%UM<7!4]01N"1T\:I)%',C1RJ'1K9*>AL01\Q -8>P:?@97<6_5
MF\W+73O.NUZG6**HQTTE;;:I4W;9_6DS8&X5&UQ@=)B[%:A1&%;[1LNUMJ<C
M$%SS1(BD@2D)RV19%#,ZYY@J[JJN04=2<@J$AKBZ+X9!H,8RS5F0XJIQ"V95
M)*@AE:UBS 6MLQ\;$:_J_ _7JY955,NQMJ,@Z@-&F6]F$:^@)EJ(E"IVN%U,
M-*5:^6SFUX>O41!*8,7G/([<82MW4AQ@=>S0<@ZZ0ECRX@6)8VYELS(\I>QD
M(#9.P%K8KL.K98C2( !DY %A?'T0BQA;A02,4!-[W:YZA<9"C\)]3);"$ZR/
MLC9>H:DN$=79B47-$N)8NT]D;1$R"4H1W8!37B!2:'#9G#CNM1"8+*EFB4^R
M#C5M;*5(LH+"S,"^1 5E%N_9;*S X@97N^1WJPTT8(-R0#=5LMA<@GHMVW4$
M9$X_<V%9Q1X>Z:4ZO@T]DN/:4*.Q:HLI"5M'7B!6)>GJIK>GUH1@'!7QEI"]
M@MU=7";!#T#',8PG:3 DK8)@A@(;63-*9K@2%95R&0($SR.Q!R)N#*P4WV
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M<4NNE5<<8B,%3=3>Z!@)+Y>GBV)(L"%6XN+F3I8R;AI <F;9K;,02FP]"X)
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M8#VC;6K3,DUC=(Y9+?5F @_O*M7RKAM"0K$!"C177%F,B)'*YOO;)WPBE 8
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M:Y+7L<B,06#*@.Y"1FY15*V8W)*Y(U1I(U"A; +_ *HW.)4L>@+,#9F(-QL
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M7Z+L_JN#Z#AFO?B^JU\$Z\275,L:Z2'32(8?-=1IR&8SMGF7%E&-C>_3Q_2
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MKZ_9R!VSUYZ:32&_2PF_>5*_RLNW#$*O9OLRS,;*JQ<68L?4 .(W)^2OS_2
M?)_\G]#_ -AV!]=<>W/7_!-)_;?O*C[;/MM^+O9?;_\ #XKM\O\ PB;4_I /
MD_\ D_H?^P[ ^NN/;GK_ (+I/[;][4?;:=MOQ=[+_1\5_B-/Z0#Y/_D_H?\
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M 'L>5EME%J$4^P$L9YQ^N@9B;\N?UR9G$Q*N5/46"P5T$K 5<*ULVA9+YR*
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MYI\,PS2(BHYA0B?=SR8$89Q1=]2]=Y5Q;;NMO<C8D$7L2/6+[7%6N/6/4?\
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MFXC;:UPHN5><%XC)&I!R4 .+>D%.P+(#LWO@">A.U^"A](GKYR46E$IEN9-
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MR264X%FVQ8.R2OE92R&XKJ'))2'O(4("L!NLB%@,]B>838=T%5L +@EX?"H
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MV1K6&+*!K(WV'%]2 04B),B27)EZI+#*!CS<#WH$&14N%+*&"V S/#8;K9W
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MZ>.0LDZ<H[I.N4KLS"2BIIB)AEPN,TF>4F>'<F6>>7!GF>>5YGMDYN;7L-K
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M;V"R,6[]P9V.,(%$2T9ERC+@@%HV<0 (@T-GD>1LG-R  + * !X!5 4"Y)L
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M-@;G&7SD26CN8V(+-L2N0P(6YVP*\SU'(@ G:L1+;_..BJI5 =1276+W1CA
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MRRU:F@9ZX8J\V)4#NU=S7F0AD#.JT.O<JJ"-%568@)BNS<P9 A<EE'--I%(
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8XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g937421g81u30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g81u30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1O>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &\*^<08X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #?P
M!V0          0                         !              =D   #
M?P                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M?P    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   W\     4F=H=&QO;F<
M  =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M3Q_.
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( 1X"70,!$0 "$0$#$0'_Q  ?  $   <! 0$!
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ML)1AXI9U)! ,4+F.1MXZ&!W<2 2 0#B[65RI*F,Y62.)@""1)*H9 <=8(!/
M$@$Y(K6[(5&L6,+Y=\9W%FG'6['=PLM%M+!)PD[28V*HS3VOSK5%T@8Z#M)O
M)QSM%-R@8R2Z9"K)&,F<HCL1NLL:2H<I(BR(<8)5U#*2#O!P1D'>.!WU@D1H
MW>-QAXV9&'4RD@[^G>./35H;; (".W@#F @/AY@(\A#V0 !]GG>J5$1W['?V
M0VY!]D?6WWVY /5N.E*AL&X=8^(0'P>+<=@'Q\N8;<NK?2E1#<>OGX! -O"'
MV!#P[[<QY#U;J5 1#?EL/C]C;<=Q\/AY!N&W@ =M*4VV'?81Y!ZW,-NOQ=6_
M/QAR#81!2H\^L0Y" ;<@\.W@#GRWY!]G2E0#EUB B/5OORY#]CF/,-P\77R4
MJ([>(>7/Q;;<]M_L]>WA#P!I2H;!N "(>#EUCU;;;^QU"'A\ <M*54H41+,1
M7,>4DQ$!VV'LBND=MA#P@.W,=]Q#8-]5?[QOT6^(U9/OU_27XQ7]$;@#DGSR
M5D0<N5EP$ZFW;#B;8/F_&.WL_3];7E'3GN8X#P_;Y*]&;P#(^,5UDU-*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*_E[\?.WG
MZ.,T1WY<5?$)U;[ 'FLVSQ>L(^OL(^L.O3K'\"L_YK;_ .Q2O/[O\+NOYQ-_
MM&K4SES#J#F(]0[!N'BZO6W#JY[\MM;5:]-QW#;8 ZA#F'(>>_@V'D/K /4(
M\]E*@//?D AZW/Q__4/C\6W6(@&E*B/,.OV!W'J'KY\O" ^ =@#?;2E '< Y
M!L'(0V'^?B';P>$=*4'P>#L=]^L0Y\_9';;<0VV]<-*4Y^L'5U>/<.77X-@W
MV]?D/6"E0W 3"'(=P\6_TAZ]Q#;P#L.WC'DI4>?/EN/+?GR 0\/5[ \M_L!N
MI4>O;P;<]^O?V.>XAS ?7ZN6E*K-:GWM4LE?M485N>2K4Y$V"/*Z3.LU.^A7
M[>1:$<I)J(G4;&<M4@6(19$ZB79D(JF(@<(90RLISA@5.-QP1@X._?CN5*L5
M96'%2&&>&0<C-;Z1G2;<13:17D)MC1;9Y(Q[<,7J)29<BUIUY3+CF*NYL/%I
M67&V2:)<T0KMGJT' UM5*S$%K0V2-,DBRT21,A- [,ML84R)]T27=S3#6L+0
MYT2Q2)VRNS-E=\AUC#<=T;0N <G0WW-HM_.*=#2"7&J.1'&EE55[;<@"'*[J
ML*K<=698+#T3P\R18.:PDQAY6JN:F#16/FC5*SY2@\G6B-BK4*SUW%R<H6+E
MJ(TG%V<JM&4&XVROIM5TY(JK?(]C TQN!J6<D,'SE=:Q&)"4W A00^D$9=$;
M(P<U6]F6%;<X:$ J5W@E6D$C -O()P4S@X1F7&_=C_&_$Y;<30F8X*CU.C1:
M.9(NRP,@],C;0?U:NVR(FH&6K\$FRN$?#3L.2(G%4XAADN(O[6N3+&)MU<2B
M+A'(3X7EM4F,+2,Y,+*PWIAF0JP9LH64Y49,;1EE+(VI"5K''<O$LJHB#G0R
MDX;*JP(*C#!2,'<'#A2 RX89K+"''_E-K:6]R:X\PLWL$O;)2_99>MJO:VPY
M[N\O0[[CIW9\IE0O:1D70U_*.0W!8W&:F.*_Y8;=,6%6&4E56KAMB.SX2A0R
M3E0@CA!=#V/&KI($B^Y[QJBCP9>=<*BKJQFLO9TFK6(X0Q<R2D(PY]RCIJEP
M_L9).UCYM=3LVG)JG1/'+<XB&)4RX;P+(T%I2DZ'#X^EX+([^K0T*TSI<.(>
M'.T[+*1)Y^[A,A764!B2P3LS'O*^UCHB<CYCM;UR^EK)&.KGIQ(7YPR*T8<M
MS"6[9^Y%1JC09TJI#992-P$"\8#3S,!31H$960J )FG&/NFHD.QQEB"N 0>)
MQ9-<15CDKW9,D-(2';W&_P".LE4G)TY)*/95]?9_,T7<(_)V0Y$B2T6SC[),
MC>)885I$LFD)!-6$&W4CY59H_>2F5;=518R24CDB>)1@"-8"ABC&<DJO-J6R
M2S$L<KD 8FG8NT@4!WCD20G>7:4.)'/ !CK.   H"\2"3L%/])7GVZ.1+D*O
MXLR% =U^(.2&I6:#N"<"2.XEPJZF1JJDO7+U 61"LMW]71E:LU0L*4A"OI:;
M[9*/F;AHS88%V;;IGFVEC;%N-2E"V;;7S;]M&RER'(<E2& & ",UG:_F<]NL
M3KF;M&5M.)].M=SAM(*Y4:L@D[R#@6#<..#*U\Q'>\+VBO41W4KQ<U;JF,8&
M0:RK4W"=.Q/CZ&K]>A*MD&%HTE5ZE3L*X_@JA%WZHW9: 1BEG;-X$F\5>ZR)
M911S1S*SZXTT8/-L'!>5V9BT9D#L\TC.T;IJ+8(P,51[R5XY(F5"LCZ]VM=)
M"(BJH5PA55C0*'5].,@YJ8>\<V5IB"X@J[.5JA2T;Q(2\1/W=,JV3J\,;,05
M/G:3%NX$E-R;6V[YFA$V)^X4@+RA=:R]E$F3M["N"M2(#'840:W8/(#;!A'^
M]-D,ZN0VN)L'*KAH^;8#(!WU'9DFF=2J$3D%_P!\4@JI0:=$B[L,<J^I2>(.
M*NBW=)-Q-W6P!<):7KJ=Q9U:0I5;MC5G832]-JCO)V.\NLH*K$D+/(13)I 7
M#'+?N*H\C))TE 66QUJ0<24(C4F55HFS;6-="JV@N'9"5P[B*2$ER$#'4DAU
M $ NJN &+E[MM"X8ZLJ'TE%<!M2J9(Y,+EB,!HQC(/:LRG(TA9..Z17B):3$
M%8GYJ)8)Z ?1#]K*S%:<)*+C!YFR3G6-9+,(.8A8AG$L[KE2U-FD1"QL5'1U
M:&+@HMNQ0C4U3SZ76V&4"158,"H<;M4,4!()5FR8XD[8DL7RY))Q3L^?*L=#
M,I!!*G?B5Y0,!@H :1@   %P!C JJ1W28\448XJ\DVDZ.I8*_!8EJDG99*F,
MYR>O54PN2[EJ]>NSF=<R3=^UDPR#9#7&0B6L'8+2X70>2,R9ZB+E6IV9:D."
M'TL96"AR%1IM&ID"XP1S:Z 2RIC 7!Q0;0N05(*:E$2EB@+.L6O2KDDY!YQM
M1&"Q/&K)QOQQ95QC9&UBA*[170-L"-^&]*(75R5 -0QTTR%'Y,:F1FZ%DFG7
M9E84;%&-$1E(VV,D7,.56,>,723MPHKDDLHI5*LT@S.;G/W)ONIC,1[62)XR
MNDGM2A(."&! JJ7DD;:@J;H>8 S(N(PXD&&217#!@!D-O&X@Y-4?#W&AF7!-
M<G:CC@:O%5JS/LINIZ(=1DI(,Y6/RU0F>/;!7WI7,X)W<-%1\7"SM9(Y.K(Q
M5KA(J;6DGXMO(Y[36<,[J\NMF41:2"!@Q2&16&%XDDJV, H2N!G(B*[FA5DC
M*A6,A88)!YU C Y.\  %>D, 23C%7C$\?V7(*P5^XQ=-Q*UN[6V42YY"N1*]
M:0GLX36-FJK6J#E3:[=S%&J1USRDTWQ]&X^&UV$C:SVE28L#)C)ML;6$+*R%
MY3&4DCC34NF!9?ON:[3.>A3(9-*]JN%)!L+Z4%6"1!]2.[Z3JF*?>\YVV.Z>
M;":CVS9(!'YK/'OE*H3L?)0=!PTVKE6CL?-L:8Y-7+6:CXIF,472\Y&Q[;*8
MEY>@M#RRUV_9/R/;#K7JTW2+GY2[S9+3%3D>6+8QAK")U(:28LYD,DFI \HE
M2..1'^YZ0K1Q1IB-8RH1=!4ZB2WLBMD1PA0(Q''H;1$8G>1&3M]6H/)(Q+LX
M8N=0(P!]Z)Q]9)Q^:FO(G&V)'5CIV)GV$O+FJ?,D';K'CM[*FFB1,W+TK,=4
M!D\8RHF<LYBHH565-V1V[UT\9G.W,DL(Y-8,DH1Y1/HQ"R+(!C*B2%R01Q5R
MXSO !HE[(F@B.(LD9BU_=E=D))P2DJ8P3N*A3UYK%6.^)RP8]"U,!QQBN\U>
MQWUCE*,I.0(JX3E:H^0H8TLG"6>J'9WB)L"JL<PF740ZB+=/VVNV>.0CD[O#
M6=S&,'+?-);+)H/.2HRH8B\917>-L:D?M"N\J&#(J,I)T,@)%8X[EDU_<XG5
MG$@20,RHXSAE[<,< D8=F5AC6&(!J\KKQV<0N1,5V[#UQG(F;J5Z@:M#V8[R
M-=+2S^2JN8;AFU*XD>GDC(,;?/6^[2[6UOV#-M'V" :0+)W%>38&,DF^-+&V
MCF2=%(="Q7!  #0I!HP "45$4H"25?40V&93=[VXDB>%V#(X4-G))*RM+KXX
M#,S$,0,%<#&0"/A#\:.08*9H]UBJ+BIGEFD0C>N)YI;PUN;Y)L<-&8OF</5]
M">>MKPC7$'D!3)A%%M.U>M5JPR\I 5R8M<K87K!91Y)LXV#HSRF&1M9A+)S8
M8RK,V.TUD,ZY*N[* S!0H(Q NY%*.$B$J +SH5A(RB(Q*&(?2,(0,JJL2JEB
M2*N)WT@&;YJAWS'UO85>[QN0Z/C6C6&9L,OEIO9W3?%%,N5%JLV]F*SE*N#9
MYDT3>9EU-L[PWM-5FI9&,>O*P<K($%*]@0"2.1"T9C>5U55A*?=I$D=0K1-H
M7* +H*NHSA]^:GLV8H\;A7#HB%F,@?$:LBDLLBZB0YU!]2L0"5W5:UVXSLFW
M5"$8K5O']>BH#$-_PQ&Q$#'VQ6/:UG)J786UTQ+8KC8',*LHH4'$%6J\YB,;
M5)P=T>JT2'3E)<C^R6<2%B&D8M,DY+%<ZH_O0=*+JZF=@TC[M;G Q$EW))I!
M6-0L3Q *&QID^^/;.Q!ZE!"+_%09-8\B<[R;/%)<33F/<97=C%^6DM%M]OA[
M"ZNN,TKF5 ;*A3WL/:86 =MGKM \NP:W6NW!"MSKR2G*NG"RDD^=K9# #+SJ
MR2(3HYQ$*Z)-&=)<,C," <$HR%E 5M0 %8Q.1%S1CC<#5H=U)>/7]]H(8#>=
MXU*VEB67!)-?:S9[D+0\JEK=U.N-LFU)]B)*/O")'3A *O@G%5&Q7CRM>5:1
M5?1"I%6=):6"Y/) TBG99<[9%HP@HILZCY(L 4,H=N;;GB4SCMIYI)I&U#!&
M^0J@73I&<EB01+3EBK%%YQ3%A]_WL,:1HNDY'\0,Q_C'@ -U9%M7&KE&SYNQ
M?G<M>H<'9L0)*ITZ"CV]VEZX55Y<+=?9-S+N;I>+7=)4TC:KS8Y!1%S<191R
M+I",@VL3%M&[(N-+*)898-4C),<N245MR)&,".-$7"QJ,A,DC+:B2:N]Y*\T
M<V$5HOO -97[YG.2[LYRS$[VP,X&!5LL.*J],,:-<?EK&/7$U%X\GL.P.7G<
M--GRM7\0VE_,OK#CB,D4K(C3S0TH2RV:)-,R=+D+NRK5CEZO'6IE7CM8UK8V
ML9E,FJ0*THF:$,O,M,H4+(5TZ]0T(=(<(617*%@2:BY<1A-,>H1M$)2&YU8F
M)+(#JT8(9ER4+A6*A@, 5JC<7ULH6/J_B^+QKBB2I,>K9U+A#S;3(STF4B6N
MIV.E22-Q.CDEF,"4L%9GI.WXH\S1[)R$=7)6P.IF1K$&X8UDLTDD:4R2ASHT
M%3&.:T.K@I]S[;MD!Q+SH +!0H9@;)=ND:QB.(H,ZP0YYS4K*=?W3M=S'?%S
M9)"EB2HQ](+C<SY5K]E#)]:F*]"7?+>3HO*MFF6]:8/D$)6*8Y+BB5R+@YGN
MG7@I#V,RK/L)&MS$3,H.&L=7DRKI!&K>3365N\<43JS)#$85!<C*GFCJ9EPV
ML&)2K!A@L^XY&"WDZO)(I4/+()&8*.(#C2 <KH(D.5(.<+U'-9=<?7$>:JI5
M:)L<37"JU)2DS\_$Q2RUFM\";$>*\,(>6:3GW\XBXEH^KX=ILI#S\<SC)N&N
M";ZS1,@S?'8]SX[ MM6HH6[;6JDC0C<[+,= 4+@%YG#*259-*$$ YL;ZXTZ0
MP7*:&8 ZG'-QQ=L6)RP6)2& #!B6!!QC6_+62[#F7)]^RS;48Q"UY)ML[=K*
M2$:KLXH\]9)%>5EUV35V[?+MTW<@Y7<BFH\<&!14X=L$!  V(HUABCB3.B)%
M1-1!.E0%4$@ ;@ -P [E:\LC32/*V TC%VP"!J8Y) ))WG?QK'NP"'@'GX '
MP=7A#8  0Y?MZR5CJ.W( Z^OF/AW'<>L?#XPW';<0TI0.L1Y[>'Z0!X_ /K
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M0X?-8<GKB_1'[(B@/9MQ9RQR+J:'FHX0DO:N!(LUW*ED-.Y)I(R7*2967I_
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M#%:W!C!,K@!"D3+I50%&&)W9))R3O%YH4#Z7WCX,<D_>GK@>P9_9V?PCL_\
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M:5P2C*P!MX\$@@[_ +IW*PW/]FIM^YMKBV;D)L=%N()8&8;9O25$L;1E@#9
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M;2E-*4TI32E-*4TI32E-*4TI32E-*50)6KP,VH563C&SM0H; =5,#&VWWZQ
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M[F1F=R[N[,[N[EG=F.69F8$LS$DEB2222236XJZ5"J%55 555<*JJ, * 0
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MMD&;)DSC$6S1FT;)%0;-6K9!0B+=LW1(1%!!$A$DDB%33*4A0 -H!% 55PH
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M#J1B 8[=E4\VSQG2[2IJ5B&*D[N S6\DTA<RH47"A!A@"0\JLPUJKC4H1L,
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MAFM^:V4K1GG@P5@C ZF$BB:0%RJJ&5N;6,DYTN).U0%&)J)-H,'!B*L1J!!
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MRO<,PD"QQ1)*$#)&I"]HVL$:F9LELYR3NW    46$+H)9Y&0L59VRW; *0<
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M,&^PE 0'5S@X.H#<HP0W$* >"D='750<9&"<$GHZ22.FM>1Z0'A\ 1 7%TW
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M=K!82 LLVS+]I'=KQ@2&C5510%))-65=\89!O\;W*G[=CE9KS^9)C.R@//K
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M74HP9I2 -P2-4C0*,O)_E'R4V%9B%;N\N+J7#75T]I<$RR ?>QAL\W#'DB-
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M 1VXC,FSQ$]R@V?W-[_;T<8=60,A?!1</B>NY^KCD]^,3^]9OF_8;^%?+O\
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MV]')\\'(7P47'XE_/;V-=O\ 5QR>_&)_>TWS:^;?[4[T9OR/LCX?V=]+3O\
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M)58YW5G7FKB(ZU&G)*\0:U;[_;T<GSP,A?!1</B>N,]7/)[\8G]ZS?-KO?\
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M""2=^ 8ZBD;*N[!;&< DC(,-PSYZL,3$SD'BZT2L9.0I[%&.63=NN9>%(:&
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M8TXIOX3(D%(-#AUE6;K&,00\7/PZYSDU_#^R?Y[#Y#GCT?;O'R?T=?\ H?\
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M?N[-V?NZ_P!RP_7D=(K\1_11_P"DKT1?^_7+#/\ X@VC\N*QQ^"7OT*N%?\
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M9=W^,W'CY?G5',0>TQ>+0;\?H]55:$Z/F=B9%N[;$:M^P63.H+=!-$QRD-N
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MU^41[[F\WG]VFF'CV(?$)\7&KRHW!I8*K8(^22K=A11;N2+G3;Q#9(#F*)1
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MHT'O'S8J7)7SC:LM7J#%^O)MJ/AQA3ZW 6AN9>5<.Y&U762:G<.F!7#I1RE
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M0+)J8+'A8UE;*A2P,99B-ZUEYZ=(T>1!(3),'"(R$)&DI32I9\L[1K@D@8<
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M=/WM5_Y@'AZM:'\4]>I>C)QVV?<Z_#T5M=/N'Y/M_P ZW;P?^AO7?#^(TO\
M4#^?B\6H\/3Q[YX8Z/L=]!Q;O_(*RWI4TTI32E-*4TI32E-*4TI32E-*5(2?
MY4-_EV?[\;ZD<?</Q&H/ ]X_;=4_J*FM-\[0V+>+B(OG#?6\MQ$/DK'LY7IR
MP#"MWDK8L?2[-)D_9KJ'B)JJ3T!+J14^U69R%;M]>G6B<FU.H[<0[R0BI/<@
M:6T:.Y:%FCD5E75@+(#D'&I75@&4Y#(RD@C (!&M*$N \*R .C*6P"60C!'
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MW*<I3 !BF*.VQ@$!$!D'!SN..OAU5!&1CKK1WB(N?$55YA-#%TH!&(@ F!S
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M^V_^G%\RN]=BP>U_^9_G5\O,LH7J>1]VR?QW3L^[]M_].+YE.Q8/:_\ S/\
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M.SS&2WC=I6>02OK9E+,KR .R$E"V\K6-+^]3F^;N[A.:4)&%FD4(JH8UT ,
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MLI2NN1D0'FXI&P6&0I R< ZUQD-:OI=ECG9GT(SD*;:X0'2@9B-;JNX;L@G
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MYQ*SF+S3TZK3#5^^6*MD;H$JLW84E5E'<402D=@@G.H,(9K+H1#+WOT/]G[
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M]_Z><&_=N![QA)]'#>8V-D)$]X8JDCV3MZ=,M7?D,H5J@HN8@&&4,!1."8E
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M)SI&#D\  2>%6>XXM^%AH:-*YXD,%MS3-66O$05;*U'3-*TYNM/-G%HC2FG
M,^@F[BJV=%Q*-@5:(*UN>(JJ0T/(@VOV)=;_ -S3]JXC/W)]SG3A3VNYCK7
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MJ!!$DF)1*I<L=)!B)TC@I81*I9=)*DA]>$T:D]J)V+%V3,9C8*!VP(<#4>+
M<X2 V0" 5TDMJL['/1K8]QYD"FY(+E')=EFZC!3T,6.GWC%>LR*]DFN)*?>3
MZ\ DB1IY9HE[Q,6]C5;&Z%_.U^O-5H4LD\):+2YE+R;1DDC:/FXU5F4Y4'4
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M51\XOCW<?Z+U (_D3> =A_2>SMX_6\#?UCP'YU1JW#NG'A&1\GU]+SB^//\
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< "Y]U%6II2FE*:4II2FE*:4II2FE*:4II2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g937421g87n61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g937421g87n61.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2=\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )V"^$ @#A"24T$!       %QP!6@ #&R5'' %:  ,;)4<< @   @   #
MA"24T$)0      $,==%^5TM6[UV[XYE,#I>5PX0DE-!#H      1D    0
M   0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT96
M5N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
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M]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M  3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T
M]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M!'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D5%
M5N=$8C4FQT                0FQD(%5N=$8C4FQT                4G
M-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'
M-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M    !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M       !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;V
MUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%
M)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M   ! !+     $  @$L     0 ".$))300F       .             #^
M X0DE- _(       H  /_______P  .$))300-       $    'CA"24T$&0
M      !    !XX0DE- _,       D           $ .$))32<0       *
M$          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0
M"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M   3A"24T#^       <   _____________________________P/H     /
M____________________________\#Z     #_______________________
M______ ^@     _____________________________P/H   X0DE-! @
M   !     !   "0    D      .$))300>       $     #A"24T$&@
M #-0    8              P0   =D          $
M       0             '9    P0                      0
M                 0     0       &YU;&P    "    !F)O=6YD<T]B:F
M,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;V
MYG          !"=&]M;&]N9P   P0     4F=H=&QO;F<   =D    !G-L:6
M-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&
MQO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$
M53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D
M53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#
M$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6
MQO;F<   ,$     %)G:'1L;VYG   '9     -U<FQ415A4     0       &
MYU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%
M0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%
M0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M       0$ .$))3004       $    $#A"24T$#      <J     $   "@
M  00   >   'G@   <C  8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6
MYO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R
M!S4D="               !  #VU@ !     -,M2% @(
M                                              $6-P<G0   %0
M  ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H
M(8    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&
M0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&
MUE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\
M (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=V
MQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.3
M8V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                    !865H@
M      \U$  0    $6S%A96B                      6%E:(        &
M^B   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X
M0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M     6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                   &1E<V,         +DE%0R V,3
MDV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M      +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("
MT@<U)'0@                            !D97-C         "Q2969E<F
M5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M     L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3
M(N,0                                  =FEE=P      $Z3^ !1?+@
M 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
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M $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2
M99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^
M4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1 ))0DZ"4\)9 EY"8\)I
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M">KI\=D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( /<"70,!$0 "$0$#$0'_Q  ?  $  00# 0$!
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M(J=,8PX_F/&PI>&&LK[^BWA:L)QY=\\XFOA2FKJNGBSRX:F:)-QRVQ)&5<G
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M%Y2A"$)QE2UJSA*4XSE6<8QWY4 D@ $DD  =22?  >))\P&J$@ DD #J23@
M>DD^&NJ)-AD(S,R!+C3HDA'K&)41]J3&?1WRGTV7V5K:<1Z6,I])"E8[XSCO
MWQGAE96*LI5E."K A@?'!!P0<>G165@"K!@1D%2""/2".A&O3RFJZ<::<::<
M::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::<::@SJ>GSA
M?3AOHD-ER(!"#I[8\J%-B/.1Y424S42RV9$9]K*76'V7,)<:>;4EQIQ*5H4E
M:<9QG6M5>Y6]' 96K:965@"&4S(""#D$$="",'SZY/CV:6GX(XOG@D>&:+AF
M^212Q.T<D<BVVI*/&ZX9'4@%74AE(!!! U\<^$XQ0$=L8[YN,COG&.W?/P+&
MSYX^?'?\7[O/:_\ .?1\ /FZR'S#IZAX#7Y@DYL8)\?=9O\ P::]DWRUC6?D
MS\?K[^[\7-:?-\^?=Y?B^3A?VU-_S%/_ *RI^?\ O\VI9O\ )RW?]=WG_P !
M8M6+]/?.<=NWT?/W^G\./^K('Z?IUS\V#K2?I^GHUO<\%/\ WQO;Y]5_R[#Y
MY]QUXVS_ $:K_P":'7V%]2G\3C?_ $N'_P"B\:WN\\_U]?:<::<::<::<::<
M::<::<::<::<::<::<::L/8.T->ZJ"JL&Q+>#J(K^R)9>+S4,OSG6DX6N,+@
M(]80+3,(SA>(0R++EJ1W4EG*<9SC(IJ6IK).52PR3N,$B-20H/G=OBHOW3E1
M\NHI9XH%WS2+&O@"Q\3XX4>+'Y "?DUKBV+XJ^M@KKL36E LEX6A2D8+'9C-
M/$.>_"'XC'LQHS);SVQG+4T>'>QW[9PG/ESIZ;A"KD&ZJJ8:?/[B-3/)YLAN
ML<:^)ZJ[C(Z9\=:F:^0(<11/+]TQY:>.,^#-CS]57[VL4+#XJ^_)KJL *EK.
MOQ\]\HP\,/F92<>EGMA4A^P1(ZU8QCMG.(*,9SYX0GOVYN(N#[<JYDGJY2#U
MPT2 CQ/=$;$#T=XX\,]-83WJI/Q$A48\ZNW7YRXS\N!JR%^)]U3>>4S=?)QW
MS^QQ3,YQCZ,=R^<^[YU=_P"3F1]:EHVYVU/B/]_\W3[@?T'KZ1JWW8K<=3%G
MQ_8B!@X]+_T#7G5XH/51C&<XGZ^]_;/>E^[WY^Z_XOE[]O+Y^5;A.T#P6IZ8
M)S/G.3C]X,>'TGY,!>*P^:+Y/@SU/3[KS>/]/376KQ0NJM*<YQ.U[G.,?XEY
M\_/_ (W_ *>7*GA.S]>[4CPZ\_H,]/.OIZZ"\U?GY(\!GEL?3U^/C]/#IKH5
MXI'59C_]NU[_ ''I?WE^_/E_POCM[_=Y^[W\N'"%GP"14^.#B;P.,_O#D>H_
MU7B[5>!GE'/7XA&/_P"[K]&O.KQ3.JW'NG:]]V/?2_E^7_9;SQ_)\OOQR_ZT
M+-YUJ?PY^]^X\<?3JHNU7Y^4?^P?RO;\^NG/BH=5^,=\3M=_)_M*S\N._GGX
M7[8S]'X^/K0LV<;*K!S_ )QUZ9^X^3H<=?1I[K56<8B]/Q#GH?06\#Z?[M?C
M/BH]6'_Q[7>/_J5_E+\J>#[+TPM5U4']G\^<'P3^[SYQJONM5?\ %?R#^5KH
M7XJO5DGMC$[7?R^?Q)_!VSC_ $X]V<?R_NU'!]E/BM5CTBH^3/[SS] /9I[J
MU6?][\/ H?O^?S?/YNISTUNPZ(NH$GU(:'$7FR.#U70<;.UFY-C(OL,%LK E
M8FP%QH>77U,-2:X2"258RXK'M#LA*<]DYQC@N(+8EJN4E-%OY#QQS0;V#/RW
M7:P+ #.V59%!P"0 3C.MU13FH@61MN\%E?;X94]"!YLK@_?UJSZTNBRN:# $
M]JC-A3R<*TWUD0!I\X"TF5!=.-FCCZ)-C287F<R/AC93;3F0K#SV<L>T.>GE
M;CG66&^S7&1:)Z9%,-*7DG5SWEBY<2XBV *27!;X0C!;"XP-:"Y6U*93.LI(
M>;"1E,D%]SD;MW4* <=W..I/36M7G4ZU.LI>G[0^[-L [+8=.9KQMVHEQC9F
MF')01U$YTA$DN#":@5QA2*26:QB-/CIR8=0_&<:[QVEX7E;>GN5RM])-%!7B
M5!+$S1U$0D!3O;70R4[I41],,>7N#= PSK+I*>HG$IIBI,90M&6 W;]V&V.#
M$WQ2,OU\0.GCFYH/HCWA;=PUC8W4-6:I3JM3)$0A'JHN#0H;)Z2*?<F#!L>M
M:]1BM#A;A5Q1(Y*FMMRR24N1%1)6)ZID/G[E?:"&AEI+7+//)4@AZB5J@M&K
M;=QYE01*SE%Y:*.X@)<$, #L:>VU,U1'+5HD<<9!V 1#>%)8($B&P*7.7+=6
MZC!!!&3W7QU/JZ/-,50=JIBKB+U83$ !2*\X*C." E5!MIDG2+5?C.0F$C(,
M9$ !%99RPVQ*-Q764+1$=1C7\,V;W>N$QK#,]-%&TM3*'82/-(0(T,I#'>Y+
MRL6ZLL; G+#6UK:D4<*B,*')"QI@!0J]6[HQT P.F.I&-:<%^+CUAI[]B.M?
M+YZ'CWY]W^S6/Q\]"7@2P$=5K,^'[9&,_@OH^3QUJ3=JH#/P7@3\0GI\VX>@
M^SS:Z%>+MUBXQWP0UG[^WG0__P!-<O\ K#X?_>5OWJKVQ'5ONM5D>,>=V/V/
M/FSCH^/T\VNE7B\=8V//!'6?R=L?$+^?X:_#RX< \/8!9*TD^BK('T1$# \1
M\_GR-6F\58)&(AU\=ASZMV/O^CY=>9?B_=9*>_8CK+W]O[POP_\ #?T<N7L_
MX>8D;*[IC_/#GJ<=>YX^'W^GRB@O%7Z8N@\.6<>L/^GT:\BO&%ZRT]_],=8^
M_MCO0?Y?].^7CL]X=S\6N^+G]N'^S']./Z=5%XK&.!RAY_V,]/D^/X?3][72
MKQB.L[';L0UA\O\ M S]'_#GN\_YO+EZ]GG#;8PM?U./VX>G3/\ !CYO5C1K
MM6 >,7C_  ?F /W1\<?)\NNE?C%]9Z4YS\(ZPSVQ_B!]'G_LYGZ>2#LYX;9M
MN+@,@']MG^CE#^[S^&HVO-: 2#%\W+_O)\?E]7F\CGC(]:2>_HD=7=^_;MF@
M9SCR_P"_>.W\_+QV<<-9.5KR!Z*P ]2/1%_1C'A\FH_=NN],7X/^_70OQE>M
M5/G@CJWY??K[/GVQY_[.8[>?N[9_=Y>.S?AD_N+AZ?VYT.3TP>5G QU'3KTQ
MXC0WNN )S%T_XO\ OUYW/&;ZUDX[X(ZL]V<_X/\ /T>7^OGO\_H^?E3V;<,_
MO*_\</\ 9#'S:C-]K_,T'AGK%UZ_,_3&1X^/WLZ\V?&>ZV>_^N6K,8\O+]3W
MW=\8[_[.^?\ %R9>S/A?&2EP\W^>9\<G^"'AC'B?O=-4%]N!.W=!D'&1'Z/D
M)./T\->9SQH^MQ.<=B6J^V<Y]^O/DQ_W\[_A_FY(.S'A<CXMP^3]>?\ VO5Y
M_#/G&K1?K@<]Z'SX^"'3'_:'7I]./'7FSXU/6]C&<_"6JOX.^_\ Y=QR0=F'
M"I_<7$_-6^D#T0GY?,?EQJ(\07//1X?/TY(^7TMG]/#S:\KGC7=<*,XQ@CJG
MW?>[_%WS_I[_ ).7#LOX4/BEPR#@_KW_ .P/0?#UZB/$ETZX:#[\/_\ U_4?
MOZR_Z/>M7Q0NM"X$P&NR.E@-:K*(;]TO]BUS*Q7Z\W/<>3"A,LQ#+DHR>((C
M2G1X>+ZG"FXSKY"<-B^C)SSO$_"_ /"]*DU9%=9JBHW"DHX*]1-,4V[W9FAV
MQ0(6"M*V3N.V-'8,!FVZY7VYR,D+4R)'@RS/#W$!)PH ;<SL <+T\,L5!U]#
MOLQN'0/9+*4B&['%I_LQ\S &Y#P"YI@+ZHH3A"%2Y^1<2?.2_*C#LSIN83+J
M(V9<G+7KE^+[HFJPT$;10M5*T,3OS7CB,P,<;R[4YC(A"L^Q-Y!;:N<#L&#"
M%@[!G$1#,J[0S;>I"DMM!/4#<<>&3K4!T3ZCUQ;.FKPPKW8ZH.+6H28OH.$5
MD+F)7D;.UQO(B]'G0V930\LA+]-KS;&2T2=F)&@(AQ<LQ7I#+OIO&%QK:;B'
MM#HZ>=XZ:=:266-0NW?'<+2%96*EXC^N92PC9 [,6;+!6'(V*FIY;7PQ/+$'
ME3G(K$GXIIJPX9<A7&(D"[@=NU0I &#L(ZU-XG>F;I8V]NBH!81FPT6NP55\
M;-:=6+:)&CPBL0)T^-&6PZ\,#/&6RLR(T]&S)BP7(R9$?#GKF^+X3LT5_P"(
MK5:*B9X(*VI99I$P9.7%#+42+&6R!)*L31JQ#89PVTXP=_>J][9:ZNMBC$DD
M$:\M6SLW/(D2LX!!V(7#, 1D C(SD?'3;?%1Z^K>4C%9O4;:Q"H4MN;#'U05
M4ZH*:<:7EQMF5" @(#9>'WQZ+L,XHG&D(_L<EMY&>V?JNF[,^":6)HEL4$V]
M"C254U54R]X8+!Y9SL;P(:(1LIR5*DZ\;FXLO\KAVN,J;6R$B2&)/2,A8UW+
MTQMD+#Q!W>)F_P 1GK=W%U(ZLZ2AY4Q)&4RX:*9O%W&@5+& KEM49L6_ZWM4
MDI#C*2S(C"I.OV" D%(];&"N'WY#3:DR8DCFFX!X.M-ANG$[I$LU71W@T5%)
M4!9)Z2W24-%<*<1,P.V25:TQR3IM:44X&1B1=;#B2^UMQI;2I<QPST'E$RQ'
M8DM4M3/32[AGJ$,"LB'*H9,^)75R>"%N?9]3ZOJYI\ 5*R]9;,!7+-SJJGY#
MX$;)KU5*V(5;HT+OF(,+-%!,,&\2:0UF=#,J@2,O.9@>HQ^V*T6VHX7FNTT<
M:7*@GI%I:D!5GE6>H2&6E9\!I8S'(\XC8L$:$.FT<P/)P-75<=VCHT=VI:F.
M<S1DED1HXFD64#XJN'54+@=Y9"K9&S;OK\5GJOVST@Z+H>PM.SJW%LE@VT-I
ML]JS!$GHCX253KF<D*CQ<S(2VI+,X".Q[0EQ24M.N-K1W<0I/BO9QPW;>)[S
M5T-T2H:GAMLM4IIYN2RRI54L*[FV."I69QMP,G!STUW/%]XK++;Z>IHFB$LE
M9' PFCYBF-HIG;"[E(8,B]03TR,=01H23XX'75GMW):E\_FUSW_!_L]C^3GL
M_O0\'_O+E^/?_9UYN>/^(>N'H_/C-)U_UI_H.?1KO3XWO71GT?\ 3+4^>_\
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MM/INS)/33>41&4XQG.5/RL)5'93C&,YRIUQ&,8]^>W;.;$X7[/)CMAN].[^
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MQ1!^?_VGROOC5GV,IOP\OY.J>XL>".?)DG.=J^K&OPKP1]>JQVSOBZ8^;M4
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MI_N>72<<RD_!6Z-5'AS*AG/R_%B0 GY,_?U#2_4JV]5'EO&-7*^.\*2T0TZ
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MSWAXUV43B_4?9EQ+3Q<%4E-(7J*RCKJVWTU%"#)5U!:0U\85%#%8E2J9>8P
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M7&5#]9[8EY_,IU#Z&HW5V3B.&U4K4TE )R96DYR2*CL& &UPT;YVX[IW= <
M#J3\^]I_8K<>T#B"*]TO%;6V)*""C]SZBEFJ886A>1FDIFBJX0BS\S=*ABSS
M07YC!@J:)=XZ8':"VA:-4W*]W:0<K#\-+DX90AZA1.&1'Q"< D,<F;/B27HD
MB)+;RE3L=I;;Z7H[B<.LK3CT&WUGNE215D%-"(Y0W=>H.]&1F5E<+2, 05/@
M2".HZ:^0^+N%H.#>(*_AVZ7F[M5T#19F@M,)IJB*>&.>&>G:6^1.T;I(/C(K
M*ZNC ,AQ$OHT3M_?QL+'N\_B$&\O?\^U_/OCY?G\OE[\S0)OXK3G'C\.^/\
MPG3UZYPBSC'^&+YUZ?XII?'^?]/0HON^/&P^_;OYT(+\O_A7QV\_+S[_ "Y[
M>7;C;-_%:?\ #OU_^#]FJ?X&&?\ #-\]'2TTV?E_X?ZCZ-/0HW^/&POP_$(+
M^Y_A6[9_%_%QMF_BU/X _L[^?_N?]W353[C=/\,WS^::;IYNO^'^G@!_=KG*
M*+[OCQL+O\G^H(+\O?MGO^JQ[^V,_)V^CW<;9OXK!^'?\SU3_ V,>[-\]/\
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MPR_K@3J>^\]HK/\ _*7_ +?]./W>V,]O=Y]N/>.X?^R]X_\ @OS70=H-V/\
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MON$D\QBC2&,R.;CEBD4:1J3X*@ \-664ZIJ04&$1BND+ID'I(PI4%4\57+?
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M)I$YI+3J8IEBW(S71\-5<SU$=/-#-Y*]%'*2M5$1Y?*\:,(YZ6*1DBV%Y6"
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MQS;'6"WAZOZ1\H_I'SC5-<_NNWS8SC'[N?I_R^_Y?+EXSC(\Q/F_T>GW_/\
M(/GU>1X?*,_2==HT82-$(8@./FEBQ.8S!'"QL5Z:0(3)+B6HT2%#C-NR)4F0
MZI+;+##:W77%)2A*E9[92,B1%W=41%W.[L%5%'QF9B0%"C))/0 'PU?M9RJJ
M"Q( 4 $DL3C  \_R=?#P]&=0ND:^Z1(D2Q;4@!-D]1RV&)U:U*X^T4IVJG7V
MDO03NRWXCSD8S9F4.(E0*FPZMB+W9F.O8R[ *Q>=EJ*F^LT5&TE):LE)JP*4
MFK0"08Z52 5AST:8CO=1CHR'/"16\!IE6:L(RD/QHX"?!I2.A8 @A03Z01T;
M6*=[OUOV9:"=SO1Z=8K&6=]9+(3G,9]%M.599B0X[:6XH\?%2K+<0?"9CPXK
M?[!AE">^,[BGIH*2%8*:-8HDSM4#J2?%F/BSM@;F8EC@9. -:^6629S)*Y=V
MQDD^CP '@H'F P!JT.3ZLTXTTXTTXTTXTUD<OJ:N* 0,..K-(%3A-6H5)FVF
M' .+LE@J.NB8LR!KY21,L$L;$@OE PZ886!%AY9149MA^3B(GV?.K%I@,CR/
M-4NKS5-0L+-$(HYJI72250L*L[JDCB+F.RQYR 2<C*\LD"HJI$I6.&)I 'WO
M'"594;+E0"5!;: 3C'@<"L$>K[:Q".4%XCU.!6S8V]PBU:@!%MP9L[8-B,VL
MS8,DG9CUDCFXI\M&(BGHAN/#B/  *G(3^8;N9$:6.B0HX:=IHWIVCF=P75*:
M*.%(=H40F,QQE6W1%F$LG>'3%YKYR"F(Q&RR!D"]&:1VD9\DEPP9@PPX *+W
M2!C55QUG[.9<@2AX:HBYJKN$V';'(:+1B!>;4 F_"44@8K[]G>KH;,\FEHL=
MQ3A5:<-%8\>9,=5ZE#6+?<&C.\-)4,OD\M+3AC#NIH95"%4EY/-DV)E(A.\H
MC0E5&26U7W1G&,+&I,B328WXD=#N!92^U=S89S&$+L,GITU;2NJ;8!%@&,MH
MJK7:O#-?,ZR*U^QQ"SD*TU:#8L68*DU)@&8)1HQ7R+4/X&-AYXN?&;@L8><D
M..3')4HL]*F\P23T[FJ-7%)$8PT,S1"&38#&4Y<J9YD;JZG<<8"J!8:Z=MHD
M$<BB'DNKAB)$WAUW=X'<A V,"#XY\3GVA>K"[@CY*R0JI0D$<AQ8"I88'&Q\
M>A@P@>:"& @38P_#46KK4"?(>E5VXN6402+909(19!!*WG+9++32QI$TU44+
MO+49>-S4R22"5Y)-\9V2EE 66#E.D>8T(7.:I73([.$ASA4CPK+R416547:R
M[DPQRCEE+=XY)UTU/JHNE1FC"L.KTB69 4FH4BNF9$,_'(B85,#2P(V0M\98
MH'PPU.@S''#5?.)(U4E.8A3' :'(B,*K/9Z>=9$>:H"2U$]1+&#$4=JB19&
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MH@!75H0.M[8XFSUFT!J=K@2[4-P[NW4 $P!-@:##[9O>MB:U98C,5=E6\T"
ML!84ZIP6I*'1LY.<3)1*$EN&WER<&4,U/44\M97RBJM5HL\\KR0&5Z6S54E3
M Q84X!FE,C15#E=LD?@B2$N<=;[.LL4R04Z-%65U;&BK)L62X11Q2 *7!Y<7
M+5XL$%6'4L.[JX*UXBG44%E5.8=(5R_2*,9T:9JJ[>*E.9$OZ"7>U57&/@,F
M#Q,>.KV/97+L5(8E';)(?9EO%&I;67UX\_9]8)%J5@2>A%9#>(:H4LB_"K>_
M)/* >='-L2G\B@%'$F(8 &"QD$ 31\37%3"93'4<B6A>'FJPV-;VF$1/+=-S
M2^4/SW8;Y" Q;.O77/$/W!1KH0O&O*U2J87*V[5ES)H9([/MJ9Y'5D'9 >'!
MED-B;'N!UX-: &SSX&T"U%\1W!D46@%@'(9ER)EE1V?VFMI(:.NJ:RJC@I[E
M2QDQV^F*I<O(79D2CH*>(34TUOAGIY0F[FM(9S,N%%8^):N"=YZ:*"!I):29
MP'J90QI?*5"EJBHE8I,E4Z2IN V!>7M.3K'*Y[VMMYH"M<EH %@(O=&Q=YYD
MP(LYHE\;-EB:L&.P<//D9$? *+&J0Y8R-F-[<R^],5)(2DN-(9Z&CL=-17!;
MC%),919Z*R['9#%Y-0S3S0R8$:MSV:H<2-NV%0NV-3G6LGN$L],:5E0(U=45
M^Y0X835"11NN69ARP(E"Y&_<>I;SPI[NWR>[Y^W;'?MY_P OGG'T9[XYN]:_
M'4'P  &<GP\?1CY,[CCY\:XQGY_+S]^/=GWY^;W?+W\_?W[X\^SY/_7I\^GA
M@'IUSTP!YSCP\,#Z>NF?=GR[>7EY=OQ]^_EZ/?\ R9QY]FGS#PQ@8P?G\<],
M^/IZ@^.N>_S>[Y\]_?C/;S^7Y^^<_C^7'&A\/#IXGP\1YNA\^,>?'33S^;OG
M&?P=O+&?GS]'T=_/W]LY:=3GIGKX'YAD=1X9'S'TYQI[OP9[]\]_=[OE[>7;
MS[?3^'C0D^&,YSTR/DQUP,8.0//G'R:J(<.7L!8<" "R)LX8F11H@.(@RB94
MH1FNICPX X?#:>ESITN0MMB-%C-.OR'5(::;6XI.,Q3SPTT,E1/+'#!"C22S
M2NL<4:)U=Y)'(1$4 EF8@  Y(U?%')(ZQHC/(Y541%9W9STVJ "68^  R<=-
M;C=8]-.K>BB$,V!U+AP&UNII^+%+4?IN<D,%J7JEQ]IJ2-LN\941UV&6L32'
M$RQNO8RGHC6$L2"#\CVR-.#>(\1<:UW$CRV[AR::@LH)BJ[V 8ZJOVEE>&V*
M</# ?!ZHE9'_ '/+ V2:SB[C&Q=F\!2K2GO7%\D8DI; '$E':PZJ8JJ]R1L0
M'"D214"$RRC:7V12+.D4;-VA?-Q6\E>MC6*=9;(35C#DJ6K"(T.(WE>8PH3
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M[YRZH,TW(K3CJEYRMU]P(J0ZO.5./9SG.>;NEXANM* @J#/&/!*D<W[P<XE
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M3O\ W/TZ>C9?MP/\FG_I?'3T'UCV:=_[GZ=/1LGVX'^2S_TOCN^@^L>S3O\
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M@?Y-/_2^.GG!]>/ZCIW_ +GZ=/1LOVX'^33_ -+XZ>@^L>S3O_<_3IZ-E^W
M_P FG_I?'3T'U_W:=_[GZ=/1LOVX'^33_P!+XZ>@^L>S3O\ W/TZ>C9?MP/\
MFG_I?'3T'U^?U?1].G?^Y^G3T;+]N!_DT_\ 2^.GH/K'LT[_ -S].GHV7[<#
M_)I_Z7QT]!]8]FG?^Y^G3T;+]N!_DT_]+XZ>@^L>S3O_ '/TZ>C9?MP/\FG_
M *7QT]!]8]FG?^Y^G3T;+]N!_DT_]+XZ>@^L>S3O_<_3IZ-E^W _R:?^E\=/
M0?6/9IW_ +GZ=/1LOVX'^33_ -+XZ>@^L>S3O_<_3IZ-E^W _P FG_I?'3T'
MU_W:=_[GZ=/1LOVX'^33_P!+XZ>@^L>S3O\ W/TZ>C9?MP/\FG_I?'3T'UCV
M:=_[GZ=/1LOVX'^33_TOCIZ#Z_[M._\ <_3IZ-E^W _R:?\ I?'3T'UCV:=_
M[GZ=/1LOVX'^33_TOCIZ#ZQ[-._]S].GHV7[<#_)I_Z7QT]!]?\ =IW_ +GZ
M==\9)O#R,S'12H_[+UB8S$M#V?V*O1]!;LE:,=E^CE7I(5W3Z6,=LYQG%.GW
M_G_JQ_7JHW>?'WL_UZJO&JZ<::<::<::<::<::<::<::<::L_8=I71J#=[JW
M"23<J%1LEG0.7(S$1/6 #S"J82Y269"HR92HN&%2,1W\LX7ES#+F4^@J:FA\
MHJ(("VP3310E\9V\R14W8R,[=V<9&<8R-1RORXI),9Y<;OC.,[%+8S@XSC&<
M''HUC-5^L_7YR8:3,A%6X, 3K3(IL"$MEDLEBME\%VHM/JXBIPZTV:FJ 0ZK
M-EJ)1(\B'+@MRIBE1F8O=W;36*JC6/:5+,]7S#(\,444-,\*+-).TO+42-,H
MVL58,54;BPUAI<(G+9#858L;5=F>219&,:H$W$H(V.1TP">@!U='Z\KIVRRE
MYN^*>]:T\]%8:KUD7,G(:"UBP->PPL"?:Y3D\9;PC@UEIG+T^0Y.A1FW)HDH
MQ$@]Q;GG'DQZ':V9(@%/-FA(<EP%VR02*Y)PF%9B%="TGE]+C/-SD$C"MDC:
MC@@;<G*R*5 R6Z@ E6 D*R;TUU5+02J9F>:1/ @7;)9R,&IV@M6ZB*0*)G&G
M;99Q0B8"KK\L0&)SX44K/C2)+$9'JV\KF0$2L:*@J9H5F1$*R2"*)&FA269R
MZ1D0PNXDF"O(BL8U8*3U.%8K*]3"CM&S,"BEW8([)&H5F^$D52B$JI(#,"1C
M ZC,;*ZRM'HCR'')E[:FQ'O420;NK=B-V)A6*X_<,NN@E5O!)$--6C.V!9!4
M?$!L3C$U<E+.?2YE"R7 D ) 5(RL@K*0Q-\*(,"3G;"W.(C"YW%^[C.=0^Z%
M-^^DW X*<F7F#N&0$ILW8* MG'@"=7[9>H?450GUH?8;6@<Y<!-<.UF2X-*J
M'EQ5I-1 0J9%((A*A^@B9/AO$TN/-K#C)#94HF(.SF3C&AMU9.)6BA+B!Y8Y
MAO0-&\*-(ZLI8-G",$P#S'&Q-S=-2O501E \@7F!&0X;#"1@BD$#'BPS^]!W
M-@==6_4^JS1]UM=:I=>M4N2=MH^%/!MR:Y8X$*1DF$=LPL>\1G"X\&$5)UME
M1Z".F/LR9 QR,\A'IS(C3\LUHN%/!-42P8B@=DE821,5*2B!V"J[,R),>4SJ
M&4.",G:<6)74SR)$LF7D * HX!RN]025 #,G?"D[BI!QC5M_KO-9A)1<9=9,
M^ 3&VNUA,HJM5V#;H,42"V$2UR.)FYT.FQVQ<HA8H3 =R*G$N&HS.A11)(LQ
M,BR79!9JR0(T"!D:&*3,LM- S.]*M6ZQHU0Q=4B8N&R&,:L72-@4%GE\"EA(
M2"'=>XDL@"K*806(C&"7&TC& 2,%@0QJK/5YH]Z2&B_#5E;<+Q(<Y]UVA75$
M2MQIEO+4!+ESFY!9B5'V>Z!9M;FI/O051"'J<O83%=3)Y:;/7CF?!Q]PD "H
MIRTI$*5!$"\W=/F"1908@P9,D$D$:N\OILJ-[ L >L<@V R&(<SN_!_"*4._
M&&Z'75GK!T=@=%+J+6Q(J7\*2&R.=<WW,1L(!D0X5@MDAU-=SABF@"4^**+V
MIW"0L0HMV"J8J1%EH8"S5Y<QB.+> G<\JIBQ>0,8H0!*<U$JHSQP#X5D <)M
M921KZ8 ,6?:2W7E2D!4(#R'"=(T8[6D.$!Z9Z'7:6ZOM#AHV7YEH)*=3W:4/
MBU6S2BB"'QEL532&>'LBE2(YIPO4;0IL7(0U*6, DC*6\BV,RU$LUQD8!8 =
MV2&,T(3:(8IR^\R;3&(YX>^"5WRI'G>=NC5],N<NV1X@(Y8'>\>W 7.[=%)W
M<9VH6^+@GR;&ZI*Q4P^NS%7$DKH-VG6;E8ZJ<'P3& [4>LTHC;8:R:FA3KK"
M9RX;<0A&DK'S </,XL1;:B"YV6JTUIFFDJ8Y72G:DFABGC<H9-TM0D#! 74$
MIN)&"PD8!$R6&J2UJ(L3(K2+.DCQL VW"1M(,G:<9VX.<;1ECT!UX(?6=I6/
M31MFLY<T"(.R!PLI7W:7=,&8I235(-PE28H9T&DO+K30*:V5BV)$10R; <C*
MC2'I$J,P]>UDKS4/#%&DJA7=)1/ 8V19G@"EQ*468R(4,);>&!R, G5HN-,(
MEDD8H3M#(4?>"R+)D+M#% K;@X&TCJ.O35X;*ZC:+1($EJ%)DGK _K,MM,$Q
M"!VLE77ZI @393-@.V&MUX^T"KCC\9IB03<C/O(S+AMQ8<N5-AQI&/36VHJ"
M"5$<8JDI'+20)*)G95,<4,TL1EE )(0$#"L6955F$LM5%&" 2S&%IEPKLG+4
M'OLZ*X5.GQL'Q& ?#4<6SK/UP!@9D0)7M;E<NM(K6QY4H/:8P*MP;&ZM!J6-
M,/A(C)J<%0T[E@>RVF;-PE#C<)3;B5<RH;'5RE05VB:GJ)J4!X6EE,0!C5HQ
M(W+$F1ESW$Z@L".D3W"%1D'.R6..4D.%3?\ &(8KWBOF4=2<:F*];_UQK<17
M#%ND66 U9PQ&QPH$:E6TJ<@5X+"ASS9RP A0>86KHP&P1@),R3,2'@:_+:CR
M\-/8=0WA4]OJ:IY4@$3&)UB9C40)&TKEA'''(\BQR/)L<QJC,7"L5R!J>6JA
MA"F0L-ZEP!&[,$4 L[*%+*JY&XL!C/75DRNL/0\6-9Y:[$<<C5*4!'E7V*7;
M765$K(N.V+&PG\!_42B#BY36'(J74NH3Z3N$K90IS&0MFN#&$") 9Q*R SP9
MV0Y,CL.9E44*<L1@'H<-TU&:^F&_OMW"@8B.0C<_Q5R%QN.1TSZ?0<=A7K!T
M %+& I.XS(<X$#>.3\/U6U--81%!Q+),$LNN!D8>L4$'-CD)X!./A.$W[2U*
MCM21Y%B)1++<I(XY$IMR22")2)8<Y:0PJY',Z1-*I19#W&.,'#*31KA2*S(9
M"&12Q&R3S()"!W?C!#N*_& SD#!Q^GNKO1T=24R#EB95BAS=DR4N46YI4/JD
M!DU(>G$DY!]X2W&:\77#;>PE,_,>.W"<?=)B6YP6:X'.(HS^N5I!BH@[T[<O
M"+\)UQS4W>!3+;@-C[;C74X(!9@>29R.7)E8P&.YN[TSL?'I(P,DKGJ8ZPM$
MN**XFGK(#0%A'Y9%ZR:^OE>::>K2(,@H':47KL3,JQH'E1)5FNQ4O&GQQ4;(
M1"[S&4*J;+<,(5BCDYC1!1%4TTI(F+".0\N5ML19'0R-A R,">FJ"OILL"[K
ML#EB\4J %,%ERZ*"X#*=HR2&! .==4?K(T+*;&.L6&P.IGY[2O546YO8KB46
M&+5GG;:XR#<:J\>.<GCH;LDRY$CJP3&26''HQ"(\]4V2Y*SJ84!7.W,\ YI$
M338@S)\,QC1R%CW'*LA <%=!7TI"GF'O9S\')W,.$/,[O<PY"G=C&0? YU)6
MG=LP-PUXY8!X$Y7V@EVM],7$/#B0Z1(<JIJ4)]O:03'#7.TM#"')41+3C@8C
M[8"(.8*#)K36)64C44B1/)'(7@@G!C=' $\:R!24=QE=V,Y =<2*-CJ3+!.M
M0K,JLNV22,AE9<F-BN1N"Y!QZ.ARIZ@C4K]_V6$_.E6>_P#\G*<?_F_BYB:G
MUKHZKO$"#=+E\NM#*TYHT2!Z.J.V:FI1$Y'Q;#5EV38J+)J4IT75#<*MQAT
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M"F4%Q\A.5LN.J9P:WAN[6^@AN55!"E+/Y'C964<TT0N%,U70M44\,\D],E5
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MX< 7"EN=SI8ZNC%%1Q7N>EK)JRA/E*V5T$M/,J5/ZUK DT$DT,I5Z=)E:9%
M<+CTW$M//2TDQ@J.?-)01S0+!..2:\'9*A:(&:'<LBHZ K*R%48Y4G*"W]8V
MAJ)MI6EK18+$-N,:=2QA>;\0[M*I%:G[';?S0(MIV'$ OTJN/7&5%D#0""YR
M)F<39<A(QAY"\)T%+PQ>:RV>ZU/3PR4I2KDB3RRC6LJ4H"/+GIJ%IQ63K2*P
MDJ#'"PCC.\],ZV<UWH8*OR*61UF!A5VY$Q@C:HW<A9:A4,,1F*E8P[J6;NCJ
M1J K1XGW3["K3AVCBMI7Z6@IJ?U0AC4NTZ\X2IFWKZBC5K88*46H_H'JL26V
M0F5F8+:DLVTBP-JXJ1@^=&Q7-Q!V?WUJ@0U34%&IBN9,K7*W3+'5VJA>MJ+?
M.L=63!5H B3QS;&ID9ZB4"&&1A@R\2V]8FDA6IG*M2=P4U1&7AK*A:>&IC+Q
M 2PNQ8Q/'N$S (AW.N;IK'B%Z&]?K^N;%M8NM7G8UFMP0,+KPV^V"NCH0K=%
MPTM59UELI.D5M%9S:;34Y 6.H]!'07#[1!L=-( XS)R3C2\%WLQUE11TDDU)
M0TU+/-)-)1P3.9;32W:H6GITK)S4"FIJI9FY#R.*<QM*D4S- DJ7^@#P0S3*
MLT\LT:")9I(T"5DU%&TLAB01<V6)HP7"J9 P5F0!S;A?Q.>GY8,,8H0S9U\=
M+W#4 %H:UJK:%=F2*SM^U$JD(OH)LO2,.V:OQBH&PB8[@=E]HS:13=2@R\&"
MHIN7.G 5]666.K-!1B*END[N]RM\RI/:J>.IFHIC#5,M/4M%-#+LF*F.!S4.
M.4DC+&W$E 41X!43EY:6,(*:IC8QU<K0QU";XAOA#I(FY<AY$,:MN(!V,XSW
MQC/GYX[^>.V?QXSYXS]'.)UT&G&FF<]L9S\V._&FHXVY?7=8:HV'LID8V:>H
MM)L5N;#N2\P&R:P(F233 7.3'EJB)E9C^IS)Q%D99POUF&7<I]#.31T_E553
M4V[9Y1/%#OV[MO,<+NVY&[&<XR,^&=:3B2[FP</WJ]K *IK3;*VXBF,AB$YI
M*>2<1&4)(8P^S:7"/MSG:?#6/P+K1UP4.7."Y'+RQH![70JMYK%>MUFM-RL=
MWK]IL9 **I<"MX/+771U3)SI4MB/)BK&QY<YYR(U&[.Y\EEJ42%LHID%0\AE
M>***&*"2*)9'F:4H!(TR*%)!#,%&[.=<=2=I]DJ*JYQ;*F6"C-D@HO(*.XUU
M?<JZZT=QK)Z2FMD5$*IFHH;=-*\B(Z&%9)69 @#5U_K6Z<&(K,Q=\=4S*ADI
MX]**W9LR"D092ZYL!QX;%R)Q*E^UUFU!GQC3;.7B1%V4$AMNF1T^!&C]QKCD
MKY/U5@C?"Q85C-)3X8[\#;+$X8DX50KDA'1FS6[3^"4C24WD;98IYX<4E;OG
MB@ME'=V:&/R??)S**OIFA4+OFF9Z6-6J898DDFT[VUY3K7BFFY5@^%X]>1;#
MSXNGVDX%IU;?085#-7<\&$SA%2@3LU\VF(^<F0TN?!<QU7JX[67LX\5#430\
M]!'L,G*C#31(\\H*!D@1G#3,G-C+! <!U\20-;NOXLLULN/N9525?E*48N%6
M\%NKZJEME"XJ3%5W6KIJ>6GMT$WD=4(GJI(PWD\I.U%+:C-OK/TB[%4\A6R<
M3LD0(N/7UZ@V8U:)TRTUJT7&O8'UMVKH,38I6LTXX88(1HCD!F*PWF9*C+=P
MA.3[BUP8 ^3!2LCF7RREY*B*6*&3?*)=B,DL\:,K$-D] 1UUHQVF\+-$7#7K
MF\VCA6B/#M\6XRR7"AK[E0\FA:@6IF2IH;=55*31QM"L:#FR1G<%N^T]3VEJ
M95*G>;#;%PJE>:?F]54ZD*:D0R]>[UGU;C/J(#CS1&0U;@LB,&D--%9$9<Y]
MJ&I HEF+!%;:R:66".',T$O)EC+HK))\(#D,P[JF)PS_ !0=H)RRYV5?QUPO
M;+=;KM67+E6Z[6TW6WU?DU4T531_K$JR[82RS.MQIG2G=5G=#*PCQ!-LHC?5
M_H-VZ!Z$BWR\GCAY^MP5YKEAP'P51;35$@-R3GP;\$QHYZVUXP%KTQV7B*8?
MBH>B/+B3($B5+[D5_)DG,($<:"1AS(]Y3DI4,5CW;R8X)$DD&,HI.1E7"X@[
M1^$3<Z:T"YL:NKJFHHCY)5BF%1[HU5IA62J,(@1*RY453244I?EU,D8,;&.6
M%Y*5?.JFL:\)[.!FV79YVHD9(ZL ZH!O-L-DL#M;5_8!<C91XFJ+;#" [5@A
M9)FA\PP%@C9@Y<XC$*R'1;-8+7-4+2NA"I, 7DF>"&-2U3)3HL;/,"[.4.U&
M".S!@JE0';'N_']OLLU]IJH--56V62*BI+=276XU<W(LE+>*F:NAIK<12TU,
MM5%SZF&2JIXH986EGCJ'-.E' =;^CWA@UJTV50>TM:TAW^SCH0.PD1(R0UKF
M+LZP5T>98&N0R9H157GC'P3&>=GNP65I0TN:T_%:D>R5VYFBB+PFI-/$[/&K
MN#4FECD9"P98WEPF\@+N/C@@G&I.U/A5H(%N%=Y-7BR17>NABIJR:G@D6RQW
MVLHHJE86CFJJ:WNU3Y.K-,T*D!3(DB+3[/ULT:')B0*J M1*1)@[5^$9EEI]
M_JL:I%];46'>VX]H'2:;).11YD04$DLRF1ZI4,'/CDVX,Y;J(>:I9:CO&5XE
M4-2;1%-!,TR54[09@*S!'>.1'0J7"F1&3<,$ZLK.T^T(\<-!2U\TCQ<0<Z2M
MMMWM\=NJ+%:H;L$N,4EM>KAAJZ:HIYQ(L!ECI)XYQ#(S+&>BG]:55F%MAO;"
MA_$.FU$W\50EBDB+JN,?/ ]92=H7%>")&JB13,- *++D5.$W(>-GAT-@FJ#'
M38 $:76:RSJE-R#SYIXN>\:M#F*.2J%+""HE9]QD*B5BHCC9B@9N7(5CMO:;
M;Y:B]/>$6T6RVUGN=2ULD%S*5M726)K_ ')A/-04].L2TB2-01*S555#"L[1
M1^5TL3WMU =4M6TM2"!B..-F[D[0)]^!U9-6M<E,45&S%C1IUXD"A,O-'$R2
MLV*&S.L*AR$$5OL9RG$&>N+%;K7+73I'NCCAYZP/*985RYR66 .Z\]P@+[8]
MV5Q^^4'9<8\?4'"UJGJ4@JJNYFSS7>EH!07"01TZ&...6ZO3T\GN73O4RQTQ
MDK##B8NIP(IFC"NK+6L<RNKW(Q&%V-RP;=B,-A!5Q+"(5;U/;;+6BIRPEY=7
M%L!LQ\5F=\+N+P^&B36'O8C$\6\/(S*-:JHIS88R\8CHV)=H4=I*R&*1$C02
MN6R9 $&=[*5+(K$J*P=H=B2I:@N-5'!6&KXDC44L%RJ*:*BX=N-=0U-56U,E
M!3QTI3R&45).^FBE1^74RP-%-)Y(76WT^$P3)X8?M1-MTA.A*#C-=7PC9X\8
M8 CVHB=EUF%7GS<:MP:[+BE99YV$D<PW(1#<>232[!;N:R7!7*/'$G<5@[U-
M.L3%Y&B1%E,@C,CR*R*F[<=I8#9WM1Q=J/!\](M7!5U\X::6(TT%FNT]>D<%
M&EPFJY*&&C>J6ABH98JB2J,7*42+$3Y1F$>['67H#,6Q3<V@OB'5ZK4;>7E9
MIUL]0V/O<6KS*G 8<P'RF0?.-72LX@ FO2)2723K3+"UB3>!MON/7_!?!)F:
M6:*,<V+):G:19F^/TC0PR[G^*H3)P'CWS'M*X0"5LGE]1RK?06ZX5,@MU>8Q
M%=HZ&2W0HPI\25=6MSH1#2J3+(TY5%8T]5R)LUQL>H;7J<"ZT@DHH!(/3XB'
M7HDH?+BSQ4Z0,*C2 ^<TQ,@SQQ&))B2HTAE"DN-96WEQA;3KF#44\M+,T$Z[
M)$P2 0P*LH965E)5E92&5@2"#Z>FNGLMZMW$%OANEKG,]),TT89HY(9(YJ>9
MZ>H@FAE5)(IH)XWBE1U&&4E2RD,;YY#K:Z<::<::<::<::<::<::<::<::<:
M:<::<::<::<::<::I%@ BK2!-UD[&]M"6(21!F(>'GXV98LM#>@3XWM$5UB4
MQZ^+(=:]='>:?:]+TVG$.)2K%\4CPR1S1G;)$Z21M@':Z,&4X8$'# '!!!\"
M"-6NJNK(PRKJ589(RK @C(((R">H(/H.L?M@ZJZ>8LJO0[G$6),W E2*?47Q
M]DN(VR2"M-''(%4CUV=7RC1@9)%ASIZ,0+0GHB7!<^7\8)KD3.%)V%/67%A(
M8")$A2HGG#Q4[Q!)VC,S2I*AC</)'&41@W?4<I=V <66GI05$@*M(8HT(>17
M+1*XCVE&# JK."PQW2=QQJOIZ8M$(( BC>NA#4VLXHF CC4@HAN!G6JYRZ:M
M+"9^&'G1?PC*2\]);>=+-99:,+GMQ8R6K/=6X%9$-2Y64U/,!"$L:L+Y1DE<
MC?M!&"-A)*;2S9N\CI@581*"G*VX)Z<C/+\_BN<$G)88#9 &KAL>D-:6RT3;
M>=!2I)@J#>KAQJ/8;(."V,0\-*!\1K-7!I>( L2V!9HI B23(V;*B1IBFX[S
M>&8V68HJ^IAA6"*11&D@EC/+B:2*0.DFZ&5D:6++1H66-U5MHW @G-[TT,CF
M1E)9EV, [A77:RX= P5\*[ %@2 >A&!J.1'3YT[5.S0 ,83*^-QL582T-DQ=
M;P<-$Q,:MMZ].2LRC%@GO.QX-;L\8 VEQ[&(4>5$S ;:<ALNQ\EKG<I8F<R#
MDQO&C%(*>.-',OE4:[4C 4F6$RD8PS!RV=Q!B6DI8W "G>RL1NDE8E0G*8Y+
M'P1PG4] 1CJ 1<-BU)H>_P H/KJP !APAK*CO!Q05PB801KM+O(.=2E)]J8F
MLR7$%1(6; CS'Y+Y",_!S/COQIV&I2HX:VX4H>HBD>)*J?>\FV,QRST\J5'@
M00"DDBLRX"L&V$,N5U=)34LVR)T#&&,JHW,"L<B&,]003N52 2201D$'KJNB
M=#:K W:#L +6G!-D@#!XEA0\Y8(@9R.)!HK0MZ96F2J*Z0(#Z^VT(ADIPN1/
M8A,1T-R,*C1UM1/7U4L#4\DHDC9G8[XXVD!DDYKA9BAE17D^$9%<*6+$CO-F
M]::%)!*J;6 "C#,%PJ[%RF=A(7H"1G '7H-6E9=/=/\ 7YB9-D"(@2MD6J*"
M:4X9M:_ANT&;\_MV+!:3%(N-Q'95W&OGTJPF)$0EA0Q3C8M>("\B.ON4J%8I
M"ZTT)D("0]R%*;R)FR5!;%._+P2S$D,/A.]J-X*5""ZA>;(%ZL_>=IN>H&#T
M)E&1X#'=^+@:MU72#J^1LF5=IT:5) *$#6(=,06L\8?\/M;%M^S3!<XZS8TQ
M[.-+V>T-$$5DX.EB!TL3&>BM^IRW%CW^[57Y,L"N ^]BTVR(N8S2P4D:1@QY
MA9(8"AEC99'5F#'Q)L\@@,QD()7:,)ND W<V29BW?PZL\F[8RE05'R 7L7Z9
MM*FP=8KA"HNJ#U&*6'"(D:QVF"IP,>)-ES=?,R8)J/*L5=*DV6)DT">?(BGG
M6&>\7T6\)Y"MUKDDEE6<<R9D=V,43?"1(4CEC#(5BF120DL01U!.&&=2-1T[
M(B&/NH&"@.XRKL&9&(8%T9@"5<LI(&1TUW'.FS2]A;M.)U,;9D7&U"[L<(B3
M!X(55:@T!X8.,C2@@I"GA)+$*5.9RD-(@L/_  F5=D,NO$YSDBD=TK8^5MJ"
M5@A>GC21(Y8Q"[;VC>.1&20;MI',5BNR, @1H%JU'3MOS& 9'$C,K,K;U&T,
M&4AE(!/Q2 =S9!W'/HV!1]/"*>&(WV%B+4]:!2HH9,DD[&[\$";/7GZ"41(>
MA3'211TB$+O#7)<[,^:EZ5D@E]$].)B;::>L:9TICNFJG1V15B&]XI14(0&
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MUUB+K;I5M=?MFN+;;#05U-*N]NLK%7%V:^'15<%&:,.KH\16BEH?<*D,/VB
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MU0XZ>D^H>W3KZ!ZS[-/:K=]PJ[^=)'ZH<=/2?4/;IU] ]9]FGM5N^X5=[?\
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ML Q;=D(*]O88;F9C8>(-18BW<*:]+E.1-7U\D-!0S\R>>4T]O@CEGFC4NS+
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MJ['CLHQCMC"6VFT(3C'NPG'/J?C"FAH^&(J2F01T]+)04T$:@!8X8 (HHU
MPJ(JJ/D&O/\ ZFVHFJ^UAJNH<RU%59.):B>1NK233TS2RR,?WSR,S$^<D^G7
MHZN?_?3/"Z^7_2_J3\_D\]<.^?O_ *=OEY)=_P#*OA+_ /J_WO\ !YZ'Y=8W
M9_\ [AW;C_I\$?\ GBZ\6^LX^S1]"^/EQT_[G[X^7'>N;3[9_'VSVY=7G_\
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M=S)!#RE8+,V>Z9"J=.K#PU.W3)MJ'J.V6R5)KIBSR+QKH[KH4-!>IS-R7LI
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MLHF#"0IQ.!'&REMQI[TJ*TW$DN-QY"FWEI1FB5-=(VV.6H=@"2J;V8 $ D@
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M@-%8LJUD8XYR)78TD6\R2COF'H;3X]YJ8TM49Q#BK_**XASOJL1]9#MEQ&,
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M!X #P \PVXP.FOI(+M4+ECC'4G+'!\23XD^)/B?GUMR\1O\ P<:;_P"-B/\
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MSUZ$[CTU?%9N-(XH3/<Q6.@M\DVZHA2?<(V%V2CJ/(!Y,]27=(9 $V94!H$
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M62DI \-.\P$J01U"SK'&XZX,N3S2=?5'_4V_^ ;J._YWJ[_T+C<WEF_8I_\
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M\(6,ON;KR]JE-K=_F_'[QVXY61C=N5U;IU&KED9G";1^Z)8-E2%V?%Z#.>8
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MK%G(9FBH\T1/.PBAA;3P)BQ+2Y*[I2JDQKS.63'O>M:D9 ^X#* <TC.X@XP
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MM6*AMH#((SY<>9EZ/.U*!#"B,5"$C4")$T)(7DQ.GSZO7UG,#LX5@\$P CC
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MCY=SD% A)[WQBH +##'J2<EB9*TUTDUW6FX>K+<Y50,C9.IZPU2,]@&)<#Y
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MC;-R;OA 52&),L[I+*3M4;F=XD8DDG(Z'!QJ,4=,@#88@!,%I'; 1'C0#).
MJ2, !X9SX@$1::\)*IDMZ4VP#;HQ7>G2I-5.0]J$3)VI\-V&?3>GN9TYB7#4
MLAM2?KQPX[3G!B9VQX&NA][?$!8E:Q-2J87L)&1;FXAD4J6J'SB9N5A U0*@
MX B$@',!^#YACR2=O@HL- IE1@VV)2#RP9,L5A,(R2Y7)4C+A0^% R<YUDU:
M/#:Z6;7B.]) WP(4B,4N#%L-0VI?Z?98P>CZG_4/A HY^NGAQ-D*<U?E=7MD
M!N0ENQL.*F3\J();E(QUKZE?!D898[7BC=26EYVXJRD967OKC&",# R-3M20
M-YG![N"LCJ1MCY0&58'!3ND'H?$]=5NI>'QTPTB!6AM>J1V+$J5FHUN"(>N5
MEE*CG-=:!D=,U5D.K?(+S(:AZBDO!)$9[TF)I!6#LI#A9*96*/6U+[M\@.Y7
M5NX@RLDXJ7'11C,PWY&"/B@["5T6D@0 *A 5E8=YCAEBY(/4G/P?=P<C]UC=
MUUD[J[6]3TYK:A:FH<*0.I.M:A7:+4A\N=*)RH5<JPJ*%#19!&<Z]-G/,0(;
M#;LN6\[(D+3EUYQ;BE*SCR2/+(\KG+R,SN< 99B2QP  ,DGH  /-J9$6-%C0
M85%"J,DX51@#)ZG Z9))])U??+-7Z<::<::<::<::<::<::<::<::<::<::<
M::<::<::QGD=.%9(6[;ELN=BL!0!L2ZPKN[3VSQ$948+@K3M%U<Q-*CTR/5R
MR8]-2(&XDAIZ():E2@Q24+D'ZR',Q)Q.P6)5"AHT*!]H+',K2="? 9;&""<9
M&<,08N4-TC,20[!L9( Q&D?49Z_%)]&2.F0#JL ==:AV.S4=GTRR.V2FFQVO
M[,(>I]QR2UU?V:4J.5UK;WLC)$D>?<$*:'31I@;-;CG6!M?0=R;A  #(ZTM)
M&6C==K*71@Z8="W1TPPRIST((!4EL8+'-0J/AU.Y2%(*ME& SM/0D$=<@^?
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5:<::<::<::<::<::<::<::<::__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
